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ABSTRACT
The publications forming this submission cover two broad 
fields. A series of papers deal with experimental hypertension ; 
possible roles for angiotensin and prostanoid substances in the 
pathogenesis of hypertension were investigated. The results 
indicated that the capacity of kidney to inactivate angiotensin 
II could be quite profoundly altered by inducing hypertension 
using the one and two-clip Goldblatt methods or by altering the 
sodium chloride content of the diet. The possibility that a 
reduction in the endogenous formation of vasodilator 
prostaglandins might occur in experimental hypertension was 
investigated; there was a clear reduction in prostaglandin E2 
generation by kidneys of rats given increased dietary sodium and 
by the ischaemic kidneys of rats which had been subjected to 
uninephrectomy and clipping of the surviving renal artery. The 
lungs of genetically hypertensive rats inactivate both 
constrictor and vasodilator prostaglandins to a lesser extent 
than the lungs of normotensive controls.
Further papers describe clinical investigations of 
antihypertensive medicines in man or studies in healthy 
volunteers and patients on the ancillary effects of drugs 
commonly used in the treatment of hypertension. Several relevant 
reviews are also presented for consideration. These studies have 
provided some insights into aspects of drug efficacy and safety 
which are sometimes overlooked by the practising physician.
I declare that this work is my own or has been aided, in 
some cases, by close associates with whom I have collaborated 
in laboratory or clinical work. Statements from Professor 
Reyes and Dr. Ledingham are presented. This work is 
submitted for the degree of Doctor of Science (Medicine) in 
the University of the Witwatersrand. Papers number 1 - 4  
formed part of a thesis submitted for the degree of Doctor of 
Philosophy in the University of Oxford. No other portion of this work has been submitted for any other degree.
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closely associated with Professor W.P.P. Leary in numerous 
clinical and laboratory studies during recent years. We have 
been equal partners in most of our research endeavours and, as a 
matter of course, have tended to rotate first authorship of 
publications arising from this work. Additional junior authors 
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the result of the collaboration between Professor Leary and the 
undersi gned.
This submission represents over 15 years work which 
could not have been completed without the assistance, 
patience and forebearance of many people including 
colleagues, patients, secretarial staff, loving friends and 
family. My thanks are due to them all and in particular, to 
my wife and to Mrs. Peta Gordon who compiled the papers which 
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PREFACE
Several generations of medical scientists and clinicians 
have studied the complex problems presented by raised 
arterial blood pressure. Specialised units devoted to the 
investigation of hypertension commonly employ a 
multidisciplinary approach, using experimental animals, 
computer models, healthy volunteers, patients and analyses of 
hospital records and surveys in their efforts to determine 
the causes, prognosis and optimum management of this 
condition.
As the title implies, the publications which form this 
submission cover two broad fields. First a series of papers 
dealing with aspects of experimental hypertension is 
presented. These publications report studies in which 
possible roles for angiotensin and prostanoid substances in 
the pathogenesis of hypertension were investigated. In 
some cases laboratory work was actually carried out by the 
applicant, in others a major contribution to the initiation, 
direction and final presentation of studies was involved. 
Thereafter further papers are divided into 6 groups which 
either describe clinical investigations of antihypertensive 
medicines in man or studies in healthy volunteers and 
patients of the ancillary effects of drugs commonly used in 
the treatment of hypertension. Several relevant reviews are 
also presented for consideration. The applicant made a major 
contribution to each of these studies in terms of conceiving, 
initiating, directing and reporting them. The mathematical
theory applied to much of this work was conceived by 
Professor A.J. Reyes in its entirety.
SECTION A
A1
Pressor Response to Infusion of Angiotensin into the Portal 
Vein of the Rat: WP Leary, JGG Ledingham. Nature (1968)220: 1-5.
A2
Removal of Angiotensin by Isolated Perfused Organs of the Rat: WP Leary, JGG Ledingham. Nature (1969) 222: 959-960.
A3
Inactivation of Angiotensin II Analogues by Isolated Perfused 
Rat Liver and Kidney: WP Leary, JGG Ledingham. Nature(1970) 227: 178-179.
A4
Renal and Hepatic Inactivation of Angiotensin in Rats: 
Influence of Sodium Balance and Renal Artery Compression: WP 
Leary, JGG Ledingham. Clinical Science (1970) 38: 573-582.
A5
Metabolism of Angiotensin I in the Pulmonary Circulation: JW 
Ryan, JM Stewart, WP Leary, JG Ledingham. Biochem J. (1970) 120: 221-223.
A6
In Situ Perfusion of Isolated Rat Lung: WP Leary, U Smith. 
Life Sciences (1970) 9 (1): 1321-1326.
A7
Catabolism of Angiotensin II: JG Ledingham, WP Leary. 
"Angiotensin". Ed. I. Page & M. Bumpus. Berlin: Springer Verlag (1974) 111-125.
A8
Impaired Prostaglandin Release from the Kidneys of Salt- 
Loaded and Hypertensive Rats: WP Leary, JG Ledingham, JR Vane. Prostaglandins (1974) 7: 425-432.
A9
Pulmonary Inactivation of Prostaglandin by Hypertensive Rats: 
WP Leary, AC Asmal, J Botha. Prostaglandins (1977) 13:697-700.
A10
Enhanced Release of ’PG^-Like" Substance in Experimental 
Hypertension: JH Botha, WP Leary, AC Asmal. Prostaglandins 
and Medicine (1979) 3: 251-252.
All
Enhanced Release of a 'Prostacyclin-Like" Substance from 
Aortic Strips of Spontaneously Hypertensive Rats: JH Botha, 
WP Leary, AC Asmal. Prostaglandins (1980) 19 (2): 285-289.
A12
Mechanical Reduction in Pressure and Pulse Pressure Decreases 
the Ability of Hypertensive Rat Aortas to Produce "PG^-Like" 
Activity: JH Botha, WP Leary. Prostaglandins and Medicine (1981) 6: 267-26.
A13
Platelets of Spontaneously Hypertensive Rats are not 
Abnormally Sensitive to PGI^: JH Botha, WP Leary.
Prostaglandins and Medicine (1981) 7: 499-500.
Thirteen original papers reporting basic laboratory 
studies are presented. The experiments described were 
designed to assess whether imbalances between naturally 
occurring vasodilator and vasoconstrictor substances might be 
associated with raised arterial pressures in certain animal 
models for hypertension. This approach is justified by the 
fact that the basic disorders which account for the 
occurrence of essential hypertension have yet to be 
identified, in spite of what is known about the regulation of 
blood pressure under physiologically normal circumstances and 
the extensive data which has accumulated in the course of 
critical studies in hypertensive man and animals over many 
years.
Since it is known that total peripheral arterial 
resistance is a fundamental determinant of arterial blood
pressure at any time, it follows that factors which influence 
resistance might, in turn, be involved in the homeostasis of 
arterial blood pressure. N a t u r a l l y  occurring 
vasoconstrictors and vasodilators might, theoretically at 
least, be counted amongst the factors which modulate 
arteriolar tonus. The early studies, carried out at Oxford 
University, concentrated upon the powerful vasoconstrictor 
angiotensin II which, at that time, was thought to be formed 
in plasma, notably during passage through the pulmonary 
circulation, by the action of a converting enzyme upon 
relatively inert angiotensin I. Subsequent investigations 
have indicated that angiotensin II formation also occurs 
locally in some tissues, certainly within the kidney. The 
Oxford studies examined the hypothesis that reduced enzymatic 
inactivation of the vasoconstrictor angiotensin II, which is 
destroyed during circulation through major organs, might 
contribute to the elevation of arterial blood pressure noted 
in various animal models for hypertension. This postulate 
was investigated by isolating certain organs in the rat and 
perfusing them with solutions containing angiotensin II. The 
results which emerged were interesting and indicated that the 
capacity of liver and kidney to inactivate angiotensin II 
could be quite profoundly altered by inducing hypertension 
using the one and two-clip Goldblatt methods or by altering 
the sodium chloride content of the diet. Other papers in 
this section dealing with angiotensin II describe techniques 
developed and used and provide an overview of the possible 
relevance of angiotensin catabolism to hypertension.
Subsequently the possibility that a reduction in the 
endogenous formation of vasodilator prostaglandins might 
occur in experimental hypertension was investigated. It was 
found that when comparisons with appropriate controls were 
made there was a clear reduction in prostaglandinEj 
generation by kidneys of rats given increased dietary sodium 
and by the ischaemic kidneys of rats which had been subjected 
to uninephrectomy and clipping of the surviving renal 
artery. Later work resulted in the finding that the lungs of 
genetically hypertensive rats inactivate both constrictor and 
vasodilator prostaglandins to a lesser extent than the lungs 
of normotensive controls.
The discovery of PGI2 (prostacyclin) stimulated further 
investigations of a similar nature. It was found that aortic 
strips taken from genetically hypertensive rats as well as 
those from rats with experimentally induced hypertension 
generated more of this vasodilator than their controls, 
possibly representing an adaptive response to hypertension.
The subsequent finding that platelets taken from 
genetically hypertensive and normotensive rats are equally 
sensitive to prostacyclin indicated that the increased 
generation of prostacyclin might reduce platelet aggregation 
in hypertensive rats, thereby possibly retarding the genesis 
of degenerative vascular changes.
The relevance of all these findings to human 
hypertension remains uncertain. If nothing else they may 
illustrate the great complexity of the interactions involved
in blood pressure control; it appears unlikely that any 
valid, simple, explanation for the pathogenesis of essential 
hypertension will soon emerge.
SECTION B
B1
Treatment of Uncomplicated Essential Hypertension with 
Xipamide: WP Leary, AC Asmal, PC Williams, M Herron. Curr Ther Res (1978) 24 (8): 884-888.
B2
Evaluation of the Efficacy and Safety of Guanabenz versus 
C1onidine: WP Leary, AC Asmal, PC Williams. S Afr Med J (1979) 55: 83-85.
B3
Treatment of Hypertension with Verapamil: WP Leary, AC Asmal. Curr Ther Res (1979) 25 (5):747-752.
B4
Aldactone and Acebutolol in Treatment of Hypertension: WP Leary, AC Asmal, PC Williams, B. Marwick. J Int Med Res (1979) 7: 29-32. i
B5
Antihypertensive Effects of Sotalol and Atenolol Given Once 
Daily: WP Leary, AC Asmal, P Brayshaw, P Williams. S AfrMed J (1980) 57, 692-695.
B6
Antihypertensive and Metabolic Effects of a Combination of 
Hydrochlorothiazide and Amiloride: WP Leary, AJ Reyes. S Afr Med J (1981) 60: 381-384.
B7
Effects of Low Doses of Xipamide Given as Monotherapy in 
Essential Hypertension: WP Leary, AJ Reyes. Curr Ther Res (1983) 34 (5): 888-899.
B8
Effects of a Hydrochlorothiazide and Amiloride Combination on Plasma Magnesium in Patients with Essential Hypertension: WP Leary, K. van der Byl. Mag Bull (1984) 4: 127-132.
B9
Once-Daily Administration of Captopril and Hypotensive 
Effect: AJ Reyes, WP Leary, TN Acosta-Barrios. J Cardio
Pharma (1985) 7: S16-S19.
BIO
Captopril Once Daily As Monotherapy in Patients with Hyperuricaemia and Essential Hypertension: WP Leary, AJ 
Reyes, TN Acosta-Barrios, B Maharaj. Lancet (1985) 1.
This section includes 10 publications describing trials 
in which hypertensive patients were treated with various 
medicines.
Under ideal circumstances and before a rational verdict 
upon the efficacy or safety of a new drug can be given, it is 
necessary to compare new and established medicines in 
substantial numbers of patients and in double-blind fashion. 
This obviously reguires preparation of drug formulations and 
randomisation of patients in such a way that both doctor and 
patient are unable to distinguish which of the trial 
formulations is being administered at any time; a code held 
by another party can be broken in the event of an emergency. 
This approach removes much of the bias from clinical trials 
and allows relatively objective comparisons to be made 
between drugs.
During the early phases of drug testing in man and when 
a new or innovative approach is made to the use of an 
established drug it is common practice to maintain an open 
protocol, largely for ethical reasons. This approach ensures 
that the medical investigator is aware of the medication 
being used in each patient throughout the study and that 
immediate steps can be taken to intervene in the event of any 
untoward or adverse reaction. The results of such studies
are taken into account in the subsequent planning and design 
of scientifically objective, double-blind, studies used to 
test the validity of inferences based upon the preliminary 
open work.
The first study, although double-blind in the sense that 
neither the observer nor the patients were aware of the 
change from placebo to active therapy, was a simple 
preliminary investigation carried out to determine some 
characteristics of xipamide, a new antihypertensive diuretic. 
As reflected by the reference list, this was an early 
publication on the subject. The second paper describes a 
fairly typical clinical trial in which guanabenz, a recently 
developed substance, was compared to clonidine, an 
established drug of similar character.
Subsequent papers report upon the effects of various 
other compounds upon raised arterial pressure in man; several 
are of some interest: Paper B7, "Effects of low doses of 
xipamide given as monotherapy in essential hypertension", was 
one of the first studies to confirm earlier claims that 
antihypertensive diuretics markedly reduce blood pressure 
when administered at doses well below conventional diuretic 
dosages. This fact is of potential clinical importance since 
diuretics are commonly prescribed in antihypertensive 
regimens and the use of lower doses may well reduce the 
incidence of medium or long term side-effects of these drugs. 
Paper B8 records that the addition of amiloride to 
hydrochlorothiazide does not prevent the fall in plasma
magnesium level induced by hydrochlorothiazide during 
prolonged treatment, a finding at variance with earlier 
reports. The following study (B9) explored the theory that 
once daily treatment with the angiotensin converting enzyme 
inhibitor captopril would be effective in essential 
hypertension, particularly if sodium intake was restricted. 
A further novel finding with respect to captopril is 
presented as a letter (BIO). Studies in healthy volunteers 
showed that single doses of captopril induced an increase in 
urinary uric acid excretion (paper C13). This stimulated a 
prospective study in hypertensive patients with gout which 
proved that, in the short term at least, captopril may be 
used to reduce both blood pressure and serum urate levels. 
Given the frequency with which hypertension and gout coexist, 
the potential significance of this finding is obvious, 
although it needs to be confirmed by prolonged studies.
SECTION C
Cl
Comparative Effects of Xipamide, Furosemide and 
Hydrochlorothiazide in Healthy Adults: WP Leary, AC Asmal. 
Curr Ther Res (1978) 24 (6): 662-672.
C2
Xipamide: Diuretic Effects of Low Dosage in Healthy Adults: 
WP Leary, AC Asmal. Curr Ther Res (1978) 24 (6): 656-661.
C3
Urine Volumes and Flows after Oral Administration of Xipamide, Furosemide and Hydrochlorothiazide to Healthy 
Adults: AJ Reyes, WP Leary, AC Asmal. Curr Ther Res (1980)28 (2): 230-234.
A Mathematical Model for the Clinical Pharmacology of 
Diuretics: AJ Reyes, WP Leary. Curr Ther Res (1981) 30 (2): 227-235.
C5
A Formal Method for the Therapeutic Classification of 
Antihypertensive Diuretics: AJ Reyes, WP Leary. Curr Ther 
Res (1981) 30 (6): 1073-1088.
C6
Mathematical Evaluation of the Effects of Tizolemide, 
Furosemide and Placebo in Healthy Adults: WP Leary, AJ
Reyes. S Afr Med J (1982) 61, 398-401.
C7
Urinary Magnesium and Zinc Excretions after Monodosing 
Healthy Volunteers with Chlorothalidone: AJ Reyes, WP Leary. Curr Ther Res (1982) 32 (1): 128-137.
C8
The Magnesiuric Effect of a Single Dose of Furosemide in 
Healthy Adults: AJ Reyes, WP Leary. Curr Ther Res (1982) 32 (3): 406-416.
C9
The M a g n e s i u r i c  E f f e c t  of a S i n g l e  D o s e  of 
Hydrochlorothiazide in Healthy Adults: WP Leary, AJ Reyes. 
Curr Ther Res (1982) 32 (3): 425-430.
CIO
Urinary Magnesium and Zinc Excretions after Two Different 
Single Doses of Amiloride in Healthy Adults: WP Leary, AJ 
Reyes, K van der Byl. Curr Ther Res (1983) 34 (1): 205-216.
Cll
Effects of Hydrochlorothiazide Plus Sotalol on Acute Urinary 
Electrolyte Excretion in Normal Subjects: WP Leary, AJ
Reyes, K van der Byl. S Afr Med J (1984) 66, 680-681.
C12
Effects of Several Diuretic Formulations on Urinary Magnesium 
Output in Healthy Adults: WP Leary, AJ Reyes. Diuretics 
Jules B. Puschett (Elsevier Science Publishing Co., Inc. ) (1984): 494-496.
C13
Effects of Captopr i1, Hydrochlorothiazide, and their 
Combination on Timed Urinary Excretions of Water and 
Solutes: WP Leary, AJ Reyes, K van der Byl, TN Acosta- 
Barrios. J Cardio Pharma (1985) 7 : S56-S62.
The Effects of Single Doses of Muzolimine Upon Urinary Solute 
and Fluid Excretion: WP Leary, AJ Reyes, K van der Byl. Z 
Kardiol (1985) 74 (2): 135-140.
Fourteen publications are submitted, each describing 
certain pharmacological effects of diuretics. Diuretics are 
used by many clinicians throughout the world as medications 
of first choice in the treatment of hypertension. They are 
relatively cheap and, in negro patients at least, appear to 
be as effective as more expensive alternatives. Those who 
prefer to initiate treatment with a beta-receptor-antagonist 
or calcium channel blocker generally add an antihypertensive 
diuretic to the treatment regimen as a second step in 
managing patients who do not respond to monotherapy with the 
first-line drug used. Since diuretics occupy such an 
important place in the treatment of hypertension it is 
essential that all their characteristics be described in 
detail and that the possible adverse effects of both short­
term and prolonged therapy should be identified.
Paper Cl reports upon a simple study comparing the 
responses of healthy volunteers to standard diuretic doses of 
furosemide (40mg), an established loop diuretic, and xipamide 
( 2 0 , 4 0 , 6 0 mg) , a compound just introduced into medical 
practice at that time. A contemporary study by the same 
authors (C 2) proved guite clearly that far lower doses of 
xipamide (5,10mg) could produce a satisfactory diuretic 
effect; it is unfortunate that this finding was largely
ignored at the time, particularly in the light of the 
subsequent finding that low doses of xipamide effectively 
reduce raised blood pressure (B7). The drug is still 
commonly prescribed in doses of 20-40mg daily.
Papers C3-C5 introduce the well-established concept of 
mathematical modelling to analysis of the diuretic and 
antihypertensive effects of drugs. The particular value of 
this method of presenting data is that it provides a 
relatively simple and accurate means of comparing the results 
of experiments involving different drugs, patients and 
investigators, provided that the protocols followed have 
certain similarities.
Papers C6-C11 deal with the urinary excretions of 
electrolytes in response to a variety of commonly prescribed 
diuretics. All the formulations studied are widely 
prescribed as monotherapy or in combination with other drugs 
for the treatment of hypertension. The effects that these 
compounds have upon plasma and tissue levels of ions such as 
sodium, potassium, magnesium, calcium and zinc may have an 
important bearing upon both serious and trivial adverse 
responses to prolonged therapy with diuretics.
The analytical technique employed is novel and has 
provided new insights into the excretion of certain 
electrolytes, notably magnesium. Since magnesium depletion 
appears to increase arterial tone and therefore elevate blood 
pressure it is important to determine the effects which 
antihypertensive regimens may have upon magnesium balance. 
Despite the fact that this work has illustrated apparent
differences between drugs, it has the weakness that results 
generated by acute studies in healthy volunteers cannot 
readily be accurately extrapolated to clinical situations in 
which the same medicines are administered chronically to 
patients with essential hypertension.
SECTION D
D1
Cardiovascular Effects of Salbutamol: A Comparison with 
Isoprenaline: AJ Coleman, WP Leary. S Afr Med J (1972) 46: 1177-1179.
D2
The Immediate Cardiovascular Effects of Pancuronium, 
Alcuronium and Tubocurarine in Man: AJ Coleman, JW Downing, 
WP Leary, DG Moyes, M Styles. Anaesthesia (1972) 27 (4): 415-422.
D3
The Immediate Cardiovascular Effects of Althesin (Glaxo CT 
1341), a Steroid Induction Agent, and Thiopentone in Man: AJ 
Coleman, JW Downing, WP Leary, DG Moyes, M Styles. Anaesthe­sia (1972) 27 (4): 373-378.
D4
Cardiovascular Effects of Acebutolol (M & B 17803A), in 
Exercising Man; A Comparative Study with Practolol and 
Propranolol: AJ Coleman, WP Leary. Curr Ther Res (1972) 14 (10): 673-678.
D5
Some Hemodynamic Effects of Sodium Nitroprusside: M Styles, 
AJ Coleman, WP Leary. Anaesthesiology (1973) 38 (2): 173- 176.
D6
Isoproterenol Blockade in Man: Comparison Between Penbutalol 
and Acebutolol: AJ Coleman, WP Leary, AC Asmal. Curr Ther Res (1974) 16 (1): 64-79.
D7
The Cardiovascular Effects of Etilefrine: AJ Coleman, WP 
Leary, AC Asmal. Europ J Clin Pharmacol (1975) 8: 41-45.
Cardiovascular Effects of Intravenous Indoramine 
Hydrochloride in Man: AJ Coleman, WP Leary, AC Asmal. J Int 
Med Res (1979) 7: 511-518.
The drugs described in these papers all have some effect 
upon the cardiovascular system with resultant changes in 
arterial blood pressure. The medicines investigated are 
primarily used in the management of general anaesthesia, 
bronchial asthma, angina pectoris and also in hypertension 
per se. Clinically significant changes in blood pressure, 
cardiac output, pulse rate or peripheral resistance occur 
when these medicines are administered to patients with 
healthy cardiovascular systems and it is important that 
medical practitioners be aware of the possible occurrence of 
such changes both in normotensive and hypertensive patients. 
The same technique involving dye-dilution as a direct means 
of measuring cardiac output was used in all the studies 
included in this section of the submission. Each contributed 
new knowledge and represented an early.investigation of the 
drug's cardiovascular effects in man.
SECTION E
El
The Effects of Adrenergic B-blockade with Oxprenolol on 
Peripheral Metabolism: AC Asmal, AJ Coleman, WP Leary.
Postgrad Med J (1975) 51: 173-177.
E2
Immediate Metabolic Effects of Adrenergic Beta-Blockade: WP 
Leary, AC Asmal, J Carboni, S. Wattrus. Pharmatherapeutica 
(1978) 2 (2): 70-75.
The ancillary or secondary effects of medicines may have 
a profound influence upon their overall efficacy and safety. 
Thus for example, the fact that beta-receptor antagonists 
influence a number of metabolic variables is of some 
importance when hypertensive patients with metabolic 
disorders such as diabetes mellitus are treated. The two 
papers presented report some peripheral metabolic effects 
associated with beta blockade by oxprenolol (El) acebutolol, 
propranolol or practolol (E2). The effects of beta 
stimulation by isoprenaline were also assessed.
SECTION F
FIDiuretics: WP Leary, AJ Reyes. S Afr Med J (1981) 59: 9-13.
F2
Diuretics, Magnesium, Potassium and Sodium: WP Leary, AJ 
Reyes. S Afr Med J (1982) 61: 279-280.
F3
Diuretics and Zinc: AJ Reyes, WP Leary, CJ Lockett, L
Alcocer. S Afr Med J (1982) 62: 373-375.
F4
Magnesium Deficiency Provoked by Diuretics: AJ Reyes, WP 
Leary. S Afr Med J (1983) 63: 410-412.
F5
Prophylaxis and Treatment of Magnesium Depletion: WP Leary, 
AJ Reyes. S Afr Med J (1983) 64: 281-282.
F6
Magnesium and Sudden Death: WP Leary, AJ Reyes. S Afr Med J (1983) 64: 697-698.
F7
Magnesium and Deaths Ascribed to Ischaemic Heart Disease in 
South Africa: WP Leary, AJ Reyes, CJ Lockett, DD Arbuckle, K 
van der Byl. S Afr Med J (1983) 64: 775-776.
Urinary Zinc Excretion, Diuretics, Zinc Deficiency and Some 
Side-Effects of Diuretics: AJ Reyes, JV Olhaberry, WP Leary, CJ Lockett, K van der Byl. S Afr Med J (1983) 64: 936-941.
F9
Drug Interactions with Diuretics: WP Leary, AJ Reyes. S Afr Med J (1984) 65: 455-461.
F10
The Antihypertensive Effect of Diuretics: AJ Reyes, WP
Leary. Cont Med Educ (1984) 2: 85-93.
Fll
Diuretic-Induced Magnesium Losses: WP Leary, AJ Reyes. Drugs (1984) 28 (1): 182-187.
F12
Cardiovascular Toxicity of Diuretics Related to Magnesium 
Depletion: AJ Reyes, WP Leary. Human Toxicol (1984) 3: 351-372.
Papers included in this section review aspects of the 
actions and uses of diuretics, medicines which are commonly 
prescribed in the management of hypertension.
The initial review provides a simple classification of 
these drugs and briefly discusses their pharmacokinetics, 
adverse reactions, interactions with other drugs and clinical 
uses. As in the subsequent reviews, reference is made to the 
authors' own work. The second brief review (F2) concentrates 
upon the effects diuretics have upon urinary sodium, 
potassium and magnesium excretions. F3 provides an insight 
into urinary zinc losses which may complicate the treatment 
of hypertension with certain diuretics.
Papers F4-F7 provide an overview of the theoretical 
relationship between diuretics, magnesium deficiency and 
ischaemic heart disease and could, logically, have formed a 
single paper; limited journal space resulted in division of
this work into 4 short articles. Paper F8 is complimentary 
to F 3 but provides a much more detailed account of the 
relationship between zinc and diuretics. A significant 
proportion of the data presented was collected and analysed 
by the authors.
The two reviews which follow (F9, F10) deal in some 
detail with the antihypertensive effects of diuretics and 
with potential adverse or beneficial interactions which could 
take place between diuretics and other drugs, many of which 
might be coprescribed to hypertensive patients. The last two 
papers in this section (Fll, F12) are similar in content. 
Both deal with the possible importance of urinary magnesium 
losses a consequence of prolonged diuretic administration to 
hypertensive patients. Much of the authors' original work 
is included in these reviews, which summarise many of the 
ideas presented in the shorter papers in this section. The 
suggestion is made that the failure of treatment with 
diuretics to reduce the incidence of sudden cardiac deaths in 
patients with hypertension might be explained by potassium 
and magnesium imbalances caused by prolonged treatment with 
these compounds.
SECTION G
G1
Tratamiento De La Hipertension: La Farmacologia De Los 
Agentes Vasoactivos: WP Leary. Medicina (1977) 37 (1): 102-109.
Effectos Colaterales Adversos En El Tratamiento De La 
Hipertension Humana: WP Leary. Medicina (1979) 39 (1): 100-105.
The last 2 review articles in this submission are 
presented as light relief and to give some indication of the 
global interest which exists in the treatment of 
hypertension.
SECTION A : LABORATORY STUDIES, EXPERIMENTAL HYPERTENSION
The publications in this section deal with aspects of 
the renin-angiotensin system and of some prostanoid 
substances as they relate to experimental hypertension in 
animals.
The role played by the renin-angiotensin system in the 
cause, pathogenesis, prognosis and treatment of raised 
arterial pressure has been controversial for many years and 
continues to be the subject of intense investigation. 
Many studies, including those presented here, suggest that 
derangements of this system undoubtedly are of some 
importance, at least in experimental models of hypertension.
The finding that certain endogenous prostanoid 
substances, including prostacyclin, are vasodilators and may 
therefore be involved in the homeostasis of arterial pressure 
gave rise to the obvious hypothesis that a reduction in the 
synthesis of prostanoids might contribute to the development 
of hypertension. The findings in several of the studies 
presented here have been confirmed subsequently in man.
Pressor Response to Infusion of Angiotensin into the Portal 
Vein of the Rat
This work was based on previously published investigations by 
quoted authors. I personally carried out all laboratory 
experiments. The paper was prepared in cooperation with Dr.
J.G. Ledingham.
(Reprinted from Nature, Vol. 220, No. 5163, pp. 180-181, 
October 12, 1968)
Pressor Response to Infusion of 
Angiotensin into the Portal Vein 
of the Rat
T h e  physiological importance o f enzym es that degrade 
angiotensin in plasm a and in tissue extracts has been 
questioned by Johnson and R yan 1. T hey have shown 
that aqueous extracts o f rabbit liver hydrolyse all the 
peptide bonds o f A spl -Hes-angiotensin I I  amide and 
A sp1-Vals-angiotensin amide when incubated a t p H  7-4 
and 37° C. There is also evidence that the liver p lays an  
active part in the destruction o f angiotensin in  vivo2-1. 
Bum pus et al .* have shown that the liver o f nephrectom- 
ized rats infused w ith tritiated angiotensin accum ulates 
more labelled peptide fragments than do other organs. 
Chamberlain et al.3 found a smaller rise in the blood  
pressure o f four dogs and two humans when A sp1-Vals- 
angiotensin amide was infused into the portal venous 
system  than when it was infused into the femoral vein. 
I t  is difficult to interpret their results because full details 
of the techniques used are lacking, and it is not clear 
how the doses were m atched against each other. Hodge 
et al.* have measured concentrations o f angiotensin in 
circulating blood both before and after passage through  
various tissues in anaesthetized dogs. T hey find a 
marked decrease in the concentration o f angiotensin  
after passage through the liver, as shown by the change in 
response o f the isolated gut preparations used to  assay 
angiotensin in their experiments.
In  1964, Methot et al.3 reported that angiotensin caused 
a much smaller rise in the arterial pressure o f W istar rats 
when infused into the hepatic portal system  than when  
infused into the femoral artery or the external jugular 
vein. W e have repeated this work using smaller doses 
of angiotensin and have introduced some additional 
modifications to their technique.
T w enty Sprague-Dawley rats (eleven female and nine 
male) on m ixed diets were used; weights ranged from  
160 to  230 g  (mean 200 g). Each rat was anaesthetized  
with intraperitoneal pentobarbitone (veterinary Nem butal, 
Abbott), 60 m g/kg, and given a subcutaneous injection of 
2’5 m g/kg o f pentolinium tartrate in polyvinyl-pyrrolidone 
(Ansolysen Retard, May and Baker) and atropine sulphate 
(1*5 mg/kg).
After a small flap o f skin had been removed from the 
anterior aspect o f the throat, a glass cannula was intro­
duced into the trachea and the left external jugular vein  
and right common carotid artery were mobilized. A  m id­
line abdominal incision was m ade and the gut was drawn
to one side and covered w ith a gauze swab saturated w ith  
warm saline. The portal vein was opened and a polythene 
cannula was introduced and tied into place. The abdom ­
inal wound was either closed w ith surgical clips (three 
experiments) or covered with damp swabs. I f  any diffi­
culty was experienced in setting up the preparation, the 
particular experiment was abandoned and a fresh one 
was prepared.
The external jugular vein and carotid artery were cannu- 
lated and the arterial cannula was connected to  a Condon 
type manometer, recording the arterial pressure changes 
on a kymograph. Heparin (2,000 u/kg) was injected into 
the jugular vein before each experim ent was continued.
Asp1-He5-angiotensin I I  was prepared in concentrations 
o f 0-1 fxg/ml. and 1-0 fig/ml., in sterile 0-9 per cent sodium  
chloride, p H  5-7. Injections o f angiotensin were washed  
in with 0-2 ml. o f  0-9 per cent sodium chloride, over a 
period o f 10-20  s.
In  eleven rats the pressor response to  every infusion o f  
angiotensin into the hepatic portal system  was compared 
with infusions of two different strengths into the external 
jugular vein (“bracket assay”, see Figs. 1 and 2). In  
nine rats various doses o f angiotensin were infused and 
the pressor responses were measured, but a precise 
quantitative comparison was not made. In  every experi­
m ent the smaller doses o f angiotensin were given first 
and no doses in excess o f 40 ng were given until the re­
sponses to the smaller doses had been assessed.
A t the end o f each experim ent a suspension o f carbon 
particles (‘Statex E - 12’) was injected through the portal 
vein cannula. The liver was then exam ined and the  
perfused lobes were weighed.
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Fig. 2. Explanation in text.
Figs. 1 and 2 were prepared from the data collected in 
the first eleven experiments. The y  axis represents the 
dose o f angiotensin (ng) required to  produce a given  
pressor response when infused into the external jugular 
vein; the values on the x  axis are those o f doses infused  
into the portal vein to produce an equivalent response. 
Fig. 1 shows that there is no difference between the re­
sponse to infusions into the portal vein and the external 
jugular vein in the range of doses used (5-15 ng). Fig. 2 
demonstrates that when doses o f 20 ng or more are infused 
a marked difference appears (P  =  0-001).
Fig. 3 illustrates the pressor response obtained when 
doses of 5-80 ng were infused into the portal and jugular 
veins. The doses {y) are expressed logarithmically and 
the pressor response (x ) in mm of mercury. There is a 
significant difference between the two dose response 
curves obtained ( P =  0-01).
Fig. 4 provides an exam ple of pressor responses recorded 
on a kymograph after infusions o f different strengths.
Methot et al.b suggest that the liver, by virtue of angio- 
tensinase activity, plays a specific and important part 
in  the metabolic destruction of circulating angiotensin. 
The strain of rat, the anaesthetic, the type o f angiotensin 
and the pH  of the infused solution were different in our 
work. In spite of these differences, we were able to con­
firm that when large doses o f angiotensin were used the 
pressor response in the portal vein was relatively less than 
in the jugular vein: here there is no conflict. When 
smaller doses were used, the pressor responses were 
identical. This observation does not support the view  
that the liver usually plays any specific part in the de-
Fig. 3. Explanation in text.
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Fig. 4. Blood pressure response to infusions of angiotensin II into the 
hepatic portal vein (L) and external jugular vein (J). The figures 12 to 20 
indicate the dose of angiotensin infused (m/ig). I t  can be seen that 
15 mug angiotensin (L) has a pressor eifect of between 12 and 20 ng (J).
struction of circulating angiotensin. Larger doses were 
observed to cause marked blanching of the liver in our 
preparations. Damage to hepatic cells w ith release of 
intracellular peptidases could explain the loss o f pressor 
activ ity  observed and this possibility is now being 
explored.
W e thank Sir George Pickering for facilities and for 
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PAPER A2
Removal of Angiotensin by Isolated Perfused Organs of the 
Rat
The techniques used were developed in consultation with 
Professor H. Krebs and Dr. H.F. Woods. Every experiment was 
carried out by me and the publication was prepared with 
considerable contributions by Dr. J.G. Ledingham, who was 
also available for consultation throughout the period of 
experimentation.
Removal of Angiotensin by 
Isolated Perfused Organs of 
the Rat
Tissue peptidases are the enzymes chiefly responsible 
for the removal of angiotensin II in rat liver and kidney
by
W. P. LEARY 
and
J. G. LEDINGHAM
Department of the Regius Professor of Medicine, Radcliffe 
Infirmary, Oxford
K n o w l e d g e  o f  m e ta b o l ic  p ro c e sse s  in  in d iv id u a l  o rg a n s  
h a s  g ro w n  c o n s id e ra b ly  s in c e  t h e  in t r o d u c t io n  o f  th e  t e c h ­
n iq u e s  o f  is o la te d  p e r fu s io n . W e h a v e  a p p l ie d  th e s e  
te c h n iq u e s  to  th e  s tu d y  o f  a n g io te n s in  re m o v a l in  t h e  r a t .
W e used female Sprague-Dawley animals, weighing 
180 to 250 g, fed on a standard small animal diet (Spillers 
Ltd, Banbury, England), and given unrestricted access to  
water. Rats were anaesthetized by intraperitoneal 
injection o f pentobarbitone (Veterinary Nembutal: 
Abbott), 60 mg/kg. Perfusion of the liver and kidney was 
performed as described by Hems et a l.1 and Nishiitsutsuje- 
Uwo et a l.2 w ith some modifications.
A technique for the perfusion of rat lung was developed  
(Woods and W. P. L., unpublished work) in which the 
chest of an anaesthetized rat was opened and small bags of 
crushed ice applied to the lungs and heart. The inferior 
vena cava was tied and a nylon catheter introduced into 
the cavity  o f the right ventricle through the superior 
vena cava and secured by a ligature around the right 
atrio-ventricular groove. A catheter was placed in the 
left ventricle by way o f the ascending aorta which was 
then tied off. Medium was circulated through the right 
heart catheter and the 5 to 10 ml. of blood washed out 
in this w ay was discarded before perfusion was started  
using the same medium and apparatus that is used in 
liver perfusion. All glass surfaces were coated with silicone. 
No more than 10 min elapsed from thoracotomy to  lung 
perfusion w ith angiotensin.
All three organs were perfused in  situ  and Asn1 V al5 
Angiotensin I I  was added to the medium to provide an
accurately measurable concentration o f 133 ng per ml. 
Organs were perfused at rates ranging from 2 to  4 m l./g  
of tissue per min. In the case o f liver perfusions the effect 
of adding washed aged human red cells, rat red cells and 
concentrations of angiotensin of up to 1,100 ng per ml. 
was assessed. The time course of angiotensin II  destruc­
tion by medium alone and b y  perfused liver, kidney or 
lung was determined by  bioassay o f serial samples of 
perfusate using techniques previously described3,4. D e­
struction was expressed in ng o f angiotensin per g wet 
weight of tissue and corrected to  a standard flow rate. 
Perfused organs did not produce detectable pressor 
or depressor substances, nor did circulating medium  
destroy angiotensin in the absence of liver or kidney. 
The addition of washed aged human red cells or rat red 
cells did not alter the angiotensinase activ ity  of the 
medium, nor of the perfused organs.
Three other methods o f assessing angiotensin destruc­
tion in vascular beds have been described5-7. The tech­
niques favoured by  Biron and his colleagues have draw­
backs which the authors them selves have emphasized9. 
The method of Regoli and Vane6, involving superfusion of 
a series of assay organs, is perhaps the m ost physiological 
technique available, but it is complex.
The techniques of Hems et a l.1 and Nishiitsutsuje-Uwo 
et al.2 can be quickly mastered and the apparatus required 
is simple. A perfusion can be set up and an experiment 
completed in less than 1 h. Results are remarkably repro­
ducible so that small numbers of experiments produce 
definitive answers. Pharmacologically active substances 
can be added or subtracted at will.
Rates of destruction of angiotensin II are shown in 
Table 1. The inability of the lung to extract angiotensin II  
has previously been noted8,9. Survival o f the peptide 
recirculating through the lung for up to 10 min adds weight 
to the view that this tissue bed plays no important part in 
angiotensin II  disappearance in  vivo.
The perfused liver and kidney both extracted angio­
tensin II  rapidly, depending on the amount o f peptide 
added. At a concentration o f 133 ng per ml. the kidney 
removed angiotensin II at a faster rate than the liver 
(P <  0-001). From 0-5 to 1 per cent of the total angio-
Table 1. disappearance of asm1 val5 angiotensin ii + standard error
OF THE MEAN IN THE FIRST 6 MIN OF PERFUSION
Organ
Lung
Liver
Angiotensin Angiotensin No. of
concentration Inhibitors added loss (ng/ experi­
(ng/nil.) g/min) ments
133 — No loss detected 3
67 — 238-9+ 11-6 14
67 Edetic acid 3 x 10~3 M 174-8 + 12-9 4
133 — 498-1 ±5-1 5
133 Dimercaprol 4 x 10-* M No loss detected 2
1,100 — 4,475-5 + 130-37 2
133 — 841-4 ±36-5 8
133 Edetic acid3 x 10-3 M 389-6 ±80-7 4
Kidney
tensin II  lost could be detected as vasoactive substance in 
the urine collected during kidney perfusions. I t  was not 
possible to determine the concentration of inactive peptide 
fragments. The mechanism of the disappearance of 
angiotensin II in the liver and kidney is not known. 
P Aspartyl-angiotensin II  has been found resistant to the 
action of plasma aminopeptidases, but is lost in tissues 
at the same rate as its a analogue8. Such loss could be 
caused by tissue enzymes distinct from those identified in 
plasma or, as suggested by  Biron, to  storage at receptor 
sites. The destruction of [i aspartyl-angiotensin II  
reported by  Biron et a l.a had been previously investigated  
with conflicting results10. Edetic acid and dimercaprol 
are potent inhibitors o f angiotensin destroying enzym es11. 
Addition of these compounds to  the perfusing medium  
resulted in significant reduction in the loss o f angiotensin II  
suggesting a dominant if  not exclusive role for tissue 
peptidases.
The techniques that we have used provide a simple 
and reproducible means o f examining organ destruction  
of angiotensin in a variety o f situations. Preliminary 
work12 has indicated that the rate o f angiotensin d is­
appearance can be altered profoundly by changes in 
sodium balance or blood pressure in albino rats.
We thank Sir G. Pickering and Sir H . Krebs for 
making facilities available and Drs H. F. Woods,
A. J. Honour and D. H em s for technical instruction and 
advice. W. P. L. is a Nuffield Dominions Fellow and is 
also grateful to the CSIR, Pretoria, for their support.
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PAPER A3
Inactivation of Angiotensin II Analogues by Isolated Perfused 
Rat Liver and Kidney
The techniques used were developed in consultation with 
Professor H. Krebs and Dr. H.F. Woods. Every experiment was 
carried out by me and the publication was prepared with 
many contributions by Dr. J.G. Ledingham, who was also 
available for consultation throughout the period of 
experimentation.
Inactivation of Angiotensin II 
Analogues by Isolated Perfused Rat 
Liver and Kidney
C h a n g e s  in the activ ity  o f enzym es which destroy angio­
tensin m ay be concerned in the developm ent o f hyper­
tension. but many relevant studies have involved tissue  
hom ogenates1-7 which m ay not reflect accurately th e  
capacity o f intact organs to remove circulating angio­
tensin. Intracellular enzym es, that normally have limited  
or no access to perfusing blood, are released when tissue 
extracts are prepared. Others8-11, however, recognizing 
this problem, investigated angiotensin inactivation by  
perfused organs in  vivo, and demonstrated the dominant 
role of organ vascular beds in the inactivation o f angio­
tensin in rats and dogs and the relative unimportance o f  
circulating angiotensinases. A  tentative explanation is 
that tissue enzym es are involved rather than storage o f  
angiotensin at receptor sites (results o f \Y. P . L., J . G. L. 
and J. W . Ryan, unpublished).
Alterations in sodium balance or the application o f a 
silver clip to one renal artery are followed by changes in 
the capacity of isolated perfused rat kidneys to  inactivate  
[Asn1, V al5]-angiotensin II , but angiotensin inactivation  
by the isolated perfused rat liver is not so affected12*13. 
We report here similar findings when rat kidney and liver 
were perfused w ith  medium containing other analogues 
of angiotensin II.
Isolated rat kidney and liver were perfused as de­
scribed1311. One group o f female Sprague-Dawley rats 
(Carworth. Alconbury) weighing 180 to 280 g  were given  
a standard small animal diet (Spillers Ltd, Banbury) 
and unrestricted access to tap water. The estim ated  
daily intake o f sodium was 1 m equiv and o f potassium  
4 m equiv per rat. Another group o f similar animals 
were given the standard diet but tap water was replaced 
by 1 per cent NaCl-0-2 per cent KC1 in water. The daily 
intake for each rat was approxim ately 11 m equiv N a + 
and 5 m equiv K+. For kidney perfusion, [Asn1, V al5]- 
angiotensin II , (3-[Asp1, V al5]-angiotensin II , a-[Asp1, 
Val5]-angiotensin II, and a-[Aspl , l i e 5]-angiotensin II  were 
used at a substrate concentration of 133 ng/m l. medium. 
For liver perfusion, the [Asn1, V al5]-angiotensin II  and  
(3-[Asp1, V al5]-angiotensin I I  analogues were used.
Experim ental conditions were m aintained for at least 
2 weeks before perfusion and organs from the two experi­
mental groups were perfused w ith different angiotensin  
analogues in random order to minimize the influence o f  
chance factors or im provem ents in technical skill. The 
rate o f angiotensin destruction was determined as de­
scribed13;11 and expressed as ng peptide destroyed per g  
wet weight o f perfused organ after 6 min perfusion. The
M ill
Fig. 1. Kidney perfusion. Inactivation of angiotensin II analogues by 
rats given the standard diet and tap water. Mean peptide removed at 
2, 4 and 6 min ( ±s.e.) expressed as ng angiotensin/g kidney, corrected 
for flow rate. • — • ,  Perfusions with [Asn1, Vals]-angiotensinII; O — O 
and A — e., those with [Asp1, VaP]-angioteDsin II and [Asp1, Ile5]- 
angiotensin II, respectively.
initial concentration o f angiotensin presented to the per­
fused organs was 133 ng/ml.
Differences in the rates o f disappearance of the various 
analogues during kidney perfusion are documented in 
Fig. 1 and Table 1. a-fAsp1, V al5]-, a-fAsp1, l ie 0]- and 
[Asn1, Val5]-angiotensin II were all rapidly inactivated, 
but ^-[Asp1, Val5]-angiotensin II  was not detect ably de­
stroyed after 6 min perfusion. The perfused isolated kid­
neys of rats drinking saline removed significantly less 
[Asn1, V al5]-, [Asp1, V al5]- or [Asp1, I le5]-angiotensiu II  
from the perfusate than kidneys from control animals in 
group 2 (Table 2, Figs. 2 and 3).
[3-fAsp1, V al5]-angiotensin II and [Asn1, V al5]-angio- 
tensin II were inactivated by the isolated liver at similar 
rates (Table 3). In single experim ents it was shown that 
[Asp1, He5]- and [Asp1, V al5]-angiotensin II  were also 
destroyed. An increase in dietary intake of Xa~ did not 
Table 1. inactivation or axgiotf.xsix ii ANALOG! L; by isolated per-
F t 'SE D  KIDNEYS OF RATS DRINKING TAP WATER
Disappearance of peptide after 6 min 
perfusion, corrected for flow rate
Peptide loss
Analogue (ng/g kidney) Xo. of
(m ean±s.e.) experiments
fl-[Asp', Vald-angiotensin II Xo loss detected 5
[Asn1, Yals]-angiotensin II 4,797-7 ± 240-6 10
a-fAsp1, VaPl-angiotensin II 2,447-9 ± 192-3 9
a-[Asp‘, Ile‘J-angiotensin II 1,605-0 ± 208-4 3
Table 2. INACTIVATION OF ANGIOTENSIN II ANALOGUES by ISOLATED PER­
FUSED KIDNEYS OF RATS DRINKING 1 TER CENT SALINE
Disappearance of peptide after 6 min 
perfusion corrected for flow rate
Peptide loss
Analogue (ng/g kidney) Xo. of
(mean ± s.e.) experiments
2,694-3 + 196-9 S
917-7 ± 87-5 4
780-8 ±68-1 3
[Asn1, Vald-angiotensin II  
a-[Asp‘, VaPJ-angiotensin II 
a-[Asp‘, IliPJ-angiotensin II
.Mill
Fig. 2. Kidney perfusion. Kffect o f increased dietary sodium on 
inactivation o f [Asp1, ValM-angiotensin II. Mean peptide loss at 4 and 
6 min (± s .e .)  expressed as ng angiotensin/g kidney, corrected for flow 
rate. •  and C — O, animals drinking tap water and 1 per cent
saline respectively.
alter the rate of removal o f angiotensin II  amide by the 
isolated perfused liver. ~
The perfused rat liver inactivates a number o f angio­
tensin analogues at similar rates, suggesting a variety of 
active enzymes, whereas the kidney destroys oc-aspartic 
acid analogues of angiotensin II  at less than half the rate 
o f [Asn1, Val5]-angiotensin II and does not inactivate  
*3-[Aspl, V al5]-angiotensin II. The latter findings resemble 
those reported in studies of human plasma by Khairallah  
and Page15, who identified two distinct avninopeptidases 
and an endopeptidase. One aminopeptidase (angioten- 
sinase A x) destroyed only [Asn1, V al5]-angiotensin II  and 
was highly active at pH  7-4. The other aminopeptidase 
(angiotensinase A ,) was relatively inactive at this pH  and 
specific for [Asp^-angiotensin analogues. Neither of 
these peptidases destroyed p-angiotensin and both could 
be inhibited by EDTA. The endopeptidase (angiotensin­
ase B) was similar to that previously described15. At 
p H  7-4 it was 10 per cent as active as angiotensinase 
A! and it was not inhibited by EDTA. This peptidase 
destroyed [Asn1, V al5J-angiotensin I I  twice as rapidly as 
other angiotensin analogues. Destruction of angiotensin  
by peptidases in the rat kidney such as leucine-anuno- 
peptidase, which inactivates [Asn1, V al5]-angiotensm II  
more rapidly than [Asp ^ -angiotensin II  analogues15, or 
enzymes similar to those described by Khairallah and 
Page15 in human plasma, could explain the results o f the 
kidney perfusion experiments.
The finding that the rate o f destruction of angiotensin 
Table 3. inactivation of angiotensin ii axalogfes by isolated
PERFUSED LIVERS OF RATS DRINKING TAP WATER
Disappearance of peptide after 6 min 
of perfusion
Peptide loss Ko. of
Analogue (ng/g liver) (mean ± s.e .) experiments
[Asn1, Val‘]-angiotensin II  376-5 ± 78-4 4
A-[Asp‘, VaPJ-angiotensin II 289-7 ±32-9 3
Mill
Fig. 3. Kidney perfusion. F.ifect of increased dietary sodium on 
inactivation of [Asp1, Ile3J-angiotensin II. Mean peptide loss at 4 and 6 
(±s.o.) expressed as ng angiotensin/g kidney, corrected for flow rate.
• — •  and O — O, rats drinking tap water and 1 per cent adine 
respectively.
b y  th e  is o la te d  r a t  k id n e y  is a l te r e d  b y  c h a n g e s  in  s o d iu m  
b a la n c e  h a s  im p l ic a t io n s  in  t h e  u n d e r s ta n d in g  o f  th e  
r e n in - a n g io te n s in - a ld o s te r o n e  s y s t e m 13. T h e  e ffec t o f  
so d iu m  lo a d in g  is a s  c le a r ly  s e e n  w i th  n a t u r a l ly  o c c u r r in g  
a n a lo g u e s  a s  w i th  th e  s y n th e t ic  c o m p o u n d , w h ic h  f u r th e r  
im p l ic a te s  r e n a l  a n g io te n s in a s e  in  th e  r e g u la t io n  o f  tis su e  
le v e ls  o f  a n g io te n s in  in  t h e  k id n e y .
T h is  w o rk  w a s  p a r t l y  s u p p o r te d  b y  th e  N u ff ie ld  D o m in ­
io n s  F o u n d a t io n  a n d  th e  S o u th  A fr ic a n  M e d ic a l R e s e a rc h  
C o u n c il.
W . P .  L e a r y  
J .  G . L e d in g h a m
D e p a r tm e n t  o f  th e  R e g iu s  P ro fe s s o r  o f  M e d ic in e , 
a n d
M e ta b o lic  R e s e a r c h  L a b o r a to r y ,
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S U M M A R Y
1. Rates of inactivation of asn^al5 angiotensin II by isolated perfused rat liver 
and kidney have been investigated in a variety of experimental conditions.
2. The liver inactivates angiotensin at a rate independent of sodium balance.
3. Sodium loading reduces and sodium depletion enhances the capacity of the kid­
ney to remove angiotensin.
4. In the presence of a silver clip on one renal artery with contralateral kidney 
intact, the clipped organ destroys angiotensin at a normal rate, and the capacity of 
the contralateral intact kidney to inactivate the peptide is reduced.
5. The kidney with its renal artery constricted by a silver clip, when the contra­
lateral kidney has been removed, has a reduced ability to destroy angiotensin.
Many attempts have been made to associate increases in blood pressure in experimental or 
naturally occurring hypertension with changes observed in the renin-angiotensin-aldosterone 
system. Repeated measurements have been made of kidney renin content, circulating renin 
and angiotensin and of aldosterone metabolism, but to date the evidence that any, or all, of 
these factors are critically involved remains conflicting (Page & McCubbin, 1968; Pickering, 
1968; Lee, 1969). The possibility that changes in the activities of enzymes destroying angio­
tensin might be concerned in the development of high blood pressure has been considered 
previously in studies relating to the disappearance of the peptide in plasma or in tissue homo­
genates (Dexter, 1942; Bing, 1962; Hickler, Lauler & Thorne, 1963; Lagrue & Meyer, 1963; 
Biron, Landesman & Hunt, 1964; Birbari & Hickler, 1965 ; Itskovitz & Miller, 1966; Itskovitz, 
Dudrick & Dyrda, 1967). The results of these studies are of doubtful significance. The capacity 
of organs to destroy angiotensin is unlikely to be reflected accurately by work using tissue 
homogenates (Johnson & Ryan, 1968).
Vane and his colleagues have recently demonstrated the importance of organ vascular beds
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in the inactivation of angiotensin in vivo and the relative unimportance o f circulating angio- 
tensinases (Vane, 1969). Vane’s observations have been supported by Biron, Meyer & Pannisset 
(1968) and by Leary & Ledingham (1969). It is critical therefore to determine whether or not 
manoeuvres known to alter electrolyte balance or blood pressure can simultaneously alter the 
capacity of individual organs to inactivate angiotensin. This point has been investigated using 
the techniques of isolated organ perfusion in the rat.
M E T H O D S
Female Sprague-Dawley rats in a weight range of 180-250 g were supplied by Carworth 
Europe, Alconbury, England.
Perfusion techniques
Perfusion of the liver was performed as described by Hems, Ross, Berry & Krebs (1966) and 
of the kidney by the method of Nishiitsutsuji-Uwo, Ross & Krebs (1967) with certain modifica­
tions. Both the organs were perfused in situ for periods of not less than 6 min and were isolated 
by ties placed around appropriate vessels. Rates of perfusion were measured in each experi­
ment and varied between 3-5 and 9 ml min-1 g kidney-1 or 13 and 20 ml/g liver. No attempt 
was made to regulate perfusion rates outside these limits. Livers were perfused at a constant 
hydrostatic pressure of 23 cm water, and kidneys by pulsatile flow at pressures adjusted to 
120-200/60-100 mmHg. Details of anaesthetic, perfusion medium, apparatus used and 
angiotensin bioassay have been previously described (Leary & Ledingham, 1969; Hems et al., 
1966; Nishiitsutsuji-Uwo et al., 1967). By these techniques adequate oxygen to preserve 
biochemical function can be provided without added red cells (Ross, 1966). Red cells were 
therefore omitted from the perfusing medium in this series of experiments.
Addition o f angiotensin
In all experiments asparagine'valine5 angiotensin II (asnVaFangiotensin II) was used. The 
peptide was added to the medium 3 min before an organ was included in the circuit, allowing 
time for equilibration to. take place. The concentration of angiotensin initially presented to the 
organ was 133 ng/ml of perfusate. The time course of angiotensin inactivation by medium 
alone and by perfused kidney or liver was determined by bioassay of serial samples of perfusate 
taken at 2 min intervals. Destruction of angiotensin was expressed as ng/g wet weight of tissue 
per min, corrected to a standard flow rate per g wet weight of perfused tissue. Livers were 
weighed at the end of perfusion. In the case of the kidney the weight of the organ was taken to 
be that of the unperfused contralateral kidney or, in those experiments when one renal artery 
was constricted, the ischaemic kidney was weighed after the experiment and a correction made 
for the change in weight induced by perfusion.
Inactivation of angiotensin II by the isolated perfused liver and/or kidney was studied in 
groups of rats on the following regimes: 1
1. Standard small animal diet (Spillers Ltd, Banbury, England) with unrestricted access to 
tap water. The estimated daily intake of sodium was 1 mEq and of potassium 4 mEq per rat. 
(Liver perfusion in four and kidney perfusion in ten rats.)
2. Same standard diet with replacement of tap water by 1 % sodium chloride solution. Daily
intake of sodium was approximately 11 mEq and of potassium 5 mEq per rat. (Liver perfusion 
in five and kidney perfusion in eight rats.)
3. Standard diet and 2 /  sodium chloride solution to drink. Fluid intake was higher in this 
group and estimated daily sodium intake was 30 mEq, and potassium 4 mEq per rat. (Kidney 
perfusion in five rats.)
4. Standard diet, unlimited tap water, one renal artery constricted by the application of a 
silver clip, leaving the contralateral kidney intact. (Liver perfused in three, ischaemic kidney 
in five and intact kidney in five rats.)
5. Standard diet, tap water or 1% sodium chloride solution to drink, uninephrectomy. 
(Kidney perfusion in five rats drinking water and five taking 1 % saline.)
6. Standard diet, tap water or 1 % sodium chloride solution, with hypertension induced by 
renal artery clip and contralateral nephrectomy. (Liver perfusion in three rats; kidney perfused 
in five rats taking water and in five taking 1 % sodium chloride solution to drink.)
7. Sodium depletion induced by a single peritoneal dialysis with 5% dextrose in water, 
followed by tap water to drink and a diet modified from that of Struyvenberg, de Graeff & 
Lameijer (1965) providing approximately 0-2 mEq sodium and 1 -3 mEq potassium per rat per 
day. (Liver perfusion in two and kidney perfusion in seven rats.)
8. Same fluid and diet as Group 7, with supplements of sodium chloride bringing the 
sodium intake to 5 mEq per rat per day. (Liver perfusion in three and kidney perfusion in - 
seven rats.)
The Struyvenberg diet of Groups 7 and 8 differed from the Spillers diet of Groups 1-6 not 
only in sodium and potassium content but also in the amount of other ions present, notably 
calcium.
In each of these groups of rats, constant experimental conditions had been maintained for 
not less than 2 weeks before perfusion was undertaken. Organs from the eight experimental 
groups were perfused in random order over a period of 6 months so that any influence of 
chance factors or improvement in technical performance could be minimized.
The blood pressures of the animals in all groups except 7 and 8 were measured. Conscious 
animals were warmed to 39° for 10-20 min and systolic pressure was recorded using a pneu­
matic tail cuff and a distal pressure transducer attached to an oscilloscope (Beilin, Garcia & 
Blackwell, 1969).
R E SU L T S
Blood pressure. All five animals in Group 6 were hypertensive (systolic pressure over 150 
mmHg) within 2 weeks of surgery. Hypertension also developed in six of the thirteen animals 
in Group 4, but the other rats in this group were found to have systolic pressures between 110 
and 140 mmHg. The blood pressures of animals in the other experimental groups examined 
were less than 120 mmHg systolic.
Effects o f changes in sodium intake
Liver perfusion. After 6 min perfusion, the livers of animals taking 1 mEq sodium per day 
inactivated from 230-4 to 558-0 ng angiotensin II, mean 376-5 +  78-4 (SEM) ng. These results 
were not significantly altered by giving rats 1% sodium chloride solution to drink (range
264-0 to 528-5 ng; mean 359-3 +  30-1 ng). These results are shown in Fig. 1. The livers of 
sodium depleted animals inactivated 313-8 to 329-8 ng with a mean of 321-8 +  8-0 ng which 
was not significantly different from their sodium replete controls (range 267-2 to 350-3, mean 
297-6 ±26-4 ng).
F ig. 1. Liver perfusions: effect of salt loading on inactivation of angiotensin. Inactivation of 
asn‘val5 angiotensin II ng per g wet weight of tissue±SEM. Open circles represent animals of 
Group 2 given 1 %  sodium chloride solution (n = 5) and closed circles rats of Group 1 taking a 
normal diet (n =  4). There was no significant difference in angiotensin loss at 6 min between the 
two groups (P> 0-45).
Kidney perfusion. In contrast to the findings in the liver, Figs. 2 and 3 show considerable 
changes in the rates of inactivation of angiotensin by the kidneys of salt loaded or salt depleted 
animals compared with controls. The amount of peptide destroyed at 6 min was reduced by 
almost 50% in those animals which had drunk 1% saline and even more in those given 2% 
saline (Fig. 2). Renal inactivation of angiotensin by salt depleted animals (Group 7) was 
significantly more than that by animals from Group 8, whose diet was identical apart from 
sodium intake (Fig. 3).
It is apparent from Figs. 2 and 3 that kidneys of animals taking 0-2 mEq sodium in the- 
Struyvenberg diet (Group 7) inactivated approximately the same amount of angiotensin as 
did those of rats on Spiller’s diet taking 11 mEq sodium per day (Group 2). The potassium 
intake was four times greater in animals taking the Spiller’s diet than those of Groups 7 and 8 
and major differences in the content of other ions including calcium were also present.
Kidney perfusion: effects o f renal artery clip
Unilateral clip: contralateral kidney intact. There was no significant difference between the 
rates of inactivation of angiotensin by kidneys with clipped arteries and kidneys of intact 
animals. The kidneys contralateral to those with the arterial clip, on the other hand, destroyed
considerably less peptide (Fig. 4). There was no detectable relationship between the presence 
or absence of hypertension and change in the capacity of the artery-clipped or contralateral 
kidneys to inactivate angiotensin.
Unilateral clip with contralateral nephrectomy. The effects of uninephrectomy alone were
Fig. 2. Kidney perfusions: effect of salt loading on inactivation of angiotensin. Removal of 
asn‘val5 angiotensin II ng per g wet weight of tissue±SEM. Closed circles represent control 
animals of Group 1 taking a normal diet (n =  10); open circles animals of Group 2 given \°/a 
sodium chloride solution (« =  8); closed triangles animals of Group 3 given 2/  sodium chloride 
solution (« =  5). The 6 min loss of angiotensin was significantly decreased in both the saline 
groups compared with controls (P< 0-0025).
Fig. 3. Kidney perfusions: effect of salt depletion on inactivation of angiotensin. Removal of 
asn'val5 angiotensin II ng per g wet weight of tissue ± S EM. Open circles represent animals of 
Group 8 on a normal salt intake (« =  7); closed circles sodium depleted animals of Group 7 
(«=7). The difference between the two groups was significant after 6 min perfusion (P<0'05).
studied. The remaining hypertrophied kidney destroyed angiotensin at the same rate as did 
organs taken from animals with both kidneys intact. The effects of salt loading were also similar 
in these two groups (Fig. 5). However, if the solitary kidney had had an arterial clip applied 
the situation was different and the clipped organ destroyed much less angiotensin than control
Minutes
F ig . 4. Kidney perfusions: effects of unilateral arterial clip with contralateral kidney intact on 
inactivation of angiotensin. Removal of asn1 val5 angiotensin II ng per g wet weight of tissue ± 
SEM. Closed circles represent control animals of Group 1 with both kidneys intact and taking a 
normal diet (n= 10), open circles experiments in which a kidney with artery clipped was perfused 
(n=5) and closed triangles those experiments in which the contralateral unclipped kidney was 
perfused (n=5). With a clip on one renal artery, the contralateral organs destroyed less angiotensin 
at 6 min than normal control kidneys (P< 0 0005) or than the organs with clipped arteries 
(jP < 0-05). There was no difference between kidneys with arterial clip and normal control organs 
(P>0-2).
F ig. 5. Kidney perfusions: effects of uninephrectomy and salt loading on inactivation of angio­
tensin. Removal of asn‘val5 angiotensin II ng per g wet weight of tissue + SEM. Closed circles 
represent a control group on a normal diet with kidneys intact («= 10), open circles uninephrec- 
tomized animals on the same diet (n= 5). Animals given 1 %  sodium chloride solution are rep­
resented by closed triangles (both kidneys intact, n=8) and open triangles (uninephrectomized 
animals, /i=3). Loss of angiotensin at 6 min was significantly reduced by salt loading in both 
groups (.P<0-0025). Loss was not significantly different during perfusion of kidneys from the 
intact animals and from the uninephrectomy group, regardless of sodium intake.
kidneys or than kidneys similarly clipped with the contralateral kidney intact (Fig. 6). In the 
absence of the contralateral kidney the capacity o f the clipped organ to destroy angiotensin 
could not be reduced further by increasing dietary salt intake.
Fig . 6. Kidney perfusions: effects of unilateral nephrectomy and of arterial clip and salt loading 
on inactivation of angiotensin. Removal of asn'val5 angiotensin II ng per g wet weight of tissue ± 
SEM. Closed circles represent animals with unilateral nephrectomy alone (n=5), closed triangles 
animals with uninephrectomy, a Goldblatt clip and systolic BP 150 m m H g  («= 5). Open circles 
represent uninephrectomized animals given l°/0 sodium chloride solution (n=3). Loss of angioten­
sin was reduced at 6 min in the presence of a Goldblatt clip (P<0-0025) or after salt loading 
(P< 0-0025).
Liver perfusion: effects o f renal artery clip
The isolated rat liver inactivated angiotensin II amide at rates unaltered by renal artery 
constriction (P>0-05). The perfused livers of rats with renal artery constriction and uni­
nephrectomy removed 223-0-313-5 ng angiotensin in 6 min, mean 254-4 ng, SEM 29-6. The 
livers of rats with unilateral renal artery constriction and an intact contralateral kidney 
inactivated from 329-6-437-1 ng in 6 min (mean 380-9±31-1). In control animals the range 
was 230-4-558-0 ng (mean 376-57+8-4).
D IS C U S S IO N
Perfusion of the isolated rat liver and kidney is a reproducible method o f studying the rate of 
disappearance of angiotensin passing through these organs (Leary & Ledingham, 1969). The 
liver inactivates the peptide at rates which are not altered by sodium loading or depletion. In 
contrast the changes in capacity o f the isolated kidney to inactivate angiotensin with altered 
sodium intake are great. Angiotensin destruction varied inversely with salt-intake in rats given 
the Spiller’s diet (Groups 1-6) and in rats taking the Struyvenberg diet (Groups 7 and 8). 
Kidneys from animals on the Struyvenberg diet containing 0-2 mEq sodium per day (Group 
c
7) inactivated less angiotensin in 6 min than those o f animals on the Spiller’s diet of 1 mEq 
sodium per day (Group 1). In addition the kidneys of animals taking 5 mEq sodium in the 
Struyvenberg diet (Group 8) destroyed angiotensin at rates similar to animals on the Spiller’s 
diet taking 30 mEq sodium daily (Group 3). These inconsistencies deserve comment. Major 
differences in constituents of the two diets other than sodium may be important. Eggleston & 
Krebs (1969) have shown that 3-5 fold differences in the activities of pyruvate-kinase and 
a-glycerophosphate dehydrogenase can be induced in the livers of rats of various strains by 
alterations in diet. Enzymes destroying angiotensin may also be responsive to changes in intake 
of many dietary constituents other than sodium, and direct comparisons o f angiotensinase 
activity between rats of Groups 1-6 (Spiller’s diet) and 7 and 8 (Struyvenberg diet) cannot 
properly be made.
In rats with one renal artery constricted and the other intact, considerably less peptide was 
removed by the intact kidney than by the ischaemic kidney, while ischaemic kidneys inactivated 
angiotensin at about the same rate as controls. In rats with one kidney removed and the remain­
ing renal artery constricted by a silver clip the ischaemic kidney removed less peptide from 
perfusate than its controls and inactivation was not further reduced when these animals had 
been given saline to drink.
Bing (1962) showed that in the rat the capacity o f kidney extracts to destroy asn1val5angio- 
tensin II was reduced when DOCA-salt or renovascular hypertension had been established. 
Blaquier et al. (1961) using similar methods and investigating the same peptide, were unable 
to demonstrate any difference in angiotensinase activity between normal rat kidneys and those 
taken from animals rendered hypertensive by arterial clip. Our findings do not support those 
of Blaquier’s group, but extend and largely confirm those of Bing.
The question arises as to whether the changes observed are o f physiological or pathological 
significance or whether they are artefacts. Our studies were performed on organs taken from 
single strains of one species: high concentrations of angiotensin had to be used to achieve 
reliable bioassay results; the perfusing medium did not contain plasma or red cells, and the 
use of an anaesthetic could not be avoided. All these points must be taken into account in 
assessing the possible significance of the results. However, the difference induced in the 
behaviour of the kidney by the various experimental manoeuvres used were great, consistent 
and statistically highly significant. No such changes were observed in the liver experiments. 
The changes observed in renal inactivation of angiotensin are not limited to the synthetic 
peptide, asnIval5angiotensin. Recent experiments indicate that the amount of naturally 
occurring angiotensin II free acids inactivated during kidney perfusion is significantly reduced 
in rats drinking 1% sodium chloride solution when compared with those given water (Leary,
1969).
The possible mechanisms by which the isolated kidney may inactivate angiotensin at widely 
differing rates depending on experimental circumstances is not clear. Disappearance of the 
peptide during perfusion could result from breakdown of the molecule by enzymes (Bakhle, 
Reynard & Vane, 1969; Leary & Ledingham, 1969) or by attachment to receptor sites in the 
perfused organs (Biron et al., 1968). The observation that inactivation of angiotensin by tissue 
vascular beds can be inhibited by edetic acid or dimercaprol (Leary & Ledingham, 1969; 
Bakhle et al., 1969) favours an enzymatic process, but does not distinguish with certainty 
between these two possibilities.
Alteration of the rate of removal of angiotensin by the kidney could reflect change in the
affinity of enzymes or binding sites for the peptide, or could reflect changes in the distribution 
of blood flow between areas o f the kidney with different inherent capacities to inactivate 
angiotensin. Horster & Thurau (1968) have demonstrated differences in filtration rate between 
superficial and juxtamedullary nephrons of rat kidneys. In rats taking a standard diet con­
taining approximately 1 mEq sodium/day superficial nephrons have a lower individual glomeru­
lar filtration rate than do juxtamedullary nephrons. This difference in individual nephron GFR 
and distribution of renal bloodflow is reversed if sodium intake is increased to 5 mEq/day. If 
renal angiotensinase were located mainly in juxtamedullary nephrons, animals with a normal 
sodium intake would inactivate angiotensin at a faster rate than those of salt-loaded animals, 
in which perfusion of juxtamedullary nephrons would be reduced. This redistribution of renal 
bloodflow could possibly be mediated by the changes in kidney renin content that occur in 
response to renal artery clipping and changes in sodium balance (Gross et al., 1964). This theory 
must remain unproven until the angiotensinase activity o f superficial and juxtamedullary 
nephrons has been measured.
The changes in the capacity of the rat kidney to inactivate angiotensin are of potential 
importance in any assessment of the role of the renin-angiotensin-aldosterone system in states 
of altered electrolyte balance or blood pressure. Decreased removal of angiotensin in the kidney 
would induce increased local tissue concentrations of the peptide with a resultant rise in renal 
vascular resistance. The concentration of angiotensin in the renal venous blood and later in the 
arterial circulation would not necessarily be detectably altered. Reduced kidney blood flow 
with increased vascular resistance, particularly in the efferent arterioles, is a consistent finding 
in all states of high blood pressure (Goldring et al., 1941; Friedman, Selzer & Rosenblum, 
1941; Bradley et al., 1950; Cargill & Hickam, 1949; Bolomey et al., 1949). The possibility 
exists therefore that tissue concentrations of angiotensin in the kidney could be altered critically 
in certain circumstances, with resultant renal vasoconstriction caused by angiotensin, but not 
reflected by alterations in circulating concentrations of renin, angiotensin or aldosterone.
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There is a growing body of evidence suggesting 
that angiotensin I is converted into angiotensin II 
during passage through the pulmonary circulation. 
The major finding in support of this hypothesis is 
that the venous effluent of lungs perfused with 
angiotensin I has a greater capacity to contract the 
rat colon and raise systemic arterial blood pressure 
than can be explained by the concentration of 
angiotensin I entering the pulmonary artery (Ng &  
Vane, 1967,1968o,6; Biron &  Huggins, 1968). These 
results are obtained by using lungs perfused -with 
blood or Krebs-Henseleit solution (Krebs &  
Henseleit, 1932), indicating that the postulated 
conversion cannot be entirely accounted for by 
enzymes in blood. Bakhle, Reynard &  Vane (1969) 
have also shown that the enhanced biological effects 
are not due to release of endogenous catecholamines 
or prostaglandins B 2 or F 2a.
The change in biological activity of angiotensin I 
after passage through the lung could be due to 
conversion of the decapeptide into angiotensin II 
by tissue enzymes. However, this possibility is not 
proved by the bioassay of unfractionated perfusate. 
The biological assay preparations that have been 
used are highly selective in terms of known c o m ­
pounds, but previous studies have not ruled out the 
possibility that angiotensin I acts on the lung to 
stimulate the release of an unknown compound 
capable of contracting the rat colon and raising 
arterial blood pressure. The possibility also exists 
that metabolic products of angiotensin I potentiate 
the effects of the parent compound, perhaps as the 
C-terminal pentapeptide of bradykinin potentiates 
the effects of bradykinin on the guinea-pig ileum 
(Garbe, 1967).
Conversion of angiotensin I into angiotensin II 
in the pulmonary circulation could be of major 
physiological importance and therefore an attempt 
has been m ade in this study to obtain biochemical 
evidence of any such conversion.
Perfusion studies were performed by using female 
Spraque-Dawley rats, weighing 0.2-0.4kg, fed on a 
standard small-animal diet (Purina Laboratory 
Chow) and given unrestricted access to water. 
Three rats were given tap water and three were 
given tap water containing 2 %  (w/v) NaCl. The
latter three rats received the salt water for 10-12 
days before use. All rats were anaesthetized b y  an 
intraperitoneal injection of chloral hydrate (300 
mg/kg body wt.). Lungs were perfused in  situ as 
described by Leary &  Ledingham (1969) by a 
method developed by F. W o o d s  &  W .  P. Leary 
(unpublished work).
All glassware except the chromatography column 
was coated with silicone (Siliclad, Clay-Adams;Inc., 
N e w  York, N.Y., U.S.A.). Krebs-Henseleit solu­
tion, aerated with 0 2+ C 0 2 (95:5) and heated at 
37°C, was pumped through the lungs at a rate of 
5-6ml/min until the venous effluent was free of 
blood (2-3min). Then (10-L-(14C]leucine)-angio­
tensin I (25 p,Ci//xmol, lot no. 6901; Schwarz Bio- 
Research Inc., Orangeburg, N.Y., U.S.A.) was 
added to the Krebs-Henseleit solution to a concen­
tration of 700/xg (about 0.5nmol)/ml and the per­
fusion rate was maintained at 6ml/min. Venous 
effluent from the perfused lung was collected 
over the next 3min into an Erlenmeyer flask con­
taining 20ml of cold 1 0 %  (w/v) trichloroacetic 
acid stirred constantly with a magnetic stirring 
device.
This perfusate was centrifuged at 1690g for 10 
min at 4°C to remove a small (0.2ml) brown pre­
cipitate. The supernatant was extracted five times 
with 2 vol. of diethyl ether. The aqueous layer was 
evaporated to dryness in a rotary evaporator. Its 
residue was dissolved in 1.1ml of lM-pyridine, and 
1.0 ml of the solution was chromatographed on a 
Bio-Gel P-2 column (98cm x 1.2cm). The column 
was eluted with lM-pyridine, and 50-100 2ml 
fractions were collected. The column was calibrated 
previously to determine elution volumes of angio­
tensin I. angiotensin II, histidyl-leucine and 
leucine (Fig. la).
A  20 pi sample of each fraction was applied to 
pieces (1 c m  x 1 cm) of filter paper (Whatman no. 1) 
to detect radioactivity. The papers were dried and 
then placed in scintillation vials containing 18 ml 
of an 0.4%(w/v) solution of Omnifluor (New England 
Nuclear Corp., Boston, Mass., U.S.A.) in toluene. 
The radioactivities of vials were counted in a 
Unilux II liquid-scintillation counter (Nuclear- 
Chicago).
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Fig. 1. (a) Molecular-sieve chromatography of angiotensin 
I and selected lower homologues. Angiotensin I and some 
of its homologues were chromatographed on a column 
(98cmx 1.2cm) of Bio-Gel P-2. Fractions (2ml) were 
collected. Fractions containing (10-L-[14C]leucine)-angio- 
tensin I and (5-L-[14C]isoleucine)-angiotensin II (45^ tCi/ 
/zmol; Schwarz BioResearch Inc.) were located by 
scintillation counting. Histidyl-leucine and leucine were 
located with ninhydrin (E570). O, Angiotensin I; 
• . angiotensin II; A, histidyl-leucine; A, leucine. 
(6) Molecular-sieve chromatography of the effluent of 
lungs perfused with (10-L-[14C]leucine)-angiotensin I. 
The effluent was treated with trichloroacetic acid and 
extracted as described in the text. The extract was 
chromatographed on a column (98 cm x 1.2 cm) of Bio-Gel 
P-2 and fractions were collected as described above. 
Samples were tested for radioactivity and for ability to 
contract the rat colon and raise arterial blood pressure. 
O, Radioactivity; □, blood pressure; •, ability to contract 
rat colon.
In four experiments the fractions were recom­
bined to correspond to peaks of radioactivity. 
In two experiments fractions were freeze-dried 
individually. Each residue was dissolved in 2 ml of
water and tested for effects on the rat colon (Regoli 
&  Vane, 1964) and on the arterial blood pressure of 
the rat (Peart et al. 1966).
Further analysis of radioactive peaks was carried 
out by paper electrophoresis at p H  1.9 (formic 
acid-acetic acid-water, 6:13:81, by vol.), p H 5  
(O.lM-acetic acid adjusted to p H  5 with pyridine) 
or p H  9 [ 1 %  (w/v) ( N H 4)2C 0 3]. W h a t m a n  no. 1 
paper was used for analytical runs and W h a t m a n  
3 M M  paper was used for preparative electrophoresis. 
With any of these systems electrophoresis was 
carried out at 22V/cm, 10-20mA, for Ih.
In all experiments the activity of the solution 
entering the lungs was compared with that of the 
venous effluent in terms of ability to raise mean 
arterial blood pressure. In none of these experiments 
was there a clear increase or decrease of activity. 
In contrast, the ability of the venous effluent to 
contract the rat colon was 2-5 times greater than 
could be accounted for by angiotensin I. O n  average, 
the rat colon was 15 times as sensitive to angio­
tensin II as to angiotensin I.
In the two experiments in which column fractions 
were assayed individually, as m u c h  as half of the 
pressor activity and well over half of the colon­
contracting activity was found to be eluted m u c h  
later than expected for angiotensin I or angiotensin 
II (Fig. 16). The identity of the substance(s) of the 
second peak is not known. Control experiments 
were performed to rule out the possibility that the 
second peak of biological activity is a substance 
leached from the tubing of the perfusion circuit. 
Chromatography of the perfusate obtained by 
pumping angiotensin I through tubing but not 
through lungs showed a single peak of activity 
corresponding in elution to angiotensin I. Under 
the conditions of our chromatography an impurity 
of the column matrix would not be expected to 
be eluted as a peak.
The substance of the first biologically active peak 
was identified as angiotensin II. Its elution volume 
corresponded to that of authentic angiotensin II, 
being slightly less than that of angiotensin I. 
Fractions corresponding to the first peak of activity 
were combined and freeze-dried. The residue was 
dissolved in 0.5 ml of pyridine—acetic acid buffer, 
p H  5. The entire sample was applied to a strip of 
W h a t m a n  3 M M  paper and electrophoresis was 
carried out at p H  5, 22V/em, 10-20 m A ,  for lh. 
Arginine and picric acid were included in the run 
as reference compounds. Radioactivity was located 
by strip counting (ActigraphHI; Nuclear-Chicago). 
Then the paper was cut at 1.0 c m  intervals from the 
origin towards the cathode. Each piece of paper 
was eluted with 2.0ml of Tyrode’s solution, and the 
eluates were tested for effects on the rat colon and 
arterial blood pressure. Biological activity was 
found as a single peak (UArg 0.18-0.27) correspond­
ing to the migration of authentic angiotensin H  
(I?Arg 0.24). This area of the eleetrophoretogram 
was devoid of radioactivity.
The electrophoretogram contained two peaks of 
radioactivity, a small one (60c.p.m; background 
6c.p.m.) corresponding in migration (UArg 0.47) to 
angiotensin I, and a larger peak (700c.p.m.), which 
migrated m u c h  faster (f?Arg 0.69). The second peak, 
judged from its early elution from the Bio-Gel P-2 
column and its rapid migration, is probably a large 
(7-terminal fragment of angiotensin I.
As shown in Fig. 1(6), over half of the radioactivity 
applied to the column was eluted in fractions 
expected for peptides of two to five amino acid 
residues. None of the radioactivity was accounted 
for as free leucine. This point rules out the possi­
bility that angiotensin I is converted into angio­
tensin II by the stepwise removal of leucine and 
then histidine (Ng & Vane, 1967).
Subsequent analysis showed that virtually all of 
the radioactivity in fractions 28-40 was incorporated 
into histidyl-leucine. Fractions 28-32 and 33-40 
were freeze-dried and analysed by electrophoresis 
at p H  5 and p H  9. Samples were run with or without 
the addition of carrier histidyl-leucine. Carrier was 
located after reaction with ninhydrin. At either 
p H  value radioactivity of fractions 28-32 and 33-40 
was not distinguishable from that of authentic 
histidyl-leucine (pH 5, H Arg 0.71; p H  9, /?picrIc add 
0.53).
Our results show that angiotensin I is converted 
into angiotensin II during a single circulation 
through rat lung washed free of blood. Conversion 
occurs by removal of the C-terminal dipeptide, 
histidyl-leucine, and not by the stepwise action of 
a carboxypeptidase. M u c h  of the radioactivity 
associated with the large-molecular-size (mol.wt. 
about 900) material can be accounted for as a 
large (7-terminal homologue of angiotensin I. This 
suggests that the converting enzyme of lung 
competes with an aminopeptidase. Angiotensin II
is not the only biologically active substance found 
in the venous effluent of lungs perfused with angio­
tensin I. There is a second substance, separable by 
chromatography on Bio-Gel P-2, that contracts 
the rat colon and raises arterial blood pressure. 
The relatively late elution of the second substance 
suggests that it either is of small molecular size 
or is adsorbed by the Bio-Gel matrix. Whether the 
second substance is an endogenous compound in 
lung or a lower homologue of angiotensin I is not 
known. The (7-terminal heptapeptide of angiotensin 
II is known to have biological activity. However, 
this peptide would not be expected to separate from 
angiotensin I or angiotensin II dining chromato­
graphy on Bio-Gel P-2. It remains to be determined 
whether smaller homologues are capable of con­
tracting the rat colon and raising arterial blood 
pressure.
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Enzymes that convert angiotensin I and angiotensin II or inactivate both 
peptides have been found in extracts of animal and human tissues (l-U). The 
role of these enzymes in living animals is uncertain, since non-specific pep—  
tidases capable of degrading angiotensin may be released by cells damaged in 
the preparation of tissue extracts. Hodge, Ng and Vane (5) and other workers 
(6-7 ) have recognised this problem and advocated the use of intact perfused 
organs in the study of angiotensin metabolism.
A simple method for perfusing the rat lung in situ, with minimal damage 
to parenchymal cells, is described in this paper. This technique was used to 
study the conversion of (10-L-leucine-^C)- angiotensin I (25 u ^*/u mole, lot. 
No. 69OI; Schwarz Bioresearch, Inc., Orangeburg, N.Y., U.S.A.) to angiotensin 
II by the rat lung (8).
Methods
Six female Wistar rats were anaesthetised with sodium pentobarbitone (Vet­
erinary Nembutal, Abbott), 60mg/kg, intraperitoneal and fixed to a perspex 
dissection platform placed above a collecting vessel. The lung was prepared 
for perfusion by a modified technique based on that of Woods and Leary (9).
The sternum was exposed and skin flaps reflected to expose the rib-cage. The 
chest was opened and the anterior chest wall removed en-bloc to the mid-axillary 
line bilaterally. Polyethylene bags of crushed ice were applied to the lungs 
and heart. The inferior vena-cava was tied below its junction with the right 
atrium. A nylon cannula (size FP270, Portland Plastics Ltd., Hythe) was intro-
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duced into the cavity of the right ventricle through the right precaval vessel 
and secured by a ligature tied around the right atrioventricular groove. An 
identical cannula was placed in the left ventricle through the ascending aorta 
and tied in place at the level of the coronary vessels. The left border of the 
heart was displaced anterolaterally so that the left precaval and azygos veins 
could be mobilised and tied.
Perfusion medium, prepared as previously described (7), was passed into 
the right heart cannula at 6 ml/min by a pressure dependent finger pump (Pro­
cess and Instruments, Brooklyn, U.S.A.). The first 10 ml of perfusate was dis­
carded after passage through the lung to avoid contamination of medium in the 
collecting vessel with plasma or erythrocyte peptidases. Lungs were aerated by 
a mixture of O2 and COg (95:5) bubbled through the perfusion medium. In some 
experiments lungs were ventilated with a Starling pump which delivered air 
through a tracheostomy tube at 30 ml/min. Perfusion medium was kept at 37°C 
and pH 7.*+ (9 ), and lungs were perfused with (lO-L-leucine-ll+C) angiotensin I 
at a concentration in the perfusate of 700 mg/ml for 10 min before fixation for 
electron microscopy. Venous effluent from the perfused lung was collected into 
an Erlenmeyer flask containing 20 ml of cold trichloroacetic acid 10 g$ w/v, 
stirred constantly with a magnetic device. Analytical methods for peptide 
fragments and angiotensins I and II in the effluent perfusate are described 
elsewhere (8).
To determine what damage, if any, the lungs suffered from the perfusion, 
specimens were examined by electron microscopy after a full 10 min period of 
perfusion. Tissue was fixed by perfusion with 0.25 M  glutaraldehyde in 0.5 M 
cacddylate buffer at pH 7.*+ and containing 0.17 M  sucrose. After 3 min perfu­
sion at 37°C both lungs were removed and cut into small cubes approximately 0.2 
mm of side and transferred to fresh fixative. To ensure rapid penetration of 
the fixative a light vacuum was applied via a water aspirator until the speci­
mens sank to the bottom of the vial. After fixation overnight the tissue pieces 
were washed in several changes of 0.05 M cacodylate buffer containing 0.3*+ M
sucrose and placed in 1^ osmium tetroxide in veronal acetate buffer (10) at pH
7.U for 90 min at 1+°C. Dehydration was carried out in an ethanol series and 
the tissue was imbedded in Araldite (A.R.L. Ciba, Duxford, England) via propy­
lene oxide. Sections were cut on an L.K.B. Ultrotome III, mounted on copper 
grids, double stained using lead citrate and saturated ethanolic uranyl acetate 
and examined in a Philips EM 100 or EM 200 electron microscope.
Results
Clear evidence was obtained that the isolated rat lung preparation remain­
ed enzymatically competent and has been published elsewhere (8). Angiotensin 
I weis converted to angiotensin II during a single passage through the lung 
washed free of blood. Analysis of peptide fragments indicated conversion by 
removal of the C-terminsil dipeptide His-leu.
Large areas of lung were scanned in the electron microscope. Fig. 1 is a 
representative field showing that the general arrangement and relationships be­
tween the component cell types within the lung are preserved. The vessels are 
conspiciously free of blood cells and plasma. Fig. 2 illustrates that the 
pinocytotic vesicles of the endothelial cells retain their circular profiles 
and that the intercellular junctions between capillary cells retain their integ­
rity. There is no evidence of stretching or excessive pressure in the vessels. 
Apeirt from the absence of blood Figs. 1 and 2 illustrate those features which 
are presumed to obtain in the living tissue and provide good evidence that the 
fine structure of the lung has been preserved during perfusion.
Discussion
It is widely recognised that adequate fixation of mammalian tissue for 
electron microscopy cannot be achieved by simple diffusion and requires per­
fusion techniques that satisfy certain biochemical, pharmacological and physio­
logical criteria of preservation, lung tissues examined in the electron micro­
scope may show inadequate clearance of blood cells and plasma and considerable 
mechanical damage as a result of over-dilatation of vessels (12). This damage 
may be manifested by broken cell membranes, stretched intercellular junctions,
PIG 1.
Electron micrograph showing the relationship between capillaries (C) and alveo­
lar space (A). An endothelial nucleus (N), septal cell (S) and giant alveolar 
cell (Al), containing lamellar bodies (*) and mitochondria (M) are also shown. 
Note absence of blood cells within lumina of blood vessels.
Micrograph showing portions of the endothelium lining the capillary lumen (C), 
basement membrane (BM), and epithelium bordering on the alveolar space (A). 
Intercellular junctions between the endothelial cells are shown by arrows.
Except in areas where the endothelium is extremely narrow, the circular profiles 
of pinocytotic vesicles feature prominently.
extruded cytoplasmic contents and swollen mitochondria. These changes were not 
found after perfusion of the lungs by the method described in this paper.
The technique described appears to provide a useful means of distinguish­
ing physiological changes in peptide metabolism within the lung from changes 
due to cell disruption such as that which occurs in the preparation of tissue 
extracts. It may be used in conjunction with established techniques for per­
fusing the liver and kidney (5, 6, 7, 9).
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Catabolism of Angiotensin II
It has long been evident that there are substances in blood and tissues which 
are capable of destroying angiotensin. The effects of temperature, pH changes 
and dialysis on angiotensin survival in renin assay systems indicated that en­
zymes were probably involved (Braun-Menendez and Fasciolo, 1939: Page 
and Helmer, 1940). The generic term “angiotensinase” is used to describe these 
enzymes, although their specificity is unproven.
The study of angiotensinases in tissue homogenates, lysed red cells, plasma 
and serum in vitro has provided good data about the biological pathways by which 
angiotensin may be destroyed. This approach probably has no value in the evalua­
tion of the contribution of specific organs or tissues to the metabolism of angio­
tensin in health and disease. The presence of these enzymes in blood and in tissue 
extracts of kidney, liver, lung, uterus, intestinal mucosa, adrenal, pancreas, spleen, 
brain, skeletal and cardiac muscle (Fasciolo et ah, 1940; Itskovitz and Miller, 
1967; Matsunaga et al., 1969) does not imply that they are in any way specific 
for angiotensin or necessarily play any part in the metabolism of Ang. II in 
vivo. For instance homogenates of lung contain angiotensinases in amounts 
comparable to those in other organs (Itskovitz and Miller, 1967; Matsunaga 
et ah, 1969) but studies of intact lungs indicate that this peptide is not detectably 
metabolized in the pulmonary circulation in man or other animals (Hodge et ah, 
1967; Leary and Ledingham, 1969; Biron et ah, 1969; Biron and Campeau, 
1971; Osborn et ah, 1969).
Nature of Angiotensinases
Yeast aminopeptidase, pepsin, trypsin, chymotrypsin, carboxypeptidases and 
papain have been shown to destroy angiotensin by Croxatto and Croxatto (1942), 
Croxatto et ah (1943), and Plentl and Page (1943). The availability of synthetic 
angiotensin in 1958 led to further studies into the nature and source of angio­
tensinases in plasma, serum, red cells and tissue slices or homogenates. Enzymes 
capable of hydrolyzing the N-terminal bond (aminopeptidases), the middle of the 
peptide (endopeptidases) and the C-terminal bond (carboxypeptidases) of Ang. II 
have been described (Table 1).
Aminopeptidases (Angiotensinase “A ”) .  Glenner et ah (1962) found an enzyme 
specific for N terminal a-L-glutamyl and a-L-aspartyl residues in rat kidney 
microsomes. Khairallah et ah (1963) later described a peptidase of very similar 
properties, in human plasma and lysed washed red cells. Both enzymes were 
calcium-dependent, pH optima were similar and neither would destroy fl-Asp1- 
Ang. II. These enzymes, which had much in common, were named Aminopeptidase 
A by Glenner et ah and Angiotensinase A by Khairallah et ah (1963). Nagatsu
et al. [1965 (1 and 2) and 1970] then produced evidence that separate amino- 
peptidases were responsible for hydrolyzing the Asn1 and Asp1 analogues of Ang. II. 
Khairallah and Page (1967) suggested the enzyme active at pH 7.4, which hydroly­
zed the Asn1 peptide, be called Angiotensinase Aj and the peptidase specific to [Asp1]- 
Ang. II Angiotensinase A2. Matsunaga et al. (1969) have found similar neutral
Table 1. Identified angiotensinases
Angiotensinase Authors p H  Inhibitors Source Site of
Opti- Action
m u m
Aminopeptidase A Glenner e t al., 
1962
7.0
Angiotensinase Aj K hairallah and 
P age, 1967
7.4
Aminopeptidase Nagatsit  et al., 
1965,1970
Angiotensinase A2 
Aminopeptidase
Nagatsu et al.,1965 7.4 
K hairallah and 
P age, 1967;
Nagatsu et al., 1970
Microsomal
Aminopeptidase
Matsunaga and 
Masson, 1970
7.4
7.4
Angiotensinase B  
(Endopeptidase)
R egoli e tal., 1963; 
K hairallah and 
P age, 1967
7.4
Lysosomal
Endopeptidase
Matsunaga, 1971 5.5
Carboxypeptidase J ohnson and 
R yan, 1968
7.4
Angiotensinase C 
Carboxypeptidase
Yang et al., 1968 5.6 to
5.7
Lysosomal
Carboxypeptidase
Matsunaga, 1971 5.5
E D T A Kidney
Microsomes
Asp1-Arg2
Sodium H u m a n  plasma 
pyrophosphate 
E D T A  H u m a n  serum 
H u m a n  red cells 
Kidney extracts
Asn1-Arg2
E D T A H u m a n  serum 
Red cell and 
kidney extracts
Asp1-Arg2
E D T A Kidney 
Microsomes 
(SH group 
independent)
Asn1-Arg2
E D T A  and Liver microsomes [ 
Thiol reagent (SH group !
dependent) l
Asp1-Arg2
Asn1-Arg2
v
E D T A
Rat serum 
H u m a n  plasma 
Rat kidney
Tyr*-Val5
S H  group 
dependent
Kidney and liver 
lysosomes
Tyr‘-Val5
N.E.M. E D T A  dialyzed 
Rabbit-liver extract
Pro7-Phe8
D.F.P. Hog kidney 
H u m a n  urine
Pro7-Phe8
D.P.P. Kidney and liver 
lysosomes
Pro7-Phe8
amino-peptidases in the microsomal fragments of many organs, most concentrated 
in kidney and liver (Table 2). Liver cell sap aminopeptidase may be dependent on 
sulphhydryl (SH) groups in contrast to the renal microsomal enzyme.
Endo'peptidases (Angiotensinase “B ”). The effects of rat serum, human plasma 
and rat kidney homogenate on six analogues of Ang. II were observed by Regoli 
et al. (1963). Analogues stable to aminopeptidases were destroyed by all three 
media, and chromatography of the peptide fragments showed individual amino 
acids and the tetrapeptide Asp1-Arg2-Val3-Tyr4. The C-terminal tetrapeptide was
not found intact, but the evidence was taken to suggest the presence of an endo- 
peptidase, hydrolyzing the tyrosine-valine linkage. A similar plasma endo- 
peptidase, active at pH 7.4 and inhibited by diisopropyl-fluorophosphate (D.F.P.) 
was described by Khairallah and Page (1967) and labelled Angiotensinase B. 
Matsttnaga (1971) has recently shown chymotrypsin-like activity in the presence 
of dithiothreitol (D.T.T.) and inhibited by D.F.P. in the lysosomal fraction of rat 
kidney and liver. This SH group-dependent lysosomal enzyme may be identical 
to that described by Regoli et al. (1963) but differs from the Angiotensinase B 
of Khairallah and Page in that it is not inhibited by D.F.P.
Carboxypeptidase.s (Angiotensinase “G”). Pancreatic Carboxypeptidase A was 
shown to release phenylalanine from Ang. II by Lentz et al. (1956) and Johnson 
and Ryan (1968) have found evidence of carboxypeptidase activity in aqueous 
extracts of rabbit liver. Another enzyme with the capacity to hydrolyze the
Table 2. Neutral aminopeptidases in extracts of various tissues 
(Adapted from Matsunaga  et al., 1969)
Tissue Activity per 
10 ng of tissue
Protein
m g
Kidney 343 0.55
Liver 309 0.76
Spleen 175 0.70
Adrenal — 0.35
Lung 137 0.30
Heart 28 0.24
Brain 35 0.16
Muscle 17 0.17
» Activity is expressed in nanograms of angiotensin 
inactivated by 0.46 ng of protein at 37 °C for 15 min.
terminal peptide bond when proline is the penultimate amino-acid has recently 
been described by Yang et al. (1968). This enzyme, isolated from porcine kidney 
cortex or human urine has been called Angiotensinase C. It can be distinguished 
from Carboxypeptidase A, Cathepsins and other known enzymes; it is inhibited 
by D.F.P., though not by chelating agents, and has a pH optimum of 5.6 to 5.7.
Matsunaga and his colleagues (Saito et al., 1969; Matsgnaga et al., 1969;” 
Matsttnaga, 1971) have shown interest in the angiotensinases found in the lyso­
somal fraction of various tissues, particularly kidney. The evidence now suggests 
that the main enzyme of this fraction is a carboxypeptidase, inhibited by D.F.P., 
active at acid pH, and independent of SH groups.
Angiotensinases in Plasma, Serum, and Blood
Peptidases in plasma, serum or whole blood have been the subject of intensive 
investigation. In-vitro methods have suggested the presence of both amino­
peptidases and endopeptidases in plasma and serum [Regoli et al., 1963; Khai­
rallah and Page, 1967; Pickens et al., 1965; Nagatsh et al., 1965 (1 and 2),
1970]. Studies of the metabolism of (3SS) Phenyl thiocarbamyl-Ang. II in human 
plasma confirm the presence of both types of enzymes, but suggest a dominant 
role for amino peptidases (Doyle et al., 1967). Degradation of Ang. II  in blood,
once thought all-important, is now known to be a slow process of minor significance 
compared with the rapid catabolism of the peptide in tissue vascular beds (Hodge 
et al., 1967; No and Vane, 1968; Bakhle et al., 1969).
Kidney Angiotensinases
Tissue Extracts. Renal angiotensinases have been measured in homogenates of 
dog, rat and rabbit kidney by Fasciolo et al. (1940), Regoli et al. (1963), Lee 
(1965), Itskovitz and Miller (1967) and J ohnson (1967). Yang et al. (1968) 
reported the presence of a carboxypeptidase in extracts of hog kidney cortex while 
other workers have fractionated kidney homogenates and demonstrated that most 
angiotensinase is present in microsomal and lysosomal fractions (Dengler and 
Reichel, 1960; Glenner et al., 1962; Matsunaga et al., 1968). The nature of 
these peptidases has been investigated by incubation of [AsnLVaFJ-Ang. II or its 
analogues with kidney homogenates under standard conditions with subsequent 
bioassay of residual pressor activity. In some experiments, peptide fragments have
Table 3.
Species Fraction Angiotensinase identified Authors
R at Microsomes Aminopeptidase Glenner e t al. (1962)
R at Homogenate Aminopeptidase and Endopeptidase R egoli e t al. (1963)
Pig Cortex Carboxypeptidase Yang e t al. (1968)
R at Lysosomal Endopeptidase Saito e t al. (1969)
R at Lysosomal Endopeptidase and Carboxypeptidase Matsunaga (1971)
R at Microsomal Aminopeptidase Matsunaga and Masson (1970)
been identified by chromatography (Regoli et al., 1963; Saito et al., 1969; 
Matsunaga et al., 1969; Matsunaga, 1971).
Data collected from these studies is presented in Table 3.
Intact Organ Experiments. The probability that nonspecific intracellular 
enzymes with limited access to perfusing blood are released in the preparation of 
tissue homogenates has stimulated the development of other techniques for the 
measurement of angiotensinases in the kidney.
Hodge et al. (1967) used the superfusion technique of Regoli and Vane (1966) 
to study angiotensin metabolism in anaesthetized dogs. Blood drawn from the 
renal vein superfused a series of assay organs before returning to the dog’s circula­
tion. Ang. II was infused into the renal artery or directly into blood perfusing the 
assay organs. Comparison of the assay responses to peptide infused by these two 
routes allowed the calculation of angiotensin loss during passage through the intact 
kidney. Biron et al. (1968) studied renal angiotensinase activity in the anaesthe­
tized rat and dog, using the animals own blood pressure response to assay the 
peptide. Angiotensin analogues were infused into the renal vein at a rate producing 
a stable elevation of 20 to 25 mmHg in arterial pressure. The same analogue was 
then infused into the renal artery at gradually increasing rates to produce the same 
diastolic B.P. response. Both H odge et al. (1967) and Biron et al. (1968) were 
able to show significant inactivation of angiotensin in the intact kidney, but did 
not prove that this was due to angiotensinases. In a similar study, Osborn et al. 
(1969) found renal inactivation of [Asn1-Val6]-Ang. II and (35S) Phenylthio- 
carbamyl-Ang. II in the sheep and dog. These findings were confirmed in the rat
by Leary (1970) who measured pressor responses to [Asp1-Heu5]-Ang. II infused 
into the renal artery, jugular vein and inferior vena —  cava in the same animal.
The technique of isolated organ perfusion has been applied to the study of 
renal angiotensinases in several species by Bakhle et al. (1969) and Leaby and 
Ledingham (1969). Bakhle et al. (1969) studied Ang. II  metabolism in isolated 
kidneys perfused with Krebs’ solution to distinguish angiotensinase activity in the 
renal vascular bed from activation of plasma or erythrocyte peptidases during pas­
sage through the organ. Isolated kidneys from cats and dogs were perfused through 
the directly cannulated renal artery. Renal veins were cut to allow perfusate to 
escape from the organ. In rats both kidneys were perfused by tying a cannula into 
the aorta below the origin of the renal arteries. The aorta was tied above the renal 
arteries and kidneys and aorta then excised. The excised preparation was suspended 
in a perspex chamber and perfused with Krebs’ solution gassed with 95% 0 2 and 
5% C02 at 37 °C. Angiotensin inactivation was measured by comparing the 
responses of rat colon to [Asn^Val-j-Ang. II infused proximal or distal to the 
perfused kidney.
Leaby and Ledingham (1969) perfused isolated rat kidney by the methods of 
Nishutsutsitje-Uwo et al. (1967) with certain modifications [Leary, 1970;Leary 
and Ledingham, 1970 (1)]. Rat kidney was isolated from the general circulation 
by ligation of appropriate vessels and perfused in situ for periods of not less than 
6 min with an oxygenated artificial medium at pH 7.4 and 37 °C. The time course 
of Ang. H  destruction by perfusate alone and by the isolated kidney was determined 
by a rat bioassay technique (Peart, 1955; Lee , 1965). Bakhle et al. and Leary 
and Ledingham both reported inactivation of [Asn1-Val5]-Ang. II in the isolated 
perfused rat kidney and their results have been confirmed by Biron and Campeatj
(1971). B akhle et al. (1969) also described inactivation of the peptide by cat and 
dog kidneys and Leaby and Ledingham (1969) found that angiotensin loss in 
their preparation was partially inhibited by edetic acid 3 x 10 3M. Later it was 
demonstrated that «-[Asp1-Val5]-Ang. II and a- [Asp1-Ileu5]-Ang. II  were inactiv­
ated by isolated rat kidney whereas the /?-Asp1-Val5 analogue was not [Leaby and 
Ledingham, 1970 (2)]. Osborne et ai. (1970) have also perfused isolated rat 
kidneys by the method of N ishhtshtsuji-Uwo et al. (1967) using [Asp1-H3-Tyr4- 
Val-]-Ang. II as substrate and the superfusion technique of Regoli and Vane 
(1966) to assay biological activity of the peptide. Identification of radioactive 
compounds in the effluent perfusate was achieved by Sephadex filtration, immuno- 
absorption, paper chromatography and immunoassay. Disappearance of Ang. II 
during perfusion was found to be due to enzymatic hydrolysis rather than to 
specific or non-specific binding to receptor sites. The presence of 2-8 heptapeptide, 
3-8 hexapeptide and 1-4 tetrapeptide in the perfusate suggests predominant 
aminopeptidase and endopeptidase activity in the isolated perfused kidney.
Indirect evidence for the importance of the kidney in angiotensin inactivation 
has been presented by several workers. Bttmptjs et al. (1964) showed that in rats 
infused with tritiated angiotensin, the radioactivity was concentrated largely in 
kidney, uterus and the adrenals. Botjbgoignie et a. (1969) reported an increased 
sensitivity to infused angiotensin in nephrectomized rats. Using an immunoassay 
technique in the dog Ballie et al. (1971) have found that Ang. H  in the renal vein 
plasma is less than that in arterial plasma, indicating renal extraction of the 
peptide from plasma. Since no evidence was found to indicate significant plasma 
angiotensin entry into renal lymph, it was suggested that hydrolysis of the peptide 
occurred in the kidney.
Conclusions. Inactivation of Ang. II analogues by the kidney has been measured 
in a variety of circumstances. Methods of study include incubation of the peptide
with kidney homogenates or sub-cellular fragments and perfusion of intact organs 
in vivo and in vitro. Inactivation has been expressed in biological terms and, in 
some studies, peptide fragments have been identified by chromatography. This 
evidence, taken in conjunction with the behaviour of kidney peptidases in the 
presence of enzyme inhibitors, suggests that an aminopeptidase and one or more 
other angiotensinases exist in mammalian kidney.
Liver Angiotensinases
Tissue Extracts. In a study comparing angiotensinase activities from various 
tissues in the rat Itskovitz and Miller (1967) found extracts of intestinal mucosa, 
kidney cortex and liver to be the most potent sources. Matsunaga and his 
colleagues, in their investigation of microsomal and lysosomal angiotensinases in 
rat tissues, have found liver extracts second only to kidney in content of acid and 
neutral angiotensinases (Matsunaga et al., 1969). J ohnson and R yan (1968) 
investigated the degradation of [Asn1-Val5]-Ang. II and its lieu5 analogue by 
aqueous extracts of rabbit liver, buffered at pH 7.4. Chromatography after 
incubation showed hydrolysis of all bondsjn each peptide, implying the presence 
of several enzymes. When aminopeptidases were inhibited by dialysis of the 
extract against ethylene-diamine-tetraacetic acid (EDTA), angiotensinase was 
reduced by 60%. The residual peptidase activity was shown to be due to a carboxy 
peptidase, similar to pancreatic Carboxypeptidase A.
Intact Organ Experiments. Following the claim that experimental renal hyper­
tension in dogs can be reversed by anastamoses of the renal and portal veins, 
Methot et al. (1964) in the rat and Chamberlain et al. (1964), in dogs and man, 
performed experiments to show whether or not intact liver was capable of destroy­
ing Ang. II. Both groups compared portal with systemic venous injections of 
[Asn^VaPj-Ang. II, and both found considerable reduction in blood-pressure 
response when the peptide was given via the portal vein. Wernze and F ujn  (1966), 
using the same technique in rats confirmed hepatic inactivation of [Asn1-Val5]- 
Ang. II when injected into the portal vein, but found no difference between the 
pressor effects of the /9-Asp1-Val5-peptide given by femoral or portal vein. Leary 
and Ledingham (1968) also compared pressor responses to injections of angio­
tensin given by portal and jugular veins of rats but used small doses (5 to 15 ng) of 
[Asp1-Ileu6]-Ang. II in contrast to the much larger doses (500 to 1000 ng) of Asn1 
analogue given by both Methot et al. and Wernze and Fujn. No difference was 
found in pressor response to portal and jugular vein injections between 5 ng and 
15 ng; but as the doses of angiotensin were increased from 20 ng to 200 ng there 
was an increasing and significant deficit in the portal vein pressor response. The 
failure to detect loss of angiotensin in the hepatic circulation of the rat when small 
amounts of peptide were injected, may reflect the insensitivity of pressor assay 
used. Biron et al. (1968) report 60 to 70% inactivation of [Asn1-Val5]-Ang. II and 
of its 86 % pure /l-Asn1 analogue in the he'patoportal circulation of both rats and 
dogs.
The in vivo studies so far discussed necessitate the use of very large amounts 
of Ang. II. More physiological doses can be assessed by the superfusion techniques 
of Regoli and Vane (1966). Losses of about 70% were found during infusions 
containing 1 to 5 ng/ml of [Asn^VaFj-Ang. II into the hepatic circulation of dogs 
(Hodge et al., 1967).
The isolated liver perfusion technique of Leary and Ledingham [1969; 
1970 (1)] allows the effects of peptidase inhibitors to be assessed in the inactivation
of angiotensin analogues by the intact rat liver. Livers perfused with an artificial 
Krebs’ medium are very active in extracting a-fAsn^Val6]-, a-[Asp1-Val6]-, 
«-[Asp1-Heu8]- and /8-[Asp1-Val5]-Ang. II (Leary and Ledingham 1970 (2)]. 
Inactivation of a-JAsn^VaPj-Ang. II is partially inhibited by EDTA, 3 x 10~3M, 
and dimercaprol 4 x 10-4M in the medium completely prevented hepatic extraction 
of this analogue (Leary and Ledingham, 1969).
Conclusions. A variety of experimental techniques indicate conclusively that 
the liver is an important site of Ang. II catabolism. The precise nature of the 
angiotensinases concerned is not yet known, but the large number of analogues 
inactivated by the liver, and the effects of inhibitors suggest the presence of a 
number of different enzymes.
Lung Angiotensinases
Tissue Extracts. Ang. II is inactivated when incubated with extracts of rat 
and dog lung (Itskovitz and Miller, 1967; Bakhle, 1968; Matstjnaga et al., 
1969).
Intact-Organ Experiments. Inactivation of Ang. II in the intact lung has been 
studied in man and animals by a variety of methods. No change in systemic-pressor 
response to the peptide was observed in rats by Goffinet and Mulrow (1965) in 
rats and dogs by Biron et al. (1968) or in sheep and dogs by Osborn et al. (1969) 
whether they infused the peptide proximal or distal to the pulmonary circulation. 
Subsequently Biron et al. (1969) repeated these experiments in man and found 
that the pressor potency of Ang. II given into the pulmonary artery was equivalent 
to that obtained from aortic injection of the peptide.
Hodge et al. (1967) detected no apparent inactivation of Ang. II in the lungs 
of anaesthetized dogs investigated by the infusion — superfusion technique of 
Regoli and Vane (1966).
Bakhle et al. (1969), Leary and Ledingham (1969) and Biron and Campeau 
(1971) reported negligible losses of Ang. II biological activity during passage of the 
peptide through isolated lung of several species perfused with erythrocyte free 
solutions.
In the studies reported above, angiotensinase activity was measured in the lung 
by bioassay only. The fact that Ang. II loses no biological activity diming passage 
through the lung does not rule out the possibility that some hydrolysis of the 
peptide occurs, coupled with the release of a second biologically active substance 
by the perfused organ. Ryan et al. (1970) and Turker et al. (1971) have both 
reported the presence of substances in effluent from isolated rat lung preparations 
that support this possibility. These results are not conclusive. Before studying the 
metabolism of Ang. II in the lung Turker et al. (1971) excised the organ and 
perfused it for 30 to 40 min. This prolonged period of perfusion might have 
damaged the lung with release of intracellular enzymes not normally active in vivo. 
Ryan et al. (1970) perfused lung by the method of Leary and Smith (1970) which 
causes negligible tissue damage as assessed by electron microscopy, but used highly 
unphysiological concentrations of peptide in their experiments.
Conclusions. Peptidases capable of hydrolysing Ang. II are present in lung 
tissue. Evidence from in-vivo lung perfusion studies indicates that only negligible 
inactivation of the peptide occurs during passage through the lung. Recent studies 
suggest that peptidase activity coupled with more complex changes, including the 
release of a hitherto unidentified vaso-active substance, may occur within the lung.
Cardiac Angiotensinases
Homogenates of cardiac tissue are capable of hydrolyzing Ang. H, but the 
angiotensinase content is low compared with homogenates of intestinal mucosa, 
kidney and liver ( F a s c i o l o  et al., 1940; I t s k o v i t z  and M i l l e r , 1967). Rat 
coronary vascular bed perfused with modified Kreb’s solution is active in extract­
ing [Asp1-Val5]-Ang. H , hydrolyzing some 30 to 70% of injected peptide in a 
single circulation ( B i r o n , 1969; O s b o r n e  et al., 1970; T u r k e r  et al., 1971).
Hind Quarter Angiotensinases
The metabolism of Ang. II  in isolated hindquarter preparations has been 
studied in dogs ( H o d g e  et al., 1967; B i r o n  et al., 1968), rats ( B i r o n  et al., 1968; 
B a k h l e  et al., 1969; B i r o n  and C a m p e a u , 1971), and sheep (O s b o r n  et al., 1969). 
Hind limbs were perfused through femoral artery catheters and peptide in the 
effluent blood or Krebs’ solution was assayed by superfusion ( H o d g e  et al., 1967; 
B a k h l e  et al., 1969) rat colon bioassay ( B i r o n  and C a m p e a t j , 1971) or monitoring 
of the pressor response in the experimental animal ( B i r o n  et al., 1968; O s b o r n  
et al., 1969). All groups reported that 50 to 70% of the peptide was inactivated 
during a single passage through the limbs.
Changes in Angiotensinase Activity in Various States 
Changes in Plasma and Serum
There have been many attempts to correlate changes in plasma angiotensinase 
activity with disease or altered physiology, but results have been largely incon­
sistent (Page and McCttbbin, 1968). The lack of a standardized method of angio­
tensinase assay and the relative unimportance of plasma enzymes in angiotensin 
catabolism (Hodge et al., 1967), lessen the significance of the findings reviewed 
below.
1. Hypertension. There is no consistent evidence of altered angiotensinase 
activity in plasma in various forms of spontaneous and experimental hypertension 
in man or animals (Dexter, 1942; Haynes and D exter, 1945, 1947; Wole et al., 
1961; Wood, 1962; Klaus, 1962; Hickler et al., 1963; Lagrue and Meyer, 1963; 
Biron et al., 1964; N agatsu et al., 1965; Itskovitz et al., 1957; Lubash et al., 
1967).
2. Liver Disorders. Marked increases in plasma angiotensinase activity in 
patients with cirrhosis and other hepatic disorders have been reported from many 
laboratories (Hickler et al., 1963; Klaus et al., 1963; Biron et al., 1964; Kokubu 
et al., 1965; Hirasawa, 1968; Page and McCubbin, 1968). It has been suggested 
that such increased activity might contribute to the improvement of arterial blood 
pressure in some hypertensive patients who have developed liver disease. (Kokubu 
et al., 1965; Hirasawa, 1968; Page and McCubbin, 1968). More recent studies 
comparing a-[Asn1-Ya]5]-Ang. II  and a-L-aspartyl-/?-naphthalmide (a-ANA) as 
substrates in serum from normal and cirrhotic patients, suggest the increased 
enzyme activity found in liver disease may relate only to angiotensinase Ax and 
not to the peptidase more specific to naturally occurring Ang. II [Nagatsu et al., 
1965 (2); Lubash et al., 1968). A physiologically important change in plasma 
angiotensinase activity in cirrhosis remains unproven.
3. Pregnancy. Klaus et al. (1963) and Landesman et al. (1963) were unable to 
find differences in the rates of destruction of [Asn^VaFj-Ang. II in the plasma of 
pregnant women compared with non-pregnant controls. Nagatsu et al. [1965 (2))
also found inactivation of [Asn1-Val6]-Ang. II to be normal, while a-ANA was 
more rapidly destroyed in the serum of pregnant women in the third trimester, 
suggesting a selective increase in Angiotensinase A2 activity. L u b a s h  et al. (1969) 
differ from N a g a t s u  et al., claiming not only increased hydrolysis rates of a-ANA 
but also of [Asn1-Val5]-Ang. II in the third trimester sera. It is unlikely that such 
changes, even if consistently detected, are of serious importance.
4. Shock. Itskovitz et al. (1969) have reported enhanced inactivation of both 
[Asn1] and [Asp1]-Ang. II analogues by plasma from dogs shocked by haemorrhage 
or by E. coli endotoxin.
Effects of Changes in Sodium Balance and Other Conditions 
on Angiotensin-II Catabolism
Sodium balance. L e a r y  and L e d i n g h a m  [1970 (1 and 2)] have perfused isolated 
rat liver and kidney from animals previously fed on low- and high-sodium diets. 
[Asn1-Val5]-Ang. II or its Asp1-Vals- and Asp1-Ileu5-analogues were added to the 
perfusion medium, and the time course of destruction of peptide determined by 
bioassay of serial samples over a 6-min period. Hepatic inactivation was not 
altered by changes in sodium balance. In contrast the capacity of the isolated 
kidney for to inactivation of Ang. II analogues was markedly reduced after sodium 
loading and significantly increased after depletion of salt. B i r o n  and C a m p e a u
(1971) , using a different technique, have found a 20% increase in inactivation of 
Ang. II analogues in kidneys from adrenalectomized salt-depleted rats, and a 
20% decrease when the animals had previously been salt loaded, but their results 
•were not statistically significant.
There is other evidence that changes in sodium balance may alter angiotensin 
catabolism. J o h n s t o n  et al. (1972) have examined the metabolic clearance rate 
(MCR) of Ang. II in hypertensive and normotensive man in states of sodium 
loading and depletion. In normotensives, the MCR increased significantly from 
2.23 ± 0.36 L/min in repletion, to 3.19 ± 0.34 L/min in depletion of sodium. 
MCR in hypertensive patients on a high salt intake was significantly higher than 
in normotensives and did not increase with sodium depletion. B r u n n e r  et al.
(1972) infused rabbit Ang. II anti-body intravenously in anaesthetized rats, and 
determined the amount required to prevent the pressor response to exogenous 
Ang. II. This amount was found to be 8-fold higher in sodium-loaded animals than 
in those on a low-salt diet. Although B r u n n e r  et al. (1972) have suggested their 
data may indicate to changes in the affinity of vascular receptors to Ang. II, with 
changes in sodium balance, their results, and those of J o h n s t o n  et al. (1972), are 
also compatible with a reduction of tissue-angiotensin degradation in sodium- 
loaded animals. L u b a s h  et al. (1971) report results differing from those of J o h n ­
s t o n  et al. The latter found plasma Ang. II levels to rise less in sodium depletion 
than in sodium repletion, during infusion of Ang. II amide: L u b a s h  et al. report 
the opposite, and found the half-life of Ang. II prolonged in the presence of salt 
depletion.
J e l i n e k  et al. (1971) have recently reported that the angiotensinase content 
of rat kidney homogenates is lower than normal in both sodium-depleted and 
sodium-loaded animals. These results are difficult to interpret, since the capacity 
of organs to destroy angiotensin in vivo is unlikely to be reflected accurately by 
work using tissue homogenates [ J o h n s o n  and R y a n , 1968; L e a r y  and L e d i n g ­
h a m , 1970 (1); O s b o r n e  et al., 1970; B i r o n  and C a m p e a u , 1971)].
Conclusion. There is now suggestive but not conclusive evidence that renal 
angiotensin catabolism may be reduced in salt loading and increased in salt
depletion, perhaps selectively in the renal vascular bed. This hypothesis is com­
patible with the long recognized variation in pressor sensitively to angiotensin 
with changes in salt balance in man and animals ( R e i d  and L a r a g h , 1965; 
O s t r o v s k y  and G o r n a l l , 1964; K u c h e l  et al., 1964; L a r a g h , 1962; K a p l a n  
and S i l a h , 1964; A m e s  et al., 1965).
Experimental Hypertension. L e a r y  and L e d i n g h a m  [1970 (1)] examined the 
effects of unilateral renal artery clips with or without contralateral nephrectomy 
on the capacity of isolated perfused rat kidneys to inactivate [Asn1-Val5]-Ang. II. 
In rats with one renal artery constricted and the other intact, considerably less 
peptide was removed by the intact kidney than the ischaemic kidney: in this 
situation the ischaemic kidney inactivated angiotensin at the same rate as control 
normal organs. In rats with one kidney removed and the remaining renal artery 
constricted by a silver clip, the ischaemic kidney removed less peptide from 
perfusate than its controls. Thus the overall capacity of the renal vascular beds 
to inactivate angiotensin is reduced in both experimental hypertensive situations, 
perhaps relating to sodium retention at least in the uninephrectomized rats. 
B r u n n e r  et al. (1972) also studied renovascular hypertension with or without 
contralateral nephrectomy in rats, and showed a 2-fold increase in the amount 
of rabbit anti-angiotensin II antibody required to block the pressor effects of 
exogeneous angiotensin. Taken together, the data suggest the possibility that a 
decreased catabolism of Ang. II may contribute to G o l d b l a t t  hypertension in 
the rat.
Experiments relating kidney homogenate angiotensinase to experimental renal 
hypertension have not produced consistent results ( B l a q u i e r  et al., 1961; B i n g , 
1962; H i r a s a w a , 1969; J e l i n e k  et al., 1971).
Effects of Carbon Tetrachloride in Rat Liver. W e r n z e  and F u j i i  (1966) found 
the pressor sensitivity to [Asn1]-Ang. II of rats was reduced if they had previously 
been given carbon tetrachloride (CC14), but the response to portal vein versus 
femoral vein injections indicated that the capacity of the liver to inactivate 
angiotensin was not impaired. B i r o n  and M e y e r  (1968) confirmed reduced pressor 
sensitivity in CCl-treated rats, but also reported a partial or total loss of the 
capacity of the poisoned livers to destroy either «-Aspl or /5-[AspJ - Ang. II. 
H i r a s a w a  (1968) in contrast found evidence of increased angiotensinase activity 
in liver homogenates, intact infused livers, and the plasma of rats previously 
given CC14. Data so far is therefore conflicting: the different doses of carbon tetra­
chloride used, and the poor and variable state of health of the animals may 
account for these discrepancies.
Angiotensinase Assays
In ideal circumstances, enzymes are assayed after purification, in conditions of 
constant pH, temperature, ionic strength, specific ionic concentration and amount 
of substrate present. The rate of the reaction may then be taken as an index of 
the activity of the enzyme, and such activity may be expressed as units per mg of 
protein or per mg nitrogen. The kinetics of the reaction between the enzymes and 
its substrate should be determined by a series of estimations of substrate or 
reaction product concentrations, with time, in the presence of a standard amount 
of enzyme. In zero-order kinetics, the reaction is linear with time and rate is 
simply estimated. In first-order kinetics, when the reaction rate depends on the 
substrate concentration, the equation describing the first -order reaction may be 
used to express enzyme activity. When higher-order or more complex reactions
occur the empirical device often used to establish an assay is the measurement of 
the initial rate of the reaction, which tends to approach zero order.
In the assay of angiotensinases in vitro or in vivo, these simple principles of 
enzyme assay (M e h l e r , 1957) either cannot be, or too often have not been, 
observed. Most estimates of angiotensinase activity in vitro have depended upon 
the incubation under standard conditions of a known concentration of Ang. II (or 
an analogue), with plasma, serum or tissue extract, and assay of residual pressor 
activity after variable time intervals. It cannot be over-emphasized that single­
point assay systems are valueless in the assessment of enzyme activity, unless the 
reaction kinetics have been studied, and it is known whether zero-, first- or higher- 
order kinetics pertain. Estimates of enzyme activity based on single-point assay 
systems occur all too frequently in the literature on angiotensinases. This kind of 
error is easily avoided but there are other difficulties which are not so easily solved.
In-Vitro Assays: plasma, serum and tissues contain a variety of peptidases, 
so that more than one enzyme is always present, and pure preparations of angio­
tensinase enzymes have only very rarely been achieved ( N a g a t s u  et al., 1970). 
In spite of these difficulties some useful estimate of angiotensinase activity in vitro 
can be achieved provided samples are assayed at frequent intervals after incubation 
and rates are calculated from the linear part of the curve relating angiotensin 
survival with time. The time taken for a 50-percent loss of substrate (T50%) may 
be the best index, and has been successfully used by J o h n s o n  (1967), J o h n s o n  
and R y a n  (1968), Y a n g  et al. (1968) and J e l i n e k  et al. (1971). Substrates other 
than Ang. II may occasionally be of value in the assay of individual angiotensinases 
[ N a g a t s u  et al., 1965 (2), 1970] and reaction rates may be estimated from rate 
of yield of individual amino acids [ N a g a t s u  et al., 1965 (1)].
In-Vivo Assays: The single-pass superfusion assay of angiotensinase activity 
( H o d g e  et al., 1967; B a h k l e  et al., 1969; B i r o n  et al., 1968; B i r o n  and C a m p e a u , 
1971; O s b o r n e  et al., 1970) whether applied to anaesthetized animals, or to 
isolated perfused organs does not allow any estimate of rate of loss of angiotensin 
with time. Activity of angiotensinases in organ vascular beds can therefore only 
be assessed in terms of percentage loss of angiotensins in a single circulation. 
Change of activity in altered physiological or in pathological states may therefore 
be difficult or impossible to quantitate.
The isolated perfused organ techniques of L e a r y  and L e d i n g h a m  [1961, 1970 
(1 and 2)] allow recirculating medium to be assayed for residual angiotensin at 
regular intervals over relatively prolonged periods. [Asn1-Val5], [Asp1-Val5] and 
[Asp1-Ileu5]-Ang. II in concentrations of 66 or 133 ng/ml were destroyed by the 
perfused rat liver or kidney at a rate linear with time up to 6 min. Between 6 and 
14 min there was evidence of substrate concentration becoming rate-limiting 
( L e a r y  and L e d i n g h a m  — unpublished observations). This technique therefore 
allows rates of inactivation to be compared in various physiological and patho­
logical states, with or without the addition of enzyme inhibitors to the medium. 
Application of immunoassay methods to this technique, so that more physiological 
concentrations of angiotensin can be used, will offer obvious advantages over the 
bioassay methods so far employed.
Metabolic clearance rates of angiotensin. J o h n s t o n  et al. (1972) have devised a 
method of estimating the metabolic clearance rate (MCR) of Ang. II in man. 
[Asn1-Val-]-Ang. II (Hypertensin Ciba) was infused intravenously at a subpressor 
dose of 100 ng per min for 2 h. Plasma renin and angiotensin levels were measured 
before and after the infusion and the clearance rate calculated with a correction 
applied for the renin-suppressing effect of the infusion. The MCR was shown to be
constant over infusion rates of 100 to 1000 ng/min and was not therefore altered 
by the infusion itself.
Difficulties particular to Ang. II metabolism arise in the accurate estimation 
of MCR, and these have been discussed by J o h n s t o n  et al. Moreover clearance data 
data do not distinguish receptor uptake (L i n  and G o o d f r i e n d , 1970; G o o d f r i e n d  
and L i n , 1970) from tissue degradation of angiotensin.
Summary
The term angiotensinase is used to describe a number of enzymes capable of 
hydrolyzing Ang. II, but not proven to be specific to it.
Tissue extract and homogenate experiments have been helpful in the detection 
of separate aminopeptidases, endopeptidases and carboxypeptidases, but cannot 
be taken to reflect angiotensin catabolism in vivo.
The techniques devised over the last 5 years for the study of angiotensin 
inactivation by intact organs have been productive. There is now more than a 
hint that angiotensin catabolism in tissue vascular beds may be as important as 
its rate of formation in determining physiological activity at receptor sites.
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ABSTRACT.
Prostaglandin (PG) release by the isolated perfused Kid­
ney of the rat has been stimulated by nor-adrenaline infusion 
and measured by bioassay. There was no basal output of PGEj- 
like activity, but stimulated release reached mean concentra­
tions of 9.1 ng/g kirlney/ml perfusate in kidneys from female 
albino rats drinking water and 2.9 ng/g/ml in those from anim­
als given 1.5% NaCl to drink. Kidneys from uninephrectomised 
animals with mock-clipped renal arteries released 7.3 ng PG/ 
g/ml and those from rats with uninephrectomy and constricted 
renal arteries 3.3 ng/g/ml.
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INTRODUCTION.
Prostaglandins (PG) are released continuously by the kid­
neys of anaesthetised dogs and may be detected in their renal 
venous blood(l). PG release Increases after several different 
stimuli to the kidney including ischaemia, renal sympathetic 
nerve stimulation, and intra-arterial infusion of nor-adren- 
allne, bradykinin or angiotensin(2). The main PG detected is 
PGE^* or like PGE^, and probably acts intrarenally as a vaso­
dilator and natriuretic(3). Abolition of PG release by indo- 
methacin, a potent inhibitor of PG synthesis, greatly augments 
the renal vasoconstrictor effects of angiotensin II and inter­
feres with the autoregulation of renal b1oodflow(4,5). Thus, 
PGs probably play an important role in the regulation of ren­
al blood flow and because of this, we have studied the capac­
ity of rat kidneys to release PGs under conditions known 
to induce hypertension. PG release by the isolated perfused 
rat kidney was stimulated by nor-adrenaline infusion in var­
ious groups of normotensive and hypertensive albino rats and 
measured by bioassay.
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Female albino rats were kept on a standard diet and given 
tap water to drink ad lih. Sodium chloride was added [1.5% 
w/v) to the drinking water of some rats ("high salt") and a 
unilateral nephrectomy performed on others. The remaining 
kidney in these rats was either manipulated ("mock clip") or 
mobilised, after which the renal artery was constricted with 
a small silver cllo.
Each week animals were weighed and arterial blood pres­
sure was measured by the tail-cuff method. Experimental con­
ditions were maintained for at least.one month before kidney 
perfusion was carried out. Mean blood pressures (mm Hg ± SEM) 
in the four groups were then: 119 ± 2.4 for controls. 126 +
4.5 for the "high salt" group, 134 ± 3.8 for "mock clip" uni- 
nephrectomised animals, and 163 ± 11.2 for uninephrectomised 
rats with a constricted renal artery.
Rats were selected in random order and a single kidney 
was perfused in situ using the method previously described(6) . 
Oxygenated Krebs' solution (pH 7.4) was warmed to 37°C and 
delivered to the renal artery from a constant output pump at 
5 ml/min. A second roller pump took half of the renal outflow 
to superfuse a series of isolated assay tissues, the excess 
effluent running to waste against a hydrostatic pressure of 
4 - 8  cm. Three assay tissues were used, usually including a 
rat stomach strip, rat colon, and chick rectum to allow diff­
erentiation between prostaglandins of the E and F series(7). 
Assay tissues were rendered insensitive to catecholamines, 
acetylcholine, histamine and 5-hydroxytryptamine by infusing 
a mixture of antagonists(7) into the Krebs' solution distal 
to the perfused kidney. Indomethacin (4 pg/ml) was added to 
the solution superfusing these tissues to inhibit any syn­
thesis of prostaglandins by them and to make them somewhat 
more sensitive to PGs(8). The perfusion rate of 5 ml/min. 
gave a renal perfusion pressure of 100-140 mm Hg.
When perfusion of the kidney was first started, the assay 
tissues contracted, representing a PG-like activity of 0.2 -
3.0 ng/ml (assayed as PGE^). The assay tissues then relaxed 
and returned to their previous baseline within a few minutes, 
as blood washed out of the kidney.. At this time the PG pre­
cursor arachidonic acid (40 ng/ml) was infused into the renal 
perfusion inflowj there was no increase in PG output in 
response to arachidonic acid alone. After a further 5 min­
utes, nor-adrenaline was infused intra-arterially for 5 min 
at a rate (6 - 10 ng/ml) which gave a rise in arterial pres­
sure of 100 mm Hg. Renal perfusion pressure was measured on 
a mercury manometer and.recorded manually. It returned to 
previous values within two minutes of discontinuing the infus­
ion. A substantial release of PG-like activity into the renal 
effluent took place and this was estimated by bracketing the 
effects on the assay tissues between contractions induced by
PGE^ infusions given directly to the assay tissues immediately 
before and after each nor-adrenaline infusion.
RESULTS.
The PG-like activity released had the same pattern of 
activity as PGE^ on the three assay tissues. Any appreciable 
release of PGF would have caused a much greater relative con­
traction of the rat colon preparation than that recorded in 
these experiments.
A second infusion of nor-adrenaline induced a similar 
release of PG-like activity, except after infusion of indometh- 
acin (4 pg/ml) through the kidney, when release of PG-like 
activity by nor-adrenaline was abolished.
The results of the experiments in the four different 
groups of rats are shown in Tables I and II. After nor-adren­
aline stimulation, the PG-like activity of renal effluent 
reached a mean peak concentration of 10.4 ng/ml in control 
rats with both kidneys intact and 10.9 ng/ml in the unineph­
rectomy "mock clip" group. Expressed as output per g kidney, 
release was 9.1 and 7.3 ng/g/ml. PG-like activity in renal 
effluent of the two other groups was much less. kidneys from 
salt-loaded animals released a mean of 3.5 ng/ml (2.9 ng/g/ml) 
and those from animals with constricted renal arteries, 5.2 
ng/ml (3.3 ng/g/ml). Compared with the relevant control 
groups, each of these reductions was highly significant (p
0 .0 0 1) .
DISCUSSION.
No single cause for the development and maintenance of 
raised arterial pressure has been found in experimentally 
induced hypertension or in human benign essential hyperten­
sion, although the probable aetiological importance of the 
kidney has been repeatedly stressed(9).
The discovery of renomedul1 ary PGs with marked hypoten­
sive and natriuretic properties has renewed interest in the 
antihypertensive properties of the kidney and in the possib­
ility that humoral vasodilators and constrictors are both of 
importance in the control of arterial pressure(10).
There are at least two general ways in which release of 
a vasodilator PG can contribute to a lowering of blood pres­
sure. The first is by a local vasodilation within the kidney, 
thereby tending to reverse a reduction in oxygen supply caus­
ed by a reduction in blood flow or in oxygen availability.
Such a local effect may modify renin release. The second is 
for the released PG to have a circulating function, inducing
vasodilatation not only in the kidney but also in other parts 
of the body.
Prostaglandins of the A series are more likely candidates 
for a circulating role, for they escape prodigious inactivat­
ion in the pulmonary circulation(11), as occurs with PGs of 
the E series(12).
All the stimuli so far tested increase release of PGEs 
from the kidney and increased PGA release has not yet been 
detected(4,5,13,14). Thus, it is likely that renal PG 
release has a local, rather than a circulating role. This 
conclusion is supported by experiments in which PG synthesis 
and release are abolished by indomethacin; blood flow and 
autorepulation are decreased, and the effects of vasoconstric­
tor agents are increased selectively in the kidney(4,5).
Our experiments show that chronic sodium loading or renal 
arterial constriction impair the ability of the rat kidney to 
release PGs. Zusnan et al (15) found low PG levels in the 
plasma and kidney of salt-loaded rats and Nekrasova et al 
(161 reported a decrease in the PG content of ischaemic kid­
neys in uninephrectomised rabbits. These results may also 
reflect an impaired PG biosynthesis.
Leary S Ledingham(B) showed that kidneys from rats sub­
jected to similar experimental procedures had a reduced 
capacity to inactivate angiotensin II. Thus, a reduced 
availability of renal PGs and an increased activity of angio­
tensin II could both contribute to the pathogenesis of exper­
imental hypertension.
Certainly, our results show that interference with a 
prostaglandin mechanism cannot by itself account for hyperten­
sion. Thus, the rats with uninephrectomy and manipulation of 
the other kidney in the "mock clip" control group also showed 
a raised blood pressure, possibly due to slight inflammation 
around the remaining kidney, with some compromise of the renal 
circulation. However, in this group, there was no significant 
fall in PG release and no clear correlation between arterial 
pressure and PG release in individual animals. The failure 
of sodium loading to produce hypertension, despite the reduct­
ion in PG release is another indication that more than one 
mechanism must be involved, as is the fact that chronic treat­
ment with prostaglandin synthetase inhibitors, such as aspirin 
and in domethacin, has never been reported to cause hypertension,
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TABLE I.
PROSTAGLANDIN RELEASE BY ISOLATED 
PERFUSED KIDNEY FROM THE RAT: EFFECT OF SODIUM LOADING
Experimental
Group
Weight 
(g ± SEM)
No. Arterial Kidney
of pressure weight
rats (mm Hg ± SEM) (g ± SEM)
Stimulated 
PG output 
per Kidney 
(ng/ml per 
fusate ± 
SEM)
PG output 
(ng/g Kid 
ney/ml 
perfusate 
± SEM)
Controls 279.0 ± 13.7
7 119.4 
± 2.4
1.14 
+ 0.05
10.4
±1.18
9.1
±0.98
High salt 250.3 6 126.6 1.18 3.5 2.9
intaKe ± 5.7 ± 5.6 ±0.05 ± 0.61 ±0.49
Signif- 
can ce ns ns ns P <0.001 P <0.001
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TABLE Ii;
PROSTAGLANDIN RELEASE BY ISOLATED
PERFUSED KIDNEY FROM THE RATi EFFECT OF A
CLIP ON RENAL ARTERY.
Experimental
Group
Weight 
(g ± SEM)
No
of
rata
Arteri al 
pressure 
(mm Hg ± SEM)
Kidney 
weight 
(g ± SEM)
PG output 
per kidney 
(ng/ml per­
fusate ± 
SEM)
PG output 
(ng/g kid- 
ney/ml 
perfusate ± 
SEM)
Uninephrec­
tomy "Mock 
Clip"
Uninephrec- 
tomy Clip
Significance
260.1 
± 11.9
7 134.1 
± 3.9
1.67
±0.09
10.9 
± 1.16
7.3
±0.71
244.7 
± 14.7
7 163.3 
± 11.2
1.63
±0.11
5.2
± 0.62
3. 3 
±0.52
n s P <0.05 ns P <0.001 P <0,001
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PULMONARY INACTIVATION OF PROSTAGLANDIN BY HYPERTENSIVE
RATS.
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Department of Clinical & Experimental Pharmacology, 
University of Natal, Durban, South Africa.
ABSTRACT .
Lungs of normotensive and genetically hypertensive 
(GH) albino rats were perfused in situ with 5 ml/min Krebs 
solution containing 100 ng/ml PGE2 or F20C . Inactivation 
rates of 76,0 ng PGF2 oc and 146,3 ng PGE2/g dry wt. lung/ 
min were recorded for GH rats. Values for normotensive 
controls were 191,2 and 226,1 ng/g/min.
The authors wish to thank Mr. C. Lockett and Mrs.
J. Carboni and Mrs. P. Williams for technical help. 
W.P.L. was supported by a Medical Research Council 
(S.A.) Grant.
INTRODUCTION
Differences in systemic arterial pressure observed 
between genetically hypertensive (GH) albino rats and 
their controls may be related to a variation in the 
metabolism of vasoactive substances including catacholamines, 
angiotensin and prostaglandins. This paper reports experi­
ments in which the lungs of GH and normotensive rats were 
perfused in situ and the pulmonary inactivation of PGE, 
and F2o<. measured.
MATERIALS AND METHODS
Forty six male Wistar rats were studied. Twenty 
three were of the New Zealand genetically hypertensive 
(GH) strain and the remainder their normotensive controls.
All weighed 220-350 g and were housed and fed identically 
with tap water ad libitum for a minimum of 10 weeks before 
any experiment. Systemic arterial pressures were measured 
in conscious animals every 1 4 - 2 1  days by the tail-cuff 
method and, in anaesthetised rats, by carotid cannulation 
immediately before thoracotomy. Normotensive and GH rats 
were perfused in random order, but experiments with PGE2 
were completed 12 months after PGF2o«. studies.
Rats were weighed immediately before study and 
anaesthetised with intraperitoneal pentobarbitone 60 mg/kg.
A fine plastic cannula was introduced into the left carotid 
artery and blood pressure measured by Statham strain-gauge 
transducer and traced on a Unicorder U400 pen recorder.
The thorax was then opened and the great vessels, heart
and lungs prepared for perfusion in situ as described 
by Leary and Smith (1). The inferior vena cava was tied 
below its junction with the right atrium and the heart 
rotated anti-clockwise so that the left precaval and 
azygos veins could be mobilised and tied. Cannulae were 
placed in the left and right ventricles through the aorta 
and right precaval vessels which were then tied to secure 
the cannulae and prevent back perfusion.
Perfusion commenced at a pressure of 10-12 mm.Hg with 
5ml/min unoxygenated Krebs Ringer solution (pH 7,4,
37°C), containing 100 ng/ml PGE2 or F2 *< . The initial 
2-5 ml blood-stained pulmonary venous effluent was 
discarded and subsequent perfusate collected for 15 
minutes and assayed for PG-like activity by superfusion, 
of a rat stomach strip, chick rectum and rat colon using 
the method of Ferreira and Vane (2). Responsiveness of 
these tissues to PG was increased by continuous superfusion 
with a solution of pharmacological antagonists and 
indomethacin in normal saline at 37°C (3) . Percentage 
PG activity was measured by bracket assay of pulmonary 
venous effluent with perfusate collected at the right 
ventricular cannula. Heart and lungs were excised after 
perfusion and dessicated over calcium chloride at room 
temperature so that dry weight of these tissues could be 
determined. In 4 additional experiments the lungs of 
2 normotensive and 2 GH rats were perfused without 
adding PG to the Krebs solution. Effluent was assayed 
for the presence of endogenous PG.
The mean of 3 bracket assays for each perfusion was 
used to calculate PG inactivation as ng/g dry weight of 
lung. Mean data for control and GH rats were compared 
by an unpaired t test for sample means (Hewlett Packard 65, 
programme 1-38A).
RESULTS
The results of this study are shown in Table 1. GH 
rats have significantly heavier hearts and higher arterial 
pressures than their controls. Endogenous PG was not 
detected in the 4 samples assayed.
Pulmonary inactivation of PGE- was slightly greater 
than that of PGF2®< for both GH ana control rats although 
this difference was not statistically significant except 
when percentages inactivated by GH rats were compared 
(P=<0,025). Both prostaglandins were metabolised to a 
significantly greater extent in normotensive than GH 
animals.
DISCUSSION
Intravenous infusion of PGF2#< elevates the systemic 
arterial pressure in man and various animals including 
the rat, dog, monkey and baboon (4). Pressor activity 
is not mediated through the sympathetic nervous system
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TABLE I
Pulmonary perfusion of normotensive and GH male rats with prostaglandins.
Data expressed as Mean + S.E.M.
GROUP DRY HEART 
MASS (g)
DRY LUNG 
MASS (g)
SYSTOLIC B.P. 
(mm.Hg)
PGF, OC 
INACTIVATED 
%
PGF- <4
INACTIVATED ng/g 
DRY LUNG WT.
Uormotensive 0,17 0,34 108,8 60,8 191,2
n = 14 +0,01 +0,02 + 3,00 + 8,12 + 29,24
Hypertensive 0,22 0,29 157,2 23,0 76,0
n = 11 +0,01 +0,01 + 3,89 + 8,70 +30,86
P value £0,005 <0,025 <0,0005 <0,0025 <0,01
GROUP DRY HEART 
MASS (g)
DRY LUNG 
MASS (g)
SYSTOLIC B.P. 
(mm.Hg)
PGE,
INACTIVATED
%
PGE- INACTIVATED 
ng/g DRY LUNG WT,
Normotensive 0,19 0,37 102,2 73,3 226,1
n = 9 +0,01 +0,05 + 6,19 + 6,22 + 33,43
Hypertensive 0,27 0,39 173,3 53,7 146,3
n = 12 +0,01 +0,03 + 6,20 + 9,17 + 27,53
P value ^0,0005 >0,3 <0,0005 >0,05 <0,05
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in rats, but probably results from peripheral veno- 
constriction leading to an increased venous return and 
cardiac output. Prostaglandins of the E series lower 
arterial pressures in most laboratory animals, (4) but 
may produce a biphasic response in the rat with a 
resultant nett increase in blood pressure (5). The part 
played by endogenous PG in regulating arterial pressure 
is uncertain, although the cardiovascular and renal 
effects of prostaglandins may be as important to homeo­
stasis as those of angiotensin, aldosterone and the kinins. 
Abnormal synthesis or inactivation of PG might contribute 
to the pathogenesis of.hypertension in some circumstances.
Leary, Ledingham and Vane (6) have shown that chronic 
sodium loading or renal arterial constriction impair the 
ability of the rat kidney to release PGs and similar findings 
have also been reported by Zusman et al (7) and Nekrasova 
et al (8). The experiments reported in this paper indicate 
that pulmonary degradation of PGE2 and PGF2 is reduced 
in albino rats of the New Zealand^GH strain. This is 
consistent with the findings of Armstrong et al (5) who 
have described a similar defect in the kidneys of GH rats. 
Unpublished work by the same group, using elegant in vitro 
techniques, confirm that lung tissue of GH rats is relative­
ly deficient in PG 15-hydroxy-dehydrogenase. Whether this 
deficiency is limited to the GH strain of albino rats or 
whether it occurs in other forms of experimental and natural­
ly occurring hypertension remains to be seen.
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Prostaglandins and Medicine 3: 251-252, 1979. Short note
ENHANCED RELEASE OF 'PGI -LIKE* SUBSTANCE IN EXPERIMENTAL HYPERTENSION
J.H. Botha, W.P. Leary and A.C. Asmal. Pharmacology Department, University of 
Natal, Box 17039, Congella 4013, South Africa. (Reprint requests to JHB).
Blood vessels of spontaneously hypertensive rats increase conversion of 
arachidonic acid to PGI^ (1) and generate increased endogenous PGI^ (2,3).
This short communication describes experiments which measured release of 
PG^-like substance from aortic strips of rats with surgically induced hyper­
tension and their age, sex and weight matched normotensive controls.
Materials and Methods. Blood from a healthy human volunteer who had taken no 
drugs during the previous 2 weeks was processed as described by Sagel et al 
(4) using plastic apparatus to yield platelet rich (prp) and platelet poor 
plasma (ppp). Plasma was stored at room temperature under carbogen and used 
within 2h of venepuncture. Platelet aggregation was determined by the method 
of Born (5) in a dual channel model 340 Chronolog Aggregometer. Threshold 
aggregation was induced by ADP (l,6^ uM), (Sigma Ltd., St. Louis, U.S.A.). 
Calculations of percentage aggregation were made as described by Sagel et al(4) 
and two parameters were used for quantitation and comparison; a) the initial 
rate of aggregation, as indicated by the extent of aggregation in the first 
0,5 minutes, and b) the extent of permanent aggregation at 4 minutes.
A group of male, weanling Wistar rats (University of Natal inbred strain), 
+_150g weight, were anaesthetised with pentobarbital (6mg/100g) . A left uni­
nephrectomy was performed in every animal through a midline abdominal incision. 
The right kidney was mobilised and wrapped with Mersilk in half the rats in 
order to induce hypertension (6). After 10 weeks systemic arterial pressures 
were measured in conscious animals, using the tail cuff method. Paired control 
and hypertensive rats were given water ad libitum and sacrificed by a blow to 
the neck after an overnight fast. The abdominal aorta was removed, cleared and 
rinsed with ice cold tris buffer (0,5 mmol/1 pH 7,5). After adjustment to an 
approximate wet weight of 16 mg, the tissue was stored in 1,5 ml of buffer on 
ice until tested (within 30 minutes). Using a slight modification of the me­
thod of Moncada et al (7), each aorta was cut longitudinally into 2 strips which 
were then incubated in 700jul tris buffer at room temperature. PG^ 9enerati°n 
was stimulated mechanically using a small plastic covered magnetic stirrer bar. 
At various times after incubation began, 20jul of supernatant were added to prp,
1 minute before the addition of ADP. The percentage inhibition produced by the 
incubate was assessed by comparing the two parameters a) and b) with those of 
control curves obtained by adding 20yul tris, at room temperature, to prp 1 min­
ute prior to addition of ADP. Values for percentage inhibition were converted 
into absolute units, (ng PGI^/wet weight of aorta), by comparison with standard 
curves obtained when synthetic PGI sodium salt (Upjohn Ltd., Kalamazoo), was 
added to samples of the human donor^s prp.
Results and Discussion. The results which are summarised in Table I show that 
generation of PGIj-like activity by hypertensive rat aortas was significantly 
greater at each sampling time them that of their matched controls. The fact 
that the same ability to generate increased levels of P G ^  has been found in 
induced hypertension as has been reported for spontaneous hypertension (1,2, 
3) adds further credibility to the suggestion that this may be an adaptive 
response to raised arterial pressure.
NORMOTENSIVE RATS (n=5) HYPERTENSIVE RATS (n=5)
AGE: 19 weeks 
WT: 287,00 + 10,68g 
BP: 109,80 + l,50mmHg
AGE: 19 weeks 
WT: 229,60 + 15,39g 
BP: 144,00 + 7,31mmHg
INCUBATION 
TIME (MIN) ng PGI^/mg WET WEIGHT AORTA
LEVEL OF 
SIGNIFICANCE p
2
-8
18
3,04 + 0,38 
5,89 +0,34 
6,19 +0,35
4,90 + 0,81 
7,56 + 0,44 
8,04 + 0,29
< 0,05
< 0 ,0025
< 0,01
Table I : ng 'PGI.-like' activity produced by normotensive and hypertensive 
rat aortas. Results expressed as mean value +_ SEM.
Acknowledgement: Miss A. von Middelkoop gave statistical advice; Upjohn Ltd.,
PGI^; and M.R.C. (S.A.) financial support.
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ENHANCED RELEASE OF A 'PROSTACYCLIN-LIKE' SUBSTANCE FROM AORTIC STRIPS 
OF SPONTANEOUSLY HYPERTENSIVE RATS
J.H. Botha W.P. Leary A.C. Asmal
Department of Clinical & Experimental Pharmacology, 
University of Natal, Medical School 
Durban, South Africa
ABSTRACT
The release of an endogenous 'prostacyclin-like' substance from 
aortic strips of 8 male Wistar rats of the New Zealand genetically hyper­
tensive strain (GH) was compared with that of 8 weight, age and sex 
matched normotensive Wistar control rats. The amount of 'prostacyclin­
like' substance released by the aortic strips into tris buffer, under the 
influence of mechanical stimulation, was measured by its ability to in­
hibit human platelet aggregation as compared to the inhibitory effect of 
standard prostacyclin sodium salt. It was shown that generation of this 
substance increased with incubation time and that a significantly greater 
amount was produced by GH rats.
INTRODUCTION
The isolation of prostacyclin (PGX later PGI2 ) from vascular tissue 
by Moncada et al (1) and the suggestion that prostacyclin generation in­
duced vasodilation and could inhibit intravascular platelet aggregation 
aroused interest in the production of this substance in pathological 
conditions associated with vascular disease, such as hypertension. Spon­
taneously hypertensive rats provide a useful experimental model for human 
essential hypertension (2) and have been widely studied, although the 
aetiology of the condition remains obscure. Pace-Asciak et al (3) have 
reported increased conversion of arachidonic acid to prostacyclin by in­
tact rings and homogenates of aorta from spontaneously hypertensive rats 
of the Wistar Aoki-Okamoto strain, compared with their controls, and 
Minoru Okuma et al have shown significantly increased generation of 
prostacyclin by vessels of both stroke-resistant and stroke-prone spon­
taneously hypertensive rats of the Wistar-Kyoto colony prior to stroke (4).
In this paper we demonstrate that aortas of male rats of the New 
Zealand genetically hypertensive strain (GH) produce significantly more 
'prostacyclin-like' substance than those of their age, weight and sex 
matched controls.
MATERIALS AND METHODS
Blood was withdrawn from the antecubial vein of a healthy human 
volunteer who had taken no drugs during the previous 2 weeks. The blood 
was processed as described by Sagel et al (5) using plastic syringes, 
containers and pipettes to yield platelet rich (prp) and platelet poor 
plasma (ppp). Plasma was stored at room temperature, under carbogen and
used within approximately 2 h of venepuncture. Platelet aggregation was 
determined by the method of Born (6) in a dual channel model 340 Chrono- 
log Aggregometer. Threshold aggregation was induced by ADP l,2]iM, (Sigma 
Ltd., St. Louis, U.S.A.). Calculations of percentage aggregation were 
made as described by Sagel et al (5) and two parameters were used for 
quantitation and comparison :
a) The initial rate of aggregation, as indicated by the extent of
aggregation in the first 0,5 minutes
b) The extent of permanent aggregation at 4 minutes.
Systemic arterial pressures were measured in conscious animals 
prior to the study, using an adaptation of the tail cuff method (7).
Rats were given water ad libitum and sacrificed by a blow to the neck 
after an overnight fast. The abdominal aorta was removed, cleared and 
rinsed with ice cold tris buffer (0,5 mmol/1 pH 7,5). After adjustment 
to an approximate wet weight of 21 mg, the tissue was stored in 1,5 ml 
of buffer on ice until tested (within 30 minutes). Using a slight 
modification of the method of Moncada et al (8), each aorta was cut 
longitudinally into 2 strips which were then incubated in 700yl tris 
buffer at room temperature. Prostacyclin generation was stimulated by 
mechanical means, using a small plastic covered magnetic stirrer bar.
At various times after incubation began, 20yl of supernatant were added 
to the prp, 1 minute before the addition of ADP. The percentage in­
hibition produced by the incubate was assessed by comparing the two 
parameters a) and b) with those of control curves obtained by adding 
20yL tris, at room temperature, to prp 1 minute prior to addition of 
ADP. Values for percentage inhibition were converted into absolute units, 
(ng prostacyclin/mg wet weight of aorta), by comparison with standard 
curves obtained when synthetic prostacyclin sodium salt (Upjohn Ltd., 
Kalamazoo) was added to samples of the human donor's prp (9).
RESULTS & DISCUSSION
The results which are summarised in Table I (and illustrated in 
Figure I), show that under the influence of mechanical stimulation genera­
tion of'prostacyclin-like' activity of GH rat aortas was significantly 
greater at each sampling time than that of their matched controls. This 
was consistent with the results of preliminary experiments with 10 pairs 
of matched rats in which mechanical stimulation was not used and 'prosta­
cyclin-like' substance was produced at a slower rate.
These results are consistent with the findings of Pace-Asciak et al 
(3), who demonstrated increased prostacyclin synthesis from arachidonic 
acid by aortas of Aoki-Okamoto GH rats and with Minoru Okuma et al (4) 
who showed that, prior to stroke, elevated amounts of 'prostacyclin-like' 
substance were produced by spontaneously hypertensive rats (stroke-prone 
and stroke-resistant), of the Wistar-Kyoto colony.
Our findings support the suggestion that elevation in prostacyclin 
levels could be an adaptive response to hypertension and associated plate­
let activation and vascular injury although it remains to be seen whether 
such increases occur in all forms of experimental hypertension and if 
they cam be reversed by hypotensive agents.
NORMOTEN SIVE RATS HYPERTENSIVE RATS
AGE : 34-36 weeks 
WT : 350,25 + 6,10 g 
BP : 121,25 + 3,79 mmHg
AGE : 34-36 weeks 
WT : 303,75 + 3,24 g 
BP : 198,75 + 4,30 mmHg
INCUBATION ng PGI2/mg WET WEIGHT AORTA LEVEL OF
TIME
(MIN)
SIGNIFICANCE
E
2 1,66 4_ 0,30 2,30 + 0,23 < 0,025
3 3,17 + 0,25 3,94 + 0,20 < 0,025
14 3,80 + 0,15 4,37 + 0,13 < 0,005
1
TABLE I. ng 'PROSTACYCLIN (PGI2)-LIKE' ACTIVITY PRODUCED BY NORMOTENSIVE 
AND HYPERTENSIVE RAT AORTAS.
The assumption that prostacyclin caused the inhibition of platelet 
aggregation is supported by the fact that aliquots of supernatant in­
jected intravenously into pentobarbitol anaesthetised rats lowered the 
blood pressure (10). This fall in pressure was greater in response to 
extracts from GH rats than to samples of equal volume from their controls 
The 'prostacyclin-like' activity generated was transient, which further 
supports the argument that the effects noted were not due to another PG. 
However, the 'prostacyclin-like' substance responsible for the biological 
changes observed requires positive identification and further studies 
are in progress to determine whether similar differences can be found 
between normotensive rats and others with secondary hypertension.
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igure 1. Apparent prostacyclin production by incubates of aortic strips 
from normotensive (N) and hypertensive (H) rats.
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PAPER A12
Mechanical Reduction in Pressure and Pulse Pressure Decreases 
the Ability of Hypertensive Rat Aortas to Produce "PGI2- 
Like" Activity
This work was based on my ideas and followed a protocol which 
I designed. Dissections were carried out largely by me and 
platelet aggregation was measured by Dr. J. Botha. The 
publication was prepared in consultation with Dr. Botha and 
with editorial assistance from Professor A.C. Asmal.
MECHANICAL REDUCTION IN PRESSURE AND PUI£E PRESSURE DECREASES THE 
ABILITY OF HYPERTENSIVE RAT AORTAS TO PRODUCE 'PGE2-LEKE' ACTIVITY
J.H. Botha and W.P. Leary. Pharmacology Dept., University of Natal,
Box 17039, Ccngella 4013, South Africa. (Reprint requests to JHB.)
Blood vessels frcm rats with various forms of hypertension (spon­
taneous, induced renovascular and DOCA saline) have been shewn to 
produce increased amounts of PGE2 (1 - 5) . To investigate whether 
this ability may be related to a local pressure effect we have 
measured production of a 'PGI2-like' substance by rat abdominal aortas 
in which pressure had been lowered mechanically.
Materials and Methods. The systemic arterial blood pressures of a 
group of 16 male Wistar rats of the New Zealand genetically hypertensive 
strain (± 300g in weight and 12 - 16 weeks old) were measured in 
conscious animals using the tail cuff method. Pairs of rats were then 
anaesthetised with pentobarbital (6mg/100g). The aorta just below the 
diaphragm was mobilised in both animals through a midline abdominal 
incision. One animal acted as a sham control. The aorta of the other 
was constricted above the hepatic artery and as near to the diaphragm 
as possible by a silver clip (Sooville Lewis JN 1300IW) thus producing 
hypotension distally (6) . Eighteen hours after the operation distal 
aortic pressures were measured by the tail cuff method in both clipped 
(C) and sham (S) rats which had been fasted overnight. Paired animals 
were then sacrificed by a blow to the neck. The abdominal aortas were 
removed, cleared and rinsed with ice cold tris buffer (0,5mmol/l pH 
7,5). After adjustment to an approximate wet weight of lOmg, the 
tissue was stored in buffer on ice until tested (within 30min). Each 
aorta was cut once longitudinally and thrice transversely to produce 
eight approximately equal pieces which were then incubated in 700 yl 
tris buffer at roan temperature. PGE2 generation was stimulated 
mechanically using a small plastic covered magnetic stirrer bar.
'PGI2-like' activity produced by the vessel at various incubation 
times was assessed as described previously (3,4).
Results. As indicated in Table 1 application of the clip caused a 
significant reduction in tail pressure. Abcfcminal aortas in which 
pressures had been reduoed produced decreased amounts of 'PGE2-like' 
activity* (Table 2) This tendency was consistent at the 8 and 14 
minute sampling times and when analysed by the Wilcoxon matched-pairs 
signed-ranks test reached a level of significance of p 4 0,02.
BLOOD PRESSURE (mm Hg)
M E A N DIFFERENCE WITHIN PAIRS
C S MINIMUM MAXIMUM
Prior to operation 178 180 0 12
Post operation 95 160 34 93
Table 1 : Tail pressures of conscious rats
ng PGI, PRODUCTION/mg WET WT . AORTA
INCUBATION
time M E A N
MEAN DIFFERENCE WITHIN PAIRS 
(NUMBER OF PAIRS IN BRACKETS)
(MIN) C S C > S S » C
2 1,50 1,58 0,26 (4) 0,41 (4)
8 * 3,14 3,75 0,14 (1) 0,72 (7)
14 * 3,54 4,05 (0) 0,50 (8)
Table 2 : ng 'PGI2-like' activity produced by rat abdominal aortas 
*Canparing C to S p < 0,02
Discussion. The results indicate that the ability to produce PGI2 may 
be influenced by prior local changes in pressure and/or pulse pressure. 
Elevated PGE2 production by aortas of hypertensive rats may be a 
mechanical effect related ta raised pressure/pulse pressure; vena cavae 
from spontaneously hypertensive rats do not shew an increased ability 
to produce PGT2 when compared with controls (7) .
Acknowledgements. Miss A. van Middelkoop gave statistical advice; Prof. 
J. van Dellen silver clips; Upjohn Ltd. PGI2 and MRC (SA) finance.
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PAPER A13
Platelets
Abnormally
This paper 
Dr. Botha
of Spontaneously Hypertensive Rats are not Sensitive to PGI2
resulted from discussions between the authors, 
carried out all the laboratory work and we
collaborated in writing this paper
PLATELETS OF SPONTANEOUSLY HYPERTENSIVE RATS ARE NOT ABNORMALLY
SENSITIVE TO PG12
J.H. Botha and W.P. Leary. Pharmacology Dept., University of Natal,
Box 17039, Congella 4013, South Africa. (Reprint requests to JHB.)
It has been suggested that haemostatic balance in various path­
ological conditions is influenced not only by vascular PGI2 generation 
but also by changes in platelet sensitivity to PGI2 (1)- For ex­
ample; when atherosclerosis is induced in rabbitsi decreased PGI2  
generation occurs together with increased sensitivity of platelets 
to PGI2 (2,3). This communication describes the effect of PGI2  on 
ADP-induced aggregation of platelets from Wistar rats of the New 
Zealand genetically hypertensive strain (GH) and on those of age, 
weight and sex matched normotensive Wistar control rats (N). These 
two groups have previously been shown to differ significantly in 
their aortic generation of PGI2 (4).
Materials and Methods. Using the tail cuff method, systemic arterial 
blood pressures were measured prior to the study in 21 conscious 
3 month old male animals from each group (approximate wt. 270g). 
In each of 7 experiments three animals from each group were anaes­
thetised with intraperitoneal pentobarbitone (6mg/100g). Blood 
was collected from the abdominal aorta into disposable plastic sy­
ringes containing heparin (10 U/ml blood). Platelet rich plasma 
(prp) was prepared by centrifugation of the blood at 160g for 18 
minutes. Further centrifugation of the remaining blood at 2000g
for 15 minutes yielded platelet poor plasma (ppp) . Aggregation 
of pooled prp from the 3 rats in each group was carried out in
a dual channel model 340 Chronolog Aggrometer using ADP (final 
cone. l[iM) added to prp 1 minute after the addition of tris buffer 
(pH 9,7) or the buffer containing various concentrations of PGlg 
as sodium salt (Upjohn). Maximum aggregation was measured an a 
percentage of the distance between prp and ppp.
Results. Systemic arterial pressures of the two groups differed 
significantly : mean 115, (range 80 — 125)mmHg and mean 172, (range 
158 - 190) mmHg for N and GH rats respectively. Platelet counts
in prp differed by no more than 4% in the two groups. As illus­
trated in Figure 1 the response of the platelets to ADP did not
differ significantly between the 2 groups whether ADP followed 
tris buffer alone or buffer containing various concentrations of
Added PGI2 (ngjml)
Fig. 1: Effect of PGI2 on ADP induced rat platelet aggregation.
Discussion. Recent work has shown decreased sensitivity of human
platelets to PGI2  during long-term intraarterial infusion in per­
ipheral vascular disease (5). The possibility therefore existed 
that increased aortic generation of PG12 in hypertension (4) might 
be associated with reduced platelet sensitivity. However, the 
results indicate that platelets from both GH and N rats are equally 
sensitive to the anti-aggregatory effect of PGI2 . The significance 
of this is not clear at this stage. It is interesting that in 
•experimental atherosclerosis and hypertension, in which arterial 
thromboses appear superficially similar, changes in vascular PGL 
generation and platelet sensitivity are not consistent.
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SECTION B : CLINICAL TRIALS IN HYPERTENSION
These papers represent a small percentage of clinical trials 
published during the last 10 years. They are typical 
examples however and all have similar shortcomings. Many 
open or only partially blind trials are initiated in my 
department at an early stage in the development of new 
antihypertensive drugs. Other studies may involve innovative 
approaches to the use of established medications and are also 
conducted in an open fashion since double-blind trials would 
be unethical. Generally, such preliminary work is followed 
by double-blind, controlled studies elsewhere if justified by 
the results of the pilot study.
PAPER B1
Treatment of Uncomplicated Essential Hypertension with 
Xipamide
I carried out all the work reported here with the assistance 
of two nurses. Professor A.C. Asmal provided editorial help.
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ABSTRACT
Xipamide, a relatively new non-thiazide diuretic was used as sole therapy 
in 21 patients with mild to moderate elevations of blood pressure. 
Supine and erect systolic and diastolic pressures were significantly 
reduced. Changes recorded in arterial pressure, plasma urate, potassium 
and glucose were similar to those associated with established diuretics.
INTRODUCTION
Saliuretics of the benzothiazine type are commonly used, alone or as 
adjunctive therapy, in the management of hypertension and oedema of 
cardiac, hepatic or renal origin. These medicines vary slightly in potency 
and duration of action, and are generally effective and safe, although 
associated with a tendency to cause hypokalaemia, hyperuricaemia and 
hyperglycaemia, particularly when used for prolonged periods. Since
Figure 1 —Structural formula o f  xipam ide.
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these adverse effects occasionally have serious consequences, attempts to 
synthesise improved diuretics continue.
Xipamide (Fig. 1) is a new non-thiazide diuretic antihypertensive 
compound with marked saliuretic effects in animals and man.1 Pre­
liminary studies in healthy adults indicate that xipamide 20 mg is 
approximately equipotent with furosemide 40 mg and hydrochloro­
thiazide 100 mg.2
This paper reports the results of an early double-blind study 
designed to determine the effects of xipamide upon arterial blood pres­
sure in patients with uncomplicated* mild to moderate essential hyper­
tension.
PATIENTS AND METHODS
The blood pressures o f 200 clerks and semi-skilled workers em ployed at a Durban 
factory were measured by nursing staff attached to a clinic within the building. 
Those with raised pressures were referred to a medical practitioner for possible 
treatment.
On referral, a medical history was recorded and general clinical examination 
carried out. Arterial pressures were measured in the right arm by standard tech­
niques, using the first appearance and final disappearance o f Korotkov sounds to 
define systolic and diastolic pressures, respectively. Patients rested supine for 3 
minutes and stood upright for 2 minutes before measurement o f supine and erect 
pressures, which were each measured twice. Lowest systolic and diastolic pressures 
recorded were adjusted upwards to the nearest 2 mmHg. Blood pressure was mea­
sured again, at the same time o f day, 2 weeks later. Patients who gave their consent, 
and with supine diastolic pressures o f 90 to 120 mmHg, entered the clinical trial, 
unless disqualified by any exclusion driterion.
Patients who fell within one or more o f the following categories were excluded 
from the trial and given alternative therapy:
1. Clinical evidence or history o f gout.
2. History o f severe congestive cardiac failure.
3. History o f  severe renal or hepatic impairment.
4. Gross obesity.
5. Pregnant women and wom en likely to becom e pregnant.
6. Abnormal pretreatment laboratory tests.
7. Patients taking cardiac glycosides, psychotropics, antihypertensives or oral con­
traceptives.
8. Retinopathy more severe than slight irregularity or narrowing o f vessels.
Patients were examined by the same physician every week for 6 weeks, and
monthly thereafter for a further 5 months. Weight and blood pressure were 
recorded at the same time o f  day at each visit, (1200-1400 hr). Xipamide was ad­
ministered double-blind as a single daily dose taken at breakfast (0600-0700 hr). 
Patients were given 20 mg placebo tablets for two weeks, follow ed by 20 mg active 
xipamide for 4 weeks. This was increased to 40 mg daily if an adequate blood pres­
sure response was not obtained after 4 weeks at the lower dose. They were then 
maintained on 20 or 40 mg xipamide per day to the end o f the study. Patients with 
untreated supine diastolic pressure of 90 to 109 mmHg were classified as having 
mild hypertension; those with a pressure of 110 to 120 mmHg were classified as
suffering from moderate hypertension. A controlled response was regarded as a 
diastolic pressure below 90 mmHg in mild and below 96 mmHg in moderate hyper­
tension.
Serum urate, potassium and random glucose estimations were carried out at 
each visit and a 12-lead EKG was recorded at the beginning and at the end o f the 
study. Patients were questioned about adverse reactions at each examination.
Results were analysed for statistical significance o f responses to treatment using 
Student ‘t ’ test for comparison o f  paired data.
RESULTS
Twenty-one patients entered the study, but 2 were excluded before 
Week 6 because of non-compliance with prescribed treatment. Two of 
the remaining patients were female and 17 male; all were Indian with 
the exception of 3 Zulu males. Ages ranged from 25 to 60 years (mean 
47). No evidence of a primary cause for hypertension was noted in any 
case. Patients took 20 mg (13) or 40 mg (6) xipamide daily.
Detailed results are presented in Tables I and II. Thirteen patients 
had “mild” and 6 “moderate” hypertension, as defined above. Sig­
nificant falls in systolic and diastolic pressures occurred during both
Table I — E ffect o f  xipam ide on arterial pressure.
SUPINE STANDING
A R TER IA L  PRESSURE A R TER IA L  PRESSURE
(Systolic!I (Diastolic) (Systolic) (Diastolic)
PRE-THERAPY 168.6 104.4 165.7 106.5
5.14 2.40 4.89 2.39
IN ITIAL THERAPY 149.8* 93.8* 146.6* 99.3*
4.71 2.24 4.19 1.88
STABILISED  THERAPY 139.6* 90.3* 139.8* 98.1*
4.00 1.91 3.88 1.97
Results expressed in mmHg as mean ± SEM
Significant differences: Pre-therapy vs Initial and Stabilised Therapy; * P = <0.005
Table I I  — E ffect o f  xipam ide on serum potassium , urate and glucose levels.
POTASSIUM URATE GLUCOSE
PRE-THERAPY 3.9 0.40 7.0
0.13 0.03 0.65
IN ITIAL TH ERAPY 3.9 0.42 6.8
0.13 0.03 0.48
STABILISED  TH ERAPY 3.6* 0.45* 7.0
0.13 0.02 0.43
Results expressed in m.mol/l as mean ± SEM
Significant differences: Pre-therapy vs Stabilised Therapy; * P = <0.025
initial and stabilised periods of therapy. Mean supine systolic pressure 
fell from 168.6 to levels of 149.8 and 139.6 mmHg.
Mean supine diastolic pressure fell from 104.4 to 93.8 and 90.3 
mmHg. These changes were similar to the responses in standing blood 
pressure: Systolic pressure fell from 165.7 to 146.6 during initial 
therapy and 149.8 mmHg in the stabilised period. Equivalent diastolic 
pressure readings were 106.5, 99.3 and 98.1 mmHg respectively. These 
responses to initial and .stabilised therapies all represented values 
recorded during the placebo phase (P= < 0.005).
Supine diastolic pressure was reduced by xipamide in all 6 patients 
with moderately severe hypertension and fell below 96 mmHg in 4. 
Both patients who responded relatively poorly were given 40 mg xipa­
mide daily during the period of stabilised therapy. Systolic pressure also 
fell in this group of hypertensives from an initial mean level of 187.7 to
145.0 mmHg (P= < 0.0025).
Thirteen patients were classified as “mild” hypertensives. Supine 
diastolic pressure fell below 90 mmHg in 9 cases during stabilised 
therapy and was effectively reduced during initial therapy in 2 others. 
The cause of the slight pressure rise noted during stabilised therapy in 
these 2 cases is uncertain, but might be due to non-compliance. In the 
remaining patients only slight changes in diastolic pressure occurred. 
Similar changes in systolic pressure were noted and overall control 
during stabilised treatment was significantly better than that during 
placebo therapy (P= < 0.0005).
No change in pulse rate occurred. M°an serum potassium level fell 
from 3.9 to 3.6 m mol/1 in the course of this clinical trial. Though rela­
tively unimpressive,, this change was statistical^ ’'gnificant (P= < 0.025), 
reflecting falls of 0.1-1.2 m mol/1 in all but 5 patients. Plarma urate rose 
slightly from a mean of 0.40 m mol/1 during placebo therapy to 0.45 on 
stabilised treatment. This increase, which ranged from 0.01 to 0.17 
m mol/1 in the 14 patients so affected, was statistically significant 
(P= < 0.025). No change in glucose level was detected despite slight 
differences in time elapsed since the meal preceding each clinic visit.
DISCUSSION
The preliminary study described in this paper was designed to answer 2 
relatively simple questions. These concerned the capacity of xipamide 
20 to 40 mg to reduce raised arterial pressures in man and whether 
hypokalaemia, hyperuricaemia or hyperglycaemia would occur in a small 
group of patients taking the diuretic daily for 6 months without potas­
sium supplements.
Xipamide lowered systolic and diastolic pressures to a significant
degree whether patients were standing or supine during measurement. 
This resembled the response to other diuretics of the thiazide type3 and 
suggests that zipamide 20 to 40 mg daily may be used in hypertension 
as an alternative to compounds such as hydrochlorothiazide, chlorthali­
done, chlorexolone and cyclopenthiazide. Blood pressure control over 
24 hours was not studied, although the- relatively prolonged diuretic 
effect of xipamide suggests that it might be effective if prescribed once 
daily.2
The changes in urate and potassium levels observed in this clinical 
trial were slight, but consistent with the findings of other investi­
gators.1’4 Increases in fasting blood glucose levels have been reported in 
patients given xipamide,4 though no change in random levels was 
detected in the present study.
Xipamide administered once a day is an effective new saluretic with 
some of the clinical characteristics of the benzothiadiazine diuretics. It 
remains to be seen whether this preparation has any advantage over 
alternative diuretics in the management of essential hypertension.
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Evaluation of the Efficacy and Safety of Guanabenz versus 
Clonidine
I carried out all the work reported here with the assistance
of one nurse. Professor Asmal provided editorial help.
Evaluation of the Efficacy and Safety of Guanabenz
versus Clonidine
W. P. LEARY, A. C. ASMAL, P. C. WILLIAMS
SUMMARY
The antihypertensive efficacy and safety of guanabenz 
were evaluated against clonidine in two groups of 18 
patients with uncomplicated essential hypertension. Both 
compounds reduced systolic and diastolic blood pressure 
at the doses used, whether pressures were measured in 
the supine or standing positions. Side-effects, such as dry 
mouth and drowsiness, were similar in both groups of 
patients. No postural hypotension occurred.
S. Afr. med. ]., 55, 83 (1979).
Guanabenz (2,6-dichlorobenzylidine amino guanidine ace­
tate) (Fig. 1), is a potent hypotensive agent structurally 
related to clonidine and thought to act by stimulating 
sympathetic vasoconstrictor inhibitory centres and peri­
pheral adrenergic outflow.1 Preliminary studies in laboratory 
animals and man demonstrated no contraindication to
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the use of guanabenz in hypertensive patients and showed 
that arterial blood pressure could be reduced in most 
patients by doses of 4 -24  mg twice daily.1,3
Fig. 1. Guanabenz (2,6-dichlorobenzylidine amino guani­
dine acetate).
The purpose of the study reported here was to evaluate 
the antihypertensive efficacy and the safety of guanabenz 
against clonidine in two groups of patients with uncompli­
cated essential hypertension.
PATIENTS AND METHODS
The arterial pressures of clerks and metal-workers em­
ployed at a Durban factory were measured by trained 
nursing staff at a casualty clinic on the factory premises. 
Those with a supine diastolic pressure above 90 mmHg
were referred to a medical practitioner (A.C.A.) for assess­
ment and possible treatment.
On referral, a medical history was recorded and a general 
clinical examination was carried out. Patients rested supine 
for 3 minutes or stood upright for 2 minutes before mea­
surement of supine and erect pressures by standard sphyg- 
momanometry, using the first appearance and final dis­
appearance of Korotkoff sounds to define systolic and 
diastolic pressures respectively. Blood pressures were 
measured again, at the same time of day, 7 and 14 days 
later. Lowest systolic and diastolic pressures recorded were 
adjusted upwards to the nearest 2 mmHg.
Patients who had not been previously treated for hyper­
tension, and who had supine diastolic pressures consistently 
between 90 and 130 mmHg, entered the trial after giving 
their consent, unless disqualified by any exclusion criteria. 
Venous blood was drawn from these patients for measure­
ment of creatinine and urea nitrogen levels, and a 12-lead 
ECG was recorded at rest.
Patients with any of the following disorders were ex­
cluded from the study: (i) severe cardiac disease including 
cardiac failure, angina pectoris and arrhythmias other 
than sinus arrhythmia; (ii) malignant hypertension or 
retinopathy more severe than grade II/IV; (iii) a recent 
history of stroke; or (iv) a severe concomitant pathological 
state, including malignancy, overt psychosis, drug depen­
dence, endocrine disorders, severe infection, renal or 
hepatic disease.
The grades of essential hypertension and criteria of 
effective management were arbitrarily defined as follows:
Mild hypertension. Supine diastolic pressure 90 - 104 
mmHg. Effective reduction: below 90 mmHg.
Moderate hypertension. Supine diastolic pressure 105 - 
114 mmHg. Effective reduction: below 95 mmHg.
Moderately severe hypertension. Supine diastolic pressure 
115-129 mmHg. Effective reduction: below 105 mmHg.
Patients were assigned randomly to groups given guana- 
benz 8-24 mg twice a day (group A) or clonidine 0,05 - 
0,30 mg 3 times a day (group B). Medicines were taken in 
equal divided doses with initial doses at the lower limit 
of the above ranges. Blindness was achieved by separating 
dispensing and recording of blood pressure assessments.
Clinical symptoms, pulse rate, blood pressure and weight 
were recorded twice a week during the 1st and 2nd 
week, and once a week from the 3rd to the 8th week. 
Arterial pressures were measured by the same observer 
and at the same time of day. Doses of both medicines 
were increased at weekly intervals in relation to response 
and side-effects.
An ECG, funduscopy and laboratory data were recorded 
at the end of the 4th and 8th weeks. A physical examina­
tion was carried out at the end of the 8th week when the 
trial was completed.
Results were analysed for antihypertensive efficacy and 
side-effects of both compounds within and between 
patients of the same group and between groups.
RESULTS
Forty patients were selected for study (Table I); 36 com­
pleted the trial and 4 were disqualified for non-compliance
with the protocol. Each treatment group included 18 
patients. No significant changes in funduscopy and labora­
tory or ECG data were recorded.
TABLE I. DETAILS OF PATIENTS IN GUANABENZ AND 
CLONIDINE GROUPS (DATA EXPRESSED AS MEAN ±  SD)
Guanabenz Clonidine
Number of patients 21 19
Age (yrs) 44,9* ±  7,6 50,9 ±  5,9
Weight (kg) 71,68 ±  12,8 72,18 ±  11,7
Baseline severity of
hypertension
Moderate/severe 7 5
Moderate 5 7
Mild 9 7
* Comparison significant (PCO.OI).
The mean daily dose of each medication was gradually 
increased over the study period. The average starting 
dose was 16,0 mg guanabenz or 0,45 mg clonidine. Titra­
tion increments were larger for patients with a relatively 
severe degree of initial hypertension. The overall mean 
daily dose of guanabenz was 22,8 mg (range 12,0 - 48,0 mg) 
and 0,56 mg for clonidine (range 0,45 - 0,90 mg).
Eleven patients in group A (guanabenz) and 13 in group 
B (clonidine) experienced at least one adverse effect (Table 
II), but these responses did not discriminate between the 
two treatment groups. Dry mouth and drowsiness were 
the most frequent adverse responses to both medications.
TABLE II. DRUG-RELATED ADVERSE EFFECTS
Adverse response Guanabenz Clonidine
Dry mouth ................. 7 10
Dizziness ......................... ... 2 5
Drowsiness ..................  .... 10 10
Weakness ......................... 0 1
Disorders of micturition 0 1
Disturbed sexual function ... 0 1
Total affected........... 11 13
Systolic and diastolic blood pressures in both standing 
and supine positions were significantly decreased (P<0,01) 
from the baseline measurements in each treatment group 
(Tables III and IV). Pulse rate in both positions was 
usually reduced by both guanabenz and clonidine. 
Systolic and diastolic blood pressure averages were 
generally lower in the guanabenz group throughout the 
study. In the supine position, this difference was significant 
at weeks 5 and 8 (systolic pressure). Average standing 
systolic pressure was significantly lower in the guanabenz 
than in the clonidine group at week 5. Postural hypotension 
did not occur with either compound.
At the end of the study 10 patients in group A and 
7 in group B were rated as having effective reductions in 
supine diastolic pressure. However, the difference between 
the groups was not statistically significant.
TABLE III. MEAN BLOOD PRESSURE AND PULSE RATE IN SUPINE POSITION
Systolic pressure Diastolic pressure Pulse rate
(mmHg) (mmHg) (beats/min)
Trial period Guanabenz Clonidine Guanabenz Clonidine Guanabenz Clonidine
Control 163,9 163,6 104,8 106,9 76,5 76,9
Treatment week 
5 133,0* 144,6 88,3 88,9 68,5* 76,1
6 135,1 139,1 90,1 90,8 66,6 72,6
7 137,7 142,6 91,0 89,2 71,6 68,4
8 134,1* 146,7 90,7 94,0 66,5 70,3
Difference between treatment groups significant (/><0,05).
TABLE IV. MEAN BLOOD PRESSURE AND PULSE RATE IN STANDING POSITION
Systolic pressure Diastolic pressure Pulse rate
(mmHg) (mmHg) (beats/min)
Trial period Guanabenz Clonidine Guanabenz Clonidine Guanabenz Clonidine
Control
Treatment week
159,9 162,9 107,9 110.1 79,9 80,2
5 126,6* 140,5 93,1 98,2 73,0* 80,7
6 130,5 134,5 92,4 95,0 72,9 77,9
7 133,1 129,4 93,2 90,2 76,4 73,6
8 125,8 133,4 93,3 95,1 72,6 74,4
* Difference between treatment groups significant (P<0,05).
DISCUSSION
The structural and pharmacological similarities of clonidine 
and guanabenz are reflected by results of the present 
clinical trial. Guanabenz was at least as effective as cloni­
dine in the patients treated and within the dosage ranges 
used, and similar adverse responses were associated with 
both preparations. Care should be exercised in selecting 
patients for treatment with guanabenz since serious adverse 
reactions to clonidine have been reported.* These may 
logically be expected when related preparations are given, 
although rebound hypertension has not yet been reported 
in man after withdrawal of guanabenz therapy.
Clonidine-like compounds should be used cautiously in 
patients with coronary or cerebral insufficiency and in de- 
pressives. Patients should not drive or operate machines 
since drowsiness and inattention could have serious con­
sequences. Withdrawal of treatment must be gradual to 
minimize the danger of a hypertensive crisis occurring 8 - 24 
hours after withdrawal.'
Further clinical experience with guanabenz is required 
before its properties and potential uses in hypertension can 
be clarified. Present experience indicates that guanabenz is 
effective when administered twice daily, and may be used 
as an alternative to clonidine in the treatment of patients 
resistant to other medication or unable to tolerate adrener­
gic neuron-blocking drugs because of severe postural 
hypotension.
REFERENCES
1. Laverty, R. (1973): Brit, tried. Bull., 29, 152.
2. Nash, D. T. (1973): J. clin. Pharm., 13, 416.
3. Baum, T. and Shropshire, A. T. (1976): New Antihypertensive Drugs. 
New York: Spectrum.
4. Hansson, L. and Hunyor, S. N. (1973): Clin. Sci. mol. Med., 45, 181.
5. Bailey, R. R. and Neale, T. J. (1976): Brit. med. J., 1, 942.
Treatment of Hypertension with Verapamil
I carried out all 
of 2 nurses and
the work reported here with the assistance 
a technician. Professor Asmal provided
editorial help.
C U R R E N T
T H E R A P E U T I C
R E S E A R C H
VOL. 25, NO. 5, M A Y ,  1979
TREATMENT OF HYPERTENSION WITH VERAPAMIL
W.P. LEARY, M.SC., M.B.B.CH. (WITS), D.PHIL (OXON),
M.R.C.P. (LOND,), F.C.P. (S.A .,* and 
A.C. ASMAL, M.D. (LOND.), M.R.C.P. (LOND.), F.C.P. (S.A )**
D epartm ent o f  Clinical and Experim ental Pharmacology,
University o f  Natal Medical School, P.O. B ox 17039, Congella 4013,
Durban, Natal
A ssisted by:
P.C. WILLIAMS, S.R.N., B. MARWICK, S.R.N.,
AND J. CARBONI, SENIOR TECHNICIAN
ABSTRACT
The effects of verapamil upon arterial pressure were assessed in 16 
Negro and 24 Caucasian patients, with mild to moderate hypertension. 
Verapamil 80 mg given thrice daily in combination with reserpine 0.1 
mg significantly reduced systolic and diastolic pressures, producing mean 
falls of 8.2, 6.5, 8.4 and 9.8 mmHg in supine and standing systolic and 
diastolic pressures, respectively. When verapamil 160 mg was given twice 
daily as sole medication, falls of 21.0, 8.9, 17.6 and 8.4 mmHg were 
recorded. It is concluded that verapamil has a mild hypotensive effect 
useful in managing hypertension of mild to moderate degree.
INTRODUCTION
Verapamil is a synthetic papaverine derivative which has proved useful 
in the management of angina pectoris and supraventricular tachyarrhyth­
mias.1 It blocks the uptake of ionised calcium by myocardial cell 
membranes thus limiting energy release from ATP by the action of 
calcium dependent ATPase and reducing myocardial contractility and 
oxygen consumption. The increased coronary vascular resistance noted 
during treatment with beta adrenergic blockers does not occur2 in 
response to verapamil.
Verapamil induces a degree of relaxation in vascular smooth muscle 
presumably by an effect on calcium ions similar to that which is ob­
tained in the heart. The pharmacological responses to this drug are vaso­
dilation and a slight negative inotropic effect which result in a fall in 
arterial blood pressure, an effect which has proved useful in managing 
patients with hypertensive crises.3
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Whereas the efficacy of intravenous verapamil in the treatment of 
emergency situations has been established, relatively few studies on its 
oral use in hypertension have been carried out.4’5’9’10’11 Verapamil 
disappears rapidly from plasma after oral administration, as a result of 
intensive hepatic first pass metabolism, indicating that doses of 120 to 
160 mg must be given at least 2 or 3 times daily to maintain thera­
peutic concentrations in man. Unsubstantiated independent reports6-7 
suggest that verapamil acts synergistically with methyldopa or reserpine 
to reduce raised arterial pressures in man; this effect may allow dosage 
reductions in reserpine and methyldopa with resultant decreases in their 
side effects. This paper describes a double-blind clinical trial designed to 
establish the effects upon arterial pressure of verapamil given alone or in 
combination with small doses of reserpine. A subsequent open extension 
of the trial examined the effect of verapamil given twice daily as sole 
medication to the same patients.
MATERIALS AND METHODS
Forty male patients (16 Zulus and 24 Caucasians) with uncomplicated essential 
hypertension o f mild to moderate severity were studied. All were clerks or semi­
skilled workers em ployed at a Durban factory and were selected from personnel 
referred for medical assessment when raised pressures were detected at routine 
exam inations made by trained nursing staff attached to the factory clinic.
On referral, a medical history was recorded and general clinical examination 
carried out. Patients rested in the supine position for 3 minutes or stood upright for 2 
minutes before measurement of supine and erect pressures by standard sphygmomano- 
metry, using the first appearance and final disappearance o f Korotkov sounds to  define 
systolic and diastolic pressures, respectively. Blood pressures were measured again, at 
the same time of day, 7 days later. Lowest systolic and diastolic pressures recorded 
were adjusted upwards to the nearest 2 mmHg. Patients w ho gave their consent and 
had supine diastolic pressures consistently between 94 and 134 mmHg entered the 
trial unless disqualified by any exclusion criterion. Venous blood was drawn for 
measurement o f urea nitrogen levels, routine urinalysis was carried out and a 12-lead 
EKG recorded at rest before entry into the trial.
Patients with any o f the following disorders were excluded from the study:
(a) Severe cardiac disease including cardiac failure, angina pectoris and arrhyth­
mias other than sinus arrhythmia or occasional extrasystoles.
(b) Malignant hypertension or retinopathy more severe than grade II/IV.
(c) Recent history o f stroke.
(d) Severe concom itant pathology, endocrine disorders, severe infection, renal 
or hepatic disease.
Each patient was given placeboes for reserpine 6.1 mg and verapamil 80 mg thrice 
daily for 2 weeks. Thereafter they were randomly assigned to groups taking active 
reserpine 0.1 mg and active verapamil 80 mg t.d.s. (Group A) or active reserpine 0.1 
mg and verapamil placebo t.d.s. (Group B). After 6 weeks o f therapy, active medica­
tions were again replaced by placeboes and 2 weeks later regimens were crossed over 
between Groups A and B. Blindness was achieved by the use o f placeboes identical 
in appearance to active medicines and by separating dispensing and recording of 
blood pressure assessments.
Clinical sym ptom s, pulse rate, standing and supine blood pressure were mea­
sured every 14 days throughout the trial. Arterial pressures were measured by the 
same observer and at the same time of day. Serum urea and electrolytes were mea­
sured and a 6-lead EKG recorded at the end o f each treatment period.
On com pletion o f the double-blind portion o f  the trial, reserpine was withdrawn  
and replaced by verapamil 160 mg given twice daily for 8 weeks. Active therapy 
was then replaced with verapamil placebo taken for 4 weeks before reintroduction  
of any active medication. Patients were held blind during this section o f the clinical 
trial.
Results were examined for antihypertensive efficacy o f the regimens used. Data 
collected during the final 4 weeks o f each treatment period were analysed using a 
Students ‘t ’ test programme for comparison of paired data prepared for the 
Hewlett-Packard H-P 67 computer. Responses during the initial and “w ashout” 
placebo periods were pooled, but data collected during the final placebo period 
were treated separately for statistical purposes since they formed no part o f the 
initial double-blind study.
RESULTS
Results are set out in Tables I and II. Forty patients, including 16 Black 
Africans and 24 Caucasians completed the double-blind study. Mean
Table I — Effects o f  .thrice-daily reserpine and verapamil on blood pressure (mmHg) 
and heart rate, (beats/m in.). Results expressed as mean ± SEM (n = 40).
PLACEBO
RESERPINE  
0.1 mg t.d.s.
RESERPIN E  
0.1 mg + 
VERAPAM IL  
80 mg t.d.s.
SUPINE
Pressure Systolic
Diastolic
158.7 ±2.87
102.8 ±1.46
162.2 ±3.15 
100.9 ± 1.64
150.5 ±3.20  
96.3 ± 1.54
STANDING
Pressure Systolic
Diastolic
153.5 ±2.43 
106.9 ± 1.47
156.8 ±3.01 
104.1 ±1.98
145.1 ±3.05  
97.1 ± 1.38
Heart rate 77.7 (±1.66) 71.0(± 1.23) 68.4(± 1.48)
Table II — Effects o f  tw ice-daily verapamil on blood pressure (mmHg) and heart rate 
(beats/m in.). R esults expressed as mean ± SEM (n =  40).
PLACEBO
VERAPAM IL  
160 mg b.d.
SUPINE
Pressure Systolic
Diastolic
178.3 ±4.04
110.4 ±2.22
157.3 ±2.83 
101.5 ± 1.54
STANDING
Pressure Systolic
Diastolic
171.5 ±2.77
114.5 ± 1.39
153.9 ±2.91 
106.1 ± 1.40
Heart rate 77.0 ± 2.03 79.0 ± 1.86
supine systolic pressure ± standard error of mean fell from 158.7 
( ± 2.87) to 150.5 ( ± 3.20) mmHg in response to reserpine 0.1 mg and 
verapamil 80 mg thrice daily. This fall in pressure was statistically signi­
ficant (p = 0.001). Mean pressure was 162.1 ( ± 3.15) mmHg when 
reserpine was given alone. Supine diastolic pressure was reduced from a 
mean of 102.8 ( ± 1.46) to 100.9 ( ± 1.64) mmHg by reserpine and fell 
to 93.6 ( ± 1.54) mmHg when verapamil was added. This pressure 
change was significant when compared with placebo (p = 0.001) or 
treatment with reserpine alone (p = 0.005).
Similar changes in standing pressures were recorded. Systolic pres­
sure fell from 153.5 ( ± 2.43) to 145.1 ( ± 3.05) mmHg in response to 
the reserpine-verapamil regimen (p = 0.001), but actually rose slightly to 
156.8 ( ± 3.01) mmHg when reserpine was the only medicine used 
(p = 0.001). Standing diastolic pressure was reduced from a mean level 
of 106.9 ( ± 1.47) mmHg to 104.1 ( ± 1.98) mmHg when placebo was 
replaced by active reserpine (p = 0.05). A further significant reduction 
to 97.1 ( ± 1.38) mmHg followed the addition of active verapamil to 
the regimen (p = 0.001). Extended analysis of these data demonstrated no 
significant differences in response to therapy by these patients when 
grouped by race or the order in which therapeutic regimens were fol­
lowed. Mean heart rate fell slightly from 77.7 ( ± 1.66) to 71.0 ( ± 1.23) 
and 68.4 ( ± 1.48) beats/minute in response to reserpine and the 
verapamil reserpine regimen, respectively. These changes were statis­
tically significant (p 0.0005 and 0.025).
In the course of the open extension to the trial which followed, 
patients were given verapamil 160 mg twice daily for 8 weeks followed 
by verapamil placebo for 4 weeks. Responses to verapamil resembled 
those to combined therapy with reserpine and verapamil although pres­
sures actually rose slightly when the verapamil dosage was adjusted and 
reserpine withdrawn. However, pressures increased significantly when 
active medication was replaced by placebo. Thus mean standing pres­
sures were 171.5 ( ± 2.77) and 153.9 ( ± 2.91) mmHg in response to 
placebo, and verapamil, respectively (p = 0.005). Diastolic pressures were 
110.4 ( ± 2.22) and 101.5 ( ± 1.54) mmHg and these changes were also 
significant (p = 0.025). Supine pressures were similarly affected, mean 
systolic pressure falling from 178.3 ( ± 4.04) to 157.3 ( ± 2.38) mmHg 
(p = 0.005) and diastolic from 114.5 ( ± 1.39) to 106.1 ( ± 1.40) mmHg 
(p = 0.0025). An additional finding emerged on further analysis. The 
blood pressures of Black Africans were significantly reduced by 
verapamil 160 mg' twice daily whether standing or supine, systolic or 
diastolic pressures were considered (p = 0.0025). No such change 
occurred in response to verapamil in Caucasian patients, although the 
overall effect on the whole group was significant, as noted above.
No changes in serum urea, electrolytes or EKG were recorded
during the studies reported here, and no side effects were reported 
except for 1 case of impotence which developed during a placebo phase 
of management and responded to the intramuscular injection of sterile 
saline 1 ml.
DISCUSSION
The protocol followed in this study may be criticized on several 
grounds. Thus, the fixed doses of reserpine and verapamil were used 
throughout the double-blind portion of the trial thereby limiting its value 
since the clinical effects of increasing doses of either medication were 
not assessed. In addition, a 2-week washout period between treatments 
was at least theoretically inadequate, since the effects of verapamil or 
reserpine might persist for the first weeks of the therapeutic regimen. 
This was not borne out by the results obtained, however; combined 
therapy with reserpine and verapamil was superior to treatment with 
reserpine alone, irrespective of the order in which the 2 regimens were 
followed.
Despite these reservations a number of useful points have emerged 
from this study:
Reserpine in a dose of 0.3 mg daily resulted in no clinically signifi­
cant fall in systolic or diastolic pressures whether measured with 
patients in the supine or erect posture. The addition of verapamil 80 mg 
t.d.s. to this regimen reduced arterial pressure significantly, when 
compared with placebo or reserpine alone. No racial difference in these 
results was observed.
In a subsequent open extension to the trial, Caucasian patients 
responded poorly to verapamil 160 mg given twice daily as sole medica­
tion. In black (Zulu) hypertensives, however, significant reductions in 
arterial pressure were obtained when this regimen was used. This 
apparent racial difference, though unexplained at present, is not unpre­
cedented. Racial differences in the response of raised arterial pressures 
to beta blockers have been described elsewhere.8
The response in both groups to verapamil given in combination with 
reserpine appears to support the conception that these compounds may 
act synergistically to reduce blood pressure, although the lack of 
response to reserpine alone suggests that verapamil is of greater impor­
tance in the regimen used.
The results of this study confirm that verapamil has a mild hypo­
tensive effect in the doses tested, and that it offers a rational alternative 
to other treatments currently used in managing hypertension of mild to 
moderate degree. Further studies are required in greater depth to deter­
mine the efficacy of higher doses of verapamil given alone, at different 
intervals, and in combination with various other hypotensive agents.
References:
1. Vohra, J.K.: Clinical use o f verapamil. Drugs 23:219 , 1977.
2. Nayler, W.G., and Krikler, D.: Verapamil and the myocardium. Postgraduate 
Med. J. 5 0 :441, 1974.
3. Schmitt, G.: Uber die protektive Wirkung von Iproveratril bei hypertonie 
b e d i n g t e n  M yokarderkrankungen im Tierexperiment. M edizinische Welt. 
1 8 :2943, 1967.
4. Bender, F.: Die Behandling das tachycardia arrythmien und der arteriellen 
hypertonie uit verapamil. Arzneim ittel-Forschung 2 0 :1310, 1970.
5. Lewis, G.R.J., Morley, K.D., Lewis, B.M., and Bones, P.J.: The Treatment of 
Hypertension with verapamil. New Zealand Med. J. 8 7 :351, 1978.
6. Fuster, A.P., Cortes, A.M., and Nieto, L .P .: Valoracion clinica de los efectos 
antihipertensivos del clorhidrato de Isoptin. Rev. Med. ISSSTE 8:2, 1973.
7. Nunez-Encinas, J.L., and Bittrick, H.: Verapamil 120 mg en hypertension 
arterial estudio hospitalario. Proc. V lth  Peruvian Congress Cardiology, Lima, 
1977.
8. Humphreys, G.S., and Delvin, D.G. Brit. Med. J. 2 :601, 1968.
PAPER B4
Aldactone and Acebutolol in Treatment of Hypertension
I carried out all the work reported here with the assistance 
of two nurses. Professor Asmal provided editorial help.
J  I n t  M e d  R e s  (1979) 7 ,2 9
Reprinted from
The Journal of International Medical Research 
Vol 7 No 1 1979
Aldactone and Acebutolol in Treatment of Hypertension
W P Leary, MSc, MB, BCh (Witwatersrand), DPhil (Oxon), MRCP (London), FCP (SA),
H e a d , D e p a r tm e n t  o f  C lin ic a l  a n d  E x p e r im e n ta l  P h a r m a c o lo g y ,  U n iv e r s i ty  o f  N a ta l ,  
S o u th  A fr ic a
A C Asmal, MD (London), MRCP (London), FCP (SA), P r in c ip a l  P h y s ic ia n /S e n io r  L e c tu r e r ,  
D e p a r tm e n ts  o f  C lin ic a l  a n d  E x p e r im e n ta l  P h a r m a c o lo g y  a n d  M e d ic in e ,  U n iv e r s i ty  o f  N a ta l ,  
S o u th  A fr ic a
P C Williams, SRN, U n iv e r s ity  o f  N a ta l ,  S o u th  A fr ic a  
B Marwick, SRN, U n iv e r s i ty  o f  N a ta l ,  S o u th  A fr ic a
Twenty-one essential hypertensives were randomly treated with Aldactone, 
acebutolol or a combination o f the two drugs. Statistically significant fa lls in 
systolic and diastolic pressures were demonstrated during treatment with 
Aldactone 100 mg daily, also when acebutolol and Aldactone 200 mg daily 
were administered. When the combination o f  Aldactone and acebutolol was 
given, diastolic pressures were lowered to a greater degree than seen with 
individual treatments.
Introduction
Their efficacy and low cost have placed  
thiazide diuretics in an important position in 
the therapy o f  hypertension (Dollery 1977). In 
m ilder grades o f  hypertension  they are 
em ployed alone; in the moderate and severer 
grades they are used in com bination with 
agents such as reserpine, P-blockers and 
m e t h y ld o p a .  P o t a s s iu m  d e p le t i o n ,  
h yp erg lycaem ia  and h yperuricaem ia are 
important adverse effects accom panying their 
long-term use.
The potassium -sparing diuretics such as 
Aldactone® are free o f these adverse effects 
but their use has not been widespread, 
probably because o f  their greater expense. 
They are primarily indicated in hypertensive 
states if associated with hypokalaem ia, and
possibly in situations when thiazides are 
contraindicated (Sim pson 1976). In the present 
paper the efficacy o f  A ldactone in com bination  
with a P-blocker has been investigated in the 
treatment o f  mild to moderate hypertension.
Methods
T w en ty-on e patien ts w ith  u n com p licated  
essential hypertension were studied. Ten were 
Zulus and eleven Indians. All were m ales aged 
28 -  63 years, who attended a clinic held at the 
factory where they were em ployed in various 
capacities. O f the tw enty-one patients, nine 
had been on no previous anti-hypertensive 
therapy and twelve had taken a thiazide 
diuretic either alone or in com bination with 
acebutolol. All m edication w as discontinued 2
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weeks before this study. Informed consent was 
obtained.
Patients attended the clinic every 14 days 
and were given the following treatments, in 
random order, single-blind. Placebo was 
substituted for the relevant active m edication  
as patients were moved between regimens 
3 - 5 .
1. Placebo alone
2. A ldactone 100 mg daily plus acebutolol 
placebo
3. A ldactone 200 mg daily plus acebutolol 
placebo
4. A cebutolol 300 -  400  mg daily plus 
A ldactone placebo
5. A cebutolol 300 -  400  mg daily plus 
A ldactone 100 mg daily
Arterial pressures were measured at 0900  
hours by the sam e observer throughout the 
trial using the standard indirect auscultatory  
method. Patients rested for 5 minutes and 
stood for 3 minutes before measurement o f  
supine and erect pressures respectively. The 
low est o f  three measurements in each position  
was recorded at every exam ination, diastolic 
p ressu re  b e in g  tak en  at th e c o m p le te  
disappearance o f sounds.
M edicines were taken at 07 0 0  hours as a 
single dose. A ldactone was given as a fixed 
d o s e , e ith er  100 m g or 2 0 0  m g d a ily . 
A cebutolol dosage was chosen on the basis o f  
previous experience with this (3-blocker in 
individual patients, where this was available, 
or in accordance with the clinical response 
monitored by the observer. A cebutolol dosage  
was increased by 100 mg daily until supine 
diastolic pressure was less than 100 mm Hg on 
two separate occasions or pulse rate fell below  
5 0  p er m in u te . E a c h  tr e a tm e n t  w a s  
adm inistered  for 8 w eeks or until the 
maximum acebutolol dosage had been in effect 
for a month.
T o minimize the ‘carry-over effects o f each  
preceding m edication, the only data recorded  
at W eeks 6 and 8 were analyzed for purposes 
o f  com parison between the regimens followed.
Resting E C G s were recorded and venous 
blood sam ples drawn for measurem ents o f  
plasm a urea and electrolytes during treatment 
with placebo, and acebutolol plus A ldactone.
D ata collected from each patient were 
an alyzed  for sta tistica l sign ificance o f  
responses to therapy using Student’s t test for 
paired com parisons.
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Results
T w enty-one patients were studied. Three did 
not com plete therapy. Mean acebutolol dose 
was 399 mg when taken as sole medication  
and 365 mg in com bination with A ldactone 
100 mg.
The mean supine systolic and diastolic 
pressures (Table 1) fell from 154/103 during 
placebo therapy to 144/98  when A ldactone  
100 mg was given. This change was significant 
for both systolic and diastolic pressures 
(p < 0 -0 2 5 ; p < 0 -0 1 ) respectively. Significant 
falls in pressure also occurred when acebutolol 
or A ldactone 200 mg were given alone. These 
p ressu re  c h a n g e s , h o w ev e r , w ere n ot  
statistically different to those seen with 
A ldactone 100 mg. Com bination o f A ldactone 
100 mg with aceb u to lo l low ered b lood  
pressure to 144/92. The diastolic response was 
significantly better than o f  either A ldactone 
(p < 0 -0 0 5 ) or acebutolol (p < 0 -0025) given 
alone.
The blood pressure responses in the erect 
posture were similar to those described above 
(T able 2). M ean sy sto lic  and d iasto lic  
pressures fell from 144/105 during piacebo  
treatment to 140/100  in response to A ldactone 
100 m g. A ld a c to n e  2 0 0  m g d a ily  and  
acebutolol given singly reduced pressure to 
141/101 and 143/98 respectively. All three 
regimens produced significant lowering o f  
diastolic pressures only. The com bination o f  
acebutolol and A ldactone 100 mg, however, 
lowered both systolic and diastolic pressures in 
relation to the other schedules o f  therapv 
(p < 0-05).
N o  significant change in E C G , resting pulse, 
urea or electrolyte levels was detected (Table 
3), although in seven patients serum potassium  
rose slightly during therapy.
Discussion
T h e aim  in trea tin g  u n c o m p lic a te d  
hypertension is to lower pressure, thereby 
forestalling the development o f  com plications 
and improving prognosis, without causing 
major discom fort or inconvenience to the 
patient (Simpson 1974). This was achieved to 
som e degree by the regimens used in this 
study, although prolonged trials might reveal 
shortcom ings in therapy not apparent here.
Small but significant falls in both systolic  
and diastolic arterial pressures were produced
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T a b le  1
Effects of Aldactone and acebutolol on supine arterial 
pressures
Therapy
Systolic
pressure
Diastolic
pressure
1. Placebo 154-3
5-28
103-4
1-51
2. Aldactone 100 m g I4 4.3****
3-75
97-5**
2-26
3. Aldactone 200 m g 148-1
4-21
99-2*
1-87
4. Acebutolol 149-8**
5-08
98-5***
1-86
5. Acebutolol and 144-4 91-8"
Aldactone 100 m g 4-37 1-86
Pressures expressed in m m  Hg, as mean ± S E M  
Significance of treatment cf. placebo data (paired 
comparison):
* p < 0-025 
** pcO-Ol  
*** p < 0-005 
**** p < 0-0025 
Treatment 5 compared to 4 and 2:
=  p < 0-005
T a b le  2
Effects of Aldactone and acebutolol on erect arterial 
pressure
Therapy
Systolic
pressure
Diastolic
pressure
1. Placebo 143-9
4-23
104-8
1-97
2. Aldactone 100 m g 140-4
4-66
100-4***
2-21
3. Aldactone 200 m g 140-0
3-03
101-3*
1-58
4. Acebutolol 143-2
5-14
98-4**
2-13
5. Acebutolol and 
Aldactone 100 m g
134-8
3-59
95-2 = 
1-66
Pressures expressed in m m  Hg, as mean ± S E M  
Significance of treatment cf. placebo data (paired 
comparison):
* p < 0-05 
** p < 0-025
*** p<0-01
Treatment 5 cf. 2 and 4:
=  p < 0-05
T a b le  3
Effects of Aldactone and acebutolol on pulse beat, urea and electolytes
Pulse Urea Na Kf
Placebo 74-3 
± 2-81
4-1
±0-39
140-7 
± 0-84
4-4
±0-13
Aldactone 100 m g 78-8 
± 3-63 — — —
Aldactone 100 m g  
and Acebutolol
72-7 
± 3-38
4-5
±0-44
141-2 
± 0-91
4-5
±0-07
Values expressed as group mean ± SEM. Pulse, beats/min, urea, N a +, K +, mmol/1. 
N o  statistically significant changes occurred.
by A ldactone or acebutolol given as sole 
m e d ic a t io n . T h e h y p o te n s iv e  e ffe c t  o f  
A ldactone was not dose-related as indicated 
by the fact that responses to 100 and 200 mg 
doses were indistinguishable.
Increase in daily dosage above 100 mg is 
therefore not warranted, particularly since 
larger doses o f  this steroid often cause 
g y n a e c o m a s t ia  in m en  and m en stru a l 
irregularities in wom en.
Com bination o f  A ldactone with acebutolol 
produced a marked improvem ent in both 
supine and erect blood pressure consistent 
with results o f  studies in which P-blockers have 
been prescribed with amiloride, an unrelated 
potassium -sparing diuretic (A .M .A . Drug  
Evaluations, 1977).
Satisfactory control o f  arterial pressure may 
be obtained by acebutolol administered once 
daily (Fournier e t a l  1976). Though pressures 
were not measured throughout the day during 
the present study, the fact that control at 0900  
hours was enhanced by A ldactone which has a 
relatively prolonged action suggests that 
improved blood pressure control might also be 
obtained by this com bination over 24 hours. 
This approach to m anagem ent with A ldactone  
requires further detailed investigations.
Over the short period o f  observation o f  this 
trial the com bination o f  acebutolol and
Aldactone has dem onstrated efficacy and 
re la t iv e  sa fe ty . H o w e v e r , it is w orth  
rem em b erin g  th a t th e m a n a g em en t o f  
hypertension is that o f  chronic disease. 
Chronic injudicious use o f  A ldactone may 
cause gynaecom astia, hyponatraem ia and 
h yperkalaem ia. T he frequency o f  th ese  
problems as well as the sustained efficacy o f  
this drug over prolonged periods has been 
in v e s t ig a te d  by a lo n g -ter m  s tu d y  in 
hypertensive patients, however, and it appears 
that adverse responses to A ldactone should be 
relatively uncom m on (Cangiano e t a l  1977).
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PAPER B5
Antihypertensive Effects of Sotalol and Atenolol Given Once Daily
I carried out all the work reported here with the assistance 
of two nurses. Professor Asmal provided editorial help.
Reprinted from the “SA Medical Journal”, Vol. 57, 26 April 1980, pages 692 - 695
Antihypertensive Effects of Sotalol and Atenolol Given
Once Daily
W . P. L E A R Y , A . C. ASM AL, 
SU M M A R Y
Twenty-five male patients aged 21-65 years and with 
supine diastolic arterial pressures of 96-120 mmHg 
entered an open, controlled cross-over study, in which 
the effects of single daily doses of sotalol and atenolol 
were compared. Data collected indicate that moderately 
elevated blood pressure is effectively controlled for 24 
hours by single daily doses of both /3-blockers (sotalol 
160-800 mg and atenolol 100 - 500 mg). No important 
side-effects occurred.
S. Afr. med. J., 57, 692 (1980).
The management of raised arterial pressure in m a n  poses 
various problems for both medical attendant and patient. 
Despite attempts at patient education and motivation, non- 
compliance with prescribed therapy is c o m m o n 1 and may 
reflect the patients’ difficulty in remembering to take mul-
Departments of Clinical Pharmacology and Medicine, Univer­
sity of Natal, Durban
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tiple doses of medicine in the course of a busy day, or 
reluctance to use medicines which cause unpleasant side- 
effects. Since improved patient compliance m a y  be ex­
pected if simple treatment regimens are followed for 
chronic conditions such as hypertension, it is important 
to establish whether the medicines prescribed are effective 
for 24 hours when given in single daily doses.
Sotalol and atenolol are /3-adrenergic blocking agents, 
both of which effectively reduce raised arterial pressure in 
m a n  despite slightly different pharmacological characteris­
tics.2’3 Sotalol is a non-selective /3-blocker with no intrinsic 
sympathomimetic or membrane-stabilizing activity, and a 
plasma half-life of 15 - 17 hours. Atenolol, like sotalol, 
lacks intrinsic sympathomimetic and membrane-stabilizing 
activity, but is relatively cardioselective and has a shorter 
half-life in m a n  —  only 8 hours. Both these components 
m a y  provide satisfactory control of raised blood pressure 
in m a n  for up to 24 hours, but their relative efficacies 
within a single group of patients have not been estab­
lished.
The controlled, open, cross-over study reported in this 
article was designed to compare the effects of single daily 
doses of sotalol and atenolol given to patients with m o d e ­
rately elevated arterial pressures. Particular attention was 
paid to side-effects and the relative potencies of the two 
agents concerned.
PATIENTS AND METHODS
The arterial pressures of clerical and manual workers 
employed at a local factory were measured by trained 
nursing staff at a casualty clinic on the factory premises. 
Subjects with supine diastolic pressures above 95 m m H g  
were referred to a medical practitioner for assessment and 
possible treatment. O n  referral a medical history was 
obtained and a general clinical examination carried out. 
Arterial pressure was measured at this examination and 
again 7 days later. Patients rested supine for 5 minutes 
or stood upright for 2 minutes before measurement of 
arterial pressures by standard sphygmomanometry. The 
first appearance and final disappearance of Korotkov 
sounds were used to define systolic and diastolic pressures 
respectively. Pulse rate was counted over 30 seconds in 
both postures. The protocol and aims of the study were 
explained to those patients whose supine diastolic pres­
sures remained consistently above 95 m m H g ,  so that 
informed consent for further studies could be obtained. 
Venous blood samples were collected from each patient 
and evaluated for serum bilirubin, cholesterol, triglyceride, 
transaminase, uric acid, urea, creatinine, sodium and 
potassium concentrations. A  full blood count, standard 
urinalysis and a 12-lead E C G  were also performed.
A  total of 25 male patients in the age group 21-65 
years and with supine diastolic pressures between 96 and 
120 m m H g  entered the study. Patients were excluded 
from the clinical trial and given alternative treatment if 
they suffered from congestive cardiac failure, secondary 
hypertension, atrioventricular block, active hepatic or 
renal disease, diabetes uncontrolled by diet alone, major 
respiratory disease, asthma, oedema of any cause, or 
obesity. Patients with a history of adverse reaction to 
^-blockers, laboratory or clinical evidence of significant 
disease unrelated to hypertension, or receiving concomi­
tant medication for any other ailment were also excluded 
from the trial.
Previous antihypertensive therapy was discontinued and 
patients were randomly allocated to one of two groups: 
placebo tablets for sotalol 160 m g  (group A) or for atenolol 
100 m g  (group B), with the instruction that one should 
be taken every morning at 08h00. After 4 weeks this was 
replaced by active sotalol 160 m g  (group A), or atenolol 
100 m g  (group B). Patients attended the clinic weekly for 
the first 4 weeks and every 2 weeks thereafter for the 
duration of the clinical trial. Throughout the trial blood 
pressure recordings were taken in the early morning before 
drug administration (24 hours after the previous medica­
tion), and in the late afternoon (8 hours after previous 
medication).
If the supine diastolic blood pressure of any patient 
remained above 90 m m H g  at the end of the first 2 weeks 
of active therapy, the dose of sotalol was increased to 
320 m g  or that of atenolol to 200 m g  daily. Further 
adjustments to 480, 640 and 800 m g  sotalol or 300, 400 
and 500 m g  atenolol per day were made every 2 weeks 
if arterial pressure remained inadequately controlled. 
Active medication was given for a total of 14 weeks, 
followed by a 4-week wash-out period during which 
atenolol placebo was given to patients in group A  and 
sotalol placebo to patients in group B. This was followed
by dosage with active medication, following the protocol 
used during the previous 14-week treatment period. Thus 
patients in group A  were given sotalol and atenolol in 
turn, and patients in group B  took the same medicines 
but in reverse order. Laboratory investigations and E C G s  
were repeated during the final week of each treatment 
period.
Means of pulse rates and supine and standing systolic 
and diastolic pressures recorded for each patient during 
placebo therapy and at each treatment stage were noted 
and used for statistical analysis. Significance of responses 
to placebo, atenolol (100 - 200 m g  and 100 - 500 mg) and 
sotalol (160 mg, 160 - 320 m g  and 160 - 800 mg) was 
determined by Student’s t test for paired data using a 
programme prepared for the Hewlett-Packard 637 c o m ­
puter, after pooling of data collected from groups A  and
B.
RESULTS
Results are set out in Tables I - IV. A  total of 23 patients 
of w h o m  12 were Blacks and 11 Whites completed the 
study. T w o  patients were excluded during placebo therapy. 
N o  significant differences emerged relating to the order in 
which the drugs were given.
Effect of Sotalol on Blood Pressure
Supine systolic and diastolic pressures were reduced 
8 hours after the m a x i m u m  dosage of sotalol (Table I). 
These changes were statistically significant for both 
systolic and diastolic pressures (P =  0,05). Diastolic 
pressure remained significantly reduced after 24 hours 
(P =  0,005). The mean m a x i m u m  dose of sotalol given 
was 459,2 m g  per day (range 160 - 800 mg). Each patient 
took sotalol 160 mg, 17 were given 320 m g  daily and 13 
graduated to higher doses.
Similar changes were noted for erect systolic and 
diastolic pressures 8 hours after sotalol. These changes 
were statistically significant for both systolic (P =  0,0025) 
and diastolic pressures (P =  0,0025) and were maintained 
after 24 hours (P — 0,005).
Analysis of responses to lower doses of sotalol given 
early in the trial showed no significant differences between 
the means of supine pressures recorded during treatment 
with sotalol 160 or 320 m g  and the m a x i m u m  dose given. 
In 6 patients sotalol 160 m g  was the highest dose used; 
arterial pressure fell slightly in a further 7 after sotalol 
320 m g  and 480 - 800 m g  caused further reductions in 
another 8 patients. These changes were not statistically 
significant, however. Standing arterial pressure responded 
similarly, although control at 8 hours was significantly 
improved by doses above 160 mg. Thus diastolic pressures 
were reduced by sotalol 320 m g  (P =  0,025) and a further 
significant reduction in both systolic and diastolic pres­
sures was recorded at the m a x i m u m  dose (P =  0,05).
Effect of Atenolol on Blood Pressure
The mean dosage of atenolol was 282,6 m g  daily (range 
100 - 500 mg). Every patient took atenolol 100 mg, 17 
were given 200 m g  daily and 11 eventually took higher 
doses. Supine systolic and diastolic pressures were reduced
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TABLE 1. EFFECTS OF SOTALOL ON ARTERIAL BLOOD PRESSURE (mmHg)
P la ce b o 160 mg 160 mg 1 6 0 -3 2 0  mg 160 - 320 mg 160 -8 0 0 mg 160 -8 0 0 mg
(24 h) (8 h) (24 h) (8 h) (24 h) (8 h) (24 h)
S y s D ia s S y s D ia s S y s D ia s S y s D ia s S y s D ia s S y s D ia s S y s D ia s
Supine
Mean 151,5 104,3 148,6 97,0 145,8 96,6 147,4 94,1 147,2 93,0 145,7 92,6 147,7 91,2
SEM 1,95 1,15 3,25 2,22 2,27 2,55 3,54 2,62 3,41 2,27 3,68 2,28 4,16 2,29
Erect
Mean 151,7 109,5 149,0 105,9 145,1 99,5 147,4 100,0 145,1 100,0 142,1 97,5 144,7 99,4
SEM 2,01 1,39 3,63 2,24 3,49 1,94 3,07 2,00 2,89 2,41 2,61 2,80 2,69 2,01
TABLE II. EFFECTS OF ATENOLOL ON ARTERIAL BLOOD PRESSURE (mmHg)
P la ce b o 100 mg 100 mg 1 0 0 -2 0 0  mg 1 0 0 -2 0 0  mg 100 - 500 mg 1 0 0 -5 0 0 mg
(24 h) (8 h) (24 h) (8 h) (24 h) (8 h) (24 h)
S y s D ia s S y s D ia s S y s D ia s S y s D ia s S y s D ia s S y s D ia s S y s D ia s
Supine
Mean 153,1 98,2 146,4 93,8 146,6 96,2 144,4 91,4 144,8 92,7 145,8 90,9 141,5 87,4
SEM 3,43 2,49 4,24 3,36 4,16 3,75 4,17 2,85 3,93 3,19 4,65 3,00 3,86 2,25
Erect
Mean 152,4 107,9 148,7 102,8 148,7 103,5 146,6 99,4 145,4 98,5 147,3 100,6 144,7 97,4
SEM 3,70 2,27 3,71 2,97 4,14 3,34 3,61 2,26 3,12 2,55 3,55 2,12 2,77 1,98
8 hours after dosage with atenolol (Table II). These 
changes were statistically significant for both systolic 
(P — 0,025) and diastolic (P =  0,0025) pressures. The 
lowered pressures were maintained 24 hours after the last 
dose of atenolol and remained significantly lower than 
those recorded during placebo therapy (P =  0,0025).
Erect arterial pressures were reduced 8 hours after 
dosage with atenolol. The slight fall in systolic pressure 
noted was unimportant but the change in diastolic pressure 
was statistically significant (P =  0,005). The changes were 
maintained 24 hours after the last dose of atenolol (P =  
0,005).
Responses to atenolol 100 and 200 m g  daily were also 
analysed. M e a n  supine pressures were reduced 8 and 24 
hours after atenolol 100 m g  (Table II). These pressure 
changes were significant when compared with responses to 
placebo (P =  0,01), but systolic and diastolic pressures 
were slightly higher 24 hours after atenolol 100 m g  than 
at the same time after m a x i m u m  dosage (P =  0,05). 
Responses to atenolol 200 m g  were indistinguishable from 
those to the m a x i m u m  dose used, although 11 patients 
required more than 200 m g  atenolol daily. As in the case 
of sotalol, 6 patients responded satisfactorily to the lowest 
dose used.
N o  clinically important differences were found between 
responses to maximal doses of the two compounds tested. 
Erect systolic and diastolic pressures were slightly lower 
after sotalol than after atenolol at the 8-hour examina­
tion. whereas 24-hour supine systolic pressure was best 
controlled by atenolol (P =  0,05).
Three patients responded poorly to both these c o m ­
pounds and their supine diastolic pressures remained 
above 100 m m H g ,  despite doses of sotalol 800 m g  or 
atenolol 500 m g  daily. T w o  patients were relatively re­
sistant to sotalol 800 m g  and 3 to atenolol 500 mg. Six of 
these patients were Blacks (Zulu) and 2 were of Indian 
descent.
Effect on Pulse Rates
Supine and erect pulse rates were reduced 8 hours 
after m a x i m u m  doses of sotalol and were maintained after 
24 hours. These changes were highly significant (P =  
0,0005). Pulse rates were also markedly reduced, below 
the levels produced by placebo, by sotalol 160 and 320 
m g  (P =  0,005), but were slightly higher at 24 hours than 
those recorded at m a x i m u m  dosage (P =  0,025).
Responses to atenolol were similar. Supine and erect 
pulse rates were reduced 8 and 24 hours after m a x i m u m  
doses (Table IV). These changes were highly significant 
(P =  0,0005) with the exception of that in the erect pulse 
rate at 24 hours, which barely achieved acceptable signi­
ficance levels (P =  0,05). Pulse rate was also reduced by 
atenolol 100 or 200 m g  daily, although supine and erect 
pulse rates were higher at 8 hours after 100 m g  than after 
m a x i m u m  doses of atenolol (P =  0,025). Pulse rates were 
significantly lower 24 hours after m a x i m u m  doses of 
sotalol than after similar doses of atenolol, although in 
practical terms the difference was slight (P =  <0,005). 
O n  detailed analysis only 3 patients appeared relatively 
resistant to the negative chronotropic effects of the two 
compounds tested. All 3 showed satisfactory responses 
in arterial pressure, however. N o  major side-effects were 
reported in this study although three Blacks complained 
of relative impotence while on placebo therapy. N o  im­
portant changes in electrocardiographic or laboratory 
values were recorded.
TABLE III. EFFECTS OF SOTALOL ON PULSE RATE (PER MINUTE)
P la ce b o  
(24 h)
160 mg 
(8 h)
160 mg 
(24 h)
1 6 0 -3 2 0  mg 
(8 h)
1 6 0 -3 2 0  mg 
(24 h)
160 - 800 
(8 h)
mg 160 - 800 mg 
(24 h)
S E S E S E S E S E S E S E
Mean
SEM
77,7 84,0 
2,25 2,29
68,6
2,28
75,0
2,50
70,7 76,3 
2,62 2,66
68,7 73,4 
2,59 2,59
70,7 77,3 
2,47 2,72
67,1 72,2 
2,68 3,25
66,1 71,4 
2,39 2,59
S = supine. E = erect.
TABLE IV. EFFECTS OF ATENOLOL ON PULSE RATE (PER MINUTE)
P la ce b o  
(24 h)
100 mg 
(8 h)
100 mg 
(24 h)
100 - 200 m g 
(8 h)
100 - 200 mg 
(24 h)
1 0 0 -5 0 0  
(8 h)
mg 100 - 500 mg 
(24 h)
S E S E S E S E S E S E S E
Mean
SEM
74,2 80,5 
2,39 2,77
70,1
2,39
74,3
2,62
70,4 76,0 
2,08 2,11
68,0 70,8 
2,03 2,23
70,2 77,1 
2,45 2,71
65,7 70,2 
1,86 2,24
68,3 76,4 
2,22 2,63
S =  supine, E =  erect.
DISCUSSION
The data presented in this article indicate that moderately 
elevated arterial blood pressure m a y  be effectively con­
trolled for 24 hours by single daily doses of sotalol or 
atenolol, as is the case with other /3-adrenoceptor antago­
nists, including acebutolol and timolol.'1’5 Atenolol proved 
slightly more potent than sotalol by a factor of about 1 ,6, 
but patients required an average of 2 - 3 tablets daily, 
irrespective of the preparation in use. Single doses of both 
compounds reduced resting pulse rates, but sotalol was 
more effective than atenolol at 24 hours, possibly indica­
ting slightly superior maintenance of anti-anginal and anti- 
arrhythmic effects.
N o  significant haematological or biochemical changes 
were observed during the study and very few adverse 
reactions were reported. Three patients developed impo­
tence during placebo therapy; 2 were excluded from 
further studies and 1 responded to reassurance and was 
able to complete the trial. N o  patient complained of 
excessive fatigue, and bronchospasm did not occur. Thus 
the relative cardioselectivity of atenolol offered no obvious 
advantage over sotalol, in terms of either blood pressure 
control or freedom from side-effects, in this group of 
otherwise healthy hypertensives. Cardioselectivity might 
nevertheless be important in the management of hyper­
tensives with bronchial asthma or insulin-dependent dia­
betes mellitus, although therapists would be well advised 
to use all /3-adrenoreceptor antagonists cautiously in the 
presence of these conditions.
Compliance with prescribed treatment was not investi­
gated by measurement of serum drug levels in this study, 
although the fall in heart rate which was recorded in 
almost 9 0 %  of patients taking either medication suggests 
that it was remarkably good. Certainly there is no reason 
to suspect that compliance was inferior to that obtained 
with multiple-dose regimens.
Taken as a group, these patients fared almost as well on 
low doses of sotalol or atenolol as on the m a x i m u m  doses 
given. This suggests that the practice of increasing doses 
of expensive /3-antagonists above levels which reduce the' 
pulse rate by 10 - 20%  m a y  be wasteful and that a diuretic 
should probably be added to the regimen at an early 
stage when hypertension is treated with /3-antagonists.
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Antihypertensive and Metabolic Effects of a Combination of 
Hydrochlorothiazide and Amiloride
This work was carried out by me and analysed and prepared for 
publication in collaboration with Professor A.J. Reyes.
Antihypertensive and metabolic effects 
of a combination of hydrochlorothiazide 
and amiloride
W. P. LEARY, A. J. R EYES
S u m m a r y
A combination of hydrochlorothiazide 50 mg and 
amiloride 5 mg (HTZ + AMI) was administered twice 
daily for 12 weeks to 18 hypertensive patients, as a 
monotherapy. There was a statistically and 
clinically significant decrease in the mean blood 
pressure level throughout the treatment period.
Significant steady or random changes in blood 
variables included decreases in chloride, 
magnesium and bilirubin levels and increases in 
sodium , ca lc iu m , phosp horus, creatin in e , 
triglycerides, total protein, albumin, alkaline 
phosphatase and SG PT levels. Blood urea nitrogen 
values changed biphasically. Most of these 
statistically significant metabolic changes had no 
clinical relevance.
The dosage problem with HTZ + AMI is 
discussed. «'
S. Afr. m ed J „  60, 381 (1981).
Diuretics are the drugs of first choice in the treatment of 
hypertension. 1 A  combination of hydrochlorothiazide 50 m g  and 
the potassium-sparing diuretic amiloride 5 m g  ( H T Z  +  A MI) 
has been demonstrated to be an effective antihypertensive 
medication when used as monotherapy.2’4 However, published 
observations on-the metabolic effects of this drug combination 
do not provide comprehensive cover of biochemical variables in 
blood and are not consistent with each other.2’ 4
The principal objective of this study was to evaluate the 
metabolic effects of H T Z  +  A M I  administered to hypertensive 
patients at its highest recommended dose of 2 tablets per day.
P a t i e n t s  a n d  m e t h o d s
Patients
Eighteen ambulatory male patients aged 2 1 - 6 5  years 
consented to participate in the trial after they had been fully 
informed about its objectives and implications. Patients had 
mild-to-moderately severe hypertension with supine diastolic
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blood pressure readings between 90 and 120 m m H g .  Fourteen 
were Blacks and 4 were Whites.
Patients who fell within one or more of the following 
categories were not included in the trial: secondary or renal 
hypertension, congestive cardiac failure, a history of severe 
cerebrovascular or hepatic impairment, impaired renal function 
(creatinine >  2 mg/dl), hyper- (> 5,5 mEq/1) or hypokalaemia 
(< 3,5 mEq/1), clinical evidence or history of gout, abnormal 
pretreatment laboratory tests (except high blood glucose which 
was not an exclusion criterion), or retinopathy more severe than 
slight irregularity or narrowing of vessels. Patients taking cardiac 
glycosides or psychotropic drugs were also excluded.
M easurem ents
Arterial pressures were measured in the working arm by the 
standard indirect technique, using the first appearance and final 
disappearance of KorotkofPs sounds to define systolic and 
diastolic pressures, respectively. The mean arterial blood 
pressure was defined as the diastolic pressure plus one-third of 
the pulse pressure. Patients rested supine for 10 minutes and 
stood upright for 3 minutes before measurement of supine and 
erect pressures, which were each measured three times, the 
average values being recorded. All blood pressure measurements 
were done between 08h00 and 09h30. The sphygmomanometer 
and stethoscope used for blood pressure measurements were the 
same throughout the trial. Clinical evaluations were carried out 
by the same observer physician throughout the trial.
The following variables were measured in blood or serum 
samples by standard laboratory techniques in 14 patients: 
chloride, sodium, potassium, calcium, phosphorus, magnesium, 
osmolality, blood urea nitrogen, creatinine, uric acid, glucose, 
cholesterol, triglycerides, total protein, albumin, bilirubin, 
alkaline phosphatase, y-glutary ltransferase, S G O T  and SGPT.
Procedure
All diuretic and/or antihypertensive medication being taken 
by the patients was discontinued and 1 placebo capsule was 
prescribed twice daily for 4 weeks. H T Z  +  A M I  was then 
substituted for 12 weeks, and thereafter placebo was prescribed 
as in the run-in period for 4 more weeks.
Diet was not restricted, and contained approximately 2 g 
sodium per day. Complete clinical evaluations were carried out 
every 4 weeks. Laboratory analyses were done at the beginning of 
the trial, at the end of the run-in placebo period (referred to as 
week 0 hereafter) and at the end of the 4th, 8th and 12th weeks of 
active treatment.
Statistics
Results are expressed as mean values ±  standard errors of the 
means (SEM). Values during treatment and after treatment were 
contrasted with pretreatment (week 0) values. Variance 
homogeneities were tested through the F ratio. W h e n  variances 
were homogeneous, a paired t  test was used to compare meanDate received: 20 May 1981.
values and, when variances were not homogeneous, Wilcoxon’s 
signed rank test was used instead. All tests were two-tailed and P 
= 0,05 was considered the upper limit of significance.
R e s u l t s
Effects o f  HTZ +  AMI on arterial blood  
pressure and heart rate
H T Z  +  A M I  decreased mean blood pressure significantly 
compared with control values (Fig. 1). These changes were of 
clinical significance but 4 weeks after treatment was 
discontinued mean blood pressure did not differ significantly 
from control (week 0) levels (Fig. 1).
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Fig. 1. Mean blood pressure values (± SEM) in 18 hypertensive patients 
before (week 0), during (weeks 4 - 8 )  and after (week 16) treatment with 
HTZ + AMI twice daily.
A  significant increase (P<0,05) in heart rate was observed at 
the end of week 8. However, it had no clinical importance, 
ranging from 77,8 ±  2,6/min in week 0 to 83,1 ±  2,0/min in week 
8.
Effects o f  HTZ +  AMI on serum electrolytes
The results are shown in Table I. Serum chloride decreased
significantly throughout the treatment period, its lowest level 
being found at the end of week 4; it recovered, but was still below 
control levels thereafter. Serum sodium had increased 
significantly by the end of week 8. Serum potassium did not 
change significantly during treatment. Serum calcium was 
significantly increased at the end of week 8. Serum phosphorus 
was significantly increased at the end of weeks 4 and 8 and 
returned to control levels at the end of week 12. Serum 
magnesium was significantly below control level at the end of 
week 12.
Effects o f  HTZ +  AMI on biochem ical blood  
variables other than electrolytes
The results are shown in Table II. Plasma osmolality did not 
change significantly during H T Z  +  A M I  treatment. Blood urea 
nitrogen increased significantly by the end of week 4, decreasing 
to control values at the end of week 8 and finally decreasing 
significantly compared with pretreatment levels at the end of 
week 12. Serum creatinine was found to be significantly 
increased at the end of weeks 4 and 8 and returned to normal 
values at the end of week 12. It followed a decreasing trend 
throughout treatment that paralleled that of blood urea nitrogen. 
Serum uric acid did not change significandy during H T Z  +  
A M I  treatment.
Blood glucose did not change significandy during H T Z  +  
A M I  treatment. However, as 4 patients were diabetics under 
dietary treatment, two different biological populadons as regards 
blood glucose should be considered; one group, consisting of 10 
patients, was a population of non-diabetics whose blood glucose 
values did not change significantly during treatment (Table II). 
The other population consisted of 4 diabetics who were not fully 
compensated and whose management was not changed during 
H T Z  +  A M I  treatment; blood glucose did not change 
significantly in this group either during treatment with H T Z  
+ A M I .
Plasma cholesterol did not change significantly during H T Z  
+ A M I  treatment and serum triglycerides were found to be 
increased compared with week 0 only at the end of week 8 of 
treatment.
Total plasma protein was significantly increased at the ends of 
week 8 and week 12 of treatment, whereas plasma albumin was 
significantly increased throughout treatment. Serum bilirubin 
was found to be significantly decreased at the end of weeks 4 and 
12. Serum alkaline phosphatase was significantly increased at the 
end of weeks 8 and 12 of H T Z  +  A M I  treatment. Serum y -  
glutaryltransferase and S G O T  did not change significantly 
during treatment. S G P T  increased significantly at the end of 
week 12 of treatment, but remained well within the normal 
range.
TABLE I. SERUM ELECTROLYTE CONCENTRATIONS (MEAN ± SEM) IN 14 HYPERTENSIVE 
PATIENTS BEFORE AND DURING TREATMENT WITH A COMBINATION OF HTZ + AMI
Pretreatment At the end of treatment week:__________
Electrolyte (last on placebo) 4 8 12
Chloride (mEq/l) 102,6 + 0,8 97,7 ± 0,8§ 100,2 ± 0,6' 100,8 ± 0,7
Sodium (mEq/l) 145,1 ± 0,6 146,5 ± 0,9 147,0 ± 0,8* 100,8 ± 0,7*
Potassium (mEq/l) 4,11 ± 0,06 4,21 ± 0,01 4,23 ± 0,10 3,93 ± 0,08
Calcium (mmol/l) 2,44 ± 0,04 2,53 ± 0,03 2,64 ± 0,03t 2,47 ± 0,04
Phosphorus (mmol/l) 1,12 ± 0,03 1,33 ± 0,05f 1,26 ± 0,04+ 1,04 ± 0,07
Magnesium (mmol/l) 0,85 ± 0,02 0,86 ± 0,02 0,85 ± 0,02 0,79 ± 0,02+
Significances of differences with respect to pretreatment means:
*P<0,05.
tP<0,02.
tP<0.01.
§P<0.001.
TABLE II. HAEMATOLOGICAL VARIABLES (MEAN + SEM) OTHER THAN SERUM ELECTROLYTES  
IN 14 HYPERTENSIVE PATIENTS BEFORE AND DURING TREATMENT WITH HTZ + AMI
TWICE DAILY
Pretreatment At the end of treatment week:
Variable (last on placebo) 4 8 12
Osmolality (mOsm/kg) 281,3 ± 1,8 283,9 ± 3,9 277,1 ± 1,4 276,5 ± 3,4
BUN (mmol/l) 4,05 ± 0,33 5,48 ± 0,42f 3,61 ± 0,29 2,12 ± 0,26*
Creatinine (mmol/l) 101,4 ± 3,7 120,5 ± 5,7§ 113,0 ± 4,4* 111,4 ± 3,3
Uric acid (mmol/l) 0,31 ± 0,02 0,32 ± 0,02 0,33 ± O o is 0,33 ± 0,02
Glucose (N = 14) (mg/dl) 120,7 ± 16,2 140,5 ± 20,3f 120,8 ± 12,5$ 131,2 ± 17,1
Glucose (N = 10) (mg/dl) 95,5 ± 5,0 103,3 ± 6,2U 102,0 ± 6,8 107,8 ± 11,6
Cholesterol (mmol/l) 4,69 ± 0,27 4,70 ± 0,30 4,96 ± 0,24 4,97 ± 0,24
Triglycerides (mmol/l) 2,07 ± 0,25 2,31 ± 0,24 2,85 ± 0,34* 2,67 ± 0,42
Total protein (g/l) 76,6 ± 1,4 77,0 ± 1,3 81,6 ± 1,4* 80,6 ± 1,7
Albumin (g/l) 43,5 ± 1,2 46,3 ± 0,6 49,1 ± 1,0t 47,9:± '1,2H§
Bilirubin (Mmol/l) 9,69 ± 1,23f 5,27 ± 0,98 9,33 ± 0,94U 5,30 ± 0,91*
Alkaline phosphatase (U/l) 120,1 ± 7,9 135,0 ± 10,6 148,5 ± 13,3f 138,1 ± 8,9t
y-glutaryltransferase (U/l) 51,4 ± 10,2 59,8 ± 11,5 56,7 ± 14,2 51,2 ± 12,6
SGOT (U/l) 21,1 ± 1,9 23,4 ± 2,2 22,8 ± 3,5 25,0 ± 3,8
SGPT (U/l) 14,1 ± 1,3 16,2 ± 1,9$ 14,9 ± 2,3 19,9 ± 2,4|
Significances of differences with respect to pretreatment means: 
*P<0,05.
+PC0.02.{PC0.01.
§P<0.001.
f  Data from 13 patients.
SData from 12 patients.
N o  change occurred in biochemical variables in individual 
patients that could indicate a toxic effect of the drug 
combination. H T Z  +  A M I  was well tolerated and no clinical 
signs of side-effects were observed.
Discussion
Effects o f  HTZ +  AMI on serum  electrolytes
The significant decrease found in serum chloride values is a 
well-recognized effect of thiazide diuretics. The trend whereby 
serum chloride levels returned toward reference levels as 
treatment progressed indicates that homeostatic adjustments 
take place during prolonged diuretic treatment.5
The transient significant increase in serum sodium found at 
the end of week 8 of treatment was irrelevant in clinical terms.
Serum potassium values did not change significantly during 
H T Z  +  A M I  treatment, thus demonstrating that 10 m g  
amiloride daily can prevent the development of hypokalaemia 
without raising serum potassium to dangerous, abnormally high 
levels, when 100 m g  hydrochlorothiazide is administered 
conjointly. However, these results should not be considered as 
the end-point of the potassium problem during diuretic 
treatment, since what actually matters, both physiologically and 
clinically, is the intracellular potassium level. 1 Normal serum 
potassium levels do not necessarily reflect normal intracellular 
levels since potassium has to be actively pumped into the cells in 
order to keep its high intracellular concentration; the activity of 
the potassium p u m p  is critically determined by the intracellular 
level of magnesium . 1 Diuretics increase renal magnesium 
excretion and may provoke magnesium depletion, which is 
usually observed as a decrease in serum magnesium occurring 
rather late in treatment,5 as was the case in this trial, in which 
serum magnesium was found to be significantly decreased only 
at the end of week 12. A  thorough assessment of these 
complicated interactions and of the effects of H T Z  + A M I  in this 
respect requires more detailed long-term studies. However, 
serum potassium is one of the determinants of intracellular 
potassium6 and during hydrochlorothiazide treatment it is 
preferable to keep it within the normal range by using a
potassium-sparing diuretic like amiloride, since potassium 
supplements induce a higher percentage of side-effects.7
The transient increase in serum calcium levels that occurred at 
the end of week 8 is indicative of an increase in calcium 
reabsorption in the proximal tubule which is provoked by 
hydrochlorothiazide and may be related to the proximal tubular 
increase in sodium and water reabsorption that occurs during 
treatment with thiazide diuretics; these changes might in turn be 
secondary to plasma volume contraction provoked by these 
diuretics.7 A  regulatory effect of the increased calcium 
reabsorption elicited by hydrochlorothiazide could be an 
increased secretion of thyrocalcitonin, whose augmented activity 
could explain the significant increases in serum phosphorus 
levels that were observed at the end of weeks 4 and 8 of H T Z  +  
A M I  treatment. Thyrocalcitonin is known to decrease renal 
excretion of magnesium through an increased reabsorption of 
this cation at the ascending limb of the loop of Henle8 and would 
then tend to raise serum magnesium levels. Therefore, the 
decrease in serum magnesium observed at the end of week 12 of 
H T Z  +  A M I  treatment should not have been expected. 
However, such a decrease also occurs with loop diuretics that 
increase calcium excretion and are supposed consequently to 
decrease thyrocalcitonin secretion.6 The renal loss of magnesium 
provoked by diuretics therefore does not appear to be related to 
the altered renal handling of calcium induced by these drugs.
Effects o f  HTZ +  AMI on biochem ical blood  
variables other than electrolytes
The significant increase in blood urea nitrogen and serum 
creatinine levels at the end of week 4 of H T Z  + A M I  treatment 
tended to return towards control values, surpassing them in the 
case of blood urea nitrogen. The mechanisms whereby these 
changes occur are similar to those discussed for calcium.
Serum uric acid and blood glucose are usually increased 
during treatment with a thiazide diuretic. However, neither of 
them was found to be significantly increased during H T Z  +  
A M I  treatment. The reason serum uric acid levels did not rise 
significantly is far from clear, although the intimate 
renal handling of uric acid is obscure, despite extensive
research.9 The reason for the lack of any significant change in 
blood glucose during H T Z  +  A M I  treatment is also uncertain. 
Amiloride does not increase serum uric acid and blood glucose 
per se, whereas hydrochlorothiazide does, and the lack of change 
during H T Z  +  A M I  treatment could be particularly important 
when diabetes-prone populations are being treated.
Plasma cholesterol levels did not change significantly and 
triglycerides were found to be significantly increased only at the 
end of week 8 of H T Z  +  A M I  treatment. Serum lipids are 
increased by thiazide and loop diuretics, 10' 14 because of an 
augmented lipolysis in adipose tissue and a subsequent 
augmented synthesis of mainly very-low-density lipoprotein in 
the liver. Whether the increase in lipolysis is elicited by an 
increase in the sympathetic drive, secondary to plasma volume 
contraction provoked by diuretics, or is due to the fact that 
diuretics inhibit phosphodiesterase activity, thus increasing 
intracellular levels of cyclic adenosine monophosphate, is not 
known. For a better description of the effects of H T Z  +  A M I  on 
serum lipids, it would be necessary to study the different 
lipoprotein fractions. The ultimate significance of the serum 
lipid-raising effect of diuretics on overall cardiovascular 
prognosis is not known.
The significant increases found in total serum protein and 
albumin levels during H T Z  +  A M I  treatment could be due to 
haemoconcentration secondary to the volume depletion 
provoked by diuretics.
The significant increases in serum alkaline phosphatase levels 
during H T Z  +  A M I  treatment are not obviously due to 
intrahepatic obstruction as assessed by the lack of significant 
increases in plasma cholesterol and albumin; they cannot be 
explained on the basis of the changes in calcium either. 
Nevertheless, these increases in serum alkaline phosphatase were 
of no clinical relevance.
Serum 7 -glutaryltransferase and SGOTlevels didnot change 
significandy during treatment and S G P T  only increased 
significandy at the end of week 12 of treatment; this change was 
of no clinical importance, thus indicating that H T Z  +  A M I  is a 
safe medication from the point of view of the liver.
HTZ +  AMI dosage in hypertension
As the principal aim of this study was to evaluate the metabolic 
safety of H T Z  4- AMI, high doses were used. However, it is now 
known that effective antihypertensive diuretics exert their 
maximal hypotensive effect at a dose lower than their standard 
diuretic dose. Therefore, even though H T Z  +  A M I  wasfoundto 
be safe at the dosage studied, it would be reasonable to prescribe 
a dose of V 2 - 1 tablet per day in the initial treatment of 
hypertension. Lower doses may spare magnesium and 
potassium6 and, in addition, cause less long-term derangement 
of metabolism.
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Effects of Low Doses of Xipamide Given as Monotherapy in 
Essential Hypertension
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ABSTRACT
T w en ty-three am bulant m ale p atien ts, including B lacks and Cau- 
ca sion s w ith  mild or m oderate uncom plicated essen tia l hyperten­
sion , w ere  treated  w ith  xipam ide at the substandard diuretic  
doses o f  5 and 10 mg daily , each form ulation  g iven  as m onother­
apy for random ly allocated  periods o f  9 w eek s.
B oth dosage reg im en s caused sta tistica lly  and clin ica lly  s ig ­
n ificant decreases in sy sto lic  and d iasto lic  blood pressures w hich, 
from the first w eek  o f  treatm ent onw ards, evolved  as decreasing  
pow er functions o f  tim e. The 5 m g /d a y  dosage w as le ss  e ffective  
than the 10 m g /d a y  regim e in  B lack p atien ts, although 5 and 10 
m g /d a y  w ere equally effective  in C aucasians.
Laboratory evidence suggesting m agnesium  depletion in Black  
p atien ts w a s  found after 8 w eek s o f  treatm ent w ith  xipam ide 5 
m g/d ay .
X ipam ide 10 m g /d a y  should be regarded  as a m axim al dose  
for the treatm ent o f  uncom plicated essen tia l hypertension . H igher 
d oses do not reduce blood pressure further and are m ore likely  to 
have adverse effects  upon potassium , m agnesium  and zinc turn­
overs and carbohydrate, lipid and purine m etabolism s. H ow ever, 
even  w hen  xipam ide is used chron ically  at a dose o f  5 m g /d ay , it 
m ay induce som atic potassium  and m agnesium  d ep letions and 
th erefore dangerous cardiac arrhythm ias. C onsequently, clin ical 
and laboratory m onitoring and prophylactic m easures are n eces­
sary w h en ever xipam ide is  prescribed, at any dose, in long-term  
treatm ents.
INTRODUCTION
Xipamide, a high potency distal tubular diuretic,1-3 effectively lowers the
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blood pressure of patients with mild or moderately severe hypertension when 
administered as monotherapy in standard diuretic doses of 20 to 40 mg 
daily.4,5 Most antihypertensive diuretics cause untoward urinary potassium, 
magnesium and zinc losses and deleterious effects on carbohydrate, lipid and 
purine metabolisms when taken in standard diuretic doses, but there is 
evidence that some of them exert their maximal effect upon high blood 
pressure at doses as low as one-fourth or one-fifth of usually prescribed 
diuretic doses.6-8
This study was undertaken to determine whether low doses of xipamide 
are effectively antihypertensive, to describe any changes in blood pressure 
induced by such low doses mathematically and to assess their effects upon 
serum potassium and magnesium levels.
PATIENTS AND METHODS
Patients
Twenty-five males, clerical or manual workers aged 35 to 56 years, were selected for the study after 
the prognostic significance of hypertension, importance of medical supervision and objectives of 
therapy were explained to them, using the vernacular where necessary to ensure that informed 
oral consent was obtained.
Thirteen were Black and twelve Caucasian. All had morning supine diastolic pressures of 96 
to 120 mmHg recorded after 3 and 4 weeks of treatment with placebo. Individuals with any of the 
following abnormalities were excluded from the study and given appropriate alternative treat­
ment: secondary hypertension, congestive cardiac failure, history of severe cerebrovascular or 
hepatic impairment, abnormal renal function (serum creatinine >  2 mg/dl), serum potassium 
above 5.5 mEq/1 or below 3.5 mEq/1, clinical evidence or history of gout, retinopathy more severe 
than slight irregularity or narrowing of the arterial vessels, electrocardiographic abnormality 
other than supraventricular extrasystoles or any systemic disease requiring treatment with other 
drugs.
Operational Procedures
Any medicine taken by the patients was discontinued and replaced by a single placebo tablet 
administered once daily for four weeks. Thereafter, patients were randomly allocated to treatment 
with 5 or 10 mg xipamide, presented as identical tablets and taken once daily at 0700 hours for nine 
weeks of single-blind active treatment. This period was followed by a 4-week washout, when 
placebo was administered. After this period, active treatment with xipamide at the dose not 
received during the first part of active treatment was reinstituted for 9 weeks.
Arterial pressures were measured in the working arm by the standard indirect technique, 
using the first appearance and the final disappearance of Korotkoff s sounds, or their muffling 
when they persisted down to 0 mmHg, to evaluate systolic and diastolic pressures, respectively. 
Patients rested supine for 10 minutes before blood pressure measurement, which was repeated 
three times in both the erect and the supine bodily postures. Average values were recorded.
Pressures were measured each week, 1.5 to 3.5 hours after the usual daily dose of xipamide. 
The observer and instruments used for recording blood pressure remained the same throughout 
the study.
Serum sodium, potassium, magnesium, uric acid and glucose concentrations were measured 
by standard laboratory techniques (atomic absorption was used for the evaluation of magnesium'
before and during the active treatment period, on a weekly basis.
Compliance with treatment was assessed by counting the number of tablets returned at each 
visit. Complete clinical evaluations were carried out at the end of the placebo period and after the 
fourth and eighth weeks of active treatment. No other medications were prescribed or permitted 
during the trial period.
Data Analysis
Mean blood pressure is defined as diastolic blood pressure plus one-third of the difference between 
systolic and diastolic blood pressure.
Results are expressed as means and standard errors of means (S.E.M.y. Acceptable levels of 
normality of frequency distributions and homoscedasticity of variances were assessed directly or 
in transformed data, as appropriate, before carrying out statistical analysis. The paired t-test was 
used to assess the significance of differences between any two means. Data were linearised as 
reported previously,5 the standard linear correlation and regression techniques were applied to 
their analysis and the t-test for analysing the significance of the difference between two slopes 
was evaluated as necessary. All tests were two-tailed and p = 0.05 was taken as the limit of 
significance.
RESULTS
Compliance with treatment was estimated to be excellent since more than 
90% of prescribed tablets were taken in all cases.
E f f e c t s  o f  X i p a m i d e  T r e a t m e n t  o n  B l o o d  P r e s s u r e
One patient (Black) missed three weekly controls of blood pressure during the 
5 mg/day treatment period and another patient (Caucasian) missed two 
weekly controls during the 10 mg/day treatment period. For these reasons, 
neither was included in the results.
The systolic and diastolic blood pressure mean values before and during 
treatment with xipamide 5 and 10 mg/day are shown in Tables I to IV. The 
last measurement on placebo was taken as pre-treatment or untreated blood 
pressure. Xipamide 5 and 10 mg/day reduced supine blood pressure in a 
statistically significant manner from the first week of treatment. In Black 
patients, responses to 5 mg/day were not consistently significant until week 
3 of treatment; here the sample size was small and the standard deviations 
evaluated were correspondingly large (Tables I and II).
Erect blood pressure was significantly reduced by xipamide 5 mg/day 
from week 2 of treatment. This dosage did not reduce blood pressure consist­
ently in the Black subgroup. The 10 mg/day dose significantly reduced erect 
blood pressures throughout the study whether patients were ethnically sub­
divided or considered as a single group (Tables III and IV).
The changes in the ethnically undivided mean supine systolic, diastolic 
and mean blood pressure, P, values as functions of time, t, were satisfactorily 
accounted for by decreasing power functions from the end of the first to the 
end of the ninth weeks of treatment:
P = Pf - (Pu - Pf - Ps) exp (-k.ln t),
t 1
68
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Patients
Blood
Pressure
Pre-
treatmept Weekl Week 2 Week 3 Week 4 Weeks Week 6 Week 7 Week 8 Week 9
A ll 23 S ys to lic 168.9 '  
± 3 .2
156.4***
± 4 .3
162.0(N S )
± 5 .0
1 5 0 .1 " ”
± 3 .1 (n = 2 2 )
152.9**** 
± 3 .3
1 4 9 0 ” ”
± 4 .0
150 .8 ” ”
± 4 .0 (n = 2 2 )
151 .9 ” ”
± 4 .0 (n = 2 2 )
1 4 7 .6 " ”
± 3 .9 (n = 2 1 )
1 45 .8 **”  
±4.1 (n = 2 1 )
A ll 23 D ia s to lic 104.0
± 1 .6
9 4 .8 " ’
± 2 .5
9 6 .3 "
±3.1
9 0 0 ** **  
±1 6 (n = 2 2 )
9 3 1 ** *
± 2 .6
8 7 6 ” ”
± 2 .4
91 .7****
± 2 8 (n = 2 2 )
87.9****
±2.1 (n = 2 2 )
90 .7 ” ”
± 2 .7 (n = 2 1 )
8 8 .8 **”
± 2 .6 (n = 2 1 )
11 C a u ca s ia ns S ysto lic 166.5
± 4 .6
154.9(NS )
± 6 .3
159.6(N S )
± 6 .3
151 .8 ”
± 4 .9
1 4 8 2***
± 4 .3
1 4 8 .7 "
± 6 .7
148 .4 “ *
± 5 .5
1 4 9 3 ” ’
± 5 .0 (n = 1 0 )
1 4 2 9 ***
± 5 7 (n = 9 )
143.0****
± 5 .7 (n = 1 0 )
11 C a u ca s ia ns D ia s to lic 102.7
± 1 .5
93 .6 ” *
± 2 .9
90.2***
± 2 .6
9 2 . 5 " "
± 1 .4
8 9 8 ** *
± 2 .2
8 6 .4 " ”
± 2 .5
87 8**** 
±3.1
8 6 2 ** **
± 2 .5 (n = 1 0 )
8 6 . 0 " "
± 2 .8 (= 9 )
88 .0****
± 3 .1 (n = 1 0 )
12 B lacks S ysto lic 1 7 1 0
± 4 .6
157.8*
± 5 .6
164.4(N S )
± 7 .9
148.6*** 
±4.1 (n —1 1)
157.3*
± 4 .8
149 .3 “ ”
±5.1
1 5 3 3 ”
± 6 .0 (n = 1 1 )
154.5* 
± 6 .4
151 .2 ’ "
± 5 .4
148.2****
± 6 .0 (n = 1 1 )
12 B la cks D ia s to lic 105.2
± 2 .9
95.8(N S )
±4.1
102.4(N S )
± 5 .2
87 .2****
± 2 .7 (n = 1 1 )
96.2(N S )
± 4 .4
8 8 .7 “ "
±4.1
95 .6 ’
± 4 .5 (n = 1 1 )
8 9 6 ” ”
± 3 .5
94.2*
± 4 .0
89 .5****
± 4 .1 (n = 1 1 )
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Table II — Erect blood pressure (mmHg) changes during treatment with xipamide 5 mg/day. Mean ± S.E.M.
Patients
Blood
Pressure
Pre­
treatment Weekl Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9
A ll 23 S ysto lic 163.7
± 3 .0
160.6(NS )
± 4 .2
154.0*
± 4 .4
146.4****
±3.1 (n = 2 2 )
149.2***
± 3 .6
148.9***
± 3 .0
150.0**
± 4 .4 (n = 2 2 )
147.8****
± 3 .9 (n = 2 2 )
148.4****
± 3 .9 (n = 2 1 )
144.5****
± 4 .0 (n = 2 1 )
A ll 23 D ia s to lic 106.8
± 1 .7
98.4(N S )
± 2 .6
9 7 5 ** *
±2.1
93.0****
± 1 .9 (n = 2 2 )
9 7 .3** ’ *
± 2 .2
94 .3****
± 2 .2
97.4****
± 2 .8 (n = 2 2 )
qo 1*.**
± 1 .9 (n = 2 2 )
94
± 2 .8 (n = 2 1 )
95.6****
± 2 .5 (n = 2 1 )
11 C a u ca s ia ns S ys to lic 159.1
± 4 .4
151 ,3(NS) 
± 6 .0
150.4(N S )
± 6 .5
141.6***
± 4 .2
140.5***
±3.1
142.5***
± 3 .8
145.4(NS )
± 6 .2
140.5**
± 4 .4 (n = 1 0 )
141 ,8(NS) 
± 5 .3 (n = 9 )
136.0***
± 5 .6 (n = 1 0 )
11 C a u ca s ia ns D ia s to lic 105.1
± 2 .0
96.0**
± 3 .2
9 4 .7 ** ’
± 2 .4
91.8****
± 1 .8
94.4****
± 2 .0
94.2****
± 2 .8
93.6***
± 3 .6
91.6***
± 3 .1 (n = 1 0 )
87.5***
± 2 .4 (n = 9 )
9 0 4 ****
± 2 .1 (n = 1 0 )
12 B la cks S ysto lic 168.0
± 3 .9
156.2(N S )
± 6 .2
157.6(N S )
±6.1
150.7**
± 4 .4 (n = 1 1 )
157.2(NS)
± 5 .4
154.8(NS )
± 4 .0
154.5(NS )
± 6 .3 (n = 1 1 )
155.1 (NS) 
± 5 .9
153.3***
± 5 .2
151.2**
± 5 .0 (n = 1 1 )
12 B lacks D ia s to lic 108.3
± 2 .6
100.7(NS )
± 4 .2
100.4(N S )
± 3 .5
94.0****
± 3 .2 (n = 1 1 )
9 9 3 *
± 3 .7
94.3****
± 3 .4
101.1 (NS) 
± 4  2 (n = 1 1)
94.5***
± 2 .4
99.7(N S )
± 4 0
100.0*
± 3 .9 (n = 1 1 )
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Patients
Blood
Pressure
Pre­
treatment Weekl Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9
A ll 23 S ysto lic 1 6 9 6
± 3 .2
159.7**
± 3 .3
154 .7 '***
± 3 .8
1 55 .2 *** ’
± 4 .6
154 .5*’ **
± 4 .3
153.7****
± 4 .3 (n = 2 2 )
151 .5** ’ *
± 4 .2
148.8****
± 4 .6 (n = 2 0 )
147.6****
± 4 .8
146.6****
± 4 .6 (n = 2 2 )
A ll 23 D ia s to lic 103.0
± 1 .0
94.4**
± 3 .2
90.6****
± 3 .0
89  0 " * *  
± 2 .9
93.2***
±3.1
9 2 .2** ’ 
±3.1 (n = 2 2 )
85 .9****
± 2 .8
86 .9****
± 2 .9 (n = 2 0 )
89 .0****
± 2 .9
87 .4****
± 2 .8 (n = 2 2 )
10 C a u ca s ia ns S ysto lic 164.4
± 5 .5
157.8(NS)
± 6 .4
147 .6 ’ * ’ *
± 6 .5
146.8***
± 7 .5
146.6*
± 8 .2
157.1 (NS) 
± 7 .8 (n = 9 )
1 5 0 2 *
±8.1
140.0****
± 7 .0
1 4 5 .8 "
± 8 .6
141.2***
± 7 .9
10 C a u ca s ia ns D ias to lic 103.6
± 1 .3
95.6*
± 2 .8
85.8***
± 4 .3
8 8 .2 ’ **
± 3 .5
86.8***
± 3 .6
90 .0****
± 3 .2 (n = 9 )
80.8****
± 3 .8
81 .2****
± 3 .2
89.2***
± 2 .2
87.4***
± 4 .3
13 B lacks S ysto lic 173.5
± 3 .5
161.2***
± 3 .4
160 .5 ” *
±4.1
161.7*
±5.1
160.6***
± 3 .9
151.4****
±5.1
152.5****
± 4 .2
157.6***
± 4 .8 (n = 1 0 )
1 4 9 .1 * " *
± 5 .5
151 .2 ’ ***
± 5 .2 (n = 1 2 )
13 B lacks D ia s to lic 102.5
± 1 .5
93.5***
± 3 .2
94.3***
±2.1
8 9 5 **
± 4 .0
98.1 (NS) 
± 3 .3
9 3 8 "
± 2 .8
89.8***
± 3 .5
92.6***
± 2 .5 (n = 1 0 )
88 .9****
± 3 .6
8 7 .3 * "
± 2 .8 (n = 1 2 )
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Table IV — Erect blood pressure (mmHg) changes during treatment with xipamide 10 mg/day. Mean ±  S.E.M.
Patients
Blood
Pressure
Pre-
treatment Weekl Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Weeks Week 9
A ll 23 S ysto lic 168.9
± 3 .8
154 .8*“ *
± 3 .7
1 4 8 .9 " "
± 3 .4
152 .3** ’ *
± 3 .7
1 5 1 9 ****
± 4 .5
149 .7 ’ ***
± 3 .5 (n = 2 2 )
151.2****
± 3 .7
147.8****
± 4 .1 (n = 2 0 )
146 .1 *“ *
± 4 .6
143.8**** 
±4.1 (n = 2 2 )
A ll 23 D ia s to lic 106.8
±1.1
96 .9****
± 2 .3
96 .2****
± 1 .4
95.7***
± 2 .0
96.7***
± 2 .4
96 .4****
± 1 .5 (n = 2 2 )
92.7****
± 2 .3
qo
± 1 .5 (n = 2 0 )
93 .4****
± 2 .2
91 .4****
±1 5 (n = 2 2 )
10 C a u ca s ia ns S ysto lic 163.6
± 7 .7
149.1*
± 6 .9
142.2***
± 5 .6
142.8***
± 5 .4
143.0***
± 7.4
154.2(N S )
± 6 .2 (n = 9 )
1 4 6 .8 "
± 5 .7
1 3 7 .2 * "
± 4 .2
143.0***
± 7 .2
1 4 4 .0 "
± 6 .4
10 C a u ca s ia ns D ia s to lic 107.0
±2.1
97.2*
± 3 .2
96.8***
± 2 .5
96 .4 “
± 3 .6
9 1 .8 *“
± 3 .5
9 5 .1** ’
± 2 .2 (n = 9 )
91.2***
± 4 .3
9 0 .8 * "
± 2 .3
9 6 .2 "
± 2 .2
90 .4****
± 2 .4
13 B lacks S ysto lic 172.9
± 3 .1 .
159.2***
± 3 .8
154 .1 “ *
± 3 .8
159 .7 ’ **
± 4 .2
158.8***
± 5 .0
146 .6 ’ ***
± 4 .0
154.6***
± 4 .8
1 5 8 .4 "
± 5 .3 (n = 1 0 )
148.5****
± 6 .2
147.0****
± 5 .5 (n = 1 2 )
13 B lacks D ia s to lic 106.7
±1.1
96 .7***
± 3 .3
95.8***
± 1 .8
9 5 .2 * " *
± 2 .3
100.4(N S )
±3.1
9 7 .4**”
± 2 .0
93.8****
± 2 .6
93 .8****
± 2 .0 (n = 1 0 )
91.2***
± 3 .4
qp p***»
± 2 .1 (n = 1 2 )
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where Pf is a theoretical final limit value to which blood pressure tends upon 
indefinite prolongation of treatment, Pu is untreated blood pressure, Ps is the 
difference between Pu and the theoretical P value after the first week of 
treatment and k is a dimensionless constant that governs the slope of the 
function. The statistical and parametrical features of the functions for the 
supine, systolic and diastolic pressures are shown in Table V. Changes in 
supine mean blood pressure in the entire group of patients during the 5 and 10 
mg/day dosage regimens are shown in Figures 1 and 2, respectively, where 
the corresponding functions are plotted. No significant differences were 
found between the slopes of the systolic, diastolic and mean blood pressures 
derived from the xipamide 5 mg/day and xipamide 10 mg/day treatments.
Table V — Statistical and parametrical features of the linearised functions pressure (time) for 
the supine blood pressures. Entire group of patients.
Variable and 
Treatment r P
P u
(mmHg)
P f
(mmHg)
P s
(mmHg) k
S ysto lic  
b lood  p ressu re -0 .7 8 6 < 0 .0 5 168.9 135 9.0 0.3003
x ip a m id e  5 m g /d a y
D ia s to lic  
b lood  p re ssu re -0 .7 0 6 < 0 .0 5 104.0 80 8.2 0 .2648
x ip a m id e  5 m g /d a y
S ysto lic  
b lood  p ressu re ‘ -0 .901 < 0 .0 1 169.6 135 8.0 0.3129
x ip a m id e  10 m g /d a y
D ia s to lic  
b lood  p re ssu re -0 .6 7 5 < 0 .0 5 103.0 80 8.8 0 .2879
x ip a m id e  10 m g /d a y
E f f e c t s  o f  X i p a m i d e  T r e a t m e n t  o n  H e a r t  R a t e
Heart rate did not significantly change in response to treatment with xipam­
ide except during week 1, when 5 mg caused an increase from 79.1 ± 1.2 to 81.6 
±1.1 beats/min (p < 0.005). This was of no clinical significance.
E f f e c t s  o f  X i p a m i d e  T r e a t m e n t  o n  S e r u m  V a r i a b l e s
Voluntary compliance with weekly blood sampling was poor and it was 
considered unethical to insist that patients cooperated in this regard.
No statistically significant change in the serum sodium, potassium, uric 
acid or glucose levels was observed during the trial with either dose of 
xipamide, although serum potassium concentration fell below the arbitrary 
lower limit of normality (3.5 mEq/1) in one Black patient taking 10 mg of the 
diuretic after 8 weeks of treatment. The only statistically significant change 
found in serum magnesium levels was a decrease from 0.80 ± 0.01 at week 0 to
Figure 1 —  Mean values o f supine mean arterial blood pressure before (week Otand during (weeks 
from  0 to 9) treatm ent with xipam ide 5 m g day. The Ptt) function has been fitted  to the 
experim ental means, n = number o f patients; Pu : pre-treatm ent blood pressure; 
Ps : difference between Pu and the blood pressure value at week 1; P f : fin a l lim it 
value to which blood pressure tends upon indefinite prolongation o f treatm ent; 
k : dimensionless constant.
(mm Hg)
130 XIP. 5 m g
i i i
0 4 8 w e e k s
— r = 0 .790  
P < 0 .05  
Pu = 12 5.6 
P c = 8.6
Pf = 8 8
k =  0.1568
mm Hg
n =  2 3
a n = 2 2 
a a n = 2 1
0.74 ± 0.02 mmol/l at week 8 in eight Black patients taking 5 mg daily (p <
0.05).
C l i n i c a l  E f f e c t s  o f  X i p a m i d e  T r e a t m e n t
No relevant clinical effects of xipamide, except for increases in urinary 
outputs reported by some patients, were detected during the clinical assessments.
D I S C U S S I O N
Xipamide, given as monotherapy in doses of 5 or 10 mg daily, effectively 
reduced blood pressure in the ethnically undivided groups of patients and in 
Caucasoid patients with uncomplicated essential hypertension of mild to 
moderate degree. As judged by the parameter values set out in Table V,
Figure 2 — Mean values of supine mean arterial blood pressure before (week 0) and during (weeks 
from 0 to 9) treatment with xipamide 10 mg/day. The P(t) function has been fitted to 
the experimental means, n = number of patients. Pu : pre-treatment blood pressure; 
Ps : difference between Pu and the blood pressure value at week 1; P f : final limit 
value to which blood pressure tends upon indefinite prolongation of treatment; 
k : dimensionless constant.
(mm Hg)
130 XIP 10 mg
!----------------------1---------------------- 1 
0  4 8 w e e k s
r = -  0 .8 4 3  
P < 0.01 
Pu = 125.2
Ps = 98 
Pf = 88 
k -  0.1621
mm Hg
a n = 22 
a a n = 20 
(n = 23)
responses to these doses were identical and should have the same effects in 
clinical practice. In the case of Black patients, however, 10 mg appeared to be 
the more effective dose. The reason for this ethnic difference is not imme­
diately apparent but could reflect a difference in the dose-response curves of 
the two groups studied.
Doses of xipamide which are currently prescribed for the treatment of 
arterial hypertension, congestive cardiac failure, hepatic oedema and neph­
rotic syndrome (20-40 mg/day)2,3 may be excessive for the satisfactory treat­
ment of most patients with uncomplicated hypertension. Moreover, it is 
noteworthy that xipamide 5 or 10 mg/day induced changes in blood pressure 
with time that were described by power functions, as was the case when the 
antihypertensive effects of xipamide 20 or 40 mg/day were studied.4,5 This 
characteristic is shared by indapamide8 and differentiates these drugs from 
diuretics such as hydrochlorothiazide,9 cyclothiazide5 and tizolemide,10 that
lower blood pressure following smoothly decreasing linear function during 
the first weeks of treatment, even when administered at standard diuretic 
doses.
The finding that xipamide has marked antihypertensive effects at dos­
ages well below the conventional diuretic dosage is consistent with reports 
indicating that other antihypertensive diuretics, including hydrochloro­
thiazide,'Chlorthalidone7 and indapamide8 share this characteristic. The 
lack of side effects or significant changes in most plasma variables, espe­
cially in serum potassium, glucose and uric acid concentrations, suggests 
that metabolic disruption and its concomitant risks of sudden death and 
myocardial infarction can be diminished to some extent by strict limitation 
of xipamide dosage to a maximum of 10 mg/day in hypertension. Magne­
sium depletion provoked by diuretics appears to be the principal mechanism 
whereby these drugs provoke cardiac arrhythmias and sudden death when 
chronically administered.11'14 The fact that a significant decrease in the 
mean serum magnesium concentration value occurred in Black patients 
after 8 weeks of treatment with xipamide 5 mg/day indicates that magne­
sium depletion may result from that treatment. Moreover, serum magnesium 
concentration is a tardy revealer of magnesium depletion and usually falls 
significantly after three months of treatment with a diuretic.15 In addition, 
xipamide 5 or 10 mg have significant hyperkahuretic and hyper- 
magnesiuretic effects when administered as monodoses to healthy probands 
(A. J. Reyes and W.P. Leary, unpublished). Therefore, it remains a mandatory 
practice to monitor relevant plasma variables, principally potassium and 
magnesium concentrations, during long-term treatment with xipamide, 
irrespective of the dose prescribed. Appropriate manoeuvres for the pro­
phylaxis of magnesium and potassium depletion, including restriction of 
dietary sodium, supplementation of potassium and magnesium intake16 and 
the judicious use of the potassium-retaining and magnesium-sparing diuretic 
amiloride17 should be taken when necessary. The effects of prolonged ther­
apy with low doses of xipamide upon magnesium balance requires careful 
assessment, since magnesium depletion may ultimately be responsible for 
the development of arrhythmias during chronic diuretic treatment.
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Effects of a Hydrochlorothiazide and Amiloride Combination on 
Plasma Magnesium in Patients with Essential Hypertension
This trial was conceived by the two principal authors and the 
work carried out under my direction. Computer technology 
was provided by Mr. K. van der Byl and the paper written and 
edited by the first two authors.
Effects of a hydrochlorothiazide and amiloride combination on plasma 
magnesium in patients with essential hypertension
By W. P. Leary, A. J. Reyes and K. van der Byl
University of Natal, Durban, South Africa, and Universidad de la Republica and Fundacion Procardias, 
Montevideo, Uruguay
Zusammenfassung
Bei 21 ambulanten Patienten wurde 
der EinfluB von 50 mg Hydrochlorothia- 
zid allein (H) und in Kom bination mit 
5 mg Amilorid  ( H + A )  a u f  das Verhalten 
des Plasma-Mg untersucht. Die  Patienten 
wurden zufall ig  und unter D oppelblind- 
bedingungen den beiden Behandlungsar- 
ten, die 23 Wochen lang durchgefuhrt 
wurden, zugeordnet und erhielten tiiglich 
je  eine Tablette.
Beide Therapieformen waren am Ende 
der Beobachtungszeit gleichermaBen an- 
tihypertensiv wirksam, obwohl die hy p o­
tensive Wirkung der Kombinationsbe- 
handlung (H +  A) schneller einsetzte.
Nach durchschnittlich 22 Wochen fiel 
das Plasm a-M g in der (H)-Gruppe von 
0,77 a uf  0,70 mmol/1 (p < 0,05) u n d in  der 
(H +  A)-Gruppe von 0,82 a uf  
0,75 mmol/1 (p<0,05). Sieben von neun 
Patienten der (H)-Gruppe und sechs von 
zehn der (H +  A)-Gruppe hatten Plasma- 
Mg-Konzentrationen unter 0,75 mmol/1 
nach durchschnittlich 22 Behandlungs- 
wochen. Hinsichtlich des Plasma-Mg be- 
stehen zwischen der (H)- bzw. (H +  A)- 
G ruppe keine signifikanten Unter- 
schiede.
Es wird gefolgert, daB bei Langzeitbe- 
handlung die zusatzliche G a b e  von 5 mg 
Amilorid  nicht die durch 50 mg Hydro- 
chlorothiazid verursachte A bn ahm e des 
Plasma-Mg verhindert.
Summary
The effects on plasma M g o f  50 mg hy-. 
drochlorothiazide (H C T Z )  and those o f  a 
50 mg hydrochlorothiazide and 5 mg amil­
oride combination ( H C T Z  + A M 1) were 
studied in twenty-one ambulant patients 
suffering from essential hypertension. Pa­
tients were double-blind and randomly 
allocated to treatment with one daily  ta­
blet o f  either formulation, for a 23-week 
period.
Both formulations exerted equally eff i­
cacious final antihypertensive effects, 
though the hypotensive action o f  
H C T Z  + A M I  proceeded at a higher rate 
than that o f  H C T Z .
After an average o f  22 weeks o f  ther­
apy, plasma M g fell from a pretreatment 
mean value o f  0.77 to 0.70 m m o l . L - 1 
(p <  0.05) in the HCTZ-treated group, 
and from 0.82 to 0.74 m m o l . L - 1 (p <0.05) 
in the H C T Z  + AMI-treated group. Seven 
out o f  the nine patients in the H C T Z -
treated group and six out o f  ten o f  the pa­
tients in the H C T Z  + A M I-tre a te d  group 
exhibited plasma M g concentrations be­
low 0.75 m m o l .L - ' ,  after a mean duration 
o f  treatment o f  22 weeks. N o  significant 
differences existed between the effects 
the studied formulations had on plasma 
Mg.
It is concluded that the addition o f  
5 mg amiloride to 50 mg hydrochlorothia­
zide does not help preventing the fall in 
plasma Mg induced by 50 mg hydrochlo­
rothiazide upon prolonged administra­
tion.
Resume
L ’effet de 50 mg d ’hydrochlorothiazide 
( H C T Z )  et celui d ’une combinaison de 
50 mg d ’hydrochlorothiazide et 5 mg 
d ’amiloride ( H C T Z  +  A M I)  sur le Mg 
plasmatique etaient etudies chez vingt- 
et-un malades ambulatoires avec hyper­
tension arterielle essentielle. Les malades 
etaient assignes, par hasard et douple- 
aveugle, au traitement avec H C T Z  ou 
H C T Z  +  A M I  une fois par jour, pendant 
23 semaines.
Les deux formulations montrerent des 
eff icacies antihypertensives de la meme 
magnitude finale, bien que l ’effet de 
l ’ H C T Z  +  A M I  etait plus rapide que celui 
de l ’ H C T Z .  La concentration plasmati­
que du M g tomba d ’une moyenne de 
0.77 m m o l .L - '  avant le traitement a 
0.70 m m o l .L - '  (p< 0.05) apres une 
moyenne de 22 semaines de therapie avec 
H C T Z .  Pendant le meme periode, le m a ­
gnesium plasmatique descendu de 0.82 a 
0.74 m m o l.L - '  (p<0.05) chez les malades 
traites avec H C T Z  +  A M I.  Sept des neuf 
malades traites avec H C T Z  et six des dix 
des malades traites avec  H C T Z  +  A M I 
eurent chiffres de M g plasmatique infe- 
rieures au limite normal de
0.75 m m o l . L - 1, apres une moyenne de 
22 semaines de traitement.
On conclut que l ’addition de 5 mg 
d ’amiloride ne pr£vient pas la chute du 
M g plasmatique provoque par l’adminis- 
tration journaliere de 50 mg d ’hydrochlo­
rothiazide.
Introduction
Diuretics are widely used in 
the treatment of essential hyper­
tension. However, the chronic
deployment of these substances 
is not devoid of important side- 
effects [26,27], amongst which 
bodily Mg depletion is one of the 
most relevant [28], Common 
loop (e.g. furosemide) and distal 
tubular (e.g. hydrochlorothiazide, 
chlorthalidone) diuretics have 
been found to cause hypermag- 
nesiuresis in acute and chronic 
studies carried out in normal 
subjects and in patients suffering 
from various conditions [28, 
30, 34], The ensuing bodily Mg 
depletion is the principal deter­
minant of diuretic-induced car­
diac arrhythmias (hitherto as­
cribed to K depletion) [24, 
28,30], hampers the antihyper­
tensive effect of diuretics [6], 
contributes to shifting the plasma 
lipid profile towards a pattern of 
high cardiovascular risk [28], and 
predisposes to sudden death and 
coronary and cerebrovascular 
spasms [1,7, 16, 18].
The K-sparing diuretic amilor­
ide exhibits weak dose-depend­
ent, Mg-sparing actions when 
single doses are administered to 
healthy individuals [8, 17], wher­
eas hydrochlorothiazide 50 mg 
(HCTZ) causes significant hyper- 
magnesiuresis under similar ex­
perimental circumstances [15]. A 
combination of 50 mg hydro­
chlorothiazide and 5 mg amilor­
ide (HCTZ + AMI) has not been 
found to induce a statistically 
significant increase in magnesi- 
uresis when a single dose is given 
to normal subjects [10, 16]. In 
consequence, it could be postu­
lated that HCTZ + AMI would 
be less likely to induce a de­
crease in bodily Mg than HCTZ, 
when given chronically to hyper­
tensive patients.
The objective of this study was 
to comparatively assess the ef­
fects of HCTZ + AMI and of 
HCTZ on plasma Mg, during 
medium-term administration to 
patients with essential hyperten­
sion.
Patients and methods
Patients
Twenty-one males, clerical or 
manual workers, aged 35 to 56 
years, were selected for the study 
after the objectives and implica­
tions of the trial were explained 
to them, using the vernacular 
where necessary to ensure that 
informed oral consent was ob­
tained.
Twelve patients were Black 
and nine were Caucasoid. All 
had morning resting supine dias­
tolic blood pressures of 
95—110 mm Hg (inclusive), re­
corded after 2 and 4 weeks of 
treatment with placebo. Patients 
in whom comprehensive clinical 
— including ophthalmological 
—, laboratory electrical and ra­
diological investigations revealed 
one or more of the following, 
were not included in the study:
(i) secondary hypertension of 
any origin; (ii) malignant hyper­
tension; (iii) haemodynamically 
significant valvular heart dis­
ease; (iv) congestive cardiac in­
sufficiency; (v) left ventricular 
insufficiency; (vi) right ventricu­
lar insufficiency; (vii) sinus bra­
dycardia of less than 54.m in-' 
after 3 minutes supine rest; (viii) 
second or third degree atrio-ven- 
tricular block; (ix) coronary in­
sufficiency requiring pharmaco­
logical treatment; (x) myocardial 
infarction within the past six 
months; (xi) a history or clinical 
evidence of cerebrovascular im­
pairment, including retinal hem­
orrhages; (xii) renal dysfunction 
evidenced by proteinuria, by a 
serum creatinine level higher 
than 1.5mg.dL_1 or by a blood 
urea higher than 60mg.dL_1; 
(xiii) clinically relevant hyper- or 
hypokalaemia; (xiv) a history or 
clinical evidence of gout; (xv)
diabetes mellitus requiring phar­
macological treatment; (xvi) 
rheumatic conditions requiring 
drug therapy; (xvii) respiratory 
disorders requiring drug treat­
ment other than with antibiotics;
(xviii) anaemia or leucopenia;
(xix) conditions requiring topical 
application of corticosteroids;
(xx) any severe disease likely to 
interfere with the objectives of 
the study, either per se or be­
cause of the necessary medica­
tion; (xxi) psychotic disorders of 
any kind; (xxii) any specific con­
traindication for any of the study 
substances.
Measurements
Arterial pressures were mea­
sured in the working arm by the 
standard indirect technique, 
using the first appearance and 
final disappearance of Korot- 
koffs sounds to define systolic 
and diastolic pressures respec­
tively. If sounds persisted to 
0 mm Hg, the point at which 
muffling occurred was taken as 
the diastolic pressure reference. 
Patients rested supine for 
10 minutes and erect for 3 min­
utes before measurement of the 
corresponding blood pressures; 
an average was obtained from 
three readings per patient in each 
bodily posture. The same mer­
cury sphygmomanometer and 
stethoscope were used through­
out the study and all clinical 
evaluations and measurements 
were made 2—4 h after the last 
intake of medication.
Serum Mg was measured by 
atomic absorption spectroscopy, 
using a Varian 275 instrument. 
Serum Na and K were measured 
by the ion-selective technique 
using a Nova 4 analyser. All 
other chemical analyses and hae- 
matological and urinary evalua­
tions were done by standard la­
boratory methods. These deter­
minations included plasma glu­
cose, creatinine, uric acid, urea, 
SGOT alkaline phosphatase and 
bilirubin, hemoglobin, hemato­
crit, white blood cell count, pla­
telet estimation and standard 
urinalysis. Blood samples for 
laboratory analyses were taken 
2—4 h after the last intake of 
medication.
Operational procedures
At the first examination pa­
tients who were under antihyper­
tensive treatment had current 
therapy withdrawn. Precise in­
structions were given that tablets 
had to be taken at h 08.00 a.m. 
and that magnesium-based anta­
cids could not be used during the 
study. No medications other 
than the trial formulations were 
prescribed. One placebo tablet 
was indicated to be ingested 
daily for a 4-week baseline 
period. After the end of the 
second week of this period, an­
other complete clinical evalua­
tion was performed, and an elec­
trocardiogram, a chest X-ray and 
complete laboratory analyses 
were carried out.
Patients with a supine diastolic 
blood pressure of 95— 110 mm 
Hg at the end of the second and 
of the fourth week of the base­
line period and who met none of 
the exclusion criteria proceeded 
to the active treatment phase of 
the study. Patients were ran­
domly and double-blind allo­
cated to monotherapy with a 
daily tablet of either HCTZ or 
HCTZ + AMI. Arterial blood 
pressure, pulse rate and body 
weight were measured every 2 
weeks starting at the end of third 
week of treatment. Plasma Mg, K 
and Na were measured every 2 
weeks between the end of the 
fifth and of the twenty-third 
week of active treatment. A com­
plete clinical evaluation, an elec­
trographic recording, a chest 
X-ray and complete laboratory 
measurements were carried out at 
the end of the twenty-third week 
of active treatment.
Compliance with treatment 
was assessed by counting the 
number of tablets returned at 
each clinical visit.
Statistics
Results are expressed as means 
and standard errors of means.
Normality of frequency distri­
butions and homoscedasticity of 
variances were evaluated by the 
chi-square test for goodness of fit 
and the F ratio respectively. Mi­
nor departures from formal pre­
requisites for parametric tests 
were tolerated.
The t-test for dependent sam­
ples was used for assessing the 
significances of the differences 
between any two mean values 
within the same active treatment 
group, and a t-test for independ­
ent samples was used for eval­
uating the significances of the 
differences between any two 
mean values corresponding to 
different active treatment groups.
All statistical tests deployed 
were two-tailed and p = 0.05 
was considered the limit of sig­
nificance.
Results
Compliance with treatment 
was excellent in all cases.
Nine patients received HCTZ 
and twelve patients were treated 
with HCTZ + AMI.
The systolic and diastolic 
blood pressure mean values be­
fore and during treatment with 
HCTZ and HCTZ + AMI are de­
picted in Table I. The last meas­
urement on placebo was taken as 
pretreatment (or untreated) 
blood pressure. Supine diastolic 
blood pressure showed mean val­
ues below 95 mm Hg after 3 
weeks of treatment with 
HCTZ + AMI and after 5 weeks 
of therapy with HCTZ, and re­
mained within the normal range 
under either formulation for the 
rest of the study.
Since plasma Mg, K and Na 
measurements were not carried 
out in all patients at all sched­
uled instances, values from two
consecutive scheduled measure­
ments corresponding to the same 
patient, if existent, were aver­
aged. Mean results are shown in 
Table II, where values measured 
15 days apart — one or two val­
ues per patient — have been as­
cribed to the corresponding me­
dian-point in time.
Mean plasma magnesium con­
centration fell significantly, with 
respect to pretreatment, after an 
average of 22 weeks of therapy 
with either HCTZ or HCTZ + 
AMI. Individual mean plasma 
magnesium concentrations were 
all above 0.75 mmol. L_1 after 
8— 10 weeks of treatment with ei­
ther formulation. After a mean of 
22 weeks of therapy, individual 
plasma magnesium concentra­
tions were below 0.75 mmol. L-1 
in eight out of the nine patients 
taking HCTZ and in six out of 
ten of the patients taking 
HCTZ + AMI.
Table  I: Changes in b lood pressure (mm Hg) induced by treatment o f  nine hypertensive patients with hydrochlorothiazide 50 mg 
(H C T Z )  daily  and o f  twelve hypertensive patients with a combination o f  hydrochlorothiazide 50 mg and amiloride 5 mg ( H C T Z  + 
A M I)  daily. Values as means ± S .E .M .
Duration o f  treatment (weeks)
Treat- Blood
ment pressure treat­
ment
3 5 7 9 11 13 15 17 19 21 23
H C T Z Supine 156 147b 140-*** 144** 143* 14 0 * * * * 140* 141*** 144a*** 136*** 139**** 146'
systolic ± 4 ± 5 ± 4  ■ ± 4 ±  6 ± 3 ± 6 ± 5 ± 5 ± 5 ± 4 ± 8
Supine 98 96b 96" 94* 93** 91 *** 92*** 91*** 94** 90*** 91** 92'
diastolic ± 2 ± 2 ± 3 ± 2 ± 2 ± 2 ± 2 ± 2 ± 2 ± 3 ± 2 ± 3
Erect 149 l 37b* 137"* 135*** 136** 132*** 129*** 132*** 136"*** 132*** 133**** 142'
systolic ± 5 ± 4 ± 6 ± 3 ± 5 ± 4 ± 5 ± 6 ± 4 ±  6 ± 5 + 7
Erect 100 92b 94" 92 92 89* 90 90 93“ 89** 90 94'
diastolic ± 4 ± 2 ± 3 ± 2 ± 1 ± 3 ± 2 ± 2 ± 2 ± 3 ± 2 ± 3
H C T Z Supine 146 137' 136 133** 127*** 129** 129** 12 5 *** 125*** 126d*** 132d* 131b*
+  A M I systolic ± 3 ±  6 ± 5 ± 4 ± 3 ± 4 ± 4 ± 4 ± 4 ± 3 ± 6 ±6
Supine 100 93e*** 92**** 93* 90**** 90*** 89*** 86**** 87**** 8$d**** 89d*** 84b*»*
diastolic ±  1 ± 2 ± 2 ± 3 ± 2 ± 3 ± 3 ± 2 ± 2 ± 2 ± 3 ± 3
Erect 142 134' 131* 130** j 2 2 **** 132 12i** * 120*** 120*** 122^*** 127-J* 126b**«
systolic ± 3 ± 5 ± 4 ± 3 ± 2 ± 5 ± 4 ± 3 ± 4 ± 3 ± 5 ±  6
Erect 97 93' 94 93 88*** 89*** 86*** 85*** 84*** 84d*** 88d*** g4b***
diastolic ± 2 ± 3 ± 2 ± 2 ±  1 ± 2 ± 3 ± 2 ± 2 ± 2 ± 3 ± 3
2 results from eight patients.
b results from seven patients.
c results from six patients.
d results from eleven patients.
'  results from nine patients.
* p <  0.05 with respect to pretreatment mean value.
** p <  0.02 with respect to pretreatment mean value.
*** p <  0.01 with respect to pretreatment mean value. 
**** p < 0.001 with respect to pretreatment mean value.
Table  II: Changes in serum electrolyte concentrations (mmol. L - 1) induced by treatment o f  nine hypertensive patients with hydro­
chlorothiazide 50 mg (H C T Z )  daily  and o f  twelve other hypertensive patients with a combination o f  hydrochlorothiazide 50 mg and 
amiloride 5 mg ( H C T Z  +  A M I)  daily. Values as means ±  S.E.M.
g erum Averaged duration o f  treatment (weeks)
Treatment electrolyte p
concentration treatment
6 10 14 18 22
H C T Z M agnesium 0.77 ±0.03 0.81 ±0.03 0.80±0.01 0.80a±0.03 0.76b±0.02 0.70*±0.01
(8) (17) (16) (15) (18) (15)
Potassium 3.8±0.2 4.1 ±0.2 3.7 ±0.2 4.0 ±0.1 3.9 ±0.1 4.1 ±0.1
(8) (17) (16) (15) (17) (15)
Sodium 146 ± 1 146 ±  1 146 ±0.0 145 ±  1 146 ±  1 144±  1
(7) (16) (16) (12) (15) (14)
H C T Z Magnesium 0.82 ±0.02 0.87** ±0.02 0.83 ±0.01 0.83c±0.01 0.80 ±0.02 0 .74c** ±o.02
+  A M I (12) (23) (24) (15) (22) (15)
Potassium 4.6 ±0.2 4.3 ±0.1 4.0** ±0.1 4.0C ±0.2 4.4 ±0.1 4.2= ±0.2
(12) (23) (24) (15) (22) (15)
Sodium 145 ± 1 147 ± 1 146 ±0.0 145c±  1 1 4 5 + 1 144= ±  1
(12) (23) (24) (15) (22) (15)
Figures between brackets depict the number o f  measurements from which the corresponding statistics were derived. Values from two 
consecutive measurements performed 15 days apart in the same patient were averaged whenever existent, and average values were 
used for evaluating the corresponding statistics. 
a results from eight patients.
h results from seven patients.
c results from ten patients.
* p <  0.05 with respect to pretreatment mean value.
**  p <0.01 with respect to pretreatment mean value.
Plasma potassium and sodium, 
pulse rate and the clinical and 
instrumental variables studied 
did not reveal any important 
changes during treatment. Both 
formulations were equally well 
tolerated and no side-effects 
were reported or detected that 
merited withdrawal of any pa­
tient from the study.
Crossed comparisons between 
the plasma Mg, K and Na con­
centrations in the two groups did 
not yield any significant differ­
ence, either before the initiation 
of treatment or at any time du­
ring active therapy.
Discussion
The antihypertensive actions 
exerted by HCTZ and by 
HCTZ+AMI were consistent 
with the results of previous stud­
ies [26, 29].
Plasma Mg does not correlate 
linearly with tissue Mg. How­
ever, significant decreases — 
when existent — in plasma Mg 
are usually taken as tardy, albeit 
reliable, indicators of Mg deple­
tion, especially within the con­
text of studies on the effects of 
diuretics on bodily Mg status [13, 
28, 30].
Hydrochlorothiazide provokes 
renal retention of Ca [4] and thus 
depresses parathyroid function 
[32] and decreases the parathor­
mone-dependent reabsorption of 
Mg in the loop of Henle [19, 31], 
which is followed by hypermag- 
nesiuresis [15]. In addition, hy­
drochlorothiazide hypercalcae- 
mia per se might reduce Mg 
reabsorption in the loop of Henle 
[22], thus further contributing to 
the diuretic-induced hypermag- 
nesiuresis.
Amiloride reduces the renal 
output of Mg, in a dose-depend­
ent manner, when single doses of 
the drug are given to healthy vol­
unteers [8, 17]. This Mg-sparing 
effect is however feeble and, 
when single standard-dose com­
binations of amiloride and com­
mon diuretics are administered 
to normal subjects, the hyper- 
magnesiuretic effects of common 
diuretics are but partly counter­
acted by amiloride [9, 10, 16].
Apparently, amiloride-hydro- 
chlorothiazide weight ratios 
higher than 1:10 would be neces­
sary for amiloride to completely 
compensate for the hypermagne- 
siuretic effect of hydrochloro­
thiazide, though these higher 
weight ratios could be hazardous 
in terms of amiloride potential 
side-effects, especially acidosis 
and K intoxication.
Amiloride directly decreases 
the amount of Mg in the end 
portion of the distal convo­
luted tubule and in the early col­
lecting duct, thus decreasing 
magnesiuresis [17,28]. Whether 
this effect is due to decreased Mg 
secretion or to increased Mg 
reabsorption remains to be eluci­
dated. The direct action of ami­
loride on Mg handling at the 
end-distal tubule and at the 
early-collecting duct is opposed 
by the Ca-mediated indirect ef­
fect of the drug on the handling 
of Mg in the early distale tubule, 
which parallels that of common 
distal tubular diuretics in so far 
as amiloride causes renal Ca re­
tention [2, 3, 8, 12, 18, 20, 21, 23].
The addition o f the Ca-retaining 
effects o f amiloride and hydro­
chlorothiazide could explain that 
HCTZ +  AM1 increases magnesi- 
uresis and lowers plasma Mg 
upon prolonged administration, 
since the positive feed-back me­
chanisms accounting for thia­
zide-induced hypermagnesi- 
uresis [24, 28] could be set to a 
level unlikely to be counteracted 
by the direct effect o f  amiloride 
on the nephronal handling o f  
Mg.
An alternative or com plem en­
tary explanation for the deleter­
ious effect o f chronic treatment 
with HCTZ +  AMI on magnesae- 
mia, could lie on the fact both 
active principles in the formula­
tion increase plasma aldosterone 
values. Hyperaldosteronaemia 
could increase magnesiuresis 
[25] to an extent that would not 
be overcome by the antagonistic 
action o f amiloride.
Irrespective o f the mechanisms 
accounting for the decrease in 
plasma Mg provoked by 
HCTZ +  AMI, which matched 
that provoked by HCTZ, the 
present findings suggest that the 
deploym ent o f HCTZ +  AMI 
should be discouraged whenever 
a more innocuous alternative is 
available. HCTZ +  AMI should 
be particularly avoided in pa­
tients under stress and in areas 
where the Mg content in drink­
ing water is low, since these fac­
tors predispose to the develop­
ment o f Mg depletion [5, 11, 20]. 
Low doses o f diuretics (e.g. hy­
drochlorothiazide 12.5m g.day~1 
or chlorthalidone 2 5 m g .d a y ~ 1) 
are sufficient for achieving maxi­
mal antihypertensive effects and 
are not as likely as standard di­
uretic doses to cause Mg deple­
tion [28, 33]. When higher doses 
of diuretics are needed for the 
treatment o f cardiac insuffi­
ciency and/or oedem a, HCTZ +  
AMI should be preferred to 
HCTZ because o f its milder ef­
fect on bodily K, though plasma 
Mg should be measured fre­
quently and Mg supplements 
given prophylactically to patients
at high risk o f developing Mg de­
ficiency [28], or therapeutically if  
plasma Mg falls below
0.75 m m ol.L -' [28].
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Summary: The usual regimens of captopril— twice or 
thrice daily administration— are based on the duration of 
the decrease in plasma angiotensin II induced by capto­
pril. In a study performed to evaluate the hypotensive 
effect of once daily captopril, 13 white patients with mild- 
to-severe uncomplicated hypertension were treated with 
one tablet of captopril 100 m g  daily, taken 1-1.5 h before 
lunch, for 8 weeks. Arterial blood pressure was measured 
weekly, 22-23.5 h after medication. The patients’ diet 
contained no more than 120 mmol/day of sodium. In the 
first week supine blood pressure fell from 210 ±  3/128 ± 
4 (mean ±  S E M )  to 179 ±  5/116 ±  5 m m  H g  (p <  0.001/ 
p <  0.01 compared with pretreatment). After the large 
decrease in the first week changes in systolic and diastolic 
pressures tailed off: they tended to fall towards stable 
values that would be maintained on prolonged treatment.
At the end of the eighth week the supine values were 155 
± 3/104 ±  3 (p <  0.001/ p <  0.001). Changes in erect 
blood pressure paralleled those in the supine posture. N o  
side effects were detected. These results confirm that 
captopril is efficacious w h e n  given alone to patients 
with essential hypertension who are taking a low sodium 
diet. Blood pressures were not, however, reduced to nor- 
motensive levels. Captopril's hypotensive effect in once 
daily administration appears to be independent of its ef­
fects on circulating angiotensin II. Captopril alone 100 
mg/day is thus indicated in essential hypertension and 
should be prescribed once daily to obtain the best pos­
sible compliance. Key Words: Angiotensin I-converting 
enzyme inhibitors— Captopril —  Essential hyperten­
sion— Once daily administration— Power antihyperten­
sives.
The development of angiotensin I-converting en­
zyme (ACE) inhibitors, such as captopril, has been 
based on the assumption that these compounds de­
crease blood pressure by reducing the generation of 
circulating angiotensin II through ACE inhibition 
(1,2). In fact, captopril effectively lowers blood 
pressure in cases where augmented circulating an­
giotensin II plays a part in the pathogenesis of the 
disease, such as in malignant hypertension and hy­
pertension secondary to renal artery stenosis. 
Moreover, captopril effectively reduced blood pres­
sure when administered alone to patients with un­
complicated essential hypertension (3 -9 ), irrespec­
tive o f plasma renin concentrations (3 -9 ), and with 
as few adverse reactions as hydrochlorothia­
zide (10).
Hitherto, captopril has been prescribed at least 
two or three times a day. The concept that captopril 
should be administered at frequent intervals has 
been derived from the results of short-term studies. 
When the drug is given to hypertensive patients
with disorders of the circulating part of the renin- 
angiotensin-aldosterone system , the hypotensive 
effect o f captopril parallels increases in plasma 
renin and angiotensin I and decreases in plasma an­
giotensin II and aldosterone (1,2). Nevertheless, re­
cent investigations in such patients indicate that, 
after an initial response unequivocally mediated by 
the circulating components o f the RAA system , 
blood pressure is reduced through other mecha­
nisms (11), which operate long-term and possibly 
account for the therapeutic action of captopril in 
essential hypertension (12).
These putative mechanisms might originate from 
effects of captopril such as inhibition of local an­
giotensin II generation in different tissues, including 
the central nervous system (13-15), an increase in 
local renal and circulating (16) levels of kinins, an 
increase in the renal production of PGE2 (17,18), 
and an increase in urinary sodium output 
(6,7,9,18,19), all o f which might account for the de­
crease in total peripheral resistance caused by cap-
Address correspondence and reprint request to Prof. Reyes at Holanda 1724, Montevideo, Uruguay.
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topril in hypertension (20,21). All these processes 
may not require frequent dosing with captopril, just 
as the possible mechanisms underlying the chronic 
antihypertensive effects of diuretics or beta-adren­
ergic blockers may not depend upon actions deter­
mined by the duration of their specific diuretic or 
beta-adrenergic blocking effects.
Our object was to investigate the intensity and 
the medium-term duration of the antihypertensive 
effect o f monotherapy with captopril prescribed 
once daily in essential hypertension.
PATIENTS AND METHODS
Patients
Thirteen white patients (two men) aged 22-77 (57.4 ±
4.0 years) were studied with their informed written con­
sent. All had resting supine diastolic pressures of 100- 
140 m m  H g  (Fig. 1) recorded on at least two occasions 
separated by 7 days before they were admitted to the 
study. Patients in w h o m  comprehensive clinical (in­
cluding ophthalmologic), laboratory, electrical, and radio- 
logic investigations showed serious concomitant disease 
were excluded from the study.
Measurements
Arterial pressures were measured by the standard in­
direct technique, using the first appearance and final dis­
appearance of Korotkoff’s sounds to define systolic and 
diastolic pressures respectively. Patients rested supine or 
erect for 10 min before w e  measured the corresponding 
blood pressures; an average was obtained from three 
readings per patient and was adjusted to the nearest mul­
tiple of 10 m m  Hg. The same mercury sphygmomanom­
eter and stethoscope were used throughout the study and 
all measurements and clinical evaluations were made by 
the same cardiologist, 22-23.5 h after the last dose of 
captopril had been taken.
Plasma potassium, glucose, uric acid, and creatinine 
concentrations were measured immediately before the 
start of treatment and after 4 and 8 weeks' treatment. 
Blood cell counts were carried out at the same time.
PRE-TREATMENT SUPINE DIASTOLIC 
ARTERIAL BLOOD PRESSURE ImmHgl
FIG. 1. Frequency distribution of pretreatment resting su­
pine diastolic blood pressures corresponding to the 13 pa­
tients studied.
Urine samples were examined for microscopic and chem­
ical abnormalities, including proteinuria, at the start of 
the trial and every 2 weeks thereafter. Standard labora­
tory techniques were used in all cases.
Operational procedures
Precise instructions were given to ensure that the diet 
contained 50-120 m m o l  of sodium daily from 1 week be­
fore the start of treatment until its completion.
All patients were given captopril 100 mg, as a tablet to 
be taken as the only treatment at 1100 daily for 8 weeks. 
It was emphasized to the patients that they should not 
take their lunch before 1230.
Clinical evaluations were carried out weekly, between 
0900 and 1030 throughout the trial, starting 1 week before 
the initiation of treatment.
Compliance with treatment was assessed by counting 
the number of captopril tablets left at each clinic visit.
N o  other medications were prescribed during the study 
period and the use of topical corticosteroids was for­
bidden.
Statistics
Results are expressed as means and standard errors of 
means. The x2 test for goodness of fit and the F ratio 
were evaluated as appropriate for these purposes. Only 
minor departures from formal prerequisites were toler­
ated. A  paired t test was used for assessing the signifi­
cances of the differences between mean values of all vari­
ables except blood pressure. Arterial pressure values de­
viated significantly from normality (Fig. 1). Therefore. 
Wilcoxon’s signed-rank test was used for evaluating dif­
ferences between blood pressure mean values.
Standard linear correlation and regression techniques 
were applied to the descriptive analysis of linearized da­
ta (22).
All tests used were two tailed and p =  0.05 was con­
sidered the upper limit of significance.
RESULTS
Compliance with treatment was excellent in all 
cases and adherence to the prescribed diet was re­
ported by all patients.
Blood pressure mean values from measurements 
carried out 1 week before entry to the study and 
immediately before the first dose of captopril (week 
0, Table 1) did not differ significantly.
The weekly changes o f supine and erect systolic 
and diastolic blood pressures during captopril treat­
ment are depicted in Table 1. During the first week 
of treatment 100 mg/day induced statistically sig­
nificant mean decreases of 30.4/11.5 mm Hg when 
supine and 36.2/6.9 mm Hg when erect. Thereafter, 
mean blood pressure values continued to decrease 
significantly— both statistically and clinically. By 
the end o f the study the mean decreases from pre­
treatment levels were 55.0/23.8 mm Hg when supine 
and 54.3/23.1 mm Hg when erect (Fig. 2).
Patients reported no side effects and no abnor­
malities were detected on physical examination. No 
statistical changes were found at any time in any 
plasma urinary or electrocardiographic variables.
TABLE 1. Blood pressure during treatment of 13 essential hypertensives with captopril 100 mg/day as a
monotherapy (mean ± SEM)
Blood pressure 
(mm Hg)
Weeks of treatment
0 1 2 3 4 5 6 7 8
Supine systolic 210 ± 3 179 ± 5* 169 ± 4* 168 ± 4* 163 ± 4* 163 ± 4* 161 ± 4* 156 ± 5* 155 ± 3*
Supine diastolic 128 ± 4 116 ± 5** 111 ± 5* 110 ± 4* 108 ± 4* 108 ± 4* 102 ± 3* 103 ± 4* 104 ± 3*
Erect systolic 205 ± 2 169 ± 4* 160 ± 3* 159 ± 3* 157 ± 4* 155 ± 3* 151 ± 3* 151 ± 4* 151 ± 4*
Erect diastolic 130 ± 4 123 ± 5*** 118 ± 4* 111 ± 4 * 112 ± 4* 115 ± 5* 108 ± 4* 108 ± 4* 107 ± 3*
Significances of the differences compared with pretreatment (week 0) means: *p < 0.001; **p < 0.01; ***p < 0.05.
Proteinuria did not occur in any patient. Plasma cre­
atinine concentration rose from 0.62 mg/dl before 
the start o f treatment to 1.42 mg/dl at the end of 8 
weeks in one patient; the corresponding value at 
the end of the fourth week was 0.57 mg/dl.
DISCUSSION
In the present study captopril 100 mg was given 
once daily to a relatively small group of compliant, 
carefully supervised patients with mild-to-severe 
essential hypertension. Scrupulous attention was 
paid to the timing of clinical assessments relative to 
dosing with captopril and to dosing at the correct 
interval between meals, since it has been reported 
that the absorption of the drug is decreased by food 
(23,24).
We confirmed the findings of others (3 -9 ) that 
captopril is effective and safe in essential hyperten­
sion.
Our results show that single daily doses of cap­
topril 100 mg maintain their effect on blood pressure
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FIG. 2. Changes in resting supine and erect mean arterial 
pressures during treatment of 13 patients with essential hy­
pertension with captopril 100 mg/day.
for 22 -23 ,5  h, suggesting that the plasma pharma­
cokinetics of captopril do not explain the duration 
of its antihypertensive action, since the plasma half 
life of the substance has consistently been found to 
be less than 2 h in normal subjects (25,26); the du­
ration of the decrease in plasma angiotensin II pro­
voked by captopril, which parallels that o f the 
plasma concentration of the drug, may not account 
for the duration of the antihypertensive effect ei­
ther. When captopril is used alone in essential hy­
pertension, it would appear to be unnecessary to 
base the dosage scheme on the fact that the blood 
concentrations of the drug are low within 4 h of 
dosing (25,26). This issue is clinically relevant, in­
asmuch as patients’ compliance with anithyperten- 
sive treatment is principally determined by the fre­
quency of dosing. Similar considerations apply to 
antihypertensive treatment with some diuretics and 
beta-adrenergic blockers, which are taken once 
daily despite their rapid plasma turnover (27) and 
their characteristic pharmacodynamic actions, 
which last less than 24 h.
Since in all cases arterial pressure was reduced 
for a prolonged period after single daily doses of 
captopril 100 mg, the reduction in blood pressure 
cannot be accounted for solely by the decrease that 
captopril induces in plasma angiotensin II. Sodium 
intake was, however, curtailed to a maximum of 120 
mmol daily in this study, and patients would there­
fore be expected to have high plasma renin activi­
ties. Possibly the effect of captopril on these high 
concentrations triggered off further long-lasting 
changes in the overall systemic blood pressure con­
trol and regulation system.
The course of the effect of captopril on blood 
pressure was fitted by a decreasing power function 
of time. This indicates that the compound reduces 
pressure very rapidly initially, the reduction being 
statistically significant and clinically relevant in the 
first week of treatment, after which pressure con­
tinues to decline gradually towards a clinically  
stable value that may be formally regarded as a final 
value. This gradual decline and the existence of a 
limit value indicate that resistance to treatment or 
exaggerated decreases in blood pressure should not 
be expected during prolonged monotherapy with 
captopril. Antihypertensive agents with these char­
acteristics (“ power antihypertensives") (22) are 
particularly useful in hypertension uncomplicated 
by vascular insufficiency in the coronary or cere­
bral circulations. In patients with diminished blood 
flows in these areas linear antihypertensives such 
as the thiazide diuretics (22,27) are preferable, be­
cause they reduce blood pressure in a linear 
fashion, and therefore smoothly and slowly, before 
stabilization.
The results of this study require confirmation in 
carefully controlled double-blind trials, and single 
doses as low as 25-50  mg daily should also be as­
sessed. If these results are confirmed, captopril 
could be considered a drug of first choice in the 
treatment o f essential hypertension, since single 
therapy with it is efficacious and once-daily dosage 
is possible. Moreover, captopril provokes renal so­
dium excretion (6,7,9,18,19) rather than the sodium 
retention associated with most antihypertensive 
agents other than diuretics, and, unlike common di­
uretics, it has no deleterious effects on urinary po­
tassium excretion (28).
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PAPER BIO
Captopril Once Daily As Monotherapy in Patients with 
Hyperuricaemia and Essential Hypertension. Lancet 1985; 1: 1277.
This publication is only in the form of a letter but reports 
on significant findings and is therefore included in this 
presentation. Protocol, design, analysis and publication 
were joint efforts with Professor A.J. Reyes. Drs. Acosta- 
Barrios and Maharaj assisted in the collection and 
management of patients according to our instructions.
CAPTOPRIL ONCE DAILY AS MONOTHERAPY IN 
PATIENTS WITH HYPERURICAEMIA AND ESSENTIAL HYPERTENSION
Sir,—A multicentre comparative study in patients with essential 
hypertension showed that captopril 25 mg three times a day partly 
counteracted the hyperuricaemic response to hydrochlorothiazide 
15 mg three times a day when these drugs were administered 
together.1 Another study showed that prolonged therapy with 
enalapril alone (10-40 mg once daily) significantly reduced plasma 
urate levels in patients with essential hypertension.2 In a placebo- 
controlled investigation2 a single dose o f  enalapril 40 mg increased 
the renal clearance o f uric acid, corrected for glomerular filtration 
rate, in fourteen hypertensive patients whereas there was no change
in three. A  further placebo-controlled study showed that a single 
dose o f  captopril 100 mg significantly increased the mean urinary 
output o f uric acid in healthy volunteers, a single dose o f 
hydrochlorothiazide 25 mg had an opposite effect, and 24 h urinary 
excretion o f  uric acid did not change when both drugs were given 
together.3 Captopril 100 mg once daily in patients with moderate to 
severe essential hypertension significantly reduced blood pressure 
(BP) measured 22-23 • 5 h after dosing.4
We have studied twenty patients with hyperuricaemia- and 
essential hypertension. After 4 weeks without active medication 
patients were treated openly, for ethical reasons, with captopril 100 
mg daily for 4 weeks. The ten patients studied in Montevideo (all 
whites, five male) maintained a low-sodium (60-100 mmol daily), 
low-purine diet throughout the run-in and the captopril-treatment 
periods, whereas the ten male patients in Durban (nine white, one 
black) persisted with their usual high-sodium (200-300 mmol) and 
medium-purine diet. Serum uric acid and supine BP were measured 
at the end o f the run-in period and after 4 weeks o f active treatment. 
Post-captopril assessments took place 20-22 h (uric acid) and 
22-23-5 h (BP) after the last intake o f medication.
The serum urate fell from0-53±0-07 (mean±SD) to 0-46±0-07 
mmol/1 (p<0-05) in Durban and from 0-46e:0-05 to 0-35±0-07 
mmol/1 (p<0-001) in Montevideo. In Durban, BP varied from 
168±14/114±8 to 159e:18/l 12± 11 mm Hg (not significant). In 
Montevideo BP fell from 192±15/119±I 1 to 144±8/95±10 mmHg 
(both p<0-001); post-treatment diastolic values lower than 90 mm 
Hg were noted in six patients. The only recorded side-effect was 
pain in both legs in a patient with severe bilateral venous 
varicosities.
These findings support the use o f captopril alone in patients with 
hyperuricaemia and essential hypertension. However, the efficacy 
o f such monotherapy seems to depend on a reduction in salt intake, 
resulting in enhanced activity of the renin-angiotensin-aldosterone 
system which thus renders the BP contol very sensitive to 
angiotensin-I converting-enzyme inhibition.’ -" Whether the 
diminution in serum urate level, which could be secondary to 
captopril-induced uricosuria, depends on angiotensin-I converting- 
enzyme inhibition to any extent remains to be elucidated.
The development o f leg pain during treatment with captopril has 
been observed in patients with varicosities on three other occasions 
by one o f us (T. N. A. B.). The mechanism is not known.
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SEC TIO N C : PHARMACOLOGICAL EFFECTS OF D IU R E T IC S
Diuretics are used at many centres as medications of first 
choice in the treatment of hypertension. They are relatively 
cheap and, in Africa at least, appear to be as effective as 
more expensive alternatives. Those who prefer to initiate 
treatment with a beta-receptor-antagonist or calcium channel 
blocker generally add an antihypertensive diuretic to the 
treatment regimen as a second step in managing patients who 
do not respond to monotherapy with the first-line drug used. 
Since diuretics occupy such an important place in the 
treatment of hypertension it is essential that their 
characteristics be described in detail and that possible 
adverse effects be identified.
The studies included in this section of the work deal with 
the effects of various diuretics upon the acute excretion of 
solutes. The possible consequences of these effects are 
discussed.
PAPER Cl
Comparative Effects of Xipamide, Furosemide and Hydrochloro­
thiazide in Healthy Adults
I carried out all the clinical work presented here, including 
much of the analysis. Statistical analysis was carried out 
by Dr. J.J. Frey.
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ABSTRACT
The diuretic, natriuretic and kaliuretic effects o f single oral doses of 
xipamide 20, 40 and 60 mg, furosemide 40  mg and hydrochlorothiazide 
50 and 100 mg were compared in 26  healthy adults who each received 2 
treatments. Over 24  hours, furosemide 40  mg had less sodium and potas­
sium excretion than xipamide 40  or 60 mg. In general, effects of these 
medicines were similar, although furosemide had a slightly shorter dura­
tion o f activity than the others tested.
INTRODUCTION
Xipamide (Fig. 1) is a non-thiazide antihypertensive compound.1’2 
Preliminary investigation of healthy adult volunteers indicated that the 
effects of xipamide 5 or 10 mg resemble those of hydrochlorothiazide 
50 mg when these diuretics are given orally in single daily doses.3
Figure 1 — Structural formula o f  xipamide
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The study reported here was initiated to  compare the diuretic 
p o ten cy , natriuretic and kaliuretic effects following treatm ent o f  
healthy volunteers with furosemide, hydrochlorothiazide, or high doses 
o f xipamide.
E X P E R I M E N T A L  M E T H O D S
T w e n ty -s ix  h e a lth y , m ale, a d u lt v o lu n te e rs  aged  2 1  t o  4 5  ye ars  w e re  se le c te d  fo r  th e 
s tu d y . P erson s w ith  a n y  o f  th e  fo llo w in g  c h a ra cte ris tic s  w e re  e x c lu d e d :
( 1 )  R e c e iv in g  a n y  m e d ic a tio n  w ith in  3 w e e k s  o f  th e  trial,
(2 ) H is to ry  o f  card iac , ren al, or h e p a tic  d isord ers,
(3 )  H is to ry  o f  d ru g  sen sitiv ities ,
(4 ) A b n o rm a l v a lu es in p re -tre a tm e n t la b o r a to r y  te sts , and
(5 )  G ro ss  o b e s ity .
A  m e d ic a l h isto ry  w as ta k e n  an d  p h y s ic a l e x a m in a tio n  carried  o u t in e a ch  case. 
A  6-lead E K G  w a s re c o rd e d  an d  th e  fo llo w in g  fa s tin g  la b o r a to r y  te sts  w e re  carried  
o u t  b e fo r e  beg in n in g  th e  s tu d y :  H a em o g lo b in  c o n c e n tra t io n  and w h ite  ce ll c o u n t, 
b lo o d  g lu co se , u rea  n itro g e n , u ric  a cid , c re a tin in e , S G O T , and u rin alysis.
A ll  v o lu n te e rs  w e re  p la ced  on  a c o n tro lle d  stan d a rd  10  m E q  so d iu m  ch lo rid e  
d ie t w ith  a 24 h r f lu id  in ta k e  o f  20 0 0  m l. S u b je c ts  w e re  ra n d o m ly  assign ed to  a 
tre a tm e n t sc h ed u le  so  th a t e a ch  v o lu n te e r  re c e iv ed  2 o f  th e  fo llo w in g  6 a ctiv e  m e d i­
ca tio n s:
( 1 )  X ip a m id e  20 m g (X ip . 20).
(2 )  X ip a m id e  40 m g (X ip . 40).
(3 )  X ip a m id e  60 m g (X ip . 60).
(4 ) H y d r o c h lo ro th ia z id e  50 m g (H O T  50).
(5 )  H y d r o c h lo ro th ia z id e  10 0  m g ( H C T  10 0 ).
(6 ) F u ro s e m id e  40 m g (F u r  40).
M ed icin e s w e re  given  as single oral d o se s  a cc o rd in g  to  th e fo llo w in g  tim e 
sch ed u le :
P e rio d  1 :  24-hr c o n tro l p e rio d .
P erio d  2 : 24-hr a ctiv e  m e d ic a tio n .
P erio d  3: 72 -h r w a sh o u t.
P e rio d  4: 24 -hr a ctiv e  m e d ic a tio n .
M ed icin es w ere  a d m in istered  at th e d o ses a p p ea rin g  on the trea tm en t sch ed u le  
im m e d ia te ly  a fte r  th e  last 2 4 -h o u r u rin e an d  b lo o d  c o lle c t io n s  o f  th e  w a sh o u t or 
c o n tro l p eriod s.
W eight and su p in o  and stan d in g  b lo n d  pressure and pulse w ere  re co rd ed  daily  
th rough ou t, th e  trial. T h e  fo llo w in g  “ on  tr ia l”  la b o ra to ry  a n a ly se s  w ere  p e rfo rm ed  at 
d e fin e d  in tervals:
( 1 )  U rin e: V o lu m e , pH , sp e c ific  g ra v ity  and so d iu m , p o tassiu m  and c re a tin in e  e x c r e ­
tio n .
(2) B lo o d : pH , C 0 2 and so d iu m , p o tassiu m  and c h lo r id e  c o n ce n tra tio n s .
D u rin g  p eriod s 1 and 3, a to ta l 21 hr urine c o lle c t io n  and on  r b lo o d  sam ple 
w e re  o b ta in e d  fo r on trial la b o ra to ry  an alysis . T h is  p ro v id ed  c o n tro l data  prior to 
th e ra p y . D u rin g  p eriod s 2 and 4, on  trial an a ly se s  w ere  p e rfo rm ed  on b lo o d  c o l­
le c te d  a fte r  6 and 24 h ours an d  u rin e c o lle c te d  a t 3 -hr in tervals from  0 to  2 1 hours.
O n  c o m p le tio n  o f th e trial each  v o lu n te e r  w a s e x a m in e d  and E K G  and la b o ra ­
to r y  d e te rm in a tio n s  w ere  c a rr ie d .o u t as p re v io u sly  d e scrib e d .
The study was randomized so that each volunteer received 2 of the 6 therapies 
being evaluated, following a partially balanced incomplete statistical design.
Data were treated by analysis o f covariance with a model appropriate for a 
partially balanced incomplete block design. The covariate was the baseline measure­
ment for the previous 24 hours for urinary data. The fifteen paired-treatment con­
trasts were evaluated by least significant difference contrasts.
RESULTS
Table 1 presents a summary of the urinary excretion data for each post­
medication collection period and the total for 0 to 24 hours. The com­
mon baseline represents the result for the prior 24 hours. Results of 
statistical analyses are included in Table I by indicating which treatment 
contrasts were significant (P < 0.05) or by entering n.s. where none of 
the contrasts differed significantly.
There were no significant differences in urine volume at 3 to 6, 6 
to 9, 9 to 12 hours or for the entire 24 hr collection period. However, 
furosemide 40 mg had an increased diuretic effect from 0 to 3 hours 
and xipamide 60 mg caused an increased urinary output from 12 to 18 
hours by comparison with xipamide 20 mg or hydrochlorothiazide 50 
and 100 mg.
There was an initial (0-3 hr) increase in sodium excretion followed 
by a sustained reduction for the remaining collections with furosemide 
40 mg; 24-hour sodium excretion was lower than that with xipamide 
40 and 60 mg. Hydrochlorothiazide 50 mg provoked less sodium ex-< 
cretion over 24 hours than xipamide 40 mg.
Urinary potassium excretion for the 24-hr period was lower after 
furosemide 40 mg than xipamide 40 or 60 mg and hydrochlorothiazide 
100 mg. Furosemide 40 mg caused a significantly greater urinary chlo­
ride excretion for 0 to 3 hours than xipamide 20 mg or hydrochloro­
thiazide, but yielded a lower excretion thereafter with the 0 to 24-hour 
level significantly less than with all doses of xipamide or hydrochloro­
thiazide 100 mg. Chloride excretion was significantly reduced after 
hydrochlorothiazide 50 mg when compared to xipamide 40 and 60 mg 
or hydrochlorothiazide 100 mg. There were no significant differences 
between treatments for 24-hr creatinine excretion.
Urinary pH was significantly higher for the 24-hr treatment period 
after xipamide 40 and 60 mg than after hydrochlorothiazide 50 and 
100 mg or furosemide 40 mg. There were no significant differences 
between the six treatments with regard to changes in urinary specific 
gravity.
Table II presents a summary of plasma and vital data and the 
results of statistical analysis. There were no differences between the six 
treatments in plasma sodium, potassium and chloride levels or in pulse
[ 664 ]
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Common Baseline Adjusted Mean for Hours Post-Dosing and Results of Statistical Analysis*
irriur nours;
By Variable Treatment 0 - 3 3 - 6 6 - 9 9 - 1 2 12 -  18 18 -  24 0 - 2 4
Urine volume Xipamide 20 mg 426 514 281 372 329 356 2279
Xipamide 40 mg 461 541 454 486 447 280 2669
Xipamide 60 mg 506 384 471 351 565 238 2514
Common Baseline H C T 50 mg 491 579 280 255 317 251 2173
HCT 100 mg 429 484 431 338 385 241 2307
1239 ml FUR 40 mg 899 523 259 348 480 159 2668* n.s. n.s. n.s. * * n.s.
* HOURS STATISTICALLY SIGNIFICANT CONTRASTS
0 - 3 FUR 40 XIP 20, XIP 40, XIP 60, HCT 50, HCT 100
12 -  18 XIP 60 XIP 20, HCT 50, HCT 100
FUR 40 HCT 50.
18 -  24 XIP 20 FUR 40
Urine Xipamide 20 mg 1.012 1.009 1.005 1.004 1.010 1.015 1.010
Specific Xipamide 40 mg 1.010 1.011 1.009 1.008 1.012 1.013 1.010
Gravity Xipamide 60 mg 1.005 1.009 1.011 1.016 1.015 1.011 1.012
Common Baseline: HCT 50 mg 1.010 1.009 1.007 1.007 1.008 1.013 1.010
1.013
HCT 100 mg 1.011 1.010 1.008 1.009 1.009 1.012 1.010
FUR 40 mg 1.006 1.010 1.004 1.009 1.011 1.013 1.010
n.s. n.s. n.s. n.s. n.s. n.s. n.s.
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Common B a se l in e  
(Prior 24 hours)
By Variable Treatment
Adjusted Mean for Hours Post-Dosing and Results of Statistical Analysis*
0  -  -3 3 - 6 6 - 9 9 - 1 2 12 -  18 1 8 -2 4 0 - 2 4
U r i n a r y X i p a m i d e  2 0  m g 5 0 .9 7 2 .7 5 0 .2 51.1 6 1 . 6 51.1 3 3 7 . 5
S o d iu m X i p a m i d e  4 0  m g 6 5 .7 8 5 . 8 6 1 . 5 6 5 . 2 75 .1 3 8 .9 3 9 2 . 0
X i p a m i d e  6 0  m g 5 9 .9 6 6 .3 6 9 .8 6 5 .3 6 7 .0 3 3 .5 3 6 1 . 8
C o m m o n  B ase l in e :  H C T  5 0  m g 5 1 .3 6 8 .3 3 7 .2 4 1 . 0 43 .1 3 1 .8 2 7 3 .7
H C T  1 0 0  m g 6 1 .2 6 1 .2 6 5 . 2 4 6 . 0 6 5 . 0 3 3 .9 3 3 2 . 4
1 2 7 . 7  m m o l
F U R  4 0  m g 1 0 2 .5 7 2 .5 2 7 .7 13 .5 3 2 .8 6 .2 255 .1
U r i n a r y X i p a m i d e  2 0  m g 15 .0 10 .7 9.1 9 .2 5.1 12 .6 6 1 .8
P o t a s s iu m X i p a m i d e  4 0  m g 13 .4 12 .6 1 2 .6 10 .9 14 .5 12 .6 76 .7
X i p a m i d e  6 0  m g 17 .5 13.1 11 .7 11 .3 2 0 .7 7 .4 8 1 .7
C o m m o n  B a se l in e :  H C T  5 0  m g 13 .6 8 .4 8 .9 7 .4 11 .5 6 .2 5 5 .8
H C T  1 0 0  m g 16 .2 12 .9 15 .7 11 .6 18 .7 11.1 86 .1
4 5 . 2  m m o l
F U R  4 0  m g 13.1 9 .7 3 .0 2 .7 8 . 0 1.6 38.1
n.s. n.s. * * * * * * * * * *
S T A T I S T I C A L L Y  S I G N I F I C A N T  C O N T R A S T S
* 0 - 3  h r F U R  4 0  > X I P  2 0 ,  H C T  5 0 ,  H C T  100 . ** 6  - 9  h r H C T  1 0 0  > X I P  2 0 .  IH C T  50 .
6  — 9  h r F U R  4 0  < X I P  2 0 ,  X I P  4 0 ,  X I P  6 0 ,  H C T  100 . F U R  '4 0  < X I P  4 0 ,  ;X I P  6 0 ,  H C T  50 ,  H C T  10 0
H C T  5 0  < X I P  4 0 ,  X I P  6 0 ,  H C T  10 0 . 9  -  12  h r F U R  ■4 0  <  X I P  2 0 ,  ;X I P  4 0 ,  X I P  6 0 .  H C T  100 .
9  -  1 2  h r F U R  4 0  < X I P  2 0 ,  X I P  4 0 ,  X I P  60 . 12  -  1 8  h r X I P  2 0  < H C T  100 .
12  -  18  h r F U R  4 0  < X I P  2 0 ,  X I P  4 0 ,  X I P  6 0 ,  H C T  100 . 18  -  2 4  h r F U R  '4 0  < X I P  20 ,  :X I P  4 0 ,  H C T  100 .
H C T  5 0  < X I P  4 0 . 0 -  2 4 h r F U R  •4 0  < X I P  4 0 ,  :X I P  6 0 ,  H C T  100 .
18  -  2 4  h r F U R  4 0  < X I P  2 0 ,  X I P  4 0 ,  X I P  6 0 ,  H C T  100 .
0  -  2 4  h r H C T  5 0  < X I P  4 0 .
F U R  4 0  < X I P  4 0 ,  X I P  6 0 .
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Common Baseline Adjusted Mean for Hours Post-Dosing and Results of Statistical Analysis*
(Prior 24 hours) -----------------------------------------------------------------------------------------------
By Variable Treatment 0 - 3 3 - 6 6 - 9 9 - 1 2 12 -  18 18 -  24 0 - 2 4
U r i n a r y  C h l o r i d e X i p a m id e  2 0  m g 6 0 . 7 8 5 . 7 5 4 .3 5 4 .4 6 1 .9 5 2 .6 3 7 1 - 6
X i p a m id e  4 0  m g 7 1 .3 8 4 . 2 5 8 .2 6 5 .3 8 5 .0 4 5 . 6 4 0 9 . 5
X i p a m id e  6 0  m g 7 0 .3 7 1 .6 7 6 .4 6 9 .6 7 9 .4 3 6 . 8 4 0 3 . 6
C o m m o n  B a se l in e : H C T  5 0  m g 6 5 . 3 7 3 .3 4 3 .5 4 4 . 6 4 7 .5 3 3 .5 3 0 7 . 7
1 3 2 . 5  m m o l
H C T  1 0 0  m g 6 8 . 8 6 9 . 6 8 2 . 5 4 7 .4 7 7 .8 4 3 . 7 3 8 9 . 7
F U R  4 0  m g 1 1 4 .8 8 8 .9 2 4 .6 9 . 4 2 5 .9 2 .5 2 6 6 . 3
* n.s. * * * * *
U r i n a r y  S o d i u m / X i p a m id e  2 0  m g 3 . 6 7 7 . 1 6 5 .6 7 6 . 8 2 8 . 3 0 4 . 4 2 5 . 0 9
S o d iu m / P o t a s s i u m X i p a m id e  4 0  m g 5 . 4 8 9 . 1 7 6 . 7 0 6 .6 7 5 .51 3 .2 3 5 . 8 9
X i p a m id e  6 0  m g 3 . 9 7 6 . 1 9 8 .3 2 7 .9 3 7 . 5 9 4 . 6 5 6 . 1 0
C o m m o n  B a se l in e : H C T  5 0  mg 3 . 8 3 1 1 .0 0 6 . 8 2 7 . 7 0 5 .3 3 5 .5 3 5 .8 3
3 . 0 9  m m o l
H C T  1 0 0  m g 5 . 4 6 7 . 5 9 5 .8 2 5 . 6 6 4 . 2 7 5 . 0 8 5 .1 7
F U R  4 0  mg 6 . 9 3 6 . 6 0 5 .2 2 4 . 8 3 4 . 8 2 2 . 6 4 5 .4 3
* * * * n.s. n.s. n.s. n.s. n.s.
S T A T I S T I C A L L Y  S I G N I F I C A N T  C O N T R A S T S
* 0  -  3  h r  
6  -  9  h r
9  -  1 2  h r
12  -  18 hr
13  -  2 4  h r  
0  -  2 4  h r
F U R  4 0  > X I P  2 0 ,  H C T  5 0 ,  H C T  1 0 0  ** 0  -  3  h r
F U R  4 0  < X I P  2 0 ,  X I P  4 0 ,  X I P  6 0 ,  H C T  1 0 0  3  -  6  h r
H C T  1 0 0  >  X I P  2 0 ,  H C T  5 0  
X I P  6 0  >  H C T  5 0
F U R  4 0  < X I P  2 0 ,  X I P  4 0 ,  X I P  6 0 ,  H C T  5 0 ,  H C T  1 0 0
F U R  4 0  < X I P  20 .  X I P  4 0 ,  X I P  6 0 ,  H C T  1 0 0
H C T  5 0  < X i P  4 0 ,  X I P  6 0 ,  H C T  1 0 0
F U R  4 0  < X I P  2 0 .  X I P  4 0 ,  X I P  6 0 ,  H C T  5 0 ,  H C T  1 0 0
F U R  4 0  < X I P  2 0 ,  X I P  4 0 ,  X I P  6 0 ,  H C T  1 0 0
F U R  4 0  >  X I P  20 ,  H C T  5 0
H C T  5 0  > X I P  20 ,  X I P  6 0 ,  H C T  10 0 ,  F U R  4 0
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Common Baseline 
(Prior 24 hours) 
By Variable Treatment
Adjusted Mean for Hours Post-Dosing and Results of Statistical Analysis*
0 - 3 3 - 6 6 - 9  9 - 1 2 12 -  18 CN100 0 - 2 4
U r i n e  Ph X i p a m id e  2 0  mg 6 .01 6 .01 5 .7 8  5 .7 9 6 . 3 4 5 .3 7 5 .8 8
X i p a m id e  4 0  m g 6 . 3 4 6.81 6 . 3 0  6 .01 5 .6 2 5 .6 2 6 .1 2
X i p a m id e  6 0  m g 6 . 9 4 7 .5 3 6 . 8 8  6 . 2 0 5.41 6 . 0 0 6 . 4 9
C o m m o n  B a se l in e : H C T  5 0  mg 5 . 8 0 5.91 5 .9 2  5 .2 7 5 .7 2 5.31 5 .6 7
H C T  1 0 0  m y 5.91 5 .8 5 6 . 0 8  5 . 6 6 5 .4 2 5 .4 2 5 .7 2
6 . 0 5 F U R  4 0  m g 6 . 1 3 5 .3 6 5 . 7 5  5 .5 9 5 .5 5 5 .5 7 5 .6 6* * * n.s. ** * * n.s. * *
U r i n a r y X i p a m i d e  2 0  m g 2 4 9 2 .1 4 1 .7 3  3 . 3 8 1 .6 8 3 . 4 6 1 4 .8 9
C r e a t i n in e X i p a m id e  4 0  m g 3 .61 1 .4 8 2 .2 3  3 . 1 3 3 .1 9 2 .4 3 1 5 .0 7
C o m m o n  B a se l in e : H C T  5 0  mg 2 . 5 0 2 .5 7 1 .3 4  1 .93 2 .7 5 2 .5 0 1 3 .5 9
H C T  1 0 0  m g 2 . 1 8 2 . 0 5 1 .9 4  0 . 7 7 3 .1 7 2 . 8 6 1 2 .9 8
1 3 .3 0  m m o l
F U R  4 0  m g 2 . 1 8 1 .6 8 1.91 2 . 1 0 5 .0 3 1 .7 5 1 4 .6 6
S T A T I S T I C A L L Y  S I G N  I F I C A N T  C O N T R A S T S
* 6  — 9  h r X I P  4 0  > X I P  2 0 ,  H C T  50 . ** 0  - 3  h r  X I P  6 0  >  H C T  50.
H C T  5 0  < X I P  4 0 ,  H C T  10 0 ,  F U R  4 0 . 3 - 6  h r  X I P  6 0  > X I P  20 ,  H C T  50 ,  H C T  10 0 ,  F U R  40 .
12  -  18  h r F U R  4 0  >  X I P  2 0 ,  X I P  4 0 ,  X I P  6 0 ,  H C T  50 , H C T  100 . X I P  4 0  >  H C T  50 ,  H C T  10 0 ,  F U R  4 0 .
1 8  -  2 4  h r F U R  4 0  < X I P  20 . 9  - 12  H C T  50  < X I P  4 0 ,  X I P  60 .
1 2  -- 1 8  h r  X I P  2 0  > X I P  60 ,  H C T  100 ,  F U R  4 0 .
0  - 2 4  h r  X I P  4 0  > H C T  50 , H C T  100 , F U R  40 .
X I P  6 0  >  H C T  50 , H C T  100 , F U R  40 .
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W.P. LEA R Y  A N D  A .C. ASMAL
Adjusted Mean For Hours Post-Dosing and
Common Baseline Results of Statistical Analysis*
By Variable Treatment 6 Hours 24 Hours
Plasma Xipamide 20 mg 138.9 136.5
Sodium Xipamide 40 mg 139.4 138.1
Xipamide 60 mg 138.3 136.9
Common baseline: H C T  50 mg 139.7 139.0
H C T  100 mg 138.2 137.7
140.3 mmol/l F U R  40 mg 138.1 138.2
n.s. n.s
Plasma Xipamide 20 mg 4.89 3.94
Potassium Xipamide 40 mg 4.01 3.88
Xipamide 60 mg 3.80 3.81
Common baseline: H C T  50 mg 3.57 3.74
H C T  100 mg 4.98 3.66
4.14 mmol/l F U R  40  mg 4.26 3.88
n.s. n.s .
Plasma Xipamide 20 mg 100.92 99.43
Chloride Xipamide 40  mg 99.67 96.74
Xipamide 60 mg 97.83 96.21
Common baseline: H C T  50 mg 100.45 99.11
H C T  100 mg 100.96 98.49
103.9 mmol/l F U R  40  mg 100.00 100.72
n.s. n.s .
Table II (b) — Summary! o f  plasma and vital data from  the incom plete block high dose 
xipam ide electrolyte study in volunteers (N  = 26) (Single-dose assay).
Adjusted Mean For Hours Post-Dosing and
Common Baseline Results of Statistical Analysis*
By  Variable Treatment 6 Hours 24 Hours
Plasma Xipamide 20 mg 24.45 25.28
Bicarbonate Xipamide 40 mg 23.15 28.62
Xipamide 60 mg 26.44 25.99
Common baseline: H C T  50 mg 22.96 24.21
H C T  100 mg 24.88 23.90
24.68 mmol/l F U R  40 mg 25.48
n.s.
24.97
Plasma Xipamide 20 mg 0.314 0.359
Uric acid Xipamide 40 mg 0.428 0.406
Xipamide 60 mg 0.422 0.431
Common baseline: H C T  50 mq 0.442 0.423
H C T  100 mg 0.418 0.468
0.407 mmol F U R  40 mg 0.404 0.410
S T A T I S T I C A L L Y  S IG N IF IC A N T  C O N T R A S T S
* 24 hr X IP  4 0 > X I P  20. XIP 60, H C T  50, H C T  100, F U R  40
**  6 hr X IP  20 < X I P  40, XIP 60, H C T  50, H C T  100, F U R  40
24 hr X IP  2 0 < H C T  100.
Table II (c) — Sum m ary o f  plasma and vital data from  the incom plete block high dose 
xipam ide electrolyte study  in volunteers (N = 26) (Single-dose assay).
Common Baseline 
By Variable T  reatment
Adjusted Mean For Hours Post-Dosing and 
Results of Statistical Analysis*
6 Hours 24 Hours
Diastolic Xipamide 20 mg 71.1 78.0
Blood Xipamide 40 mg 76.6 76.2
Pressure Xipamide 60 mg 77.1 79.4
Common baseline: H C T  50 mg 82.1 73.4
H C T  100 mg 76.6 75.6
73.7 mm Hg F U R  40 mg 74.0• 70.9n.s.
Systolic Xipamide 20 mg 112.0 115.2
Blood Xipamide 40  mg 114.7 116.1
Pressure Xipamide 60 mg 115.9 106.8
Common baseline: H C T  50 mg- 114.9 108.4
H C T 100 mg - 113.0 114.1
115.4 mm Hg F U R  40 mg 114.9 109.1
n.s. n.s.
* S T A T I S T I C A L L Y  S I G N I F I C A N T  C O N T R A S T S
6 hr X IP  20 <  H C T  50.
F U R  40 < H C T  50.
rate and systolic blood pressure. Plasma sodium , potassium and chloride 
levels fell slightly after each treatment.
For plasma bicarbonate xipam ide 40 mg had a higher mean value 
than the other five treatments at 2 4  hours, but there were no statistical­
ly significant differences at 60 hours. All treatments caused a slight rise 
in plasma urate except xipam ide 20 mg, the mean value being lower 
than the other treatments at 6 hours, and hydrochlorothiazide at 24 
hours. Differences in diastolic pressure were slight and probably o f no 
clinical importance. Negligible changes in pulse and body mass occurred 
and are n ot tabulated.
Safety laboratory data appear in Table III. The only significant 
change from pre- to post-study were increased mean values for haemato- 
crit and red blood cell count and a decreased mean value for plasma 
urea.
SUMMARY AND CONCLUSIONS
This study was conducted on healthy male adult volunteers to  compare 
the diuretic, natriuretic and kaliuretic effects o f single oral doses o f 
xipam ide 20, 40  and 60 mg, hydrochlorothiazide 50 and 100 mg and 
furosemide 40 mg.
There were som e differences between the six treatments in urine
W.t . L H A K V  AND A C  ASMAI,
Table  I I I  — Summery o f  safety laboratory data for the incomplete block high dose 
xipamide electrolyte study in volunteers (N = 26)(Single-dose assay)
Mean ± s.e. Significance
Laboratory Test Normal Values Pts. Pre-Study Post-Study
L,evei oi
Difference
1. Hematology
Hemoglobin 13.5 -  18.0 g 24 1.56 + 0 02 1.57 ±0.03 n.s
Hematocrit 40.0 -  54.0 % 24 4.60 ±0.07 4.76 ±0.08 0.05
RBC 4 .5 -  6.5 24 5.60 ± 0.07 5.74 ±0.05 0.04
WBC 4.0 -  11.0 24 6.70 ±0.27 7.10 ±0.34 n.s
2. Urinalysis
Units
Protein (0 to +3) 0 23 0 09 ±0.09 0.13 ± 0.10 n.s.
Sugar (0 to +3) 0 23 0.13 ±0.13 0.13 ±0.13 n.s.
3. Blood Chemistry
Plasma
Urea
2.49 -  6.64 
mmol/l 24 4.65 ±0.31 3.95 ±0.24 0.02
Serum Total 
Bilirubin
3.4 - 1 7 .1  
mmol/l 26 9.55 ± 1.03 10.37 ±1.55 n.s.
SGOT up to 12 u/l 26 18.30 ±2.49 17.50 ± 1.81 n.s.
Uric Acid 
(Urate)
1 .4 9 -  4.46 
mmol/24 hrs 18 0.39 ±0.02 0.41 ±0.01 n.s.
S Serum 
Cholesterol
3.89 -  6.48 
mmol/l 16 6.74 ± 0.25 6.74 ±0.39 n.s.
Plasma
Glucose
3.33 -  6.66 
mmol/l 13 4.80 ±0.14 5.22 ±0.19 n.s.
Serum Triglycerides .34 -  1.69 
mmol/l 26 1.43 ±0.15 1.51 ±0.18 n.s.
* n.s. means not statistically significant (P >  .05).
volume, urinary sodium and potassium excretion and urinary sodium/ 
potassium ratio during the 24 hr collection period. Many of these 
results reflected the short duration of action of furosemide 40 mg. 
When results for the 0 to 24 hour period were compared furosemide 40 
mg had significantly reduced sodium and potassium excretion compared 
to xipamide 40 or 60 mg. The 0 to 24 hr urinary sodium excretion for 
hydrochlorothiazide 50 mg was significantly lower than for xipamide 40 
mg.
The results of the study indicate that the diuretic, saliuretic and 
kaliuretic effects of xipamide 20, 40 and 60 mg are similar in healthy 
adults and that they resemble those of hydrochlorothiazide 50 and 100 
mg or furosemide 40 mg, although furosemide has a relatively short 
duration of action.
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ABSTRACT
The diuretic, natriuretic and kaliuretic effects o f xipamide 5 or 10 mg 
were compared to those o f hydrochlorothiazide 50 mg in healthy male 
adult volunteers. Single doses were given in random order with suitable 
washout periods interposed.
The effects of xipamide resembled those o f hydrochlorothiazide. No 
statistically significant differences among the 3 treatments for urine 
volume, urinary sodium or potassium excretion occurred. There were 
few differences for the other parameters measured.
INTRODUCTION
Xipamide, 5-(aminosulfonyl)-4-chloro-iV-(2,6-dimethylphenyl) salicyl- 
amide, is a new antihypertensive non-thiazide compound. (Fig. 1). 
Preliminary studies in animals and man,1'3 indicate that xipamide 
stimulates increased water and electrolyte excretion, with a more 
protracted effect than equipotent doses of frusemide (furosemide), but 
causes slightly less urinary potassium loss than the latter preparation.
Figure 1 — Structural formula o f  xipamide.
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This paper reports a further study in which the effects of relatively 
low doses of xipamide were compared to those of frusemide and hydro­
chlorothiazide in healthy adult volunteers.
EXPERIMENTAL METHODS
Twelve healthy male volunteers aged 21 to 45 years were selected for the study. In 
the course o f selection, subjects with any o f the following characteristics were ex­
cluded from the study:
(1) Receiving any medication within 3 weeks o f the trial,
(2) History o f cardiac, renal or hepatic disorders,
(3) History o f drug sensitivities, and
(4) Abnormal values in pre-treatment laboratory tests.
After the medical history had been taken and a physical examination and EKG 
completed, a number o f fasting laboratory tests were carried out as follows: haemo­
globin concentration and white cell count, blood glucose, urea nitrogen, bilirubin, 
cholesterol, uric acid, creatinine, SGOT and urinalysis.
All volunteers were placed on a controlled standard 10 mEq sodium chloride 
diet with a 24 hr fluid intake o f 2000  ml. Subjects were randomly assigned to a 
treatment schedule so that xipamide 5 and 10 mg or hydrochlorothiazide 50 mg 
tablets were taken in various sequences and each volunteer received 3 active medica­
tions according to the following schedule:
Period 1: 24-hr control period.
Period 2: 24-hr active medication (single dose).
Period 3: 72-hr washout.
Period 4: 24-hr active medication (single dose).
Period 5: 72-hr washout.
Period 6: 24-hr active medication (single dose).
Medication was administered in each case immediately after the last total 24-hr 
urine and blood collections o f the control or washout periods.
During the trial, supine and standing blood pressure and pulse and weight were 
recorded daily. The. following “on trial” laboratory analyses were performed at de­
fined intervals:
(1) Urine: Volume, pH specific gravity, sodium, and potassium excretion.
(2) Venous: pH, C 0 2, and sodium, potassium and chloride concentrations.
During periods 1, 3 and 5, a total 24-hr collection and one blood sample were
obtained for on trial laboratory analysis. This served to provide control data prior 
to therapy. During periods 2, 4 and 6, on trial analyses' were done on blood col­
lected after 6 and 12 hours and urine collected at 0-3, 3-6, 6-9, 9-12, 12-18 and 
18-24 hours after administration o f active medication.
On com pletion o f the study, each volunteer was examined and EKG and labora­
tory determinations were carried out as previously described.
Single oral doses of xipamide 5 and 10 mg and hydrochlorothiazide 50 mg were 
given utilising a randomized complete crossover Latin Square design in which all 6 
possible orders o f drug administration were used to balance for possible carry-over 
effects.
Data were treated by analysis o f covariance with a model appropriate for a 
balanced Latin Square design where all possible orders are used. The covariate was 
the baseline measurement prior to treatment, or the measurement for the previous
24 hours for urinary data. The three paired-treatment contrasts were evaluated by 
least significant difference contrasts:
Xipamide 5 mg vs xipamide 10 mg.
Xipamide 5 mg vs hydrochlorothiazide 50 mg.
Xipamide 10 mg vs hydrochlorothiazide 50 mg.
RESULTS
Table I presents a summary of the urinary excretion data for each post­
dosing collection period and the total for 0 to 24 hours. The common 
baseline represents the result for the prior 24 hours. The results of statis­
tical analysis are included in Table I by indicating which treatment con­
trasts were statistically significant, (P= < 0.05), or by entering n.s. 
where none of the 3 contrasts was statistically significant.
There were no significant differences between the 3 treatments for 
urine volume or urinary sodium and potassium excretion which were all 
significantly increased by xipamide 5 or 10 mg and hydrochlorothiazide 
50 mg. Xipamide 10 mg had a greater sodium/potassium ratio than 
hydrochlorothiazide for the 3- to 5-hr collection but there were no dif­
ferences in the remaining collection period.
Mean urinary pH for hydrochlorothiazide 50 mg was higher than 
that for xipamide 10 mg at 0 to 3 hours and xipamide 5 mg was asso­
ciated with a significantly higher pH than both xipamide 10 mg and 
hydrochlorothiazide at 18 to 24 hours. Average values over the 24-hr 
period changed very little. Urinary specific gravity was higher for hydro­
chlorothiazide as contrasted with xipamide 10 mg for the 12- to 18-hr 
collection.
Table II presents a summary of plasma and vital data collected 
during the investigation. There were no significant differences among 
the treatments of either 6- or 24-hr post-medication for plasma sodium, 
chloride or bicarbonate, although sodium and chloride levels fell slightly 
during all 3 treatments. Plasma potassium was reduced slightly by 
xipamide and hydrochlorothiazide, and the latter drug caused a greater 
fall at 6 hours than xipamide 5 mg. Urea was higher at 24 hours after 
hydrochlorothiazide 50 mg than xipamide 10 mg. Diastolic pressures 
were significantly reduced by xipamide 10 mg and 5 mg at 6 and 24 
hours, respectively.
SUMMARY AND CONCLUSIONS
This study was conducted on healthy male adult volunteers to compare 
the diuretic, natriuretic and kaliuretic effects of single oral doses of 
xipamide 5 or 10 mg and hydrochlorothiazide 50 mg.
Analysis of the key urinary excretion parameters indicated there
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Table I — Summary o f  urine data from the Latin Square low dose xipamide electrolyte study in volunteers (N = 12) single 
dose assay.
Common Baseline Adjusted Mean for Hours Post-Dosing and Results of Statistical Analysi*
(Prior 24 hrs.)
Treatment 0 1 w CO I O) 6 - 9 9 - 1 2 12 -  18 18 -  24 0 - 2 4By Variable
U r in e  V o l u m e X i p a m i d e  5 mg 2 8 9 4 2 7 4 4 4 3 5 5 3 9 9 3 0 8 2 2 2 5X i p a m i d e  1 0  mg 2 7 7 4 9 0 431 4 5 0 4 9 7 3 4 2 2 4 9 0
4 7 8 2 3 7 21 5 9 0  ml H C T 5 0  mg 2 7 2 551 4 0 6 3 5 8 3 1 2
P a irw ise  C o n t r a s t s : n.s . n.s. n.s. n.s. n.s. n.s. n.s.
U r in a ry X ip a m id e  5 mg 34 .1 4 5 .8 31.1 2 4 .7 3 0 .6 15.1 1 8 1 .7
S o d iu m X ip a m id e  10  mg 3 2 .6 5 0 .4 4 1 .8 3 2 .4 2 9 .6 2 2 .0 2 09.1
C o m m o n  Base l ine :  
8 6 .9  m m o l H C T  5 0  mg 2 7 .3 4 8 .4 3 4 .5 3 3 .4 3 7 .4 1 9 .5 2 0 0 .0
P a irw ise  C o n t r a s t s : n.s . n.s. n.s. n.s. n.s. n.s. n.s.
U r in a ry X ip a m id e  5 mg 1 1 .4 1 0 .0 7.1 5 .5 8 .0 6.1 4 8 .2
P otass iu m X ip a m id e  1 0 mg 1 0 .6 10.1 8 .9 7 .6 8 .4 7 .7 5 3 .3
C o m m o n  Base l ine :  
3 3 .4  m m o l H C T  5 0  mg 9 .4 1 0 .2 6 .9 6 .4 6.1 7 .0 4 5 .9
P a irw ise  C o n t r a s t s n.s . n.s. n.s. n.s. • n.s. n.s. n.s.
U r in a ry X ip a m id e  5 mg 3 .1 0 5 .4 3 4 .7 7 5 .8 4 4 .8 9 3 .0 3 4 .21S o d iu m / P o t a s s iu m
R a t io
X ip a m id e  1 0  mg 3 .4 0 6 .0 3 5.21 6 .1 7 5 .9 6 3 .6 6 4 .5 6
C o m m o n  Base l ine :  
2 .6 9 H C T  5 0  mg 3 .01 4 .7 5 5.01 5 .4 2 6 .2 4 2 .9 4 4 .2 3
P a irw ise  C o n t r a s t n.s. X i p  1 0  >  
H C T  50
n.s. n.s. n.s. n.s. n.s.
U r in e  pH X  ip a m id e  5 mg 5 .8 9 6 .8 3 5 .9 8 5 .8 4 5 .6 6 5.91 5 .8 5
X ip a m id e  1 0  mg 5 .7 3 6 .0 6 5 .7 5 5 .5 9 5 .5 9 5.61 5 .7 2
C o m m o n  Base l ine :  
5 .8 9 H C T  5 0  mg 6 .1 9 5 .9 7 5 .9 8 5 .7 5 5 .5 6 5.61 5 .8 5
P a irw ise  C o n t r a s t s : H C T  5 0  >  X i p  10 n.s. n.s. n.s.
n s  X ip  5 >  
n s - X ip  10, H C T  50 n.s.
U r in e X ip a m id e  5 mg 1 .0 1 2 1 .0 1 0 1 .0 0 6 1 .0 0 8 1 .011 1 .0 0 9 1 .0 1 0S p e c i f i c  G r a v i ty  
C o m m o n  Base l ine :
X ip a m id e  1 0  mg 1 .0 1 3 1 .0 1 0 1 .0 0 8 1 .0 0 8 1 .0 0 8 1 .0 1 0 1 .0 1 0
1 .0 0 9 H C T  5 0  mg 1 .0 1 0 1 .0 0 8 1 .0 0 7 1 .0 0 8 1 .0 1 3 1 .0 1 2 1 .0 1 0
P a irw ise  C o n t r a s t s : n .s . n.s. n.s. n.s. H C T  5 0  >  X i p  10 n.s. n .s .
* n.s.  m ea n s  no  sta t is t ica l ly  s ig n if ica n t  (P ]> .0 5 )  resu lts  w ere  ob ta ine d  f r o m  the 3 p a irw ise  t re a tm e n t  co n tra s t s ;  w h e re  t re a tm e n ts  are spec if ied ,  
s ta t is t ica l ly  s ig n if ica n t  (P <^.05) resu lts  are p resen ted .
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Table II — Summary o f  plasma and vital data from the Latin Square low dose xipa- 
mide electrolyte study in volunteers (N = 12) single dose assay.
Common Baseline Adjusted Mean for Hours Post-Dosing and
By Variable Treatment Results of Statistical Analysis*
6 hours 24 hours
Plasm a X ip a m id e  5 mg 2 4 .7 2 5 .3
B ic a rb o n a te X ip a m id e  10  mg 25.1 2 5 .4
C o m m o n  Base line : H C T  5 0  mg 25.1 2 5 .2
2 4 .8  m m o l/ l P a irw ise  C o n t ra s ts : n.s. n.s.
P lasm a X ip a m id e  5 mg 4 .2 2 4 .3 0
U rea X ip a m id e  10  mg 4 .0 7 3 .8 5
C o m m o n  Base l ine : H C T  5 0  mg 4 .3 6 4 .3 7
4 .1 0  m m o l/ l P a irw ise  C o n t ra s ts n.s. H C T  5 0 >  
X i p  10
B o d y  w eight X ip am ide  5 mg 6 4 .4 6 4 .0
X ip a m id e  1 0  mg 6 4 .2 6 4 .0
C o m m o n  Base l ine :  
6 4 .4  kg
H C T  5 0  mg  
P a irw ise  C o n t ra s ts :
6 4 .3 6 3 .8
n.s. n.s.
P lasm a X ip a m id e  5 mg 1 3 9 .6 1 4 0 .8
S o d iu m X ip a m id e  10  mg 1 3 9 .0 1 4 0 .8
C o m m o n  Base line :  
1 4 2 .0  m m o l/ l
H C T  50  mg 
P a irw ise  C o n t ra s ts :
1 3 9 .9 1 4 0 .5
n.s. n.s.
P lasm a X ip a m id e  5 mg 4 .1 8 4 .1 0
P otass iu m X ip a m id e  10 mg 3 .9 5 4 .1 0
C o m m o n  Base l ine : H C T  5 0  mg 3 .8 6 4 .1 2
4 .3 4  m m o l/ l P a irw ise  C o n t ra s ts : X i p  5 >  
H C T  5 0
n.s.
P lasm a X ip a m id e  5 mg 100 9 9
C h lo r id e X ip am ide  10 mg 9 9 98
C o m m o n  Base l ine :  
10 3  m m o l/ l
H C T  5 0  mg 
P a irw ise  C o n t ra s ts :
10 0 10 0
n.s. n.s.
S y s t o l i c X ip a m id e  5 mg 112.7 112.1
B lo o d  Pressure X ip a m id e  10 mg 113.1 1 11.7
C o m m o n  Base line :  
11 2 .8  m m  Hg
H C T  5 0  mg 
P a irw ise  C o n tra s ts :
1 1 4 .5 11 1.2
n.s. n.s.
D ia s to l ic X  ip am ide  5 mg 7 8 .5 7 5 .6
B lo od  Pressure X ip a m id e  1 0 mg 7 2 .8 7 7 .7
C o m m o n  Base l ine :  
78.1  m m  Hg
H C T  5 0  mg 8 0 .4
H C T  5 0  >  
X i p  10
80.1
P a irw ise  C o n t ra s ts : H C T  5 0  >  X ip  5
* n.s. m ea n s  no sta t is t ica l ly  s ig n if icant  (P >  .05)  resu lts  w e re  ob ta ined  f ro m  the 3 p a irw ise  t re a tm e n t  
co n tra sts ;  w h e re  t re a tm e n ts  are spec if ied ,  s ta t is t ica l ly  s ig n if ica n t  (P <^.05) results  are presented.
were no significant differences between the 3 treatments with respect to 
urine volume, urinary sodium or potassium excretion and no important 
differences between observed responses in urinary pH, or specific 
gravity. A number of slight, though statistically significant, differences 
between the 3 treatments were noted on analysis of plasma and vital
W.P. L E A R Y  A N D  A.C. A S M A L
data collected.
The results of this study indicate that single doses of xipamide 5 or 
10 mg have similar diuretic, natriuretic and kaliuretic effects to hydro­
chlorothiazide 50 mg in healthy adults, as measured over a 24-hr period.
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PAPER C3
Urine Volumes and Flows After Oral Administration of 
Xipamide, Furosemide and Hydrochlorothiazide to Healthy 
Adults
The mathematical analyses reported in this paper were the 
responsibility of Professor A.J. Reyes who designed the 
models concerned. I carried out the clinical work and wrote 
much of the paper in its final form including the editing of 
the section dealing with mathematical methods.
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ABSTRACT
Urine volumes and flows as functions o f time after oral administration 
of xipamide 20 and 40 mg, furosemide 40 mg and hydrochlorothiazide 
100 mg to healthy male individuals are described through mathematical 
models.
Urine volumes as functions o f time, V, are accounted for by sigmoid 
functions that allow evaluating the percentage of the 24-hour urine 
volume that has been excreted at any time after intake. Fourteen hours 
after dosing, urine volume amounts to 74% for xipamide 20 and 40 mg, 
to 84% for furosemide and to 76% for hydrochlorothiazide, so that all 
the substances tried may be regarded as diurnal diuretics.
Urine flow s as functions of time are defined and described as dV/dt.
They show time to peak activity after dosing is about 4 to 4.5 hours for 
xipamide and hydrochlorothiazide and about 2 hours for furosemide.
INTRODUCTION
The comparative time-courses of the diuretic effects of xipamide 10 mg 
and hydrochlorothiazide 50 mg in healthy individuals have been 
described through mathematical techniques.1
The aim of the present article is to formally describe the corres­
ponding effects of current therapeutic doses of xipamide, furosemide 
and hydrochlorothiazide. The experimental results backing the present 
analysis have been published.2
EXPERIMENTAL METHODS
Twenty-six healthy male volunteers aged 21 to 45 years were selected for the study. 
They were placed on a controlled standard 10 mEq sodium chloride diet with a
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24-hour fluid intake o f  2000 ml. Subjects were randomly assigned to a treatment 
schedule so that each o f the following active medications was received per os by 
eight volunteers:
(1) Xipamide 20 mg.
(2) Xipamide 40 mg.
(3) Furosemide 40 mg.
(4) Hydrochlorothiazide 100 mg
Medicines were given as single doses according to the following time schedule: 
Period 1: 24-hr. control period.
Period 2: 24-hr. active medication.
Period 3: 72-hr. washout.
Period 4: 24-hr. active medication.
Medicines were administered at the doses appearing on the treatment schedule 
immediately after the 24-hour urine collections of the washout or control periods.
During periods 1 and 3, a 24-hour urine collection was obtained which provided 
control data prior to treatment. During periods 2 and 4, urine was collected at 
hours 3, 6, 9, 12, 18 and 24 after dosing.
The study was randomized so that each volunteer received 1 or 2 o f the 4 
therapies, following a partially balanced statistical design.
Data were treated by analysis o f covariance with a model appropriate for a 
partially balanced incomplete block design. The covariate was the baseline measure­
ment for the previous 24 hours for urine volume.
MATHEMATICAL METHODS
The urine volume, V, adjusted mean experimental values accumulated at the end of 
each fractioning collection period were plotted as functions o f time, t. After inspec­
tion o f the dispersion diagrams, a differential equation was postulated that upon 
integration yielded:
20 V / log (100-V) = 10tt/(a+bt)l , (1)
where a (tim e) and b (dimensionless) are parameters of the function.
The fitnesses o f (1) to the experimental data were evaluated through the 
standard linear correlation technique applied to:
t / [log 20 V — log log (100-V )] = a + bt ,
from where a and b were evaluated through linear regression.
Urine flow , U, as a function o f time, was defined as:
U = dV/dt = a/ (a+bt)2 [(0 .4 3 /V ) + [(0 .4 3 2 )/(100-V ) log (100-V )] J
Standard statistical techniques (appliable t-tests) were used for assessing signifi­
cance o f differences between slopes (b) and intercepts (a).
RESULTS
Urine volumes after dosing as functions of time are shown in Figures 1 
and 2. No significant differences were found between the values of any
Figure 1 — Experimental adjusted mean values o f  accum ulated urine volumes, V, as 
functions o f  time, t, after xipam ide 20 and 40  mg. The describing func­
tions have been p lo tted .
Figure 2 — Experim ental adjusted mean values o f  accum ulated urine volumes, V, as 
functions o f  time, t, after hydrochlorothiazide 100 mg and furosem ide 40  
mg. The describing functions have been p lo tted .
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Figure 4 — Urine flow s, U, as functions o f  time, t, after hydrochlorothiazide 100  
mg and furosem ide 40 mg. The function for furosemide 40  mg has been 
extrapolated to  the left o f  hr 3 after dosing with the objective o f  
showing approxim ate peak diuretic activity.
two slopes (b) of the linear transformations of V(t). The intercept value 
(a) for furosemide 40 mg was found to be significantly lower than for 
any other of the formulations tried (p < 0.05).
Fourteen hours after intake, 74% of the 24-hour urine volume had 
been excreted after xipamide 20 and 40 mg, 84% after furosemide 40 
mg and 76% after hydrochlorothiazide 100 mg.
Urine flows after dosing as functions of time are shown in Figures 3 
and 4. The time to peak diuresis after dosing was about 4 to 4.5 hours 
for xipamide and hydrochlorothiazide and about 2 hours for furo-
semide. The overall time-courses of the xipamide and hydrochloro­
thiazide induced diuresis were gentle whereas that of furosemide pro­
ceeded at a higher rate.
DISCUSSION
The time-courses of the diuretic effects of xipamide 20 mg and 40 mg 
and of hydrochlorothiazide 100 mg are similar and differ from that of 
furosemide. Time to peak diuresis after dosing is shorter for furosemide 
than for xipamide and hydrochlorothiazide. All three compounds tried 
may be regarded as diurnal diuretics because if given early in the 
morning they induce most of the forced urine volume within 14 hours 
after administration.
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PAPER C4
A Mathematical Model for the Clinical Pharmacology of 
Diuretics
This paper describes a method for dealing with data generated 
by diuretic studies. The mathematical model was designed by 
Professor A.J. Reyes. My major responsibility was to assist 
in expressing the model in terminology which could be 
understood by clinicians who needed to grasp the practical 
significance of the techniques involved.
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A B S T R A C T
Current research in the clinical pharmacology of diuretics uses an experi­
mental design whereby, after voiding urine and single dosing with a 
diuretic, urine is collected at definite times, t, with the purpose of evalu­
ating the time-courses of several renal excretory variables, Y, in normal 
or diseased subjects.
A mathematical model is presented that accounts for any Y as a 
continuous function of t: 20Y/log (100 — Y) = exp [2,3(t-t!)/(a+bt)], 
where a (time), b (dimensionless) and t, (time) are parameters. This 
model describes the accumulated values after dosing and its derivative 
with respect to time, y = dY/dt, describes the corresponding flows as 
functions of time.
The mathematical model has been found to fit the experimental 
data very accurately (highly significant r values), even when the minimal 
number of urine collections and analyses compatible with the evalua­
tions of correlation and regression (three) are considered. For similar L 
and b values which frequently occur for a variable after different 
diuretics, higher a values mean slower overall rates of excretion, longer 
times to peak effect after dosing and less intensity and longer delay in 
onset of any rebounds which may exist.
The mathematical model has been found to hold after the administra­
tion of placebo and of all the diuretics that have been studied in this 
respect. It also applies to any renal excretory variable (volume, physio­
logical solutes, drugs and their metabolites) so far studied. The model 
describes events in normal and diseased subjects equally well.
The repetibility of the parameter values of the mathematical model 
evaluated from different experiments is very high.
Applications of the mathematical model to the formal assessments 
of experimental designs have shown that it suffices to analyse urine 
collected at 3, 12 and 24 hours post-dosing for accurately describing the
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time-courses of renal excretory variables, after the administration of 
diuretics that complete their effects within 24 hours in normal subjects.
I N T R O D U C T I O N
The scope and sophistication o f  research techniques applied to clinical 
pharmacology are continuously increasing. Nonetheless, whereas evolu­
tion has been particularly rapid with regard to  the generation o f reliable 
data in certain fields, there has been a relatively slow developm ent of 
mathematical models for the description and analysis o f such data. The 
application o f  appropriate mathematical models to data greatly enhances 
their value in terms o f the information that can reasonably be derived 
from them  and may also prove useful in the evaluation and further 
improvement o f experim ental designs.
E X P E R I M E N T A L  D E S I G N S  IN T H E  C L I N I C A L  
P H A R M A C O L O G Y  O F  D I U R E T I C S
With the purpose o f  assessing the effects of diuretics on urine and 
urinary solute outputs, an experimental design is currently followed in 
which, immediately after voiding urine, a single dose o f the test sub­
stance is administered to  normal subjects; urine is collected for ana­
lytical measurements at definite tim e intervals thereafter.1-18 Such trials 
are carried out to directly assess the effects o f new drugs,12 to compare 
them with the effects o f reference substances,3-6 -8 -1 1 -1 3-1 5 to study 
drug interactions1 -2 ’16 and to evaluate the urinary excretions of the 
diuretics and/or their m etabolites.4 '7 ’17 Similar experimental designs 
are also applied to the study o f  patients.19-25
The total duration o f experimental follow-up o f the excretory 
effects o f diuretics is usually 24  hours as was the case in 15 o f 18 
studies listed in Table I and in 5 o f  7 listed in Table II. However, trials 
in normal subjects differ w idely with respect to the timing o f urine 
collections after m edication (Table I). Analogue studies carried out in 
patients with syndromes likely to  be treated with diuretics19-25 show  
the same lack o f uniform ity in collection  times (Table II). These differ­
ences are doubtless due to  the fact that no consensus exists as to the 
experimental sensibility necessary for optimising the description of the 
time-courses o f renal excretions. Such descriptions were invariably pre­
sented either as output values accumulated at urine collection times or 
as mean flow  values corresponding to fractioning collection periods 
which are calculated by dividing the output value for the period by its 
duration until recently, when a mathematical model was designed to 
permit evaluation o f post-dosing urinary excretions as continuous func­
tions o f tim e.10,11,13-15
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Table I —  Summary o f some recent studies carried out in normal subjects where urine was collected and analyzed after 
single doses o f diuretics with the object o f describing the time-courses o f diuresis and/or with the object o f  
describing the time-courses o f diuresis and/or urinary solutes.
A u t h o r ( s ) M e d i c a t i o n ( s ) U r i n a r y  V a r i a b l e s  R e f e r r e d  
T o  T i m e
H o u r s  P o s t - D o s i n g  at  
W h i c h  U r i n e  w a s  C o l l e c t e d  
a n d  A n a l y s e d
Brater’ furosemide, Indomethacin volume, Na 0.5, 1, 1.5, 2,3 ,4,5 ,6 ,8 .24
Chennavasin et al2 furosemide, probenecid volume, Na 0.5, 1, 1.5, 2 ,3 ,4,5 ,6 ,8 ,24
Cook et al3 furosemide, piretanide volume, Na. K 2, 4, 6
Corrigan et al4 chlorothiazide chlorothiazide 0.5, 1, 1.5, 2, 2.5, 3,4,5,7,24
Gonzalez et als furosemide volume, Na, furosemide 1,2,3,4 ,5 ,6
Irvin et al6 furosemide, indacrinone volume, Na, K, uric acid 2,4,8,12,24
Knauf et al7 hydrochlorothiazide, triamterene hydrochlorothiazide, triamterene, p-hydroxitriamterene 0.5, 1,2 ,3,4 ,5 ,6 ,8,12,24,48
Kriick et al* azosemide, furosemide volume, Cl, Na, K 3.6,9,24
Kruger et al9 furosemide, xipamide volume, Na, K 3,12,24
Leary et al'° furosemide, piretanide* volume 3,6,9,12,24
Leary et al" furosemide, tizolemide* volume, Cl,Na, K,Ca,phosphate,creatinine,urea,urate 3,6,9,12,24
Piyasena et al'2 xipamide volume, Na, K 2,4,6,8.10,12,14,16,18,20,22,24
Reyes et a l'3 furosemide, hydrochlorothiazide, xipamide volume 3,6,9,12,18,24
Reyes et al'4 furosemide, piretanide* volume, Cl, Na, K, Ca, phosphate, creatinine, urea, urate 3,6,9,12,24
Reyes et at15 furosemide, tizolemide* volume 3,6,9,12,24
Smith et al'6 furosemide, indomethacin volume, Na 0.5, 1, 1.5, 2,3 ,4.5 ,6 ,8 ,24
Shah et a l'7 hydrochlorothiazide hydrochlorothiazide 1,2,3,4.5,8,11,14,24
Stallings et al” furosemide volume, Cl, Na. K 6,12,24
* The effects after placebo were also studied.
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T a b l e  I I  —Summary o f some recent studies carried out in patients where urine was collected and analyzed after single 
doses o f  diuretics with the object o f  describing the time courses o f diuresis and/or urinary variables.
H o u r s  P o s t - D o s i n g  at
A u t h o r s S y n d r o m e M e d i c a t i o n ( s ) U r i n a r y  V a r i a b l e s W h i c h  U r i n e  w a s  C o l l e c t e d
R e f e r r e d  t o  T i m e a n d  A n a l y s e d
— Brater et al'9 cardiac insufficiency furosemide furosemide 0.5, 1, 1,5, 2,3 ,4,5 ,6 ,8 ,24
t oCO Coodley et al!° cardiac insufficiency furosemide, diapamide volume 1,2,3,4,5,6,12,18,24
o Giliies et al2' cardiac insufficiency chlorothiazide, piretanide volume, Na, K 6, 12
Kampf et al22 renal insufficiency bumetanide, furosemide volume, Cl, Na. K 3, 6, 12, 24
Pozet et al23 renal insufficiency piretanide wolume, Cl, Na, K, Ca, 
phosphate, uric acid
0.5, 1, 1.5, 2 ,3 ,4,5,6
Ri'/a et al24 gestosis of pregnancy furosemide volume 2, 10. 24
Schmidt et al“ renal insufficiency furosemide, muzolimine volume, Na, K, creatinine, 6, 12, 24
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D E S C R I P T I O N  O F  M A T H E M A T I C A L  M O D E L
Let Y be any renal excretory variable (urine volum e or urinary chloride, 
sodium, potassium, etc.) accumulated at times t o f  urine collections 
after dosing. The function 20Y /log (100-Y ) = exp [2 .3  (t-t, ) /(a + b t)], 
where t, = t for Y = 0.1 and a (tim e) and b (dimensionless) are other 
parameters, has been shown to fit the experimental data very accur­
ately .1 0 -1 1 -1 3-1 5
With the object o f evaluating the correlation coefficient and the a 
and b values through regression, the function is thus linearised:
(t-t, ) / [log 20Y-log log (100-Y )] = a + bt.
For carrying out calculations, when experimental values are not 
within the range o f from above zero to below ninety-nine, it is neces­
sary to  multiply them  by ten or by a multiple or submultiple o f ten in 
order to bring them  within such a range (unit transformation). If more 
than one possibility o f multiplication exists the coefficient yielding the 
highest values for analysis should be used, thus making the condition  
resulting from the t = t, for Y = 0.1 feature o f the function itself more 
reliable if extrapolations to the left o f its experimental range o f validity 
are sought. Before proceeding to  the statistical techniques, it is also 
necessary to evaluate t, , which can be done either by iteratively finding 
the t, value yielding the highest r value, or, more easily and with suffi­
cient accuracy, by linearly extrapolating t, from the experimental 
values as the t value for Y = 0.1 if urine is collected at hour 1, as the 
t value for Y = 0 .09  if urine is collected for the first time at hours 2-4 
and as the t value for Y = 0 .08 if urine is collected for the first tim e at 
hours 4-7 post-dosing.
After having evaluated a and b, the renal excretory flow , y, as a 
function o f tim e, is derived as:
y = dY /dt = (a+btj )/(a+bt)2 1(0 .43 /Y ) + [(0 .4 3 2 )/(100-Y ) iog (100-Y )] )|
DI S C U S S I O N  O F  T H E  M A T H E M A T I C A L  M O D E L
No continuous description o f the time-courses o f  renal excretory vari­
ables existed before the present mathematical model was used because 
no other satisfactory models were applied and in order to accomplish  
such descriptions experimentally it would be necessary to  m onitor the  
urine and urinary solute flows continuously.
The mathematical model significantly fits the experimental mean 
values o f renal excretory variables such as urine volum e,10 -1 3 -1 5 
urinary chloride, sodium, potassium, calcium, phosphate, creatinine and 
urate1 1 -1 4 measured after the administration of placebo10 ,1 1 ,1 4 , 1 5  an(j 
v a r io u s  d iu r e t ic s  in c lu d in g  furosem ide,1 ° -1 1 -1 3 -a 5 hydrochloro-
Figure 1 —  The points in the upper left represent mean values o f urine volume, Y, 
accumulated at hours 3, 6, 9, 12 and 24 post oral administration o f  
xipamide 20 mg to eight healthy volunteers. The mathematical model Y  
(time — t —) was fitted to the entire set o f experimental data and is 
shown as a continuous curve. The model was also fitted to mean values 
for t = 3, 12 and 24 hours only (upper right). 11 = 0.7 hr in both cases. 
Urine flows (bottom) were derived as dY /dt. The functions have been 
extrapolated to the left o f  the first mean experimental value with the 
main purpose o f  showing their overall appearance.
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thiazide,13 piretanide,10 -1 4 tizolem ide11 -1 5 and xipam ide.1 3
The functions Y (t) are sigmoid continuous functions and their 
derivatives with respect to  time, y (t), describe the renal excretory vari­
able flows with respect to tim e (Fig. 1) showing a post-dosing increasing
segment, a maximum (“peak e ffec t”) and a further m onotonically  
decreasing segment. Times to  onset o f  activity and peak excretions and 
the magnitude o f any rebound (undershoot) w ith respect to  placebo, 
can be very accurately evaluated through use o f the mathematical 
model.
The model holds strictly for the time range from which the experi­
mental data are derived, i.e., from the first until the last experim ental 
points (urine collections and analyses). However, when there has been  
an interest in evaluating events such as maximal excretions which ante- 
cede the first urine collection, functions have been extrapolated to  the 
left o f their valid experimental ranges,10 -1 1 •* 3 >i 5 since that is the most 
accurate available m ethod o f describing the events. Such errors can be 
minimized by early urine collections after dosing, although, in practical 
terms, the extra experimental work involved is not worth the small gain 
in accuracy achieved. The mathematical m odel has been found to fit the 
experimental data satisfactorily even when only three experimental 
points (urine collections and analyses) are used.26
The a, b and t, parameter values summarise the principal features 
of the excretions studied. Com m only, t, and b values for a single renal 
excretory variable are similar for several diuretics;1 ° ’11 -1 3-1 5 then, 
higher a values indicate slower overall excretion time-courses, longer 
times to peak activity after dosing and decreased intensity and greater 
delay in onset o f undershoots (rebounds) with respect to placebo, if 
they occur.
T he mathematical model described covers physiological, post­
placebo, excretions and all the pharmacologically-induced excretions 
that have been studied so far, thus allowing evaluation o f alterations in 
normal or pathological physiology by diuretics. The model satisfactorily 
describes all the urinary excretory variables studied thus far including 
urinary volum e, physiological solutes and drugs or their m etabolites in 
urine. This has been evaluated (Reyes and Leary, unpublished) from  
published data,4 ■7 -1 7 and applies to results generated from both healthy 
and diseased subjects. The repetibility o f the results o f the evaluations 
of the mathematical model (parameter values) under different inde­
pendent but similar experimental circumstances is very high.26
Similar parameter values are obtained from evaluating different sets 
of points from the same experim ent, as shown in Figure 1, where the 
mathematical m odel has been fitted to mean experimental values for 
urine volum e measured at 3, 6 , 9 , 12 and 24 hours after the oral admin­
istration o f  the diuretic xipam ide to  normal individuals. The m odel still 
holds when the mean experimental values corresponding to  urine 
volume accumulated at 3, 12 and 24  hours post-dosing are the only  
points considered when carrying out calculations, and the a and b para­
meter values are practically the same as when all the points are entered 
into the calculations (Fig. 1 ). This coincidence has also been found  
(R e y e s  and  L ea ry  u n p u b lis h e d )  fo r  a ll  drugs and variables 
studied1 0 ’11’12 3'15 and means that, when diuretics that com plete their 
effects within 24 hours are studied, m ost current experimental designs 
can be simplified in terms o f  the number o f  times at which urine should 
be collected for analysis after m edication.
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PAPER C5
A Formal Method for the Therapeutic Classification of Anti­
hypertensive Diuretics
This paper arose from analyses of data collected in several 
studies into the effects of various diuretics upon urinary 
excretion of various solutes.
The mathematical models used were those designed in 
collaboration with Professor A.J. Reyes. The paper was 
written by both authors working together.
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ABSTRACT
When high blood pressure, P, is treated with antihypertensive diuretics as 
a monotherapy, its evolution with time, t, has been satisfactorily 
described by an exponential function:
P= f(t)= Pf + (Pu - AP ■ Pf) exp ( t/T), (I)
where Pf is a limit value to which P tends as t tends to infinity, Pu is 
untreated pressure, AP is the difference between Pu and P for t= 0  and 
T is a time-constant.
Alternatively, either a power or a linear function have been shown 
to fit the data to a statistically satisfactory degree similar to the one 
achieved by the exponential function in all cases:
P= g(t)= Pf + (Pu - Ps - Pf) exp (-k. In t); (II)
P= h(t)= Pu - Pd - bt, (III)
where Ps is the difference between Pu and P for t = 1, k is a dimension­
less constant, P(j is the difference between Pu and P for t = 0  and b is a 
pressure x time'1 dimensioned proportionality constant.
The mutually exclusive features of (II) and (III) allow classification 
of antihypertensive diuretics into “power” and “linear” types.
Comparisons between different drugs should be formally carried out 
through evaluations of the described functions. Power diuretics, such as 
xipamide, decrease blood pressure rapidly after the onset of treatment 
and should therefore be prescribed for most hypertensive patients. 
Linear diuretics, such as cyclothiazide, decrease blood pressure smoothly 
after the onset of treatment and are indicated in hypertensives with 
impaired peripheral perfusion in any vital organ.
INTRODUCTION
Antihypertensive diuretics are drugs of first choice in the treatment of 
hypertension. Changes in blood pressure induced by diuretics are usually
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expressed as differences between pre- and post-treatment values. Such 
expressions are, however, insufficient as they do not take into account 
time as a naturally occurring variable of the utmost importance in 
chronic diseases. Antihypertensive diuretics are not all identical and 
exhibit different characteristics with respect to the time-course of their 
therapeutic effect.1'8 Thus, the application of a mathematical model to 
the time-course of the antihypertensive activity of diuretics has proved 
useful in formally characterising clinically relevant variables and para­
meters.
This communication describes the formal derivation and application 
of mathematical models to the anti-hypertensive effects of diuretics.
MATHEMATICAL MODELLING OF EXPERIMENTAL DATA
Blood pressure under treatment with a diuretic (P) as a function of time 
(t) can, in common with most medical variables, be described by differ­
ent mathematical equations. The simplest approach to the mathematical 
description of a medical variable is the fitting of a linear function to the 
experimental data. This can usually be carried out in statistically accept­
able form, provided some statistical pre-requisites are met and a -suffi­
cient number of points is analysed. However, if assumptions regarding 
well established clinical facts are taken into account, the derivation 
of a mathematical model must be based upon them and be worked out 
through a suitable differential equation.1’4’5'7 Thus, for example, the 
application of a linear model to the evolution of treated blood pressure 
with time is not consistent with the assumption that blood pressure 
tends to a final limit value (Pf) as treatment is prolonged indefi­
nitely1’4'7 :
lim P = Pf . (1)
t -* ■  00
One of the simplest differential equations consistent with (1) is1:
dP/dt = -K (P - Pf), where K is a time'1 dimensional constant. (2)
Upon integration:
P= f(t)= Pf + (Pu - AP - Pf) exp (-t/T), (3)
where Pu is untreated blood pressure, AP is the difference between Pu 
and the theoretical P value for t=0 and T is a time constant.
The fit of (3) to the experimental data can be easily assessed and 
the parameter values calculated through the correlation and regression 
techniques applied to:
In (P - Pf) = In (Pu - AP - Pf) - (t/T). (4)
For evaluation purposes, a Pf value should be defined upon inspec-
Figure 1 — Systo lic  and diastolic pressure (P) responses to  xipam ide in 25 hyper­
tensive pa tien ts  treated for 16 weeks (t) with an average dose o f  23.6  
mg/day. E xponential (top  panel) and p o w er (b o tto m  panel) functions  
have been fitte d  to  the data. Data from  Castro and R eyes.1
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tion of the trend of the experimental data in a dispersion diagram.1’4*7 
Equation (2) fits the experimental data expressed as the means of 
diastolic, systolic and mean arterial blood pressures under treatment with 
xipamide1’4’7 (Fig. 1), cyclothiazide2 (Fig. 2), a combination of hydro­
chlorothiazide and amiloride,6 tizolemide5 and hydrochlorothiazide.8 
As it is consistent with the postulate in (1), the validity of equation (2) 
still holds when very prolonged periods of treatment (2 years) are con­
sidered.4’7
An elementary alternative to equation (2) is provided by7: 
dP/dt = -k (P - Pf)/t, (5)
where k is a dimensionless constant. Upon integration, (5) yields:
P= g(t)= Pf + (Pu - Ps - Pf) exp (-k. In t), (6)
where Ps is the difference between Pu and the theoretical P value for 
t=l. This equation can be linearised for statistical purposes thus:
In (P - Pf) = In (Pu - Ps - Pf) -k. In t. (7)
Equation (7) has been found to fit the experimental data with as 
high a correlation coefficient value (r) as equation (4) in the case of 
some antihypertensive diuretics such as xipamide7 (Fig. 1) and an asso­
ciation of hydrochlorothiazide and amiloride.6 The validity of equation
(7) also holds for extended periods of time as it, too, is consistent with 
the assumption in (l) .4,7
In the case of other diuretics such as cyclothiazide, hydrochloro­
thiazide, and tizolemide, equation (7) does not hold to a similarly satis­
factory statistical degree. In those circumstances a simple linear model
(8) also fits the data to a statistically satisfactory degree similar to the 
one achieved by (4), when 3-4 months studies are considered:2’5’8
P= h(t)= Pu - Pd * bt, (8)
where Pd is the difference between Pu and the theoretical P value at 
t=0 and b is a pressure x time*1 -dimensioned proportionality constant.
Equation (8) is not consistent with (1) but indicates a fixed rate 
fall in pressure; for this reason it does not hold when long-lasting 
studies are considered.5
Equations (3), (6) and (8) are sufficient to describe all data 
analysed so far. Differences between them qualify two different 
responses of blood pressure to treatment with diuretics: Equation (3), 
(exponential model), is universally applicable, whereas equation (6), 
(power model) and equation (8), (linear model), apply to distinct blood 
pressure responses to treatment with different diuretics which may be 
classed as power or linear diuretics in accordance with the common 
mathematical denominations of the describing functions.
Figure 2
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THE EXPONENTIAL MODEL
The finding that the exponential model provided by (3) describes the 
changes of blood pressure during treatment with any antihypertensive 
diuretic, formally confirms the established view that diuretics are not 
hypotensive drugs, that they do not reduce blood pressure unduly, and 
that tolerance to treatment with them does not develop.9’10
As equation (3) only applies to treated blood pressure, which repre­
sents the experimental range studied, the evolution of the independent 
variable from the onset of treatment until its first clinical evaluation is 
not covered by the model. The AP value is indicative of the parametric 
magnitude of the changes during this period, but AP only approximates 
to the actual experimental difference between untreated blood pressure 
and its first treated measurement. The use of a biexponential model 
fully covers blood pressure from the onset of treatment onwards; how­
ever, it further complicates the model. Therefore, the immediate evolu­
tion of blood pressure after the initiation of treatment is not described 
but arbitrarily represented by dotted lines in Figures 1 and 2.
Figure 3 — Rates o f  change (dP /dt) in diastolic (dia.) and systo lic  (sys.) blood pres­
sures in response to  xipam ide as functions o f  time (t) as derived from  
Fig. 1. Data corresponding to  exponential (exp.) and p o w er (pot.) 
models appear in upper and low er panels respectively. Abbreviations wk 
and ws signify week and w eeks respectively. 
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The rate of change of blood pressure as described by the exponen­
tial model is:
dP/dt = f  (t)= (-1/T) (Pu - AP - Pf) exp (-t/T). (9)
When expressed as a function of time, the rate of change increases 
exponentially and tends to zero (Fig. 3). The absolute rate of change is 
higher at the beginning of treatment and decreases thereafter, which 
means that diuretics exert a more intense antihypertensive effect im­
mediately after treatment is initiated.
The universality of the exponential model allows comparisons 
between different diuretics or between responses of different groups of 
patients to the same diuretic. For such purposes, the influence of each 
parameter in (3) on the blood pressure value at any definite time must 
be taken into account. In the discussion that follows, it is assumed that 
all variable and parameter values, other than those two whose inter-rela­
tionship is analysed, remain constant.
Blood pressure (P) increases as a linear function of Pf (Fig. 4), that 
is, the higher Pf value, the higher the P value at any time during treat­
ment. This relationship has a more marked slope, though lesser absolute 
values, earlier in ‘treatment.
Blood pressure (P) increases as a linear function of Pu (Fig. 4), that 
is, the higher the Pu value the higher the P value at any time during
Figure 4 — Diastolic blood pressure (P) during xipam ide trea tm en t as single func­
tions o f  various param eters (Pf, Pu, AP. T) as derived from  the exponen­
tial m odel in the upper panel o f  Fig. 1, a t defin ite tim es (1= one week, 
12= tw elve weeks).
treatment. This relationship has a more marked slope at the early stages 
of treatment.
Blood pressure (P) decreases as a linear function of AP (Fig. 4), 
that is, the greater the AP value the lower the P value at any time 
during treatment. This is more marked early in treatment. The slope 
relationships between these functions early and late in treatment is such 
that the absolute P values early in treatment are higher than those at 
later stages, for relatively low P values, and vice versa.
Blood pressure P is an increasing exponential function of T (Fig. 4), 
that is, the higher the T value, the greater the P at any time during 
treatment. P tends to Pu - AP as T tends to infinity. The P, T relation­
ship early in treatment lies within a higher range of P values than that 
which applies later.
The parameter values in (3) also affect the rate of change of treated 
blood pressure P when it is considered as a function of each of them. 
The single relationships between the rate of change, (dP/dt), and Pf and 
AP are increasing linear functions (Fig. 5). In both cases, the relative
Figure 5 — R ate o f  change o f  diastolic b lood  pressure, dP /dt, during xipam ide treat­
m en t as single functions o f  various param eters (Pf, Pu, AP, T) as derived  
from  the exponential m odel in the upper panel o f  Fig. 1 at defin ite  
tim es (1= one week; 12= tw elve weeks).
dP/dt
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positions of the functions at different stages of treatment are such that 
dP/dt values are higher at later than earlier phases, except when AP is 
greater than its experimentally derived value, when this relationship is 
reversed.
The rate of change of P is a decreasing linear function of Pu (Fig. 
5), that is, higher untreated P values are assocaited with lower rates of 
blood pressure decrease at any time during treatment. This relationship 
has a more marked slope at the later stages of treatment.
Rate of blood pressure change with time, dP/dt, as a function of T 
(Fig. 5) is a non-monotonic function which early in treatment shows 
itself as rapidly increasing at low T values, its rate decreasing at higher 
T values. Thus, during the early stages of treatment the rate of change 
in P increases as T increases, this being true for T values higher than the 
t value considered. At later stages in treatment, dP/dt (T) is a clearly 
biphasic function with a minimum at T=t as derived when its first deriv­
ative is equated to 0:
(dP/dt)/dT = j(T) = [l-(t/T)] / T 2 . (10)
In general, the rate of change of blood pressure as a function of T 
at any time is a decreasing relationship for the T value range below that 
T value equalling the time t considered; it is an increasing function 
thereafter.
When different treatments are compared, or the same treatment is 
evaluated in different groups of patients, the experimental data yield 
different parameter values. Comparisons between parameters arising 
from any two such experiments are limited to the Pu (t-test) and T 
values (t-test for the significance of differences between the slopes of 
linearised or linear functions). Therefore, between group comparisons of 
AP and Pf should be derived through their relationships with Pu and T 
as well as their intrinsic relationship. This necessity should be dealt with 
by an analysis of functions of multiple variables.
The analysis of the relationship between any two parameters, other 
parameters remaining constant, constitutes a simpler approach but is not 
as trustworthy. However, the technique will be briefly described, as an 
indication of the main directions of change in the relative relationships 
between variables.
When untreated blood pressure (Pu) is considered as a function of 
Pf, AP or T, it gives rise to linearly decreasing, linearly increasing and 
decreasing exponential relationships respectively, (Fig. 6):
Pu = Pf + AP + (P - Pf) exp (t/T). (11)
Higher Pf values mean lower Pu values and vice versa, all other variables 
and parameters being constant. The greater the AP value, the higher the 
Pu value and conversely. The higher the T value, the lower the Pu value, 
this relationship being more marked for low values of T or high values 
of Pu.
AP bears an increasing linear relationship with Pf and an increasing 
exponential relationship that tends to Pu - P with T:
AP = Pu - Pf - (P - Pf) exp (t/T). (12)
The higher the Pf value, the higher the AP and conversely. The 
higher the T value, the higher AP and vice versa, this relationship being 
steeper for small values of either variable. The Pf relationship with T is
Figure 6 — Single inter-relationships betw een several param eters (Pu, AP, P f and T) 
o f  the exponential m odel as derived from  the diastolic blood pressure 
values, during xipam ide treatm ent, in the upper panel o f  Figure 1.
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“an almost linear in shape” exponential function (Fig. 6):
Pf = [P-(PU - AP) exp (-t/T)] / [l-exp(-t/T)]. (13)
The higher the T value, the lower the Pf value, and conversely.
The time constant T as a function of all other parameters is ex­
pressed by:
T= -t/[ln (P-Pf) - In (Pu - AP - Pf)]. (14)
This equation clearly shows that solution of the multiple relationship 
T(PU, Pf, AP) is necessary to allow an overall comparison between two 
different experiments through the T value. This relationship T (Pu, Pf, 
AP) constitute the “equivalent time constant” when evaluated at 
definite time, t, and could practically summarise the slopes of the P(t) 
functions. Thus, in order to determine the equivalent time-constant for 
purposes of comparisons between data, particularly when different 
diuretics are compared, it is necessary to multiply correct T in accord­
ance with Pu, Pf and AP values for both sets of data. When the equiva­
lent time-constant has a low value, that is, when P decreases markedly 
in the first weeks of treatment, the exponential model is matched by a 
power model. Power diuretics that exhibit a relatively high time-
constant value when compared to other diuretics whose effects upon 
blood pressure are not fitted by power functions, have in fact a low 
time constant value if it is corrected relative to the value of the other 
parameters (low equivalent time-constant value).
When the reductions in P that immediately follow the onset of 
treatment are of a mild degree, the exponential model also holds, and is 
not matched by a power but by an alternative linear model in terms of 
statistical correlation. The equivalent time-constant value is low in these 
circumstances. Thus, the great versatility of exponential functions makes 
them always applicable to the phenomena under study, whereas the 
value of the corrected time-constant allows differentiation between 
power and linear diuretics.
THE POWER MODEL
Equation (6) provides a power function which is a statistical equivalent 
alternative to equation (4), when the long-term evolution of blood pres­
sure under treatment with diuretics such as xipamide is studied. The 
fact that the exponential term of the function varies with the logarithm 
of time makes this function evolve rapidly when the time values are 
small and continue with a smoother slope thereafter. For this reason, 
the power function satisfactorily describes events when they proceed 
rapidly after the onset of treatment, does not fit the data when blood 
pressure changes very gradually with time after the initiation of treat­
ment and therefore formally characterises a group of antihypertensive 
diuretics.
Figure 3 shows how the slope of a power function varies with time. 
The initial evolution of the slope is such that small changes in time 
correspond to big changes in the slope, whereas after the first few 
weeks of treatment the rate of change of blood pressure slows down to 
a rate which tends asymptomatically to zero. Figure 3 clearly shows 
that even for the same data, fitted to analogous degrees of accuracy to 
power and exponential functions, different slopes arise from each 
model, thus proving that the justification for the denomination “power 
diuretics” lies in this mathematical uptake.
So far only xipamide and a combination of amiloride and hydro­
chlorothiazide have been shown to behave as power diuretics.1’6*7’11 
The data on xipamide to which power models fit have been derived 
from three independent studies covering periods which extend to two 
years of continuous treatments, whereas the only experiment dealing 
with the hydrochlorothiazide and amiloride combination was limited to 
8 weeks and thus requires confirmation.
Comparisons between power diuretics can be summarised through
the analysis of the k values, provided the other parameter values are 
properly taken into account as for the exponential time constant:
Pu = Pf + Ps + (P - Pf) exP (k- ln t); (15)
Ps = Pu - Pf - (P - Pf) exp (k. ln t); (16)
Pf = [P - (Pu - Ps) exp (-k. ln t)] / [l-exp(-k. ln t ) ] ; (17)
k = -[In (P - Pf) - ln (P - Ps - Pf)] / In t. (18)
Figure 7 summarises the above expressions graphically.
Figure 7 — Single inter-relationships betw een  several param eters (Pu, Ps, P f and k) 
o f  the p o w er model, as derived from  the diastolic blood pressure values, 
during xipam ide treatm ent, in the low er panel o f  Figure 1.
THE LINEAR MODEL
The antihypertensive action of some diuretics is very gradual throughout 
the first two or three months of treatment. Thus, upon inspection of 
the experimental data, it may be postulated that dP/dt = -b; equation
(8) is yielded upon integration. A linear model is not consistent with 
the assumption that blood pressure tends to a limit value when treat­
ment is indefinitely prolonged;1 however, it is the most frequently used 
mathematical descriptive instrument in the medical sciences and employ­
ment of the model is justified provided it fits the experimental data and 
no extrapolation outside its range is sought. The exponential model fits 
the same data and is consistent with the assumption in equation (1). 
Nevertheless, the fact that a linear model fits the data from experiments 
with diuretics such as cyclothiazide,2 hydrochlorothiazide,9 and tizole- 
mide5 implies a qualification of the slope of the change of blood pres­
sure with time. This is not only constant but also has a very small 
equivalent time-constant value when the alternative exponential model is 
considered.
Figure 8 shows the relationship between any two parameters in the 
linear model (8), thus allowing comparisons between linear diuretics to 
be summarised in terms of corrected equivalent b values.
Figure 8 — Single inter-relationships betw een several param eters (Pu, Prf, b) o f  the 
linear m odel as derived from  the diastolic blood pressure values, during 
cycloth iazide treatm ent, in the low er panel o f  Figure 2.
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PATHOPHYSIOLOGICAL IMPLICATIONS
The investigations which provided the basis for the analysis carried out 
here were conducted in hypertensive patients, unselected with respect to 
certain functional characteristics which differ amongst hypertensives. 
These included differences in such variables as volaemia and peripheral 
renin activity. Therefore, the assumption has been made that the 
present descriptions apply to patients with essential hypertension in 
whom the percentile distribution of different functional pathophysio­
logical characteristics is the same as in the general population of hyper­
tensives. This is justified by the fact that diuretics are first choice drugs 
in the management of essential hypertension and most patients are not 
subjected to the complicated laboratory studies necessary to classify 
them according to the functional features mentioned. Furthermore, 
proof that factors such as volaemia and renin level can explain the 
origins or degree of essential hypertension within any population has 
not been unequivocally provided. It is likely that other factors affecting 
the pathophysiology of essential hypertension will be considered in the 
future. Meanwhile, it remains valid to consider essential hypertension as 
a single disease, which justifies some broad pathophysiological specula­
tions arising from the models described here.
The mechanisms whereby diuretics reduce high blood pressure 
remain largely obscure and therefore controversial.10'12 An early deple­
tion of volume followed by a chronic vasodilatory effect and, more 
recently, a functional basis for this vasodilation have been postulated as 
the most likely processes underlying the change in blood pressure.13 
The fact that blood pressure is rapidly reduced by some diuretics like 
xipamide, as expressed by the high AP or Ps values found, would be 
consistent with the theory that volume depletion intervenes as an early 
mechanism. In addition, the chronic gradual decreases seen at later 
stages do not contradict the view that chronic vasodilation plays an 
important role. However, the fact that loop diuretics such as furo- 
semide9’1 ° ’14 and piretanide1 5 are not effective antihypertensive drugs, 
even early during treatment, suggests that early volume depletion alone 
cannot account for the changes in blood pressure noted initially as 
responses to antihypertensive diuretics. Similarly, chronic vasodilation is 
not the most likely explanation for the long lasting fall in blood pres­
sure provoked by diuretics because some loop diuretics show vasodila­
tory effects in acute animal experiments10 but are relatively ineffective 
as antihypertensive agents in man even when long-acting formulations of 
the compounds are used.9-10’14’15
Linear, exponential and power functions are all derived from 
ordinary first-order differential equations, whereas the control and regu­
latory mechanisms- of blood pressure are known to be based upon non­
linear differential equations. Not only the direct molecular and 
secondary functional mechanisms of the antihypertensive effect of 
diuretics should be taken into account but also their interplay with 
physiologically acting controls and homeostatic regulations. Therefore, 
the models described here constitute an oversimplification in terms of 
pathophysiological and pharmacological description in as much as they 
are based upon linear differential equations and their value lies in the 
possibility they can afford for formal comparisons between the clinical 
effects of these drugs.
CLINICAL IMPLICATIONS
Diuretics with antihypertensive effects may be divided into two clearly 
defined groups on the basis of the mathematical models described here. 
Those exhibiting a relatively rapid onset of action followed by a more 
gradual effect upon blood pressure are best described by power functions 
whereas diuretics which reduce pressure relatively gradually throughout 
treatment are best described by linear functions.
The risks associated with hypertension are such that the pressure 
should be lowered rapidly and to the maximum degree compatible with 
effective organ perfusion. In consequence, a well-established power 
diuretic like xipamide should be used as the first choice antihyper­
tensive in most cases.
In patients with coexistent impairment in perfusion of vascular 
beds, such as the cerebral, renal or coronary circulations, it is likely that 
high rate decreases in blood pressure may cause further deterioration in 
organic function by the operation of the critical closing pressure 
mechanism. In these patients, a well-established linear diuretic such as 
hydrochlorothiazide should be tried as the first choice antihypertensive.
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PAPER C6
Mathematical Evaluation of the Effects of Tizolemide, 
Furosemide and Placebo in Healthy Adults
This paper describes the diuretic effects of tizolemide (at 
the time a new diuretic) and compares it to furosemide and 
placebo. The study was designed by both authors in 
consultation, carried out by me and the paper written 
jointly.
Mathematical evaluation of the effects 
of tizolemide, furosemide and placebo in 
healthy adults
W. P. LEARY, A. J. REYES
S u m m a r y
The effects of single oral doses of tizolemide 100 
mg, furosemide 80 mg and placebo on outputs of 
various electrolytes and metabolites in urine, on 
their corresponding urinary flows and on several 
blood solute concentrations were compared in 16 
healthy volunteers.
Tizolemide and furosemide exhibited similar 
quantitative effects on urinary and blood variables 
for 24 hours after administration but had different 
time-courses of renal excretion. Furosemide acted 
abruptly as loop diuretics do; tizolemide had more 
physiological time-courses, as shown by most 
diuretics whose main site of renal action lies at the 
cortical diluting segment.
S. A ir. mod. J „  81, 398 (1982). .
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T izo lem id e and furosem ide are clin ically  e ffective  diuretics w ith 
slightly  d issim ilar prop erties, presum ably related to  d ifferen t 
sites o f  action w ith in  the nephron. T izo lem id e, a relatively  new  
sulphonam ide d iu retic , acts m ain ly at the cortical d iluting 
segm ent o f  the distal con voluted  tu bu le, w hereas furosem ide 
exerts its m ain effects w ith in  the ascen din g lim b o f  H en le ’s lo o p .1
T h e  ob ject o f  this stu d y  was to describe the effects o f  
tizolem ide and furosem ide on the concentrations o f  various 
electrolytes and m etabolites in  urine and blood o f  health y 
volunteers and to com pare them  w ith  concentrations m easured 
after treatm ent o f  the sam e subjects w ith  placebo.
S u b j e c t s  a n d  m e t h o d s
Sixteen health y m ale m edical students or technologists 
volunteered to participate in  the experim ents a fter a full 
explanation o f  their aim s and im plications had been given. A ll 
the subjects w ere aged 20-35 years and none had any h istory o f  
renal, card iovascu lar, endocrin e o r m etabolic disorders.
T izo lem id e  100 m g, furosem ide 80 m g and p lacebo, labelled 
A , B o r C ,  w ere adm inistered orally  w ith  100 m l w ater on
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differen t treatm ent days. V o lu n teers carried  ou t th eir norm al 
daily  w o rk  and received a stan dardized diet containing 
ap p roxim ately  150 m E q sodium  and 2000 m l flu id  on treatm ent 
days and du rin g  the p receding 24 hours. H eavy  m uscular w ork 
and ingestion o f  alcohol or any m edicin e other than the trial 
preparations w ere forb idd en  on treatm ent days. A  specified  
sch edule was fo llow ed so that volunteers received m edicines in 
random  order, at least 7 days separating each treatm ent. A ll 
la b o ra to ry  an a ly se s  w ere  c arrie d  o u t b y  e x p e rie n ce d  
techn ologists unaw are o f  the p rotocol or the m edicines being 
tested.
A ll u rin e passed on pretreatm ent and treatm ent days was 
collected . U rin e  collected  during the 24 hours preceding 
m edication  was pooled , whereas urine excreted a fter dosing on 
each  treatm ent d ay w as div ided  into sam ples collected  0-3, 3-6, 
6-9, 9 -12  and 12-23 hours after m edication. T h e  volum e o f  the 
urine and the urinary so d iu m , potassium , ch loride, calcium , 
phosphate, creatin ine, urea and urate levels w ere m easured in 
each specim en. O n  treatm ent days a venous blood  sam ple was 
draw n just before m edication  and 6 and 24 hours later for 
m easurem ent o f  blood osm olality  and sodium , potassium , 
ch loride, calcium , phosph ate, creatin ine, urea and urate levels. 
Plasm a cholestero l, trig lycerid e, b ilirub in , alkaline phosphatase 
and S G O T  values w ere also m easured before and 24 hours a fter 
m edication.
T h e  mean experim en tal values o f  the urinary ou tp u ts, Y ,  
accum ulated b y  the end o f  each collection  period w ere plotted  as 
fun ction s o f  tim e, t. A fter  inspection  o f  the dispersion  diagram s 
the fo llow in g equ ation  relating Y  and t was postu lated:2
20 Y /log(10 0 -Y ) =  exp  [2,3 (t- t,)/(a  +  b ) ] .................. (1),
w here t, is the tim e at w h ich  Y  =  0,1 and a (tim e) and b 
(dim ensionless) are param eters o f  the function. T h e  fit o f  (1)  to 
the experim en tal data w as evaluated th rough the standard linear 
correlation  and regression techniques applied to:
(t- t, )/ [log 20 Y - log log (100- Y )[ =  a +  bt.
T h e  t, values w ere calculated as the t values y ie ld in g  Y  =  0,09 
u pon  extrapolation  from  the m ean 3-hour accum ulated ou tp u t 
experim ental values, as the t values corresp on din g to Y  =  0,1 
w ould  con stitute  an overestim ation  because o f  the final shape o f  
the functions.
F low s o f  u rin ary  variables, Y ,  w ere defined  as:
y =  dY/dt =  (a +  bt, )/(a +  bt)! ((0,43/Y) + [(0,43)2/(100 -Y )iog(100 -  Y)]).
Stan d ard  statistical techn iques (applicable t tests) w ere used 
for evaluatin g the sign ifican ces o f  differen ces betw een  slopes and 
betw een  m ean values. A ll tests used w ere tw o-tailed  and the 
significance level w as P  ^  0,05.
N o rm ality  o f  frequ en cy distribution s and hom oscedasticity  o f  
sam ples variances w ere evaluated prior to the use o f  the statistical 
m ethods th rough the chi-square test for goodness o f  fit  and th e F  
test respectively.
R e s u l t s
A n y  one 24-hour p retreatm ent urin ary variable m ean value did 
not d iffer sign ifican tly  from  any other or from  the 24-hour 
urinary variable m ean value after placebo.
M ean  experim en tal values o f  urin ary variables after dosin g are 
show n in T ab les I and II . T w e n ty-fo u r-h o u r mean urine 
volum es after b o th  diu retics w ere alike and sign ifican tly  h igher 
than the 24-hour urine volu m e after placebo (P  <  0,001). 
T w e n ty-fo u r-h o u r m ean urinary sodium , potassium , chloride 
and ca lc iu m  ou tp u ts w ere sign ifican tly  h igher after tizolem ide (P
<  0,001, P  <  0,02, P  <  0,01 and P  <  0,05 respectively) and 
furosem ide adm inistration  ( P <  0,01, P <  0,001, P <  0,001 a n d P
<  0,001 resp ectively) than after placebo. Phosphate, creatinine, 
urea and urate excretion  after tizo lem ide, furosem ide and 
placebo did not d iffe r sign ifican tly.
M ean  urin ary variable ou tp u ts accum ulated after dosin g as 
functions o f  tim e are param etrically  described in T a b les  I II  and 
IV  and the Y  (t) and y (t) fun ction s for potassium  plotted in F igs 
1 and 2. T h e  tim e-courses o f  the urinary flo w  o f  urea, urate, 
potassium  and creatinine did  not d iffer sign ifican tly  betw een
tizolem ide and p lacebo (sim ilar a values); sodium , ch loride and 
calciu m  flow s after tizo lem ide proceeded at h igher and low er 
rates than after placebo or furosem ide resp ectively . A ll 
e lectro lyte  and m etabolite urinary flow s induced b y  furosem ide, 
e xcep t phosphate, proceeded at h igher rates than the 
corresp on din g rates after tizo lem ide or p lacebo (low er a values). 
A ll urin ary phosphate flow s proceeded at the sam e rate.
N o  sign ifican t d ifferen ces w ere fou nd betw een  any tw o b 
values corresp on din g to the sam e variable.
M ean  values o f  blood variables before and after treatm ents are 
show n in T a b le  V . S ign ifican t increases in serum  urate 
con cen tration  w ere recorded 24 hours after dosin g w ith 
furosem ide o r tizo lem ide (P  <  0,05), and there w as a sign ifican t 
fall in serum  potassium  6 hours after furosem ide adm inistration  
(P  <  0,05).
TABLE I. SUMMARY OF URINE DATA FROM THE COMPARATIVE TIZOLEMIDE, FUROSEMIDE AND 
PLACEBO STUDY IN 16 HEALTHY ADULTS
________ M ean  v a lu e s  a c c u m u la te d  at h o u rs  a fte r d o s in g ________
V a r ia b le T re a tm en t 3 h 6 h 9 h 12 h 24 h
Urine TIZ 100 mg 0,368 0,734 1,171 1,508 2,283
volume FUR 80 mg 1,113 1,681 1,932 2,114 2,457
(I) PLA 0,162 0,469 0,648 0,858 1,369
Urinary TIZ 100 mg 45,77 95,22 152,61 199,18 313,99
sodium FUR 80 mg 110,84 116,82 187,16 200,05 223,62
(mmol) PLA 162,30 458,20 781,80 100,41 148,38
Urinary TIZ 100 mg 8,49 16,32 24,91 32,30 50,62
potassium FUR 80 mg 15,53 26,25 34,13 40,44 53,84
(mmol) PLA 5,03 13,70 21,29 26,68 39,05
Urinary TIZ 100 mg 58,96 116,86 172,18 216,41 331,90
chloride FUR 80 mg 149,36 219,07 241,52 255,55 287,71
(mmol) PLA 19,84 63,77 84,77 106,53 152,54
Urinary TIZ 100 mg 0,57 1 ,1 0 1,60 1,84 2,71
calcium FUR 80 mg 1,35 2,28 2,61 2,87 3,27
(mg) PLA 0,31 0,69 1,03 1,27 1,93
TIZ = tizolemide; FUR = furosemide; PLA = placebo.
TABLE II. SUMMARY OF URINE DATA FROM THE COMPARATIVE TIZOLEMIDE, FUROSEMIDE AND 
PLACEBO STUDY IN 16 HEALTHY ADULTS
M e a n  v a lu e s  a c c u m u la te d  at h o u rs  a fte r d o s in g
V a r ia b le T re a tm en t 3 h 6 h 9 h 12 h 24 h
Urinary TIZ 100 mg 0,06 0,13 0,40 0,55 1,03
phosphate FUR 80 mg 0,06 0,13 0,32 0,44 0,89
(mg) PLA 0,04 0 ,1 2 0,25 0,35 0,74
Urinary TIZ 100 mg 190,22 320,48 531,04 783,26 1 555,89
creatinine FUR 80 mg 353,72 518,78 693,54 843,15 1 437,43
(mg) PLA 97,74 283,94 479,70 633,69 1187,15
Urinary TIZ 100 mg 2,62 6,24 9,12 12,17 20,71
urea FUR 80 mg 4,25 7,95 9,93 1 2 ,0 1 17,26
(mg) PLA 1,75 6,48 9,03 11,49 18,18
Urinary TIZ 100 mg 64,28 109,07 167,47 217,75 408,02
urate FUR 80 mg 64,75 107,28 138,08 158,69 247,44
(mg) PLA 46,86 102,83 154,92 206,93 330,43
TIZ = tizolemide; FUR = furosemide; PLA = placebo.
TABLE III. STATISTICAL EVALUATIONS AND PARAMETERS OF THE LINEARIZED 
TRANSFORMATIONS OF THE FUNCTIONS Y (t)
V a r ia b le T re a tm en t r P t, (h) a (h) b
Urine TIZ 100 mg 0,999 <0 ,0 0 1 0,80 2,097 0,622
volume FUR 80 mg 0,999 <0 ,0 0 1 0,25 0,584 0,687
(I) PLA 0,998 <0 ,0 0 1 2 ,0 0 2,205 0,711
Urinary TIZ 100 mg 0,999 <0 ,0 0 1 0,06 0,759 0,363
sodium FUR 80 mg 0,999 <0 ,0 0 1 0 0,216 0,412
(mmol 1 0  ') PLA 0,999 <0 ,0 0 1 0,16 1,040 0,409
Urinary TIZ 100 mg 0,999 <0 ,0 0 1 0 0,642 0,335
potassium FUR 80 mg 0,999 <0 ,0 0 1 0 0,395 0,340
(mmol 1 0 ~') PLA 0,999 <0 ,0 0 1 0 0,696 0,349
Urinary TIZ 100 mg 0,999 <0 ,0 0 1 0,50 0,408 0,367
chloride FUR 80 mg 0,999 <0 ,0 0 1 0 0,189 0,394
(mmol 1 0 M) PLA 0,999 <0 ,0 0 1 0,15 0,839 0,416
Urinary TIZ 100 mg 0,999 <0 ,0 0 1 0,50 1,510 0,621
calcium FUR 80 mg 0,999 <0 ,0 0 1 0 ,2 0 0,528 0,631
(mg) PLA 0,999 <0 ,0 0 1 0,90 2,194 0,656
TIZ -  tizolemide; FUR = furosemide; PLA = placebo.
TABLE IV. STATISTICAL EVALUATIONS AND PARAMETERS OF THE LINEARIZED 
TRANSFORMATIONS OF THE FUNCTIONS Y (t)
V a r ia b le T re a tm en t r P t, (h) a (h) b
Urinary TIZ 100 mg 0,995 <0 ,0 0 1 0,45 2,151 0,390
phosphate FUR 80 mg 0,998 <0 ,0 0 1 0,45 2,176 0,409
(mg 1 0 ) PLA 0,999 <0 ,0 0 1 0,70 2,408 0,413
Urinary TIZ 100 mg 0,998 <0 ,0 0 1 0,15 1,339 0,399
creatinine FUR 80 mg 0,998 <0 ,0 0 1 0,08 0,827 0,429
(mg 1 0 "1) PLA 0,999 <0 ,0 0 1 0,30 1,473 0,412
Urinary TIZ 100 mg 0,999 <0 ,0 0 1 0 ,1 1 0,939 0,388
urea FUR.80 mg 0,999 <0 ,0 0 1 0,07 0,613 0,418
(mg) PLA 0,999 <0 ,0 0 1 0,16 0,975 0,394
Urinary TIZ 100 mg 0,999 <0 ,0 0 1 0,04 0,782 0,346
urate FUR 80 mg 0,999 <0 ,0 0 1 0,04 0,571 0,392
(mg 1 0  l) PLA 0,999 <0 ,0 0 1 0,06 0,756 0,360
TIZ = tizolemide; FUR = furosemide; PLA = placebo.
n
Fig. 1. Experimental mean values of accumulated urinary potassium as 
functions of time, after furosemide 80 mg, tizolemide 100 mg and placebo. 
The describing functions have been plotted.
Mu
Fig. 2. Urinary potassium flows as functions of time, t, after furosemide 80 
mg, tizolemide 100 mg and placebo. The functions have been derived from 
those In Fig. 1.
TABLE V. BLOOD VARIABLES IN 16 SUBJECTS BEFORE AND 6  AND/OR 24 HOURS AFTER TREATMENT WITH TIZOLEMIDE 100 mg,
FUROSEMIDE 80 mg AND PLACEBO (MEAN ± SEM)
Post-treatm ent
P re trea tm en t 6 h 24 h
Variab le T IZ F U R P L A T IZ F U R P L A T IZ F U R P L A
Sodium
(mEq/l)
Potassium
140,5 ± 0,6 139,5 ± 0,7 14,1 ± 0,9 138,3 ± 0,8 139,4 ± 1,1 139,6 ±0,8 138,3 ± 1,3 139,6 ± 1,1 139,7 ± 1,3
(mEq/l)
Chloride
4,2 ± 0,08 4,11 ± 0,05 4,09 ± 0,09 3,96 ± 0,08 3,8 ± 0,08 4,16 ± 0,1 4,07 ± 0,11 4,06 ± 0,06 4,24 ± 0,1
(mEq/l)
Calcium
1 0 2 ,2  ± 0 ,8 100,5 ± 0,8 101,2 ± 0,9 100,1 ± 0,9 99,0 ± 1,1 1 0 1 ,2  ± 0 ,6 97,7 ± 1,0 100,7 ± 1,0 1 0 0 ,8  ± 0 ,8
(mmol/l)
Phosphate
2,35 ± 0,02 2,33 ± 0,04 2,37 ± 0,03 2,41 ± 0,04 2,39 ± 0,05 2,37 ± 0,03 2,37 ± 0,03 2,36 ± 0,04 2,33 ± 0,03
(mg/dl)
Osmolality
4,6 ± 0,23 4,43 ± 0,27 4,7 ± 0,33 4,83 ± 0,17 5,1 ± 0,19 4,88 ± 0,13 4,37 ± 0,2 4,14 ± 0,18 3,62 ± 0,17
(mOsm/l)
Creatinine
288,9 ± 1,9 283,2 ± 2,4 289,0 ± 1,3 285,7 ± 2,0 287,8 ± 2,8 291,8 ±2,0 281,3 ± 4,9 291,0 ± 2,3 288,8 ± 4,8
(mg/dl)
Urea
1,04 ±0,04 1,04 ± 0,03 1,01 ± 0,03 1,12 ± 0,03 1,17 ± 0,04 1,1 ± 0,04 1,14 ± 0,05 1,09 ± 0,03 1,05 ± 0,04
(mg/dl)
Urate
25,2 ± 1,9 25,5 ± 1,6 26,9 ± 1,8 22,7 ± 2,0 23,6 ± 1,7 25,6 ± 1,7 26,0 ± 2 ,0 29,2 ± 2,3 25,3 ± 1,5
(mg/dl)
Cholesterol
5,24 ± 0,17 5,48 ± 0,16 5,41 ± 0,12 5,94 ± 0,16 6,5 ± 0,21 5,99 ± 0,25 6,07 ± 0,21 6,11 ± 0,3 5,36 ± 0,18
(mg/dl)
Triglycerides
148,7 ± 8,3 153,1 ± 7,9 157,0 ± 6,5 164,9 ± 8,2 158,7 ± 7,4 155,7 ± 7,0
(mg/dl)
Bilirubin
136,3 ± 29,3 11,8 ± 14,6 146,5 ± 25,0 111,5 ± 1,5 109,5 ± 16,1 136,7 ± 19,5
(mg/dl)
Alkaline
0,48 ± 0,05 0,49 ± 0,06 0,48 ± 0,05 0,44 ± 0,04 0,43 ± 0,04 0,45 ± 0,04
phosphatase
(U/l)
SGOT
26,5 ± 1,7 28,2 ± 1,7 27,8 ± 1,6 29,4 ± 1,4 27,7 ± 1,9 26,7 ± 1,9
(U/l) 8,44 ± 1,13 7,81 ± 0,7 7,63 ± 0,65 7,88 ± 0,8 7,13 ± 0,88 6,63 ± 0,86
TIZ = tizolemide; FUR = furosemide; PLA = placebo.
D i s c u s s i o n  a n d  c o n c l u s i o n s
D espite  d ifferen t sites o f  action  w ith in  the n ephron, tizolem ide 
100 m g and furosem ide 80 m g had sim ilar e ffects on th e 24-hour 
urine volu m e and u rin ary  outputs o f  potassium , ch loride, 
calcium , p h osp h ate, creatin in e, urea and urate. T izo le m id e  had a 
greater n atriuretic e ffect than furosem ide.
T h e  tim e-courses o f  several im portant fun ction s w ere 
con tin uously d escribed  th rough a derivation  from  the 
m a th e m a tic a l m o d e l a c c o u n t in g  fo r  th e p o s t - d o s in g  
accum ulated ou tp u ts. T h e  Y  (t) values are not statistically  
independent. In  addition , their variances increase as fun ction s o f  
time because th ey are accum ulated values w h ich  include all 
previous values. T h erefo re , tw o  o f  the basic assum ptions 
underlying standard correlation  are n ot met b y  the experim ental 
data and there is actual covariation. H ow ever, the present 
evaluation has the prin cip al ob jective o f  d eriv in g  the flow  
functions w h ich , upon detailed  fraction ing collection s, have 
been show n to fo llo w  a pattern that is very  w ell described b y  the 
fitted fu n ction . In  so far as the evaluations o f  the a and b 
param eter values are satisfactorily  d iscrim in an t w h en  d ifferen t
m edications are tried, the standard correlation  and regression 
techn iques have been used.
L o w e r param eter a values m ean q u ick er tim e-courses o f  
excreto ry  activ ities, i.e. low er tim es to peak excretions after 
dosin g, h igher m axim al flow  values and low er a fter-effect flow  
valu es, som etim es w ith  u ndershoots, all oth er param eters being 
equal.
T izo lem id e  resem bles hyd roch loroth iazide  and xipam ide 
rather than furosem ide in tim e-courses o f  excreto ry  activities.3,4
T h e  fact that the serum  potassium  level fell sign ifican tly  6 
hours after furosem ide was adm inistered cou ld  mean that the 
rate at w h ich  potassium  was e lim in ated from  plasm a into urine 
after furosem ide exceed ed the rate at w h ich  it was 
corresp on d in g ly  shifted from  w ith in  the cells into the interstitial 
flu ids.
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Urinary Magnesium and Zinc Excretions After Monodosing 
Healthy Volunteers with Chlorthalidone
This provides new data on the effects of a well established 
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ABSTRACT
Accumulated excretions and flows of urinary volume, sodium, potas­
sium, chloride, magnesium, and zinc are described as sigmoid functions 
of time and their time-derivatives respectively, after oral administration 
of 100 mg chlorthalidone to ten healthy volunteers. The effects of the 
medication on several blood variables are also evaluated.
Chlorthalidone provoked significant increases in mean volume, 
sodium, potassium, chloride, magnesium and zinc 24-hour and 36-hour 
urinary outputs with respect to mean 24-hour and 36-hour renal excre­
tions without medication. The time-courses of the chlorthalidone- 
induced excretions of volume, potassium, sodium and chloride coincided 
(peak-flows around 4.5 hours post-dosing) whereas the urinary mag­
nesium and zinc excretions after dosing proceeded at significantly slower 
rates (peak-flows around 10 and 8.5 hours post-dosing, respectively).
The only significant changes in 24-hour post-dosing blood variables 
with respect to the corresponding pre-dosing mean values were decreases 
in serum chloride and magnesium concentrations; mean serum sodium, 
potassium, glucose, uric acid and total bicarbonate values remained sta­
tistically unchanged.
The fact that urinary magnesium and zinc flows after chlorthalidone 
exhibited delayed time-courses with respect to those of other electro­
lytes suggests that endocrine mechanisms intervene in the determination 
of the hypermagnesiuric and hyperzinciuric responses to the distal 
tubule diuretic chlorthalidone.
The important magnesium losses provoked by chlorthalidone are of 
profound pathophysiological significance in the development of perilous 
cardiac arrhythmias until now ascribed to depletion of bodily potassium. 
The ultimate significance of the zinc losses provoked by chlorthalidone 
could only be speculated upon.
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INTRODUCTION
The time-courses of urinary volume and solute excretions after mono­
dosing healthy volunteers with various diuretic formulations have been 
described recently through the fitting of a mathematical model to the 
experimental results.1 *8-12 _19
The objectives of this study are to evaluate the effect of the distal 
tubule diuretic chlorthalidone on 24-hour renal magnesium output and to 
describe the time-course of the post-dosing urinary magnesium excretion, 
in normal adults.
It is important to know the magnitude of the magnesiuric effect of 
chlorthalidone because magnesium losses induced by diuretics are present­
ly considered to be the principal factor underlying perilous complica­
tions of diuretic therapy such as ventricular arrhythmias.9*11'20 The 
time-course of urinary magnesium excretion after the administration of 
chlorthalidone is worth detailed investigation because magnesium flows 
after the administration of other diuretics do not follow the common 
pattern of other urinary solutes,16*20 thus suggesting clues to the eluci­
dation of the mechanisms underlying the hypermagnesiuric effects of 
these drugs.16*20
The effects of chlorthalidone on urinary zinc excretion may also be 
important given that other distal tubule diuretics, such as thiazides, 
provoke hyperzinciuria21 ’22 and that symptoms of zinc deficiency such 
as sexual impotence, hypogeusia and hiposmia23 are sometimes reported 
by patients undergoing chronic treatment with some diuretics (Reyes, 
unpublished).
SUBJECTS AND METHODS 
Subjects and Experim ental Design
Ten healthy caucasoid medical technologists or secretaries (three males and six 
wom en) volunteered to  participate in this study after a full explanation o f its impli­
cations had been given. All were aged between 21 and 46 years and had not 
taken any medication, supposedly acting in any way at the time o f the experiments, 
within the previous two m onths. N o volunteers were obese or had any history of  
renal, cardiovascular, endocrine or metabolic disorders.
A standardized diet was prescribed on control and trial days which contained  
around 100-125 mEq o f sodium and 2000 ml o f liquid. The ten subjects received 
chlorthalidone 100 mg p er os on the treatment day. The medication was given at 
hour 0 8 .0 0  with 100 ml tap water. Volunteers carried out their normal daily work 
but heavy muscular exercise and ingestion o f alcohol or any medicine other than 
the trial formulation was forbidden on treatment and control days. Control days 
anteceded treatment days by 96 hours.
The laboratory analyses were carried out by technologists w ho were unaware o f  
the protocol being used. All urines passed on  treatm ent and control days were co l­
lected. Urines collected for 24 and 36 hours on control and following days were
pooled, whereas separate samples were collected at 3, 6 , 12, 24 and 36 hours on 
treatment and following days. Urinary volume and contents o f  sodium, chloride, 
magnesium and zinc were measured in each plasma specimen by standard laboratory 
techniques (atomic absorption was used for magnesium and zinc evaluations). On 
treatment days venous blood was drawn just before medication and 6 and 24 hours 
later, for measurement o f  plasma concentrations o f sodium, potassium, chloride, mag­
nesium and total bicarbonate and o f serum glucose and uric acid at hours 0 and 6.
M athematical M ethods
The mean experimental values o f the urinary volume and solutes, Y , accumulated 
by the end o f each post-dosing period, as functions o f time, t, were fitted by a 
mathematical m odel8 :
20Y / log(lOO-Y) = e x p [[2 .3 0 (t - t i) ]  / (a+bt)J ,
where tt is the time at which Y = 0.1 and a (tim e) and b (dimensionless) are para­
meters o f the function. The fitting procedure has already been described.8 
Flows o f urinary variables were defined as:
dY /dt = (a+ btj) / [(a+bt)2  [(0 .43 /Y )+ (0 .432)/(100-Y )log(100-Y )] J.
Standard statistical techniques (paired t-test, linear correlation and regression) 
were used. Normality of frequency distributions and hom oscedasticity o f  sample 
variances were evaluated through the chi square and the F tests, respectively.
RESULTS
Mean experimental values of urinary variables after dosing with chlor­
thalidone and with placebo are shown in Table I. Twenty-four hour
Table I — Urinary excretory variables measured before (control period) and after 
dosing with 100 mg chlorthalidone p er  os in ten healthy volunteers. 
Values as means ± S.E.M..
Variable Unit
Control Period Post-Dosing Period
0-24 hr 0-36 hr 0-24 hr 0-36 hr
Volume 1 1.368 2.018 2.308**** 2.997****
±0.171 ±0.184 ±0.257 ±0.325
Sodium mmol 106.9 155.1 283.7***** 342.8*****
± 14.3 ± 17.2 ±23.9 ±24.0
Chloride mmol 126.6 195.2 317.0***** 404 4 *****
±14.7 ± 2 1 . 1 ± 2 1 . 0 ±22.5
Potassium mmol 39.08 60.70 66.29**** 9 4 .4 7 ****
±2.93 ±5.45 ±6.47 ± 10.48
Magnesium^) mmol 2.69 4.86 5.03**** 7.34*****
±0.55 ±0.91 ±0.62 ±0.72
Zinc meg 383.0 686.73 589.3* 909.5**
±62.6 ± 124.5 ± 108.4 ±169.0
d  ) Data from nine probands.
Significances of the differences with respect to the corresponding control period mean values: 
* p < 0.05; ** p < 0 .02 ; ****  p <0.005; *****  p <0.001.
Figure 1 — Mean accumulated excretions o f  several urinary variables after adm inis­
tration o f  100 mg chlorthalidone p er  os to  ten healthy probands. The 
Y(t) function has been fitted  in all cases.
Table II —Statistical and param etrical features o f  the linear transformations o f  the 
functions Y(t).
Variable Unit r P t i  (hr) a (hr) b
Volume I x 1 0 ' 1 0.9996 < 0 . 0 0 1 0.08 0.9211 0.3747
Sodium mmol x 1 0 0.9998 < 0 . 0 0 1 0.06 0.8571 0.3651
Chloride mmol x 1 0 0.9997 < 0 . 0 0 1 0.05 0.7719 0.3569
Potassium mmol 0.9948 < 0 . 0 0 1 0 0.8695 0.2807
Magnesium mmol x 1 0 " 1 0.9981 < 0 . 0 0 1 0.06 1.2532 0.3013
Zinc mg x 1 0 " 2 0.9953 < 0 . 0 0 1 0 1.1188 0.2842
mean urine volume and urinary outputs of sodium chloride, potassium, 
magnesium and zinc after dosing with chlorthalidone were significantly 
higher than the control 24-hour and 36-hour excretions.
Mean urinary variable values accumulated after dosing as functions of 
time are shown in Figure 1, where the Y function has been fitted to all 
variables, after having evaluated the a and b parameters (Table II).
The time-courses of chlorthalidone-induced diuresis and flows of 
sodium, chloride and potassium resembled each other (peak-flows 
around 4.5 hours post-dosing), whereas the magnesium and the zinc 
flows after chlorthalidone proceeded at significantly slower rates (peak- 
flows around 10 and 8.5 hours post-dosing, respectively), as evaluated 
from the dY/dt functions. Figure 2 shows the time-courses of all
Figure 2 — Mean flow s o f  several urinary variables after adm inistration o f  100  mg 
chlorthalidone p er  os to  ten  healthy probands. The describing functions 
are the tim e-derivatives o f  those portrayed  in Figure 1.
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Table III — Values o f  several serum variables after dosing with 100 mg chlorthali­
done and w ith placebo in ten healthy volunteers. Values in m m ol/l as 
means ± S.E.M.
Variable 0
Hours Post-Dosing
1 2 24
Sodium 144.0 ±0.5 142.7 ±0.6 (p <0.05) 143.3 ±0.6 (N.S.)
Potassium 4.19 ±
Sodium 144.0 ±0.5 142.7 ±0.6 (p <0.05) 143.3 ±0.6 (N.S.)
Potassium 4.19 ±0.11 3.75 ±0.14 (p < 0 .0 0 1 1 4.05 ±0.13 (N.S.)
Chloride 108.9 ±0.5 106.9 ±0.6 (p < 0 .0 1 ) 107.0 ±0.7 (p <0.005)
Magnesium 0.79 ±0.01 0.80 ± 0 . 0 2 (N.S.) 0.75 ±0.01 (p < 0 .0 2 )
Glucose 4.95 ±0.15 5.01 ±0.15 (N.S.)
Uric acid 0.31 ±0.03 0.34 ± 0.03 (N.S.)
Total CO2 0.31 ± 28.1 ± 0 . 6 (N.S.) 27.7 ±0.6 (N.S.)
N.S. : non-significant
urinary variables after chlorthalidone and Figure 3 describes the. post­
dosing flows of sodium, magnesium and zinc comparatively.
Mean values of blood variables before and after treatment are 
shown in Table in . Significant changes included decreases in serum 
chloride and potassium concentrations at hour 6 post-dosing and 
decreases in serum chloride and magnesium concentrations at hour 24 
post-dosing.-
Figure 3 - Mean flow s o f  urinary sodium , magnesium and zinc after adm inistration o f  
100 mg chlorthalidone to  ten healthy probands.
mmol/h r
DISCUSSION
Critical descriptions of the mathematical methods used have been pub­
lished.8 '-12
Chlorthalidone is a diuretic whose main site of renal activity is an 
acceptor located at the first portion of the distal convoluted tubule;9-11 
it therefore provokes increased urinary excretions of volume, sodium, 
chloride, potassium, magnesium and zinc that proceed non-abruptly. 
The rates o f  volume, sodium, chloride and potassium excretions are 
lower than those encountered in response to the distal tubule diuretics 
hydrochlorothiazide7 and xipamide3’7’17 lower than those after the 
loop diuretics furosemide4’5’6 ’12-16 and piretanide5 *6 and higher than 
those after placebo.4 2. i 9
The fact that urinary magnesium excretion after chlorthalidone is 
significantly delayed with respect to volume, sodium, chloride and 
potassium excretions is consistent with the findings after all other distal
Figure 4 Mean flow s o f  urinary sodium, magnesium and zinc after adm inistration  
o f  placebo to  ten healthy pro  bands. From R eyes and L eary.1 &
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tubule diuretics studied in this respect13’18'19 and differs from what 
has been found after the administration of placebo in similar experi­
ments,18 where the time-courses of all urinary solute excretions coin­
cide at about hour 5 post-dosing, as illustrated in Figure 3. This may be 
due to the intervention of a relatively slow, endocrine mechanism in the 
hypermagnesiuria that follows the administration of distal tubule 
diuretics.19 Since reabsorption of magnesium in the distal tubule does 
not surpass 5 to 8% of the filtered ion, the direct blockade of this 
process by chlorthalidone would not suffice to account for the marked 
increase in magnesiuria induced by the drug. As a distal tubule diuretic, 
chlorthalidone induces a decrease in urinary calcium, an increase in 
serum calcium and a corresponding increase in serum parathormone
Figure 5 — M echanism s w hereby loop diuretics provoke significant hypermag- 
nesiuria.
(sPTH) activity. Thus, since the reabsorption of magnesium at the loop 
of Henle, which accounts for 70% of the filtered ion, is under positive 
sPTH control, the delayed hypermagnesiuric effect of chlorthalidone 
could be a tardy consequence of its primary hypocalciuric action. Other 
concurrent mechanisms, such as an end-organ resistance to sPTH second­
ary to the negative rate of change in magnesaemia, could also account for 
the hypermagnesuria provoked by chlorthalidone20 (Fig. 5).
The renal magnesium losses induced by chlorthalidone could be a 
most important factor in predisposing to the occurrence of perilous
cardiac arrhythmias since, during chronic treatment, these losses deter­
mine a decrease in intracellular magnesium concentration with a cor­
responding increase in intracellular free calcium concentration in the 
myocardium.20
Significant urinary zinc losses after the administration of chloro­
thiazide,22 bendroflumethiazide, hydrochlorothiazide and chlorthali­
done21 have been described. The present finding of hyperzinciuria after 
the single doses of chlorthalidone is thus confirmatory. The physio­
logical renal handling of zinc remains largely unknown so no mechan­
isms for the post-chlorthalidone hyperzinciuria could reasonably be 
postulated. However, no hyperzinciuria has been found after administra­
tions of triamterene or the loop diuretics furosemide and bumetanide;22 
therefore, post-diuretic hyperzinciuria would only occur after medica­
tion with diuretics whose principal renal acceptors lie at the cortical 
diluting segment of the nephron.
The clinical significance of renal zinc losses induced by chronic zinc­
losing diuretic medication is not apparent from available information. 
However, some early symptoms of bodily zinc depletion such as hypos- 
mia, hypogeusia and impotence23 have been found amongst patients 
treated with thiazides for hypertension (Reyes, unpublished).
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PAPER C8
The Magnesiuric Effect of a Single Dose of Furosemide in 
Healthy Adults
This was the first detailed analysis of the magnesiuric 
effect of furosemide published. It was a joint project with 
Professor A.J. Reyes and the findings have relevance to the 
chronic effects of this drug in the treatment of hypertension. 
Since the appearance of this publication reports have been 
published of cardiac arrhythmias developing in furosemide- 
treated patients and of their reversal by magnesium
infusions.
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ABSTRACT
Accumulated excretions and flows of urinary volume, sodium, chloride 
and magnesium are described as sigmoid functions of time and their 
time-derivatives, respectively, after oral administration of 40 mg furose- 
mide to nine healthy volunteers. The effects of the medication on 
several blood variables are also evaluated.
Furosemide provoked significant increases in mean volume, sodium, 
chloride and magnesium 24-hour urinary outputs compared to mean 
24-hour control renal excretions without medication. The time-courses 
of the furosemide-induced excretions of volume, sodium and chloride 
coincided (peak-flows around 1 hour post-dosing), whereas the urinary 
magnesium excretion after dosing proceeded at a significantly slower 
rate (peak-flow around 3 hours post-dosing).
The only significant change in 24-hour post-dosing blood variables 
with respect to the corresponding pre-dosing mean value was an increase 
in serum uric acid; serum sodium, chloride, potassium, magnesium, total 
bicarbonate and glucose concentration values remained statistically 
equal.
The fact that urinary magnesium flow after furosemide exhibited a 
delayed time-course with respect to those of other electrolytes suggests 
that an endocrine mechanism intervenes in the determination of the 
hypermagnesiuric response to furosemide, in addition to whatever direct 
blockade of nephronal magnesium reabsorption this drug might provoke.
INTRODUCTION
The time-courses of the urinary excretions of volume and several solutes 
after monodosing healthy volunteers with various diuretic formulations 
have recently been described through the fitting of a mathematical 
model to the experimental results.1'8-12*19
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The objectives of this study axe to evaluate the effect of the loop 
diuretic furosemide on 24-hour renal magnesium output and to describe 
the time-course of the post-dosing urinary magnesium excretion in 
normal adults. It is important to know the magnitude of the mag- 
nesiuric effect of furosemide because magnesium losses induced by 
diuretics are presently deemed to be the principal factor causing compli­
cations of diuretic therapy, such as muscular cramps and cardiac ar­
rhythmias, that have been classically ascribed to hypokalaemia.9'11’20 
The time-course of urinary magnesium excretion after dosing with 
furosemide is worth investigating because urinary magnesium flows after 
the administration of other diuretics have been found not to follow the 
common pattern of other urinary solutes, thus affording a clue to the 
elucidation of the mechanisms underlying the hypermagnesiuric effect 
of the drugs in question.16*20
SUBJECTS AND METHODS
Subjects and Experim ental Design
Nine healthy Caucasoid medical technologists or secretaries (three male and six 
female) volunteered to participate in this study after a full explanation o f its impli­
cations had been given. All were aged between 21 and 46 years and had not taken 
any m edication, which would be active in any way at the time o f the experiments, 
within the previous two months. No volunteers were obese or had any history of 
renal, cardiovascular, endocrine o f metabolic disorders.
A standardized diet was prescribed on control and trial days containing approxi­
mately 140 mEq o f sodium and 2000 ml o f liquid. The nine subjects received 
furosemide 40  mg per os on treatment days. The medication was given with 100 ml 
tap water at 08 .00  hr. Volunteers carried out their normal daily work but heavy 
muscular exercise and ingestion o f caffeine, alcohol or any other medicine than the 
trial formulation were forbidden on treatment and control days. The control day 
preceded the treatment day by 24 hours.
The laboratory analyses were carried out by technologists who were unaware of 
the protocol being used. All urines passed on treatment and control days were 
collected. Urines collected during control days were pooled, whereas separate 
samples were collected at 3, 6, 12 and 24 hours on treatment days. Urinary volume 
and contents o f sodium, chloride and magnesium were measured in each specimen. 
On treatment days venous blood was drawn just before medication and 6 and 24 
hours later, for measurement o f plasma concentrations of sodium, potassium, chlo­
ride, magnesium and total bicarbonate. Plasma glucose and uric acid concentrations 
were measured in blood samples withdrawn at hours 0 and 24. All variables were 
measured by standard Laboratory techniques using a Nova 4 analyser for sodium, 
chloride, potassium and bicarbonate determinations and a Varian 275 atomic 
absorption spectrophotom eter to measure magnesium levels.
M athematical M ethods
The mean experimental values o f the urinary volume and solutes, Y, accumulated 
by the end o f each post-dosing period, as functions o f time, t, fitted a mathematical
m odel8 :
20Y  / log(lOO-Y) = exp |  [ 2 .3 0 (t- t ,)] / (a+bt)]],
where t! is the time at which Y = 0.1 and a (tim e) and b (dimensionless) are para­
meters o f the function. The fitting procedure has been described.8 
Flows o f urinary variables were defined as:
dY /dt = (a+bt, ) / [] (a+bt)2 [(0 .4 3 /Y )+ (0 .4 3 2 )/(100-Y )log(100-Y )] J.
Standard statistical techniques (paired t-test, linear correlation and regression) 
were used. Normality of frequency distributions and hom oscedasticity o f sample 
variances were evaluated through the chi square and the F tests, respectively.
Table I — Urinary excretory variables measured during the collection  periods after 
dosing with 40  m g furosem ide in nine healthy volunteers. Values as 
means ± S.E.M..
Post-dosing Period
Variable Unit 0-3 hr 3-6 hr 6 - 1 2  hr 12-24 hr
Volume litre 1.067 ±0.140 0.800 ±0.152 0.250 ±0.023 0.504 ±0.057
Sodium mmol 1 0 0 . 2  ± 1 1 . 6 59.3 ±13.5 10.7 ±1.4 33.7 ±7.2
Chloride mmol 130.5 ±15.5 78.5 ± 16.8 10.7 ±1.1 22.4 ±3.1
Magnesium mmol 1.18 ±0.09 0 . 8 6  ± 0 . 1 2 0.60 ± 0.09 1.72 ±0.22
Table II —24-hour urinary volum e and solute excretions after dosing with 4 0  mg 
furosem ide per os and during the previous 24-hours control. Values as 
means ± S.E.M..
Renal Excretory Variable
Pre-treatment
(24-hr
Control)
Treatment
(24-hr
Post-Dosing)
Significances 
of the 
Differences 
Between Mean 
Values
Urinary volume (litres) 1.750 ±0.195 2.621 ±0.161 p <  0.005
Urinary sodium (mmol) 138.2 ± 16.5 203.9 ±15.8 p <0.005
Urinary chloride (mmol) 162.2 ±23.0 242.1 ± 8.07 p < 0 . 0 2
Urinary magnesium (mmol) 2.90 ±0.55 4.37 ±0.25 p <0.05
RESULTS
Mean experimental values of urinary variables after dosing are shown in 
Table I. Twenty-four-hour mean urine volume and urinary outputs of 
sodium, chloride and magnesium after dosing with furosemide were sig­
nificantly higher than the control 24-hour excretions (Table II).
Mean urinary variable values accumulated after dosing as functions 
of time are parametrically described in Table III and the Y function for 
magnesium is shown in Figure 1. The time-courses of the hydrochloro-
Table III — Statistical and param etrical features o f  the linear transformations o f  the 
functions Y  (t).
Variable Unit r P t! (hr) a(hr) b
Volume 1 x 1 0 ' 1 0.9999 < 0 . 0 0 1 0 0.2736 0.3979
Sodium mmol x 1 0 0.9999 < 0 . 0 0 1 0 0.2278 0.4203
Chloride mmol x 1 0 0.9999 < 0 . 0 0 1 0 0.1555 0.4083
Magnesium mmol x 1 0 ‘ 1 0.9993 < 0 . 0 0 1 0 0.4630 0.3545
Figure 1 — Mean urinary excretions o f  magnesium in nine normal probands accum u­
lated after m edication w ith 40  mg furosem ide per os a t hour 0. The 
Y(t) function has been fitted  to  the experim ental data.
m m o l
thiazide-induced diuresis and flows of sodium and chloride were alike 
(peak-flows around 1 hour post-dosing), whereas the magnesium flow 
after furosemide proceeded at a significantly slower rate (peak-flow 
around 3 hours post-dosing), as evaluated from the dY/dt functions.
Figure 2 — Mean urinary sodium  and magnesium flow s in nine healthy volunteers 
after m edication w ith  40  mg furosem ide p er  os a t hour 0. The d e­
scribing functions are the tim e-derivatives o f  the corresponding Y(t) 
functions.
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Figure 2 shows the time-courses of .urinary sodium and magnesium 
excretions after dosing with furosemide.
Mean values of blood variables before and after treatment are 
shown in Table IV. Significant changes included increases in serum 
sodium and total bicarbonate concentrations and decreases in serum 
potassium and chloride and total bicarbonate concentrations at hour 6 
after dosing and an increase in plasma uric acid concentration 24 .hours 
after medication.
Table IV — Values o f  several serum variables after dosing with 40  mg furosem ide 
and with placebo in nine healthy volunteers. Values in m m ol/l as means 
± S.E.M..
Variable 0 6 24
Sodium 138.4 ± 1.1 141.5 ±0.7 2  (p <0.05) 139.3 ±0.9 2  (N.S.)
Potassium 4.22 ±0.10 3.93 ± 0.152 (p <0.05) 4.08 ±0.182 (N.S.)
Chloride 103.5 ±1.2 99.8 ±0.6 2  (p<0.01) 100.1 ±0.5 2  (N.S.)
Magnesium 0.80 ±0.04 0.80 ± 0.022  (N.S.) 0.79 ± 0.022  (N.S.)
Glucose 5.09 ±0.25 5.16 ±0.142 (N.S.)
Uric acid 0.25 ± 0.02 0.30 ± 0.032 (p <0.005)
Total CC>2 23.4 ±0.6 26.0 ±0.6 2  (p <0.005) 24.4 ±0.7 2 (N.S.)
2 Data from eight volunteers
The p values indicate the significance of the differences with respect to hr 0 — mean values. 
N.S. = non significant.
DISCUSSION
Critical descriptions of the mathematical methods used have been pub­
lished.8-12
Furosemide is a diuretic whose main site of renal activity is an 
acceptor located at the thick portion of the ascending limb of the loop 
of Henle;9'11 it therefore provoked increased urinary excretions of 
volume, sodium and chloride that proceeded abruptly. The rates of 
volume, sodium and chloride excretions resemble those encountered 
after the loop diuretics furosemide 80 mg4-5-6-12-16 and piretanide5-6 
and are higher than those after the distal tubule diuretics hydrochloro­
thiazide,7 xipamide,3-7-17 chlorexolone1 8 and chlorthalidone19 or after 
the administration of placebo.4-7-12-19
The fact that magnesium excretion after furosemide is significantly 
delayed with respect to the volume, sodium and chloride excretions 
differs from what is found after the administration of placebo in similar 
experiments,18 when the time-courses of all urinary solute excretions 
coincide, as illustrated by Figure 3. This is possibly due to the inter­
vention of a relatively slow endocrine mechanism in the hypermag- 
nesiuria that follows the administration of distal tubule diuretics.19-20 
The hypercalciuria elicited by furosemide induces an increase in serum 
parathyroid hormone (sPTH) activity, which in turn tends to reduce the 
effect of furosemide on urinary magnesium reabsorption because mag­
nesium reabsorption at the loop of Henle is under positive sPTH con-
Figure 3 — Mean urinary sodium  and magnesium flow s from  nine healthy volunteers 
after adm inistration o f  placebo p er  os a t hour 0. The describing func­
tions are the tim e-derivatives o f  the Y (t) functions fitted  to  the experi­
m ental data in R eyes and L eary.17
mmol/hr P LA
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trol. However, the primary negative rate of change of serum magnesium 
concentration caused by the hypermagnesuria induced by furosemide 
gives place to a series of events, including an end-organ resistance to 
sPTH, that reinforce the renal magnesium losses determined by the 
direct blockade of magnesium reabsorption provoked by furosemide20 
(Fig. 4).
The renal magnesium losses induced by furosemide may well be a 
most important factor in the development of potentially lethal arrhyth­
mias since, during chronic treatment, such losses determine a decrease in
the intracellular magnesium concentration with a corresponding increase 
in the intracellular free calcium concentration in the myocardium,20 as 
shown in Figure 5.
The changes encountered in blood solute concentrations after the 
administration of furosemide correspond to what could be expected 
upon the basis of established knowledge.
Figure 4 — Orientated graph showing the mechanisms whereby there is an increased 
urinary magnesium excretion  after a loop  diuretic such as furosemide.
[ 414 ]
Figure 5 — Orientated graph showing the mechanisms whereby diuretic-induced hypermagnesiuria conduces to a decrease 
in intracellular magnesium and to an increase in free intracellular calcium.
M
A
G
N
E
S
IU
R
IC
 E
F
F
E
C
T
 O
F
 A
 S
IN
G
L
E
 D
O
S
E
 O
F
 F
U
R
O
S
E
M
ID
E
 IN
 H
E
A
L
T
H
Y
 A
D
U
L
T
S
References:
1. Reyes, A.J.: Descripcion matematica de un estudio clinicofarmacologico de la 
xiparpida con m odelo experimental simplificado. Sistole 30:85-91, 1980.
2. Leary, W.P., Asmal, A.C., and Reyes, A.J.: Time-courses of the diuretic, 
natriuretic and kaliuretic effects o f xipamide. Curr. Therap. Res. 2 7 :16-21, 
1980.
3. Reyes, A.J., Leary, W.P., and Asmal, A.C.: Urine volumes and flows after oral 
administration o f xipamide, furosemide and hydrochlorothiazide in healthy 
adults. Curr. Therap. Res. 2 8 :230-234, 1981.
4. Reyes, A.J., Leary, W.P., and Venter, C.P.: Mathematical models o f diuresis 
after oral administration o f tizolem ide, furosemide and placebo to healthy 
adults. J. Int. Med. Res. 9:18-20, 1981.
5. Leary, W.P., Reyes, A.J., Venter, C.P., and Blake, G.T.W.: Mathematical descrip­
tion o f diuresis after oral administration o f piretanide, furosemide and placebo 
to healthy adults. Curr. Therap. Res. 2 9 :249-252, 1981.
6. Reyes, A.J., Leary, W.P., and Venter, C.P.: Mathematical evaluation of the 
effects o f piretanide, furosemide and placebo in healthy adults. Curr. Therap. 
Res. 2 9 :253-259, 1981.
7. Reyes, A.J., and Leary, W.P.: Antihypertensive diuretics: difference from non­
hypertensive diuretics in time-course of excretory activity. Curr. Therap. Res. 
3 0 :217-226, 1981.
8. Reyes, A.J., and Leary, W.P.: A mathematical model for the clinical pharma­
cology o f  diuretics. Curr. Therap. Res. 3 0 :227-235, 1981.
9. Reyes, A.J., and Leary, W.P.: Farmaco’ogia clinica y usos terapeuticos de los 
diureticos. Temas Med. 4 :199-223, 1981.
10. Reyes, A.J., and Leary, W.P.: Diuretics: practitioners’ review. S. Afr. Med. J. 
59:9-13, 1981.
11. R e y e s , A .J .:  Bases farmacologicas de la terapeutica cardiovascular con  
diureticos. Arch. Inst. Cardiol. Mex. 5 1 :291-303, 1981.
12. Leary, W.P., and Reyes, A.J.: Mathematical evaluation o f the effects o f tizole­
mide, furosemide and placebo in healthy adults. S. Afr. Med. J. 61:398-401 , 
1982.
13. Leary, W.P., and Reyes, A.J.: Diuretics, magnesium, potassium and sodium. S. 
Afr. Med. J. 6 1 :279-280, 1982.
14. Leary, W.P., and Reyes, A.J.: Urinary volume and solute flows after a single 
dose o f chlorexolone in healthy adults. Curr. Therap. Res. 32:391-398 , 1982.
15. Leary, W.P., and Reyes, A.J.: Urinary volume and solute flows after a single 
dose o f hydrochlorothiazide-amiloride in healthy adults. Curr. Therap. Res. 32: 
406-412, 1982. 16
16. Reyes, A .J., and Leary, W.P.: Urinary volume and solute flows after a single 
dose o f hydrochlorothiazide-triamterene in healthy adults. Curr. Therap Res 32- 
413-420, 1982
17. Reyes, A.J., and Leary, W.P.: Urinary excretions o f magnesium and zinc after 
different xipamide single doses in volunteers: mathematical description. Manu­
script in preparation.
18. Leary, W.P., and Reyes, A.J.: The magnesiuric effect o f a single dose o f hydro­
chlorothiazide in healthy adults. Curr. Therap. Res. 3 2 :399-405, 1982
19. Reyes, A .J., and Leary, W.P.: Urinary magnesium and zinc excretions after 
monodosing healthy volunteers with chlorthalidone. Curr. Therap. Res. 32:128- 
137, 1982.
20. Reyes, A.J., and Leary, W.P.: Diuretics, potassium and magnesium. Manuscript 
in preparation.
PAPER C9
The M a g n e s i u r i c  E f f e c t  of a S i n g l e  Dose of 
Hydrochlorothiazide in Healthy Adults
This was the first detailed analysis of the magnesiuric 
effect of hydrochlorothiazide. It was another joint project 
with Professor A.J. Reyes and the findings have relevance to 
the chronic effects of this drug in the treatment of 
hypertension.
CURRENT
THERAPEUTIC
RESEARCH
VOL. 32. NO. 3, SEPTEMBER, 1982
THE MAGNESIURIC EFFECT OF A SINGLE DOSE 
OF HYDROCHLOROTHIAZIDE IN HEALTHY ADULTS
W.P. LEARY* AND A.J. REYES**
*Departm ent o f  Clinical and E xperim ental Pharmacology, University o f  Natal,
Durban, South Africa  
and
**Departam ento de Biofisica y  B iom atem aticas Cardiovasculares, 
Fundacion Procardias and Universidad de la Republica, 
M ontevideo, Uruguay
ABSTRACT
Accumulated excretions and flows of urinary volume, sodium, chloride 
and magnesium are described as sigmoid functions of time and their 
time-derivatives, respectively, after oral administration of 50 mg hydro­
chlorothiazide to nine healthy volunteers. The effects of the medication 
on several blood variables are also evaluated.
Hydrochlorothiazide provoked significant increases in volume, 
sodium, chloride, and magnesium mean 24-hour urinary mean outputs 
with respect to 24-hour renal excretions without medication. The time- 
courses of the hydrochlorothiazide-induced excretions of volume, 
sodium and chloride coincided (peak flows around 3.5 hours post­
dosing), whereas the urinary magnesium excretion after dosing pro­
ceeded at a significantly slower rate (peak flow around 6 hours post­
dosing).
The only significant changes in 24-hour post-dosing blood variables 
with respect to the corresponding pre-dosing mean values were a 
decrease in serum chloride and an increase in total plasma bicarbonate. 
Serum sodium, potassium and magnesium values remained statistically 
unchanged.
The fact that urinary magnesium flow after hydrochlorothiazide 
exhibited a delayed time-course with respect to those of other electro­
lytes suggests that an endocrine mechanism intervenes in the determina­
tion of the hypermagnesiuric response to the distal tubule diuretic 
hydrochlorothiazide.
INTRODUCTION
The time-courses of the urinary excretions of volume and several solutes 
after monodosing healthy volunteers with various diuretic formulations 
have recently been described through the fitting of a mathematical
R equests for reprin ts to  Prof. Dr. A .J. Reyes, H olanda 1724, M ontevideo, Uruguay. 
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model to the experimental results.1'8-12'19
The objectives of this study are to evaluate the effect of the distal 
tubule diuretic hydrochlorothiazide on 24-hour renal magnesium output 
and to describe the time-course of the post-dosing urinary magnesium 
excretion, in normal adults.
SUBJECTS AND METHODS 
Subjects and Experim ental Design
Nine healthy Caucasoid medical technologists or secretaries (three males and six 
females) volunteered to participate in this study after a full explanation o f its impli­
cations had been given. All were aged between 21 and 46 years and had not taken 
any medication, which might act in any way at the time o f the experiments, within 
the previous tw o months. No volunteers were obese or had any history of renal, 
cardiovascular, endocrine or metabolic disorders.
A standard diet was prescribed on control and trial days containing approxi­
mately 140 mEq o f sodium and 2000 ml o f fluid. The nine subjects received hydro­
chlorothiazide 50 mg p er  os given with 100 ml tap water at 08.00 hour oh the treat­
ment days. Volunteers carried out their normal daily work but heavy muscular exer­
cise, tobacco and the ingestion o f alcohol, caffeine or any medicine other than the 
trial formulation were forbidden on treatment and control days. The control day 
anteceded the treatment day by 24 hours.
The laboratory analyses were carried out by technologists who were unaware of 
the protocol being used. All urines passed on treatment and control days were 
collected. Urines collected during control days were pooled, whereas separate 
samples were collected at 3, 6, 12 and 24 hours on treatment days. Urinary volume 
and contents o f sodium, chloride and magnesium were measured in each urine speci­
men. On treatment days venous blood was drawn just before medication and 6 and 
24 hours later for measurement o f  plasma concentrations of sodium, potassium, 
chloride, magnesium and total bicarbonate and o f serum glucose and uric acid at 
hours 0 and 6. All variables were measured by standard laboratory techniques using 
a Nova 4 analyser for determinations other than magnesium levels, which were 
measured on a Varian 275 atomic absorption spectrophotom eter.
M athematical M ethods
The mean experimental values o f the urinary volume and solutes, Y, accumulated 
by the end o f each post-dosing period, as functions o f time, t, were fitted a mathe­
matical m odel8 '•
20Y / log(100-Y ) = exp [ [2 .3 0  (t-tx )] / (a+bt)]|,
where t 1 is the time at which Y = 0.1 and a (tim e) and b (dimensionless) are para­
meters o f the function. The fitting procedure has been already described.8
Flows o f urinary variables were defined as:
dY /dt = (a + b tj) / [(a+ bt)2 [(0 .4 3 /Y )+ (0 .4 3 2 )/(100-Y )log(100-Y )] J.
Standard statistical techniques (paired, t-test, linear correlation and regression) 
were used. Normality o f  frequency distributions and homoscedasticity o f  sample 
variances were evaluated through the chi square and the F tests, respectively.
Table I — Urinary excretory variables measured during the collection periods after 
dosing with 50 mg hydrochloroth iazide in nine healthy volunteers. 
Values as means ± S.E.M..
Post-dosing Periods
Variable Unit 0-3 hr 3-6 hr 6-12 hr 12-24 hr
Volume litres 0.455 ± 0.086 0.392 ± 0.050 0.547 ± 0.066 0.968 ±0.124
Sodium mmol 42.3 ±2.3 36.2 ±6.0 62.1 ±9.3 85.4 ±6.5
Chloride mmol 53.0 ±8.1 41.6 ±7.1 77.6 ± 10.0 85.8 ± 6.6
Magnesium mmol 0.50 ± 0.09 0.47 ± 0.09 1.02 ± 0.05 2.18 ±0.27
RESULTS
Mean experimental values of urinary variables after dosing are shown in 
Table I. Twenty-four-hour mean urine volume and urinary outputs of 
sodium, chloride and magnesium after dosing with hydrochlorothiazide 
were significantly higher than the control 24-hour excretions (Table II).
Mean urinary variable values accumulated after dosing as functions 
of time are parametrically described in Table III and the Y function for 
magnesium is shown in Figure 1. The time-courses of the hydrochloro-
Table II — 24-hour urinary volum e and solute excretions after dosing with 50 mg 
hydrochlorothiazide p er os and during 24-hour previous control. Values 
as means ± S.E.M..
Renal Excretory 
Variable
Pre-treatment 
(24-hr Control)
T reatment 
(24-hr Post-dosing)
Significances of 
the Differences 
Between Mean 
Values
Urinary volume (litres) 1.750 ±0.195 2.320 ± 0.279 p <0.05
Urinary sodium (mmol) 138.2 ± 16.5 222.0 ± 20.0 p <0.005
Urinary chloride (mmol) 162.2 ±23.0 258.0 ±21.3 p <0.05
Urinary magnesium (mmol) 2.90 ± 0.55 4.17 ±0.40 p <0.05
Table III — Statistical and param etrical features o f  the linear transformations o f  the 
functions Y  (t).
Variable Unit r P ti (hr) a(hr) b
Volume I x 10'1 0.9995 <0.001 0.06 0.7095 0.3890
Sodium mmol x 10 0.9997 <0.001 0.06 0.7283 0.3910
Chloride mmol x 10 0.9998 <0.001 0.05 0.6375 0.3837
Potassium mmol 0.9997 <0.001 0 0.5001 0.3411
Magnesium mmol x 10'1 0.9988 <0.01 0 0.9021 0-.3401
Figure 1 Mean values o f  the accum ulated urinary excretions o f  magnesium after  
dosing w ith 50 mg hydroch loroth iazide in nine healthy volunteers. The 
Y(t) functions have been f itte d  in the experim ental data.
mm o.l
Figure 2 — Urinary flow s o f  sodium  and magnesium after dosing w ith 10 mg furose- 
mide in nine healthy volunteers. The p lo tte d  functions are the time- 
derivatives o f  the corresponding Y (t) functions.
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thiazide-induced diuresis and flows of sodium and chloride were alike 
(peak flows around 3.5 hours post-dosing), whereas the magnesium flow 
after hydrochlorothiazide proceeded at a significantly slower rate (peak 
flow around 6 hours post-dosing), as evaluated from the dY/t functions. 
Figure 2 shows the time-courses of urinary sodium and magnesium 
excretions after dosing with hydrochlorothiazide.
Mean values of blood variables before and after treatment are 
shown in Table IV. Significant changes included decreases in serum
Table I V —Values o f  several serum variables after dosing w ith 50 mg hydrochloro­
thiazide and w ith placebo in nine healthy volunteers. Values in m m ol/l 
as means ± S.E.M.
Variable 0 6 24
Sodium 143.8 ±2.0 136.5 ±0.9 (p <0.02) 138.7 ±1.5 (N.S.)
Potassium 4.31 ±0.13 3.94 ±0.08 (p < 0 .0 2 ) 4.22 ±0.14 (N.S.)
Chloride 108.8 ± 0 . 6 103.7 ±0.9 (p <0.001) 103.7 ±0.7 (p <0.001)
Magnesium 0.80 ± 0 . 0 2 0.80 ±0.02 (N.S.) 0.80 ±0.02 (N.S.)
Glucose 5.49 ±0.21 5.33 ±0.26 (N.S.)
Uric acid 0.25 ± 0.02 0.28 ±0.02 (N.S.)
Total CO2 24.7 ± 0.7 26.8 ±0.5 (p <0.005) 26.3 ±0.8 (p<0.01)
* Data from ten volunteers.
The p values indicate the significance of the differences with respect to hr 0 — mean values. 
N.S. = non significant.
sodium and potassium concentrations at hour 6 post-dosing, increases in 
serum bicarbonate concentration at hours 6 and 24 post-dosing and 
decreases in serum chloride concentration at 6 and 24 hours after medi­
cation.
DISCUSSION • -
Critical descriptions of the mathematical methods have been pub­
lished.8-12
Hydrochlorothiazide is a diuretic whose main site of renal activity is 
an acceptor located at the first portion of the distal convoluted 
tubule;9'11 it therefore provokes increased urinary excretions of 
volume, sodium, chloride, and magnesium that proceed non-abruptly. 
The rates of volume, sodium, and chloride excretions are similar to 
those that have been encountered after hydrochlorothiazide 100 mg7 
and xipamide,3-7’17 lower than those after the loop diuretics furose- 
mide4’5*6 '1 2 ’16 and piretanide5-6 and higher than those after 
placebo4-7'12'19 and the distal tubule diuretics chloreoxolone18 and 
chlorthalidone.19
The fact that urinary magnesium excretion after hydrochloro­
thiazide was significantly delayed with respect to the volume, sodium 
and chloride excretions resembles what has been found after all the 
other distal tubule diuretics studied in this respect.13'17-19 This fact is 
possibly due to the intervention of a relatively slow endocrine mechan­
ism in the genesis of the hypermagnesiuria that follows the administra­
tion of distal tubule diuretics.19 In so far as distal tubule reabsorption 
of magnesium only affects 5-8% of the filtered ion, the direct blockade 
of this process by hydrochlorothiazide cannot account for the marked 
increase in magnesiuria induced by the drug. Hydrochlorothiazide 
reduces urinary calcium excretion causing an increase in serum calcium 
and a corresponding decrease in serum parathormone (sPTH) activity. 
As the reabsorption of magnesium at the loop of Henle, which accounts 
for 70% of the filtered ion, is under positive sPTH control, the hyper- 
magnesiuric effect of hydrochlorothiazide could follow its primary 
hypocalciuric action.
The changes in blood variables after medication with hydrochloro­
thiazide were those that could be expected on the basis of established 
knowledge.
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ABSTRACT
Accumulated excretions and flows of urinary volume, sodium, 
potassium, chloride, magnesium and zinc are described as functions qf 
time and their time-derivatives, respectively, after oral administration 
of placebo, amiloride 5 mg and amiloride 10 mg to thirteen healthy 
volunteers. The effects of the treatments on several blood variables are 
also evaluated.
Both doses of amiloride provoked significant increases in mean 
24-hour urinary volume and sodium outputs compared to the corres­
ponding excretions after placebo. The 24-hour urinary excretion of 
potassium was significantly reduced by both doses of amiloride and that 
of zinc was significantly decreased by the higher dose. Magnesium out­
put was unaffected by amiloride. The time-courses of urinary volume, 
sodium and potassium flows after amiloride were accelerated by com­
parison with the corresponding events after placebo, whereas the time- 
courses of chloride, magnesium and zinc urinary excretions were not 
significantly altered by amiloride. The fact urinary magnesium flow was 
unaltered by amiloride would indicate the drug did not affect the tubular 
handling of the cation.
The effects of amiloride on the blood variables measured were 
unremarkable.
INTRODUCTION
Urinary potassium losses caused by loop and distal tubule diuretics such as 
furosemide and the thiazides, respectively, have been of concern to clini­
cians largely because subsequent depletion of intracellular potassium may 
cause electrical destabilisation of the sarcolemma and serious cardiac 
arrhythmias.1'5 The coprescription of potassium-sparing diuretics such as
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amiloride, triamterene, and spironolactone with common diuretics is used as 
a therapeutic manoeuvre for limiting urinary potassium losses; however, it 
does not influence the hypermagnesiuria and consequent depletion of bodily 
magnesium which also results from the use of diuretics.1-3611 Since 
magnesium is a cofactor for the myocardial Na+, K+ -ATPase responsible 
for the active incorporation of potassium into cells, intramyocardial 
potassium concentration may remain abnormally low when magnesium is 
depleted despite normal serum potassium levels.6 In addition, other changes 
encouraging arrhythmias such as increased intramyocardial sodium and 
free cytosolic calcium levels develop in association with magnesium deple­
tion.10 Thus, simple measures which conserve or replace extracellular 
potassium may not be adequate to prevent cardiac arrhythmias com­
plicating treatment with diuretics.12
Common distal tubule diuretics increase zinc excretion and a syndrome 
of zinc depletion with clinical manifestations such as impotence, impaired 
senses of taste and smell and retarded wound-healing may develop during 
treatment with these preparations.13
This study evaluates the effects of separate single doses of amiloride (5, 
10 mg) on the urinary excretions of magnesium and zinc in healthy 
volunteers.
SUBJECTS AND METHODS
Subjects and experimental design
Thirteen healthy male Caucasoid medical technologists or students volunteered to participate 
in this study after a full explanation of its implications had been given. All were aged between 
20 and 45 years and had taken no other medication within the previous two months. None 
were obese or had any history of renal, cardiovascular, endocrine or metabolic disorders. 
Smokers were not studied.
A standardized diet containing 130 to 150 mEq of sodium and 2000 ml of liquid was 
prescribed on “treatment” days and on the previous 24 hours “control” days. Subjects 
received placebo, 5 mg amiloride, and 10 mg amiloride separately and in random order on 
three different “treatment days”, separated by at least 96 hours. Medications were given at 
0800 hr with 100 ml tap water. Volunteers carried out their normal daily work but heavy 
muscular exercise and ingestion of alcohol, caffeine or any medicine other than the trial 
formulation was forbidden on treatment days.
All laboratory analyses were carried out by technologists who were kept unaware of the 
protocol being used. All urines passed on treatment and control days were collected. Urine 
samples were collected at 3, 6, 12, and 24 hours on treatment days. Urinary volume and con­
tents of sodium, potassium, chloride, magnesium and zinc were measured in each urine 
specimen by standard laboratory techniques (flame photometry was used for sodium, 
potassium and chloride evaluations and atomic absorption for magnesium and zinc evalua­
tions). On treatment days venous blood was drawn just before medication and 6±1 and 24±1 
hours later, for measurement of plasma concentrations of sodium, potassium, chloride, total 
bicarbonate and magnesium. Serum glucose and uric acid were measured at 0 and 24 ± 1 hours 
after dosage.
Mathematical methods
The mean experimental values of the urinary volume and solutes, Y, accumulated by the end 
of each post-dosing period, as functions of time, t, were fitted by a mathematical model:'4
20Y/log (100-Y) =  exp {[2.30(t-t,)]/(a+bt)},
where t, is the time at which Y=0.1 and a (time) and b (dimensionless) are parameters of the 
function. The fitting procedure has been described previously.14 
Flows of urinary variables were defined as:
dY/dt=(a+bti)/{(a+bt)2[(0.43/Y)+(0.432)/(100-Y)log( 100-Y)]}.
Standard statistical parametrical techniques (paired t-test, linear correlation and regres­
sion) were used. Normality of frequency distributions and homoscedasticity of sample 
variances were evaluated through the chi square and the F test, respectively. However, the 
non-parametrical sign test was used for evaluating the significance of the differences between 
the post-amiloride and the post-placebo 24-hour urinary zinc outputs, since no evidence exists 
that the variable is normally distributed. All tests were two-tailed and p=0.05 was considered 
the limit of significance.
RESULTS
No significant difference was detected between the 24-hour accumulated 
urinary outputs of volume and electrolytes after placebo and those yielded 
on control days.
The timed urinary excretions of volume, sodium, potassium, chloride, 
magnesium and zinc are shown in Table I. When the subjects failed to void 
urine just at the end of a collection period, the urines corresponding to that 
and to the following periods were pooled. Amiloride caused a dose-related
Table I — Urinary excretory variables measured during different fractioning collection 
periods after dosing with placebo, amiloride 5 mg (AMI 5) and amiloride 10 mg 
(AMI 10) thirteen healthy volunteers. Values as means ± S.E.M.
Variable Unit Treatment 0-3
Hours post-dosing 
3-6 6-12 12-24
Placebo 0 ,2 3  0 .0 3 0 .2 6 ± 0 . 0 4 0 . 3 3  ± 0 . 0 6 0 . 6 6  ± 0 . 0 7
Volume litre AMI 5 0 . 3 3 ± 0 . 0 6 0 .3 3 ± 0 . 0 6 0 . 4 5  ± 0 . 0 6 0 . 6 3  ± 0 . 0 6
AMI 10 0 .41  ± 0 . 0 5 0 .4 3 ± 0 . 0 4 0 . 5 7  ± 0 . 0 8 0 . 7 2  ± 0 . 0 7
Placebo 1 7 .3 ±  2 .1 1 9 .4 ±  2 .7 2 7 .0  ±  4.1 5 8 .3  ±  6 .3
Sodium mmol AMI 5 3 0 .4 ±  7 .0 26 .1 ±  4 .1 4 5 .9  ±  4 .9 6 5 .9  ±  4 .6
AMI 10 3 3 . 9 ±  3 .3 3 3 .3 ±  3 .3 6 0 .8  ±  7 .2 7 4 .0  ±  7 .8
Placebo 8 .6 8  ± 1 .0 5 1 1 .4 7  ±  1 .6 7 1 0 .7 4  ± 1 .7 3 1 4 .6 5  ± 1 . 1 3
Potassium mmol AMI 5 9 .7 4  =t 1 .2 0 5 .1 8 ± 1 . 0 6 6 .9 2  ± 0 . 9 0 1 0 .3 8  ±  0 .8 8
AMI 10 9 .31  ± 0 . 9 8 5 .0 3 ± 1 . 2 9 6 . 7 6  ± 0 . 7 6 1 0 .0 3  ±  1 .4 9
Placebo 2 3 .0 ±  2 .4 2 8 .2 ±  4 .0 2 9 .0  ±  4 .3 5 0 .6  ±  5 .2
Chloride mmol AMI 5 3 1 .9  ±  5 .8 2 2 .2 ±  3 . 6 3 3 .7  ±  2 .8 5 4 .3  ±  4 .4
AMI 10 3 5 . 5 ±  3 .5 2 8 .5 ±  3 .3 4 9 .2  ±  6.1 5 9 .9  ±  5 .7
Placebo 0 . 4 9 ± 0 . 0 6 0 .4 8 ± 0 . 0 6 0 . 8 7  ± 0 . 1 0 2 .2 2  ± 0 . 0 8
Magnesium mmol AMI 5 0 .5 5  ± 0 . 1 4 0 .2 8 ± 0 . 0 6 1 .0 2  ± 0 . 1 8 2 .1 4  ± 0 . 2 1
AMI 10 0 . 4 8 ± 0 . 0 6 0 .3 5 ± 0 . 0 6 0 . 9 6  ± 0 . 2 1 1 .9 9  ± 0 . 2 3
Placebo 0 .0 8  ± 0 . 0 1 0 .0 7 ± 0 . 0 1 0 . 1 2  ± 0 . 0 2 0 . 2 6  ± 0 . 0 2
Zinc mg AMI 5 0 .0 8  ±  0 .0 2 0 .0 4 ± 0 . 0 1 0 . 1 2  ± 0 . 0 2 0 . 2 4  ± 0 . 0 3
AMI 10 0 .0 9  ± 0 . 0 1 0 .0 3 ±  < 0 . 0 0 0 .1 1  ± 0 . 0 2 0 .2 3  ± 0 . 0 3
Data from eleven cases for AM110 hours 0-3 and from twelve cases for placebo hours 0-3 and AMI 5 hours 3-6.
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Figure 1 — Mean urinary flow after the administration of placebo, amiloride 5 mg (AMI 5) 
and amiloride 10 mg (AMI 10) per os to thirteen healthy volunteers. The area 
under the curve indicates the absolute amount excreted.
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Figure 3 — Mean urinary potassium flow after the administration of placebo, amiloride 5 mg 
(AMI 5) and amiloride 10 mg (AMI 10) per os to thirteen healthy volunteers. The 
area under the curve indicates the absolute amount excreted.
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Figure 5 — Mean urinary magnesium flow after the administration of placebo, amiloride 5 
mg (AMI 5) and amiloride 10 mg (AMI 10) per os to thirteen healthy volunteers. 
The area under the curve indicates the absolute amount excreted.
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Table II — 24-hour urinary excretory variables measured after dosing with placebo, 
amiloride 5 mg (AMI 5) and amiloride 10 mg (AMI 10) per os thirteen healthy
volunteers. Values as mean ± S.E.M.
Variable Unit Placebo AMI 5 AMI 10
Volume litre 1.45 ±0.11 1.72 ±0.14* 2.07 ± 0 .1 3 *****
Sodium mmol 119.3±  9.3 166.3 ± 11 .7** 196.8 ± 13 .9*****
Potassium mmol 44.2 ± 2.9 31.8 ± 3 .1 *** 30.0 ± 2 .2 ****
Chloride mmol 127.3 ± 7 .7 140.5 ±8.1 168.2 ± 1 0 .0 ****
Magnesium mmol 3.99 ±0 .12 3 .80± 0 .35 3.71 ±0 .38
Zinc mg 0.52 ±0 .05 0.48 ±0.06 0.46 ±0 .05*
Significances of the differences with respect to the corresponding placebo mean values: 
*p <0 .05 ; **p < 0 .02 ; ***p < 0 .0 1 ; ****p < 0 .0 05 ; ............ p<0.001
Table III - Statistical and parametrical features of the linear transformations of the func­
tions Y(t). A M I 5 =  amiloride 5 mg; A M I 10 =  amiloride 10 mg.
Variable Unit Treatment r P t. (hr) a (hr) b
Volume litre
Placebo 
AMI 5 
AMI 10
0.9992
0.9997
0.9998
<0.001
<0.001
<0.001
0.1174
0.0818
0.0659
0.9899 0.4198 
0.7723 0.4122 
0.6934 0.3992
Sodium mmol x 10
Placebo 
AMI 5 
AMI 10
0.9988
0.9995
0.9997
<0.01
<0.001
<0.001
0.1563
0.0889
0.0796
1.1815 0.4312 
0.8523 0.4122 
0.8217 0.3980
Potassium mmol
Placebo 
AMI 5 
AMI 10
0.9999
0.9996
0.9996
<0.001
<0.001
<0.001
0.0311
0.0277
0.0290
0.5132 0.3492 
0.4507 0.3767 
0.4684 0.3804
Chloride mmol
Placebo 
AMI 5 
AMI 10
0.9996
0.9994
0.9996
<0.001
<0.001
<0.001
0.1173
0.0847
0.0760
0.8911 0.4356 
0.7847 0.4315 
0.7615 0.4147
Magnesium mmol x 10-
Placebo 
1 AMI 5 
AMI 10
0.9981
0.9981
0.9980
<0.01
<0.01
<0.01
0.0551
0.0491
0.0563
0.9069 0.3432 
0.8781 0.3475 
0.9341 0.3469
Zinc mg x 10-2
Placebo 
AMI 5 
AMI 10
0.9987
0.9984
0.9976
<0.01
<0.01
<0.01
0.7167
0.0338
0.0300
0.7167 0.3317 
0.7354 0.3368 
0.7345 0.3408
increase in 24-hour urinary volume and output of sodium and a dose-related 
retention of urinary potassium (Table II). The higher dosage induced a 
significantly greater 24-hour urinary excretion of chloride than placebo and 
slight, though statistically significant, zinc retention (Table II). 24-hour 
urinary magnesium output was not affected by either dose of amiloride 
(Table II).
Urine flow (Fig. 1) and the urinary flows of sodium (Fig. 2) and 
potassium (Fig. 3), were accelerated by both doses of amiloride, proceeding 
at higher rates after amiloride than after placebo. These changes were dose- 
independent. The urinary flows of chloride (Fig. 4), magnesium (Fig. 5) and 
zinc (Fig. 6) were not significantly affected by either dose of the diuretic. 
The graphs in Figs. 1 through 6 are the derivatives with respect to time of 
the Y(t) functions whose statistical and parametrical characteristics are 
shown in Table III.
Table IV — Values of several plasma variables after dosing with placebo, amiloride 5 mg 
(AMI 5) and amiloride 10 mg (AMI 10) in thirteen healthy volunteers. Values in 
mmol/l as means ± S.E.M.
Variable Treatment 0
Hours post-dosing 
6 24
Placebo 147.4±  0.5 147.2 ± 0.4 148.1 ± 0.6
Sodium AMI 5 147.1 ± 0.4 146.9 ± 0.4 147.4 ± 0.4
AMI 10 147.4±  0.4 146.2±  0.4 146.9 ± 0.4
Placebo 4.11 ±0.05 4.03 ±0 .05 4.19 ±0 .06
Potassium AMI 5 4.33 ±0.09 4.27 ±0 .05 4.34 ±0.06
AMI 10 4.21 ±0 .08 4.23 ±0.04 4.38 ±0 .06*
Placebo 110.7±  0.9 110.2±  0.8 111.7±  0.8*
Chloride AMI 5 109.1 ± 0.6 108.9±  1.9 109.7 ± 1.9
AMI 10 108.1 ± 0.4 108.0 ± 0.5 108.6±  0.5
Placebo 24.5 ± 0 .5 0 ) 23.7 ± 0.5 25.0 ± 0.6
Total C02 AMI 5 24.5 ± 0.5 24.6 ± 0.7 24.1 ± 0.5
AMI 10 24.8 ± 0.5 22.9 ± 0.5* 22.9 ± 0 .4**
Placebo 0.78 ±0.01 0.80 ±0.01 0.81 ±0.01
Magnesium AMI 5 0.81 ±0.01 0.81 ±0.01 0.81 ±0.01
AMI 10 0.80 ±0.01 0.81 ±0.02 0.80 ±0.01
Placebo 5.39 ±0.22 5.42 ±0.22
Glucose AMI 5 5.05 ±0 .18 5.26 ±0.24
AMI 10 4.63 ±0.17 5.39 ± 0 .21***
Placebo 0.30 ±0.02 0.31 ±0.02*
Uric Acid AMI 5 0.30 ±0.02 0.31 ±0.02
AMI 10 0.24 ±0.07 0.24 ±0.02
CUData from twelve probands.
Significances of the differences with respect to pre-treatment (0 h) mean values: 
*p < 0.05; **p < 0 .02 ; — p<0.01
The effects of the medications on blood variables are shown in Table IV. 
Serum potassium increased significantly 24 hours after amiloride 10 mg. 
Total serum bicarbonate decreased significantly 6 and 24 hours after 
amiloride 10 mg. A significant increase in serum glucose occurred 24 hours 
after amiloride 10 mg and a minor but statistically significant increase in 
serum uric acid was observed 24 hours after placebo.
DISCUSSION
The mathematical methods used for describing urinary flows have been 
discussed elsewhere.1415
The increases in 24-hour urinary outputs of fluid and sodium and the 
retention of urinary potassium provoked by amiloride in a dose-related 
manner could be expected upon the basis of established knowledge. Flows 
derived from the data revealed that amiloride accelerated the excretions of 
volume, sodium and potassium but to a lesser extent than the thiazides do.4
Neither the 24-hour urinary magnesium output nor the time-course of 
its excretion were affected by amiloride, indicating that this diuretic does 
not affect the renal handling of magnesium. Further investigations are
needed to determine whether amiloride can induce a retention of pre-urinary 
magnesium when its concentration in the preurine has been increased by the 
action of a loop or common distal tubule diuretic at nephronal sites prox­
imal to that where amiloride acts.
Amiloride 10 mg provoked a clinically small but statistically significant 
zinc-retention, without affecting the time-course of zinciuria. This suggests 
that the zinc-sparing effect of amiloride is not directly dependent upon the 
renal handling of sodium and potassium after the administration of the 
diuretic. This issue also merits further investigation.
The effects of amiloride on blood variables could be expected on the 
basis of established knowledge.
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PAPER Cll
Effects of Hydrochlorothiazide Plus Sotalol on Acute Urinary 
Electrolyte Excretion in Normal Subjects
The finding that a combination of sotalol and 
hydrochlorothiazide may cause considerable urinary losses of 
potassium and magnesium is of particular interest and may 
have a bearing on the cardiovascular effects of this 
combination. As before Professor Reyes shared the tasks 
involved and Mr. van der Byl provided computer facilities.
Effects of hydrochlorothiazide plus sotalol 
on acute urinary electrolyte excretion in 
normal subjects
W. P . L E A R Y , A. J .  R E Y E S , K. V A N  D E R  BY L
S u m m a r y
j Twenty-four-hour urinary outputs, total volume and 
jr urinary chlorine (Cl), sodium (Na), potassium (K), 
calcium, magnesium (Mg), total inorganic phosphate 
>; and creatinine levels were measured in 12 biologically 
equivalent healthy volunteers given single oral doses I 
■ of placebo, hydrochlorothiazide (HCTZ) 50 mg and a 
combination of HCTZ and sotalol (STL) 320 mg in a 
i*; double-blind, random study. ‘ -f
HCTZ and HCTZ + STL increased urinary volume 
! 5 and Na, K, Cl, phosphate and Mg levels significantly 
and to a similar extent. Since HCTZ causes hyper- 
‘ kaliuresis and hypermagnesiuresis with or without 
simultaneous administration of STL, the latter does not 
change the acute effects of HCTZ in healthy subjects.• r., ■ $ . , i
S  A ir  M ed J  1984; 66: 680-681.»<• . > : '
Uatfl*,*"■•■ii ' %-r t  < • O k  ‘ v .
Diuretics are considered drugs of first choice in the treatment of 
arterial hypertension;1 however, these drugs have recognized 
deleterious effects, including somatic depletion of potassium 
(K)1-3 and magnesium (Mg)4"8 and derangements in carbohydrate, 
purine and lipid metabolism.9,10 Depletion of K  is regarded as 
particularly important because, although it seldom develops 
during chronic diuretic treatment unless other causes of K  
deficiency are also present, serious cardiac arrhythmias may 
supervene. In addition, it has been suggested that K  deficit 
contributes to the evolution and maintenance of elevated blood 
pressure,11 thus hampering the antihypertensive effect of 
diuretics. Several measures have been proposed to counteract 
the hyperkaliuretic effects of diuretics, including limitation of 
dietary sodium (Na) intake and the co-administration of K  
supplements or K-retaining diuretics such as amiloride, tri­
amterene or spironolactone/'4
The idea that cardiac arrhythmias complicating prolonged 
diuretic therapy are usually due to K  depletion has recently been 
challenged by evidence in support of the view that urinary M g  
loss is the principal causative factor.4"8 Ionic K  is actively 
pumped into myocardial cells irrespective of the serum K  level, 
provided that normal activity of Na, K-ATPase is maintained.6 
This active process depends upon an adequate intracellular 
concentration of M g  (acting as a co-factor to the enzyme) and is 
inhibited when M g  depletion occurs.6,7,9 Moreover, the myo-
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cardial concentration of free cytosolic Ca is increased by M g  
depletion, further destabilizing the myocardial electrochemical 
balance.6,7,9
The objective of this study was to determine whether the 
well-established hyperkaliuretic and hypermagnesiuretic effects 
of hydrochlorothiazide (HCTZ) 50 m g  are modified by the 
co-administration of the E-adrenergic blocking agent sotalol 
(STL) 320 m g  to healthy young volunteers.
S u b j e c t s  a n d  m e t h o d s
Twelve healthy adult male students volunteered to participate in 
the study after a full explanation of its implications. All were 
Whites aged 18-22 years and none had taken any prescribed 
medication during the previous 2 months. None was obese or 
had any history of renal, cardiovascular or metabolic disorder. 
Smokers were not included in the study.
A  standardized diet containing 130 - 160 mmol N a  and 3,5-4 
litres water (including 2,5 litres tap-water) was given on test days 
and during the preceding 24-hour control period. Subjects 
received placebo, H C T Z  50 m g  and a combination of H C T Z  50 
m g  and S T L  320 m g  (presented in identical form) separately and 
in random order on 3 different treatment days at least 7 days 
apart. Medications were given at 08h00 with 100 ml tap-water. 
Volunteers were confined to a metabolic ward for the first 10 
hours after administration of medication. Thereafter they were 
allowed to return home until 07h00 the following day. During 
the urine-collection period all exercise and ingestion of alcohol or 
caffeine and any medicine other than the trial material were 
forbidden.
O n  treatment days venous blood was drawn just before 
medication and 6 ±  1 h and 24 +  1 h later for measurement of 
plasma concentrations of chlorine (Cl), Na, K, total calcium 
(Ca), Mg, carbon dioxide (C02), total inorganic phosphate, 
creatinine and urate.
All laboratory analyses were carried out by technologists 
unaware of the protocol. All urine passed on control and 
treatment days was collected at 3,6,12 and 24 hours after dosing 
and analysed accordingly on treatment days. Urinary volume 
and contents of Cl, Na, K, Ca, Mg, total inorganic phosphate and 
creatinine were measured.
Solute concentrations in both urine and serum specimens 
were analysed as follows: the Na, K, Cl and total bicarbonate 
contents were measured by the ion-selective technique using a 
Nova 4 analyser. Total inorganic phosphate was measured 
colorimetrically with a Clinical Sciences kit. Ca and M g  
concentrations were measured by atomic absorption using a 
Varian 275 instrument. Creatinine and urate were measured 
colorimetrically using Boehringer Mannheim kits. Colorimetrical 
determinations were carried out on a Beckman 3 spectrophoto­
meter.
M athem atical methods
The mean experimental values for urinary volume and solutes 
accumulated by the end of each period after administration were
Fitted as functions of time by a mathematical model which has 
been described previously.10 Urinary flow was calculated and the 
time to maximal flow after administration evaluated via an 
iterative computer design.11
Standard statistical parametrical techniques, paired t test and 
linear correlation and regression were used. Normality of 
frequency distributions and homoscedasticity of sample variances 
were evaluated via the chi-square test and the F ratio respectively. 
All statistical tests were two-tailed and a P value of 0,05 was 
considered the limit of significance.
R e s u l t s
N o  significant differences were detected in the 24-hour accumu­
lated mean urinary output as regards volume and electrolytes 
after placebo and on control days.
Accumulated 24-hour excretions are shown in Table I.
TABLE I. URINARY EXCRETORY VARIABLES MEASURED OVER 
24 HOURS AFTER ORAL ADMINISTRATION OF PLACEBO, HCTZ 
50 mg OR A COMBINATION OF HCTZ 50 mg AND STL 320 mg IN 
12 HEALTHY VOLUNTEERS
Variable Placebo HCTZ HCTZ + STL
Volume (1) 2,69 ± 0,12 3,34 ± 0,12*** 3,13 + 0,14*
Na (mmol) 146,4 + 9,7 306,5 ± 12,8*** 242,2 + 16,7***
K (mmol) 55,8 ± 4,2 70,2 ± 3,4** 82,5 + 4,9***
Cl (mmol) 184,2 ± 10,1 359,5 + 13,4*** 305,2+ 15,0***
Mg (mmol) 5,15 ± 0,47 6,38 + 0,41* 6,16 + 0,44*
Ca (mmol) 
Phosphate
4,46 ± 0,41 4,27 ± 0,34 3,89 ± 0,47
(mmol)
Creatinine
28,2 + 1,0 33,1 + 2,4* 33,0 ± 2,3*
(mmol) 19,1 + 0,8 19,4 ±1,0 19,2 ± 1,3
Values expressed as mean ± SEM.
Significances of the differences with respect to the corresponding mean values on 
placebo:
*P< 0,05;
**P< 0,005;
***P< 0,001.
Both active treatments caused significant increases in 24-hour 
urinary outputs in terms of volume and Cl, Na, K, phosphate 
and M g  content. Ca and creatinine excretions were unchanged.
The time courses for volume, Cl, N a  and K  practically’ 
coincided after H C T Z  or H C T Z  +  STL, as revealed by the 
times to peak excretions after dosage which were calculated as 
2,68, 1,95, 1,96 and 2,66 hours respectively after H C T Z  and 
3,17,2,44,2,45 and 2,90 hours respectively after H C T Z  +  STL. 
Peak excretions of Mg, phosphate and creatinine were delayed in 
relation to those of volume and the other electrolytes, occurring 
4,11,6,30 and 4,39 hours respectively after H C T Z  and 4,83,6,55 
and 4,88 hours respectively after H C T Z  +  STL. These delays 
were less apparent (although still present) after placebo.
Serum values of the variables measured did not change in a 
clinically significant manner.
D i s c u s s i o n
The mathematical methods used for describing urinary flows 
have been discussed elsewhere.10'11'12 The fact that H C T Z  +
S T L  significantly increased urinary output in terms of volume 
and Cl, Na, K, M g  and phosphate levels confirms that the 
co-administration of S T L  320 m g  does not change the acute 
renal actions of H C T Z  50 mg, despite the fact that non-selective 
6-blocking agents usually reduce renal blood flow. This was 
possibly reflected by the finding that the time to peak excretion 
of all solutes was slightly longer after H C T Z  +  S T L  than after 
H C T Z  alone.
Most antihypertensive diuretics tested under similar conditions 
so far (chlorthalidone,13 chlorexolone14 and H C T Z 11), cause 
significant urinary M g  and K  losses. The present results from a 
small sample of healthy, biologically equivalent subjects indicate 
that the effect of a single dose of H C T Z  +  S T L  is indistinguish­
able from that of H C T Z  in this regard.
If the preliminary findings reported in the present study are 
confirmed, prolonged daily treatment with H C T Z  or H C T Z  +  
S T L  could lead to clinically significant depletion of somatic M g  
and K. Serum K  and M g  levels should therefore be monitored 
and the institution of adequate prophylactic measures should be 
considered. 2"8
Urinary volume and Cl, N a  and K  levels approximately 
coincided after both active preparations, but urinary M g  was 
delayed with respect to other urinary electrolytes, confirming 
studies indicating that excretion of this cation is not Cl- or 
Na-dependent but involves intervention by hormones other than 
aldosterone.5
Diuretics cause a rise in tissue catecholamine levels and M g  
depletion which, in turn, further augment each other.8'1 
Myocardial electrolytic imbalance due to a rise in catecholamine 
levels and M g  depletion is a likely determinant of cardiac 
arrhythmias.5"8’12 Whereas fi-adrenergic blockade does not 
influence diuretic-induced M g  losses, some benefits may be 
obtained from the co-administration of these agents since fi- 
blockers should moderate the catecholamine-mediated effects of 
diuretics.
The changes found in serum variables could be expected on 
the basis of established knowledge of the acute systemic effects of 
distal tubular diuretics.
REFERENCES
1. Whitworth JA, Kincaid-Smith P. Diuretics; first line treatment for hyper­
tension. Ini J  Cardiol 1983; 2: 536-540.
2. Laragh JH. Amiloride, a potassium-conserving agent new to the USA: 
mechanisms and clinical relevance. Curr Ther Res 1982; 32: 173-188.
3. Morgan T, Myers J. Potassium maintenance: potassium supplements or 
potassium-sparing agents? Acta Med Scand (Suppl) 1981; 647: 117-123.
4. Leary WP, Reyes AJ. Diuretics, magnesium, potassium and sodium. SAfrM ed  
J  1982; 61: 279-280.
5. Reyes AJ, Leary WP. Magnesium deficiency provoked by diuretics. SA frM ed  
J  1983; 63: 410-412.
6. Dyckner TO, W'ester PO. Relation between potassium, magnesium and cardiac 
arrhythmias. Acta Med Scand (Suppl) 1981; 647: 125-137.
7. Whang R, Tjien OO, Aikawa JW et al. Magnesium and potassium inter­
relationships, experimental and clinical. Acta Med Scand (Suppl) 1981; 647: 
139-144.
8. Reyes AJ. Arritmias cardiacas causadas por deficiencia de magnesio: compli- 
cacion principal del tratamiento usual con diureticos. Prensa Med Argent 1983; 
70: 448-456.
9. Reyes AJ, Leary WP. Pathogenesis of arrhythmogenic changes due to 
magnesium depletion. 5  Afr Med 3  1983; 64: 311-312.
10. Reyes AJ, Leary WP. A mathematical model for the clinical pharmacology of 
diuretics. Curr Ther Res 1981; 30: 227-235.
11. Leary WP, Reyes AJ. The magnesiuric effect of a single dose of hydro­
chlorothiazide in healthy adults. Curr Ther Res 1982; 32: 425-431.
12. Leary WP, Reyes AJ. Mathematical evaluation of the effects of tizolemide, 
furosemide and placebo in healthy adults. 5  Afr Med J  1982; 61: 398-401.
13. Reyes AJ, Leary WP. Urinary magnesium and zinc excretions after monodosing 
healthy volunteers with chlorthalidone. Curr Ther Res 1982; 32: 128-137.
14. Leary WP, Reyes AJ. Urinary volume and solute flows after a single dose of 
clorexolone in healthy adults. Curr Ther Res 1982; 32: 417-424.
PAPER Cl2
Effects of Several Diuretic Formulations on Urinary Magnesium 
Output in Healthy Adults
This paper summarises the results of studies involving 
several diuretic formulations and includes both previously 
published and new data. Work was shared, as in the previous 
collaborative studies, with Professor A.J. Reyes.
EFFECTS OF SEVERAL DIURETIC FORMULATIONS ON URINARY MAGNESIUM 
OUTPUT IN HEALTHY ADULTS
W. P. LEARY,* AND A. J, REYES**
‘Department of Clinical Pharmacology, University of Natal, 
Durban, South Africa; **Departamento de Investigacion 
Cardiovascular, Fundacion Procardias, Montevideo, Uruguay
ABSTRACT
The effects of monodoses of placebo and a number of 
diuretic formulations on 24 h urinary excretions of several 
electrolytes, including Mg, were studied in healthy volunteers. 
All common (loop and thiazide-like) diuretics, except indapamide
2.5 mg, induced hypermagnesiuresis. Amiloride did not affect 
24 h urinary Mg output significantly.
INTRODUCTION
Magnesium depletion caused by diuretics contributes to the 
pathogenesis of cardiac arrhythmias, sudden death, myocardial 
infarction, vasospasm in the coronary and cerebral vessels and 
partially underlies alterations in lipid and carbohydrate metab­
olism induced by diuretics. The objective of this study was to 
evaluate the acute effects of several diuretics on the urinary 
eliminations of Mg and K.
SUBJECTS AND METHODS
Healthy student volunteers aged 18-25 were studied. Mono­
doses of diuretics o* placebo were given double-blind and in 
random order, at 08h00 and urine was collected at intervals for 
24 h thereafter. Seven days elapsed between experiments and a 
standard diet was prescribed throughout.
RESULTS
The 24 h percentage changes in urinary outputs after 
medication, in comparison with placebo, are shown in Table I; 
statistical results refer to mean values.
FIGS. 1, 2 and 3 show the urinary Na and Mg flows after 
placebo, furosemide 40 mg or hydrochlorothiazide 50 mg respec­
tively. While flows of both cations were almost parallel after 
placebo, Mg flow was delayed with respect to Na after furosemide 
or hydrochlorothiazide.
DISCUSSION
All formulations which cause acute hypermagnesiuresis may 
,induce Mg depletion upon prolonged administration. Since urinary 
Mg flows were delayed with respect to Cl, Na and; volume flows 
after administration of the diuretics concerned,' the hypothesis 
was advanced that slow-acting endocrine-type mechanisms might 
account, at least partially, for the hypermagnesiuresis. A 
system analysis of pertinent data reveal loop diuretics
(c) 1984 Elsevier Science Publishing Co., Inc.
Diuretics, Jules B. Puschett, Editor
TABLE I. Percentage changes in mean 24-h urinary excretions 
after monodosing with several diuretic formulations with respect 
to corresponding outputs after placebo.
N° Drug and dose
of (mg)
cases
% change in 
Cl Na
24-h renal 
Volume K
output
Mg
13 amiloride 5 io- 29e 19a -27® _4ns13 amiloride 10 32d 65® 43® -32d
9 chlorthalidone 100 152® 165® 6<r| 69d 87d
9 furosemide 40 49b 48e 49d 21 52a19 hydrochlorothiazide 50 63e 61d 38® 31a 24a9 hydrochlorothiazide 50 59a 63d 35a 22 44a
7 indapamide 2.5 87c 139® 26° 23® -8nS
10 muzolimine 30 38® 34 14® 20nS 8nS
13 xipamide 5 39e 46e 20 403 27C13 xipamide 10 106® 120 63® 55a 50®
13 xipamide 20 101® 111® 63 79® 40
Significances of the differences between.mean excretions 
after drug and after placebo: aP<0.05; DP< 0.02; ®P< 0.01; 
dp< 0.005; P< 0.001; ns: non-significant.
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FIG. 1. Urinary Na and Mg 
flows after placebo 
administration to healthy 
volunteers. Adapted from 
Reyes and Leary [1], by 
courtesy of Current 
Therapeutic Research.
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FIG. 2. Urinary Na and Mg 
flows after administration 
of furosemide 40 mg to 
healthy volunteers. Adap­
ted from Reyes and Leary 
[2], by courtesy of Current 
Therapeutic Research.
cause hypermagnesiuria by direct blockade of Mg reabsorption 
which is aggravated by a further increase in Mg filtration at 
the glomerulus which follows Mg mobilisation from bone secon­
dary to an increase in plasma parathyroid hormone (PTH) level 
which occurs in response to hypercalciuria provoked by loop 
diuretics. Thiazide-type diuretics block Mg reabsorption in 
the early portion of the distal tubule but the principal mechan­
ism whereby they provoke hypermagnesiuresis is a decrease in
0 6 2*
HOURS
FIG. 3. Urinary Na and Mg 
flows after administration 
of hydrochlorothiazide 50 mg 
to healthy volunteers. Adap­
ted from Leary and Reyes [3], 
by courtesy of Current 
Therapeutic Research.
reabsorption of Mg at the loop of Henle. This occurs because 
decreased Ca excretion induced by these substances reduces 
plasma PTH and thus diminishes PTH-dependent Mg reabsorption 
in the loop [4] (FIG. 4).
FIG. 4. Causal diagram of the determination of Mg defic­
iency provoked by loop and distal tubular diuretics. The 
diagram depicts changes (+: augmentation; -: diminution) 
resulting from increases in the variables at which arrows 
start (system dynamics notation). PTH: parathyroid hormone. 
Adapted from Reyes [4], by courtesy of La Prensa Medica 
Argentina.
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Effects of Captopril, Hydrochlorothiazide, and their 
Combination on Timed Urinary Excretions of Water and 
Solutes
This provides further data which gives insight into 
diuretic effects of captopril an angiotensin conver 
enzyme inhibitor. Important new findings are described, 
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Effects of Captopril, Hydrochlorothiazide, and 
Their Combination on Timed Urinary Excretions of
Water and Solutes
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tTulio N. Acosta-Barrios
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Summary: The effects of single doses of captopril 100 
mg, hydrochlorothiazide 25 mg, and a combination of 
both on 24-h outputs of fluid and several solutes were 
compared in healthy volunteers. Thirteen subjects were 
studied in a metabolic ward under strictly controlled con­
ditions. Single doses of placebo, captopril, hydrochloro­
thiazide, and a combination of captopril and hydrochlo­
rothiazide were given double-blind in random order on 4 
separate days. Urine was collected at regular intervals 
for 24 h after medication. The combination of captopril 
and hydrochlorothiazide and hydrochlorothiazide alone 
significantly increased the 24-h urinary outputs of CD, 
N a+, fluid, and K* compared with placebo and also ac­
celerated the corresponding urinary flows. Captopril did 
not change the 24-h urinary excretions of CD, N a+, fluid, 
and K + significantly, though it advanced the time courses
of their urinary flows. All medications significantly in­
creased the 24-h renal outputs of Mg:+ and creatinine. 
Captopril significantly increased the 24-h urinary output 
of urate and advanced its urinary flow. Hydrochlorothi­
azide significantly decreased the output and retarded the 
flow. The combination of captopril and hydrochlorothi­
azide did not change the 24-h urinary output and retarded 
its flow. It is concluded that the renal excretory actions 
of captopril are more prolonged than the plasma levels of 
the drug would indicate. Captopril has diuretic effects 
which may vary in potency with aldosterone concen­
trations and uricosuric properties unrelated to aldoste­
rone status. Key Words: Angiotensin-I-converting en­
zyme inhibitors—Captopril— Diuretics—Gout— Hyper­
tension— Magnesium— Uric Acid.
The pharmacologic properties of the angiotensin- 
I-converting enzyme inhibitor captopril are of both 
academic and clinical interest. The mechanisms 
whereby captopril reduces arterial blood pressure 
when used as monotherapy in essential hyperten­
sion remain obscure, however (1-4), and cannot be 
ascribed solely to inhibition of circulating angio- 
tensin-I-converting enzyme (5-10).
The kidney is of the utmost importance in the 
regulation of cardiovascular homeostasis. Nu­
merous reports have referred to the renal actions of 
captopril (11-13), but information on the renal clin­
ical pharmacology of the drug is incomplete, since 
the effects of captopril on the excretion of various 
urinary solutes have not been evaluated and the 
renal pharmacology of captopril has not been com­
pared with that of established antihypertensive di­
uretics such as the thiazides. Renal actions of cap­
topril merit investigation since there is a dissocia­
tion between the time courses of the plasma 
concentration of the substance, paralleled by cir­
culating angiotensin-I-converting enzyme inhibi­
tion, and that of the hypotensive effect of captopril 
in patients with essential hypertension (14,15). 
Renal effects might partly explain the mechanism 
of action of captopril and some of the discrepancies 
between the known, conventional, time-dependent 
pharmacokinetics of the drug (14,16) and its phar­
macodynamics. Since the coprescription of capto­
pril and hydrochlorothiazide reduces raised blood 
pressure effectively and safely (17), the renal ex­
cretory actions of this combination also merit in­
vestigation.
The objective of this study was to compare the 
effects of 100 mg captopril, 25 mg hydrochlorothi­
azide, and their combination on the 24-h urinary 
outputs and flows of fluid and several solutes, after 
administration of single doses of the formulations.
SUBJECTS AND METHODS
Subjects and operational procedures
Thirteen healthy male adult students volunteered to 
participate in the study after a full explanation of its im-
Address correspondence and reprint requests to Professor Leary at P.O. Box 17039, Congella 4013, Natal, South Africa.
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plications. All were aged between 18 and 24 and had 
taken no other medication within the previous 2 months. 
None were obese nor had any history of renal, cardio­
vascular, or metabolic disorders. Smokers were not 
studied.
A standardized diet containing roughly 160 mmol of 
Na+ and 3.5 L of water was prescribed on treatment days 
and during the 24 h before each of them. Subjects re­
ceived placebo, captopril 100 mg, a combination of cap- 
topril 100 mg and hydrochlorothiazide 25 mg, and hydro­
chlorothiazide 25 mg, all presented in matching tablets. 
Formulations were adm inistered separately and in 
random order on 3 different treatment days, at least 7 
days apart. Medications were given at 0800 with 100 ml 
tap water. Volunteers were confined to a metabolic ward 
on study days, when ingestion of alcohol, caffeine, or 
medicines other than the trial formulation was forbidden.
All laboratory analyses were carried out by technolo­
gists who were unaware of the protocol being followed. 
All urine passed on treatment days and during the pre­
vious 24 h was collected. Urine collected 0-3, 3-6. 6-9. 
9-12. and 12-14 h after dosing on treatment days and 
pooled urine collected during the previous 24 h were an­
alyzed. Urine volumes were measured at the end of each
collection period and samples were kept frozen until 
chemical analysis. Urine contents of Cl", N a+, K + , 
Ca2 + , Mg: + , total inorganic phosphate, creatinine, and 
urate were analyzed.
On treatment days venous blood was drawn by vene­
puncture just before medication and 6 ± 1 and 24 ± 0.5 
h later for measurement of serum concentrations of Cl", 
Na+, K + , total Ca2 + , Mg2 + , total inorganic phosphate, 
creatinine, urate, and total C 02. The serum glucose con­
centration was measured in blood samples withdrawn be­
fore and 24 h after medication. Blood was collected in 
plain glass tubes and serum was separated by centrifu­
gation and frozen until chemical analysis.
Laboratory methods
Urinary and serum variable concentrations were mea­
sured as follows: Cl" and K + were evaluated with an IL 
943 flame photometer with cesium as diluent. Cl" and 
total C 02 were measured with an IL 446 analyzer with a 
mercuric diluent and a pC 02 electrode, respectively. 
Mg2+ and urinary Ca2+ were measured by atomic ab­
sorption with a Varian 1275 instrument. Total inorganic 
phosphate, creatinine, urate, glucose, and serum Ca2 + 
were all evaluated colorim etrically on a Model 34
TABLE 1. A c c u m u l a t e d  e x c r e t io n s  o f  u r in a r y  v a r i a b l e s  a f t e r  m o n o d o s i n g  13 h e a l th y  v o lu n t e e r s  w i th  p l a c e b o ,  
c a p t o p r i l  100  m g ,  a  c o m b i n a t i o n  o f  c a p t o p r i l  100 m g  p l u s  h y d r o c h l o r o t h i a z i d e  ( H Z )  25  m g ,  
a n d  h y d r o c h l o r o t h i a z i d e  2 5  m g  (m e a n s ± S E M )
Urinary
variable Medication
Hours after dosing
3 6 9 12 24
Chloride Placebo 29 ± 3 65 4 92 ± 6 118 ± 6 175 8
(mmol) Captopril 30 2 66 ± 6 95 8 120 ± 6 159 ± 7
Captopril + HZ 80 ± 7 162 9 227 ± 8 258 ± 10 299 ± 11
Hydrochlorothiazide 51 4 111 ± 6 146 ± 7 181 ± 8 ± 8
Sodium Placebo 24 ± 3 53 ± 5 76 ± 6 99 ± 6 151 ± 7
(mmol) Captopril 25 ± 3 59 ± 6 87 9 110 ± 8 146 ± 9
Captopril + HZ 71 ± 7 157 8 200 9 227 ± 10 264 II
Hydrochlorothiazide 48 ± 3 101 ± 6 130 7 161 7 201 7
Volume Placebo 0.22 0.03 0.86 ± 0.08 1.33 0.10 1.68 0.10 2.44 ± 0.12
(L) Captopril 0.38 0.05 0.96 ± 0.10 1.47 0.13 1.93 ± 0.15 2.62 0.18
Captoprol + HZ 0.52 0.04 1.33 ± 0.09 1.95 0.11 2.30 -t- 0.13 2.87 0.18
Hydrochlorothiazide 0.50 0.06 1.30 ± 0.08 1.75 0.11 2.24 ± 0.14 2.94 -f- 0.15
Potassium Placebo 7.6 0.8 18.2 ± 1.7 24.1 2.3 31.2 2.4 48.3 3.1
(mmol) Captopril 10.1 1.1 19.7 1.8 27.6 2.5 34.2 2.3 46.0 ± 3.0
Captopril + HZ 15.1 ± 1.6 29.9 2.3 39.3 3.0 46.2 3.2 57.5 3.4
Hydrochlorothiazide 11.3 1.4 23.5 ± 2.5 30.6 ± 3.0 41.2 4.2 58.2 5.2
Calcium Placebo 0.71 ± 0.10 1.58 0.16 2.22 0.22 2.77 ± 0.29 4.44 ± 0.45
(mmol) Captopril 0.62 0.08 1.49 ± 0.15 2.09 ± 0.20 2.73 ± 0.20 4.48 ± 0.28
Captopril + HZ 1.06 ± 0.12 2.15 ± 0.20 2.90 ± 0.22 3.41 0.28 4.90 ± 0.41
Hydrochlorothiazide 0.81 ± 0.08 1.72 0.20 2.19 0.22 2.74 ± 0.31 4.12 ± 0.37
Magnesium Placebo 0.65 0.07 1.31 ± 0.07 1.87 0.14 2.37 ± 0.15 4.14 ± 0.35
(mmol) Captopril 0.62 ± 0.09 1.33 ± 0.17 2.02 0.21 2.64 ± 0.24 4.87 0.31
Captopril + HZ 1.02 ± 0.11 2.04 ± 0.13 2.70 0.19 3.47 ± 0.26 6.01 0.40
Hydrochlorothiazide 0.74 0.08 1.92 0.25 2.69 -f- 0.32 3.69 ± 0.31 7.18 ± 0.44
Phosphate Placebo 2.4 0.3 5.6 ± 1.1 7.7 1.2 11.3 ± 1.3 28.5 ± 1.1
(mmol) Captopril 4.1 0.7 8.5 ± 1.0 14.1 1.7 21.4 ± 2.1 39.6 ± 3.4
Captopril + HZ 3.2 0.3 7.1 ± 0.7 11.3 1.0 15.4 1.3 31.8 ± 2.2
Hydrochlorothiazide 2.7 0.4 6.0 ± 0.9 9.2 ± 1.3 14.9 -t- 1.5 34.8 1.9
Creatinine Placebo 1.6 0.2 3.3 ± 0.3 5.6 ± 0.4 8.0 ± 0.4 18.7 0.5
(mmol) Captopril 3.4 0.4 6.5 0.5 9.2 ± 0.6 11.7 0.6 20.7 0.7
Captopril + HZ 3.9 0.3 7.2 ± 0.4 10.1 0.5 13.1 -f- 0.5 23.3 ± 1.4
Hydrochlorothiazide 2.9 0.3 5.3 ± 0.4 7.1 ± 0.6 10.1 0.7 20.5 0.8
Urate Placebo 0.78 0.07 1.58 0.08 2.04 ± 0.09 2.51 ± 0.07 4.49 0.18
(mmol) Captopril 0.86 ± 0.07 1.78 0.11 2.51 0.17 3.29 0.14 5.41 ± 0.26
Captopril + HZ 0.93 ± 0.14 1.71 ± 0.18 2.41 0.19 2.98 0.16 4.36 Hh 0.22
Hydrochlorothiazide 0.65 ± 0.10 1.29 0.20 1.61 0.26 2.17 0.33 3.46 0.45
Beckman Trace II spectrophotometer; Boehringer-Man- 
nheim kits were used for the Ca:+ and creatinine m e a ­
surements and a Clinical Sciences kit for the total inor­
ganic phosphate chemical colorimetric reactions: a Boeh- 
ringer-Mannheim Peridochrom kit was used for urate 
determinations and a Beckman endpoint for the glucose 
enzymatic colorimetric reactions.
Mathematical methods
The m e a n  experimental values, M, of the urinary 
volume and solutes accumulated by the end of each post­
dosing collection period, as functions of time, t, were 
fitted by a mathematical model;
20A//log( 100 -  M) = exp{[2.3
(/ -  /,)]/(« + bt)}, (1)
where t ] is the time at which Af = 0.1 unit used in the 
calculations and a (time) and b (dimensionless) are pa­
rameters of the function. The fitting procedure has been 
described previously (18). Flows of urinary variables 
were defined as
d M I d t = (a + b t f f { ( a + b t) - [(0.43/Af)
+  (0.43):/( 100 -  A/)log( 100 -  M)]}.
(2)
Normality of frequency distributions and homoscedas- 
ticity of sample variances were evaluated as appropriate, 
through the x: test and the F ratio, respectively. Minor 
deviations from prerequisites for parametric statistics
were tolerated. Standard statistical techniques (paired t 
test and linear correlation and regression evaluated by 
least squares) were used. All statistical tests were two- 
tailed and p =  0.05 was considered the limit of signifi­
cance.
Times to peak flow after dosing were evaluated on a 
computer by an iterative procedure.
RESULTS
N o significant differences were found between  
the mean 24-h urinary outputs of each studied vari­
able on any of the 24-h pretreatment control days 
and the corresponding mean excretions after pla­
cebo.
Table 1 depicts the absolute urinary excretions of 
fluid and electrolytes accumulated at the end of 
each fractional collection period after monodosing 
with placebo, captopril, hydrochlorothiazide, and 
the combination of captopril and hydrochlorothia­
zide. The probability values derived from paired t  
tests contrasting any two mean 24-h urinary outputs 
of each variable after each formulation are shown 
in Table 2.
The mean accumulated excretions of all studied 
variables after all formulations, as functions of time, 
were satisfactorily fitted by (M )t, as shown by the
T A B L E  2. P r o b a b i l i t ie s  c o r r e s p o n d in g  to  d e p e n d e n t  t s ta t i s t i c s  e v a lu a t in g  th e  s ig n i f i c a n c e  
o f  th e  d i f f e r e n c e s  b e tw e e n  a n y  tw o  m e a n  2 4 -li u r in a r y  v a r ia b le  o u tp u ts  a f te r  m o n o d o s in g  13 
h e a l th y  v o lu n te e r s  w ith  c a p to p r i l  100 n ig ,  a  c o m b in a t io n  o f  c a p to p r i l  100 m g  p lu s  
h y d r o c h lo r o th ia z id e  (HZ) 2 5  m g .  a n d  h y d r o c h lo r o th ia z id e  25  m g
Urinary
variable Medication
Medication
Placebo Hydrochlorothiazide
Captopril + 
hydrochlorothiazide
Chloride Captopril 0.0962 <0.0001* <0.0001*
Captopril + HZ <0.0001* 0.0001*
Hydrochlorothiazide 0.0008*
Sodium Captopril 0.7073 <0.0001* <0.0001*
Captopril + HZ <0.0001* 0.0002*
Hydrochlorothiazide 0.0006*
Volume Captopril 0.0700 0.0809 0.2263
Captopril + HZ 0.0133* 0.5780
Hydrochlorothiazide 0.0009*
Potassium Captopril 0.4975 0.0281* 0.0281*
Captopril + HZ 0.0336* 0.9217
Hydrochlorothiazide 0.0873
Calcium Captopril 0.8848 0.2430 0.1889
Captopril + HZ 0.2272 0.0221*
Hydrochlorothiazide 0.4140
Magnesium Captopril 0.0048* <0.0001* 0.0258*
Captopril + HZ 0.0006* 0.0091*
Hydrochlorothiazide <0.0001*
Phosphate Captopril 0.0142* 0.3486 0.0843
Captopril + HZ 0.2857 0.3203
Hydrochlorothiazide 0.0026*
Creatinine Captopril 0.0008* 0.8335 0.0538
Captopril + HZ 0.0017* 0.1047
Hydrochlorothiazide 0.1227
Urate Captopril 0.0348* 0.0070* 0.0290*
Captopril + HZ 0.5236 0.1285
Hydrochlorothiazide 0.0674
* Significant at p s  0.05.
rvalues in Table 3, where the regression parameters 
of the linearized functions are also shown. The 
derivations o f (M )t with respect to time allowed 
evaluation o f the times to peak excretions after 
dosing, which are also shown in Table 3. Figures 1 
and 2, respectively, depict the M(t) and (dM /dt)t- 
flow-functions for urate.
The evolution of serum variables after dosing and 
the significances of their differences with respect to 
pretreatment means are described in Table 4.
No clinical or laboratory abnormalities occurred 
in any subject during the study period.
DISCUSSION
The mathematical model describing the flows of 
urinary variables as functions of time has been dis­
cussed previously (18,19). The times to peak flows 
after dosing (Table 3) serve as an overall estimation 
of the corresponding flow rates.
All the urinary excretory actions of captopril 
lasted longer than the presence of the drug in the
plasma of normal subjects, and times to peak ex­
cretions were delayed beyond the time to peak 
plasma concentration of captopril reported after its 
oral administration in hypertensive patients (14). 
Studies are necessary to determine whether the 
captopril-captopril disulfide and other metabolites 
of captopril (20), that persist in plasma far longer 
than free captopril, account for this time shift.
The combination of captopril and hydrochloro­
thiazide and hydrochlorothiazide alone significantly 
increased the 24-h urinary excretions of C l- , N a+ , 
fluid, and K + (Table 2) and accelerated their cor­
responding flows with respect to those after placebo 
dosing (Table 3). Captopril did not change the 24-h 
renal excretions of C l- , N a + , volume, or K + sig­
nificantly. The fact that captopril did not induce 
overt natriuresis in this study is at variance with the 
results of a study in which primary hypertensives 
were treated with captopril (12). Since N a+ intake 
was severely limited to 20 mmol of N a + in that trial, 
whereas N a+ intake was fairly high in the present 
investigation, captopril may have an intrinsic natri-
TABLE 3. S t a t i s t i c a l  f e a t u r e s  a n d  p a r a m e te r  v a lu e s  o f  th e  l in e a r  t r a n s fo r m a t io n s  o f  th e  f u n c t i o n s  M ( t ) .
H Z  = h y d r o c h lo r o th ia z id e
Urinary
variable
Unit used in 
calculations Medication r P (h)
Cl
(h) b
Time to 
peak 
excretion 
(h)
Chloride mmol x  10 Placebo >0.999 <0.0001 0.093 0.7997 0.4079 3.45
Captopril >0.999 <0.0001 0.090 0.7072 0.4191 3.21
Captopril + HZ >0.999 <0.0001 0.034 0.3744 0.3810 1.96
Hydrochlorothiazide >0.999 <0.0001 0.053 0.5093 0.3979 2.46
Sodium mmol x  10 Placebo >0.999 <0.0001 0.113 0.8949 0.4174 3.94
Captopril >0.999 <0.0001 0.107 0.7610 0.4237 3.46
Captopril + HZ >0.999 <0.0001 0.038 0.3681 0.3908 1.96
Hydrochlorothiazide >0.999 <0.0001 0.057 0.5158 0.4071 2.22
Volume litre x  10“ 1 Placebo >0.998 <0.0001 0.125 0.8693 0.3734 4.43
Captopril >0.999 <0.0001 0.071 0.6982 0.3773 3.67
Captopril + HZ >0.999 <0.0001 0.052 0.5204 0.3775 2.70
Hydrochlorothiazide >0.999 <0.0001 0.054 0.5734 0.3742 3.18
Potassium mmol Placebo >0.999 <0.0001 0.036 0.6067 0.3391 3.88
Captopril >0.999 <0.0001 0.027 0.4752 0.3474 2.91
Captopril + HZ >0.999 <0.0001 0.018 0.3641 0.3357 2.19
Hydrochlorothiazide >0.999 <0.0001 0.024 0.5175 0.3295 3.39
Calcium mmol x  10_I Placebo >0.999 <0.0001 0.038 0.6322 0.3444 3.88
Captopril >0.999 <0.0001 0.043 0.6895 0.3412 4.12
Captopril + HZ >0.999 <0.0001 0.026 0.4783 0.3434 2.91
Hydrochlorothiazide >0.999 <0.0001 0.033 0.5515 0.3530 3.16
Magnesium mmol x  10“ ' Placebo >0.998 <0.0001 0.041 0.7063 0.3472 4.12
Captopril >0.998 <0.0001 0.043 0.7733 0.3329 4.84
Captopril + HZ >0.998 <0.0001 0.026 0.6253 0.3245 3.87
Hydrochlorothiazide >0.997 <0.0002 0.036 0.7988 0.3036 5.56
Phosphate mmol Placebo >0.993 <0.0006 0.111 1.2791 0.3536 7.28
Captopril >0.998 <0.0001 0.066 0.9625 0.3390 5.82
Captopril + HZ 0.998 <0.0002 0.083 1.0424 0.3526 6.07
Hydrochlorothiazide >0.995 <0.0004 0.101 1.2533 0.3381 7.76
Creatinine mmol Placebo >0.995 <0.0004 0.167 1.4856 0.3770 7.80
Captopril >0.998 <0.0001 0.080 0.8818 0.3930 4.39
Captopril + H Z >0.998 <0.0001 0.070 0.8557 0.3848 4.39
Hydrochlorothiazide >0.995 <0.0004 0.092 1.0823 0.3876 5.36
Urate mmol x  10“ ' Placebo >0.998 <0.0001 0.034 0.6511 0.3445 3.88
Captopril 0.999 <0.0001 0.031 0.6110 0.3350 3.87
Captopril + HZ >0.999 <0.0001 0.029 0.5314 0.3496 2.91
Hydrochlorothiazide >0.999 <0.0001 0.041 0.6490 0.3623 3.64
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FIG. 1. A c cu m u la te d  e x c re t io n s  o f urate  in u r in e  afte r s in g le  
a d m in is t ra t io n  o f p la ce b o , c a p to p r ii (CL), a c o m b in a t io n  o f 
c a p to p r il an d  h y d ro ch lo ro th ia z id e  (CZ) an d  h y d ro c h lo ro th i­
a z id e  (HZ) to  13 h e a lth y  v o lu n te e rs  at h o u r  0 (0800). T he  
m a th e m a tica l m o d e l f itt in g  the  da ta  is  p re se n te d  in e q u a ­
t io n  (1).
uretic capacity which becom es apparent when  
plasma aldosterone concentration is high, as oc­
curs when dietary N a+ is restricted. Moreover the 
combination of captopril and hydrochlorothiazide 
induced significantly higher 24-h renal outputs of 
C l-  and N a + than hydrochlorothiazide (Table 2) 
and advanced the urinary C l-  and N a + urinary 
flow s more than hydrochlorothiazide (Table 3). 
Thus, the chloriuretic and natriuretic properties of 
captopril are exhibited as a potentiation o f the 
chloriuretic and natriuretic effects of hydrochloro­
thiazide, possibly because the natriuretic action of 
the diuretic raises plasma aldosterone. Captopril 
also accelerated the urinary flows of Cl" and Na + ,
0,4.
0,2.
0.
HYDROCHLOROTHIAZIDE 25 m g
0 3 5 9 12 24
H O U R S
FIG. 2. U rin a ry  u ra te  f lo w s , d e r ived  from  the  c u rv e s  d e p ic te d  
in F ig . 1, a s  fu n c t io n s  o f tim e. T h e  m a th e m a tica l m o de l a c ­
c o u n t in g  fo r  th e  fu n c t io n s  is  p re se n ted  in  e q u a t io n  (2). T h e  
a re a s  u n d e r th e  c u rv e s  be tw een  any tw o  t im e s  re p re se n t the  
to ta l am o u n t o f u ra te  e x c re te d  d u r in g  the  in te rva l.
a fact that may be regarded as the expression of 
chloriuretic and natriuretic capacities o f a sub­
stance, since the time courses o f urinary flows are 
sensitive indicators of the urinary excretory effects 
of a drug when small samples are studied.
Captopril did not affect the 24-h urinary excretion 
of K + significantly, whereas the combination of 
captopril and hydrochlorothiazide and hydrochlo­
rothiazide alone increased it to a similar extent (Ta­
bles 1 and 2). All formulations accelerated urinary 
K + flow s; the advance provoked by captopril 
(Table 3) was possibly a consequence of its similar 
effect on N a + flow. Studies with amiloride, fol­
lowing a similar protocol, have shown that both uri­
nary N a + and K + flow s are accelerated by the 
drug, although N a + urinary excretion and K + re­
tention are induced (21). Since urinary K + output 
depends largely on the N a+-K + , H + exchange at 
the end of the distal convoluted tubule (22), which 
is under positive control by aldosterone, captopril 
should act as a urinary-K + sparer (23) by de­
pressing angiotensin-I-dependent aldosterone syn­
thesis (24). Some investigations into the chronic ef­
fects of captopril on plasma K + in hyperaldoster- 
onem ic patients confirm this view  (12,24,25). 
Studies in hypertensive patients have shown that 
captopril attenuates hydrochlorothiazide-induced  
urinary K + losses (12,17,26). These reports are 
consistent with the present finding that 6 h after 
dosing plasma K + was significantly reduced by hy­
drochlorothiazide in comparison with pretreatment, 
but not by the combination of captopril and hydro­
chlorothiazide (Table 4).
All active formulations significantly increased 24- 
h magnesiuria compared with placebo (Table 2). 
Since neither captopril, the combination of capto­
pril and hydrochlorothiazide, nor hydrochlorothia­
zide alone affected calciuresis, their magnesiuretic 
effect might be due to direct blockade of Mg2 + reab­
sorption from the nephron, to inducement of Mg: + 
excretion through the nephronal wall, or to the in­
crease in renal 24-h phosphate excretion which all 
three active medications induced (Table 2). The 
magnesiuretic effect of hydrochlorothiazide is well 
known (27,28). Captopril caused significantly less 
24-h magnesiuresis than the combination of capto­
pril and hydrochlorothiazide and hydrochlorothia­
zide alone, and the combination significantly re­
duced the 24-h urinary Mg2 + losses caused by the 
diuretic. These results indicate that the combination 
of captopril and hydrochlorothiazide is less likely 
to induce somatic Mg2+ depletion than hydrochlo­
rothiazide alone, since captopril counteracts the 
m agnesiuretic effect o f hydrochlorothiazide to 
some extent. The acute and chronic effects of cap­
topril and the combination of captopril and hydro­
chlorothiazide on calciuresis and magnesiuresis 
merit further detailed assessments (27-30). Mg2 + 
depletion induced by diuretics, especially in pa-
T A B L E  4. Serum variables before (hour 0) and after monodosing 13 healthy volunteers with placebo, 
captopril 100 mg, a combination o f  captopril 100 mg plus hydrochlorothiazide (HZ) 25 mg, and 
hydrochlorothiazide 25 mg (means ± SEM)
Serum
variable M edication
Hours after dosing
0 6 24
Chloride Placebo 106.1 ± 0.2 104.6 ±  0.2***** 106.0 ± 0.6
(mmol ■ L ~ ') Captopril 104.7 ± 0.8 104.6 ± 0.5 105.5 ±  0.4
Captopril + H Z 104.9 ± 0.7 103.2 ± 0.8 104.1 ±  0.6
H ydrochlorothiazide 105.4 ± 0.3 103.9 ± 0.5***** 103.6 ± 0.4*****
Sodium Placebo 145.9 ± 0.5 146.0 ± 0.4 147.8 ± 0.7***
(mmol • L _l) Captopril 146.5 ± 0.6 146.7 ± 0.5 147.1 ± 1.0
Captopril + HZ 145.3 ± 0.3 144.2 ± 0.8 145.0 ± 0.8
Hydrochlorothiazide 146.3 ±  0.5 145.0 ± 0.5* 146.5 ± 0.5
Potassium Placebo 4.32 ± 0.07 4.17 ± 0.06 4.48 ± 0.10
(mmol • L _1) Captopril 4.39 ± 0.13 4.41 ± 0.08 4.62 ± 0 .1 1
Captopril + HZ 4.05 ± 0.05 4.08 ± 0.08 4.14 ± 0.13
Hydrochlorothiazide 4.26 ± 0.07 3.93 ± 0.04**** 4.30 ± 0.07
Calcium Placebo 2.49 ± 0.02 2.54 ± 0.02* 2.58 ± 0.03***
(mmol • L “ ') Captopril 2.55 ± 0.02 2.58 ± 0.04 2.56 ± 0.05
Captopril +  HZ 2.51 ± 0.02 2.49 ± 0.06 2.57 ± 0.3*
Hydrochlorothiazide 2.55 ± 0.05 2.66 ± 0.06**** 2.71 ±  0.03****
Magnesium Placebo 0.85 ± 0.01 0.88 ±  0.02* 0.86 ±  0.03
(mmol • L " ') Captopril 0.88 ± 0.02 0.86 ± 0.02 0.88 ± 0.02
Captopril + H Z 0.82 ± 0.01 0.83 ± 0.01 0.82 ± 0.01
Hydrochlorothiazide 0.84 ± 0.01 0.82 ± 0.01 0.82 ± 0.01*
Phosphate Placebo 1.48 ± 0.11 1.47 ± 0.08 1.44 ± 0.07
(mmol • L ~ ') Captopril 1.32 ± 0.07 2.18 ± 0.12***** 1.46 ± 0.05
Captopril + HZ 1.35 ± 0.04 1.52 ~t- 0.04***** 1.39 ± 0.05
Hydrochlorothiazide 1.29 ± 0.08 1.52 ± 0.07*** 1.42 ± 0.07
Creatinine Placebo 94.1 ± 4.1 96.5 ± 3.7 102.0 ± 3.4**
(p.mol • L " ') Captopril 105.4 ± 5.8 100.5 ± 3.7 109.6 ± 3.2
Captopril + HZ 95.0 ± 2.3 101.5 ± 2.9** 100.7 ± 2.8***
Hydrochlorothiazide 111.5 ± 9.5 108.5 ± 3.0 109.8 ± 2.6
Urate Placebo 0.35 ± 0.02 0.32 ± 0.02***** 0.35 ± 0.02
(mmol • L  ~ ') Captopril 0.35 ± 0.02 0.33 ± 0.02***** 0.35 ± 0.02
Captopril + HZ 0.32 ± 0.01 0.32 ± 0.01 0.35 ± 0.02****
Hydrochlorothiazide 0.34 ± 0.01 0.34 ± 0.01 0.37 ± 0.01****
Total C O , Placebo 22.1 ± 1.1 23.2 ± 1.0** 21.1 ± 1.7
(mmol • L ~ ') Captopril 22.6 ± 0.6 23.4 ± 0.5** 23.2 ± 0.7
Captopril + HZ 23.8 ± 0.5 24.7 ± 0.4 24.0 ± 0.6
Hydrochlorothiazide 24.6 ± 1.8 26.6 ± 0.9 27.5 ± 0.6
G lucose Placebo 5.2 ± 0.1 5.3 ± 0.1
(mmol • L _l) Captopril 5.3 ± 0.2 5.2 ± 0.2
Captopril + HZ 5.4 ± 0.1 5.3 ± 0.1
Hydrochlorothiazide 5.0 ± 0.1 5.3 ± 0.1
Significances o f  the differences with respect to hour-0 means: *p <  0.05: **p <  0.02; ***p <  0.01; ****p <  0.005;
*****p <  0.001.
tients also treated with cardiac glycosides, is a more 
important determinant of cardiac arrhythmias and 
myocardial infarction than K + depletion (see 29- 
30 for reviews). If the magnesiuretic effect of cap­
topril is confirmed, it might explain why patients 
with cardiac insufficiency have apparently died of 
cardiac arrhythmias or myocardial infarction within 
1-6 months of adding captopril to a regimen that 
already included diuretics and digoxin (31).
The effects of captopril, the combination of cap­
topril and hydrochlorothiazide, and hydrochloro­
thiazide alone upon renal creatinine excretion might 
be expected on the basis of established knowledge.
Captopril significantly increased the 24-h renal 
output of urate compared with placebo. The mean 
24-h excretion after captopril was also significantly
higher than those after the combination of captopril 
and hydrochlorothiazide and hydrochlorothiazide 
alone. The combination of captopril and hydrochlo­
rothiazide did not affect 24-h urinary urate excre­
tion, and hydrochlorothiazide significantly de­
creased it (Table 2). Captopril did not affect urinary 
urate output flow, whereas the combination of cap­
topril and hydrochlorothiazide and hydrochlorothi­
azide alone accelerated it (Table 3). Captopril de­
creased mean plasma urate serum concentration 6 
h after administration, while the combination of 
captopril and hydrochlorothiazide and hydrochlo­
rothiazide alone did not affect it (Table 3). Con­
versely, the mean plasma urate concentration rose 
significantly 24 h after the combination of captopril 
and hydrochlorothiazide and hydrochlorothiazide
alone, while it did not change 24-h after captopril. 
These results identify captopril as an uricosuric 
agent. Previous studies in hypertensives chronically 
treated with captopril, hydrochlorothiazide, and 
captopril plus hydrochlorothiazide have shown that 
captopril helps attenuate the increase in plasma 
urate induced by hydrochlorothiazide (17,26). The 
mechanism by which captopril increases the renal 
excretion of urate might be an increase of glomer­
ular filtration rate, a decrease in proximal tubular 
reabsorption of filtered and/or secreted urate, or an 
increase in urate tubular secretion (32,33).
The uricosuric effect of captopril has important 
clinical implications. Captopril would be particu­
larly useful in patients with hypertension or heart 
failure complicated by gout or asymptomatic hy­
peruricemia, when administered alone or with the 
purpose of reducing urate retention due to diuretics. 
N evertheless, caution should be exercised when 
using captopril in patients with hyperuricemia due 
to increased uric acid production (daily urinary ex­
cretion of urate higher than 4.76 mmol), with uri­
nary urate stones, or with dehydration (32,34). In­
creasing fluid intake to at least 2 L daily and alka- 
linization or urine would prevent the precipitation 
or urate in the urinary tract of these patients (32).
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PAPER C14
The Effects of Single Doses of Muzolimine Upon Urinary Solute 
and Fluid Excretion
This paper described the first in-depth study of acute 
urinary responses to muzolimine, a new loop diuretic. The 
concept, clinical work, mathematical analysis and preparation 
of the manuscript were shared by the first two authors. Mr. 
van der Byl provided computer facilities.
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fluid excretion
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Sum m ary: The natriuretic effect of many loop 
diuretics is followed by an important decrease -  
rebound undershoot -  in renal Na* excretion, 
which is accompanied by thirst and fluid reposi­
tion. Also most loop diuretics increase K* and 
Mg2^ urinary outputs, thus leading to somatic de­
pletion of these cations and subsequent cardiac 
arrhythmias. The objectives of the present study 
were to describe the urinary outputs and flows of 
several solutes after various doses of muzol­
imine.
Experiments were carried out in ten healthy 
adult volunteers given monodoses of placebo 
and of muzolimine 20, 30 and 40 mg on separate 
days and in random order. Urine collected at 3, 
6, 9, 12 and 24 h after dosing was analysed for 
solutes.
Muzolimine 20 mg did not increase mean 24 h 
urinary Na+ output significantly with respect to 
placebo. Muzolimine 30 mg exerted maximal 
diuretic, chloriuretic and natriuretic effects, while 
not affecting the mean 24 h urinary outputs of K+ 
and Mg2+ significantly. Muzolimine 30 mg caused 
a small undershoot in urinary Na* flow after com­
pletion of its natriuretic effect.
Muzolimine 30 mg should be considered a first 
choice loop diuretic since it only causes a mild 
post-natriuretic undershoot and does not in­
crease urinary Mg2+ output significantly.
K ey  w o rd s: diuretic, magnesium, muzolimine, 
potassium, sodium
Introduction
Urinary flows of fluid and solutes after the ad­
ministration of placebo and various diuretic formu­
lations have recently been described, as continuous 
functions of time, through fitting a mathematical 
model to the corresponding outputs accumulated at 
definite times after dosing and by evaluating its 
time derivative (8). This procedure greatly facili­
tates the analysis and description of the dose- and 
time-dependent pharmacodynamics of different 
diuretic formulations (4, 8-13).
The loop diuretic muzolimine has been studied 
from the point of view of its acute effects on uri­
nary excretion of fluid and solutes in healthy vo­
lunteers (2. 3), though not in sufficient detail to 
cover all essential electrolytes or to allow close 
comparison between different doses of the diuretic 
through utilization of the Reyes and Leary mathe­
matical model (8).
The objectives of the present study were to de­
scribe the continuous time courses of renal fluid
and solute excretion after single doses of muzol­
imine 20, 30 and 40 mg and to compare these to re­
ference standards collected for furosemide 40 mg. 
The solutes studied included Mg:+, given that the 
urinary loss of this cation provoked by furosemide 
40 mg constitutes the principal determinant of ser­
ious diuretic-induced cardiac arrhythmias (1, 9, 
14).
Subjects and methods
Subjects and experimental design
Two separate experiments wnre conducted each 
involving ten healthy male adult students who vol­
unteered to participate in the study after a full ex­
planation of its implications had been given. All 
subjects were aged between 18 and 24 and had 
taken no other medication within the previous 2 
months. None were obese or had a history of renal, 
cardiovascular or metabolic disorders. Smokers 
were not studied.
A standardised diet containing 200 to 220 mmol All laboratory analyses were carried out by tech- 
of Na+ and 2500 ml of water was prescribed on nologists who w'ere unaware of the protocol being 
treatment days and during the 24 h preceding each followed. All urines passed on treatment days and of them (control days). In the first experiment sub- during the previous 24 h were collected. Urine col- 
jects received placebo, 20 mg muzolimine and 30 lected from 0-3, 3-6, 6-9, 9-12 and 12-24 h after mg muzolimine separately and in random order on dosing on treatment days and pooled urine collect- three different treatment days, separated by at least ed during the control days was analysed. Urinary 
7 days. Placebo and muzolimine 40 mg were ad- volumes and the concentrations of Cl", Na*. K+. ministered alike in the second experiment. Medica- Mg:f Zn2+, total inorganic phosphate and creatin- 
tions were given at 80’clock with 100 ml tap water, ine were measured in each urine specimen. 
Volunteers were confined to a metabolic ward du- Solute concentrations in urine specimens were 
ring study days when ingestion of alcohol, caffeine analysed as follows; Na+, K+ and Cl" were measured 
or medicines other than the trial formulations was by the ion-selective electrode technique using a 
forbidden. Nova 4 analyser. Mg:+ and Zn2+ were measured by
Table 1. Accumulated excretions of urinary variables after the administration of placebo and of several doses of muzolimine to ten 
healthy volunteers. Mean +  S.E.M.
Urinary
variable
Medication and dose Hours after dosing
3 6 9 12 24
Volume Placebo for MUZ 20 & 30 0.30±0.04 0.78 ±0.14 1.45 =  0.19 1.92 = 0.17 2.84 +0.15
(litres) Muzolimine 20 0.60 ±0.09 1.07 ±0.10 1.63=0.17 2.01=0.19 2.83 = 0.21
Muzolimine 30 0.88 = 0.13 1.44c +  0.15 2.05 =  0.15 2.44 + 0.17 3.25" = 0 .15
Placebo for MUZ 40 0.19 ±0.02 0.57 +0.08 1.21 +0.15 1.77 = 0.15 2.54 =0.14
Muzolimine 40 0.88 ±0.1 1 1.53b = 0.12 1.93=0.14 2.17 + 0.17 2.80 =0.17
Chloride Placebo for MUZ 20 & 30 38 ± 4 71 + 8 113=12 148= 11 210 = 12
(mmol) Muzolimine 20 70 ±  10 129"= 10 166= 1 1 192= 12 233 =12
Muzolimine 30 117+17 177c± 2 1 221 + 18 248 = 20 290J = 19
Placebo for MUZ 40 35 ± 5 68 ±  9 119=13 170= 13 234 =18
Muzolimine 40 122 ±  11 191b± 11 233=10 254=10 289b= 10
Sodium Placebo for MUZ 20 & 30 31 ±  5 57 ± 8 95=  11 128= 12 1S6 =13
(mmol) Muzolimine 20 54 ±  8 102"+ 9 137=11 162=14 199 =16
Muzolimine 30 97=  16 145"= 19 183 + 18 209 = 22 248" = 21
Placebo for MUZ 40 31 ±  5 60 ±  8 111 =  13 161 = 14 225 =18
Muzolimine 40 102 ±  10 158h= 1 1 199=11 222=11 264a = 10
Potassium Placebo for MUZ 20 & 30 11.0± 1.8 21.6 ±3.4 31.7 = 3.3 39.9 = 3.5 53.7 =5.4
(mmol) Muzolimine 20 13.2+1.9 26.7 =2.6 34.8 = 2.8 40.2 = 2.5 53.8 =4.1
Muzolimine 30 19.7 + 2.8 34.6b = 4.0 45.5 =  3.2 52.7 = 3.9 65.2 =5.1
Placebo for MUZ 40 7.8 ±1.3 17.3 ±2.7 29.0 = 3.1 39.7 = 3.3 40.4 =4.9
Muzolimine 40 19.6 + 2.4 35.7b±3.0 44.7 = 3.4 50.4 = 3.7 60.Sa =  3.9
Magnesium Placebo for MUZ 20 & 30 0.77±0.07 1.28 ±0.12 2.02 =  0.19 2.69 = 0.27 4.68=0.48
(mmol) Muzolimine 20 1.08 ±0.19 1.71 ±0.23 2.21 ±0.23 2.72=0.27 4.38 = 0.34
Muzolimine 30 1.30 = 0.14 1.94" ±0.18 2.58 = 0.17 3.19 =  0.29 5.OS = 0.40
Placebo for MUZ 40 0.76 + 0.08 1.22 ±0.12 1.96 =  0.19 2.65=0.28 4.77 = 0.52
Muzolimine 40 1.54 = 0.18 2.24b±0.23 2.78=0.23 3.20 =  0.27 5.31 =0.34
Zinc (mg) Placebo for MUZ 20 & 30 0.12 = 0.02 0.20 = 0.03 0.31 ±0.04 0.38 = 0.05 0.62 = 0.06
Muzolimine 20 0.15 ±0.03 0.25=0.03 0.33+0.04 0.39+0.04 0.68=0.07
Muzolimine 30 0.14±0.02 0.22 =  0.03 0.31 ±0.04 0.38=0.04 0.61 =0.04
Placebo for MUZ 40 0.13+0.02 0.19 + 0.02 0.27 = 0.03 0.36 + 0.03 0.66=0.07
Muzolimine 40 0.16 = 0.02 0.25 = 0.02 0.31 =0.03 0.35=0.04 0.63 = 0.05
Total inorganic Placebo for MUZ 20 & 30 3.3+0.5 7.3 ±0.9 11.9 = 0.6 16.3=0.9 29.2 = 3.0
phosphate Muzolimine 20 4.1 ±  1.0 6.8+ 1.1 11.2= 1.5 15.1 = 1.8 30.0 = 3.3
(mmol) Muzolimine 30 3.9 = 0.6 7.5 =  0.9 13.2=1.0 17.0= 1.1 32.9=2.7
Placebo for MUZ 40 2.8 =  0.4 6.3 ±0.6 11.5 = 0.6 17.6=1.2 30.7 = 3.4
Muzolimine 40 4.4 = 0.9 8.9 ±  1.1 14.1 = 1.4 18.1 =  1.5 37.4=1.4
Creatinine Placebo for MUZ 20 & 30 3.3+0.2 5.2 ±0.4 7.4 =  0.5 10.8=0.6 19.3= 1.1
(/rmol) Muzolimine 20 2.6 ±0.3 4.7 ±0.5 6.6 =  0.6 8.9 ±0.6 16.8 = 1.4
Muzolimine 30 3.3 ±0.3 7.2" ±1.3 9.6= 1.2 11.9 = 1.2 20.1 =2.1
Placebo for MUZ 40 3.0=0.3 4.8 ±0.5 7.3 ±0.5 11.0 = 0.6 19.5= 1.2
Muzolimine 40 3.3+0.1 5.5 ±0.2 7.7+0.3 9.9 ±0.5 19.8+0.5
MUZ = Muzolimine.
All values corresponding to hour 3 were derived from nine volunteers ans missing values were added to hour 6 accumulated outputs.
Significances of the differences with
"p < 0.01; b p < 0.001.
respect to mean 6 and 24 hour accumulated values after placebo: ap < 0.05; bp < 0.02:
atomic absorption using a Varian 275 275 instru­
ment. Total inorganic phosphate was evaluated colorimetrically (Clinical Sciences kit) on a Beck­
man Trace 3 spectrophotometer. Creatinine was measured using a Peridochrom (Boehringer Mann­heim) kit and the same spectrophotometer.
Mathematical methods
The mean experimental values of the urinary volume and solutes. M, accumulated by the end of 
each post-dosing collecting period, as functions of 
time. t. were fitted by a mathematical model:
20M/log( 100-M) = exp {[2.30(t-t,)] / (a + bt)}, where L is the time at which M = 0.1 unit used for 
the fitting and a (time) and b (dimensionless) are re­
gression parameters of the function. The fitting 
procedure has been described previously (8). Flows 
of urinary variables were defined as:
dM/dt = (a + bt,)/{(a + bt)2 [(0.43/M) + (0.43)7 
(100-M)log(100-M)]}.
Times to mean peak excretion of urinary varia­
bles after dosing were evaluated on a computer 
from the flow functions, through an iterative proce­dure.
Standard parametric statistical techniques, paired 
t-test and correlation and regression on linearized data (4) were used. Normality of frequency distri­
butions and homoscedasticity of sample variances 
were evaluated, as appropriate, through the chi 
square test and the F ratio respectively. All statisti­cal tests were two-tailed and p = 0.05 was consid­ered the limit of significance.
Results
No significant differences were found between 
the mean 24-h accumulated urinary outputs of 
fluid and solutes after placebo and those yielded on 
control days.
The urinary outputs of fluid. Cl", Na\ K+, Mg:+, 
Zn2L total inorganic phosphate and creatinine ac­
cumulated at 3, 6, 9, 12 and 24 h after the intake of 
placebo and of muzolimine 20, 30 and 40 mg are 
shown in Table 1. The significances of the differ­ences between the post-muzolimine and the post­placebo mean outputs accumulated 6 and 24 h 
after dosing are also listed in Table 1. Muzol­imine 20 mg significantly raised the mean 6 h accu­
mulated outputs of Cl" and Naf but did not affect the mean 24 h outputs of fluid or of any of the 
studied solutes significantly (Table 1). Muzolimine 
30 and 40 mg significantly increased the mean urinary outputs of fluid. Cl", Na+, K+ and Mg2+ pro­duced during the first 6 h after dosing with respect to placebo (Table 1). However, many of these signi­
ficances were lost for the 24 h outputs (Table 1). 
Muzolimine 30 mg exhibited significant maximal 
24 h diuretic, chloriuretic and natriuretic effects 
but it did not increase the 24 h outputs of K+ or 
Mg2+ significantly (Table 1). Muzolimine 40 mg sig­
nificantly increased the 24 h urinary outputs of 
Cl", Na+ and K+, but did not augment those of fluid and Mg2+ to a statistically significant extent (Table 
1). None of the formulations affected the mean 24 h outputs of Zn2" and creatinine consistently or sig­
nificantly (Table 1), though they increased the mean 24 h output of inorganic phosphate in a dose- related but insignificant manner (Table 1).The statistical features of the linearized versions 
of the M(t) functions and their parameter values are 
shown in Table 2. The Reyes and Leary mathema­tical model (8) fitted the data satisfactorily in all 
cases, thus permitting evaluation of the urinary 
fluid and solute flows as functions of time and the 
times to peak flows after dosing (Table 2). Figure 1 
depicts the mean urinary Na+ outputs accumulated after the administration of muzolimine 40 mg and 
the corresponding urinary Na+ flow'. After an initial 
natriuretic effect, muzolimine 40 mg gave rise to 
an important “undershoot” in urinary Na* flow.
m m o l
mmol.h"1
n = 10
Fig. 1. Top: mean accumulated urinary Na+ flow after the ad­
ministration of muzolimine 40 mg per os to ten healthy volun­
teers at hour 0 (0800 h). The Reyes and Leary (8) mathematical 
model (continuous-function curve) has been fitted to the experi­
mental means (dots).
Bottom: mean urinary Na+ flow after the administration of 
muzolimine 40 mg per os to ten healthy volunteers at hour 0 
(0800 h). The graph has been evaluated as the time derivative of 
the function in the top panel. Any segment of area under the 
curve represents the amount of electrolytes excreted between the 
times that constitute the area limits.
Table 2. Numerical features of the functions M(t) accounting for the time courses of accumulated excretions of urinary variables and 
times from dosing to peak urinary flows to the variables derived as the t values at which d2M/dt2 = 0
Urinary Unit used in Medication Corre- Signif- Original Slope Time to
variable calculations lation of icance ordinates of peak
linearized of r value of lineariz- excretion
M(t) with lineariz- ed M (t)
respect 
to 0
ed M (t)
r P tl a b tmax
(hour) (hour) (hour)
Volume litre x 1CH Placebo for 
MUZ 20 & 30
0.9997 <0.001 0.0912 0.S68O 0.3633 4.64
Muzolimine 20 0.9998 <0.001 0.0452 0.5957 0.3778 3.17
Muzolimine 30 0.9998 <0.001 0.0307 0.4636 0.3730 2.44
Placebo for 
MUZ 40
0.9992 <0.001 0.1427 1.0728 0.3603 6.35
Muzolimine 40 >0.9999 <0.001 0.0308 0.3888 0.3873 1.96
Chloride mmol x 10 Placebo for 
MUZ 20 & 30
0.9997 <0.001 0.0701 0.7381 0.3950 3.43
Muzolimine 20 >0.9999 <0.001 0.0386 0.3972 0.4006 1.73
Muzolimine 30 >0.9999 <0.001 0.0231 0.2866 0.3884 1.47
Placebo for 
MUZ 40
0.9997 <0.001 0.0765 0.8060 0.3822 4.15
Muzolimine 40 >0.9999 <0.001 0.0221 0.2467 0.3901 1.23
Sodium mmol x 10 Placebo for 
MUZ 20 & 30
0.9995 <0.001 0.0878 0.8446 0.4005 3.92
Muzolimine 20 >0.9999 <0.001 0.0498 0.4690 0.4102 1.98
Muzolimine 30 >0.9999 <0.001 0.0278 0.3224 0.3992 1.48
Placebo for 
MUZ 40
0.9995 <0.001 0.0873 0.8785 0.3818 4.64
Muzolimine 40 > 0.9999 <0.001 0.0263 0.3083 0.3948 1.47
Potassium mmol Placebo for 
MUZ 20 & 30
0.9999 <0.001 0.0245 0.4876 0.3357 2.91
Muzolimine 20 0.9999 <0.001 0.0204 0.4031 0.3395 2.43
Muzolimine 30 0.9999 <0.001 0.0137 0.3369 0.3279 2.18
Placebo for 
MUZ 40
0.9998 <0.001 0.0346 0.5572 0.3371 3.40
Muzolimine 40 >0.9999 <0.001 0.0138 0.2975 0.3346 1.94
Magnesium mmol x 10_l Placebo for 
MUZ 20 & 30
0.9982 <0.001 0.0349 0.7184 0.3382 4.36
Muzolimine 20 0.9986 <0.001 0.0251 0.5409 0.3506 2.91
Muzolimine 30 0.9985 <0.001 0.0208 0.5212 0.3408 3.15
Placebo for 
MUZ 40
0.9989 <0.001 0.0355 0.7526 0.3358 4.60
Muzolimine 40 0.9990 <0.001 0.0176 0.4804 0.3401 2.90
Zinc mg x 10"2 Placebo for 
MUZ 20 & 30
0.9987 <0.001 0.0216 0.5785 0.3232 3.63
Muzolimine 20 0.9977 <0.001 0.0184 0.5583 0.3191 3.62
Muzolimine 30 0.9985 <0.001 0.0193 0.5340 0.3273 3.39
Placebo for 
MUZ 40
0.9982 <0.001 0.0213 0.6656 0.3166 4.59
Muzolimine 40 0.9985 <0.001 0.0167 0.5266 0.3258 3.38
Total mmol Placebo for 0.9992 <0.001 0.0821 0.9542 0.3610 5.35
inorganic MUZ 20 & 30
phosphate Muzolimine 20 0.9969 <0.001 0.0663 0.9733 0.3608 5.34
Muzolimine 30 0.9983 <0.001 0.0700 0.9527 0.3533 5.10
Placebo for 
MUZ 40
0.9995 <0.001 0.0951 1.0626 0.3514 6.32
Muzolimine 40 0.99-87 <0.001 0.0609 0.9245 0.3463 5.57
Continued Table 2
Urinary
variable
Unit used in 
calculations
Medication Corre­
lation of 
linearized 
M(l)
Signif­
icance 
of r 
with 
respect 
toO
Original 
ordinates 
value of 
lineariz­
ed M (t)
Slope
of
lineariz­
ed M (t)
Time to
peak
excretion
r P
(hour)
a
(hour)
b Imax
(hour)
Creatinine /imol Placebo for 
MUZ 20 & 30
0.9969 <0.001 0.0825 0.9916 0.3953 4.63
Muzolimine 20 0.9972 <0.001 0.1034 1.0577 0.4046 4.89
Muzolimine 30 0.9991 <0.001 0.0809 0.8213 0.3972 3.92
Placebo for 
MUZ 40
0.9984 <0.001 0.0896 1.0514 0.3914 5.36
Muzolimine 40 0.9980 <0.001 0.0821 0.9975 0.3942 4.87
MUZ = Muzolimine
H O U R S
Fig. 2. Mean accumulated Na+ flows after the separate adminis­
tration of placebo and of muzolimine 40 mg to ten healthy vol­
unteers at hour 0 (0800 h). Any segment of area between one of 
the curves and the time axis represents the amount of electrolyte 
excreted between the times that constitute the area limits. The 
How function after muzolimine 40 mg shows a natriuretic phase, 
where it is above the after-placebo Na+ flow curve, and an under­
shoot phase which follows, where the postmuzoliminc urinary 
sodium flow is below its after-placebo counterpart. Peak excre­
tions occurred 4.64 h after placebo and 1.47 h after muzolimine 
40 mg. The turning point is the first point after peak excretions 
where the functions after each formulation assume an equal val­
ue: this point marks the end of the natriuretic phase and the be­
ginning of the undershoot phase of the post-muzolimine urinary 
Na* flow.
i.e.. to a Na* flow level below that after placebo (Fi­
gure 2). This undershoot counterbalanced the ear­
lier natriuresis induced by muzolimine 40 mg to a 
great extent. All formulations of muzolimine accel­
erated the flows of fluid and of all solutes with 
respect to placebo (Table 2). However, fluid, Cl", Na" and K+ flows were accelerated more than the urinary Mg2* flows; muzolimine 20, 30 and 40 mg decreased the times to peak Mg2+ flow by 1.4, 1.2 
and 1.7 h with respect to placebo, whereas the corresponding values for urinary Na+ flows, which
were dose-related, were 1.9, 2.4 and 3.2 h respec­tively (Table 2).
Discussion
The mathematical method used for describing 
urinary flows has been discussed elsewhere (8). 
When all other parameter values are kept constant, 
higher t, and a and lower b values indicate lower 
rates of urinary flow. Time to peak excretion stands 
for a fixed relationship between t, a and b, since it 
is the time at which d:M/dt: = 0. Thus, time to 
peak excretion is an overall expression of the rate 
of urinary flow, and consequently has clear phy­
siological and mathematical meaning.
The fact that monodosing with muzolimine 20 mg did not increase the mean 24 h urinary output 
of fluid, Cl" and Na+ significantly, in this standard 
sample of healthy volunteers, disqualifies the for­mulation as an effective diuretic.
Muzolimine 30 mg induced significant increases in mean 24 h excretions of fluid, Cl" and Na+, and 
thus appears to be an effective diuretic formulation. 
The time-related pharmacodynamics were those of a loop diuretic (4) and consistent with the pharma­cokinetics of the drug (5), although the effects of 
muzolimine 30 mg on urinary excretion of fluid 
and electrolytes were slightly more prolonged than 
those of the loop diuretics furosemide 40 mg (11) 
and piretanide 12 mg (4).
Muzolimine 30 and 40 mg significantly increased urinary mean Na+ output with respect to placebo 
during the first 6 h after dosing (154% and 163% re­
spectively, Table 1). However, both formulations reduced the urinary mean Na+ output between 6 
and 24 h (-20% and -35% respectively, Table 1), as 
depicted in Figure 2 for muzolimine 40 mg. This undershoot in urinary Na+ flow, which occurs after the initial natriuretic response to all loop diuretics, 
would be caused principally by secondary hyper- aldosteronism and by an increase in serum anti­
diuretic hormone (ADH), since the renin-angio- 
tensin-aldosterone system and ADH secretion are 
activated by the prime renal effects of diuretics, and aldosterone and ADH attain a maximal 
concentration in plasma 4-6 h after the adminis­tration of a loop diuretic (6). The undershoot in 
natriuresis is usually accompanied by thirst and fluid reposition by the patients (A. J. Reyes, un­published). Appropriate manoeuvres during the natriuretic response to loop diuretics might speed 
the relief of oedema, and minimize the hormonal 
response and therefore the undershoot. If patients 
with gravitational oedema remain supine for 2 to 3 
h starting 1 h after the intake of muzolimine 30 mg, an increase in the amount of fluid and Na+ with­
in the vascular compartment could result when the diuretic-induced haemodynamic and metabolic 
shifts are stimulating the hormonal response; thus, 
natriuresis would be increased and the hormone- 
induced undershoot decreased.
Although muzolimine 30 mg did not increase 
the mean 24 h urinary K+ and Mg:+ output signif­
icantly. it accelerated their corresponding flows 
(Table 2). These accelerations, which were also present after muzolimine 20 and 40 mg, were dose- 
related. Perhaps if the sample size had been larger, muzolimine 30 mg would have provoked signif­
icant 24 h hvperkaliurcsis and hypermagncsiuresis; for this reason, the possibility that chronically ad­ministered muzolimine 30 mg could provoke K+ 
and Mg:+ depletion when should be considered and 
plasma concentrations of these cations should be monitored during treatment.After an initial rise in Mg:+ output with respect 
to placebo (52% increase during the first 6 h after 
dosing, Table 1), muzolimine 30 mg caused an un­dershoot in magnesiuresis (8% decrease in output 
between 6 and 24 h post dosing, Table 1). This counterbalance could be due to increased parat­
hormone (PTH)-dependent reabsorption of Mg2+ in 
the loop of Henle (9), because loop diuretics aug­
ment renal Ca:+ excretion and thus reduce plasma 
free Ca2+ and elevate plasma PTH (7). In any event, 
comparisons between the present results and those 
of similar experiments where the loop diuretic fur- osemide 40 mg and the distal tubular diuretics clor- exolone 10 mg, chlorthalidone 100 mg, hydro­chlorothiazide 50 mg and xipamide 5, 10 and 20 
mg were studied under similar experimental cir­
cumstances (9), indicate that muzolimine 30 mg 
may be safer than the above formulations, all of which provoked mean increases in 24 h urinary Mg:+ excretion which were statistically significant 
and of a greater magnitude than the small percen- 
tual rise induced by muzolimine 30 mg.
All doses of muzolimine delayed urinary Mg2+ flows with respect to urinary Na+ flow. This phe­
nomenon occurs after all hypermagnesiuretic 
diuretics, whether they be loop or distal tubular 
substances (9), and confirms Mg:+ and Na+ are han­
dled to a great extent independently by the kidney. 
The processes underlying this delay have not been 
fully elucidated though they would appear to be, at 
least partly, endocrine in nature (8).
The fact that muzolimine did not affect 24 h 
urinary Zn2+ output could be expected on the basis 
that loop diuretics, unlike distal tubular drugs (13), 
do not cause hyperzinciuria.
References
1. Dyckner T. Wester PO (1981) Relation between potassium, 
magnesium and cardiac arrhythmias. Acta Med Scand Suppl 
647:163-169
2. Hanisch M (1983) Pharmacodynamic studies with muzol­
imine in healthy volunteers: an overview. Clin Nephrol 19: 
S32-36
3. GarthofT B. Hanisch M (1984) Muzolimine. In: Scriabine A 
(ed.) New Drugs Annual: Cardiovascular Drugs. Vol 2. Ra­
ven Press New York, p 51 -70
4. Leary WP, Reyes AJ, Venter CP. Blake GW (1981) Mathe­
matical description of diuresis after oral administration of 
piretanidc. furosemide and placebo to healthy adults. Curr 
Thcr Res 29: 249-252
5. Loew D. Ritter W, Dvcka J (1977) Comparison of the phar­
macodynamic effects of furosemide and BAY g 2821 and 
correlation of the pharmacodynamics and pharmacokinetics 
of BAY g 2821 (muzolimine). Eur J Clin Pharmacol 12: 
341-344
6. Ogawa K, Hatano T, Yamamoto M. Matsui N (1984) Hor­
monal response to acute diuresis -  a comparative study of 
furosemide and azosemide. Int J Clin Pharmacol Ther Toxi­
col 22 :284-290
7. Ogawa K, Hatano T, Yamamoto M. Matsui N (1984) In­
fluence of acute diuresis on calcium balance -  a comparative 
study of furosemide and azosemide. Int J Clin Pharmacol 
Ther Toxicol 22: 401 -405
8. Reyes AJ, Leary WP (1981) A mathematical model for the 
clinical pharmacology of diuretics. Curr Ther Res 30: 
227-235
9. Reyes AJ, Leary WP (1984) Diuretics and magnesium. Ma­
gnesium-Bull 6 :8 7 -9 9
10. Reyes AJ, Leary WP (1983) Pathogenesis of arrhythmogenic 
changes due to magnesium depletion. S Afr Med J 64: 
311-312
11. Reyes AJ, Leary WP (1982) The magnesiuric effect of a sin­
gle dose of furosemide in healthy adults. Curr Ther Res 32: 
406-416
12. Reyes AJ. Leary WP, Asmal AC (1980) Urine volumes and 
flows after oral administration of xipamide, furosemide and 
hydrochlorothiazide to healthy adults. Curr Ther Res 28: 
230-234
13. Reyes AJ, Leary' WP, Lockett CJ, Alcocer L (1983) Diure­
tics and zinc. S Afr Med J 62: 373-375
14. Sheehan J, White A (1982) Diuretic associated hypomagnes- 
aemia. B rM ed J  285: 1157-1159
A uthors’ address:
Prof. W. P. Leary, P.O.Box 17039, Congella 4013 (South A fri­
ca)
SECTION D : CARDIOVASCULAR EFFECTS OF MEDICINES
Many medicines used in the treatment of a variety of 
conditions also have some effect upon arterial blood 
pressure. The papers which follow describe the 
cardiovascular effects of drugs used in the course of general 
anaesthesia, the treatment of bronchial asthma and angina or hypertension. Clinically significant changes in blood 
pressure, cardiac output, pulse rate or peripheral resistance 
are possible when these medicines are administered to 
patients with healthy cardiovascular systems and it is 
important that medical practitioners be aware of the possible 
occurrence of such changes both in normotensive and hypertensive patients.
Cardiovascular Effects of Salbutamol: A Comparison with 
Isoprenaline
The technical expertise required to measure cardiac output 
was provided by Professor A.J. Coleman. Intubation of 
arteries was a shared procedure as was the analysis of data 
and preparation of the publication. The protocol followed 
was a joint venture.
Cardiovascular Effects of Salbutamol:
A Comparison with Isoprenaline*
A. J. C O L E M A N ,  m.b. b.s . univ. lond., f .f.a. r.c.s . eng., Professor o f Anaesthetics and W .  P. L E A R Y ,  
m.sc., m.b. b.ch. univ. rand, d .phil. univ. oxon., F.c.p. (s.A.), m .r.c.p . lond., Senior Lecturer, Division  
o f Pharmacology, Faculty o f M edicine, University o f Natal, Durban
SUMMARY
The immediate cardiovascular effects of inhaled saibuta- 
mol (2 0 0  /J.q) and an isoprenaline-phenylephrine (80 
jxg, 120 ju.g) mixture have been compared. Both drugs 
were administered by pressurized aerosol to normal 
volunteers. Significant increases in pulse rate and cardiac 
output and a decrease in peripheral vascular resistance 
followed inhalation of the isoprenaiirie-phenylephrine mix­
ture. No such changes were noted after salbutamol.
S. Afr. Med. J., 46, 1177 (1972).
In recent years it has been suggested that a link exists 
between deaths from bronchial asthma and the use of
•Date received: 15 F eb ru ary  1972.
pressurized aerosols containing sympathomimetics.1'* The 
precise nature of this link has not been established, but 
the cardiac effects of nonselective /3-adrenergic stimulants 
such as isoprenaline, m a y  be involved.2-'*
Salbutamol is a potent bronchodilator with 
little effect upon the 0-adrenoreceptors of the
heart at clinically effective doses.3-* The effects of 
salbutamol and isoprenaline on pulse rate and arterial 
pressures are well documented,*'7 as is the effect of iso­
prenaline on cardiac output, but the effects of inhaled 
salbutamol on cardiac output have not been adequately 
studied in man. In this study a comparison has been 
made between the effects on pulse, blood pressure, and 
cardiac output of salbutamol, and a preparation con­
taining isoprenaline hydrochioride and phenylephrine 
bitartrate, when administered by inhalation.
METHODS
Cardiac output, arterial pressure, and pulse rate were 
measured in 5 healthy volunteers, by previously described 
techniques.'1 Pressures were recorded continuously by 
Statham gauge and cardiac output was measured by dye 
dilution using a Philips X O  1000 oximeter/densitometer. 
These measurements were recorded 5 and 10 minutes after 
a 15-minute rest in the laboratory, and again 5, 10 and 15 
minutes after the inhalation of placebo, 0,2 m g  salbutamol, 
or a mixture of 0,08 m g  isoprenaline hydrochloride and 
0,12 m g  phenylephrine bitartrate. This represented twice 
the normally recommended dose of each agent, and was 
given to simulate the kind of misuse that m a y  commonly 
occur during a severe episode of bronchospasm. The 
bronchodilators were used in random order, 4 hours apart. 
Each subject was carefully instructed in the correct tech­
nique of inhalation. Rest periods and control measure­
ments, as described above, preceded the inhalation of each 
sympathomimetic.
Stroke volume and total systemic arterial resistance 
were calculated mathematically. Tests of statistical sig­
nificance were applied to the mean differences in mea­
surements made before and 5, 10 and 15 minutes after 
inhalations of the drugs studied. Student's r-test was 
applied to the paired comparisons.
RESULTS
Detailed results are set out in Tables I - IV.
Placebo effect: N o  changes in pulse rate, mean arterial 
pressure, cardiac output, stroke volume, and peripheral 
vascular resistance, were noted after inhalation of placebo.
Salbutamol: N o  significant changes in mean arterial 
pressure, cardiac output, pulse rate, peripheral vascular 
resistance, and stroke volume, were noted.
Isoprenaline with phenylephrine: N o  significant changes 
in stroke volume, and mean arterial pressure occurred.
TABLE I. THE EFFECT OF ISOPRENALINE-PHENYLEPHRINE MIXTURE UPON HEART RATE, BLOOD PRESSURE AND
CARDIAC OUTPUT
Heart rate (beats/min) Mean blood pressure (mmHg) Cardiac output (L./min)
Min after inhalation Min after inhalation Min after inhalation
Subject
No.
Con­
trol +5 +10 +  15
Con­
trol + 5 +  10 +  15
Con­
trol + 5 + 10 +  15
1 71 75 72 71 77 80 76 72 7,5 7,0 7,4 7,4
2 71 83 83 88 86 84 80 80 4,4 5,9 6,0 6,7
3 58 71 64 65 93 100 100 94 4,7 6,9 6,1 6,9
4 69 79 79 75 95 76 78 76 6,0 7,5 6,8 6,1
5 80 100 83 83 107 100 100 100 5,0 5,9 6,6 4,4
Mean 70 82 76 76 92,0 88,0 87,0 84,0 5,5 6,6 6,6 6,3
SD 7,9 11,2 8,2 9,2 11,1 11,3 12,1 12,0 1,3 0,7 0,6 1,2
SEM 3,1 4,5 3,3 3,7 4,5 4,5 4,9 4,8 0,5 0,3 0,2 0,5
t
Signifi­
cance of 
diff. from
5,121 3,466 2,568 0,892 1,365 2,468 2,758 3,667 1,431
control P<0,01 P<0,05 NS NS NS NS NS P<  0,025 NS
TABLE II. THE EFFECT OF ISOPRENALINE-PHENYLEPHRINE MIXTURE UPON PERIPHERAL VASCULAR RESISTANCE
AND STROKE VOLUME
Peripheral vascular resistance (dynes/sec cm'5) Stroke volume (ml)
Min after inhalation Min after inhalation
Subject No. Control +5 + 10 +  15 Control + 5 +  10 + 15
1 837 914 822 778 103 93 103 104
2 1 572 1 139 1 067 955 62 71 72 76
3 1 599 1 159 1 312 1 090 100 87 83 90
4 999 811 918 997 88 95 86 81
5 1 719 1 356 1 212 1 818 62 59 80 53
Mean 1 345 1 075 1 066 1 128 83 81 85 81
SD 398,0 215,5 202,0 402,0 20,2 15,5 11,4 18,8
SEM 159,2 86,2 80,8 160,8 8,1 6,2 4,6 7,5
t 3,080 3,029 1,086 0,546 0,301 0,602
Significance of
diff. from
control P<0,05 P<0,05 NS NS NS NS
TABLE III. THE EFFECT OF SALBUTAMOL UPON HEART RATE, BLOOD PRESSURE AND CARDIAC OUTPUT
H ea rt ra te  (beats/m in) M ean b lood p re ssu re  (mm Hg) C a rd ia c  ou tput (l/m in)
Sub ject M in  a fte r inha la tion M in a fte r inha la tion M in  a fte r inha la tion
No. C o n tro l + 5 +  10 +  15 C o n tro l + 5 +  10 +  15 C o n tro l + 5 +  10 +  15
1 60 58 56 54 77 76 74 76 6,2 5,6 5,4 5,6
2 79 79 83 75 73 80 78 76 5,2 5,9 5,5 5,0
3 64 63 63 65 104 100 100 100 5,5 5,8 6,4 6,0
4 74 75 68 71 87 88 84 84 6,5 6,0 6,2 6,3
5 63 68 58 63 97 100 100 102 4,8 5,2 4,9 6,3
Mean 68 69 66 66 88 89 87 88 5,6 5,7 5,7 5,8
SD 8,1 8,6 10,8 8,0 13,1 11,1 12,2 12,7 0,7 0,3 0,6 0,6
SEM 3,2 3,4 4,3 3,2 5,2 4,4 4,9 5,1 0,3 0,1 0,2 0,2
t 0,555 1,486 2,083 0,723 0,244 0,000 0,260 0,157 0,606
Signifi-
cance of
diff. from
control NS NS NS NS NS NS NS NS NS
TABLE IV. THE EFFECT OF SALBUTAMOL UPON PERIPHERAL VASCULAR RESISTANCE AND STROKE VOLUME
P e r ip h e ra l v a s c u la r  re s is ta n ce  (dynes se c  c m '5) S tro k e  vo lum e  (ml)
M in a fte r in ha la tion M in a fte r inha la tion
Sub je ct No. C o n tro l +5 +  10 +  15 C o n tro l -f5 +  10 +  15
1 996 1 086 1 096 1 086 104 97 96 104
2 1 123 1 085 1 135 1 216 67 75 66 67
3 1 517 1 379 1 250 1 333 86 92 102 92
4 1 074 1 173 1 050 1 067 88 80 91 89
5 1 637 1 537 1 633 1 295 76 77 85 100
Mean 1 269 1 252 1 233 1 199 84 84 88 90
SD 287,6 200,1 235,7 120,1 13,9 9,7 13,8 14,4
SEM 115,0 80,0 94,3 48,1 5,6 3,9 5,5 5,8
t 0,39 0,666 0,925 0,000 1,032 1,511
Significance
of diff. from
control NS NS NS NS NS NS
An increased pulse rate was noted at 5, 10 and 15 minutes. 
This change was significant at 5 (P<0,01) and 10 minutes 
(P<0,05). Peripheral vascular resistance fell, but this, 
too, was significant only 5 and 10 minutes after using the 
aerosol (P<0,05).
There was a mean increase in cardiac output of 18,2% 
during the 15-minute period after inhalation of the iso- 
prenaline-phenylephrine mixture. This change was sig­
nificant at 10 minutes ( P < 0,025).
ticularly in patients with limited cardiac reserve. In 
anaesthetized animals these effects m a y  lead to cardiac 
arrest.10 In the experiments reported here, salbutamol, 
unlike isoprenaline, did not stimulate cardiac /3-adreno­
receptors and thus appears unlikely to cause serious 
cardiac arrhythmias when it is given by aerosol inhalation. 
It must be stressed, however, that the relevance of such 
arrhythmias has recently been questioned,11 and that the 
development of resistance to bronchodilators m a y  also 
contribute to the death rate from asthma.
DISCUSSION
The efficacy of inhaled salbutamol as a bronchodilator 
is well established. S ome of its effects on the cardio­
vascular system have been reported,1'1 but to date cardiac 
output has not been measured directly in normal subjects.
Positive inotropic and chronotropic stimulation of the 
heart increases the metabolic demand for oxygen, which 
may not be met by patients with impaired gaseous ex­
change. L o w  arterial oxygen tensions m a y  be worsened 
in asthmatics, even though airway obstruction is re­
versed,6’” thereby further aggravating the situation, par-
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The Immediate Cardiovascular Effects of Pancuronium, 
Alcuronium and Tubocurarine In Man
The clinical work described was shared by the authors as was 
preparation of the manuscript.
The immediate cardiovascular effects of 
pancuronium, alcuronium and tubocurarine in man
A. J. Coleman J. W. Downing W. P. Leary D. G. Moyes M. Styles
Previous studies in man on the cardiovascular effects of the muscle 
relaxant pancuronium have been conflicting. Kelman & Kennedy1 found 
a significant increase in heart rate, blood pressure and cardiac output. 
McDowell & Clark2 and Kolliker3, reported a fall in blood pressure with 
no change in heart rate. Baird & Reid4 and Fastner & Agoston5, found no 
significant effect on the heart rate and blood pressure and Loh6 found that 
pancuronium increased both blood pressure and heart rate.
The discrepancies between their reports can be reasonably attributed to 
differences in methods of study. There were differences in premedication 
and in the degree of surgical stimulation. Measurements were sometimes 
made during endotracheal intubation7, which is a procedure well known 
to cause tachycardia8 and several patients were receiving digitalis. Arterial 
carbon dioxide levels were not always controlled and some studies were 
performed upon patients receiving volatile anaesthetic agents. There have 
also been discrepancies too, for similar reasons, in reports on the cardio­
vascular effects of tubocurarine and alcuronium9-13.
In evaluating a new drug it is useful to compare it with established agents 
which fulfil similar roles in clinical practice. In this study pancuronium, a 
relatively new drug, has been compared with tubocurarine and alcuronium 
administered in similar circumstances. There are no previous reports of 
this nature so far as the authors are aware and, to our knowledge, no data 
on the a b s o l u te  l e v e l  of cardiac output in man following the administration 
of muscle relaxants has been revealed by a study of the literature.
M A T E R I A L
Twenty-eight unpremedicated patients, who gave their consent, were 
investigated prior to elective minor surgery. All patients were males aged
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25 to 36, who weighed between 52 and 67kg and were between 160 and 
170cm in height. No clinical evidence of cardiopulmonary disease was 
found in any case.
M E T H O D
Radial artery and right atrial catheters were inserted in all patients under 
local analgesia when they arrived in the operating theatre and the patients 
were then left undisturbed for a period of twenty minutes prior to the 
induction of anaesthesia.
Pressures were recorded continuously by Statham gauge, and cardiac 
output was measured at 5 minute intervals by dye dilution, using a Philips 
XO 1000 Oximeter/Densitometer. Blood required for estimating acid base 
and blood gas status was drawn from the arterial catheter 10 and 25 min­
utes after induction of anaesthesia.
Anaesthesia was induced in all patients by giving 200mg of 2.5% thio­
pentone intravenously over a period of twenty seconds. All patients 
received 50mg suxamethonium intravenously to facilitate spraying of the 
vocal cords and glottis with 1ml 4% lignocaine, and intubation of the 
trachea. Continued apnoea was achieved by giving the patients 0.2mg of 
fentanyl initially, followed by 0.05mg every 15 minutes. Patients were 
connected to a Manley respirator delivering an expired minute volume of 
5 litres (3.5 litres of nitrous oxide, 1.5 litres of oxygen).
Patients were then assigned to one of five groups in random fashion. 
Three patients (group 1) served as controls and received no further muscle 
relaxant drugs. Ten patients (group 2) received 6mg of pancuronium 
(approximately O.lmg/kg). Five patients (group 3) received atropine 1.2mg 
and 6mg of pancuronium. Five patients (group 4) received 30mg of tubo- 
curarine (approximately 0.5mg/kg). Five patients (group 5) received 15mg 
of alcuronium (approximately 0.25mg/kg). The muscle relaxants used in 
this study were supplied in ampoules and contained no preservatives. All 
drugs were administered intravenously.
The doses of muscle relaxant (groups 2-5), were considered as represent­
ative of the usual intubating dose, and were given upon completion of a 
20 minute control period following induction of anaesthesia. Observations 
continued thereafter for a further period of 15 minutes.
Patients in group 3 were managed in identical manner to group 2 except 
1.2mg atropine was given intravenously 10 minutes after induction of 
anaesthesia.
At the conclusion of each experiment the cardiac output densitometer 
was calibrated using the patient’s own blood and known doses of cardiac 
green. Cardiac output was calculated using the method of Williams e t  
a/14, to prepare an appropriate programme for the Olivetti 101 computer.
Total peripheral resistance (p v r ) was calculated from the formula of 
Aperia15.
P V R = m e a n  arterial pressure ( m m  Hg) 
cardiac output (litres/min) X  80 dynes sec c m -5
Tests of statistical significance were applied to the mean differences in 
measurements made before and after injection of muscle relaxants by 
applying Student’s t-test to the paired comparisons.
R E S U L T S
B l o o d  g a s e s  a n d  p H  m e a s u r e m e n t s
In all groups the mean arterial pH, arterial carbon dioxide tension (Paco 2) 
and arterial oxygen tensions P a c >2 taken 10 minutes after the induction of 
anaesthesia were within normal limits for patients under anaesthesia. The 
values were as follows: pH 7.35 to 7.46 (mean 7.39), P a c o 2 30 to 45mm Hg 
(mean 35), and P a o 2 130 to 180 (mean 150). Comparison with measure­
ments taken 15 minutes later revealed no greater changes than 0.05 in pH, 
4mm Hg in P a c o  2 and 30mm Hg in P a o 2.
C a r d io v a s c u la r  m e a s u r e m e n t s  in  g r o u p  1 ( c o n t r o l  p a t i e n t s )
There were no significant changes in the three control patients.
C a r d io v a s c u la r  m e a s u r e m e n t s  in  g r o u p s  2  to  5  { r e l a x a n t p a t i e n t s )
The results in the relaxant groups are set out in tables 1 to 4. Control 
values are the mean of observations made in the anaesthetised patients 0, 
5, 10 and 15 minutes prior to the administration of the muscle relaxant 
drugs.
Changes in the measurements began 20 seconds after the administration 
of the relaxant drugs and were complete in 45 seconds; thereafter a new 
steady state existed until the studies were discontinued 15 minutes later.
G r o u p  2  P a n c u r o n iu m  a lo n e  (table 1). There was a significant increase in 
heart rate (7 to 10 beats per minute) and a significant increase in mean 
blood pressure (13 to 14mm Hg). The mean central venous pressure (c v p ) 
fell significantly by 2mm Hg, and cardiac output increased significantly by 
1 litre/minute. Neither systemic vascular resistance nor stroke volume 
changed.
G r o u p  3  P a n c u r o n iu m  a f t e r  a t r o p in e  (table 2). The administration of 
1.2mg atropine produced a significant increase in heart rate, blood pressure 
and cardiac output. Central venous pressure and peripheral vascular 
resistance were significantly reduced. No further changes were seen after 
administration of pancuronium.
t a b l e  1
Observation Control
Minutes after pancuronium M e a n
maximum
change+5 +  10 +  15
Heart rate (beats/min) 60.5 67.8[| 68.5|| 70.2|| +  9.9
S E M 2.3 2.4 2.6 2.4 1.2
M e a n  blood pressure
( m m  Hg) 73.8 86.0J 86.7J 87.211 +  14.8
S E M 3.2 5.1 4.9 4.8 3.1
Central venous pressure
( m m  Hg) 5.7 4.111 3.5|| 3.9|| —  2.3
S E M 0.67 0.6 0.6 0.5 0.4
Cardiac output
(litres/min) 5.6 6.7|| 6.7|| 6.7|| +  1.2
S E M 0.37 0.5 0.5 0.5 0.2
Peripheral vascular
resistance (dynes/sec-5) 1083 1026 1035 1044 —  -45
S D 218 233 237 234 8.0
Stroke volume (ml) 92 99 98 95 +  5
S D 8 7 8 8 1.0
Significance levels: P<0.05*; P<0.025f; PcO.OlJ; P<0.005lf; P <0.0011|
The mean maximal change in individual patients is given without regard fo r  time
t a b l e  2
Control
period
one
Minutes after atropine Minutes after pane:uronium
Observation
+ 5
control 
+ 1 0  period 
(two)
+ 5 + 1 0 + 1 5
Heart rate 
(beats/min) 69.3 101.2H 101.0H 101.6 100.0 100.0
S E M 6.0 7.0 6.9 8.9 8.0 8.0
M e a n  blood 
pressure 
( m m  Hg) 78.8 95.0* 86.8 89.4 87.0 87.6
S E M 6.2 6.6 3.2 5.3 4.8 4.3
Central venous 
pressure 
( m m  Hg) 7.1 4.6* 5.3 4.8 4.8 4.8
S E M 1.3 0.5 0.7 0.7 0.7 0.7
Cardiac output 
(litres/min) 4.4 6.4|| 6.6|| 6.6 6.4 6.3
S E M 0.5 0.4 0.5 0.6 0.3 0.3
Peripheral
vascular
resistance
(dynes/sec-5) 1432 1188* 1052* 1084 1088 1099
S D 231 202 217 178 184 200
Stroke volume 
(ml) 63 63 65 65 64 63
S D 10 12 14 13 12 14
Significance levels: P<0.05*; P<0.025f; P<0.01J; P<0.005H; P < 0.0011| 
The mean maximal change in individual patients is given without regard to time
G r o u p  4  A l c u r o n i u m  a lo n e  (table 3). There was a significant increase in 
heart rate of 13 beats/minute and a significant drop of mean blood pressure 
of 9 to 10mm Hg. The mean central venous pressure fell significantly by
0.7mm Hg. Cardiac output increased but this was not significant. Peri­
pheral vascular resistance fell significantly by 150 to 250 dynes sec cm-5. 
The stroke volume declined insignificantly.
G r o u p  5  T u b o c u r a r in e  a lo n e  (table 4). There was a significant increase
TABLE 3
Observation Control
Minutes after alcuronium Mean
maximum
change+ 5 +10 +15
Heart rate (beats/min) 71.7 84.211 84.9H 84.51J +  13.5
SEM 6.9 6.5 6.5 6.3 1.1
Mean blood pressure
(mm Hg) 85.1 74.6J 75.0| 76.0 -8.7
SEM 5.1 4.0 4.1 5.0 2.7
Central venous pressure
(mm Hg) 5.3 4.6f 4.6f 4.6f — 1.9
SEM 0.9 0.6 0.6 0.6 0.3
Cardiac output
(litres/min) 4.6 4.8 5.0 5.0 +  0.6
SEM 0.3 0.4 0.4 0.3 0.1
Peripheral vascular
resistance (dynes/sec-5 ) 1486 1243* 1200* 1216* —250
SD 150 157 200 120 20.0
Stroke volume (ml) 65 57 59 60 — 3
SD 7 6 4 5 0.5
Significance levels: P<0.05*; P<0.025f; PcO.OlJ; P<0.0051[; P < 0.0011|. 
The mean m axim al change in individual p a tien ts  is given without regard  fo r  tim e
table 4
Observation Control
Minutes after tubocurarine Mean
maximum
change+ 5 +10 +15
Heart rate (beats/min) 68.1 74.0| 74.4t 71.4* +7.9
SEM 2.4 3.7 4.2 3.6 1.5
Mean blood pressure
(mm Hg) 77.1 63.4* 65.8* 65.5* — 17.5
SEM 2.8 6.2 3.2 4.1 5.0
Central venous pressure
(mm Hg) 4.3 2.6* 2.3* 2.5* —2.3
SEM 1.1 1.0 1.1 1.2 0.7
Cardiac output
(litres/min) 3.6 3.6 3.7 3.6 0.1
SEM 0.2 0.6 0.5 0.4 0.01
Peripheral vascular
resistance (dynes/sec-5 ) 1713 1408* 1422* 1456* —300
SD 150 120 170 145 35.0
Stroke volume (ml) 53 49 49 50 —5
SD 7 8 8 10 0.5
Significance levels: P<0.05*; P<0.025f; PcO.OlJ; P<0.005H; P <0.0011|.
The mean m axim al change in individual p a tien ts  is  given  w ithout regard  f o r  tim e
in heart rate of 3 to 6 beats/minute and a significant drop in mean blood 
pressure of 12 to 14mm Hg. Central venous pressure fell significantly about 
2mm Hg. There was no change in cardiac output. The peripheral vascular 
resistance fell by about 300 dynes sec cm-5. Stroke volume fell insignifi­
cantly.
DISCUSSION
The absence of systematic changes after induction of anaesthesia in group 
1 patients, who received no muscle relaxant, confirms that changes record­
ed in groups 2 to 5 were due to the muscle relaxants; with the exception of 
Kelman & Kennedy1*9 few previous clinical investigators have presented 
data on control groups but, if valid conclusions are to be drawn, such 
studies appear essential in view of the many factors which may influence 
cardiovascular responses in anaesthetised man.
In a study on pancuronium in ten patients premedicated with papavere- 
tum and hyoscine, Kelman & Kennedy1 reported a 25 % rise in heart rate, 
9 % rise in arterial pressure and an 8 % increase in cardiac output with 
peripheral vascular resistance unchanged. In this study slightly larger doses 
of pancuronium in unpremedicated patients (group 2), produced in­
creases of 16% in pulse rate, 20% in blood pressure and 19% in cardiac 
output. These changes did not occur when the pancuronium was preceded 
by atropine (group 3); this suggests that the cardiovascular effects of pan­
curonium are mainly due to vagolytic activity, which supports the hypo­
thesis first advanced by Kelman & Kennedy k
Kelman & Kennedy9 have also investigated the cardiovascular effects 
of alcuronium. In five premedicated patients they reported no change in 
arterial pressure, 9% increase in heart rate, and an initial 10% increase in 
cardiac output followed 8 minutes later by a 6 % reduction. They reported 
a 12% reduction in peripheral vascular resistance which returned to con­
trol levels after 5 minutes. The results reported above are different. There 
was an 18% increase in pulse rate, a 14% reduction in arterial blood 
pressure and a 17 % fall in peripheral vascular resistance after the injection 
of alcuronium. It should be realised, however, that larger doses of alcuron­
ium (0.2mg/kg) were given in the present investigation in keeping with 
current clinical practice, that patients were unpremedicated and that 
cardiac output was measured directly and a possible source of inaccuracy 
in the method used by Kelman & Kennedy1*9 was thus avoided. In their 
study relative changes in cardiac output were determined from the dye 
curves of a non-calibrated earpiece densitometer which is a method liable 
to errors consequent upon changes in pinna blood volume.
Interpretation of previous reports on the cardiovascular effects of tubo- 
curarine is difficult because other factors known to influence cardiovascular 
stability were present. In many investigations no attempts were made to
control alterations in cardiac output consequent upon changes in arterial 
carbon dioxide level16, and frequently cardiovascular effects have been 
attributed to tubocurarine in patients anaesthetised with halothane or 
pethidine, either of which might have confused the results. In the present 
study tubocurarine was associated with a 9% increase in pulse rate, 18% 
fall in arterial pressure, 17 % fall in peripheral vascular resistance, and no 
change in cardiac output. It was not possible to demonstrate significant 
differences between the cardiovascular effects of tubocurarine and 
alcuronium.
The ideal muscle relaxant would be a drug which produces relaxation of 
skeletal muscle with no side effects whatsoever. If its cardiac accelerator 
action is disregarded pancuronium emerges as closest to this ideal at the 
present time and, relative to tubocurarine and alcuronium, appears to be 
the best non-depolarising muscle relaxant currently available.
S U M M A R Y
The cardiovascular effects of pancuronium, alcuronium and tubocurarine 
have been investigated in unpremedicated patients prior to elective minor 
surgery.
Heart rate, arterial and central venous pressures and cardiac output were 
measured in 28 patients after induction of anaesthesia and after the 
intravenous injection of clinically equivalent doses of one of three muscle 
relaxants in 25 patients. A control group of three patients were given no 
muscle relaxant drugs and served as controls.
There was no significant change in measurements made after induction 
of anaesthesia in the control patients. Pancuronium was associated with a 
significant increase in heart rate, blood pressure and cardiac output, but 
did not effect peripheral vascular resistance. These responses were com­
pletely inhibited by intravenous atropine. Alcuronium and tubocurarine 
were both associated with a significant increase in heart rate and falls in 
blood pressure and peripheral resistance.
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The immediate cardiovascular effects of Althesin 
(Glaxo CT 1341), a steroid induction agent, and 
thiopentone in man
A. J. Coleman J. W. Downing W. P. Leary D. G. Moyes M. Styles
The steroid anaesthetic agent, Althesin (Glaxo CT 1341), was first des­
cribed in 1971 by Child e t  a l . 1. Campbell e t  a l . 2 introduced the drug into 
clinical practice and reported its effects upon the cardiovascular system of 
six patients with major cardiac disease. Cardiovascular effects were also 
studied by Savege e t  a l .3 in healthy unpremedicated patients prior to 
surgery.
In this study some acute effects of Althesin upon the cardiovascular 
system have been investigated in healthy unpremedicated patients prior to 
surgery and compared with the effects of thiopentone in similar circum­
stances.
M E T H O D S
Twenty-three unpremedicated patients, who gave their consent, were 
investigated prior to elective minor surgery. All were males, aged between 
25 and 35 years, who weighed between 52 and 68kg, and were between 165 
and 175cm in height. No clinical evidence of cardiopulmonary disease was 
found in any case.
Two dose levels of Althesin were used. Ten patients (group 1) received 
0.15ml/kg of Althesin (approximately 10ml) and five patients (group 2) 
were given 0.06ml/kg (approximately 4ml). A further eight patients (group 
3) were given thiopentone 4mg/kg (approximately 250mg).
The dose levels of Althesin used in this study were based on our initial 
experience with the drug and upon the sleep dosages suggested by others 
(0.06ml/kg by Clarke e t  a l . 4 and 0.15ml/kg by Campbell e t  a l . ) 2 . The 4mg/ 
kg dose level of thiopentone was adopted because it is regarded as equi-
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potent with 0.06ml/kg Althesin5. Both drugs were given intravenously 
over a period of 20 seconds.
Pressures were measured electrometrically by Statham gauge and car­
diac output by dye dilution, using a Philips XO 1000 Oximeter/Densito- 
meter. Arterial oxygen saturation was measured at the same time as 
cardiac output. A lead 1 electrocardiograph and arterial and venous 
pressures, were recorded on a Philips 3T Cardiopan recorder. Radial 
artery and right atrial catheters were inserted in all patients under local 
analgesia on arrival in theatre. Patients were left undisturbed for a period 
of ten minutes following introduction of the catheters. Control measure­
ments were then made at three minute intervals for a period of nine 
minutes.
Anaesthesia was induced by giving an intravenous injection of either 
Althesin (groups 1 and 2), or thiopentone (group 3). The patients breathed 
air throughout the investigation and airways were carefully maintained 
until completion of the subsequent surgical procedures.
Measurements were made 1, 3, 6 and 9 minutes after induction before 
routine inhalational anaesthesia was introduced prior to surgery. Some 
patients began to regain consciousness before the end of the nine minute 
period; in such cases measurements were discontinued and inhalational 
anaesthesia was started.
Aliquots of each patient’s blood containing known doses of indo­
cyanine green (cardiac green) were used to calibrate the cardiac output 
densitometer at the end of each study under conditions prevailing during 
the actual experiment. Cardiac output was calculated from dye curves 
using the method of Williams e t  a l . 6 to prepare the appropriate programme 
for an Olivetti 101 computer.
Total peripheral resistance (p v r ) was calculated from the formula of  
Aperia7.
P V R m e a n  arterial pressure ( m m  Hg) 
cardiac output (litres/min) x 80 dynes sec c m -5
Tests of statistical significance were applied to the mean differences in 
measurements made before and after induction of anaesthesia by applying 
Student’s t-test to the paired observations.
Differences between CT 1341 and thiopentone were sought by comparing 
the recorded changes consequent upon induction of anaesthesia by the 
two drugs.
R E S U L T S
Results are set out in tables 1, 2 and 3. The control values shown in the 
tables are the mean of observations made in each patient 9, 6, 3 and 1 
minutes prior to induction of anaesthesia.
G r o u p  1 , A l t h e s i n  0 .1 5 m l / k g  ( t a b l e  1)
There was a significant increase in heart rate at 1, 3 and 6 minutes after 
injection. The maximum increase in heart rate (mean 21.8 beats per 
minute) occurred in all patients within three minutes of the injection of 
the drug. There was a consistent fall in arterial blood pressure which was 
significant at each period of measurement. The drug was generally asso­
ciated with a fall in central venous pressure, but this was only significant 
at the end of the ninth minute. The cardiac output increased insigni­
ficantly by a mean amount of 200ml per minute.
Peripheral vascular resistance was significantly reduced at each period 
of measurement. Arterial oxygen saturation fell significantly at one and 
three minutes after induction, but returned to pre-induction values in every 
patient after the elapse of nine minutes.
TABLE 1
Minutes after injection Mean
Ob servation Control
+  1 + 3 + 6 + 9
maximum
change
Heart rate (beats/min) 85.6 107.3tt 99.2^ 99.8n(9) 103.4(7) +21 8
SEM 6.56 6.25 4.39 4.59 3.49 2.79
Mean blood pressure (mm Hg) 96.1 74.9tt 77.4ft 75.0ff(9) 75.7$(6) —24.1
SEM 3.18 3.24 2.76 3.18 4.82 3.0
Mean venous pressure (mm Hg) 4.2 4.0 4.0 4.5(6) 2.4f(7) —0.86
SEM 0.47 0.57 0.44 0.38 0.49 0.02
Cardiac output (Iitres/min) 6.75 6.9 7.0 6.8(7) 7.1(4) + 0 .2
SEM 0.48 0.46 0.42 0.51 0.67 001
Peripheral vascular
resistance (dynes/sec-3) 1205 915tt 939ft 917ff(7) 901ff(4) —325
SEM 108.9 81.8 86.6 112.6 124.5 48.9
Arterial oxygen saturation % 95.6 88. I l l 89.3$ 93.8 95.6 —8.0
SD 1.8 4.1 4.6 2.3 2.7 2.1
Significance levels: P<0.05*; P <0.025f; P<0.01$; P<0.0051T; PCO.OOlft
Heart rate, mean arterial blood pressure, central venous pressure, cardiac output, total systemic peripheral 
vascular resistance and arterial oxygen saturation before and after injection o f Glaxo C T 1341 (0.15ml/kg) in 
10 patients expressed as mean values (dhSE M ). The mean maximum change in individual patients without 
regard to time is given. Mean values are based upon observations in all 10 patients except when studies termin­
ated prior to elapse o f 9 minutes; in these instances, statistical comparison is based upon paired t-test o f  the 
lesser number indicated within brackets.
TABLE 2
O bservation Control
Minutes alter nduction
Maximum
change+ 1 + 3 + 6 + 9
Heart rate (beats/min) 88.5 86.0 94.3(4) 90.3(3) 88.0(2) — 1.2
SEM 7.3 7.8 6.0 6.4 6.4
Mean blood pressure (mm Hg) 104.3 83.8ft 71.0ff(4) 75.6<T(3) 99.0(2) —26.7
SEM 8.1 8.4 0.9 1.9 3.5
Central venous pressure
(mm Hg) 4.8 3.0 3.7(3) 3.0(4) — —2.0
SEM 0.98 0.7 0.34 1.1
Cardiac output (litres/min) 7.1 7.6 7.2 6.6 ___ —0.4
SEM 0.68 1.2 0.54 0.73
Peripheral vascular
resistance (dynes/sec-3) 1292 802 800 869 ___ —268
SEM 276.0 111.4 67.5 69.3
Significance levels: P<0.05*; P<0.025f; PcO.Ol*; P<0.005iT; PcO.OOlft 
Heart rate, mean arterial blood pressure, central venous pressure, cardiac output, total systemic peripheral 
vascular resistance and arterial oxygen saturation before and after injection o f Glaxo C T  1341 (0.06ml/kg) in 
5 patients expressed as mean values (dr SE M ). The mean maximum change in individual patients without 
regard to time is given. Mean values are based upon observations in all 5 patients except when studies terminated 
prior to elapse o f 9 minutes; in these instances, statistical comparison is based upon paired t-test o f  the lesser 
number indicated within brackets.
A n a e s th e s ia  v o l  2 7  n o  4  O c to b e r  1 9 7 2  
G r o u p  2 ,  A l t h e s in ,  0 . 0 6 m l / k g  ( t a b l e  2 )
There was no systematic change in pulse rate following injection of 
Althesin in this group. A consistent fall in arterial mean blood pressure 
occurred which was significant at the end of the 1st, 3rd and 6th minute. 
There was no significant change in cardiac output or central venous 
pressure. Peripheral vascular resistance fell in every patient but this was 
not statistically significant.
T h io p e n t o n e ,  4 m g / k g  ( ta b l e  3 )
A consistent increase in heart rate occurred and this was significant at 
each period of observation. Mean arterial blood pressure fell significantly 
in all patients, and mean central venous pressure fell but was significant 
only at the sixth minute after injection of thiopentone. Peripheral resistance 
fell and was significant at the end of the third and sixth minute following 
the injection of thiopentone. There was no change in cardiac output. There 
was no significant change in the arterial oxygen saturation after thiopen­
tone.
TABLE 3
Observation Control
Minutes after induction
Maximum
change+ i + 3 + 6 + 9
Heart rate (beats/min) 92.7 106.941 103.841 100.4t(7) 99.1t(7) +  17.0
SEM 5.03 4.6 5.2 4.2 5.6
Mean blood pressure (mm Hg) 95.9 8 6 .04T 82.0 t 82.0t(7) 80.3J(6) —16.9
SEM 4.2 4.4 3.7 4 3 4.1
Central venous pressure
(mm Hg) 2.2 1.6 1.1 0.7*(7) 0.8(5) — 1.3
SEM 0.57 0.3 0.3 0.3 0.8
Cardiac output (litres/min) 8.96 9.0 9.1 8.6 ___ —0.2
SEM 0.8 0.8 1.1 0 8
Peripheral vascular
resistance (dynes/sec-5) 911 882 827* 835*(7) — — 157
SEM 115.2 146.8 138.2 99.3
Arterial oxygen saturation % 95.0 91.1 95.6(5) 94.2(6) ___
SD 2.9 3.6 2.1 2.7
Significance levels: P<0.05*; P<0.025t; PCO.Olt; P < 0 . 0 0 5 ;  P < 0.001 f t  
Heart rate, mean arterial blood pressure, central venous pressure, cardiac output, total systemic peripheral 
vascular resistance and arterial oxygen saturation before and after injection o f thiopentone (4.0mgmjkg) in 8 
patients expressed as mean values ( ± S E M ). The mean maximum change in individual patients without regard 
to time is given. Mean values are based upon observations in all 8 patients except when studies terminated prior 
to elapse o f 9 minutes; in these instances, statistical comparison is based upon paired t-test o f  the lesser number 
indicated within brackets.
A l t h e s i n ,  0 . 1 5 m l / k g  v e r s u s  A l t h e s i n  0 .0 6 m l / k g
Similar changes in blood pressure, central venous pressure, cardiac output 
and peripheral vascular resistance occurred after injection of 0.06ml/kg or 
0.15ml/kg Althesin. At the lower dosage, however, the changes in heart 
rate and the peripheral vascular resistance were not significant.
A l t h e s i n  v e r s u s  t h io p e n to n e
There was a greater fall in mean arterial blood pressure following the 
administration of Althesin than after thiopentone, however the differences 
were not significant. There was a fall in peripheral vascular resistance
following the administration of both drugs, but this was significantly 
greater after Althesin at the 1,3,6 and 9 minute intervals (P < 0.05). There 
was a fall in arterial oxygen saturation after both drugs -  this was signi­
ficantly greater after Althesin (P < 0.05).
DISCUSSION
The cardiovascular effects of intravenous anaesthetic agents have been 
extensively studied both in man and animals. Comparison between these 
studies and the investigation reported here cannot readily be made 
because of species variation and differences in experimental techniques 
adopted. Dobkin8 reported a 16% rise in heart rate, 17% reduction in 
mean arterial blood pressure, 10% reduction in peripheral vascular re­
sistance and no significant change in cardiac output, when twice the sleep 
dose of thiopentone was given to unpremedicated healthy volunteers. In 
our patients sleep doses of thiopentone resulted in similar changes; heart 
rate increased 25%, mean blood pressure fell 22%, peripheral vascular 
resistance fell by 24% and there was no significant change in cardiac 
output. A reduction of cardiac output below the normal range after thio­
pentone anaesthesia has been observed by Etsten9, Fieldman10 & Flick- 
inger e t  a l . 1 1, but premedicant drugs were given prior to the induction of 
anaesthesia in these studies and might explain this finding.
Observations made in regard to Althesin are similar in every respect to 
the changes in cardiovascular status reported by Campbell e t  a l . 2 , and, 
except in regard to heart rate at the low dose range, to the report of Savege 
e t  a l 3.
The observations made after induction of anaesthesia in group 2 
patients (low dose of Althesin) differed little from those made in patients 
who had received almost treble the sleep dose of Althesin (group 1); this 
confirms the high therapeutic index of the drug which was suggested by 
animal experiments1.
The exact mechanism of the changes in cardiovascular status after 
induction of anaesthesia is uncertain, but a definite pattern follows in­
jection of both drugs. Peripheral resistance and blood pressure fall, heart 
rate increases and the cardiac output either increases or is unchanged. 
These are changes which suggest a peripheral site of action, the hypo­
tension being due to peripheral vasodilatation which produces a reflex 
tachycardia and consequent maintenance of cardiac output.
The immediate cardiovascular effects of the two drugs appear to be 
remarkably similar except that the fall in peripheral vascular resistance is 
significantly greater following Althesin and consequently it may be 
tentatively predicted that induction of anaesthesia with Althesin will be 
more hazardous in patients suffering from diseases which restrict or ‘fix’ 
the cardiac output. Patients suffering from mitral stenosis or constrictive
pericarditis are intolerant to sudden vasodilatation and fatal arterial hypo­
tension might occur if Althesin were administered to such a patient. In all 
other respects, however, Althesin offers an acceptable alternative to thio­
pentone for induction of anaesthesia.
S U M M A R Y
The acute cardiovascular changes have been measured in 23 healthy un- 
premedicated patients following induction of anaesthesia with either 
Althesin, a steroid anaesthetic agent, or thiopentone. Two dose levels of 
Althesin were used: 0.15ml/kg (group 1) and 0.06ml/kg (group 2). The 
dose of thiopentone was 4mg/kg (group 3). In all three groups the blood 
pressure fell, the pulse rate increased and cardiac output was either 
slightly increased or unchanged by comparable amounts, but the fall in 
peripheral vascular resistance was significantly greater in the Althesin 
groups.
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Cardiovascular Effects of Acebutolol (M & B 17803A), in 
Exercising Man; A Comparative Study with Practolol and 
Propranolol
The clinical work described was shared by the authors as was 
preparation of the manuscript.
CURRENT
THERAPEUTIC
RESEARCH
VOL. 14, NO. 10, OCTOBER, 1972
CARDIOVASCULAR EFFECTS OF ACEBUTOLOL (M & B 17803A), 
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ABSTRACT
A new drug, M & B 17803A, was found intrinsically more 
potent than practolol as a j3-receptor blocking agent and, unlike 
propranolol, did not reduce the cardiac output in exercising 
man.
DL — ( 2-acetyl-4-butyramidophenoxy)-2 hydroxy-3-isopropylamino- 
propane hydrochloride (acebutolol) is a potent new sympathetic 13- 
receptor antagonist. Preliminary investigations in animals indicate that 
acebutolol selectively blocks myocardial sympathetic j3-receptors and has 
little effect on bronchial or vascular muscle.1 In addition, the drug has 
quinidine-like and local anaesthetic properties.2
This paper records the findings of a study in which equal doses of 
acebutolol, practolol, or propranolol were given intravenously to healthy 
volunteers during sustained sub-maximal exercise.
METHODS
A total o f  19 subjects was studied. All were male students or technicians aged 27 ± 5 
years, weighing 65 ± 10 kg., and being 71 ± 6 cm. in height. No clinical evidence of 
cardiopulmonary disease was found in any case and all investigations were carried out 
under aseptic conditions in an operating theatre, with their consent.
Radial artery and right atrial catheters were inserted in all patients under local 
analgesia. Subjects then rested for 10 minutes before com m encem ent o f  the study. 
Pressures were recorded by Statham gauge, and cardiac output was measured by dye 
dilution, using a Philips XO 1000 O ximeter/Densitometer. Pulse rate and arterial 
pressure were recorded on a Philips 3T Cardiopan recorder.
When recording devices had been calibrated and resting pulse rate noted, subjects 
began to exercise seated on a bicycle ergometer. During the first 5 minutes, workload 
was adjusted to produce a 50 to 75 percent increase in pulse rate. Cardiac output, 
arterial pressure and pulse rate were measured at least twice in the ensuing 6 minutes. 
An injection o f 10 mg. acebutolol, (6 subjects), propranolol, (8 subjects), or 
practolol, (5 subjects), in 10 ml. normal saline was then given intravenously over 15
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seconds. Cardiac output, pulse and arterial pressure were measured 2, 4 and 6 minutes 
after injecting the drug, while exercise continued as before. The cardiac output densi­
tometer was calibrated at the end o f each study with aliquots o f the patients’ blood  
containing known amounts o f indocyanine green.
Cardiac output was calculated from dye curves using the method o f  Williams, 
O ’Donovan and W ood,3 to prepare an appropriate programme for the Olivetti 101 
computer. Total peripheral resistance (P.V .R.) was calculated by the formula of 
Aperia.4 Tests o f statistical significance were applied to the mean differences in 
measurements made before and after injection o f M & B 17803A , practolol or pro­
pranolol by applying student’s t-test to the paired observations.
RESULTS
Presentation of data has been simplified by comparing the mean of obser­
vations made during exercise b e f o r e  injection of M & B 17803A, practolol 
or propranolol with the mean of measurements made a f t e r  injecting the 
drug, since no significant differences were noted between measurements 
made 2, 4 and 6 minutes after administration of each drug.
The individual values for heart rate, mean arterial pressure, cardiac 
output, stroke volume and systemic vascular resistance appear in Tables I 
to III.
A c e b u t o l o l
A  significant fall in pulse rate followed intravenous injection of acebutolol 
(P < 0.01). Stroke volume increased in all but one subject. This was statis­
tically significant, (P < 0.05) there were no significant changes in mean 
arterial pressure, (P > 0.100), cardiac output, (P > 0.200), or systemic 
vascular resistance, (P > 0.200).
P r o p r a n o l o l
There were statistically significant falls in mean arterial pressure, (P < 
0.001), pulse rate, (P < 0.001) and cardiac output (P < 0.025) following 
the administration of propranolol to exercising man.
No significant change in stroke volume (P > 0.500) or peripheral 
resistance was recorded (P > 0.200).
P r a c t o l o l
Intravenous administration of 10 mg. practolol during sub-maximal 
exercise produced significant falls in mean arterial pressure (P < 0.001), 
pulse rate (P < 0.025) and peripheral resistance (P < 0.05). Stroke volume 
increased by 2.5 percent and cardiac output fell by 2.4 percent, but these 
changes were not statistically significant (P > 0.200).
[ 675 ]
Subject
Pulse Rate 
(Beats/min)
PRE-INJECTION 
Cardiac Stroke Mean Arterial 
Output Volume Pressure 
(L/min) ml. (mm. Hg)
P.V.R. 
(Dynes 
sec cm-5)
Pulse Rate 
(Beats/min)
POST-
Cardiac
Output
(L/min)
INJECTION
Stroke
Volume
ml.
Mean Arterial 
Pressure 
(mm. Hg)
P.V.R. 
(Dynes 
sec cm-5)
1 125 11.50 92.0 110 765.2 117- 11.7 100.3 110 750.2
2 135 15.90 117.8 136 684.3 112 14.4 128.6 118 655.6
3 107 14.31 133.7 120 670.9 104 14.2 137.4 115 638.9
4 112 17.15 .153.1 104 485.1 102 15.3 150.5 104 542.0
5 107 14.51 135.6 104 573.4 95 14.6 153.9 104 569.1
6 88 8.70 98.9 112 1029.9 83 9.3 112.4 106 908.9
Mean 112.3 13.57 121.9 114.3 701.5 102.2 13.28 130.5 109.5 677.5
± S t d .
Dev. ±14.9 ±2.82 ±21.4 ±11.1 ±171.5 ±11.1 ±2.1 ±19.3 ± 5.4 ±123.1
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Subject
Pulse
(beats/min)
PRE-INJECTION
Cardiac Stroke Mean Arterial 
Output Volume Pressure 
(L/min) ml. (mm. Hg)
Peripheral
Resistance
(dynes/sec
cm-5)
Pulse
(beats/min)
POST
Cardiac
Output
(L/min)
INJECTION
Stroke
Volume
(ml.)
Mean Arterial 
Pressure 
(mm. Hg)
Peripheral
Resisitance
(dynes/sec
cm-5)
7 125 15.98 127.8 93 465.6 94 12.5 133.8 85 540.5
8 115 14.37 125.0 94 523.3 99 13.0 132.2 83 507.3
9 112 15.25 136.2 106 556.1 99 11.8 119.2 95 644.1
10 109 13.25 121.6 96 579.6 103 12.6 122.7 90 569.6
11 150 11.08 73.9 101 729.2 122 12.4 101.6 87 561.3
12 167 13.30 79.6 108 649.6 132 11.2 85.4 103 731.1
13 132 9.30 70.5 108 929.0 107 7.6 71.0 94 989.5
14 115 12.90 112.2 120 744.2 102 9.27 90.8 99 854.3
Mean 128.1 13.18 105.9 103.3 647.1 107.3 11.30 107.1 92.0 674.7
±Std.
Dev. ±19.3 ±2.0 ±25.0 i8.5 ±140.0 ±12.2 ±1.8 ±21.8 ±6.5 ±160.2
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Subject Pulse Rate
PRE-IN JECTIO N  
Cardiac Stroke 
Output Volume 
(L/min) (ml.)
Blood
Pressure P.V.R. Pulse Rate
POST
Cardiac
Output
(L/min)
INJECTION
Stroke
Volume
(ml.)
Blood
Pressure P.V.R.
15 112 14.29 127.6 114 638.2 110 13.44 122.2 102 607.1
16 136 10.73 78.9 112 835.0 136 10.37 76.3 103 794.6
17 122 17.81 146.0 107 480.6 115 18.30 159.1 93 406.6
18 110 13.86 126.0 112 646.5 102 12.58 123.3 104 661.4
19 117 12.03 102.8 111 738.2 109 12.45 114.2 101 649.0
Mean 119.4 1374 116.3 111.2 667.7 114.4 13.42 119.0 100.6 623.7
± Std.
Dev. ±9.3 ±2.4 ±23.2 ±2.3 ±117.7 ±11.6 ±2.6 ±26.4 ±3.9 ±125.4
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DISCUSSION
It may be argued that comparing equal doses of drugs with different 
potencies limits the practical value of data collected. This difficulty was 
partly overcome in the study described here by injecting doses within the 
therapeutic range of each drug. The experiments reported here indicate 
that acebutolol is intrinsically more potent that practolol, as a j3-receptor 
blocking agent and, unlike an equal dose of propranolol, does not reduce 
cardiac output.
No change in airways resistance occurs in asthmatics given 100 or 200 
mg. acetutolol by mouth (leary and Coleman, unpublished) and animal 
studies show that acebutolol has marked quinidine-like effects and is 
significally more potent than practolol as an anti-arrhythmic agent.1’2
These studies suggest that, like practolol, acebutolol has a high degree 
of cardioselectivity and may, therefore, be administered to patients with 
obstructive airways disease and as an antiarrhythmic agent following myo­
cardial infarction or cardiac surgery, with comparative safety.
Further clinical trials of acebutolol are indicated to determine the 
efficacy of this agent in various cardiac arrhythmias in man and its relative 
safety in patients with cardiac insufficiency.
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PAPER D5
Some Hemodynamic Effects of Sodium Nitroprusside
This study was conceived by Dr. M. Styles and Professor A.J. 
Coleman. Clinical work was shared and the paper was drafted
and edited by all three authors.
Some Hemodynamic Effects of Sodium Nitroprusside
M . Sty les, M .B ., B .S ., F .F .A ., R .C .S . (Eng .), 
R .C .S . (Lo n d .) ,t W. P. Lea ry , M .S c ., M .B .,
M .R .C .P .
Arterial hypotension to about 45 mm Hg below 
control was induced in 12 patients by infusion of 
a 0.01 per cent solution of sodium nitroprusside. 
The drug was found reliable, free of tachyphy­
laxis, and evanescent of action. During the hypo­
tensive phases arterial oxygen saturation was 
maintained at 95-99 per cent. Cardiac output 
decreased insignificantly by a mean value of 200 
ml/min in conscious individuals, but increased by 
about 850 ml/min in anesthetized subjects. Blood 
pressures returned to 90 per cent of control values 
within 120 seconds of discontinuation of sodium 
nitroprusside. The use of the drug merits fur­
ther investigation. (Key words: Hypotension; So­
dium nitroprusside; Available oxygen.)
T h e  cardiovascular  e f f e c t s  of sodium nitro­
prusside in normotensive and hypertensive pa­
tients have been described by Schlant et al.,1 
and those following acute myocardial infarc­
tion, by Franciosa et al.2 Two clinical studies 
of the use of this drug as a hypotensive agent 
in anesthetic practice have been published.3’ 4 
Schlant et al.1 reported a 37.2 per cent reduc­
tion in mean arterial blood pressure in normo­
tensive patients given intravenous doses of
0.61—3.87 fj. g /k g /m in  sodium nitroprusside. 
This was associated with a mean decrease of 
peripheral vascular resistance of 31.1 per cent, 
an 8.8 per cent decline in cardiac index, and 
an increase in heart rate of 5.5 per cent. These  
effects and the hemodynamic changes found  
in patients given sodium nitroprusside after 
myocardial infarction2 suggest that the drug
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is a pure vasodilator, w ithout action upon the 
heart or sym pathetic nervous system .1’ 5 Re­
ports of the use of sodium nitroprusside as a 
hypotensive agent in clinical anesthetic prac­
tice 3> 4 stress the potency, evanescence of ac­
tion, and absence of tachyphylaxis of the drug, 
and suggest that further evaluation is indi­
cated.
The availability of oxygen to the tissues, an 
important factor in clinical anesthetic practice, 
merits special attention during induced hypo­
tension, because in this situation cardiac out­
put is commonly reduced.8-8 There are no 
published reports of the effects of sodium ni­
troprusside on cardiac output or arterial oxy­
genation in anesthetized man. In this study 
an attempt has been m ade to augment avail­
able know ledge by providing this information.
Methods
T w elve patients, five wom en and seven men, 
were investigated, with their consent. Patients 
were 20 to 50 years old and had no clinical 
evidence of cardiopulmonary or central ner­
vous system disease. In every case elective  
surgery involving structures close to the body 
surface was indicated, and the surgeons had 
requested that arterial blood pressures be con­
trolled during these procedures. Surgical pro­
cedures included excision of facial keloid mal­
formations and lipomata and a salivary gland 
exploration. All studies were performed with  
the patients supine in the horizontal position.
Patients received 100 m g pethidine (meperi­
dine) and 25 m g promethazine intramuscularly 
30 to 60 minutes before the study. Using local 
analgesia, plastic catheters w ere inserted per- 
cutaneously into the radial artery, and into the 
right atrium from a right antecubital vein. 
Pressures were measured by Statham strain- 
gauge transducers supported 3 inches above 
the surface of the operating table and re­
corded continuously on a Philips 3T recorder. 
Heart rate was measured using a SAN-E1-
T a b l e  1. Hemodynamic Data from Five Patients (Group I) Given Sodium Nitroprusside after Control 
____________________ Periods before and after Induction of Anesthesia*
C ontro l,
A w ake
Sr d ium  
Nitr«. p r  isside 
H ypo tension , 
A w ake
C ontro l,
A w ake
C on tro l,
du ring
A nesthesia
D u rin g  
A nesthesia  
an d  Sodium  
N itro p ru ssid e
D u rin g  
A nesthesia  
a  te r  Sodium  
N itrop russide
Blood pressure 
(mm Hg) 9 2 . 4  ±  7 . 3 4 8  ±  8 . 7 | | 7 9 . 5  ±  5 . 7 8 9 . 6  ±  6 . 4 4 6 . 5  ±  4 . 6 | | 9 0  ±  1 4 . 1
Heart rate 
(beats/min) 7 0 . 6  ±  1 1 . 8 7 0 . 2  ±  1 9 . 7 5 1  ±  2 . 2 8 0 . 6  ±  1 1 . 1 9 3 . 2  ±  1 0 . 3 t 6 6 . 7  ±  1 2 . 3
Central venous pres­
sure (mm Hg) 4  ±  0 . 3 1 ±  0 . 2 5 f 4  ±  0 . 2 1 2  ±  0 . 2 0  ±  0 . 1 3 f 2  ±  0 . 1 4
Cardiac output 
(1/min) 4 . 3  ±  0 . 3 4 . 1  ±  0 . 3 3 . 6  ±  0 . 2 4 . 4  ±  1 . 2 5 . 3  ±  0 . 9 3 . 8  ±  0 . 4
Stroke volume (ml) 6 3  ±  1 3 . 2 6 2  ±  1 5 7 0  ±  7 . 5 5 4  ±  1 0 . 5 5 7  ±  1 0 . 7 4 9  ±  3 . 7
Peripheral vascular 
resistance 
(dynes/sec/cm-5) 1 , 7 2 1  ±  2 2 6 9 3 1  ±  1 5 6 § 1 , 7 0 8  ±  6 1 1 , 7 2 2  ±  3 3 3 7 1 2  ±  791T 1 , 9 1 3  db  1 8 0
Oxygen saturation 
(per cent) 9 7  ±  2 . 1 9 7  ±  1 . 3 9 7  ±  2 . 4 9 9  ±  3 . 5 9 9  ±  3 . 7 9 8  ±  3 . 1
Available oxygen 
(ml/miri) 7 6 6  ±  9 3 7 5 1  ±  1 0 8 6 6 5  ±  9 0 8 2 4  ±  3 1 5 9 0 4  ±  1 9 6 6 8 3  ±  7 1
Pao2 (mm Hg) 9 5  ±  1 0 . 5 9 3  ±  1 1 . 2 9 5  ±  1 1 . 1 1 2 0  ±  2 8 . 2 1 1 0  ±  1 7 . 9 1 3 5  ±  2 5 . 3
Paco2 (mm Hg) 4 0  ±  3 . 7 3 7  ±  4 . 2 4 1  ±  4 . 7 4 0  ±  4 . 5 3 9  ±  3 . 9 4 2  ±  4 . 2
p H 7 . 4 1  ±  0 . 0 7 7 . 3 9  ±  0 . 0 6 7 . 4  ±  0 . 0 8 7 . 3 7  ±  0 . 0 5 7 . 3 5  ±  0 . 0 6 7 . 4 0  ±  0 . 0 7
Pvo2 (mm Hg) 4 5  ±  3 . 7 4 7  ±  3 . 8 4 5  ±  3 . 0 5 0  ±  4 . 3 4 9  ±  4 . 8 4 5  ± 7 . 1
P?co2 (mm Hg) 4 7  ±  5 . 0 4 2  ±  2 . 7 4 7  ±  4 . 5 4 8  ±  4 . 7 4  *. ±  5 . 0 4 7  ±  3 . 7
p H 7 . 3 7  ±  0 . 0 3 7 . 3 0  ±  0 . 0 5 7 . 3 0  ±  0 . 0 4 7 . 3 0  ±  0 . 0 5 7 . 3  ) ±  0 . 0 5 7 . 3 5  ±  0 . 0 7
* Results are means ±  SD. Statistical data relate to comparison of values obtained during infusion 
of sodium nitroprusside with those obtained in the preceding control period, 
t P <  0.05; t P  <  0.025; § P  <  0.01; If F <  0.005; || P  <  0.001.
'2D 16 pulsem eter and a finger photocell. Car­
diac ou .put was measured by dye dilution  
using indocyanine green and the Philips XO- 
1000 combined oxim eter/densitom eter cuvette. 
Arterial oxygen saturation and hem oglobin  
were measured during the cardiac output esti­
mation. Blood needed for estim ating a c id -  
base and b lood-gas status was obtained from 
the arterial and venous catheters at regular 
intervals during the studies, and analyzed in 
duplicate, using the Beckman modular b lood -  
gas assembly.
A t the conclusion of each experim ent the 
cardiac output densitometer was calibrated  
using the patient’s own blood and known doses 
of indocyanine green. Cardiac output was 
calculated using the method of W illiams et al.9 
to prepare an appropriate program for an 
O livetti digital computer. Total peripheral 
vascular resistance (PV R) was calculated from 
the formula of Aperia 10:
_  mean arterial pressure (m m Hg) 
cardiac output (1/min)
X  80 dynes sec cm-5
Available oxygen was calculated from the 
formula:
Available oxygen (m l/m in)
_  cardiac output m l/m in  
X  (hem oglobin X  1.34)
100
X  % oxygen saturation
Tests of statistical significance were applied to 
the mean differences betw een values obtained  
in the control periods preceding hypotension  
and during the hypotensive phases, induced by 
halothane on the one hand, and sodium nitro­
prusside on the other, by applying Student’s 
t test to the paired comparisons.
F ive patients (Group I) received sodium  
nitroprusside after control periods both before 
and after induction of anesthesia. Patients 
w ere left undisturbed following introduction  
of the catheters until heart rates and arterial 
pressures were steady. Cardiac output, ar­
terial oxygen saturation and hem oglobin esti­
mations were then m ade at about 3-minute in­
tervals until the areas o f at least two dye-dilu-
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T a b l e 2. Hemodynamic Data from Seven Patients (Group II) Given Sodium Nitroprusside
after Induction of Anesthesia
C o n tro l
during
A nesthesia
V alue during  
Sodium  
N itro p ru ssid e  
H ypo tension
C o n tro l
Blood pressure (mm Hg) 9 0 . 7  ±  1 3 . 6 5 4 . 6  ±  1 1 . 7 | | 9 5 . 7  =b 1 0 . 8
Heart rate (beats/min) 8 8 . 0  z b  2 2 1 1 3 . 0  ±  2 5 f 7 8 . 4  z b  2 0 . 6
Central venous pressure (mm Hg) 2  ±  0 . 3 1 z b  0 . 2 f 4  z b  0 . 5
Cardiac output (1/min) 4 . 3  =b 1 .1 5 .1  ±  1 . 0 4 . 0  z b  0 . 8
Stroke volume (ml) 5 0  ±  1 0 4 7  =b 1 4 . 8 4 8  =b 9 . 3
Peripheral vascular resistance (dynes sec cm-5) 1 , 9 3 0  ±  4 8 5 9 1 7  z b  3 8 6 | | 1 , 9 1 3  z b  4 5 6
Oxygen saturation (per cent) 9 5  z b  2 . 1 9 5  ±  2 . 3 9 6  ±  2 . 3
Available oxygen (ml/min) 6 6 5  ±  8 2 8 0 3  =b 2 2 0 6 3 2  =b 7 2
Pao2 (mm Hg) 9 2  =b  1 7 .1 8 5  ±  1 8 .3 9 5  z b  1 3 . 7
PaCo2 (mm Hg) 3 5  db 7 . 4 3 0  =b 7 . 7 3 7  z b  8 . 0
pH 7 . 3 7  z b  0 . 0 5 7 . 3 9  ±  0 . 0 4 7 . 3 7  =b 0 . 0 6
Pvo2 (mm Hg) 4 1  ±  9 . 1 4 0  ±  7 . 1 4 2  z b  5 . 3
PVcoj (mm Hg) 4 2  ±  7 . 3 3 7  z b  5 . 8 4 9  z b  3 . 7
pH 7 . 3 1  =b 0 . 0 2 7 . 3 0  d=  0 . 0 7 7 . 3 0  z b  0 . 0 6
* Results are means zbSD. Each period of hypotension was preceded by a control period. Statistical 
data relate to comparison of values obtained during infusion of sodium nitroprusside with those obtained 
in the preceding control period.
f P  <  0 . 0 5 ;  %P  <  0 . 0 2 5 ;  §  P  <  0 . 0 1 ;  If P  <  0 . 0 0 5 ;  || P  <  0 . 0 0 1 .
tion curves appeared to agree within 10 per 
cent and the arterial oxygen saturation was 
steady to within 1 per cent. Blood pressures 
and heart rates at this mom ent were recorded 
and served as control measurements. Infusion 
of a 0.01 per cent solution of sodium nitro­
prusside in 5 per cent dextrose in water was 
then com menced, at a rate adjusted to main­
tain the mean arterial blood pressure betw een  
40 and 50 mm H g below  the control level. 
W hen the hypotensive state had been estab­
lished for at least 5 minutes, all hemodynamic 
measurements were repeated. Infusion of so­
dium nitroprusside was then discontinued and 
a second series of control estimations was m ade 
when the blood pressure returned to control 
levels.
Anesthesia was induced by 100 to 200 m g  
of 2.5 per cent thiopental given intravenously 
over a period of 30 seconds. All patients re­
ceived 50 m g succinylcholine intravenously to 
facilitate intubation of the trachea. Continued  
apnea was achieved by giving each patient 
either alcuronium or pancuronium. Patients 
w ere connected to a M anley respirator deliver­
ing an expired minute volum e of about 5 liters 
(70 per cent nitrous oxide and 30 per cent 
oxygen). T he minute volum e was adjusted as 
necessary to Parf)i betw een 30 and 40 mm Hg. 
A period of 10 minutes was allowed to elapse
following induction of anesthesia and then con­
trol hemodynamic measurements were made. 
After incision of the skin, sodium nitroprusside 
infusion was com menced, and when mean  
blood pressure was 4 0 -5 0  mm H g below  the 
control level, all hemodynamic measurements 
were repeated. Surgical intervention was in­
terrupted 3 minutes prior to measurement p e­
riods. Sodium nitroprusside infusion was dis­
continued to coincide with surgical needs, and 
when the arterial blood pressure had approx­
imated control values for at least 15 minutes, 
a final series of control measurements was 
made.
Seven patients (Group II) were investigated  
after induction of anesthesia. The initial anes­
thetic managem ent and m ethods of study were 
identical to those described above.
Results
Hypotension was readily obtained following  
the infusion of sodium nitroprusside, although  
some difficulty in obtaining a steady level of 
reduced mean pressure was experienced ini­
tially. The surgeons were w ell satisfied w ith  
operating conditions in all cases.
Group I patients were unaware of the reduc­
tions in their blood pressures preoperatively, 
and experienced no ill effects whatever.
T he average reduction of mean arterial pres­
sure during sodium nitroprusside infusion (44  
mm H g) was associated w ith significant de­
creases in central venous pressure and periph­
eral vascular resistance (table 1 ). Cardiac 
output and arterial oxygen saturation w ere  
not changed, indicating that available oxygen  
was maintained at control levels.
Responses to sodium nitroprusside during 
anesthesia differed significantly from those in 
the conscious state in respect to heart rate, 
which increased by 13 beats/m in , only. In 
addition, mean cardiac output increased by 900  
m l/m in and mean available oxygen increased  
by more than 75 m l/m in , but these changes 
were not significant.
In Group II, responses to sodium nitroprus­
side were similar in every respect to those in 
Group I following induction of anesthesia  
(table 2 ) .
There was no notable change in the b lo o d -  
gas or acid-base status of patients during this 
study except a slight increase in Pac02 follow­
ing induction of anesthesia (tables 1 and 2 ) .  
Arterial hypotension, once established, was 
readily maintained by a fixed rate o f sodium  
nitroprusside infusion, indicating that there was 
no early tendency to develop tachyphylaxis.
Following discontinuation of sodium nitro­
prusside, arterial blood pressure returned to 
within 90 per cent of control in less than 120 
seconds in all cases.
D iscu ss io n
Major considerations in induced hypoten­
sion are oxygenation and the adequacy of blood  
flow, particularly to the brain. A  technique 
which provides good surgical conditions w ith­
out a reduction in available oxygen is prefer­
able to one known to reduce cardiac output 
and available oxygen.
Clinical studies 3> 4 indicate that sodium ni­
troprusside provides good surgical conditions. 
Results of the present study indicate that these 
conditions are obtained w ithout jeopardizing 
oxygen delivery, and further suggest that re­
duction of arteria l pressu re  rather than b lo o d  
flow  is the factor that facilitates surgery in  
induced hypotension. Venous blood pH  and 
blood—gas, although not strictly representative 
of mixed venous blood, were m aintained at 
control levels during the hypotensive phases 
of the study, suggesting that total-body perfu­
sion was adequate. In contrast, w hen hypo­
tension is induced by ganglionic blocking  
drugs, spinal anesthesia, or deep halothane 
anesthesia, cardiac output is reduced.8*7*8*11 
H alothane and trimethaphan, probably the 
most popular sequence, were associated in one 
study w ith a significant 11.8 per cent reduc­
tion in cardiac output,® and in another with  
3 3 -4 1  per cent reductions in cardiac index.7
It is concluded that sodium nitroprusside 
may offer important advantages as a hypo­
tensive agent and merits further scrutiny in 
depth regarding, for example, adequacy o f  
regional perfusion of vital organs.
The authors are grateful to Dr. T. H. Taylor of 
the Anaesthetic Department, The London Hospital, 
for initiating this study and for supplies of sodium 
nitroprusside. and to the surgeons of the Profes­
sorial Surgical Units of King Edward Hospital for 
their unstinting cooperation and assistance with the 
project.
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ABSTRACT
Penbutalol and acebutolol are new 0-adrenergic blocking agents.
The haemodynamic effects of isoproterenol, infused at several 
rates, have been measured before and after intravenous pen­
butalol 0.2 and 0.3 mg. or acebutolol 5 and 10 mg. Isopro­
terenol infusion increased heart rate, cardiac output, stroke 
volume and peripheral bloodflow in healthy subjects. Central 
venous pressure and peripheral vascular resistance fell. These 
effects were partly blocked by both acebutolol and penbutalol.
The effects of penbutalol upon peak flow, FEVi and FVC 
were assessed in 7 students with bronchial asthma. Five devel­
oped bronchospasm after penbutalol 0.15-0.2 mg. I.V.I. or oral 
doses of 2 to 8 mg.
Therapeutic doses of both agents effectively block cardiac 
adrenergic receptors, but acebutolol seldom precipitates bron­
chospasm in asthmatics.
INTRODUCTION
Penbutalol and acebutolol (Fig. 1) are potent new 0-adrenergic blocking 
agents. The clinical pharmacology of penbutalol has not been fully des­
cribed in man, but preliminary experiments indicate that acebutolol is 
effective in a variety of clinical situations and resembles practolol in its 
relative selectivity for 01 receptors.1-2 -
■ Tn this series of studies, the haemodynamic effects of isoproterenol 
were determined before and after administration of penbutalol or 
acebutolol. In addition, the effects of penbutalol have been measured in a 
group of asthmatics;
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Figure 1 — Structural formulas o f  Penbutalol and A cebutolol
CH  -  C H _ -  N H 0 -  C ( C H - ) -| A  A J o
OH
PENBUTALOL
O C H 2 C H O H C H 2 n h  CH (c h 3 ) 2
ACEBUTOLOL
METHODS
Medical technicians or senior medical students volunteered for this study. All were 
given a detailed explanation o f the techniques involved so that informed consent could 
be obtained. All studies took place in a laboratory equipped for human experimenta­
tion, under the uninterrupted supervision o f 3 senior clinicians and a registered nurse.
Haemodynamic Studies
Subjects weighed 60 to 75 kg. and were 20 to 35 years old. No clinical evidence of 
cardiopulmonary disease was present. Plastic catheters were inserted percutaneously, 
under local analgesia, into the right radial artery, and via a suitable vein in the right 
cubital fossa, into the right atrium. Pressures were measured electrometrically by 
Statham strain gauge transducers, supported 7.5 cm. above the surface o f the oper­
ating table, and recorded continuously on a Philips 3T recorder. Heart rate was meas­
ured using the SAN-E1-2D 16 pulse meter and a finger photo cell. Cardiac output was 
measured by dye dilution, using indocyanine green and the Philips XO-IOOO combined  
oxim eter/densitom eter cuvette. Oxygen saturation and haemoglobin were measured 
during the cardiac.output estimations. Subjects were supine and horizontal throughout 
the study.
At the conclusion o f  each experiment, the cardiac output densitometer was cali­
brated, using each subject’s own blood and known doses of cardiac green. Cardiac 
output was calculated by the m ethod o f Williams et al.,3 on an appropriate programme 
prepared for an Olivetti digital computer. Peripheral vascular resistance (PVR) was 
calculated from the formula o f Aperia.4
mean arterial pressure (mm. Hg)
PVR= ------------------------------------------------ x  80 dynes sec./cm-5
cardiac output (litre/m in.)
Peripheral blood flow  in the mid-calf region o f the left leg was measured at 3 minute 
intervals by venous occlusion plethysmography using mercury in silastic strain gauge 
transducers. Change in resistance o f the gauge was measured on a Parks 270 plethys- 
mograph, and recordings were made on a 25 cm. Beckman potentiometric recorder at 
a paper speed o f 10 cm. per minute.
Subjects were left undisturbed after introduction o f the catheters until heart rates 
and arterial pressures were steady. Cardiac output, arterial oxygen saturation and 
haemoglobin estimations were then made at 3-minute intervals until the areas o f at 
least 2 dye dilution curves appeared to agree within 10 percent and the arterial oxygen  
saturation was steady to within 1 percent. Blood pressures and heart rates were noted  
at this mom ent and served as control measurements.
Isoproterenol was then infused at several rates between 0.24 and 2.0 J^g./min., in 6 
subjects, so that dose-response curves could be plotted. Measurements were made 5 
minutes after each change in isoproterenol infusion rate and increasingly doses were 
given to raise heart rate by at least 25 percent or to a maximum of 110 beats per 
minute. Isoproterenol infusion was then discontinued.
Subjects remained supine, and cardiovascular parameters were measured at 
3-minute intervals until the heart rate and cardiac output were within 10 percent of  
control values. Penbutalol 0.2 mg. was then administered intravenously over a two- 
minute period and after a lapse o f 15 minutes the infusion o f isoproterenol was 
resumed at the rates as before.
Tests of statistical significance were applied to the mean differences in measure­
ments made in the control period preceding administration o f drugs, and during in­
fusion o f isoproterenol by applying a Student’s t-test to the paired comparisons. The 
same comparison was applied to mean differences in measurements made during 
isoproterenol infusions before and after administration o f penbutalol 0.2 mg.
In 4 further subjects, all measurements described above were recorded at rest and 
30 minutes afjer 0.3 mg. penbutalol. Isoproterenol was then infused at rates o f 0.69,
1.0 and 1.5 /ig./min. and measurements made 5 minutes after each change in infusion 
rate. The response to isoproterenol administered under these circumstances was com ­
pared to that when isoproterenol was given alone or after penbutalol 0.2 mg. Statisti­
cal significance was tested by applying Student’s t-test to the comparison o f sample 
means.
In 4 experiments, similar studies were done on acebutolol. Isoproterenol was 
infused at rates o f 0.69, 1.0 and 1.5 /ug./min. before and after intravenous injections o f  
acebutolol 5 and 10 mg.
Pulmonary Studies
The effects o f penbutalol upon peak flow, F E V i and FVC were assessed in 7 students 
with allergic Type I asthma. All were males aged 19 to 27 years and 55 to 70 kg. in 
weight. No subject had used bronchodilators in the 12-hour period before the investi­
gation. Following a 10-minute rest period, peak flow, FEV^ and FVC were measured 
using a Wright peak flow meter and a Vitallograph wedge spirometer. Penbutalol 0.05  
mg. was then injected intravenously and measurements repeated 90 minutes later. 
Further injections o f 0.05 mg. were given every 90 minutes to a total dose o f 0.2 mg. 
penbutalol. Measurements were repeated before each injection.
Six asthmatics took placebo and oral penbutalol 2, 4 or 8 mg. in random order.
O)-j
Observations Control
Isoproterenol Infusion jLtg./min. Isoproterenol Infusion/ig./min. 
Isoproterenol after Penbutolol 0.2 mg.
Stopped
0.24 0.48 0.69 1.0 1.5 10 min. 0.48 0.69 1.0 1.5
Heart rate 
beats/min.
69.6
(3.16)
76.0
(3.21)
73.4
(3.12)
77.6* * 
(3.75)
82.6* * * 
(4.61)
89.0* ** 
(4.69)
70.6
(2.98)
69.8
(2.63)
66.0*
(2.04)
71.2***
(2.71)
76.Ot 
(5.47)
Mean arterial 
pres. min./Hg 
(S.E.M.)
83.4
(2.89)
83.7
(2.60)
82.6
(3.31)
81.4
(3.34)
80.6
(2.99)
82.0
(3.90)
83.6
(2.04)
86.8
(2.98)
84.0
(2.16)
85.0*
(2.63)
86.0
(2.53)
Central Venous 
Pres. mm.Hg
4.56
(0.50)
3.63
(0.63)
3.63
(1.01)
3.06
(1.23)
2.56
(1.49)
2.56
(1.58)
4.00
(0.74)
3.50
(1.26)
2.50
(1.40)
1.81
(1.52)
1.75
(1.66)
Cardiac Output 
1/mln. (S.E.M.)
7.26
(0.67)
9.3
(0.42)
8.52
(0.85)
9.64* • 
(0.64)
10.63tt
(0.80)
11,52tt 
(0.62)
7.72
(0.35)
8.15
(0.38)
8.05*
(0.68)
9.38
(0.67)
9.90*
(0.68)
Stroke Volume 
ml. (S.E.M.)
103.2
(5.43)
122.3
(8.35)
115.6
(10.76)
124.4
(7.19)
133.0*** 
(8.22)
133.0*** 
(4.80)
109.4
(4.75)
116.0
(2.48)
121.3
(7.28)
131.4
(9.65)
131.2
(10.34)
Peripheral Vascu­
lar Resistance 
dynes cm'5 (S.E.M.
948
(85)
721
(21)
812
(100)
685* * 
(44)
624t
(58)
576t
(45)
874
(47)
853
(26)
851*
(67)
734
(35)
694*
(31)
Flow 2.49
(0.90)
3.66
(0.76)
2.95
(0.51)
3.28
(0.66)
3.71
(0.80)
3.92
(1.00)
2.87
(0.48)
3.17
(0.38)
3.20*
(0.64)
3.09
(0.42)
3.27
(0.55)
Data expressed as means i  SEM. Statistical significance tested using paired comparisons. Effects of penbutalol 0.2 mg. l.V .I. assessed by com­
parisons with responses to isoproterenol infusion before blockade. Effects of isoproterenol assessed by comparisons with control measurements.
• P < 0 .050 P < 0.025 P < 0 .010  t P < 0 .005  t t  P < 0.001• * • • *
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Peak flow, FE V j and FVC were measured immediately before taking the capsules and 
2, 4, 6, and 8 hours later. The respiratory effects o f acebutolol were investigated sepa­
rately and have been reported elsewhere.5
RESULTS
Results appear in Tables I to III and Figures 2 to 9, inclusive.
Table II — Effects o f  Penbutalol 0.3 mg. I. V.I. on Isoproterenol Infusion
Observation Control Isoproterenol Infusion jUg./min. after Penbutalol 0.3 mg. 
0.69 1.0 1.5
Heart rate 
beats/min. 
(S.E.M.
73.2 (3.15) 68.5 (2.22) 68.7 (2.10)* 70.7 (2.66)***
Mean arterial 
Pressure
mm. Hg (S.E.M.)
94.7 (1.44) 95.2 (1.80) 95.0 (2.04) 96.5 (1.71)
Central
Venous
Pressure
2.62 (1.30 1.62 (Ci.90) 1.25 (0.78) 1.00 (1.50)
Cardiac Out- 
Put 1/min. 
(S.E.M.)
7.85 (0.78) 7.07 (0.88)* 7.65 (0.45)** 8.65 (1.43)
Stroke 
Volume 
(S.E.M.) ml.
107 (11.77) 102 (9.75) 111 (3.71)* 121 (15.62)
Peripheral 
Vascular Res. 
dynes cm'5 
(S.E.M.)
993(94) 1119(115)*** 1003 (62) t 951 (119)**
Flow 4.04 (0.03) 2.97 (0.09) 3.62 (0.51) 4.11 (0.59)
Data expressed as means ± S .E .M . Tests of significance refer to differences between response to 
isoprenaline alone and isoprenaline and penbutalol 0.3 mg.
* P < 0 .0 5  * * P <  0.025 * * * P <  0.010 t P <  0.005
(a) H a e m o d y n a m i c  S t u d i e s
Isoproterenol caused significant increases, at various infusion rates, in 
heart rate, cardiac output and stroke volume. Peripheral vascular resist­
ance fell, but no statistically significant changes in central venous pressure, 
mean arterial pressure or peripheral blood flow occurred (Table I, Fig. 
2-5). Many of the effects of isoproterenol were much reduced by 
penbutalol 0.2 and 0.3 mg. by intravenous infusion (I.V.I.) Valid compari­
sons between subjects given 0.2 and 0.3 mg. penbutalol could not be made 
with respect to arterial and venous pressures or peripheral flow because of
differences in control measurements. (Tables I and II).
Figure 2 — Blockade o f  isoproterenol by penbutalol. Closed circles represent isopro­
terenol infusion. Open circles isoproterenol after penbutalol 0.2 mg. I.V.I. 
and triangles isoproterenol after penbutalol 0.3 mg.
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There was no significant difference between the effects of acebutolol 
5 mg. and penbutalol 0.2 mg. I.V.I. Acebutolol 10 mg. was more potent 
than penbutalol 0.2 mg. in blocking the effects of isoproterenol on cardiac 
output, stroke volume and peripheral vascular resistance, (P = < 0.05), 
but this comparison is possibly invalid in that control measurements were 
different in the groups studied. (Table III).
-3
o
Isoproterenol Infusion Isoproterenol Infusion/ig. Isoproterenol Infusion/ig.
/ig./min. /min. after Acebutolol 5 mg. /min. after Acebutolol 10 mg.
Observations Control 0.69 1.0 1.5 0.69 1.0 1.5 0.69 1.0 1.5
Heart rate beats/
min (S.E.M.)
67.8
(5.60)
76.5* * * 
(5.52)
83.3*
(6.05)
92.3*
(10.9)
63.5
(3.50)
71.0
(1.53)
71.5
(1.50)
67.5 7 
(2.53)
70.5*
(2.96)
76.0
(4.16)
Mean Arterial 
Pres. mm.Hg
(S.E.M.)
91.5
(2.33)
86.0*
(2.35)
85.0*
(2.12)
88.7*
(3.53)
89.0 
< 1.00)
88.3
(1.67)
85.0
(3.00)
93.5
(1.66)
91.0
(1.68)
91.3
(1.89)
Central Venous 
Pres. mm.Hg 
(S.E.M.)
4.88
(0.80)
3.13* * * 
(0.99)
2.81***
(0.86)
3.33* * 
(0.93)
4.38
(1.87)
4.08
(0.87)
3.75
(0.25)
5.06
(0.74)
4.75* * 
(0.77)
5.33* * 
(0.60)
Cardiac Output 
1/min. (S.E.M.)
5.70
(0.20)
7.65*
(0.73)
9.55t
(0.61)
9.90* ** 
(1.32)
6.60
(0.60)
7.50
(0.51)
8.10
(0.70)
6.15
(0.40)
6.93
(0.57)
7.77
(1.01)
Stroke Vol. 
Ml. (S.E.M.)
85.8
(8.70)
101.3
(12.59)
115.8**
(11.37)
111.7
(25.73)
103.5
(3.50)
104.7
(4.81)
112.5
(7.50)
91.3
(7.09)
98.5t 
(10.19)
109.0
(16.62)
Peripheral Vascu­
lar Resistance 
dynes cm"® (S.E.M.)
1288
(54)
926t
(98)
723tt
(58)
743t
(110)
1087
(87)
950
(61)
848
(103)
1232***
(98)
1078*** 
(111)
981**
(146)
Flow 2.37
(0.18)
2.67
(0.32)
2.93*
(0.22)
3.30*
(0.17)
3.36*
(1.27)
2.34
(0.60)
2.86
(0.96)
2.41
(0.59)
2.32
(0.48)
2.59
(0.74)
Data expressed as means ±S.E.M . Statistical significance tested using paired comparisons as Table I. Effects of 5 mg. Acebutolol not analysed 
statistically, because whole sample did not receive this dose.
P < 0 .050 P < 0 .025 •••  P < 0 .010 t P < 0 .005 t t P  < 0 . 0 0 1
ISOPROTERENOL BLOCKADE IN MAN
/Figure 3 — Blockade o f  isoproterenol by penbutalol. Closed circles represent isopro­
terenol infusion. Open circles isoproterenol after penbutalol 0.2 mg. I.V.I. 
and triangles isoproterenol after penbutalol 0.3 mg.
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(b) P u l m o n a r y  S t u d i e s
Results are set out in Tables IV and V. Two asthmatics developed bron- 
chospasm 90 minutes after 0.15 mg. penbutalol I.V.I. and within 4 hours 
of a 4-mg. dose given- by mouth. Two others reacted unfavourably to 
oral penbutalol 2 mg. and 1 became breathless 4 hours after taking 8 mg.
DISCUSSION
A number of /3-adrenergic blocking agents have been synthesized in recent 
years. These preparations are much alike in their pharmacological charac-
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teristics although slight differences in clinical efficacy are reported. Two 
compounds, practolol and acebutolol,5 appear to be partly selective for P i  
receptors.
Intravenous penbutalol 0.1 to 0.3 mg. or acebutolol 5 to 10 mg. block 
the cardiovascular actions of isoproterenol effectively. The duration of 
this blockade was not investigated, but experiments elsewhere indicate 
that the biological half-life of pentubalol I.V.I. is about 10 hours and that 
of acebutolol 6 hours.6'7
Penbutalol precipitates bronchospasm in asthmatics, a tendency 
shared with other non-selective j3-adrenergic blocking agents. Previous
Figure 5 — Blockade o f  isoproterenol by penbutalol. Closed circles represent isopro­
terenol infusion. Open circles isoproterenol after penbutalol 0.2 mg. I.V.I. 
and triangles isoproterenol after penbutalol 0.3 mg.
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Figure 7 — Blockade o f  isoproterenol by acebutolol. Closed circles represent isopro­
terenol infusion. Open circles isoproterenol after acebutolol 5 mg. I. V.I., 
triangles isoproterenol after acebutolol 10 mg. I. V.I.
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OUTPUT
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studies indicate that acebutolol and practolol are usually not associated 
with respiratory side effects and may be used when asthmatics require 0 
blockade.
Our preliminary studies indicate that penbutalol is a potent adrenergic 
blocking agent likely to resemble propranolol in the clinical situation, 
rather than practolol or acebutolol.
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Subject
No.
Control Measurements 
Peak
F E V i  FV C  Flow
0.1 mg. Penbutalol
Peak
F E V i  FV C  Flow
0.15 mg. Penbutalol 
Peak
F E V i  FV C  Flow
0.2 mg. Penbutalol 
Peak
F E V i  FV C  Flow
1 3.2 5.05 500 3.2 4.75 515 3.1 4.75 450 3.1 4.65 485
2 2.9 5.35 460 3.55 5.15 520 3.5 5.35 580 3.5 5.05 520
3 1.55 3.05 325 1.45 3.15 240 S T  U ID Y A B O R T E D
4 1.9 3.6 190 1.9 3.45 220 1.55 2.95 120 A B O R T E D
5 2.5 4.2 450 2.5 3.8 440 2.2 3.4 410 2.5 3.5 390
6 4.7 6.9 500 4.55 6.5 470 4.45 6.5 450 I N C O M P L  E T  E
Mean 2.79 4.69 404.17 2.86 4.47 400.83 2.96 4.59 402.0 3.03 4.40 465.0
S.E.M. 0.46 0.56 50.2 0.47 0.51 55.4 0.5 0.65 76.1 0.29 0.47 38.8
ISO
PR
O
TER
EN
O
L B
LO
C
K
A
D
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A
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Dosage Subject
No.
Control Measurement 2 hr. 4 hr. 6 hr. 8 hr.
F E V i FV C
Peak
Flow F E V i FV C
Peak
Flow F E V i  FV C
Peak
Flow F E V i FV C
Peak
Flow F E V i FV C
Peak
Flow
2 mg. 1 3.05 4.75 495 3.05 4.65 480 2.9 4.55 480 2.9 4.55 430 2.85 4.65 455
2 3.05 5.2 465 2.7 5.0 420 3.05 5.0 420 3.4 5.15 480 3.1 4.9 480
3 1.7 3.1 315 1.75 2.9 280 — — 1.2 2.7 260 1.55 3.0 260
4 2.0 3.4 220 1.5 2.8 185 1.5 2.75 170 1.15 2.25 95 A B O R T E D
5 2.15 3.4 360 1.4 2.45 220 E X P E R I M E N T A B O R T  E D
6 4.5 7.1 490 4.55 6.9 470 4.5 6.7 450 4.3 6.7 440 4.6 6.7 440
Mean 2.74 4.49 390.8 2.49 4.12* 342.5* 2.99 4.75 380.0 2.59 4.27 341.0 3.03 4.81 408.8
S.E.M. 0.42 0.62 45.49 0.49 0.70 53.19 0.61 0.81 71.1 0.62 0.82 72.2 0.63 0.76 50.26
4 mg. 1 3.35 4.4 515 3.25 4.8 460 3.25 4.75 490 3.15 4.45 460 2.95 4.55 440
2 3.3 3.3 520 2.8 2.8 450 E X P E R I M E N T A B O R T  E D
3 2.0 3.6 400 1.0 2.15 160 E X P E R 1 M E N T A B O R T  E D
6 4.5 6.6 450 4.2 6.5 440 4.35 6.5 440 4.2 6.5 430 4.3 6.5 440
Mean 3.29 4.48 471.25 2.81 4.06 377.5
S.E.M. 0.51 0.75 28.6 0.67 0.99 72.6
8 mg. 1 4.75 460 4.35 350 E X P E R 1 M E N T A B O R T  E D
6 6.65 420 6.65 440 6.7 400 6.5 405 6.5 390
Asterisks signify significant group change in paired comparisons ( P < 0 .0 5  ). 
Mean and S.E.M . not calculated for <  3 measurements.
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Summary. Intravenous etilefrine increases the pulse rate, cardiac output, stroke volume, central 
venous pressure and mean arterial pressure of healthy individuals. Peripheral vascular resistance 
falls during the infusion of 1 - 8 mg etilefrine but begins to rise at higher dosage. Marked falls in 
pulse rate, cardiac output, stroke volume and peripheral bloodflow, accompanied by rises in mean arte­
rial pressure, occur when etilefrine is infused after administration of intravenous propranolol 2,5 mg. 
These findings indicate that etilefrine has both 8j and a adrenergic effects in man.
Key words: Etilefrine, normal man, intravenous, haemodynamic effects, propranolol, phentolamine, a,
Sj stimulation.
Etilefrine, (2-ethylamino-1-(3'-hydroxy-phenyl) 
ethanol, is a sympathomimetic amine of the 3-hy- 
droxy-phenylethanolamine series used in treating 
orthostatic hypotension of neurological, cardio­
vascular, endocrine or metabolic origin. Intrave­
nous infusion of this compound increases cardiac 
output, stroke volume, venous return and blood 
pressure in man and experimental animals, suggest­
ing stimulation of both a and 3 adrenergic recep­
tors, (Nusser, Donath and Russ, 1965; Mellander, 
1966; Limbourg, Just and Lang, 1973; Tarnow et at., 
1973; Carrera and Aguilera, 1973). However, in 
vitro studies indicate that etilefrine has a much 
higher affinity for 8; (cardiac) than for a or 62 
adrenoreceptors, (Offermeier and Dreyer, 1971).
The objects of the study reported here were 
to record dose responses to etilefrine in man, to 
determine its mechanism of action, and to initiate 
investigations leading to the assessment of this 
preparation as an inotropic stimulant in the treat­
ment of cardiac failure associated with myocardial 
infarction.
Material and Methods
Nine healthy adults, 1 female and 8 males, volun­
teered to act as subjects for this investigation. 
Two were experienced medical technicians and 7 
were senior medical students. All had participated 
in previous experiments of a similar nature either 
as subjects or observers. A full explanation of 
the implications of the study was given to each 
volunteer. All studies were performed with the 
subjects supine, in a horizontal position, and
under the uninterrupted supervision of 3 senior 
clinicians and a registered nurse. Subjects weighed 
55 to 70 kg and were 20 to 35 years old. No clini­
cal evidence of cardiopulmonary disease was present.
Using local analgesia, plastic catheters were 
inserted percutaneously into the right atrium from 
an antecubital vein and into the right radial 
artery. Pressures were measured by Statham strain 
gauge transducers supported 7,5 cm above the sur­
face of an operating table and recorded contin­
uously on a Philips 3T recorder. Heart rate was 
measured using a SAN/E1/2D 16 pulsemeter and a 
finger photocell. Cardiac output was measured by 
dye dilution using indocyanine green and a Philips 
X0 1000 combined oximeter/densitometer cuvette. 
Arterial oxygen saturation and haemoglobin were 
measured during cardiac output estimation.
At the conclusion of each experiment the cardiac 
output densitometer was calibrated using the 
patients own blood and known doses of indocyanine 
green. Cardiac output was calculated using the 
method of Williams, Donovan and Wood (1966) to 
prepare an appropriate programme for an Olivetti 
Digital Computer. Total peripheral vascular resis­
tance (PVR) was calculated from the formula of 
Aperia, (1940):
PVR(dynes* sec* cm~5) mean arterial pressure (mmHg) cardiac output (1 /min)
Peripheral blood flow in the mid-calf region of 
the left leg was measured by venous occlusion 
plethysmography using mercury in silastic strain 
gauges. Change in resistance of the gauge was 
measured on a Parks 270 plethysmograph, and record­
ings were made on a Unicorder U 400 potentiometric 
recorder at paper speed of 15 cm per minute.
Subjects lay quietly for 15 - 20 min following 
introduction of the catheters after which measure­
ments of pulse, pressures, and cardiac output 
were made at 5 min intervals until the areas of at 
least 2 dye dilution curves appeared to agree with­
in 10 percent and the arterial oxygen saturation 
was steady within 1 percent. Blood pressures and 
heart rates were noted at this moment and served 
as control measurements. In 5 experiments etil- 
efrine was infused at the rate of 0,5 mg/min using 
a Sage 355 constant infusion pump. Further measure­
ments of heart rate, mean arterial pressure, cen­
tral venous pressure, peripheral blood flow and 
cardiac output were made when 1, 2, 4, 6, 8 and 
10 mg of etilefrine had been infused. These 
measurements were repeated 20 rain after cessation 
of the infusion.
In 4 experiments propranolol ( 2 - 5  mg) was in­
jected intravenously at a rate of 1 mg/2 min. 
Haemodynamic parameters were measured 5 min later 
and etilefrine 0,5 mg/min then infused to a maximum 
dose of 10 mg, or until heart rate was 20 - 30% 
below the control reading. Cardiac output and pres­
sures were measured at this point. Phentolamine
2,5 mg was then administered intravenously over 
2 min while pulse and arterial and central venous 
pressures were monitored. Cardiac output was 
measured 2 min later.
Tests of statistical significance were applied 
to the mean differences in measurements made in 
the control period preceding administration of 
etilefrine and during its infusion by applying 
a Student's t-test to the paired comparisons.
Results
A slight increase in pulse rate was noted during 
etilefrine infusion. This change was significant 
after 2 and 6 mg etilefrine (P < 0.025 and < 0.05), 
but not at any other stage(Table 1). Mean arterial 
pressure, central venous pressure, (Table 1), car­
diac output and stroke volume, (Table 2), all in­
creased progressively during the infusion of etile­
frine and these changes were consistently significant.
Peripheral vascular resistance (Table 3) fell 
during the infusion of etilefrine 1 - 8 mg, but 
rose slightly after a 10 mg dose. These changes 
were significant at 1, 4, 6, and 8 mg. No signifi­
cant change in peripheral blood flow occurred, 
although mean flow rose slightly during studies.
There was no significant difference between 
control readings and those made 20 min after in­
fusions were stopped, except in the case of arterial 
pressure which remained significantly elevated at 
91,0 mmHg compared with a control mean of 79.0 mm 
Hg (P < 0.025). Mean levels for central venous 
pressure, cardiac output, and stroke volume were 
greater than those recorded before infusions 
started, but these differences were not of statis­
tical significance.
Administration of propranolol 2 - 5 mg caused 
slight falls in pulse rate, central venous pres­
sure, mean arterial pressure and cardiac output, 
(Table 4). These changes were not significant, 
however. Total doses of 1,5 - 5 mg (mean 3,5 mg) 
etilefrine were infused; means of measurements 
made immediately after stopping the infusion ap­
pear in Tables 4 and 5. Pulse rate, cardiac output, 
stroke volume and peripheral blood-flow fell
Table 1. Effects of etilefrine 0.5 mg/min infused intravenously in man
Dose 0 mg 1 mg 2 mg 4 mg 6 mg 8 mg 10 mg 10 mg + 
20 min
Heart Rate 
(beats/min) 68.6 72.2 74.2b 75.2 77.4a 75.6 72.6 68.0
Mean
S.E.M. 3.63 2.99 3.37 3.65 3.74 2.89 2.58 2.68
Arterial 
Press.(mm Hg) 
Mean 79.0 78.6 81.8C 82.0 86.2b 89.4b 93.4C 91.0b
S.E.M. 2.00 2.71 2.31 1.70 1.43 0.87 0.60 2.65
C.V.P. (mm Hg) 
Mean 3.40 3.90b 4.70c 5.60d 6.00d 6.55C 7.40d 5.35
S.E.M. 1.06 1.12 0.97 1.03 1.04 1.19 1.07 1.38
3 P < 0.050 b P < 0.025
C P < 0.005 d P < 0.001
Levels of significance
markedly during etilefrine infusion and mean ar­
terial pressure, peripheral vascular resistance 
and central venous pressure rose. All these values 
returned to control levels after a adrenergic 
blockade with phentolamine 2,5 mg.
Discussion
The findings reported in this communication are 
in general agreement with those of other investi­
gators, (Carrera and Aquilera, 1973; Limbourg,
Just and Lang, 1973; Tarnow et al., 1973). Intra­
venous infusion of etilefrine 50 - 200 pg/kg 
causes marked increases in stroke volume, cardiac 
output, central venous pressure and mean arterial 
pressure, accompanied by slight increases in pulse
rate and peripheral blood-flow. These changes, and 
the associated fall in total peripheral resistance 
may be explained by positive inotropism, mediated 
through 6! adrenergic receptors, (Offermeier and 
Dreyer, 1971) and constriction of capacitance ves­
sels with dilatation of arterioles (Mellander,
1966). Increased venous return, mediated by raised 
tone in capacitance vessels, probably contributes 
to the rise in cardiac output which follows etil­
efrine administration.
Mellander's studies in the cat indicate the 
etilefrine causes reflex vasodilation in low 
dosage and a receptor mediated vaso-constriction 
of peripheral vessels at higher doses. In our 
studies in man, the dose related fall in peripheral 
vascular resistance associated with etilefrine 
infusion stopped when more than 100 pg/kg was ad-
Table 2. Effects of etilefrine 0,5 mg/min infused intravenously in man
Dose 0 mg 1 mg 2 mg 4 mg 6 mg 8 mg 10 mg 10 mg + 
20 min
Cardiac Output 
(1/min)
Mean 6.52 7.32 8.08d 9.34b 10.06c 10.00 9.34 7.34
S.E.M. 0.77 0.69 0.61 0.68 0.65 0.72 0.75 0.71
Stroke Volume 
(ml)
Mean 95.6 103.2 110.2d 127.6a 132.4b 134.0C 129.8C 109.4
S.E.M. 10.6 13.4 9.90 16.1 14.3 13.6 13.1 13.5
Levels of significance a P < 0.050 b P < 0.025 c P < 0.010
d P < 0.005 6 P < 0.001
Table 3. Effects of etilefrine 0,5 mg/min infused intravenously in man
Dose 0 mg 1 mg 2 mg 4 mg 6 mg 8 mg 10 mg 10 mg + 
20 min
Peripheral 
Vascular 
Resistance 
(dynes1sec-cm‘ 
Mean
■5)
1010 883a 825 715b 695b 730b 825 1023
S.E.M. 94.5 72.1 50.4 43.7 37.0 53.2 78.6 88.0
Peripheral 
Blood Flow 
(ml/100 g) 
Mean 2.68 3.01 3.06 3.14 3.27 3.35 3.16 2.92
S.E.M. 0.45 0.64 0.53 0.68 0.81 0.74 0.73 0.74
Levels of significance P < 0.050 P < 0.025
Table 4. Effects of a and 3 blockade on effects of 
etilefrine infusion in man
Dose 0 3 Blockade 
(Propran­
olol 2-5mg)
Etilefrine 
(Mean dose 
3,5 mg)
a Blockade 
(Phentol­
amine 
2,5 mg)
Heart Rate 
(beats/min) 
Mean 61,3 58,0 45,3b 64,0
S.E.M. ±6.89 ±6,11 ±4,18 ±7,64
Mean Arte­
rial Pres­
sure (mmHg) 
Mean 76,0 74,0 90,3b 73,0
S.E.M. ±3,21 ±4,00 ±4,91 ±2,08
C.V.P.
(mmHg)
Mean 5,42 5,25 9,58b 5,67
S.E.M. ±0.82 ±0.90 ±1.23 ±0.67
Cardiac Out­
put (1/min)
Mean 5,03 4,83 3,43a 5,37
S.E.M. ±0.29 ±0.12 ±0.32 ±0,50
Levels of significance , P
b P
= < 0,05 
= < 0,05
Table 5. Effects of a and 3 blockade on 
etilefrine infusion in man
effects of
Control 3 Blockade 
(Propran­
olol 2-5mg)
Etilefrine 
(Mean dose 
3,5 mg)
a Blockade 
(Phentol­
amine 
2,5 mg)
Stroke
volume
(ml) 85,3 86,0 78,3a 86,7
S.E.M. ±14,9 ±11,0 ±15,2 ±14,6
P.V.R. 
(dynes 
cm- 5) 
Mean
sec
1221 1224 2158b 1109
S.E.M. ±119 ±48,9 ±308 ±118
Muscle Flow 
(ml/I00 g)
Mean 2,34 2,34 1,81 2,12
S.E.M. ±0,66 ±0,34 ±0,08 ±0,38
Levels of significance , P = < 0,05
b P = < 0,025
ministered. The consistent dose-related elevation 
in central venous pressure suggests that capacitance 
vessels were constricted by etilefrine and not 
affected significantly by reflex vasodilation.
The changed responses to etilefrine associated 
with 6 and a blockade were impressive, and indicate 
that etilefrine is a stimulant of a and 6 adrener­
gic receptors in man, as in animals (Mellander,
1966; Carrera and Aguile, 1973). When etilefrine 
was given after 3 blockade the most striking ef­
fects were rises in central venous pressure, mean 
arterial pressure and peripheral vascular resis­
tance coupled with falls in pulse rate, cardiac 
output and stroke volume. Since propranolol blocks 
the 8i (inotropic) effects of etilefrine without 
compromising a effects on the peripheral vascula­
ture, the falls in pulse rate, cardiac output and 
stroke volume might be reflex responses to a 
mediated change in arterial pressure or represent 
an unexplained potentiation of propranolol's 
specific or non-specific effects by etilefrine.
The former possibility is favoured by the rapid 
return of all parameters to control levels after 
phentolamine administration.
Owing to the complexity of the study, atropine 
was not administered, a Blockade did not result in 
further falls in cardiac output, which suggests 
that an a mediated rise in venous return is less 
important than Bj adrenergic stimulation in 
determining increases in cardiac output following 
etilefrine administration.
The findings reported here lend support to the 
contention of Nusser, Donath and Russ, (1965), that 
etilefrine increases stroke volume and heart 
contractile force by capacitance vessel constric­
tion and by its positive inotropic effects. Further 
detailed studies are necessary, however, to clari­
fy its mechanism of action, and to assess whether 
it has a place in the management of cardiovascular 
disease.
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Cardiovascular Effects of Intravenous Indoramin Hydrochloride in Man
The technical expertise required to measure cardiac output 
was provided by Professor Coleman. Intubation of arteries 
was a shared procedure as was the analysis of data and 
preparation of the publication. The protocol followed was a 
joint venture. Professor A.C. Asmal provided editorial
assistance.
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C ardiovascular Effects o f  Intravenous Indoram in  
H ydrochloride in M an
A J Colem an, MB, BS, F F A  RCS(Eng), C o n su lta n t A n a e s th e tis t, W P Leary, MB, 
BCh(W itwatersrand), M Sc, F C P (SA ), M R C P(Lond), D Phil(O xon), P ro fe sso r  o f  C lin ica l a n d  
E x p e r im e n ta l P h a rm a co lo g y , A C A sm al, M D (Lond), F C P (SA ), M R C P(L ond), S e n io r  
L ec tu rer , D e p a rtm e n ts  o f  C lin ica l P h a rm a c o lo g y  a n d  M ed ic in e , U n iversity  o f  N a ta l, D u rb a n , 
S o u th  A fr ica
Haemodynamic effects of intravenous indoramin (5-20 mg) were measured 
in ten healthy volunteers. Slight falls in arterial and central venous blood 
pressures were noted but no significant changes in heart rate, right atrial 
pressure, cardiac output or derived values occurred, except for a fall in 
peripheral vascular resistance in three cases. An increase in skin bloodJlow 
to the feet was observed.
An attempt was made to determine the mechanism of these responses and 
it was concluded that the drug was an alpha adrenoceptor blocking agent 
which appeared to act preferentially on those receptors controlling blood Jlow 
to the skin of extremities.
Introduction
Indoramin, 3-(2-(4-bcnzamidopiperid-l-  
yl)ethyl) indole hydrochloride is a relatively 
new hypotensive agent with interesting 
pharmacological properties. Preliminary 
experiments in animals (Alps. Johnson & 
Wilson 1970) and man indicate that indoramin 
is antihistaminie. competitively blocks alpha 
adrenoreceptors and has a sedative effect upon 
the heart (Royds, Coltart & Lockhart 1972). 
Sub-hypotensive doses of indoramin increase 
hand temperature in normal individuals 
(Royds & Lockhart 1974), and blood flow in 
the .hands and feet of patients with Raynaud’s 
disease and athero-sclerosis with claudication 
(Fares & Milliken 1974).
In p r e v i o u s  s t u d i e s  f ew d i r e c t  
haemodynamic observations were made 
concurrent with estimations of [Kiipheral blood
flow. It was the purpose of the study reported 
here to measure blood flow in the lower 
e x t r e m i t i e s  t o g e t h e r  wi t h  g e n e r a l  
haemodynamic responses and to assess the 
effects of indoramin on the cardiovascular 
responses evoked in man by the alpha and 
beta agonists, noradrenaline and isoprenaline.
Materials and M ethods
Ten healthy males aged 22--28 years and 
weighing between 55 and 70 kg volunteered to 
act as subjects for this investigation. All were 
senior medical students who had participated 
in previous experiments of a similar nature as 
subjects or observers. A full explanation of the 
implications of the study was given to each 
volunteer. Subjects came to the laboratory
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after an overnight 12-hour fast, and studies 
were performed with the subjects in a supine 
horizontal position, with the head resting 
com fortably on pillows.
Using local analgesia, plastic catheters were 
inserted percutaneous!}' into the radial artery 
and into the right atrium from a right 
anteeubital vein. Pressures were measured by 
Statham gauge transducers supported 7 cm 
above the surface o f the operating table and 
recorded co n tin u ou sly  on a Philips 3T  
recorder. Pressure gauges were calibrated 
using mercury manometers. Heart rate was 
measured tiding a San-El-2D 16 pulsenrcter and 
finger photocell. Lead 1 ECG was displayed  
on an oscilloscope and recorded continuously. 
Cardiac output was measured by dye dilution 
using indocyanine green and a Philips XO- 
1000 com bined oxim eter/densitom eter cuvette. 
At the conclusion o f each experiment the 
cardiac output densitometer was calibrated 
using each subject’s own blood and known 
doses o f  cardiac green. Cardiac output was 
calculated from the dye dilution curves using 
the method- o f  Williams, O ’D onovan and 
W oods (1966) to prepare an appropriate 
programme for an Olivetti digital computer. 
Total peripheral vascular resistance (PVR) 
was calculated from the formula o f  Aperia 
(1940):
PVR — Mcan arterial pressure (mm Hg)  ^
Cardiac output (1/m in)
■ x 80 dynes see cm
An intravenous infusion o f normal saline 
(3 -5  ml/min) was given in the left arm so that 
drugs could be administered subsequently  
without disturbing the subjects.
Blood flow in the foot and ca lf regions o f  the 
left leg was measured by venous occlusion  
plrlhysm ogi aphv using, mercury in silastic 
strain gauges placed circumlcrinitially around 
the instep and mid calf. Sphygm om anom eter 
cuffs were placed just above the left knee so 
that venous blood outflow could be arrested by 
sudden application o f 6 0 -7 0  mm Hg pressure 
to the cuff for a period o f 1 5 -2 0  seconds. 
Change in resistance o f  the strain gauges was 
m easured using, Parks P lcth ysm ograph s  
(M odel 270) and recordings were made on a 
m ulti ch a n n e l p o tc n tio m e tr ic  record er  
(Unicordcr U-400). C alf strain gauges were 
attached to the limbs by an adjustable caliper
which enabled the gauge to be stretched 
precisely  for ca libration  p urposes, thus 
perm itting ca lcu la tion  o f  b lood  flow in 
absolute terms. Foot gauges could not be 
calibrated in this way because the shape o f  the 
foot did not permit use o f a calibration caliper 
and blood llow to the foot was therefore 
measured as percentage change from control. 
Subjects were left undisturbed following the 
introduction o f atrial and arterial catheters 
until heart rate, blood flow and pressures were 
steady. Cardiac output estim ations were then 
made at 3 minute intervals until the area under 
at least two dye dilution curves was the same 
(within 10%). Blood pressures, heart rate and 
blood Hows were recorded at this time and 
served as control measurements.
Two subjects were given 20 mg indoramin 
divided into four equal doses which were 
infused intravenously over 30 see at 5 min 
intervals. Cardiac output and leg blood flow 
were measured 4 | — 5 mins after each dose; all 
other  p a r a me t e r s  were moni t or e d  
c o n t in u o u s ly . In three o th er  su b jec ts  
cardiovascular responses to isoprenaline were 
measured before and after indoramin infusion. 
After the control period increasing doses of 
isoprenaline hydrochloride were given by rapid 
intravenous injection; heart rate and blood 
p r e s s u r e  m e a s u r e m e n t s  w e r e  m a d e  
continuously, cardiac output and leg blood llow 
measurements were made to coincide as 
closely as possible with peak isoprenaline 
responses. Heart rate and blood pressures 
were allowed to return to baseline for a period 
o f at least 3 minutes between isoprenaline 
injections, and maximum dosage was limited 
to increase heart rate by 3 5 -4 5  beats per 
minute, ranging from I -5—4 //g. Indoramin 
(20 mg.) was then given by slow intravenous 
injection over a period o f 5 minutes. Cardiac 
output was measured during infusion of 
indoramin after 10 mg had been given, and 
again at com pletion o f  the infusion (control 
period 2). Isoprenaline was then administered 
again and all parameters measured as before. 
In a further live subjects, cardiovascular 
responses to noradrenaline (1 -2 0 /r g ) were 
measured before and after the administration 
o f indoramin. The experiments were conducted  
in an identical manner to the isoprenaline 
study except that noradrenaline was used in 
place o f  the beta agonist and the dosage was
limited to that which increased diastolic blood  
pressure by 10-25  mm Hg.
Tests o f  statistical significance were applied 
to the mean differences in measurements made 
during the control periods, and following 
a d m in is t r a t io n s  o f  n o r a d r e n a l in e  or  
isoprenaline by applying Student’s t-test to the 
paired com parisons. Observations in the two 
control periods (before and after indoramin) 
were com pared similarly.
All subjects were interviewed 4 -6  hours 
after com pletion o f the studies and again the 
following day. Standing blood pressure was 
measured at these times using a standard 
sp h y g m o m a n o m e te r  c u ff  and m ercu ry  
manometer and subjects were asked to report 
any sym ptom s relating to the experiments.
Results
Indoramin was well tolerated by the volunteers 
although all experienced slight drowsiness for 
a short period after the injections. No other 
sym ptom s were reported and there was no 
change in blood pressure 4 -6  and 24 hours 
after the studies. In the two subjects receiving 
5 mg aliquots o f indoramin over 30 seconds a 
transient increase in heart rate o f 1 0 -1 5  beats 
per minute occurred for about 20 seconds after 
each injection: thereafter heart rate returned to 
control levels. The effect o f 10 and 20 mg 
indoramin upon heart rate, blood pressures 
and cardiac output in all ten volunteers is 
shown in Figure 1. System ic blood pressure 
was reduced by indoramin in a dose-related  
manner. The fall in blood pressure was not 
statistically significant after 10 mg but 20 mg 
caused an average fall in systolic and diastolic 
pressures o f  10 and 6 mm llg  respectively 
(p =  < 0-05). A similar fall in central venous 
pressure occurred. Although there was a slight 
drop in cardiac output after 10 mg indoramin 
this was not significant and returned to control 
levels after the dose had been raised to a 
cum ulative 20 mg.
The most striking and consistent action o f  
indoramin was on the skin blood flow o f  the 
foot. The com pound appeared to have a dose- 
related effect so that there was an average 
increase in skin blood flow to this area o f  
275%  after 20 mg indoramin (Figure 2). This 
in c r e a se  w as su s ta in e d  at lea st until 
termination o f  the experiment 45 minutes later. 
In contrast, ca lf muscle blood flow was only
marginally increased, the 20 mg dose giving a 
mean change o f 46%.
Haemodynamic effects o f noradrenaline before 
and after indoramin
H aem odynam ic responses to intravenous 
doses o f  noradrenaline 6 -2 0  /rg before and 
after administration o f  indoramin 20 mg are 
shown in Table 1. The average mean arterial 
pressure was raised by noradrenaline, and this 
effect was partially antagonized by indoramin. 
The mean rise in diastolic pressure following 
noradrenaline was dose-related for the five 
subjects investigated, and indoramin caused a 
parallel shift o f  the dose/response curve to the 
right. Linear regression analysis showed that 
the slopes o f  the dose/response lines were 
significantly different from zero (p =  < 0 -005) 
and did not significantly deviate from parallel; 
the shift in the noradrenaline response due to 
indoramin (dose ratio 2-3) was statistically 
significant (p -  0-01). The depressant effect o f  
noradrenaline on heart rate was diminished by 
indoramin; and whereas cardiac output fell 
after noradrenaline a small mean increase was 
seen after indoramin had been given.
Haemodynamic effects o f  isoprenaline before 
and after indoramin administration 
Heart rate, blood pressure and cardiac output 
responses to isoprenaline before and after 
administration o f indoramin 20 mg arc shown  
in Table 2. The upper limit o f isoprenaline 
dosage ranged from 1 -5 -4 -0 /rg  in the three 
subjects investigated, and responses tabulated 
arc the average o f peak responses o f these 
doses. Considerable increases in heart rate and 
cardiac output occurred; mean blood pressure 
fell slightly, central venous pressure and 
peripheral vascular resistance were more than 
h a lv e d .  I n d o r a m in  d id  n o t  m o d if y  
haem odynam ic responses to isoprenaline 
significantly, although a slight fall in stroke 
volum e w as recorded. Skin b lood flow, 
however, was significantly enhanced following 
indoramin.
D iscussion  and C onclusions
O f the parameters studied, the increases in 
cutaneous blood flow were most significant. 
Changes were seen after doses as small as 
5 mg and there was a 2 to 3-fold increase in 
blood flow following the administration of
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Fig 1 E ffe c t s  o f  in t r a v e n o u s  in d o r a m in  1 0  a n d  2 0  m p  u pon  h e a r t  r a te ,  b l o o d  p r e s s u r e ,  c e n t r a l  ven o u s  p r e s s u r e  a n d  
c a r d i a c  o u tp u t .  M e a n s  o f  m e a s u r e m e n t s  ±  S E M  h a v e  b e en  p l o t t e d  f o r  t en  s u b je c t s
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l-'ig 2 E ffe c t  o f  in t r a v e n o u s  in d o r a m in  u pon  p e r i p h e r a l  b lo o d  J lo w  in th e  f o o t  ( s k in )  a n d  e a l j  (m u s c le ) .  M e a n  p e r c e n ­
tage  c h a n g e  ± H E M  h ave  b een  p l o t t e d  f o r  ten  s u b je c ts
20 mg indoramin. By com parison, changes in 
calf muscle blood flow were considerably  
smaller. These observations were consistent 
with the findings o f  R oyds and Lockhart 
( 1 9  7 4 )  w h o  u s e d  s k in  t e m p e r a t u r e  
measurement and plethysm ography to show  
that indoramin (1 5 -5 -1 8 -7  mg i.v.) increased 
forearm muscle volume and skin temperature 
o f  the hand. Furthermore, increases in hand 
and fo o t sk in  b lo o d  flow  h a v e  been  
demonstrated following the administration o f  
indoram in (1 6 - 1 3 -5  mg i.v .) to patients  
suffering from Raynaud’s disease and athero­
sclerosis (Fares & Millikcn 1974).
T he a b se n c e  o f  m arked  g en er a liz ed  
h a e m o d y n a m ic  e f fe c ts  in the p resen t  
experim ents su ggests that the profound  
increases in skin b lood  flow fo llow ing
indoramin were localized phenom ena, perhaps 
confined to the limbs. In this connection. 
R oyds and Lockhart (1974) failed to show any 
effect o f indoramin on chest skin temperature. 
They argued that vasodilator responses in this 
area are the result o f  active vasodilation (Fox, 
Goldsmith & Kidd 1962) whereas vasodilation  
o f the skin o f  the hand is the result o f  release of 
vasoconstrictor tone (Gaskcll 1956). It would 
seem, therefore, that indoramin acts mainly by 
releasing vasoconstrictor tone, probably by 
alpha-adrenoceptor blockade. Following the 
administration o f  indoramin there was a 
transient tachycardia, heart rate returning to 
normal limits within a few minutes. The 
absence o f marked tachycardia following oral 
or intravenous administration o f indoramin 
has been reported by others (R oyds. Coltart &
Table I
E ffe c ts  o f  in d o ra m in  an d  n o ra d re n a lin e  u p o n  v a r io u s  h a e m o d y n a m ic  p a ra m e te rs
O b s e r v a t io n C o n t r o l  p e r i o d  I
'P e a k '  r e s p o n s e  
n o r a d r e n a l in e
6 - 2 0  tig
C o n t r o l  p e r i o d  2 
2 0  nig  
in d o r a m in
’P e a k ’ r e s p o n s e  
n o r a d r e n a l in e  
6 - 2 0 p g
1 Icart rate Mean 64-0^ 5 2 - f 65-3 56-3
0'cats/min) SEM 7-09 6-67 4-98 4-81
Mean arterial Mean 82-7 94-0^ 76-7 85-0
pressure (mm I Ip) SEM 7-13 8-08 4-81 6-56
Central venous Mean .V3V' 4-S3 1-50' 2-60
pressure (mm 1 Ip.) SEM 0-44 0-00 0-52 0-60
Cardiac output Mean 5-1 4-5 4-7 5-3
(iitres/min) SEM 1-09 0-83 0-38 0-72
Stroke Mean 78 84 73 93
volume (ml) SEM 9-94 6-00 6-66 5-84
I’c'i iplieral 
vascular re 
sisttwice (dynes Mean 1395 1769 1314 1307
sec cm •') SEM 223 231 141 98
Muscle blood
flow (ml/100 g Mean 2-10 2-32 3-25 2-19
muscle) SEM 0-37 0-62 0-70 0-64
Skin blood Mean + 1 +485 + 140
flow change) SEM 34-7 241 101
Values compared are indicated by^ Levels of significance < 0 025
^p < 0 05
T a b le  2
E ffe c ts  o f  i iu lo r n n i in  an d  is o p rc n n lin c  u p o n  v a r io u s  l in e m o u y m im ic  p a ra m e te rs
O b s e r v a t io n C o n t r o l  p e r i o d  1
'P e a k  ’ r e s p o n s e  
i s o p r e n a l in e  
1 - 5 - 4  p g
C o n t r o l  p e r i o d  2 
2 0  m g  in d o r a m in
‘P e a k '  r e s p o n s e  
i s o p r e n a l in e  
1 - 5 - 4  p g
Heart rate M ean 56-7*® *® 95-3°® ® * 58-0 94-3
(beats/min) S E M 5-24 3-28 3-06 2-67
M ean  arterial M ean 83-0 81-3 72 -7 70-0
pressure (nun Hg) S E M 3-51 2-40 2-33 6-0
C entra l  venous M ean °  4-42® ° 1 - 5 8 * ° °  2-42 0-50
pressure  (mm Hg) S E M 0-36 0-65 0-46 0-29
C a r d i a c  output Mean 5 -3®a 1 1 - 9 * * 6-1 10-3
(litres/'min) S E M 0 - 1 7 0-68 0-32 0-58
Stroke volum e M ean 104 125 106 109
(ml) S E M 8-1 10-4 7-0 7-0
Peripheral 
v a s c u la r  re­
sistance  (dvnes M ean ° ° 1 14-5®*®° 5 5 1 0 0 0 ° ° 9 5 0 550
sec cm  ■) S E M 2 7 -7 23-8 27-4 62-2
M uscle  blood
flow ( m l / 100 g M ean 2-21 3-94 2-44 3-48
muscle) S E M 0 -72 1-55 0-78 1-15
Skin  blood How M ean - 3 5 - 3 + 204 + 283
("u cha ng e) S E M 18-2 53-8 87-0
Levels  o f  signif icance *  p < 0-050 c ® p < 0-025 
®*®p < 0 - 0 1 0  ® *® *p < 0 - 0 0 5
Lockhart 1972, Fares & N4iIIik.cn 1974, R oyds 
& Lockhart 1974) and may indicate that 
indoramin has a cardio-inhibitory action  
which obtunds the anticipated reflex response.
Indoram in did' not sign ificantly  affect 
cardiac output or central venous pressure but 
produced a sm ail, though sta tistica lly  
significant, fall in blood pressure. These 
changes were similar to those observed by 
R oyds, Coltart and Lockhart (1972). The 
minimal nature o f the fall in blood pressure 
may reflect the low starting pressure o f the 
normal subjects used in both these studies.
H aem odynam ic responses to intravenous 
isoprenaline were not appreciably altered by 
the prior adm inistration  o f  indoram in, 
suggesting it to be devoid o f significant beta- 
adrenoceptor blocking activity and confirming
the findings o f Alps ct a i (1972) in their animal 
studies. In contrast, the alpha-adrenoceptor 
b lock in g  properties o f  indoram in were 
dem onstrated by a parallel shift o f the 
noradrenaline pressor dose response curve to 
the right in confirmation o f  tlie findings o f  
Royds, Coltart and Lockhart (1972).
N o adverse reactions to indoramin were 
encountered. Apart from mild drowsiness, 
presumably associated with the antihistaminic 
properties o f the com pound, no side effects 
were elicited.
W hereas alpha-blocking agents have an 
established place in the treatment o f peripheral 
vascular disease (R ose 1967) many o f these 
preparations have unwanted pharmacological 
e f fe c ts .  T o la z o lin e , p h en to la m in e  and  
p h e n o x y b e n /.a m in e  m ay c a u se  m arked
tachycardia, whereas indoramin does not 
produce this clTect. Furthermore, an increase 
in skin blood flow can be produced with little 
or no change in blood pressure. Indoramin, 
therefore, m ay prove to be a useful agent in the 
m anagem ent o f peripheral vascular disease. 
H ow ever, confirm ation  m ust aw ait the 
outcom e o f  clinical trials designed to determine 
the effects o f chronic oral administration o f  
indoramin in this condition.
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SECTION E : METABOLIC EFFECTS OF MEDICINES USED IN THE
TREATMENT OF HIGH BLOOD PRESSURE
These papers describe the ancillary metabolic effects of two 
medicines which are used primarily in treatment regimens for 
patients with raised arterial pressures.
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The Effects of Adrenergic B-blockade with Oxprenolol on 
Peripheral Metabolism
The project followed consultation between the authors. The 
technique used was developed by Professor A.C. Asmal and 
formed part of his M.D. Thesis. He was primarily responsible 
for clinical investigation but this aspect'of the work was 
also shared to some extent by the other authors. Professor 
Asmal bore the burden of writing a first draft of the paper 
which was edited by me.
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Summary
Peripheral metabolism was studied with the forearm 
technique in six fasting normal subjects before and 
after oxprenolol administration. With the forearm 
technique the product of blood flow and arteriovenous 
differences is a measure of substrate uptake or release, 
and, therefore, an index of metabolism. Blood flow 
was measured with venous occlusion plethysmography, 
and arterial and venous samples obtained through 
indwelling catheters in the radial artery and deep 
forearm vein.
Oxprenolol administration influenced both peri­
pheral flow and the basal pattern of substrate ex­
change. Before oxprenolol blockade a net uptake of 
glucose, triglycerides, and FFA, and a net release of 
glycerol were recorded across the forearm. After 
oxprenolol blockade there was a marked reduction in 
triglyceride uptake, with augmentation of glucose up­
take and inhibition of lipolysis.
Introduction
Adrenergic [3-receptor activity regulates a variety 
of metabolic events both centrally and peripherally 
(Havel, 1965; Brodie, Maickel and Stern, 1965; 
Himms-Hagen, 1970; Imura e t  a l., 1971; Fain, 1973). 
Such events have been investigated by one o f two 
basic approaches— infusions of catecholamines or 
[3-adrenoreceptor blocking drugs followed by mea­
surements o f plasma levels o f insulin, growth hor­
mone, FFA, and glucose (Imura e t  a l., 1971; 
Lundholm, Mohme-Lundholm and Svedmyr, 1968), 
or by the use of in v itro  muscle and adipose tissue 
preparations (Fain, 1973). The in v ivo  techniques 
measure the sum total of metabolic events, both 
primary, due to direct action on the [3-receptor, and 
secondary, due to initiation o f counter-regulatory 
mechanisms elsewhere (Brodie e t  a l., 1965). In  v itro  
studies have the advantage o f providing information
C orrespondence:  D r  A .  C .  A sm a l ,  D e p a rtm e n t  o f  Clinical 
and Experim ental P h a r m a co lo g y ,  B o x  39 C on gella ,  N a ta l ,  
South A fr ica .
on [3-receptor activity o f a more direct nature, e.g. 
effects on glucose utilization and lipolysis. A  short­
coming of in v itro  data is that they may not reflect 
with accuracy events as they occur in the intact 
organism.
The human forearm technique has been extensively 
utilized in the study o f peripheral metabolism  
(Butterfield and Holling, 1959; Rabinowitz and 
Zierler, 1962; Wahren, 1966; Posefsky, Felig and 
Tobin, 1969; Zampa e t  a l., 1967; Asmal, 1972). The 
basis o f the technique is the simultaneous measure­
ment o f blood flow and arteriovenous differences, the 
product o f which is a measure o f peripheral meta­
bolism. It has the virtue o f directly measuring meta­
bolic events, albeit only in the periphery, and helps to 
bridge the gap between data derived from physio­
logical studies in whole man, and those obtained 
from biochemical studies in the test-tube (Asmal, 
1972). Previous studies have reported on the role o f  
insulin in peripheral glucose utilization (Asmal e t  
a l., 1971a; Whichelow e t  a l., 1971; Karamanos e t  a l.,
1971) as well as on the complex interrelationships o f  
hormones and substrates (Asmal e t  a l . , 1971 b ; Asmal,
1972) . More recently the observation o f triglyceride 
release from peripheral tissues into the circulation 
in diabetes has raised the possibility that this may 
contribute to the hypertriglyceridaemia o f diabetes 
(Asmal e t  a l., 1973).
This study was designed to investigate the effects 
of [3-receptor blockade on the peripheral metabolism  
of glucose and lipids. This paper reports our findings 
in a group of normal volunteers.
Material and methods
E x p e r im e n ta l
The nature o f the study was explained to all six 
subjects (five males, and one female), who gave in­
formed consent. The age range was 25-35 years, and 
weight was within 10% of desirable weight (Scien­
tific Tables, Documenta Geigy, 1962). There was no 
history o f diabetes or other disorder o f metabolism.
All investigations were performed in a metabolic 
laboratory after an overnight fast. Subjects lay 
comfortably in a horizontal position for the duration 
of the study. Under aseptic conditions and local 
analgesia a ‘Medicut’® 18 gauge cannula was in­
troduced centripetally into the radial artery o f one 
arm, and a 16 gauge ‘Ezi-catheter’* inserted 
centrifugally into a deep forearm vein o f the contra­
lateral arm. A silastic strain gauge was applied around 
the circumference o f the upper third of the latter 
forearm, and connected to a plethysmograph pre­
amplifier (Parks Electronics Model 270) itself linked 
to a potentiometric recorder. Cuffs for instantaneous 
pressure application were placed at the wrist (pres­
sure 200 mmHg) and upper arm (pressure 60 mmHg) 
and when completed, the subjects were allowed to 
become ‘basal’. The arterial and venous cannulae 
were kept patent with slow infusions o f 0-9% saline 
containing no heparin.
With the subjects in a basal state, the wrist cuff 
was inflated to a pressure of 200 mmHg and kept at 
this level until the completion o f the study— about 
20 min. Two sets o f control flow measurements and 
blood samples, separated by 5 min, were first taken 
as follows: several flows were measured over a 2-min 
period, blood was then taken simultaneously and 
uniformly from the artery and vein over a 1-min 
period and concomitant flows measured; after 2 min 
the second set o f control values were taken. After 
this, therapeutically recommended doses of oxpreno- 
lol, ranging from 1 to 4 mg were injected slowly into 
an indwelling needle. At intervals o f 8-10 min after 
the injection, two further sets o f blood flow measure­
ments and blood samples were taken.
For the calculation of uptake, mean blood flows 
taken immediately before the sampling period were 
utilized in preference to those obtained concomi­
tantly with the sampling. This was because the samp­
ling procedure tended to produce artifacts in the flow 
configuration and made attempts to measure flow 
accurately difficult. Although this may have intro­
duced a systematic error in the measurements, the 
magnitude o f this could not be of much consequence 
because of the steady state situation prevailing. Other 
workers have also had recourse to this ploy (Jackson 
e t  a!., 1973).
C h em ica l
Plasma glucose was measured by the automated 
ferricyanide technique (modified from Hoffman, 
1937), FFA  by Duncombe’s method (1964), and 
glycerol and triglycerides enzymatically (Boehringer 
method, 1972). Standard statistical methods were 
used (Bradford-Hill, 1968). The standard deviation 
(s.d.) o f replicate analyses was 3-31, 0-013, and 
0-097 for triglycerides, FFA, and glycerol respec­
tively. The formula used was s.d. -  ( h d - j l n ) ’1, where
d  =  difference between duplicate samples, and n =  
number o f duplicate pairs which were, respectively, 
48, 24, and 48 for triglycerides, FFA, and glycerol.
Results
P id se  ra te
In the recommended therapeutic dosage range (1-4  
mg) no significant change, either in the mean pulse 
rates or in paired observations (Table 1), was noted.
P la sm a  f lo w
Although there was no significant difference in the 
mean plasma flows before and after blockade (2-69 
ml/100 ml/min and 2-36 ml/100 ml/min respectively), 
comparison o f paired values in individual subjects 
revealed significant changes (Table 1, P  <  0-01).
P la sm a  co n cen tra tio n
The plasma arterial and venous concentrations o f  
substrates before and after blockade were as follows. 
The differences before and after oxprenolol adminis­
tration are not significant. Blockade is accompanied 
by an increase in the arterial values o f glucose (from 
93 to 98 mg/100 ml) and glycerol (from 0-84 to 0-97 
mg/100 ml) and decrease in the arterial levels o f  
FFA  (from 0-43 to 0-37 mmol/1) and triglycerides 
(from 117 to 115 mg/100 ml). The effects of blockade 
on the plasma venous concentrations are less pro­
nounced— the glucose and FFA levels remain more 
or less unchanged while those of glycerol show a slight 
fall (from 0-95 to 0-90 mg/100 ml) and those o f tri­
glyceride a rise (108 to 114 mg/100 ml).
A r te r io ve n o u s  d iffe re n c es  (Table 1)
In every subject blockade is accompanied by a re­
duction in the magnitude o f the arteriovenous differ­
ences o f triglycerides { P  <  0-025), and an increase in 
the magnitude o f the exchange of glucose (P <  0-01). 
The reduction in FFA, and increase in glycerol arte­
riovenous differences on blockade are not significant 
changes.
P e r ip h e ra l ex c h a n g e  (Fig. 1)
In the control period there is net uptake o f tri­
glycerides, FFA and glucose, and net release o f  
glycerol. On oxprenolol administration, triglyceride 
uptake falls from a value of 267 nmol/100 ml/min to 
16 nmol/100 ml/min. The fall is significant ( P  <  
0-025). There is also an attenuation of FFA uptake 
(P  n.s.). In contrast net glucose uptake is augmented 
from low basal levels of 510 nmol 100 ml/min, to 
990 nmol/100 ml/min on adrenergic blockade. 
Glycerol release is suppressed by oxyprenolol as 
shown by the reduction in plasma venous concen­
tration. The stimulation of peripheral glycerol uptake 
on blockade is an unexpected finding.
Subjects and  dose 
o f  oxprenolol
Pulse
rate/min
Plasma f low *  
m l/100 ml 
forearm/min
A rter iovenous difference (jimol/l
Triglycerides* G ly c e r o l ! F F A f G lu c o s e !
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post
1 4 mg 51 48 1-8 1-7 110 7 37-3 - I I 2-3 80 20 165 275
2 2 mg 71 67 3-9 3-3 80-2 5-7 -12-4 -0-6 80 0 -220 220
3 2 mg 54 51 2-1 1-8 8 5 1 14 7 -46-3 - 2 1 4 -250 - 1 1 0 110 357
4 2 mg 63 62 2-6 2-3 75-8 66-7 -5-6 -7-9 160 80 825 1100
5 4 mg 65 62 3 0 2-8 76-8 -28-5 -6-8 4-5 110 60 110 303
6 1 mg 63 69 3 0 2-4 162-7 -61-0 0 135 140 -60 - -
Significance o f  pre- and  post-b lo ck ade  differences obtained by the 'paired / lest ’ .
* P < 0 025; f  P,  n.s.; J P  < 0 01.
T h e  minus signs preceding arteriovenous dilferences designate that venous concentrations are greater than arterial.
P
eriph
eral m
etabolism
F ig . 1. T h e  effects o f  o xp ren olo l  b lo ck ad e  on  the peripheral exchanges 
(m ean ±  s.e.) o f  glucose ( P  n.s.), F F A  ( P  n.s.), glycerol ( P  n.s.) and 
tr iglycerides ( P  < 0 025).
Discussion
The metabolic events described represent the sum 
total o f biochemical changes in all tissues o f the fore­
arm— of which muscle and adipose tissue predomi­
nate. A  limitation o f the forearm technique is that it 
cannot discriminate between metabolic activity in 
these tissues. Within the scope o f the forearm tech­
nique the term uptake may denote one o f several 
events:
(1) An adsorption o f substrate molecules to the 
capillary endothelium. This may occur during the 
uptake of, e.g. triglycerides which are hydrolysed by 
lipoprotein lipase on the endothelial surface.
(2) A sequestration of substrate in the interstitial 
space where molecules may be in equilibrium between 
the plasma and cell, e.g. FFA.
(3) An attachment of the substrate to the cell 
membrane, e.g. glucose before active transport.
(4) Intracellular metabolism which may represent 
either oxidation or storage as glycogen or triglycer­
ides.
Both the adipocyte and the blood vessels o f fat 
tissue have a rich sympathetic innervation (Havel, 
1965; Brodie et a/., 1965; Fain, 1973). Metabolic 
function o f adipose tissue is considered to be under 
tonic sympathetic control. This is mediated via ,3t 
receptors (Fain, 1973), which also respond to blood 
stream-borne catecholamines, ,3-receptors also modu­
late metabolic activity in muscle.
The metabolic events occurring in the forearm 
before blockade show a net uptake o f glucose, FFA  
and triglycerides from the circulation and release of  
glycerol into it. FFA  are preferentially oxidized by 
muscle in the basal state (Andres, Cader and 
Zierler, 1956). The distribution o f glucose may be 
shared between adipose tissue where it promotes re­
esterification and muscle where it is oxidized. The
triglycerides restore depleted stores in both adipose 
tissue and muscle. Muscle has a higher concentra­
tion o f the enzyme lipoprotein lipase in the basal 
state (Robinson, 1970). If uptake of triglycerides 
were dependent solely on luminal hydrolysis its flux 
into muscle would be greater than in adipose tissue. 
Prior hydrolysis may not be a prerequisite for tri­
glyceride uptake.
Glycerol release results from both luminal hydro­
lysis and the lipolysis o f stored intracellular tri­
glycerides. Both the enzymes responsible for lipo­
lysis— lipoprotein lipase, and triglyceride lipase—are 
controlled by the level o f cyclic AM P which has 
reciprocal effects on the two enzymes (Tepperman 
and Tepperman, 1970). The level o f cyclic AM P  
activity itself is regulated by [3-receptor control.
On oxprenolol blockade FFA and triglyceride up­
take is reduced. The reduction in triglyceride uptake 
may be due either to a direct inhibition of net trans­
fer o f unhydrolysed triglycerides, or secondary to a 
suppression o f lipolysis on the capillary endothelium. 
One eifect o f this attenuated removal would be the 
observed elevation in venous plasma. The cessation 
of peripheral glycerol release is consistent with the 
suppression o f lipolysis both on the endothelium  
and in the adipocyte. Of greater interest is the finding 
of net glycerol uptake in the periphery. Evidence for 
this has been found previously in the periphery 
(Haggendal et al., 1967), and also across the myo­
cardium (Carlson et al., 1973), and is in keeping 
with the demonstration o f glycerokinase activity in 
peripheral tissues (Robinson and Newsholme, 
1967). The augmentation o f peripheral glucose up­
take on adrenergic blockade is consistent with the 
known action o f catecholamines in reducing muscle 
glucose utilization (Lundholm et al., 1968). The rise 
in arterial glucose concentration is contrary to the
fall expected from direct blockade of hepatic glyco- 
genolysis. It may be due in part to a suppression of 
insulin secretion by [3-blockade (Porte, 1967), there­
by removing, perhaps, the more potent inhibitory 
effect on glycogenolysis. In part it may reflect an 
absence o f direct influence on hepatic glycogenolysis, 
an action noted with pronetholol (Pilkington, 1962).
Over the limited period o f observation ,3-blockade 
has been demonstrated to transform the metabolic 
traffic o f substrates. There appears to be a preferen­
tial increase in glucose over lipid utilization. Whether 
these changes are transitory, or contribute signi­
ficantly to quantitative aspects o f energy utilization 
cannot be assessed on the basis o f the present study. 
These preliminary findings underline the need to 
examine the situation in different categories of 
patients, and in greater depth to measure other sub­
strate exchanges. Certainly if [3-blockers are found 
to reduce fat and promote carbohydrate oxidation 
the implications from a long term point of view may 
be profound.
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SUMMARY
Metabolic responses to isoprenaline and beta-blockade were studied in four groups of healthy 
volunteers. Group A subjects were given isoprenaline i.v. (1, 2 and 3 ^g), at 30-minute intervals. 
Pulse rate was measured and venous blood collected for metabolic analysis before the first injection 
and 10 and 30 minutes after each isoprenaline dose. Group B subjects were given 20 mg acebutolol
i.v. and measurements made before dosage with acebutolol and 30 minutes later, then the same 
protocol as for Group A was followed. Groups C and D subjects were given 1.0 mg propranolol
i.v. or 20 mg practolol i.v. instead of acebutolol. The results showed that isoprenaline induced an 
increase in pulse rate and plasma glycerol. Lactate was reduced by all 3 beta-blockers and glycerol 
fell after propranolol. Isoprenaline administration during beta-blockade caused no change of 
importance. Glycerol rose and lactate fell when isoprenaline was administered to most subjects. 
Free fatty acids increased transiently after acebutolol and propranolol. The changes recorded, 
however, were considered to be insignificant biologically.
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INTRODUCTION
Intravenous injections o f  25 m g acebutolol, 2  m g propranolo l or 10 m g practolol 
have negligib le effects on  the uptake and release by striated m uscle o f  g lucose, lipids, 
insulin  or lactate, as m easured by the forearm  technique during the 10 m inutes after 
m edication . T his applies whether or n ot there is prior adm inistration  o f  isoprena­
lin e .2 T he fact that these findings involved on ly  sm all groups o f  volunteers stim ulated  
additional studies to  co llect further inform ation  on  the effects o f  isoprenaline upon  
venous p lasm a levels o f  glucose, lipids, insulin  and lactate in the presence o f  beta- 
blockade.
METHODS AND MATERIALS
E ight senior m edical students and m edical technologists participated  in this study. 
A ll w ere m ale, aged 20 to  28 years, and w ere B lack A frican (4), Indian (3) or W hite (1) 
in  origin. A ll w ere in apparent go o d  health  and w ithout past h istory o f  cardiovascular  
or m ajor respiratory disease. Particular attention  w as paid to  the exclusion  o f  persons 
w ith  d iabetes m ellitus, bradycardia or other cardiac arrhythm ia, and obstructive air­
w ays disease. A ll volunteers understood  the aim s o f  the study and  the procedures to  
be carried out. M o st had participated in sim ilar studies previously  and  n on e were 
tak ing m edication  at the tim e of, or im m ediately prior to  th is study.
A ll investigations were conducted  betw een 0800 and 1100 hrs w ith  subjects fasted  for  
12 hours and kept supine throughout each study. V olunteers w ere d ivided  into  4  
groups (A  to  D ) in such a w ay that every subject form ed part o f  G roup A  (8 subjects)
and at least one other G roup (4 subjects each).
T he clinical part o f  each experim ent w as carried out under the supervision o f  a 
C onsultant Physician assisted by a R egistered N urse and 2  technologists. Subjective 
responses to the experim ental procedure were m onitored throughout these studies. A  
defibrillator and appropriate antidotes to  the test drugs used were kept at the bedside.
A  plastic cannula w as introduced percutaneously into a  suitable forearm  vein  
under local analgesia and kept patent by bolus injections o f  sterile 0 .9%  N aC l 
given through a 2-w ay tap fitted to  it. R ecording o f  pulse rate and rhythm  and  
sam pling o f  venous b lood  for study began 30 m inutes after placem ent o f  the cannula. 
M easurem ents were then m ade and 20  ml b lood  sam ples collected  as fo llo w s :
G ro u p  A . (i) T im e  0  m in u te s :  control m easurem ents were fo llow ed  by slow  intra­
venous injection (2 m inutes) o f  1 [xg isoprenaline. Pulse rate w as recorded through­
out the injection, (ii) T im e s  12  a n d  3 2  m in u te s :  venous b lood  w as drawn for analysis 
10 and 30 m inutes after the initial isoprenaline injection. The 30 m inute m easurem ent 
w as follow ed  by the intravenous injection o f  2  jjig isoprenaline, over 2 m inutes,
(iii) T im e s  4 4  a n d  6 4  m in u te s :  m easurem ents were m ade and 20 ml b lood  collected  10 
and 30 m inutes after the second d ose o f  isoprenaline. A  further isoprenaline injection  
(3 ;xg i.v.) w as given over 2 m inutes, and (iv) T im e s  76 a n d  9 6  m in u te s :  m easurem ents 
were m ade and b lood  sam ples drawn 10 and 30 m inutes after injecting 3 ug isopre­
naline.
G ro u p  B . These subjects were given 20 m g acebutolol i.v. Pulse rate w as m easured  
and venous b lood  drawn for analysis ju st before dosage w ith acebutolol and again  
30 m inutes later. The protocol for G roup A  w as then fo llow ed , beginning w ith
1 jxg isoprenaline i.v. as fo llow s: (i) T im e  0  m in u te s :  control m easurem ents were 
fo llow ed  by slow  intravenous injection (5 m inutes) o f  20 m g acebutolo l, (ii) T im e  
3 5  m in u te s :  a second set o f  m easurem ents w as m ade 30 m inutes after com pletion  o f  
adm inistration fo llow ed  by 1 jxg isoprenaline i.v. given over 2 m inutes, (iii) T im e s  
4 7  a n d  6 7  m in u te s :  venous b lood  w as collected  for analysis 10 and 30 m inutes after 
com pletion  o f  the first isoprenaline injection. The 30 m inute m easurem ent (at T im e 67 
m inutes) was fo llow ed  by the slow  i.v. injection o f  2 fxg isoprenaline, over 2 m inutes,
(iv) T im e s  79  a n d 9 9  m in u te s :  blood  was collected  for analysis 10 and 30 m inutes after 
com pletion  o f  the second isoprenaline injection (2 [xg). T he 30 m inute m easurem ent 
(at T im e 99 m inutes) w as fo llow ed  by the slow  i.v. injection o f  3 ug isoprenaline over
2  m inutes, and (v) T im e s  111  a n d  131  m in u te s :  blood  w as drawn for analysis 10 and  
30 m inutes after com pletion  o f  the third isoprenaline injection (3 fxg).
G ro u p  C . These subjects received 1.0 m g propranolol i.v. M easurem ents were m ade 
as for G roup B before continuing w ith  isoprenaline injections as for G roup A . 
G ro u p  D . T he protocol w as identical to  those o f  G roups B and C but practolol, the 
beta-blocker used, w as given as 20 m g i.v.
Subjects in all G roups had com pleted  this protocol once b lood  w as collected  
30 m inutes after 3 jxg isoprenaline.
L a b o r a to r y  a n a ly s e s
P lasm a and serum sam ples were separated im m ediately and stored at -2 0 °C  before 
analysis. T he fo llow ing m ethods w ere used in the analysis o f  sam ples, all o f  which  
w ere exam ined blind and in triplicate by 2  tech n o lo g ists: (i) D u n co m b e’s m ethod  for
free fatty acids,3 (ii) glycerol and triglyceride w ere m easured enzym atically using the 
com m ercially prepared Boehringer (M annheim ) k it,7 (iii) lactate determ ination was 
by the m odified W roblew ski-L a D u e  enzym atic procedure,8 (iv) the U V  hexo- 
kinase/glucose-6-phosphate dehydrogenase m ethod  w as used for plasm a g lucose,6 
and (v) Am ersham  radio-im m unoassay for insulin.
S ta tis tica l analyses
A ll analyses were carried out using program m es for the H ew lett-Packard 67 com ­
puter. M eans, standard deviations and standard errors w ere determ ined for control 
data and for each set o f  values recorded after isoprenaline (1 ,2  and 3 fig), acebutolol, 
propranolol or practolol and after isoprenaline given during beta-blockade. The 
significance o f  responses to  single regim ens given to  each group o f  volunteers was 
determ ined by Student’s ‘t’ test for paired com parisons. D ifferences betw een beta­
b locking agents were analyzed by Student’s ‘t’ test for com parison o f  sam ple m eans.
RESULTS
T he results are sum m arized in Tables 1 to  4.
Isoprenaline increased resting pulse rate by 30%  to 50% . This response was 
inhibited by beta-blockade. Plasm a glycerol fell 30 m inutes after 1.0 m g propranolol 
and w as increased by isoprenaline doses o f  2 and 3 fig. T hese changes were statistically  
significant (p =  0.05). A ll three beta-blockers slightly augm ented this isoprenaline- 
induced rise in plasm a glycerol level, but changes were not statistically significant in 
the sm all groups tested.
Table 1. Effects of intravenous isoprenaline (1 to 3 pig) on venous plasma levels of various 
metabolites in healthy volunteers: mean (+S.E.M .) values for Group A
Measurement Triglycerides 
(mg/lOOml)
Free fatty
acid
(mEq/1)
Glycerol 
(mg/100ml)
Glucose 
(mg/100ml)
Lactate
(mg/1)
Control 79.0 — 7.11 
(Time 0)
0.33 — 0.03 1.30+0.11 80.4+3.87 98.4 +  10.96
1 fig isoprenaline i.v.
10 min after 79.2+7.32 
(Time 12 min)
0.37+0.03 1.30+0.07 83.5 +  6.98 96.0 +  10.29
30 min after 80.1+8.61 
(Time 32 min)
0.34+0.03 1.29+0.07 77.9 +  3.25 91.9+9.78
2 pg isoprenaline i.v.
10 min after 82.9+7.59 
(Time 44 min)
0.36+0.03 1.44+0.08 72.9 +  2.72 91.8+9.41
30 min after 85.6 +  8.55 
(Time 64 min)
0.33+0.02 1.35+0.10 76.1+2.48 91.2+8.56
3 pg  isoprenaline i.v.
10 min after 81.4+7.29 
(Time 76 min)
0.39+0.03 1.39+0.09 77.9+3.68 86.8 +  8.33
30 min after 81.0 +  7.61 
(Time 96 min)
0.35+0.03 1.41+0.10 78.5+2.04 83.1+8.67
Table 2. Effects of intravenous isoprenaline (1 to 3 (ig) on venous plasma levels of various 
metabolites in healthy volunteers first given 20 mg acebutolol i.v.: mean (±S.E.M .) values for 
Group B
Measure- Tri- 
ment glycerides 
(mg/100ml)
Free fatty
acid
(mEq/1)
Glycerol 
(mg/100ml)
Glucose 
(mg/100ml)
Lactate
(mg/1)
Insulin
(ixU/ml)
Control 77.6± 13.42 
(Time 0 min)
0.34 ±0.07 0.92±0.11 75.2±3.52 122.2±21.31 6.5±2.75
20 mg acebutolol i.v.
30 min after 80.0±11.40 
(Time 35 min)
0.45 ±0.06 1.08±0.17 74.7±0.85 81.0±8.69
1 pg isoprenaline i.v.
10 min after 87.7±8.08 
(Time 47 min)
30 min after 89.8±9.36 
(Time 67 min)
0.45 ±0.07 
0.45 ±0.03
1.06±0.25 
1.05 ±0.22
71.0 ±6.71 
76.9±3.12
80.4±7.95
71.8±5.25
12.23 ±2.26 
6.98 ±0.88
2 pg isoprenaline i.v.
10 min after 91.6±9.50 
(Time 79 min)
30 min after 88.4±9.50 
(Time 99 min)
0.40 ±0.03 
0.38±0.04
1.01 ±0.21 
0.97 ±0.16
73.5±2.94 
80.1 ±3.67
72.0±7.32
74.4±8.01
9.30±1.44 
7.73 ±0.48
3 pg  isoprenaline i.v.
10 min after 93.4±11.84 
(Time 111 min)
30 min after 88.6±10.85 
(Time 131 min)
0.39±0.04 
0.38 ±0.04
0.97 ±0.21 
1.97 ±0.17
75.0±3.65 
77.8 ±2.69
66.0±4.67
69.2±0.92
7.63 ±2.61 
9.73 ±3.46
Table 3. Effects of intravenous isoprenaline (1 to 3 |ag) on venous plasma levels of various 
metabolites in healthy volunteers first given 1.0 mg propranolol i.v.: mean (±S.E.M .) values for 
Group C
Measure- Tri- 
ment glycerides 
(mg/ 100ml)
Free fatty
acid
(mEq/1)
Glycerol 
(mg/100ml)
Glucose 
(mg/100ml)
Lactate
(mg/1)
Insulin
(uU/ml)
Control 77.7 ±9.49 
(Time 0)
0.33 ±0.08 1.12±0.10 82.6±7.49 126.5 ±  15.61 2.43 ±1.05
1.0 mg propranolol i.v.
30 min after 76.9 ±6.48 
(Time 35 min)
0.32±0.06 0.18±0.08 79.7 ±7.30 116.7± 15.09
1 pg isoprenaline i.v.
10 min after 77.9±7.07 
(Time 47 min)
30 min after 80.5 ±10.73 
(Time 67 min)
0.31 ±0.05  
0.34±0.08
1.15 ±0.07 
1.12±0.06
81.0±6.15 
84.9 ±5.98
117.8 ±  18.28 
81.0± 12.18
5.63±3.99
8.50±3.77
2 pg isoprenaline i.v.
10 min after 70.4±7.80 
(Time 79 min)
30 min after 74.1 ±11.59 
(Time 99 min)
0.48 ±0.09  
0.45 ±0.08
1.37±0.07 
1.45 ±0.11
76.6±6.34
80.8±8.90
101.9 ±21.95 11.75 ±4.23 
124.9±32.18 5.75 ±2.35
3 pg isoprenaline i.v.
10 min after 76.9±12.40 
(Time 111 min)
30 min after 79.7 ±9.84  
(Time 131 min)
0.46±0.07
0.46±0.12
1.50 ±0.09  
1.60±0.13
85.4±13.21
78.7±6.98
118.6± 17.74 
117.8 ±29.50
3.00±1.08 
6.00 ±4.00
Table 4. Effects of intravenous isoprenaline (1 to 3[xg) on venous plasma levels of various 
metabolites in healthy volunteers first given 20 mg practolol i.v.: mean (±S.E.M . values) for 
Group D
Measurement Triglycerides 
(mg/100 ml)
Free fatty
acid
(mEq/1)
Glycerol 
(mg/100 ml)
Glucose 
(mg/100 ml)
Lactate
(mg/1)
Control 77.2 ±13.40 
(Time 0)
0.33 ±0.09 1.27 ±0.13 78.2±4.48 131.3 ±  18.67
20 mg practolol i.v.
30 min after 72.6±6.46 
(Time 35 min)
0.28 ±0.06 1.41 ±0.25 72.2±3.67 88.3 ±  16.34
1 pg  isoprenaline i.v.
10 min after 85.2±  13.47 
(Time 47 min)
0.26±0.07 1.24±0.29 72.5±6.53 86.6 ±  13.96
30 min after 71.8 ±  13.20 
(Time 67 min)
0.31 ±0.07 1.32±0.07 66.9±3.47 64.2 ±3.11
2 fig isoprenaline i.v.
10 min after 74.6±9.06 
(Time 79 min)
0.27 ±0.05 1.20±0.34 72.3 ±1.76 68.8 ±  13.05
30 min after 76.9±10.54 
(Time 99 min)
0.29±0.05 1.41 ±0.30 77.5±4.02 67.2±9.73
3 fig isoprenaline i.v.
10 min after 75.1 ±12.45 
(Time 111 min)
0.33 ±0.05 1.33 ±0.16 78.4±2.69 73.7 ±8.75
30 min after 70.8±10.05 
(Time 131 min)
0.33±0.06 1.54±0.21 73.2±5.09 65.1 ±4.14
V enous lactate fell slightly after isoprenaline, acebutolol, propranolol or practolol, 
and w as further reduced when isoprenaline w as adm inistered during beta-blockade. 
C hanges were significant (p =  0.05), 10 and 30 m inutes after each isoprenaline dose  
given fo llow in g  acebutolol, propranolol or practolol.
S ignificant rises in plasm a free fatty acid were noted  10 m inutes after 2  and 3 .^g 
isoprenaline in subjects given propranolol and also 10 and 30 m inutes after 1 p.g 
isoprenaline in those given acebutolol. N o  side-effects occurred w ith  any o f  the drugs.
DISCUSSION
T hese findings were consistent w ith  those o f  an earlier study,2 w hich  indicated that 
single intravenous therapeutic doses o f  acebutolo l, propranolol and practolol have 
no clin ically  im portant acute m etabolic effects in healthy individuals. Forearm  
m etabolism  w as not m easured in the studies reported here, but the increases in 
plasm a glycerol and free fatty acid levels recorded when isoprenaline w as given  
during beta-blockade are consistent w ith  the increased release and venous levels o f  
these substances noted  previously. Changes in lactate levels were qualitatively the 
sam e as th ose seen during earlier experim ents, though  quantitatively greater.
T hese results should be com pared to  those o f  other research groups, rem em bering, 
how ever, that only the acute responses to  lim ited  doses o f  4  com pounds were studied. 
G ibb on s e t  a l . 4 w h o studied lipolysis in isolated  rat epididym al fat and in hum an
volunteers given beta-blockers by m outh , reported free fatty  acid  release from  fat 
cells and a rise in hum an plasm a free fatty acid after stim ulation  by isoprenaline. This 
response w as inhibited by beta-blockade. A s reported here, isoprenaline caused no  
change in free fatty acid, although  acute adm inistration o f  beta-blockers w ith  isopren­
aline w as associated  w ith  a  slight rise in  plasm a free fa tty  acid  levels. H ow ever, 
changes consistent w ith  the G ibbons e t  a l .4 findings in venous p lasm a w ere recorded  
during earlier studies using slightly larger doses o f  acebu to lo l and propranolol. 
Interactions at beta-receptors w ou ld  presum ably explain  these differences but, in  
view  o f  their degree, their relevance to  clinical m edicine and to x ico lo g y  appears 
obscure.
A sm al1 reported changes in forearm  m etabolism  after oxp ren olo l adm inistration, 
but did not publish all the venous p lasm a levels o f  the param eters m easured. N ever­
theless, exam ination o f  the arteriovenous differences published indicates that glycerol 
levels fell in venous plasm a after oxprenolol adm inistration. T his w as reproduced in  
the present study by 1.0 m g propranolol.
N ew m an 5 reported a  fall in free fatty acid  after acebu to lo l or propranolol given  
orally for 48 hours. This result was n ot confirm ed by the acute studies reported here. 
T he sm all groups studied by all observers, the varied p rotoco ls fo llow ed , and vari­
ations in endogenous catacholam ine release by different volunteers during experi­
m ents m ight all contribute to  the results obtained by different investigators.
In  conclusion, the results o f  this study support other evidence that 12.5 to  25 m g  
acebutolol, 0.5 m g propranolol, and 10 to  20 m g p racto lo l have no  im portant acute 
m etabolic effects in healthy individuals. It should  be stressed, how ever, that the slight 
changes observed in plasm a lactate, glycerol and free fatty acid  levels p ossib ly  merit 
investigation in parallel w ith  studies involving adm inistration  o f  acebu tolo l for a  
period exceeding 6 to  12 m onths.
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SECTION F : REVIEWS
Papers included in this section review aspects of the action 
and uses of diuretics. These medicines are commonly 
prescribed in the management of hypertension. Some papers 
deal largely or solely with magnesium depletion which may be 
induced or aggravated by diuretics in some cases; this 
eficiency may be associated with alterations in cardiac 
rhythm and vascular tone. Most of the work included in 
publications FI -11 is presented in a single review, F12.
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Summary
Diuretics of current interest are classified according 
to their potency or site of action. The pharmacokinetics 
of furosemide, xipamide, hydrochlorothiazide and triam­
terene are briefly described, and important adverse 
reactions and drug interactions involving diuretics are 
reviewed. The clinical indications for diuresis are pre­
sented.
S. Afr. med.J. 59, 9 (1981).
Diuretics are compounds which increase urinary volume 
and renal excretion of sodium and chloride. Since they 
are of major importance in the management of hyper­
tension, cardiac insufficiency and oedema of any origin, 
and no ideal diuretic exists at present, the main charac­
teristics of currently available preparations should be 
understood and taken into consideration when prescribing 
a diuretic in clinical practice.1,5
Classification
Diuretics are usually classified according to their potency 
or site of action, two characteristics which largely deter­
mine clinical responses to these medications. A simple 
classification, taking both criteria into consideration and
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including various compounds presently in use or under 
clinical investigation, is given in Table I.
Since the response to diuretics is affected by numerous 
factors related to water and electrolyte homeostasis in 
health and disease, potency is best defined under standard 
conditions in normal healthy individuals taking 1 -2  g 
dietary sodium per 24 hours. In oral therapeutic doses, 
high-potency diuretics may induce an excretion of up to 
30% of the filtered sodium load, thereby provoking 
marked diuresis. About 10% of filtered sodium is excreted 
in response to medium-potency diuretics, whereas low- 
potency compounds are associated with an output of 
approximately 5%.3 In practical terms, at usual chronic 
therapeutic doses, high-potency diuretics provoke a re­
sponse similar to that elicited by 40 mg furosemide, 
whereas medium-potency diuretics are comparable in 
effect to hydrochlorothiazide 50 mg.
The principal anatomical sites of diuretic action are 
represented in Fig. 1. Loop diuretics have certain pro­
perties in common such as high potency, rapid onset 
and short duration of activity, ototoxicity and relative 
lack of antihypertensive effect. No real differences in 
clinical effects have been demonstrated between members 
of this group of diuretics, all of which are powerful 
inhibitors of chloride reabsorption in the ascending limb 
of Henle’s loop."'*
In physiological terms, the distal tubule is not a homo­
genous entity, but has a number of biochemical functions. 
Differences in composition of urine excreted after the 
administration of diuretics acting upon the distal con­
voluted tubule (Table I) may reflect diverse sites of 
action within the tubule and imply differences in the 
underlying biochemical mechanisms involved.
Diuretics such as the benzothiadiazides, chlorthalidone 
and xipamide all inhibit sodium and chloride reabsorp­
tion within the distal tubule, although differences in their 
potencies and diuretic time courses have been demon­
strated. Triamterene and amiloride, which are related 
in structure and activity, alter potassium exchange for
TABLE 1. CLASSIFICATION OF DIURETICS
Renal site of action High Medium Low
Ascending limb of Henle’s Furosemide, bumetanide,
loop; biochemical site A ethacrynic acid and pi- 
retanide*
Distal convoluted tubule;
biochemical site 
B Xipamide* Banzothiadiazides, chlor-
thalidone, chlorexolone 
and metolazone
C Triamterene, amiloride
D Spironolactone
E Tienilic acid*
* Compounds not commercially available in South Africa, 1 May 1980.
sodium in the distal tubule through imperfectly under­
stood mechanisms. Spironolactone has a similar effect, 
mediated through the competitive inhibition of aldo­
sterone at the distal tubule.4 Tienilic acid differs from 
other diuretics by its unique uricosuric action.1 The 
vascular effects of these diuretics cannot be fully ex­
plained by their renal actions, although they m a y  be 
mediated by events within the kidney.'•*
P h a r m a c o k i n e t i c s
In the absence of overt disease the diuretics listed in 
Table I are effectively absorbed from the h u man gastro­
intestinal tract. However, variations in lipid solubility, 
protein-binding, hepatic metabolism or clearance, and 
renal excretion exist. The pharmacokinetics of furo- 
semide, hydrochlorothiazide, xipamide and triamterene 
are described below as examples of diuretics in classes 
A, B and C, with slightly different characteristics.
Furosemide absorption is complete within 30 - 60 
minutes of oral administration, maximal at p H  5, and 
unaffected by the presence of food in the gut. Furosemide, 
which is slightly soluble in aqueous solutions, is distri­
buted throughout the body after absorption, even though 
about 8 0 %  is bound to plasma albumin. It is eliminated 
within 24 hours in urine and faeces, unchanged or con­
jugated with glucuronic acid.4 In c o m m o n  with other 
diuretics, furosemide is filtered at the glomerulus and 
actively secreted in the proximal tubule, and exerts its 
diuretic action from within the tubular lumen before 
excretion.10 Administration of furosemide in divided doses 
has little effect on its kinetics; there is a simple temporal 
additive effect.11
Xipamide has an absorption half-time of 18-27 
minutes after oral administration, with resultant peak 
plasma levels achieved in 1,2 - 2,0 hours. This compound 
is almost completely protein-bound in h u man plasma 
initially, but is subsequently distributed throughout the 
body. More than 8 0 %  is excreted by the kidney within 
24 hours of administration, approximately 2 5 %  conju­
gated with glucuronic acid, and the remainder as free 
xipamide.11
About 60 - 7 0 %  of hydrochlorothiazide, a representa­
tive benzothiadiazide of medium potency, is absorbed 
after oral administration. Absorption is linear in the dose 
range 5 - 7 5  m g  and is increased slightly by food or
medicines which delay gastric emptying.1314 M a x i m u m  
plasma levels are achieved within 1,5-3,0 hours and 
urinary excretion of the absorbed dose is complete within 
24 hours. Unlike m a n y  other benzothiadiazides, hydro­
chlorothiazide is not metabolized by the liver.413
The time courses of diuretic activity after different 
doses of furosemide, xipamide and hydrochlorothiazide 
have been extensively studied in healthy individuals.''4 
The 24-hour urine volumes after the administration of 
furosemide 40 m g  or xipamide 40 m g  are similar, despite 
differences in time course of diuretic activity. W h e n  the 
three diuretics are compared (Fig. 2), time-to-peak activity 
varies after administration of the drugs. Furosemide 
rapidly achieves peak activity (2 h), whereas xipamide 
and hydrochlorothiazide resemble each other (4,5 h).“ 
The effects of all three diuretics are complete within 
24 hours. Thus, in healthy subjects 8 4 %  of the 24-hour 
urine volume is excreted within 14 hours of ingesting 
furosemide 40 mg, 7 4 %  after xipamide 40 mg, and 7 6 %  
after hydrochlorothiazide 100 mg.0'4
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Fig. 2. Time courses of diuretic action in healthy volun­
teers (HTZ 100 =  hydrochlorothiazide 100 mg, FUR 
40 = furosemide 40 mg, XIP 40 =  xipamide 40 mg, 
and U — urine output).
Triamterene4 is rapidly but irregularly absorbed after 
oral administration and 10 - 8 0 %  excreted by glomerular 
filtration and tubular secretion within 24 hours. About 
60-70 %  of triamterene is bound to plasma protein, and 
the weak diuretic action of the drug is generally complete 
within 24 hours. The dosage must not be increased above 
300 m g  because of the danger of significant hyper- 
kalaemia.4
The pharmacokinetics of diuretics are altered to a 
different extent in diseases for which these compounds 
are indicated. In cardiac insufficiency the absorption of 
diuretics m a y  be delayed or diminished owing to oedema 
of the intestinal mucosa. These changes vary in degree 
among patients with heart failure and fluctuate from time 
to time in individuals.14'13 If diuretics are given by mouth 
during the initial treatment of cardiac oedema, double 
the standard dose should be used to ensure maximal 
diuresis.1" In toxaemia of pregnancy there is little altera­
tion in the pharmacokinetics of furosemide, even though 
the compound crosses the placenta and despite changes 
in body fluid compartments and renal function.30
A d v e r s e  r e a c t i o n s
Numerous adverse reactions to diuretics have been re­
ported and are listed in Table II. Relatively few, however, 
are of clinical importance in terms of severity or fre­
quency of occurrence.
TABLE II. POTENTIAL UNTOWARD EFFECTS
OF DIURETICS
Hypokalaemia (A, B) Azotaemia
Hyponatraemia Ototoxicity
Hypochloraemia Pseudo-Bartter syndrome
Hypomagnesaemia Acute pancreatitis
Changes in serum Hepatic damage
calcium Allergy
Hyperglycaemia Blood dyscrasias
Hyperuricaemia Hyperkalaemia (C, D)
Hypokalaemia and hypomagnesaemia. Urinary potas­
sium and magnesium excretion is increased by all the 
diuretics listed in Table I, except amiloride, triamterene 
and spironolactone, which are potassium-sparing diuretics.* 
Reduction in serum potassium levels below 3,0 mmol/l, 
whether iatrogenic or associated with primary disease, is 
undesirable and m a y  be associated with serious reactions, 
including potentially lethal cardiac arrhythmias. Potassium 
loss m a y  be diminished by limiting the sodium intake to 
approximately 1 g of sodium daily, thereby reducing 
both the pre-urine flow and the sodium load presented at 
the distal convoluted tubule for exchange with hydrogen 
and potassium ions. Alternatively, potassium supplements 
m a y  be used, but since absorption is erratic these are 
often ineffective and potassium-sparing diuretics m a y  be 
preferred, particularly if alkalosis is present.*’21 In severe 
potassium depletion associated with cardiac arrhythmias, 
intracellular potassium repletion m a y  be achieved by 
administering magnesium chloride intravenously or by 
mouth (Fig. 3).22
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Fig. 3. Schematic representation of relationship between 
K* and M g" loss in diuresis and subsequent intracellular 
K* depletion. Therapy with magnesium may be used to 
activate the Na% K ' pump, with consequent repletion of 
intracellular K'.
Hyponatraemia. Hyponatraemia associated with in­
appropriate secretion of antidiuretic hormone ( A D H )  m a y  
develop during intensive treatment with high doses of 
diuretics. This can be distinguished from hyponatraemia 
due to other causes by the presence of hypokalaemia, 
and is best treated by temporary withdrawal of diuretics 
and fluid restriction.22
Metabolic changes. Diuretic therapy can potentially 
aggravate cardiovascular risk factors, since it induces 
hyper-reninaemia, hypercholesterolaemia, hypertriglyceri- 
daemia and increased blood viscosity. The ultimate signi­
ficance of these alterations in long-term treatment re­
mains to be elucidated through appropriate trials, h o w ­
ever.2* Hyperglycaemia and hyperuricaemia m a y  compli­
cate therapy with diuretics in groups A  and B, but are 
not usually of major clinical importance except in patients 
with diabetes mellitus or gout.* In such cases the indica­
tions for using a diuretic should be reassessed, and appro­
priate adjustments made to the therapeutic regimen if 
indicated.
Deafness and equilibrium disturbances. Deafness and 
equilibrium disturbances occur occasionally when high 
doses of loop diuretics are administered, cochlear damage 
possibly arising from inhibition of chloride transport and 
competitive blockade of the crossed olivocochlear hair 
cell synapse.*'25
Pseudo-Bartter syndrome. Chronic overdosage with 
diuretics of groups A  and B m a y  produce the pseudo- 
Bartter syndrome, consisting of hypokalaemic alkalosis 
and hyponatraemia associated with increased renin 
secretion.2"
D r u g  i n t e r a c t i o n s
Diuretics may interact with a variety of other medicines 
(Table III), although clinically serious consequences sel­
d o m  occur.22 Hypokalaemia, induced by diuretics, 
carbenoxolone, laxative abuse, or other means, predis­
poses to potentially lethal digitalis toxicity and m a y  also 
potentiate the effect of non-depolarizing muscle relaxants. 
Synergism between diuretics and hypotensive agents m a y  
result in severe postural hypotension, especially in elderly 
patients. Loop diuretics and cephalosporins are potentially 
nephrotoxic in combination and renal function should be 
carefully monitored when they are given conjointly. Loop 
diuretics should be avoided in patients on aminoglyco­
sides, since both groups are ototoxic.
The natriuretic response to diuretics is decreased by 
the concomitant administration of mineralocorticoids or 
broad-spectrum anti-inflammatory agents, which possibly 
act through inhibiting synthesis of natriuretic renal 
prostaglandins.2S,2!' Appropriate adjustments in dosage
TABLE III. DRUGS WITH WHICH DIURETICS MAY 
INTERACT
Carbenoxolone
Laxatives
Cardiac glycosides
Antihypertensive agents
Cephalosporins
Aminoglycosides
Corticosteroids
Oestrogens
Phenylbutazone
Indomethacin
Clofibrate
Amitriptyline
Carbamazepine
Xanthines
Quinidine
Lithium
Neuromuscular blockers 
Sulphonylureas
should be made. Inappropriate ADH secretion, which 
may complicate diuretic therapy, may be associated with 
several other medicines, including clofibrate, amitripty­
line, carbamazepine and haloperidol. These medications 
should not be given together as a rule.”
Xanthine derivatives such as theophylline have a weak 
diuretic action and potentiate the effects of other diuretics.1 
Benzothiadiazide diuretics may enhance tubular reabsorp­
tion of quinidine or increase lithium excretion, thereby 
affecting plasma levels of these compounds.
Clinical uses
The main indication for using diuretics is in the treatment 
of oedema associated with raised venous pressure (cardiac 
insufficiency), reduced plasma colloid osmotic pressure 
(cirrhosis, nephrotic syndrome), renal sodium retention, 
or abnormal capillary permeability.4
Cardiac insufficiency. The treatment of cardiac failure 
includes a number of important measures of which 
diuretic therapy is only one. In heart failure, sodium 
retention is increased, renal cortical blood flow is de­
creased, and medullary flow and inner cortical flow are 
increased, notably in the region of the ascending limb 
of Henle’s loop. Hepatic congestion, associated with 
cardiac failure, may decrease metabolic clearance of 
aldosterone and renin, thereby aggravating the situation. 
Diuresis mobilizes sodium and water in congestive cardiac 
failure, which may be accompanied by secondary hyper­
aldosteronism, with resultant increased potassium excre­
tion. In this event aldosterone antagonists may be rational­
ly combined with thiazide diuretics. In left ventricular 
failure important haemodynamic changes occur in re­
sponse to diuretics, which probably reflect vascular 
mechanisms. Intravenous furosemide promotes a fall in 
left ventricular filling pressure and in pulmonary arterial 
pressure, with changes in the venous capacitance of leg 
veins, before the onset of diuresis.” It should be noted 
that in some patients with pulmonary oedema acute 
diuresis may induce shock through severe volume deple­
tion; a central venous line should be kept in situ to 
monitor changes. Pulmonary oedema should never be 
treated with diuretics only; classic therapeutic measures 
should always be taken.3,4
Cirrhosis of the liver. Ascites associated with cirrhosis 
should probably not be treated unless it causes distress, 
since diuretic therapy will not increase life expectancy 
and may cause severe adverse reactions. Secondary 
hyperaldosteronism is commonly present, so that potent 
diuretic agents may cause serious potassium loss leading 
to electrolyte imbalance and coma. Carefully controlled 
diuresis associated with restricted sodium and fluid intake 
is preferred.4 Spironolactone, triamterene or amiloride 
should be used as a starting regimen and furosemide may 
be added later if weight loss is unsatisfactory.31 Dilutional 
hyponatraemia may occur in cirrhotic patients and should 
be treated, when diagnosed, by fluid restriction.
Hypertension. Arterial pressure can be reduced by re­
stricting sodium intake or increasing sodium excretion, 
although exchangeable sodium and potassium are normal 
in essential hypertension. It is by no means certain that 
the hypotensive effect of diuretics is mediated through 
changes in sodium balance. In hypertension associated 
with hyperaldosteronism, spironolactone or amiloride may 
lower arterial pressure and return electrolyte levels to 
normal, whereas furosemide or a thiazide can be ex­
pected to aggravate the potassium depletion found in this 
condition.3,4,33
The mechanisms whereby diuretics lower raised blood 
pressure are largely unknown. Benzothiadiazides, xipa- 
mide, chlorthalidone, metolazone and other related 
diuretics m a y  be expected to decrease erect, supine and 
exertional arterial pressure within 7 days when adminis­
tered alone in patients with mild to moderate hyperten­
sion.33’3,‘ It has been shown that xipamide lowers blood 
pressure without altering circadian variations (D. I. Mel­
ville and E. B. Raftery —  personal communication); other 
diuretics have yet to be evaluated in this respect, although 
a similar response can be expected. Tolerance does not 
develop and the effective antihypertensive dose of these 
compounds m a y  be less than a standard diuretic dose31 
Loop diuretics are especially effective in hypertensive crises 
or as adjunctive therapy when established treatment with 
compounds such as /3-adrenergic receptor blockers, reser- 
pine, clonidine or a-methylaopa has been inadequate. 
Triamterene, amiloride and spironolactone have little ef­
fect upon blood pressure when given alone, unless they 
are given with a thiazide or hyperaldosteronism is pre­
sent 3,4
Renal disease. The benzothiadiazides are often as effec­
tive as high-potency diuretics in the maintenance therapy 
of patients with the nephrotic syndrome. In patients with 
advanced chronic renal failure benzothiadiazide diuretics 
are no longer effective, but high-potency compounds such 
as furosemide m a y  be administered. Furosemide in doses 
of 1,2 - 3,0 g daily m a y  provoke diuresis, even in patients 
with glomerular filtration rates below 4 ml per minute. 
This form of therapy may be regarded as an adjunct but 
not as a substitute for haemodialysis in renal failure.3,31 
Since adverse reactions to such high doses of loop diuretics 
m a y  occur, therapy should be initiated in hospital. Potas­
sium-sparing drugs are contraindicated, since their use 
m a y  lead to fatal hyperkalaemia.
Pituitary and renal diabetes insipidus will both respond 
to diuretics.31 The mechanism of action is uncertain, but 
a transitory decrease in plasma osmolality occurs with 
diminished thirst. It is possible that increased plasma con­
centrations of angiotensin also reduce urine volume in 
these patients.
Conclusions
Diuretics are used to increase urinary sodium and water- 
excretion in a variety of clinical situations. The incidence 
of untoward side-effects m a y  be decreased by selecting 
the most suitable preparation for a particular clinical 
situation and by avoiding the use of excessive dosages 
or polypharmacy.
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D iuretics, m agnesium , potassium  and 
sodium
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v,;: Diuretic^ increase renal magnesium excretion and, 
fr: when •chronically administered, decrease intra- 
^  cellular magriksium levels; This deficiency reduces :! 
| j active Transport of potassium Unto the cell and /? 
j-;’ Intracellular potassium decreases irrespective of ?' 
LApefUm potassium, levels: . Potassium supple- 
mentatioh 'or the co-administration of potassium- 
|7. sparing? diuretics cannot : maintain intracellular :1^  
potassium atOrlormal, levels When intracellular '? 
f- magnesilim Ms reduced. The effects of chronic 
I  Kmaghesi.lim • sujsplementation have not been 
In  adequately studied. Maintenance of the diuretic 
. dose at an effective minimum and curtailing sodium 
fejntake when diuretics are chronically prescribed are 
the simplest and safest manoeuvres which can be 
" / undertaken in order to prevent the occurrence of 
/  events .usually ascribed to hypokalaemia and in fact 
ivt principally due to iow intracellular potassiutp which 
is associated with magn&Siufh deficiency. :/  ' /
|j  S. Alnmetf. J„ *f, 279 (1982). ' ’ ; '
T h e  m a g n e s i u m - p o t a s s i u m  r e l a t i o n s h i p
Magnesium, an important cofactor for various enzymatic 
reactions,1 is a critical determinant of N a ‘ - K ‘-ATPase 
activity in several tissues, including ventricular myo­
cardium, skeletal muscle and the nephron.2,3 This enzyme is 
necessary to release energy for the sodium-potassium p u m p  that 
actively incorporates potassium into the cells of electrically 
excitable tissues, thus maintaining the intracellular concen­
tration of potassium within normal limits. Decreases in 
tissue magnesium levels may therefore result in reduced 
intracellular potassium concentrations, provided other 
determinants of potassium equilibrium potential remain 
constant. If, in addition, the serum potassium level is reduced, 
intracellular potassium concentration will be further decreased. 
Such changes may be associated with serious cardiac 
arrhythmias which-are usually ascribed to hypokalaemia but are 
in fact basically provoked by a decrease in intracellular 
potassium due to magnesium depletion.2
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D i u r e t i c s  a n d  m a g n e s i u m
The most familiar clinical situations associated with magnesium 
depletion are prolonged diarrhoea and vomiting and the chronic 
administration of diuretics; magnesium excretion is enhanced by 
most modern compounds including the thiazides,4,5 furo- 
semide6,7 and ethacrynic acid.6,7 The mechanism whereby 
diuretics increase renal magnesium excretion is incompletely 
described, although it is known that the kidney is the principal 
organ involved in magnesium homeostasis and that, normally, 
most filtered magnesium is reabsorbed at the proximal tubule 
and at the thick ascending limb of the loop of Henle.8 The 
chronic urinary losses of magnesium provoked by diuretics 
eventually decrease serum and intracellular concentrations of 
magnesium.2
Studies in progress support the view that biologically 
important magnesium losses may result from chronic 
administration of diuretics. Administration of piretanide 12 
mg/d to 9 patients with uncomplicated essential hypertension 
resulted in a statistically significant fall in serum magnesium 
after 12 weeks (Fig. 1). Other loop diuretics might be expected to 
have similar effects.9"11 W h e n  15 hypertensive patients received 
a combination of hydrochlorothiazide 100 m g  and amiloride 10 
m g  daily, serum magnesium also decreased significantly from a 
mean pretreatment value of 0,861 mmol/1 to a mean value of 
0,797 mmol/1 after 12 weeks of treatment (P <  0,02). Such 
changes could be associated with a decrease in intracellular 
magnesium, leading in turn to a diminution in intracellular 
potassium (Fig. 2).
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Fig 1. C h a n g e s  in se ru m  m a g n e s iu m  va lu es  In 9 h y p e rte n s iv e  p atien ts  
tre a te d  w ith  p ire ta n id e  12 m g /d  (m e a n  va lu e s  ±  S E M ).
Fig. 2. Schematic representation of the mechanism whereby (common) 
diuretics decrease intracellular magnesium and potassium. Potassium 
supplementation and potassium-sparing diuretics increase serum 
potassium but intracellular potassium remains low if intracellular 
magnesium is decreased. Magnesium supplementation would increase 
intracellular potassium. Sodium dietary restriction has an overall 
potassium-sparing effect.
Practical handling of patients receiving 
chronic diuretic treatment
H ypokalaem ia secon dary to  the adm inistration  o f  d iuretics may 
be to som e exten t prevented or corrected b y  appropriate 
potassium  supplem entation  or b y  the co-adm inistration  o f  
p o ta ss iu m -sp a rin g  d iu re tic s . N e v e rth e le ss , in tra c e llu la r  
potassium  levels m ay rem ain low in the presence o f  intracellu lar
m a g n e s iu m  d e p le t io n .2 T h e  e f f e c ts  o f  m a g n e s iu m  
su p p lem entation  on intracellu lar potassium  levels during 
ch ron ic  d iu retic  therapy have not been adequately described, 
although su ch  th erapy w ould be th eoretically  correct (F ig . 2), 
and it has been dem onstrated that, acu tely , m agnesium  infusions 
increase in tracellu lar p otassium .2
Potassium  and m agnesium  losses can be m inim ized by sim ple 
clin ical procedu res. In hyp erten sion , m ost th iazide-typ e 
diu retics w ill e ffectiv e ly  redu ce high blood pressure when 
prescribed at less than the standard d iu retic doses, w h ich  may 
cause electrolyte  depletion. T h u s  no enhancem ent o f  the 
antihyperten sive effects o f  ch lo rth alid o n e12 and h yd ro ch loro­
th ia z id e 1’ has been fou nd at doses greater than 12,5 m g/d . In 
addition  to the d irect e ffect on renal potassium  excretion  o f  
d im inishin g the d iu retic  dose to a m in im u m , potassium  losses 
associated w ith h yperaldosteron ism  secon dary to diuretic 
adm in istration  are also reduced.
R estriction  o f  d ietary sodium  w ill redu ce filtered sodium , p re­
urine flow s and the absolute am ount o f  sodium  available for 
interchange w ith  potassium  at the distal con vo lu ted  tu b u le , thus 
fu rth er decreasing the potassium  lo ss.9'14 R ed u cin g  sodium  
intake m ay result in an increased aldosterone secretion, in turn 
p rovokin g enhanced renal potassium  excretion. T h is  m ay 
balance the p otassiu m -sparin g e ffect o f  red u cin g  the am ount o f  
sodium  available at the nephron to  som e extent.
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D iuretics and zinc
A .  J .  R E Y E S ,  W .  P .  L E A R Y ,  C .  J .  L O C K E T T ,  L .  A L C O C E R
Summary
Distal tubule diuretics (D TD s), including  
chlorothiazide, hydrochlorothiazide, bendroflume- 
thiazide, chlorthalidone and xipamide, have been 
found to increase urinary zinc output through a 
S ' poorly understood mechanism which could involve 
both direct and hormone-mediated processes.
Significant zinc depletion may occurduring long­
term administration of DTDs, principally in 
conditions associated with diminished total body 
zinc levels such as hepatic cirrhosis, diabetes 
mellitus, gastro-intestinal disorders and several 
renal diseases.
Attention to the early symptoms of zinc deficiency 
such as hypogeusia, hyposmia, abnormal dark 
adaptation and impotence and the monitoring of 
serum zinc levels are advisable during long-term 
treatment with common DTDs.
S  A f r  M e d  J  1982; 62: 373-375. ,
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Z in c, a con stituen t o f  all cells, is one o f  the m ost abundant o f  the 
essential trace elem ents in the hum an body. T h e  m ajor functions 
o f  zinc seem  to be related to enzym es. M ore  than 70 m etallo- 
enzym es, in clu din g carboxypeptidases, th erm olysin , alcohol 
dehydrogenases and n ucleotide p olym erases,1 are know n to 
require zinc for their activities.
T h e  so-called  con verting en zym e, w h ich  intervenes in the 
m etabolic paths o f  vasoconstricting and vasodilating peptides, is 
a carboxypeptidase containing a firm ly  bo u n d  zin c  ion essential 
for the h yd ro lytic  reactions it catalyses. B ecause the role played 
b y  the vaso-active peptides such as angiotensin  II  and 
bradykinin  in the pathogenesis o f  hyperten sion  is a h ighly 
controversial issue, a possible role for zin c  in this disease is only 
speculative at present.
P articipation  o f  zinc in the m etabolism  o f  n ucleic acids, 
th rough its b in d in g to enzym es su ch  as th ym idin e kinase, D N A  
polym erase, R N A  polym erase and reverse transcriptase, affects 
b iochem ical and u ltim ately m orp h ological events in the cell. 
R N A  synthesis, protein  synthesis and increase in cell size depend 
on correspon din g zin c-related  reactions or entities: uridine
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in corporation  into R N A , D N A -d e p e n d e n t R N A  polym erase 
and R N A  stab ilization , respectively. D N A  synthesis depends on 
zin c-m ediated  processes such as th ym idin e in corporation  into 
D N A  and D N A  stabilization. M itosis provides another area for 
the effects o f  zinc on the cell cycle; som e m orphological 
characteristics o f  the nucleoli, the spindle apparatus and the 
chrom osom es have been clearly  iden tified  as zin c-d ep en d en t.2
Zinc metabolism
O n ly  5 -15%  o f  zin c  ingested in standard food stuffs is absorbed in 
the sm all intestine. Z in c  seem s to enter the m ucosal cells across a 
con cen tration  grad ien t th rough sp ecific  bin d ing to a transport 
album in. D a ily  zin c  requirem ents determ ine the am ount o f  the 
su bstance that is actually incorporated into the bo dy from  the 
cells o f  the intestinal m u co sa .’ T h e  m echanism  w h ereby zin c 
absorption  is regulated is largely unknow n; positive involvem ent 
o f  1 ,25-d ih yd roxych olecalcifero l has been id e n tified .1 Ingested 
zin c-b in d in g  substances such as phytate  and fibre reduce the 
am ount o f  fre e  zin c  liable to be absorbed w ithin  the intestinal 
lum en.
Som e 34% o f  blood zin c is firm ly  bound to protein , the 
rem ainder bein g on ly loosely boun d. T h e  principal carrier o f  
zin c in plasm a is an a ,-g lo b u lin  w h ich  accounts for 30-40% o f  
serum  zin c. T ran sferrin  and som e enzym es also bin d  zin c tightly. 
L o ose ly  boun d zin c  exists m ainly as a m acrom olecular com plex 
w ith  album in; a sm all am ount o f  the trace elem ent (1-4%  o f  ail 
serum  zinc) form s m icrom olecular com p lexes w ith  histidine, 
cystein e, threonine, g lyc in e, asparagine and other am ino acids. 
W hen  assayed b y  atom ic absorption , the plasm a zin c level is 100 
M g/dl, w ith  a standard deviation  o f  10 /ig/dl. In spite o f  being 
qu an titatively  n egligible  w ith in  plasm a, m icroligated zinc seem s 
to be the m ajor determ inant o f  zin ciu ria  because o f  the high 
filterability  o f  these com pounds.
T h e  total bo d y zinc level in a fat-free 70 kg adult ranges 
betw een  1,4 g  and 2,3 g. H igh  con cen trations exist in the liver, 
volu ntary m uscle, m yocard ium , bone, hair, skin, pancreas, 
prostate g lan d, eryth ro cytes and leucocytes. W hole blood has a 
h igher con cen tration  o f  zin c than serum  or p lasm a.’
Z in c  is prin cip ally  elim inated th rough the gu t, and the zinc 
finally elim inated by this route includes both endogenous and 
ingested zinc. F aecal excretion  o f  zin c  is approxim ately tw ice 
that via th e kidneys.
In  norm al adults mean daily  urinary zin c excretion  is 0,1 - 0,7 
mg. T h e  m echanism s w h ich  participate in determ inin g this 
ou tp u t rem ain ob scure, a lthough it has been established clearly 
that zin c reaches the nephronal lum en th rough filtration  o f  
plasm a m icroligands and that it undergoes a process o f  
reabsorption  w h ile  traversing the nephron. Z in c  is also 
elim inated in sw eat and th rough the hair, nails and the skin itself.
Zinc deficiency
Clinical and laboratory findings
Z in c  d eficien cy  is probably m ore freq u en t than clinicians 
suspect, esp ecia lly  in its early and subtle  expressions w hich 
in clu de hyp ogeusia, hyposm ia, abnorm al dark adaptation, 
im paired w oun d healing, derm atoses and im potence. J S evere 
chron ic zin c dep letion  gives rise to retarded grow th  and 
h yp ogon adism . E xistin g evid en ce is in su fficien t to characterize
zin c deficien cy fu lly  in clinical term s since abnorm ally low serum  
zin c levels have been found to coexist w ith negative taste and 
sm ell tests, and, on the other hand, oral replacem ent o f  zinc in 
patients w ith  essential oligosperm ia or azoosperm ia and norm al 
serum  zinc values has resulted in increases in the n um ber o f  
norm al m obile sperm atozoa, u ltim ately leading to p regn an cy.' 
T h e se  con tradictory observations preclude any definite 
gu idelin es for dep ictin g zinc deficien cy at the clinical level. 
S erum  or plasm a zin c values rem ain the m ost reliable criterion  
for the diagnosis o f  zinc deficien cy, how ever, although the 
relation to total bo d y zinc is not know n and decreased serum  zin c 
values m ay exist in entirely  asym ptom atic individuals.
T h e  diagnosis o f  zinc deficien cy during d iu retic treatm ent 
should  be established either w hen serum  zinc values are 
sign ifican tly  low  (<  80 /ig/dl), irrespective o f  the presence o f  
sym ptom s or signs, or w hen at least tw o defin ite  sym ptom s or 
signs develo p , even in the presence o f  norm al serum  zinc values.
A etiology and pathogenesis12
A  severe, although not unequivocally  pure zinc deficien cy 
syn d rom e has been described in m alnourished children. 
Im pedim en ts to a norm al zin c supply from  the gu t include a low 
zin c con tent in the diet, as determ ined by geological conditions, 
large am ounts o f  phytate or fibre in the diet, and exaggerated 
losses o f  zin c due to gastro-intestinal disorders.
G en e tic  disorders such as sickle cell disease and acroderm atitis 
enteropathica are related to zinc deficien cy, though in d ifferen t 
w ays. S ick le  cell disease possibly causes zin c deficien cy through 
hyp erzin ciuria. W h eth er this increased renal zin c ou tp u t is due 
to increased zinc filtration provoked by continued haem olysis or 
to an im pairm ent o f  the nephronal reabsorption o f  the ion is not 
know n. In acroderm atitis enteropathica there is a congenital 
defect in the synthesis o f  a protein related to zinc absorption.
A lcoh olism  provokes hyperzinciuria, possibly through a d irect 
e ffect o f  alcohol on the renal tubular epithelium . A  decrease in 
serum  zin c concentration  follow s excessive renal losses in 
chron ic alcoholism , and clinical evidence o f  zin c  deficien cy has 
been found in this condition. A bnorm al zinc m etabolism  occurs 
in hepatic cirrhosis in w h ich  decreased serum  and hepatic zinc 
and hyp erzinciuria  coexist. W hether this syndrom e is 
in dep en d en tly  related to cirrhosis or is a con sequen ce o f  
alcoholism  has not been determ ined.
Burns cause exten sive zinc losses in exudates, and the losses o f  
skin mass w hich m ay occu r in psoriasis afford a circum stance in 
w h ich  zin c stores cannot be m aintained. Som e diabetic patients 
exh ib it hyp erzinciuria  o f  unknow n origin. H yp ozincaem ia has 
been found du rin g p regnancy, possibly because o f  the uptake o f  
the elem ent by the products o f  conception. Z in c  deficien cy 
usually occurs in uraem ia before haem odialysis is in itiated ,’ and 
patients w ith renal diseases in w hich album in and am ino acids 
are lost in the urine m ay also present w ith zin c depletion.
Zinc and diuretics
D iuretics whose m ain site o f  renal activ ity  lies at the cortical 
d ilu tin g segm ent (rough ly, at the early portion  o f  the distal 
con voluted  tubule) such as ch lorothiazide, hyd roch loroth iazide, 
ben droflum eth iazide, chlorthalidone and xipam ide have been 
found to provoke h yperzinciuria  both w hen adm inistered as a 
single dose and w hen given  on a long-term  basis to norm al 
su bjects.11'' C on versely , the loop diuretics furosem ide and 
bum etanide and the potassium -sparing distal tubule diuretic 
( D T D )  triam terene have been found not to affect urinary zinc 
excretio n .7
H yp erzin ciu ria  fo llo w in g adm inistration o f  com m on D T D s  
could  be determ ined not on ly b y  d irect b lockade o f  zinc 
reabsorption. In a recent experim ental series in w hich excretion
o f  several urinary electrolytes fo llo w in g adm inistration o f  
various d iu retic  form ulations to norm al volunteers was 
described con tin uously  through a m athem atical m odel, it was 
found that the tim e-courses o f  w ater, sodium , chloride, 
potassium , m agnesium  and zinc urinary flow s coin cide after the 
adm inistration  o f  placebo." 11 H ow ever, zin c  excretion  after 
h y p erzin ciu ric  d iuretics was dephased w ith  regard to the 
excretion  o f  w ater, sodium , chloride and potassium , w h ich  
coin cid ed  in tim e-course (F ig . 1). U rin ary peak excretion  o f  zinc 
succeeded the peak excretion  o f  w ater and o f  the m onovalent ions 
b y  3-5 hours, su ggestin g that the process in volved  in the 
h y p e rz in c iu r ic  resp o n se  to d iu re tic s  in v o lv e s  in d ire c t 
m echanism s w h ich  take tim e to act, as w ould  be the case if  
horm one-m ediated phenom ena w ere im plicated. A  sim ilarly 
delayed response due to horm onal intervention  is observed  in the 
tim e-course o f  hyperm agnesiuria  e licited  by  d iu retics.9 11 T h e  
m echanism  w h ereby m etabolism  o f  the divalen t ions calcium , 
m agnesium  and zin c could  interact in order to p roduce this 
delayed response to diuretics is unclear.
Im p oten ce is not all that rare a sym p tom  du rin g  long-term  
diu retic  adm inistration  and we have ob served  dysgeusia  and 
dysosm ia, prin cip ally  in the form  o f  su boptim al function, in 
patients receivin g distal D T D s  on a lo ng-term  basis for the 
treatm ent o f  raised blood  pressure.
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Fig. 1. Ten healthy subjects received placebo (Reyes and Leary — 
unpublished data), chlorthalidone 100 mg9 and xipamide 10 mg (Reyes 
and Leary — unpublished data) on different trial days. Urine was collected 
at different intervals after dosing and mean chloride and zinc urinary flows 
expressed as functions of time.a The chloride and zinc flows after 
medication are shown during intervals which comprise all peak flows, thus 
allowing easy comparison of the time-courses of their excretion after each 
medication.
Prophylaxis and treatm ent o f zinc deficiency  
during diuretic treatm ent
L o n g-term  treatm ent w ith com m on  D T D s  should  be 
con du cted  w ith m inim al dosages in order to p reven t depletion  o f  
potassium , m agnesium  and zinc; although the dose-response 
relationship for the hyp erzin ciu ric  e ffect o f  d iuretics has not 
been studied, it is w orth  m aintaining m inim al dosages as a sim ple 
prim ary p rop hylactic  approach. T reatm en t o f  hyperten sion  w ith 
on e-th ird  o f  the standard daily doses o f  D T D s  perm its blood
pressure control to the same degree as that achieved with 
standard dosages.12
When zinc deficiency is diagnosed, measures should be taken 
to optimize zinc absorption and to cope with any mechanism 
actually or potentially contributing to the pathogenesis of the 
syndrome. ' Oral zinc supplementation should be provided as 
zinc sulphate administered at a dose of 50-200 mg/d, which is 
generally well tolerated.3,1
In patients undergoing long-term haemodialysis, intestinal 
absorption of zinc is often altered, apparently because of 
abnormal metabolism of vitamin D ,1 which impedes satisfactory 
replenishment of bodily stores; parenteral zinc supplementation 
is indicated in such cases and the dosage regimen should be 
individually titrated.
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M agnesium deficiency provoked by diuretics
A .  J .  R E Y E S ,  W .  P .  L E A R Y
Summary
Many diuretics cause hypermagnesiuria which may 
lead to magnesium deficiency, presenting as hypo- 
magnesaemia, cardiac arrhythmias and tetany.
Loop diuretics cause hypermagnesiuria mainly 
through direct blockade of magnesium reabsorp­
tion at the loop of Henle. Distal tubular diuretics 
block magnesium reabsorption at the distal convo­
luted tubule and also reduce magnesium reabsorp­
tion at the loop of Henle by an indirect mechanism.
S Afr M ed J 1983: 63: 410-412.
Commonly used diuretics such as the thiazides, chlorthalidone 
and furosemide increase urinary magnesium losses. Deficiency 
of the ion develops after prolonged diuretic treatment, notably 
when other factors contributing to magnesium depletion are also 
present.1 Significant magnesium losses in association with 
diuresis may pass unrecognized because the signs and symptoms 
of magnesium depletion are usually attributed to potassium 
deficiency, which may also be present.2
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Hyperm agnesiuria provoked by diuretics
Urinary magnesium excretion is significantly increased in 
healthy adults by single therapeutic doses of diuretics which act 
principally in the loop of Henle (furosemide, piretanide) or in the 
first portion of the distal convoluted tubule (hydrochlorothia­
zide, xipamide, chlorthalidone).1 ‘ Magnesium depletion may 
complicate prolonged treatment with either type of diuretic.
Pathophysiology o f m agnesium  deficiency  
provoked by loop diuretics
Approximately 70% of plasma magnesium is diffusible and 
therefore subject to filtration at the glomerulus. About half the 
filtered magnesium is reabsorbed in the thick limb of the loop of 
Henle,s where diuretics such as furosemide, ethacrynic acid, 
bumetanide and piretanide1' appear to have a common receptor 
and exert their principal biochemical effects within the kidney. 
Loop diuretics inhibit magnesium reabsorption by a mechanism 
unrelated to the interference with chloride transport in the loop 
of Henle which primarily determines their natriuretic and diu­
retic effects.*'101
Direct blockade of magnesium reabsorption within the loop of 
Henle might account for the hypermagnesiuria induced by loop 
diuretics, were it not for evidence that other processes are also 
involved. Mathematically derived curves describing sodium and 
magnesium flows in urine of healthy individuals given placebo 
show that the time courses of both excretions are parallel (Fig. 1). 
When the same individuals are given single therapeutic doses of 
furosemide, urinary magnesium flow is delayed with respect to 
sodium flow (Fig. 2).5 This strongly suggests that slow mecha­
nisms, possibly endocrine in nature, may act in conjunction with
m m o l / h  P L A
Fig. 1. Urinary sodium and magnesium flows after administration 
of placebo to 9 healthy volunteers at time 0 (08h00). Both curves 
exhibit similar time-courses and their peaks thus practically 
coincide. (From Reyes and Leary5 by courtesy of Current Thera­
peutic Research ).
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Fig. 2. Urinary sodium and magnesium flows after oral adminis­
tration of furosemide 40 mg to 9 healthy volunteers at time 0 
(08h00). Magnesium flow is retarded with respect to sodium flow 
and the peaks of the corresponding curves therefore occur at 
different times. (From Reyes and Leary, 5 by courtesy of C urrent 
Therapeutic Research .)
direct blockade of magnesium reabsorption at the loop of Henle 
in determining hypermagnesiuria.
Loop diuretics cause hypercalciuria,1'11 a negative gradient in 
serum calcium level and an increase in the serum parathyroid 
hormone (PTH) value.12 PTH  tends to mobilize calcium and 
magnesium from bone,15 thereby re-establishing normal plasma 
calcium and magnesium values. This may explain why hypo- 
magnesaemia only manifests itself after 8-12 weeks of treat­
m ent.11'15 The transfer of magnesium from bone stores to 
plasma, under PTH  control, increases the amount filtered at the 
glomerulus and ultimately excreted. However, magnesium reab­
sorption at the loop of Henle and possibly in the distal convo­
luted tubule is positively controlled by PTH ,8'10 which would 
tend to diminish the urinary excretion of magnesium.
When magnesium excretion exceeds intake an increasing 
mobilization of bone magnesium takes place, the magnesium 
balance becomes negative and deficiency may develop. This can 
be reflected by an early fall in the plasma magnesium level, or no 
change may occur before there has been a major decrease in the 
intracellular concentration of the ion affecting bone and other 
tissues.
Depletion of tissue magnesium inhibits the release of PTH , 
and, in addition, resistance to the action of this hormone deve­
lops limiting mobilization of bone calcium and magnesium and 
reduces the nephronal reabsorption of these ions.1 'n Hypocal- 
caemia develops as a result of these changes and tends to decrease 
magnesiuria slightly in a direct manner independent from 
P T H .16'18 The renal effect of PTH  is not only diminished because 
sensitivity to the hormone is decreased but also, in the case of 
furosemide, because the diuretic blocks it directly.10 Loop diu­
retics dilute pre-urinary magnesium, and its reabsorption is thus 
further reduced.
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Fig. 3. Urinary sodium and magnesium flows after oral adminis­
tration of hydrochlorothiazide 50 mg to 9 healthy volunteers at 
time 0 (08h00). Magnesium flow is retarded with respect to 
sodium flow and the peaks of the corresponding curves therefore 
occur at different times. (From Leary and Reyes, 7 by courtesy of 
Current Therapeutic Research .)
Pathophysiology o f m agnesium  deficiency  
provoked by distal tubular diuretics
Only 1 -5% of filtered magnesium is normally reabsorbed from 
the distal tubule. The hypermagnesiuria provoked by distal 
tubule diuretics therefore cannot be explained solely on the basis 
of a direct blockade of magnesium transport across the nephronal 
wall at that level. This view is supported by experiments similar 
to those described for furosemide, in which it was found that an 
im portant dephasing exists between the curves expressing time- 
courses of excretion of sodium and magnesium after the adminis­
tration of distal tubular diuretics such as hydrochlorothiazide,7 
chlorthalidone4 and chlorexolone (Fig. 3).6 This dephasing is
more pronounced than that which appears after the administra­
tion of loop diuretics and suggests that the hypermagnesiuria 
caused by distal tubule diuretics involves indirect mechanisms.
Some distal tubule diuretics, such as hydrochlorothiazide19 
and xipamide (A. J. Reyes and W. P. Leary — unpublished 
data), provoke hypercalciuria for 24 hours following their initial 
administration but hypocalciuria thereafter if treatment is pro­
longed, whereas distal tubule diuretics, such as chlorthalidone 
and indapamide, cause hypocalciuria from the onset of treatment 
of healthy volunteers or patients with uncomplicated essential 
hypertension. Diuretics which provoke hypercalciuria initially 
cause less dephasing between the time-courses than those which 
reduce urinary calcium excretion from the onset of treatment. 
Hypercalciuric distal tubule diuretics may behave as loop diuret­
ics initially, at least with respect to hypermagnesiuria during the 
first 24 hours of treatment, thereafter sharing indirect mecha­
nisms with the other distal tubule diuretics. Hypocalciuria 
results in relative hypercalcaemia and decreased PTH release 
with diminished magnesium reabsorption at the loop of Henle. 
This process per se may explain the magnitude of the hypermag­
nesiuria caused by distal tubular diuretics. Other mechanisms 
are similar to those associated with the hypermagnesiuria of loop 
diuretics.
The potassium-sparing diuretic amiloride,1"3'16 which acts at 
the last portion of the distal convoluted tubule, does not provoke 
hypermagnesiuria (W. P. Leary, A. J. Reyes and K. van der Byl 
—unpublished data) because magnesium in the pre-urine is not 
transferred to the extracellular fluid at this site and because this 
diuretic does not affect the renal excretion of calcium to any 
significant degree.
Magnesium deficiency
Circumstances other than treatment with diuretics may cause 
magnesium deficiency (Table I).16 Some of these may also pro­
voke potassium deficiency and may adversely affect patients on 
diuretic regimens.
Magnesium deficiency seldom occurs as an isolated entity, 
although its consequences — notably its cardiac effects — may 
be fatal. Ventricular arrhythmias including ventricular fibrilla­
tion1'2,16 have been attributed to magnesium depletion, and defi­
ciency of the ion increases the myocardial hyper-excitabilitv 
induced by digitalis.
Other clinical manifestations of magnesium deficiency include 
the classic signs of tetany, which are usually attributed to calcium 
deficiency, dysphagia and haemolytic anaemia.16
REFERENCES
1. Learv WP, Reves AJ. Diuretics: practitioner’s review. A A fr  M e d J  1981; 59: 
9-13.
2. Learv WP, Reves AJ. Diuretics, magnesium, potassium and sodium. S  A fr  M ed  
J  1982; 61: 279-280.
3. Wester PO, Dvckner T. Diuretic treatment and magnesium losses. A a a  M ed  
Seand 1981; suppl 647, 145-152.
4. Reyes AJ, Leary WP. Urinary magnesium and zinc excretions after monodos­
ing healthy volunteers with chlorthalidone. Curr Ther Res 1982; 32: 128-137.
5. Reyes AJ, Leary WP. The magnesiuric effect of a single dose of furosemide in 
healthy adults. Curr Ther Res 1982; 32: 406-416.
6. Leary WP, Reyes AJ. Urinary volumes and solute flows after a single dose of 
chlorexolone in healthy adults. Curr Ther Res 1982; 32: 417-424.
7. Leary WP, Reyes AJ. The magnesiuric effect of a single dose of hydrochloro­
thiazide in healthy adults. Curr Ther Res 1982; 32: 425-431.
8. Quamme GA, Dirks JH. Magnesium transport in the nephron. A m  J  Phxsiol 
1980; 239: F393-F401.
TABLE I. CONDITIONS WHICH MAY PRIMARILY CAUSE 
MAGNESIUM DEFICIENCY OR ACT AS PRECIPITATING 
OR AGGRAVATING FACTORS IN ITS DEVELOPMENT 
DURING DIURETIC TREATMENT
Factors decreasing supply of magnesium to the internal 
environment 
Dietary insufficiency
Low magnesium content in available foods 
Poor selection of foods
Global intake of food inadequate to supply magnesium 
needs
Malabsorption syndromes 
Extensive gut resection 
Enteral and biliary fistulas 
Factors which principally increase magnesium loss 
Gastro-intestinal 
Vomiting 
Diarrhoea 
Renal
Renal insufficiency with hypermagnesiuria 
Osmotic diuresis (glucose, mannitol, urea)
Alcohol
Medications inducing hypermagnesiuria 
Cis-platin 
Gentamicin 
Cardiac glycosides 
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Prophylaxis and treatm ent o f  
m agnesium  depletion
W. P.  L E A R Y ,  A .  J .  R E Y E S
Summary
Magnesium deficiency may develop during diuretic 
treatment, causing serious cardiac arrhythmias 
hitherto ascribed to potassium depletion. Intrave­
nous magnesium replacement therapy replenishes 
intracellular magnesium and potassium and inhibits . 
cardiac arrhythmias which may occur during diure- i 
tic treatment; oral magnesium supplementation is 
also effective. The co-administration of amiloride 
with a distal-tubule diuretic prevents increased 
renal excretion of magnesium. Doses of diuretics 
should be restricted to the minimum compatible 
with the achievement of clinical objectives.
S A ir Med J 1983; 64: 281-282.
Recent publications have indicated the importance of magne­
sium depletion as a complication of prolonged treatment with 
loop or distal-tubule diuretics (LDs, DTDs), laxative abuse and 
various pathological conditions. This article describes measures 
which should be taken to limit magnesium losses associated with 
diuretic therapy and to replenish depleted magnesium stores.
Limitation of diuretic dose
Diuretics are commonly prescribed for patients with oedema or 
hypertension and increase urinary magnesium losses in most 
cases. Oedema should be treated initially by appropriate 
attempts at reversal of the primary cause, optimization of dietary
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salt intake and administration of diuretics at standard doses. The 
standard, recommended dose usually amounts to one tablet 
daily, assuming a natriuretic potency equal to furosemide 40 mg 
for LDs or hydrochlorothiazide 50 mg for DTDs. Higher doses 
will be required if malabsorption is present. When prolonged 
diuresis is necessary, the initial dose should be reduced to the 
minimum compatible with therapeutic objectives, thus limiting 
urinary potassium and magnesium losses. This maintenance 
dose must obviously be individually titrated but usually lies 
between one-third and one-half of the dose initially required to 
control oedema.1"3
Unnecessarily high doses of diuretics are commonly pre­
scribed in the treatment of essential hypertension. This should 
be avoided by applying simple rules to the choice of a suitable 
therapeutic regimen. LDs such as furosemide and ethacrynic 
acid have an important role but are of limited value in the 
treatment of uncomplicated essential hypertension and do not 
satisfy all the criteria for an antihypertensive diuretic. DTDs of 
the power type, such as a combination of hydrochlorothiazide 
and amiloride or xipamide, reduce blood pressure rapidly, with 
stabilization from a clinical point of view occurring after 12 - 14 
weeks of treatment.4"6 Linear antihypertensive diuretics, such as 
hydrochlorothiazide, decrease blood pressure smoothly, al­
lowing adjustments in regional blood flow and reducing the 
likelihood of vascular accidents mediated through the mecha­
nism of critical closing pressure.4 The minimal effective antihy­
pertensive dose of both types of DTD is approximately one- 
quarter of the conventional diuretic dose. Doses as small as 10-15 
mg xipamide and 12,5 mg hydrochlorothiazide or chlorthalidone 
per day should therefore be prescribed in most cases of uncom­
plicated essential hypertension.7 At these doses hypermag- 
nesiuria and hyperkaliuria are minimized, while the antihyper­
tensive effect is similar to that achieved with standard diuretic 
dosages.
Magnesium administration
Arrhythmias developing during treatment with diuretics res­
pond to acute magnesium replacement.8 10 The intravenous 
administration of magnesium sulphate normalizes intracellular 
concentrations of both potassium and magnesium in skeletal 
muscle of patients with hypomagnesaemia and hypokalaemia
secondary to prolonged diuresis. Simple potassium replacement 
does not restore the intracellular levels of either cation to 
normal.8"9 Despite a relatively poor correlation between the 
intracellular magnesium concentrations of skeletal and cardiac 
muscles, it is likely that these tissues respond similarly to magne­
sium repletion and that the suppression of arrhythmias by mag­
nesium is due to a reactivation of N a ’,K'-ATPase.
Decreases in myocardial magnesium and potassium concen­
trations are not only caused by the administration of diuretics; 
digitalis inhibits myocardial Na*,K'-ATPase and myocardial 
ischaemia has a similar effect on intracellular electrolytes which 
might contribute to the development of the arrhythmias com­
monly associated with myocardial infarction.1112 In these cir­
cumstances magnesium infusion has an anti-arrhythmic effect; 
animal studies have shown that this measure results in repletion 
of intracellular potassium and magnesium ions in the infarcted 
area.12
Intravenous magnesium sulphate can be administered as an 
immediate measure in the treatment of ventricular arrhythmias 
associated with diuresis, infarction or digitalis therapy.13 The 
solution can be given as a bolus of 2,5 g, which usually suppresses 
arrhythmias within 20 - 30 seconds, or at a dose of 40 mg/min in 
a saline infusion. The latter dose is safer in patients with respira­
tory or cardiac insufficiency and can be continued indefinitely 
without any detectable rise in the serum magnesium level. Alter­
native parenteral dosage regimens may be used.9,121'1
During prolonged treatment with diuretics, magnesium 
should be taken orally as a prophylactic measure at a dose of 
10-15 mmol/d (20 - 30 mEq). This dose should be doubled if 
evidence of magnesium depletion appears. The magnesium 
formulations available for therapy (chloride, aspartate) are 
equally well absorbed and should be taken in divided doses at 
mealtimes.In
The only absolute contraindication to magnesium administra­
tion is an excess of the ion which sometimes accumulates in 
patients with acute or chronic renal insufficiency with a glomeru­
lar filtration rate below 30 ml/min, hypothyroidism, viral hepati­
tis, or Addison’s disease and in patients on lithium therapy. 
Hypermagnesaemia is diagnosed when the plasma level exceeds 
1,20 mmol/1 but clinical evidence of magnesium overload sel­
dom appears at levels below 2 mmol/1.17
Initially, nausea and vomiting, rashes, somnolence and reduc­
tion of deep tendon reflexes develop. The E C G  displays prolon­
gation of the P-R interval and disturbances of intraventricular 
conduction. W h e n  the plasma magnesium level reaches 5 
mmol/1, skeletal muscles, including respiratory muscles, may 
become paralysed, with cardiac arrest in diastole likely if the 
plasma magnesium concentration rises to 7,5 mmol/1. According­
ly, plasma levels should be monitored during treatment with 
magnesium supplements. Therapy should be withdrawn and 
temporary treatment with an L D  instituted if mild hypermagne­
saemia develops; if important cardiac complications due to mag­
nesium excess are diagnosed, calcium (as calcium gluconate) 
100-200 m g  should be infused intravenously over 5-10 minutes.
Magnesium-sparing diuretics
Whereas L D s  and D T D s  cause significant urinary magnesium
losses, the potassium-sparing diuretic amiloride has no such 
effect when single doses of 5 or 10 m g  are given. Preliminary 
studies, carried out in healthy volunteers, suggest that amiloride 
has a definite magnesium-sparing effect when given in conjunc­
tion with standard diuretic doses of hydrochlorothiazide and that 
the use of a D T D  with a magnesium potassium-sparing diuretic 
might limit intracellular depletion of magnesium and potassium 
ions. This is supported by other studies in m an which have 
shown that the intracellular magnesium content of skeletal 
muscle is unaffected by protracted treatment with a combination 
of amiloride and hydrochlorothiazide.
Replacement of potassium losses
One of the main objectives of attempts to maintain magnesium 
homeostasis is the restoration of N a ’,K -ATPase function to 
normal so that intracellular potassium levels are replenished. 
However, a normal plasma potassium level is an essential com­
ponent in the dynamic equilibrium of Nernst. This may be 
achieved by measures which have been reviewed elsewhere,17 
including the prescription of a sodium-restricted diet, admini­
stration of potassium supplements or -he correct use of potas­
sium-sparing diuretics.
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M agnesium and sudden death
W .  P .  L E A R Y ,  A .  J .  R E Y E S
Summary
Magnesium deficiency may result from reduced 
dietary intake of the ion or increased losses in 
sweat, urine or faeces. Stress potentiates magnesium 
deficiency, and an increased incidence of sudden 
death associated with ischaemic heart disease is 
found in some areas in which soil and drinking water 
lack magnesium. Furthermore, it has been demon­
strated experimentally that reduction of the plasma 
magnesium level is associated with arterial spasm. 
Careful studies are required to assess the clinical 
importance of magnesium and the benefits of mag- * 
nesium supplementation in man.
S A h  M e d  J  1983: 64: 697-698.
Ischaemic heart disease (IHD), seldom diagnosed before World 
War I, is a com m o n  cause of ill-health and death in the developed 
world. In South Africa, the death rate from I H D  is disturbingly 
high among young adults of European or Asian descent and the 
incidence of I H D  appears to be gradually increasing among 
urban Blacks.1 Despite the identification of risk factors related to 
the occurrence of myocardial ischaemia or infarction (such as 
hypertension, diabetes mellitus, smoking and hyperlipidaemia), 
little is known about the causes of sudden death in patients with 
relatively normal hearts.2,3 It follows, therefore, that such events 
cannot be avoided by the application of rationally based 
preventive measures.
The incidence of sudden death due to cardiovascular disease 
varies in certain geographical areas and has been ascribed to 
differences in their geological characteristics. In Canada,4,5 
Finland,6 Britain7 and the U S A 8 sudden death is commonest in 
soft-water areas, suggesting that inhabitants of these regions are 
more susceptible to serious cardiac arrhythmias. Since water, 
soil and plants are magnesium-deficient in soft-water areas6 and 
loss of myocardial magnesium and potassium predispose to 
major ventricular arrhythmias, it appears reasonable to investigate 
the possibility that'some sudden deaths are due to magnesium 
deficiency rather than to I H D  per se. Certainly the magnesium 
content of the myocardium and coronary arteries is reduced in 
individuals from soft-water areas.9 Magnesium depletion 
decreases the activity of Na*, K ’-ATPase and Ca2*-ATPase in the 
sarcolemma, with resultant increases in myocardial sodium and 
cytosolic calcium levels and falls in intracellular concentrations 
of magnesium and potassium. This imbalance electrically desta­
bilizes the myocardial sarcolemma, making the occurrence of
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ventricular arrhythmias likely. Other apparent relationships 
between magnesium balance and cardiac disease exist.10
Magnesium and stress
Individuals with so-called type A  personalities commonly 
develop I HD.11 They exhibit an intense drive towards the 
achievement of personal objectives, competitiveness, a persistent 
need for recognition, commitment to numerous projects subject 
to deadlines, an accelerated work rate, and inability to relax. 
Stress associated with a type A  personality or with measurable 
exogenous factors such as noise1113 provokes hypermagnesiuria, 
an increase in overall sympathetic drive and in plasma catecho­
lamine and lipid levels and, ultimately, magnesium deficiency.8,14 
This combination of changes might predispose to lethal arrhyth­
mias and contribute to the overall incidence of sudden cardiac 
death, particularly when magnesium intake is reduced or 
accelerated. Magnesium losses can also be due to the injudicious 
use of alcohol, cathartics or diuretics.9,12,14
Magnesium and vascular reactivity
Under experimental conditions, tone in both coronary and 
cerebral blood vessels is increased by the acute or chronic 
reduction of the extracellular magnesium concentration. Con­
versely, hypermagnesaemia or the correction of chronic magne­
sium deficiency promotes vasodilation.13"15 Vasospasm is poten­
tiated by calcium ions which replace magnesium at sites on some 
of the proteins linked with contractility, such as troponin C. In 
addition, magnesium deficiency increases vascular responses to 
angiotensin, catecholamines, acetylcholine, serotonin and potas­
sium ions.
Reduced magnesium concentrations in infarcted myocardial 
tissues and in the immediately adjacent areas were first reported 
by Condorelli,16 who studied human autopsy material and the 
hearts of several animal species subjected to coronary ligation. 
This finding has been confirmed in m a n 17,18 and, while it 
represents a response to oxygen deficiency,19"22 should be 
considered as a cause of serious cardiac arrhythmias associated 
with infarction.22 Theoretically, the severity of this local imba­
lance might be aggravated by the presence of chronic magnesium 
depletion with attendant coronary spasm.23
Prophylaxis and therapy
A n  adequate dietary intake of magnesium should be the rule, 
particularly in individuals at high risk for myocardial infarction 
or sudden cardiac death. A  diet rich in fresh vegetables and fruit 
is recommended; high intakes of fat, sugar and alcohol increase 
magnesium requirements and susceptibility to magnesium defi­
ciency.22,24"26 Supplementary magnesium should be added to the 
diet in those areas in which content of the ion in soil and water is 
low.
The dosage of supplementary magnesium should ultimately 
be based on accurate studies, similar to those which were used to 
determine rational iodine supplementation. In the mean time it 
would be reasonable to prescribe a magnesium salt, taken orally 
at a dose of 7,5 m mol of the cation (180 mg) daily, for all adults in 
w h o m  plasma magnesium levels below 0,85 mmol/1 are found on
three separate occasions. This is recommended whether or not 
signs or symptoms of magnesium deficiency are present.
In acute myocardial infarction magnesium sulphate 40 mg/h 
should be administered intravenously during the initial 72 hours 
in hospital, whether or not arrhythmias occur. This innocuous 
manoeuvre may improve contractility in the perinecrotic area 
and infarct size may possibly decrease as a result of the protective 
effects of magnesium on function of the coronary vasculature 
and the structure of myocardial cells.27"30
The possible importance of magnesium deficiency as an 
aetiological factor in sudden cardiac deaths in South Africa is 
purely speculative at present. Indeed, it should be stressed that 
the role played by magnesium ions in all such deaths, although 
critical in theory, remains unproven, despite a wealth of 
circumstantial evidence supporting the central hypothesis that 
magnesium deficiency is a potentially lethal condition.
Within South Africa’s borders the drinking water supply has a 
very low magnesium content, ranging from 1 to 5 mg/1 in several 
areas. In Durban, plasma magnesium levels and urinary excretion 
of the ion, a rough measure of daily intake, are almost uniformly 
low in otherwise healthy individuals.31 Magnesium losses increase 
when there is profuse sweating or if alcohol, laxatives or c o m m o n  
diuretics are taken, further depleting inadequate mineral stores. 
Arrhythmias are a possible consequence, particularly in patients 
treated with potentially arrhythmogenic compounds such as 
sympathomimetics and digitalis or in the presence of potassium 
depletion or myocardial ischaemia.
Careful prospective epidemiological and clinical studies 
involving multifactorial analyses are required before the exact 
role played by hy pomagnesaemia in cardiac deaths is determined. 
In the interim, supplementation of the diet with magnesium salts 
should be considered in all individuals at risk.
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W. P .  L E A R Y ,  A .  J .  R E Y E S ,  C .  J .  L O C K E T T ,  D .  D .  A R B U C K L E ,  K .  V A N  D E R  B Y L
""'’•'''I .. , ~ , ' • ‘ ' ■ . ' \ . . “
Summary
The incidence of death from ischaemic heart disease 
(IHD) and acute cardiac arrhythmias is increased in 
some regions where magnesium levels are reduced 
in soil and water.
Magnesium levels in the drinking water of twelve 
South African magisterial districts have been eva­
luated together with corrected statistics for deaths 
apparently due to IHD in White males from the same 
districts. A significant negative correlation was 
found between the incidence of deaths ascribed to 
IHD and the magnesium content of drinking water. 
Future, prospective, multivariate studies are required 
to elucidate whether magnesium scarcity in a geo­
logical environment is a major coronary risk factor.
S A I r  M e d  J  1983; 64: 775 - 776.
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In South Africa statistics based on the examination of death 
certificates indicate that there is a high death rate from ischaemic 
heart disease (IHD) among Whites, Indians and Coloureds,1 
although a significant number of deaths ascribed to I H D  by
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practitioners who sign death certificates are certainly due to 
acute cardiac arrhythmias unrelated to I H D  or, in some cases, to 
catastrophic cerebral haemorrhage. Diagnostic errors of this 
kind are commonly made in all countries, particularly in rural 
areas where pathology services are often limited.
Data from various sources suggest that the incidences of death 
from I H D  and acute cardiac arrhythmias may be influenced 
unfavourably by regional deficiencies in dietary magnesium 
content.2’4 This view is supported by clinical and pathophysio­
logical evidence that serious cardiac arrhythmias occur in 
magnesium deficiency of any origin.5,6
Magnesium concentrations in soil, water and locally grown 
fruit and vegetables vary in accordance with regional geological 
characteristics.3,4,7 W h e n  domestic water is supplied from natural 
sources its magnesium content is similar to that of the local soil 
and farm produce and, in the absence of significant supplemen­
tation from other sources, the level of magnesium in drinking 
water provides an accepted indication of magnesium intake in 
any given area.2’4 Utilizing this principle a preliminary examina­
tion of official data8,9 has been carried out to determine whether 
any apparent relationship exists between deaths ascribed to I H D  
and magnesium levels in the drinking water of several selected 
South African towns.
Methods
Data on the average magnesium content of drinking water in 
various districts during 1982 were provided by the Department 
of Environmental Affairs, Pretoria.9 These data were based on a 
sampling procedure whereby water from regional dams and 
rivers supplying them was repeatedly examined by atomic 
absorption spectrophotometry.
A  preliminary survey of the data allowed identification of a set 
of localities where the magnesium content of water varied from
0,04 to 1,85 mmol/1 (1-45 mg/1), allowing a wide range of 
possible magnesium intakes. The districts studied were those of 
Bloemfontein, Bothaville, Duiwelskloof, Durban, Hennenman, 
Mafeking, Pietersburg, Potgietersrust, Postmasburg, Venterstad, 
Virginia and Welkom. This selection preceded the acquisition of 
any data on regional death rates from IHD.
Corrected statistics10 for deaths in White males, apparently 
due to I H D  and derived from death certificates issued during 
1978, were supplied by the Department of Statistics, Pretoria.8
Spearman’s (non-parametric) correlation coefficient (rho) was 
calculated to determine whether any correlation existed between 
deaths attributed to I H D  and magnesium content in drinking 
water. The test was two-tailed and P =  0,05 was considered the 
limit of significance.
Results
A  significant negative correlation was found between the 
incidence of death apparently due to I H D  and the magnesium 
content of drinking water (Fig. 1).
D iscussion
The view that magnesium deficiency may be of pathogenic 
importance in precipitating deaths from ischaemic heart disease 
is currently supported by experimental11 and epidemiological 
findings/ 4 It may also be postulated that magnesium deficiency 
is an aetiological factor in I H D  since it decreases glucose 
tolerance12 and decreases the high-density/low-density lipo­
protein ratio.13
The death rates for I H D  used in the present study are 
undoubtedly biased by the inclusion of patients who did not 
suffer from I H D  but died as a result of unrelated acute cardiac 
arrhythmias. However, since magnesium deficiency is a proven 
determinant of cardiac arrhythmias6 this bias is of minor 
importance.
It is possible that a small percentage of sudden deaths 
attributed to I H D  were caused by acute cerebrovascular events. 
In this regard it is noteworthy that experimental evidence has 
been published indicating that magnesium depletion causes 
spasm of the cerebral arteries.14
Future prospective multivariate studies are required in which 
somatic magnesium status is related to the prevalence of I H D  
and occurrence of deaths due to acute myocardial infarction, 
independent arrhythmias and cerebrovascular accidents. The 
incidence of all other known risk factors for I H D  should also be 
evaluated. Such studies should be multicentric and be carried 
out by specially trained medical practitioners in small environ­
mentally and biologically homogeneous communities where 
patients can be followed up.
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Fig. 1. Relationship between deaths of White males certified as 
due to IHD and the magnesium content of drinking water. Each 
point corresponds to a magisterial district in the RSA. There is a 
significant negative correlation between the variables.
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Magnesium deficiency — a cardiac 
disease risk factor?
In recent years interest in the development of magnesium- 
related research has given rise to the foundation of the 
International Magnesium Society and a journal devoted to 
the mineral, Magnesium Bulletin. Magnesium depletion in 
man usually results from inadequate dietary intake of 
magnesium salts or increased excretion of the ion in urine 
or faeces. Clinical evidence of deficiency may include 
tetany, dysphagia, anaemia and cardiac arrhythmias.1
Ionic magnesium is a co-factor for the function of many 
enzymes, of which the sodium and adenosine 
triphosphatase responsible for maintaining electrolyte 
balance across myocardial cell membranes is of major 
interest. Evidence suggests that simple potassium 
replacement regimens during periods of depletion due to 
disease or drugs may be insufficient to restore intracellular 
potassium levels to normal when magnesium deficiency is 
also present.2 An argument can therefore be made for 
dietary magnesium supplementation in certain patients.
The incidence of magnesium deficiency in South Africa 
is unknown, although the low magnesium content of 
drinking water in some areas and the widespread use of 
preparations such as laxatives and diuretics, which 
increase magnesium losses, suggest that this question 
deserves attention.
An interesting parallel exists between some areas of the 
RSA and parts of Finland, in which water supplies are 
relatively magnesium-deficient and sudden death, 
apparently from cardiac causes, is common.3 Whereas 
Finnish studies have been fairly detailed, and the concept 
of magnesium deficiency as a major cardiovascular risk 
factor is gaining ground on pathophysiological and 
epidemiological evidence, no satisfactory studies have 
been carried out in South Africa. Careful epidemiological 
and clinical studies are needed to determine whether any 
link exists between magnesium deficiency and sudden 
death in South Africa and, if it exists, to determine why 
such deaths show an apparent racial bias. In addition, it 
might be wise to include magnesium and other elements in 
all future basic investigations of cardiac arrhythmias and 
the essentials of myocardial metabolism.
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Urinary Zinc Excretion, Diuretics, Zinc Deficiency and Some 
Side-Effects of Diuretics
This review was shared by the authors. Dr. J.V. Olhaberry 
provided many of the biochemically orientated references and 
also his expertise in that aspect of the work.
Review Article
Urinary zinc excretion, diuretics, zinc 
deficiency and some side-effects o f  
diuretics
A .  J .  R E Y E S ,  J .  V .  O L H A B E R R Y ,  W .  P .  L E A R Y ,  C . J .  L O C K E T T ,  K .  V A N  D E R  B Y L
Summary
Diuretics which principally act in the first portion of 
the distal convoluted tubule, such as the thiazides 
and chlorthalidone, significantly increase the urinary 
excretion of zinc. The potassium-retaining diuretic 
amiloride reduced urinary zinc excretion signifi­
cantly.
The hyperzincuria provoked by common distal 
tubular diuretics can cause zinc deficiency, espe-
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dally when other aetiologieal factors such as alco­
holism, renal insufficiency and pregnancy are also 
present. Zinc deficiency may be expressed clinically 
by hypogeusia, hyposmia, sexual impotence or 
delayed healing; the latter might be an important 
factor in cases of myocardial infarction.
S A fr  Med J  1983; 64: 936 - 941.
Urinary excretion of zinc
Urinary zinc excretion accounts for 30-50% of daily zinc output 
and is relatively constant in healthy adults, amounting to 
approximately 0,5 mg/24 h irrespective of intake. Excretion 
increases in cases of alcoholism, renal insufficiency and during 
therapy with certain diuretics.1
The manner in which the kidney handles zinc is not fully 
understood. Studies carried out in dogs artificially overloaded 
with amino acids, and based on the fact that ultrafiltrable zinc is
bound to them, suggest that the urinary concentrations of certain 
amino acids (such as cystine and histidine) are major determi­
nants of zinc excretion and that significant reabsorption of the 
cation takes place in the distal convoluted tubule.1 However, 
the validity of these findings is questionable since the studies 
were unphysiological and there are differences between dogs and 
man as regards both plasma protein patterns and nephronal 
function.
Effects o f  diuretics on urinary zinc excretion
The effects that different types of diuretics have on urinary 
zinc excretion provide some insight into the handling of zinc in 
the kidney in both healthy subjects and patients with uncompli­
cated essential hypertension.8"11 Urinary zinc excretion is un­
affected by the loop diuretics furosemide and bumetanide, or the 
potassium-retaining preparation triamterene.11 Amiloride, 
another potassium-retaining diuretic, has no effect at a dose of 5 
mg, but significantly decreases urinary zinc excretion at 10 mg.9 
‘Distal tubule’ diuretics such as the thiazides, chlorthalidone and 
xipamide increase urinary zinc losses significantly,10"12 although 
the simultaneous administration of hydrochlorothiazide 50 m g  
and amiloride 5 m g  appears to maintain urinary zinc excretion 
within control ranges (W. P. Leary, A. J. Reyes and K. van der 
Byl —  unpublished data).
W h e n  the mathematical model of Reyes and Leary13 is fitted to 
the time-courses of urinary solute excretions, urinary flows of 
volume, chloride, sodium, potassium, zinc and magnesium are 
shown to coincide in time after the administration of a placebo 
(Fig. 1). However, after chlorthalidone administration potassium, 
magnesium and zinc flows are delayed in comparison with 
volume, sodium and chloride (Figs 2 and 3).10 The time-courses 
of volume, sodium and potassium excretions in response to 
amiloride are similar and precede the corresponding flows after 
placebo by 1-2 hours (Figs 4-6); the flow curves of urinary zinc 
excretion coincide whether placebo or amiloride is given (Fig. 7).9
Since loop diuretics have not been shown to alter urinary zinc 
excretion in individuals with normal renal function, it may be 
inferred that zinc is neither excreted nor reabsorbed at the thick 
portion of the ascending loop of Henle. However, diuretics such 
as thiazides and chlorthalidone, the principal site of renal action 
of which is at the cortical diluting segment of the nephron, 
significantly increase the amount of zinc excreted in 24 hours, 
suggesting that the ion is normally reabsorbed from pre-urine in 
the first portion of the distal convoluted tubule. The dephasing 
that occurs between the zinc flow curves and those of sodium, 
chloride and volume indicates that processes other than direct 
blockade of reabsorption from the tubular lumen may be 
involved in the mechanism that ultimately gives rise to the 
hyperzincuric effect of distal tubule diuretics. Since it has been 
postulated that an endocrine mechanism is partially responsible 
for the hypermagnesiuria associated with the administration of 
diuretics,14 a similarly slow mechanism might also account for 
hyperzincuria —  however, its nature is obscure since little 
information on the endocrine regulation of zinc metabolism 
exists1,15 and various relevant biochemical and endocrine effects 
of diuretics.are poorly documented at present.18"20
The effect of amiloride on urinary zinc excretion is conceptually 
and clinically interesting; the compound can be described as a 
zinc-retaining diuretic. This effect becomes apparent if amiloride 
is administered in a 10 m g  dose alone or in a 5 m g  dose combined 
with 50 m g  of hydrochlorothiazide. It is uncertain whether zinc 
is normally excreted at the most distal portion of the convoluted 
tubule and amiloride reverses this process, or whether amiloride 
induces reabsorption of zinc when administered in high doses or 
when the amount of zinc in pre-urine is raised by the effects of a 
thiazide diuretic at relatively proximal renal sites.
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Fig. 1. Mean urinary flows of sodium, magnesium and zinc after 
oral administration of placebo to 9 healthy volunteers at time 0 of 
the experiment (08h00). All three curves have similar time- 
courses and then their peaks coincide in time. By courtesy of 
Current Therapeutic R e sea rch .'0
Implications of diuretic-induced  
hyperzincuria in cardiology
Those diuretics that cause hyperzincuria (and therefore zinc 
deficiency in some cases) act mainly at the first portion of the 
distal convoluted tubule. Coincidentally, these diuretics, which 
include the thiazides and chlorthalidone,21 lower blood pressure 
to a clinically satisfactory level when administered alone in about 
70% of patients with essential hypertension.22
Hypertensive patients treated with a thiazide or chlorthalidone 
may become impotent.23 So far this adverse effect has not been 
explained, although it could well be due to zinc deficiency 
secondary to diuretic treatment. Similarly, possible links between 
zinc and various other unexplained side-effects of diuretics24"29 
merit further investigation. As a general measure plasma zinc 
concentration should be monitored during prolonged therapy 
with thiazides or chlorthalidone, especially in patients in w h o m
Fig. 2. Mean urinary flows of chloride and zinc after oral administration of placebo, 
chlorthalidone 100 mg and xipamide 40 mg on separate days to 10 healthy volunteers at time 0 
(08h00). The urinary zinc flow coincides in time with the chloride flow after placebo but is 
delayed with respect to the urinary chloride flow, and a time lapse therefore exists between the 
peaks of both curves.21
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Fig. 3. Mean urinary flows of chloride, sodium, volume, potassium, magnesium and zinc after oral administration of 
chlorthalidone 100 mg to 10 healthy volunteers (9 for magnesium) at time 0 (08h00). The chloride, sodium and urine 
flow curves have similar time-courses and then their peaks coincide in time. The potassium, zinc and magnesium 
urinary flow curves show progressive delays with respect to the first three curves. By courtesy of Current Therapeutic 
R esea rch .'0
additional factors which could lead to the development of zinc 
deficiency are present. Simultaneous administration of amiloride 
with a thiazide or with chlorthalidone may prove to be a desirable 
precautionary measure as regards the maintenance of ‘zinc 
balance’.
A  low plasma zinc level has been described in cases of acute 
myocardial infarction, possibly having been determined by the 
hyperzincuria associated with tissue necrosis. H o w  diuretic 
therapy before or after myocardial infarction may contribute 
towards provoking zinc deficiency needs to be studied, since zinc 
depletion might retard the healing of the infarct (this also has to 
be evaluated).
Zinc deficiency
Zinc deficiency is a poorly understood condition, but there have 
been some excellent reviews of the subject recently.1'30
Pathogenesis
The supply of zinc to the body may be diminished when the 
total food intake is reduced or when the diet contains an 
insufficient quantity of the cation.2,31 In addition, nonspecific 
circumstances that result in a decrease in the absorption of 
nutrients, such as malabsorption syndromes, extensive enteral 
resection and enterobiliary fistulas, reduce zinc absorption. 
M a n y  dietary substances, including phytates and fibre, decrease 
zinc absorption and may contribute to the development of zinc 
deficiency. Inherited enteropathic acrodermatitis is apparently 
caused by zinc malabsorption, and parenteral feeding without 
adequate zinc replacement may also give rise to zinc deficiency.32
Vomiting and diarrhoea may both reduce zinc absorption and
increase zinc losses to the extent that zinc deficiency develops, 
particularly when these occur recurrently or in subjects prone to 
zinc deficiency for other reasons. Chronic blood loss from the 
gut, whether due to haemorrhoids, parasites, drugs or other 
causes, also promotes zinc deficiency since erythrocytes are very 
rich in the element.
Zinc deficiency may also follow increased losses of zinc 
through the skin in cases of extensive burns and psoriasis or 
increased zinc excretion secondary to disease or medication. In 
renal diseases hyperzincuria occurs in association with hyper­
proteinuria or because of alterations in the renal handling of 
zinc.33 36 W h e n  tissue necrosis is present increased mobilization 
of tissue zinc occurs via an endogenous leucocyte mediator with a 
resultant increase in renal zinc excretion. Significant hyperzinc­
uria always exists in cases of chronic alcoholism, presumably as a 
result of damage to the renal tubular epithelium.
The prolonged administration of comm o n  diuretics which act 
mainly at the distal convoluted tubule, such as the thiazides and 
chlorthalidone, may provoke zinc deficiency by promoting 
urinary zinc excretion.
Pathophysiology and clinical picture
The most frequently seen symptoms of zinc deficiency are 
hypogeusia, hyposmia, sexual impotence, abnormal adaptation 
to darkness, retardation in the rate of healing and dermatoses.1 
Severe zinc deficiency retards growth and causes hypogonadism 
in children and adolescents by altering protein synthesis.37 In 
zinc-deficient adults oligospermia, azoospermia and consequently 
infertility occur. In these cases replacement therapy corrects the 
disturbance and increases the plasma levels of testosterone and 
dehydrotestosterone. In pregnant women zinc deficiency is 
associated with malformations of the newborn.38
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Fig. 4. Mean urine flows after oral administration on separate 
days of placebo, amiloride 5 mg and amiloride 10 mg to 15 
healthy volunteers at time 0 (08h00). The post-amiloride curves 
have accelerated time-courses with respect to the post-placebo 
curve, and then their peaks precede the peak of the latter. By 
courtesy of Current Therapeutic R esearch ,9
Fig. 5. Mean urinary sodium flows after oral administration on 
separate days of placebo, amiloride 5 mg and amiloride 10 mg to 
the same 15 healthy volunteers at time 0 (08h00). The post- 
amiloride curves have accelerated time-courses with respect to 
the post-placebo curve. By courtesy of Current Therapeutic 
Research .9
D iagnosis
Zinc deficiency is diagnosed when concentrations fall below 
65 pg/dl in plasma. The concentration of zinc in biological 
specimens is usually measured by atomic absorption spectro­
photometry, although strict precautions are necessary to avoid 
biased results.39 Contamination of samples with tap-water, 
which generally has a zinc content the same as that of urine, or 
haemolysis of red cells, which contain zinc at ten times the 
concentration of plasma, may generate incorrect results.
Treatm ent
Zinc deficiency is easily treated in adults by the oral admini­
stration of 220 m g  zinc sulphate three times a day. This may 
disturb the digestive tract and even cause enteral bleeding; 
tolerance is improved by taking zinc sulphate capsules after 
meals.
The Committee of Nutrition of the American Academy of 
Pediatrics recommends the use of zinc acetate trihydrate solution 
in children. The preparation should be given in three equally 
divided doses daily to provide 1 m g  of zinc/kg body weight.
The normal upper level of plasma zinc concentrations in 
healthy adults is 250 pg/dl. Patients with zinc intoxication 
present with dehydration, electrolytic alterations, abdominal
pain, nausea, vomiting, lethargy, dizziness and muscular inco­
ordination, and death as a result of the ingestion of 45 g of zinc 
sulphate has been described.1
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Drug interactions with diuretics
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Summary
Interactions between diuretics and other substances 
may have beneficial or adverse consequences. Co- j 
prescription of diuretics with antihypertensive agents,
■ potassium, magnesium or acid salts, probenecid, . 
•V quinidine, anticoagulants, lithium, cardiac glycosides 
; or other diuretics can result in both beneficial and 
adverse interactions. Laxatives, oral antidiabetic. | 
agents, non-steroidal anti-inflammatory drugs, adeny- , 
; late cyclase activators, mineralocorticoids, hypolipi- - 
: daemic agents, neuromuscular blockers, chloral 
hydrate, carbenoxolone, drugs likely to produce the ' 
syndrome of inappropriate secretion of antidiuretic J 
hormone and some antibiotics may be involved in 
adverse interactions with diuretics.
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Clinically important interactions with either beneficial or ad­
verse consequences may take place when diuretics are prescribed 
together with other compounds. Interactions involving diuretics 
may occur at different anatomical and biochemical sites and 
have various mechanisms. The interactions described here have 
been reported clinically or can be postulated on the basis of 
well-established pharmacological principles. Some responses to 
treatment might be regarded as coincidental pharmacological 
effects rather than true drug interactions, but their inclusion 
here is justified by the fact that they occur in clinical practice 
when diuretics are prescribed with other medicines.
Classifications
Various criteria may be used in describing drug interactions 
involving diuretics. One approach is based upon the separation 
of these interactions in accordance with their clinical effects. 
However, a given interaction may have either beneficial or 
untoward effects upon the same variable, depending upon the 
circumstances. Thus, for example, adverse clinical effects may 
occur when interactions involve displacement of drugs from the 
plasma protein-binding sites, but once appropriate adjustments 
in dosages are made the interaction may become beneficial since 
the dosage of one or both drugs is reduced without loss of 
therapeutic effect. Interactions may also have both adverse and 
desirable effects when more than one biological variable is 
considered.
A  further model for the classification of interactions is 
presented in Table I. This approach is slightly more quantitative 
and provides some insight into directional variations in the
Departm ent of Experim ental and Clinical Pharmacology, 
University of Natal, Durban
W. P. LEARY, M.SC., M.B. B.CH., D.PHIL., F.C.P. (S.A.), F.R.C.P. 
Universidad de la Republica y Fundacion Procardias, 
Montevideo, Uruguay
A. J. REYES, DR. MED., C.E. CARDIOL., C.P. BIOMAT. BIOEST.
responses that may occur during the co-administration of 
diuretics and other medicines. This classification is open to 
criticism on the grounds that some interactions are sufficiently 
complicated to fall under more than one subheading.
In the description which follows interactions are dealt with as 
far as possible in order of overall practical clinical importance 
taking the frequency and magnitude of the interaction into 
consideration.
Antihypertensive agents
Beneficial interactions with  
antihypertensive drugs
A n tih yp erten sive  effects
Antihypertensive diuretics are the first choice in the treat­
ment of hypertension, and since other drugs are prescribed with 
diuretics to lower blood pressure further, the most important 
interactions between these agents are beneficial. For example, 
when the antihypertensive diuretics hydrochlorothiazide1 and 
chlorthalidone, which reduce blood pressure linearly, are com­
bined with reserpine2 and atenolol respectively (W. P. Leary,
K. van der Byl and A. J. Reyes —  unpublished data), the 
gradual linear hypotensive response to diuretics alone is replaced 
by a decreasing power response3,4 and the blood pressure falls 
rapidly. The mechanisms of beneficial hypotensive interactions 
are very variable and usually obscure, since the antihyper­
tensive mechanisms of interacting substances differ and are 
often unknown.
Sodium  reten tion
Antihypertensive drugs other than diuretics and angiotensin 
I-converting enzyme inhibitors cause sodium retention. Diure­
tics reduce this effect and are particularly useful if fi-blockers or 
vasodilators are used.
Since sodium retention reduces aldosterone release and 
consequently decreases renal potassium excretion, administra­
tion of other antihypertensive agents with diuretics would, 
theoretically, tend to counterbalance the potassium-losing 
effects of the diuretic. Studies aimed at measuring the overall 
result of this interaction have not as yet disclosed any clinical 
benefit.
Increased blood viscosity secondary to haemoconcentration 
induced by diuretics has been hypothetically incriminated as a 
cardiovascular risk factor. This may be balanced by the 
properties of other antihypertensive drugs, such as fi-adrenergic 
blockers and vasodilators, which provoke sodium retention and 
therefore restore the intravascular volume.
G uanethidine and glucose to lerance
Guanethidine has been shown to improve glucose tolerance 
and to reduce the need for hypoglycaemic agents and insulin in 
diabetics. C o m m o n  diuretics have the opposite effect, which 
may be counterbalanced by giving guanethidine.
P la sm a  renin a c tiv ity
Arguments in favour of pivotal aetiological and/or patho­
physiological roles for peripheral renin activity in hypertension
TABLE 1. DRUGS INTERACTING WITH DIURETICS
Drugs enhancing the effects of diuretics Drugs enhancing their therapeutic effects when interacting
Antihypertensive agents Antihypertensive agents
Digitalis Digitalis
Diuretics Potassium salts
Laxatives Magnesium salts
Probenecid Laxatives
Parasympatholytic agents Quinidine
Acid salts Anticoagulants
Neuromuscular blockers 
Lithium
Drugs inhibiting the effects of diuretics Drugs inhibiting their therapeutic effects when interacting
Vasodilators Potassium salts
Cephalosporins Magnesium salts
NSAIDs Oral antidiabetics
Phenylbutazone Anti-uricaemic agents
Mineralocorticoids Drugs enhancing their adverse effects when interacting
Hypolipidaemic agents Antihypertensive agents
Carbenoxolone Digitalis
Colestipol Potassium salts
Diuretics
Cephalosporins
Drugs enhancing adverse effects of diuretics Aminoglycosides
Digitalis Tetracycline
Potassium salts Laxatives
Magnesium salts NSAIDs
Cephalosporins Phenylbutazone
Aminoglycosides Mineralocorticoids
Oral antidiabetics Adenylate cyclase activators
Laxatives Hypolipidaemic agents
NSAIDs Quinidine
Phenylbutazone Anticoagulants
Anti-uricaemic agents Drugs that are likely to produce SIADH
Adenylate cyclase activators Neuromuscular blockers
Parasympatholytic agents Chloral hydrate
Drugs that are likely to produce SIADH Lithium
Acid salts Carbenoxolone
NSAIDs — non-steroidal anti-inflammatory drugs, SIADH = syndrome of inappropriate antidiuretic hormone secretion.
have recently been compromised to some extent by carefully 
conducted clinical research and the emergence of the kallikrein- 
kinin system as a possible balancing mechanism.5 The extent by 
which interaction between diuretics and other drugs affecting 
the renin-angiotensin-aldosterone axis might be relevant is not 
clear, except in a few situations in which secondary hyper­
tension is definitely due to hyper-reninaemia or possibly in a 
small proportion of primary cases with definitely higher peri­
pheral renin activity values at an early stage.
If the elevation of plasma renin activity caused by diuretics 
were of importance in determining the evolution of hypertensive 
disease, other antihypertensive agents which diminish plasma 
renin activity, such as most fi-adrenergic blockers, could interact 
beneficially with diuretics in this respect while those increasing 
plasma renin activity, such as vasodilators, would interact 
adversely.
Adverse interactions with  
antihypertensive agents
H ypotension
The most frequent adverse result of interaction between 
diuretics and antihypertensive drugs is an exaggerated hypo­
tensive effect of combined administration, regardless of the 
biochemical processes involved. Clinical complications include 
postural hypotension and syndromes associated with diminished 
perfusion of the myocardium, brain, intestine and kidneys. Any 
change in treatment involving such a combination should 
therefore be carefully supervised.
D iazoxide
W h e n  diazoxide is administered intravenously for the treat­
ment of hypertensive crises in patients on diuretics its effects 
upon blood glucose levels may be exaggerated with development 
of clinically significant hyperglycaemia.6
Clonidine
Clonidine and other central «2-agonists reduce salivary secre­
tion. Administration of these agents with diuretics further 
compromises salivary flow if dehydration occurs.
R enal b lood  flo w
In c o m m o n  with most antihypertensives (other than hydral- 
lazine and the converting enzyme inhibitors) antihypertensive 
diuretics1,3'4'6"  diminish renal blood flow. In patients with 
impaired renal function the co-administration of loop diuretics 
which increase renal blood flow must be considered, despite 
their relatively meagre effect upon arterial blood pressure.
G uanethidine
Thiazides are known to impede the uptake of guanethidine 
by the neuronal terminals and thus decrease or prevent its 
antihypertensive effect. This can be overcome by adjusting the 
dose of guanethidine and avoided by prescribing non-thiazide 
diuretics.
Digitalis
The benefits derived from a combination of digitalis and 
diuretics in chronic or acute cardiac insufficiency are well
known. Administration of digitalis with co m m o n  potassium­
losing diuretics usually leads to a higher incidence of arrhy­
thmias than occurs when either drug is administered alone.*'lu 
This probably results from the combined effects of potassium 
and magnesium depletion provoked by diuretics and the direct 
inhibition of M g 2*-dependent myocardial Na*,fC-ATPase in­
duced by cardiac glycosides.6,11,12
Although glomerular filtration accounts for most of the renal 
excretion of digoxin it is also excreted by the distal convoluted 
tubule, where it shares intracellular transport mechanisms with 
spironolactone and triamterene.13 These diuretics may therefore 
increase the plasma concentration of digoxin and its half-life 
and enhance all its untoward effects, including arrhythmo- 
genicity. Plasma levels of digoxin should therefore be carefully 
monitored when it is given with spironolactone or triamterene. 
N o  clinical evidence of a similar interaction with amiloride has 
yet been presented, and the possibility that furosemide could 
alter the renal excretion of digoxin has been ruled out.13
Potassium salts
The degree of hyperkalaemia attained when diuretic therapy is 
supplemented with potassium salts may be such that the 
concentration gradient across electrically excitable membranes 
(such as myocardium and skeletal muscle) overcomes the 
reduced activity of N a +,K+-ATPase resulting from concomitant 
diuretic-induced magnesium depletion. In rare instances the 
intracellular potassium content increases and causes hyperka- 
laemic paralysis or death due to cardiac arrest.14,13 These 
circumstances usually arise only after chronic administration of 
potassium, but the syndrome may develop relatively soon after 
the initiation of therapy if renal insufficiency is present.
D iabetes
The administration of potassium-sparing diuretics or potas­
sium salts to insulin-dependent diabetics with associated hypo- 
aldosteronism can have lethal effects16,17 and should therefore 
only take place under supervision.
Magnesium salts
Urinary magnesium losses caused by diuretics lead to intra­
cellular potassium depletion because Na*,K*-ATPase, a critical 
energy source for the potassium pump, depends upon intra­
cellular magnesium as a co-factor. There is definite evidence 
that severe ventricular arrhythmias occurring during chronic 
diuretic administration respond better to intravenous therapy 
with magnesium than to that with potassium; the intramyo- 
cardial content of potassium increases more after magnesium 
administration than after potassium supplementation in this 
circumstance.6,11,12,18 There is therefore a sound theoretical 
basis for chronic long-term oral administration of magnesium 
salts for the avoidance of the deleterious effects of diuretics on 
intracellular potassium. It remains to be seen whether com­
bining potassium-sparing diuretics and magnesium salts results 
in an exaggerated increase in potassium entry to the cell with 
potentially toxic effects.
Diuretics
B eneficial interactions between diuretics
Beneficial interactions between diuretics exist which can be 
exploited clinically even when untoward interactions coexist as 
side-effects.
D iu retic  p o ten cy
T o  increase diuretic potency the additive effects of diuretics 
acting at separately located or biochemically distinct principal 
renal acceptor sites may be used. W h e n  established diuretic 
therapy is reinforced by the addition of a second diuretic, the 
safest procedure for increasing diuretic potency while using the 
smallest possible doses is based on the fact that there is an 
increased tubular reabsorption of sodium at sites distal to those 
at which any given diuretic blocks sodium absorption. There­
fore, a diuretic blocking sodium reabsorption in the distal 
tubule, such as a thiazide, should be added when the response 
to a high-ceiling diuretic acting at the loop of Henle, such as 
furosemide, is regarded as being clinically inadequate.
Giving two loop diuretics together does not increase diuresis 
once maximal doses of either compound have been used6,7 since 
loop diuretics share a single renal acceptor.
Beneficial interactions between diuretics are also exploited in 
conditions such as anasarca which require rapid induction of 
sustained diuresis. In such circumstances the use of loop 
diuretics such as furosemide or bumetanide may be usefully 
complemented by adding a medium- (chlorthalidone) or high- 
potency (xipamide) diuretic6 with a longer time-course of 
action, although this may increase the incidence of side-effects.
P o ta ssiu m  turn over
A  beneficial effect upon potassium turnover is achieved by 
the co-administration of potassium-losing and potassium- 
sparing diuretics, a practice which has achieved wide clinical 
acceptance and is supported by research data.6,8,11,12,19
Beneficial antihypertensive interactions
Favourable interactions between diuretics are also useful in 
the treatment of raised arterial pressure in certain circum­
stances.
H yp erten sive  crises
The intravenous administration of a loop diuretic during 
hypertensive crises in patients receiving treatment with anti­
hypertensive diuretics lowers the blood pressure satisfactorily. 
This can be explained principally by the acute vasodilating 
properties of intravenously administered loop diuretics, al­
though temporary acute changes in plasma volume also occur.7
R esis ta n t h ypertension
Despite the fact that loop diuretics given alone generally have 
little effect on blood pressure, their oral administration some­
times lowers blood pressure in cases of resistant hypertension 
treated with distal tubular antihypertensive diuretics. The 
mechanism involved depends upon the additive sodium de­
pletion brought about by administration of the loop diuretic.7 
The addition of an antihypertensive diuretic to a therapeutic 
regimen which already includes a loop diuretic also further 
decreases blood pressure, as has been shown by the addition of 
xipamide or metolazone to inadequate previous treatment 
regimens.7
P o w er an tih yperten sive  effects
Giving a potassium-sparing diuretic with hydrochlorothiazide 
as initial treatment has been shown to change the gradual linear 
antihypertensive effect of the latter1 to a more rapid power 
response.3 Since power antihypertensive activity is sought in 
the treatment of most hypertensives this preliminary finding 
merits investigation.
Adverse interactions between diuretics
Diuretic interactions may not be simply additive, since 
diuretics such as furosemide and the thiazides have, for 
example, opposite effects upon renal blood flow and the 
glomerular filtration rate. The co-administration of loop and 
thiazide diuretics might cause greater potassium losses than 
would be expected from the sum of their individual effects; the 
raised glomerular filtration rate stimulated by loop diuretics 
increases the sodium load presented for exchange with po­
tassium.
A llergy
Most diuretics in current use are structurally related to 
sulphonamides and cross-sensitivity reactions occasionally 
occur; the frequency of such reactions increases when two 
diuretics are given together.
N eph ro tox ic ity
A n  infusion of mannitol and furosemide is commonly pre­
scribed in order to normalize dilutional hyponatraemia, but 
may cause acute renal insufficiency through a toxic effect upon 
the proximal convoluted tubular epithelium.20 Since the benefits 
of this combination are limited, it should not be prescribed.
H yperkalaem ia
Potassium-sparing diuretics, particularly amiloride and tri­
amterene, may provoke hyperkalaemia when prescribed alone 
or in combination with potassium-losing diuretics. In the latter 
case hyperkalaemia is likely to occur after chronic admini­
stration of the combination when relative tolerance to the 
hyperkaliuric effect of the potassium-losing diuretic develops 
and sodium depletion causes reduced sodium filtration and 
tubular interchange for potassium.
Antibiotics
Cephalosporins
It is well established that certain cephalosporins, such as 
cephaloridine, cephalothin and cephalexin, sometimes induce 
renal damage. This may be aggravated by the co-administration 
of c o m m o n  loop or distal tubule diuretics which share renal 
excretory mechanisms with the cephalosporins at the proximal 
tubule7 thus leading to prolongation of the serum half-life and a 
rise in the renal concentration of these cephalosporins to toxic 
levels.
Am inoglycosides
Aminoglycosides such as kanamycin, streptomycin and gen­
tamicin can impair auditory and cochlear functions, particularly 
in patients with renal disease; loop diuretics such as furosemide, 
bumetanide and ethacrynic acid may also adversely affect 
hearing and equilibrium. Aminoglycosides and loop diuretics 
have additive toxic effects on the hair cells of the inner ear, 
especially when these compounds are highly concentrated 
within the endolymphatic system.21 Experimental evidence 
from animal studies shows that kanamycin and ethacrynic acid 
exert a synergistic ototoxic action, and the existence of such 
synergism can also be inferred from case reports of fixed or 
permanent deafness following the intravenous injection of 
ethacrynic acid in patients taking low doses of aminogly­
cosides.22'23 Deafness is likely to develop in the presence of renal
insufficiency or when the drugs are prescribed at high doses or 
are administered rapidly.23
Aminoglycosides are nephrotoxic, and since diuretics may 
increase local concentrations of any nephrotoxic antibiotic 
within the kidney, renal function must be appropriately 
monitored during co-administration of these.
Oral antidiabetic drugs
C o m m o n  diuretics impair glucose tolerance in healthy and 
diabetic individuals, sometimes raising the blood glucose con­
centration.6,7 This effect has not been fully explained, but 
should not be regarded as being equivalent to a diabetic 
syndrome since long-term studies in humans to determine 
details of the general metabolic changes involved have not been 
carried out. However, hyperglycaemia —  especially if sustained 
—  may provoke serious systemic metabolic imbalance. In 
diabetics treated with oral hypoglycaemic agents blood glucose 
levels may rise significantly when diuretics are added, this 
necessitating an adjustment in the dosage of the antidiabetic 
agent. This reaction occurs irrespective of the mechanism of 
action of the antidiabetic agent (sulphonylureas or biguanides), 
but is more likely when sulphonylureas are being prescribed.7
Drugs which tend to increase the blood glucose concentra­
tion, such as diazoxide, phenylbutazone or hormones activating 
adenylate cyclase, have additive effects with diuretics in im­
pairing glucose tolerance and increasing blood glucose levels.
Laxatives
Whatever their mechanisms of action, dosage or indications for 
usage, laxatives are likely to cause significant losses of fluid and 
electrolytes, including sodium, potassium, magnesium and 
zinc. Since water and these electrolytes are excreted freely in 
response to diuretics, laxatives may marginally contribute to the 
beneficial effects of diuretics, but they are more likely to cause 
dehydration and significant depletion of sodium, potassium and 
magnesium stores.
Whenever a diuretic is prescribed patients should be warned 
about the possible consequences of concurrent laxative abuse. 
Ideally, laxatives should only be prescribed when absolutely 
necessary and while diuretic therapy is temporarily discon­
tinued. Since most laxatives are purchased without prescription 
the situation is difficult to control.
Non-steroidal anti-inflammatory agents
Non-steroidal anti-inflammatory drugs (NSAIDs) exert their 
pharmacological activity mainly by inhibiting the synthesis of 
various prostaglandins. Preparations that inhibit cyclo-oxy­
genase (e.g. aspirin, indomethacin), or selectively inhibit further 
specific steps leading to synthesis of the prostaglandin E  group, 
such as phenylbutazone, interact with those diuretics (including 
loop diuretics and thiazides) that increase the synthesis of P G E 2 
within the kidney.24-30 For this reason, the renal excretory 
effects of diuretics are reduced by adding N S A I D s  to the 
regimen.3'-34
A  second mechanism exists whereby N S A I D s  and diuretics 
interact; all these are organic acids and share their renal 
excretory pathway at the proximal convoluted tubule. For 
example, indomethacin causes prolonged elevation of plasma 
furosemide levels, decreasing its plasma and renal clearance.7 
This interaction should increase the renal effects of furosemide; 
however, the overall result of interaction between diuretics and 
N S A I D s  when both are repeatedly prescribed at standard doses
is a diminution in the renal effects of diuretics, possibly because 
of interaction at the prostaglandin level.7
The extent to which diuretics counteract the effect of 
N S A I D s  in cases where P G E 2 is deeply involved in an inflam­
matory focus has not been studied.
Phenylbutazone
Phenylbutazone and its analogues provoke increased sodium 
and water retention, decreased tolerance to glucose, hyper- 
glycaemia and increased hydrochloric acid secretion in the 
stomach. All these adverse reactions principally derive from the 
same anti-inflammatory mechanism, the inhibition of prosta­
glandin E 2 synthesis. Conversely, common diuretics increase 
the synthesis of P G E 2.28,32'33 Interaction of these drugs at the 
biochemical level is followed clinically by partial blunting of the 
natriuretic and diuretic effects of diuretics by phenylbutazone. 
In addition, both phenylbutazone and diuretics tend to raise 
blood sugar levels.
Phenylbutazone is formally contraindicated whenever diu­
retics are prescribed. If the existence of inflammation makes it 
necessary to prescribe medication, anti-inflammatory agents 
such as aspirin and indomethacin should be used.
Drugs affecting urate excretion
The effect of drugs used for lowering serum urate levels may be 
impaired by the administration of sulphamoyl diuretics which 
enhance the reabsorption and inhibit the normal excretion of 
uric acid in the renal tubule, thereby tending to raise serum 
urate level.6'7 This change does not necessarily imply any basic 
derangement in purine metabolism equivalent to that present in 
gout; however, elevated serum uric acid levels provoke further 
metabolic changes that are best avoided.
Tienilic acid
Tienilic acid is an uricosuric diuretic7 which may be ad­
ministered together with those diuretics which cause urate 
retention. This combination increases diuretic potency with no 
change or reduction in the serum urate concentration. The 
interaction between tienilic acid and conventional diuretics is 
therefore beneficial, and it may be expected that other uricosuric 
diuretics under development will also be used in this manner.6''
Probenecid
Probenecid has a definite uricosuric effect and is also used in 
laboratory and clinical situations to alter the pharmacokinetics 
of other drugs, including diuretics.35 38
Diuretics share their excretory mechanism with other organic 
acids excreted in the proximal tubule; probenecid is a weak 
organic acid, interaction of which with diuretics in the kidney 
has a biphasic effect in man.7 W h e n  furosemide is administered 
to patients pretreated with probenecid, the natriuretic and 
diuretic effect of the former is at once diminished because of 
decreased secretion of the diuretic through the proximal tubule. 
This primary response is followed by a marked increase in 
diuresis and natriuresis because the amount of furosemide 
available at renal acceptor sites is increased once probenecid has 
been cleared in the urine. Probenecid prolongs both the renal 
and hepatic clearances of furosemide, and because of delayed 
excretion elevates the serum furosemide level. Thiazide diuretics 
interact with probenecid in a similar manner, although to a 
lesser extent, this mainly being dependent upon the time lapse 
between doses. The biphasic nature of this effect is not
apparent experimentally unless urine collections after the co- 
administration of probenecid and a diuretic are made when the 
second phase has emerged. This has led to apparent contra­
dictions in the literature referring to interactions between 
diuretics and probenecid. The uricosuric effects of probenecid 
are not seriously impaired by diuretics.39
Drugs with mineralocorticoid activity
Drugs with mineralocorticoid activity include compounds such 
as desoxycorticosterone acetate, the oestrogens, progestogens, 
glucocorticoids and androgens. All these substances may cause 
sodium and water retention and potassium loss; overt oedema 
may develop as a result of their activity or as a consequence of 
the underlying pathophysiological conditions which originally 
prompted the use of a diuretic. In these circumstances the 
diuretic and natriuretic effects of diuretics will be diminished 
and potassium losses will be enhanced by the addition of 
mineralocorticoids.
Drugs that activate adenylate cyclase
Naturally occurring substances, mainly hormones like gluco­
corticoids, adrenocorticotrophic hormone, thyroxine, adrenaline, 
glucagon, androgens, somatotrophic hormone, thyrotrophic 
hormone and many of their metabolites and related synthetic 
compounds, activate adenylate cyclase, thereby increasing the 
rate of glycogenolysis. Consequently, hyperglycaemia and an 
associated chain of metabolic events develop. Since diuretics 
also have hyperglycaemic properties, the blood glucose level 
should be closely monitored when these preparations are 
prescribed together, especially in the case of diabetics or 
prediabetics and patients considered to have a fragile acid-base 
equilibrium.
Hypolipidaemic agents
Clofibrate
Clofibrate, which is still widely used as a hypolipidaemic 
agent despite controversy regarding its safety, interacts speci­
fically with furosemide by competing for common plasma 
albumin binding sites. This raises the serum concentration of 
free clofibrate, leading to a syndrome of malaise, muscle pain, 
stiffness, weakness and elevated creatine kinase levels.40 Par­
ticular care must therefore be exercised when furosemide and 
clofibrate are prescribed together, especially with patients who 
have reduced plasma binding sites due to hypo-albuminaemia 
associated with conditions such as the nephrotic syndrome or 
cirrhosis, or who receive phenprocoumon.41
C holestyram ine
Cholestyramine decreases the intestinal absorption of many 
substances, including lipids. Absorption of some diuretics is 
delayed by this compound, but this interaction causes no 
important decrease in the percentage absorption of diuretics 
and no change in their renal excretory effects.42
Colestipol
Colestipol, a bile-acid-sequestering polymer, appears to bind 
chlorothiazide within the intestinal lumen; in consequence, the 
absorption and pharmacological effects of this diuretic are 
diminished by large doses of colestipol.
Quinidine
Quinidine is partly catabolized by liver enzymes whose activity 
may be increased by spironolactone.43 Diuretics which inhibit 
carbonic anhydrase (such as the sulphamoyl diuretics) tend to 
increase the p H  value of the pre-urine within the nephron. This 
results in an increased proportion of molecular non-ionized 
quinidine, which is readily reabsorbed, with resultant significant 
elevation of plasma quinidine levels. Measures tending to 
counteract this potentially dangerous interaction should include 
a diet which does not alkalinize the urine, the avoidance of 
sodium bicarbonate or other systemic alkalinizing agents and 
the prescription of loop diuretics such as furosemide or bume- 
tanide which have little carbonic anhydrase-inhibiting capacity.
Parasympatholytic drugs that reduce 
gastro-intestinal motility
Medicines that display antimuscarinic actions or that block the 
parasympathetic ganglia serving the upper gastro-intestinal 
tract where diuretics are absorbed (e.g. atropine, propantheline, 
chlorpromazine) slow the transit of diuretics through the gut 
and increase the percentage absorption of those diuretics which 
are usually totally absorbed7 (such as hydrochlorothiazide).
Drugs likely to produce the syndrome of 
inappropriate secretion of antidiuretic 
hormone
Giving diuretics with other drugs such as clofibrate, carba- 
mazepine, cyclophosphamide, fluphenazine, haloperidol, thio­
ridazine, vinca alkaloids, amitriptyline and chlorpropamide is 
likely to produce a syndrome of inappropriate secretion of 
antidiuretic hormone.6,7 Treatment of these combinations must 
be carefully monitored in order to avoid this syndrome of water 
intoxication at an early stage. Clinical symptoms such as 
drowsiness, headache, anorexia, nausea, vomiting, depression 
and confusion suggest inappropriate antidiuretic hormone 
secretion.
Neuromuscular blockers
Preparations used together with general anaesthetics in order to 
promote skeletal muscle relaxation interfere with ionic exchange 
across the neuromuscular postsynaptic membrane, causing a 
net shift in potassium and calcium from the muscle cells to the 
extracellular compartments. The losses of potassium and mag­
nesium that diuretics provoke may interact at this level, increas­
ing the intensity and duration of neuromuscular blockade. It 
appears immaterial whether the neuromuscular blocker used is 
a depolarizing or non-depolarizing agent. This interaction is 
another reason for exercising care in the administration of 
diuretics to patients undergoing surgery with general anaes­
thesia.6
Chloral hydrate
The main metabolite of chloral hydrate is trichloro-acetic acid, 
which is highly bound to the plasma albumin sites that trans­
port furosemide. It has been reported that the rapid administra­
tion of furosemide as an intravenous bolus may provoke a 
displacement interaction whereby trichloro-acetic acid is re­
leased from binding sites with a resultant toxic syndrome 
comprising copious diaphoresis, flushing and tachycardia.44 In
consequence, chloral hydrate should be avoided in patients 
likely to be given furosemide.
Lithium
Thiazide diuretics increase sodium reabsorption at the proximal 
tubule and a secondary enhancement of lithium reabsorption 
follows, resulting in decreased lithium clearance.45,46 Serum 
lithium levels may then rise to overtly toxic concentrations (2 - 
3 mmol/1).47 Depending upon serum lithium levels, the toxic 
syndrome may range from drowsiness, muscle twitching, 
vomiting and diarrhoea to oliguria, supraventricular arrhyth­
mias, hypokalaemia and ataxia;48,49 diabetes insipidus has been 
described as a complication associated with prescribing lithium 
with chlorothiazide.31
Whenever diuretics are given with lithium, serum lithium 
levels should be carefully monitored, principally if it is ad­
ministered in long-acting formulations. However, there is no 
conclusive evidence that the potassium-sparing diuretics have 
similar effects to the thiazides with respect to lithium, and 
preliminary evidence suggests that the loop diuretics do not 
interact with it.45
Carbenoxolone
Carbenoxolone exhibits a powerful mineralocorticoid-like effect 
—  sodium and water are retained and potassium is lost in the 
urine. The diuretic and natriuretic effects of diuretics are 
therefore counteracted, while their kaliuretic action is enhanced. 
This effect of carbenoxolone may be sufficient to cause oedema 
requiring diuretic treatment, resulting in a significant reduction 
in total body potassium content. Supplementary potassium and 
magnesium salts, amiloride or triamterene should then be 
prescribed. The co-prescription of spironolactone is inadvisable 
since it has some glucocorticoid activity which may counteract 
the therapeutic effects of carbenoxolone.50
Acidifying salts
A m m o n i u m  chloride may be given with diuretics for acidifying 
the urine, thereby increasing their natriuretic effects. Admini­
stration of ammonium chloride with a potassium-sparing 
diuretic has provoked metabolic acidosis in 1 case.51
R E F E R E N C E S
1. L eary  W P, Reyes A J, Espinas R. T h e  effects o f hydroch lo ro th iaz ide upon 
arterial blood p ressure in essential hypertension: a m athem atical description. 
Curr TherRes 1981; 30: 1096-1102.
2. Saiz M , L eary  W P , Reyes A J, van dcr Byl K . F orm al d escrip tion  o f  the 
antihypertensive effect o f a com bination  o f  hydrochloroth iaz ide and  reserpinc. 
Curr Ther Res 1983; 34: 531-536.
3. Reyes A J, Leary  W P. A form al m ethod  for the the rapeu tic  classification o f 
an tihypertensive d iure tics. Curr Ther Res 1981; 30: 1073-1088.
4. Reyes A J, A costa-B arrios T , Leary  W P. T h e  effects o f xipam ide upon high 
blood p ressure in geriatric hypertensives: a m athem atical descrip tion . Curr 
TherRes 1981; 30: 1089-1095.
5. A be K , Irokaw a N , Y asujim a M  et al. T h e  kallikre in-k in in  system  and 
p rostag land ins in  the  kidney: th e ir  relation  to  fu rosem ide-induced  diuresis 
and  to the  rcn in -ang io tensin -a ldoste rone  system  in m an. Circ Res 1978; 43: 
254-260.
6. Leary  W P, Reyes AJ. D iuretics: p rac titioners’ review. 5  A /rM ed J  1981; 59: 
9-13.
7. Reyes AJ. Bases farm acologicas de la te rapeu tica  card iovascular con d iu re ti- 
cos. Arch Inst Cardiol Mex 1981; 51: 291-293.
8. Leary  W P, Reyes AJ. A ntihypertensive and m etabolic effects o f  a com bination  
o f hydroch lo ro th iaz ide and am iloride. S  A fr Med J  1981; 60: 381-384.
9. S hap iro  S, S lone D , Lewis G P , Jick M . T h e  epidem iology o f digoxin. J  Chron 
Dis 1969; 22: 361-371.
10. S m ith  T W . D igitalis glycosides (P arts  I and  II). N  Engl J  Med 1973; 288: 
719-722, 942-946.
11. L eary  W P , Reyes A J. D iu re tics , m agnesium , po tassium  and  sodium . S  A fr 
M edJ  1982; 61: 279-280.
12. Reyes A J, Leary  W P. Pathogenesis o f  arrhy thm ogen ic changes due to  
m agnesium  dep letion . S  A fr Med J  1983; 63: 311-312.
13. B row n D D , D orm o is  JC , A braham  G N . Effec t o f  furosem ide on the  renal 
excre tion  o f digoxin. Clin Pharmacol Ther 1976; 20: 395-400.
14. K alb ian  VV. Ia trogen ic  hyperkalem ic paralysis w ith  electrocard iograph ic 
changes. South M edJ  1974; 67: 342-345.
15. S hap iro  S, S lone D , Lew is G P , Jick M . F ata l d ru g  reactions am ong m edical 
inpa tien ts . JAM A  1971 ;216 :467-472 .
16. D e F ru o u zo  RA , S herw in  R S , Feliz P , Bia M . N o n -u rem ic  d iabetic 
hyperkalem ia. Arch Intern Med 1977; 137: 842-843.
17. P erez G O , L esp ie r L L , Jacobi J , O ster JR , K atz F H , V aam onde CA , 
F ishm an  L M . H yporen inem ia and hypoaldosteronism  in diabetes m ellitus. 
Arch Intern Med 1977; 137: 852-855.
18. Reyes A J. D iu re tico s , deficiencia de m agnesio y arritm ias cardiacas: fisio- 
patologia te rapeu tica. Sistole 1982; 32: 27-44.
19. Leary  W P, Reyes A J. U rin ary  volum e and solute flows after a single dose o f 
hydroch lo ro th iaz ide-am ilo ride in healthy adults. Curr Ther Res 1982; 32: 
406-412.
20. P louv ier B, B aclet J L , D e C oninck  P. U ne association nephro tox ique: 
m annito l e t furosem ide. Nouv Presse Med 1981; 10: 1744-1745.
21. Johnson  A H , H am ilton  C H . K anam ycin  o to toxicity  —  possible po ten tia tion  
by o ther drugs. South M edJ  1970; 63: 511-513.
22. N eriw eth e r W D , N ang i R J, Serpick AA. D eafness following s tandard  
in travenous dose o f ethacryn ic acid. JAMA  1971; 216: 795-798.
23. N athog  R J, K lein  W J jun . O totox icity  o f  e thacryn ic  acid and am inoglycoside 
antib io tics in  u rem ia. N  Engl J  Med 1969; 280: 1223-1224.
24. A be K , O tsuka Y, Y asujim a M , C hiba S, Seino M , T rokaw a N , Y oshinaga K. 
M etabo lism  o f P G  in m an: effect o f  furosem ide on the  excre tion  o f  the m ain 
m etabolite o f P G F  2 alpha. Prostaglandins 1976; 12: 843-848.
25. A nderson R J, Berl T , M cD onald  K M , S ch rie r RW . Prostaglandins: effects 
on blood p ressure , renal blood flow, sodium  and w ater excre tion . Kidney Int 
1976; 10: 205-215.
26. Bailie M D , C rosslan  K , H ook JB. N atriu re tic  effect o f  furosem ide after 
inh ib ition  o f  p rostag land in  synthetase. J  Pharmacol Exp Ther 1976; 199: 
469-476.
27. B ra ter C C . A nalysis o f  the  effect o f  indom ethacin  on  th e  response to 
furosem ide in  m an: effect o f dose o f  fu rosem ide. J  Pharmacol Exp Ther 1979; 
210: 386-390.
28. F anelli G M , B ohn D L , D am p  AE, S hum  W K . Inab ility  o f  indom ethacin  to 
m odify hydroch lo ro th iaz ide  d iuresis and  natriu resis  by the chim panzee 
kidney. J '  Pharmacol Exp Ther 1980; 213: 596-599.
29. O lsen U B, A hnfelt-R onne J. B um etanide induced increase o f renal blood 
flow in conscious dogs and  its relation  to local renal horm ones (P G E , 
kallikrein and ren in ). Acta Pharmacol Toxicol 1976; 38: 219-228.
30. K over G , T o st H . T h e  effect o f  indom ethacin  on kidney function: indo­
m ethacin  and furosem ide antagonism . Pflugers Arch 1977; 372: 215-220.
31. O lsen VB. Indom e thacin  inh ib ition  o f  bum e tan id e  d iu resis  in dogs. Acta 
Pharmacol Toxicol 1975, 37: 65-78.
32. Patak RV , M ookerjee B K , Bentzel C J, H y se rt P E , Balij M , Lee JB. 
A ntagonism  o f  the  effects o f furosem ide by indom ethacin  in norm al and 
hypertensive m an. Prostaglandins 1975; 10: 649-659.
33. W illiam son H E , B ourland W A , M arch an d  G R . In h ib itio n  o f  furosem ide- 
induced  increase in  renal blood flow by  indom ethacin . Prostaglandins 1974; 8: 
297-301.
34. W illiam son H E , B ourland W A , M arch an d  G R . In h ib itio n  o f  fu rosem ide- 
induced  increase in renal blood flow by indom ethacin . Proc Soc Exp Biol Med 
1975; 150: 104-106.
35. A ndreasen  F , L ig u rd  B, S teiness E. E ffect o f  p robenec id  on excre tion  and 
natriu re tic  ac tion  o f  furosem ide. E urJ Clin Pharmacol 1980; 18: 489-495.
36. H om eida M , R oberts  C , B rauch RA. In fluence  o f  probenecid  and  sp ironolac­
tone on fu rosem ide kinetics and dynam ics in  m an. Clin Pharmacol Ther 1977; 
22:402-409.
37. H onari J , B lair A D , C u tler R E . Effects o f  p robenec id  on furosem ide kinetics 
and natriu resis  in  m an. Clin Pharmacol Ther 1977; 22: R359-401.
38. Benet L Z . P harm acok inetics /pharm acodynam ics  o f furosem ide in m an: a 
review. J  Pharmacokinet Biop harm 1979; 7: 1-27.
39. Steele T H . D iu re tic-induced  hyperuricem ia. Clin Rheum Dis 1977; 3: 37-50.
40. B ridgm an J F , R osen S M , T h o rp  JM . C om plica tions d u ring  clofibrate 
trea tm en t o f  nep h ro tic  syndrom e hyperlipopro teinaem ia. Lancet 1972; ii: 
506-509.
41. A ndreasen  F , H u sted  S. T h e  b ind ing  o f  fu rosem ide to  serum  p ro te in s  in 
elderly  patien ts: d isp lacing  effect o f phencruom on . Acta Pharmacol Toxicol 
1980; 47: 202-207.
42. G allo  D G , Bailey K R , S heffner A L. T h e  in terac tion  betw een cholesty ram ine 
and  drugs. Proc Soc Exp Biol Med 1965; 120: 60-65.
43. H uffm an  D H , S ch rem an  D W , Pen tikainen  P , A zarnoff D L . T h e  effect of 
sp irono lactone on an tipy rine  m etabolism  in m an. Pharmacology 1973; 10: 
338-344.
44. N alach M , B erm an N . F urosem ide and  chloral hydrate: adverse d rug  
in teraction . JAM A  1975; 232: 638-639.
45. K erry  R J, L ud low  JM , O w en G . D iu re tics  are dangerous w ith  lith ium . Br 
M edJ  1980; 281 :371 .
46. P etersen  V, H rid t S , T hom sen  K , Schon M . E ffect o f  p ro longed th iazide 
trea tm en t on renal lith ium  clearance. Br M edJ  1974; 3: 143-145.
47. T hom sen  K , S chon  M . Renal lith iu m  excre tion  in  m an. Am J  Physiol 1968; 
215: 823-827.
48. Jefferson  JW . D iu re tics  are  dangerous w ith  lith ium . Br Med J  1980; 281: 
1217.
49. H u rtig  H , D yson W . L ith iu m  toxicity  enhanced  by d iu re tics. N  Engl J  Med 
1974; 290: 748-749.
50. D oll R , L angm an  M JS , Shaw don H H . T re a tm e n t o f gastric  u lcer w ith 
carbenoxolone: an tagon istic  effect of sp ironolactone. Gut 1968; 9: 42-45.
51. N ashford  M L , R obertson  M B. Spironolactone and  am m onium  and  potassium  
chloride. Br M edJ  1972; 4: 298-299.
PAPER F10
The Antihypertensive Effect of Diuretics
This review was shared by the authors.
The anti hypertensive effect of 
diuretics
A. J. REYES, W. P. LEARY
The high incidence of arterial hyper­
tension constitutes an important 
epidemiological problem, particu­
larly since the risks of sudden cardiac 
death, myocardial infarction, cardiac 
in su ffic ien cy , cereb rovascu lar  
disease, obstructive arteriopathy of 
the lower limbs and chronic renal 
insufficiency all increase linearly with 
arterial blood pressure (BP) values. 
Accordingly, it is commonly accepted 
that diastolic BPs above 90 mmHg 
and systolic BPs above 150 mmHg 
should be treated, provided the peri­
pheral circulation is not compro­
mised.1 Initially, if values are not too 
high, pressure may be reduced by 
non-pharm acological measures, 
including the restriction of dietary 
sodium intake.2’4 When this proves 
unsuccessful, pharmacological treat­
ment is instituted according to estab­
lished guidelines.
Chlorothiazide became available 3 
decades ago and, since then, diuretics 
have been used as first choice anti­
hypertensive agents by many clini­
cians.2,5 This approach is justified 
because a regimen of sodium restric­
tion and diuresis controls BP effec­
tively in about 65% of all cases of 
essential hypertension.6 Despite their 
widespread clinical use, a number of 
fundamental questions concerning 
diuretics remain to be answered. The 
mechanism of their antihypertensive 
action and many pathophysiological 
effects of diuretics are still poorly 
understood. In recent years academic
interest in diuretics has revived and 
this review deals with developments 
in the use of diuretics as sole medi­
cation in the treatment of essential 
hypertension.
Definition of an 
antihypertensive diuretic
Not all diuretics are effectively anti­
hypertensive when administered as 
monotherapy for essential hyperten­
sion. An antihypertensive diuretic is 
defined as a substance which consis­
tently lowers the basal supine dias­
tolic BP below 90 mmHg in at least 
55% of patients in representative 
unstratified samples of the total 
population of essential hypertensive 
subjects treated for 16 weeks. In 
addition, antihypertensive diuretics 
maintain this reduction when treat­
ment is prolonged for at least 1 year.
Those diuretics whose principal 
site of renal action is a common 
acceptor situated at the thick ascend­
ing portion of the loop of Henle 
(loop diuretics) are not antihyper­
tensive diuretics in terms of the above 
definition. Furosemide, ethacrynic 
acid, bumetanide and piretanide are 
included in this category.6,7 Loop 
diuretics presented in slow-acting 
formulations do not exhibit anti­
hypertensive efficacy either.
Those diuretics acting principally 
on specific acceptors in the first 
portion of the distal convoluted
tubule, including thiazides, chlortha­
lidone, indapamide and xipamide, 
are efficacious antihypertensive 
substances. Throughout this review 
these substances will be referred to 
as antihypertensive diuretics or 
simply as diuretics.
The relationship between anti- 
hypertensive efficacy and location of 
the principal site of renal action of 
diuretics does not imply that the 
m echanism  o f antihypertensive 
action of diuretics may be totally or 
partially accounted for by their renal 
actions.
Loop diuretics in the 
treatment of hypertension
Even though loop diuretics are not 
effective as monotherapy in the pro­
longed management of hypertension, 
they are useful in the treatment of 
hypertensive crises, resistant hyper­
tension and hypertension compli­
cated by advanced chronic renal 
failure.
In hypertensive crises, the intra­
venous administration of furosemide 
(40-120 mg as a bolus or up to 400  
mg during a 24-hour continuous 
infusion) contributes to a rapid fall in 
BP.6 The mechanism whereby this 
occurs is still controversial; vasodila­
tion and the natriuretic action of 
loop diuretics are possibly involved. 
The rapid intravenous administration 
of loop diuretics is ototoxic and 
sometimes gives rise to irreversible 
deafness.6 Consequently, intrave­
nous doses of these diuretics should 
not exceed 120 mg as a bolus or 
400 mg/d.
Resistant hypertension is present 
when it is impossible to control BP 
by the coadministration of a diuretic, 
a 15-adrenergic blocker, a vasodilator 
and a sympathoplegic drug such as 
guanethidine.8 In these circum-
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stances the addition of a loop diuretic 
sometimes achieves BP control.6,9' 11 
This effect of loop diuretics may 
result from the significant natriuresis 
induced by these substances, since 
retention of water and sodium is 
provoked by antihypertensive drugs 
such as IS-adrenergic blockers, vaso­
dilators, a-adrenergic blockers, 
reserpine, clonidine, debrisoquine 
and guanethidine in many patients 
with resistant hypertension.
In patients with hypertension and 
significant chronic renal insufficiency 
(serum  creatin ine levels above 
220 /imol/1) loop diuretics should 
be prescribed because retention of 
sodium and water usually contributes 
to the maintenance of elevated pres­
sure in these patients; furthermore, 
they are preferable to antihyperten­
sive diuretics which may decrease 
renal blood flow and glomerular fil­
tration to a clinically significant 
degree.12
Intensity of antihypertensive 
effect of diuretics
The intensity of the antihypertensive 
effect of diuretics should be evaluated 
only when a maximal effect on basal 
supine diastolic BP has been attained. 
This happens after about 7-16 weeks 
of continuous monotherapy with any 
given antihypertensive diuretic and 
consequently the introduction of an 
additional drug to the therapeutic 
regimen should not be considered 
before the completion of 16 weeks of 
treatment.
Diuretics reduce both supine and 
erect arterial pressures at rest, 
although erect diastolic BP is less 
responsive to treatment than the 
other variables. Antihypertensive 
diuretics also reduce the BP increases 
associated with isometric and iso­
tonic exercise, but do not affect the 
rate at which these changes occur. 
Diuretics control BP without altering 
its reflex regulation as is revealed by 
the lack of effect which diuretics 
have on changes in arterial BP 
induced by the Valsalva manoeuvre 
(A. J. Reyes, unpublished observa­
tions).
Antihypertensive diuretics reduce 
BP for 24 hours when they are given 
as a single daily dose,1 and this 
improves patient compliance with 
treatment.14
Time course of the 
antihypertensive effect
No experimental data recording the 
hourly level of BP immediately after 
onset of treatment with a diuretic are 
available; and only a few studies 
describe daily changes in BP. Most 
published evaluations have been  
carried out 1 week after the initiation 
of treatment and at fortnightly or 
monthly intervals thereafter. In current 
experim ental designs there is a 
tendency to decrease the frequency 
of clinical evaluations as treatment 
progresses, since further mean 
decreases in BP are unlikely to occur 
after the 4th month of treatment.
The description which follows 
refers to the mean changes in BP of 
various groups of patients treated 
with a diuretic as monotherapy.
Usually, BP decreases from the 1st 
or 2nd day of treatment. During the 
1st week there is a reduction in 
pressure which generally has statis­
tical significance and has a clinical 
magnitude which depends on the 
drug administered.
During the 7-16 weeks that follow 
after completion of the 1st week of 
treatment there is a further fall in BP. 
This period is succeeded by one of 
stability which lasts while treatment 
is maintained.15
Some diuretics (power diuretics) 
cause a clinically significant fall in BP 
during the 1 st week of treatment and 
a rapid reduction thereafter.
Diuretics of another group (linear 
d iu retics) cause a less marked 
reduction o f pressure than that 
induced by power diuretics during 
the 1st week of treatment; thereafter 
BP falls gradually in a linear manner.
Indapamide, xipamide and a com­
bination of hydrochlorothiazide with 
amiloride are power diuretics. Cyclo­
thiazide, hydrochlorothiazide and 
tizolemide are linear diuretics. Other 
diuretics have not yet been classified 
(Table I).
Fig. 1 depicts the main patterns of 
BP decrease induced by power and 
linear diuretics and shows the para­
meters involved in defining the func­
tion graphically. Fig. 2 shows an 
actual example of the action of power 
diuretics. The fact the power model 
applies to long-term treatment is 
exemplified in Fig. 3, where the 
results of a 2-year treatment study 
with xipamide are shown.
TABLE I. CLASSIFICATION OF 
DIURETICS IN ACCORDANCE WITH 
THE CHARACTERISTICS OF THEIR 
ANTIHYPERTENSIVE EFFECT  
WHEN USED
MONOTHERAPEUTICALLY IN 
ESSENTIAL HYPERTENSION 
Antihypertensive diuretics 
Power diuretics 
Indapamide16 
Xipamide17' 19
Combination of hydrochloro­
thiazide + amiloride20 
Linear diuretics 
Hydrochlorothiazide21 
Cyclothiazide22 
Tizolemide23 
Unclassified 
Bendroflumethiazide 
Benzthiazide 
Buthiazide 
Chlorothiazide 
Chlorthalidone 
Clopamide 
Clorexolone 
Cyclopenthiazide 
Diasuiphamide 
Epithiazide 
Ethiazide
Hydroflumethiazide 
Indacrinone 
Mebutizide 
Mefruside 
Methyclothiazide 
Metolazone 
Polythiazide 
Quinethazone 
Tienilic acid 
Trichlomethiazide 
Non-antihypertensive diuretics 
Bumetanide 
Ethacrynic acid 
Furosemide 
Piretanide
The rate at which BP falls after the 
1st week of treatment with a power 
diuretic is graphically represented in 
Fig. 4.
An actual example of the effect of 
linear diuretics is given in Fig. 5. The 
rate of fall in BP during treatment 
with linear diuretics is constant. The 
eventual stabilization level of BP 
cannot be differentiated from that 
which is obtained when the diuretic 
employed is a power substance.
Evolution of blood pressure 
after withdrawal of therapy
Many antihypertensive substances 
such as clonidine, 15-adrenergic
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Fig. 2. Evolution of mean supine arterial 
pressure of 14 patients with essential 
hypertension. All cases were treated with 
indapamide 2,5 mg/d as monotherapy. A 
power function has been fitted to the 
experimental results. (Adapted from 
Reyes e ta / .'6)
blockers, reserpine and hydralazine 
cause a rebound in BP in some 
patients after sudden withdrawal of 
therapy. BP values then rise above 
pretreatment levels. This withdrawal 
syndrome has not been described for 
diuretics.
When prolonged treatment with a 
diuretic is discontinued, a gradual 
return of BP to pretreatment values
weeks
Fig. 1. Schematic representation of the evolution of elevated blood pressure during 
monotherapy with a power or linear diuretic (Pu = arterial pressure before treatment; 
Pt = arterial pressure at end of 1st week of treatment with a power diuretic; Pf = limit 
value to which arterial pressure tends when treatment with a power or linear diuretic is 
prolonged indefinitely).
occurs over several days.16' This 
pattern is ofvalue since hypertensives 
are inclined to discontinue their 
medication sporadically. In some 
patients treated with a diuretic for 
very prolonged periods, a remission 
of hypertension which may last for 
several months occurs if treatment is 
stopped.1'27
Antihypertensive action of 
diuretics in different racial 
groups
Antihypertensive diuretics are of 
0 2 4
months
Fig. 3. Evolution of mean supine arterial 
pressure of 25 patients with essential 
hypertension treated with xipamide as 
monotherapy. In data for the 8th, 11th 
and 12th months 24 subjects are in­
cluded, 23 subjects in the 18th and 20th 
months, 22 in the 22nd and 24th months 
and 20 in the 14th and 16th months. 
Xipamide 20 mg/d was given during the 
first 4 weeks and thereafter 10 mg in 2 
patients, 20 mg in 16, 30 mg in 4 and 40 
mg/d in 3 patients. A power function has 
been fitted to the experimental data. 
(Adapted from Castro and Reyes,18 by 
courtesy of S isto le .)
equal efficacy in the different racial 
groups,6 whereas 15-blockers are less 
effective in Blacks.
Antihypertensive dose of 
diuretics
The dose-response curves for diuretic 
and antihypertensive actions of 
d iu retics are not parallel. The 
maximal antihypertensive effect is
weeks
Fig. 4. Evolution of the rate at which arterial blood pressure changes (as a function of 
time) dP/dt, in response to monotherapy with indapamide. The curve has been 
derived from the functions represented in Fig. 2.
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Fig. 5. Evolution of mean supine arterial 
pressure of 15 patients with essential 
hypertension. All cases were treated with 
hydrochlorothiazide alone; in all cases 
the dosage was 25 mg/d during the first 
4 weeks and in 8 patients during the last 
4 weeks. A dosage of 50 mg/d was given 
to 7 patients during the last 4 weeks. The 
arterial pressure as a function of time was 
fitted by a linear function. (Adapted from 
Leary e t a l.,2' by courtesy of Current 
Therapeutic R esea rch .)
exerted at a dose which is much 
lower than the standard diuretic dose 
(i.e., one which provokes a 24-hour 
urinary sodium excretion similar to 
that caused by 50 mg of hydrochloro­
thiazide). An added antihypertensive 
effect is not obtained when daily 
doses of hydrochlorothiazide, chlor­
thalidone, xipamide or indapamide 
exceed 12,5 , 25, 10 or 2,5 mg 
respectively. 19,28-33 Furthermore, 
xipamide (Fig. 6 ) and indapamide 
both maintain their power antihyper­
tensive effect at doses well below  
their standard diuretic dose. When 
these diuretics are given at doses 
below the maximal antihypertensive 
dose, they exhibit a dose-related 
antihypertensive effect, an example 
being chlorthalidone 12,5 mg/d.31 
When power diuretics are admini­
stered at doses within their power 
antihypertensive dosage range (e.g. 
xipamide 5-40 mg/d), the rate at 
which BP falls in response to treat­
ment decreases with the dose (A. J. 
Reyes and W. P. Leary, unpublished 
observations). For many years hyper­
tensive patients have been overdosed 
with diuretics because the commer­
cially available formulations generally 
contain a standard diuretic dose per 
tablet.
The dose that has a maximal anti-
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Fig. 6. Evolution of the mean supine 
arterial pressure of 23 patients with 
essential hypertension (data from 22 
patients at the 3rd, 6th and 7th weeks, 
and 21 at the 8th and 9th weeks). Ail 
cases were treated with xipamide 5 mg/d 
as a monotherapy. The arterial pressure 
as a function of time was fitted by a power 
function. (Adapted from Leary and 
R eyes.9)
hypertensive effect should not be 
exceeded when treating uncompli­
cated hypertension, because larger 
doses usually provoke significant 
urinary excretion of potassium, mag­
nesium and zinc and alterations in 
lipid, carbohydrate and urate meta­
bolism.
S e l e c t i o n  o f  a n  
a n t i h y p e r t e n s i v e  d i u r e t i c
The difference between BP values 
during treatment with a power and a 
linear diuretic depicted in Fig. 1 
appears irrelevant when applied to 
individual cases, especially since the 
level of BP finally attained is practi­
cally the same for both types of drug. 
It is, however, more rational to pre­
scribe a power diuretic in all cases of 
hypertension uncom plicated by 
reduced peripheral blood flows, and 
to reserve linear diuretics for patients 
with clinical impairment of blood 
flow in the cerebrovascular, renal, 
coronary or peripheral vasculature. 
In the latter situation, it would be 
appropriate to decrease BP smoothly 
so as to allow organ adaptation to the 
resulting diminution in perfusion 
pressure. These criteria also apply to
geriatric patients, in whom power 
diuretics maybe used safely provided 
the limitations already discussed do 
not exist.
M onotherapy w ith  d iu retics  
decreases the incidence of cardiac 
in su ffic ien cy , cereb rovascu lar  
disease, obstructive arterial disease 
of the limbs and renal insufficiency to 
the rates which occur in patients 
with normal BP. However, mono­
therapy with antihypertensive diure­
tics does not reduce the high inci­
dence of sudden death and myo­
cardial infarction in hypertensive 
patients. It is possible that this lack of 
effect has to do with the fact that 
chronic administration of these drugs 
in standard doses of diuretics, which 
is unfortunately common in practice, 
causes significant increases in urinary 
potassium34,35 and magnesium36,3 
excretion, eventually leading to soma­
tic depletion of these cations. Mag­
nesium  deficiency p e r  se  might 
explain the development of fatal 
cardiac arrhythmias during diuretic 
treatment,36-39 with potassium defi­
ciency also contributing towards this 
effect. Magnesium deficiency could 
also explain the higher incidence of 
myocardial infarction in hypertensive 
patients treated with diuretics in 
standard diuretic doses.40
Chlorthalidone 100 mg, hydro­
chlorothiazide 50 mg, xipamide 5,10  
or 20 mg have been shown to be 
hypermagnesiuretic when admini­
stered acutely to normal volun­
teers38,39 (A. J. Reyes and W. P. Leary, 
unpublished observations). Only two 
antihypertensive diuretic formula­
tions, indapamide 2,5 mg41 and the 
combination of hydrochlorothiazide 
50 mg and amiloride 5 mg (W. P. 
Leary et al., unpublished observa­
tions) have so far been found not to 
induce hyperm agnesiuria when  
adm inistered  as m on od oses to  
healthy individuals. Indapamide 2,5 
mg acts in this manner because the 
dose is below its standard diuretic 
dose, whereas the hydrochlorothia- 
zide-amiloride combination is not 
acutely hypermagnesiuretic because 
amiloride counteracts the effects of 
hydrochlorothiazide to some extent.
Indapamide 2,5 mg stimulates 
hyperkaliuresis when given in mono­
doses to healthy volunteers. Never­
theless, the fact that this formulation 
apparently does not provoke hyper­
magnesiuria could explain why treat-
ment w ith indapamide does not 
induce cardiac arrhythmias, as found 
in a telem etric study o f cardiac 
rhythm .42 The com b in ation  o f  
hydrochlorothiazide and amiloride 
leaves urinary excretions of potas­
sium and magnesium unchanged 
when administered acutely, although 
a recent study indicates that magne­
sium depletion may follow prolonged 
therapy with this formulation (W. P. 
Leary e t al., unpublished obser­
vations).
Diuretics usually affect the meta­
bolism of lipids, carbohydrates and 
urates, factors which increase the 
risk of cardiovascular diseases.43,44 
Indapamide 2,5 mg/d is an exception, 
presumably because this dose does 
not exert a standard diuretic effect.
With the development of new anti­
hypertensive diuretics it may be 
expected that substances will be 
found which do not influence cardio­
vascular risk factors unfavourably.
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Diuretic-Induced Magnesium Losses
W.P. Leary and A.J. Reyes
University of Natal, Durban, and Fundacion Procardias, Montevideo
Summary Long term administration of common loop or distal tubular diuretics may cause so­
matic magnesium depletion. The resultant deficiency of Mgf + destabilises the myocard­
ium electrically and is a principal cause of cardiac arrhythmias ascribed to diuretics. The 
adverse effects of diuretics caused by Mg++ depletion can be avoided by selecting diuretics 
that do not cause magnesium deficiency, minimising the diuretic dose, supplementation 
of Mg++ intake, or the concomitant use of a K+ -retaining, Mg++-sparing diuretic.
M odem  diuretics are divisible into 3 main  
groups. L oop  diuretics, including frusemide (furo- 
semide), piretanide and m uzolim ine, act m ainly at 
a com m on site in the thick ascending portion o f  
Henle’s loop and are remarkable for the speed with 
which they change urinary flows o f  fluid and sol­
utes. D is ta l tubu lar d iuretics  such as the thiazides, 
chlorthalidone, indapamide and xipam ide act in 
the proximal part o f  the distal convoluted tubule, 
inducing relatively smooth changes in urinary flow. 
A third group is com prised o f  the K +-sparin g  d i­
uretics spironolactone, triamterene and amiloride 
which inhibit normal transparietal interchange be­
tween N a+, and K+ and H + in the final portion o f  
the distal convoluted tubule (Reyes and Leary, 
1980).
Com m only used diuretics are those which act 
principally at the loop o f  Henle or in the early dis­
tal convoluted tubule, and their standard oral di­
uretic dose is that which provokes a natriuresis 
equivalent to that induced by 40mg frusemide (loop  
diuretics) or 50mg hydrochlorothiazide (distal tu­
bular diuretics) given to healthy volunteers under 
controlled experimental conditions.
Prolonged administration o f  com m on diuretics
at standard doses has been im plicated in the gen­
esis o f  various cardiac arrhythmias, sudden death 
and increases in the incidences o f  atherogenic al­
terations in lipid metabolism , atheroma, coronary 
and cerebral vascular accidents, and arrhythmias 
complicating myocardial infarction (Reyes and 
Leary, 1980). Potassium  deficiency caused by di­
uretics is usually incriminated as the major patho­
genic factor in cardiac arrhythmias provoked by 
these drugs (Morgan et al., 1980) but recently it has 
been increasingly recognised that Mg++ deficiency 
secondary to hypermagnesiuria is a principal de­
terminant o f  diuretic-induced cardiac arrhythmias 
(Dyckner and Wester, 1979, 1981, 1982; Reyes and 
Leary 1983b; Sheehan and W hite, 1982). Clinical 
experience indicates that cardiac arrhythmias sec­
ondary to diuretic administration are suppressed 
by Mg++ supplementation irrespective o f  somatic 
K+ status (Dyckner and Wester, 1979, 1981, 1982; 
Sheehan and White, 1982).
1. Hypermagnesiuria and Magnesium
Deficiency Provoked by Diuretics
At normal plasma concentrations, approxi-
mately 6 mmol Mg++ is excreted in the urine daily. 
The main site of Mg++ reabsorption in the kidney 
is the thick ascending limb of the loop of Henle, 
possibly driven to some extent by active chloride 
reabsorption. Other factors influencing Mg++ reab­
sorption, including magnesium deficiency, hyper- 
calcaemia, parathyroid hormone, and loop diuret­
ics, also act at the same site (Mountokalakis, 1983).
Common diuretics may cause significant in­
creases in urinary magnesium losses, depending on 
the type of diuretic, the dose administered and the 
duration of treatment.
1.1 Single-Dose Studies
The effects of single standard doses of common 
diuretics on 24-hour urinary Mg++ output have 
been studied under controlled conditions in healthy, 
biologically equivalent, volunteers. Chlorthali­
done, frusemide, hydrochlorothiazide and xipam- 
ide induced significant hypermagnesiuria, whereas
the loop diuretic muzolimine 30mg, the distal con­
voluted tubular diuretic indapamide 2.5mg, and the 
K+-sparing diuretic amiloride 5mg or lOmg did not 
affect urinary Mg++ output significantly (fig. 1). The 
combination of hydrochlorothiazide 50mg and 
amiloride 5mg also had no effect on 24-hour mag- 
nesiuria. All the drugs tested increased 24-hour 
urinary Na+ output significantly and chlorthali­
done, hydrochlorothiazide, indapamide, muzoli­
mine and clorexolone also increased 24-hour urin­
ary K+ output significantly (Leary and Reyes, 1982; 
Leary et al., 1983; Reyes and Leary, 1982a,b; Reyes 
et al., 1983).
1.2 Long Term Administration
No data exist on the effects of long term admin­
istration of diuretics on total body stores of Mg++. 
In a study in which plasma Mg++ was measured 
before and during treatment with the loop diuretic 
piretanide 12 mg/day in 9 patients, the plasma
No.
of
cases
13 Am iloride  5m g
13 Am iloride  10mg
7 C lo rexo lone  10mg
9 Ch lo rtha lidone 100m g
9 Frusem ide  40m g
19 Hyd roch lo ro th iaz ide  50m g
9 H yd roch lo ro th iaz ide  50m g
7 Indapam ide 2.5m g
10 M uzo lim ine 30m g
13 X ipam ide  5m g
13 X ipam ide  10mg
13 X ipam ide  20m g 
19 H ydroch lo ro th iaz ide  50m g 
+ am iloride 5m g
Fig. 1. P e rce n ta g e  c h a n g e s  in 2 4 -hou r u r in a ry  ou tpu t o f M g ++ in re s p o n s e  to  v a r io u s  d iu re t ic s  g iven  to  h ea lth y  v o lu n tee rs . N o  
s ig n if ic a n t in c re a s e s  w e re  no ted  a fte r am ilo r id e  5 o r  10m g, in d a p a m id e  2 .5m g, m u zo lim in e  30m g , o r  a  c o m b in a t io n  o f h y d ro ch lo ro ­
th ia z id e  50m g an d  am ilo r id e  5m g [au tho rs ' data].
Fig. 2. M ean  u rina ry  N a + an d  M g ++ f lo w s  a fte r the  o ra l a d m in ­
istra tion  o f p la ce b o  to  9 h ea lthy  v o lu n tee rs  at the  s ta rt o f the 
expe r im en t (8 a.m.). T h e  tim e c o u rs e s  o f n a tr iu re s is  an d  m ag- 
n e s iu re s is  a re  a lm o s t pa ra lle l; the ir p e a k s  c o in c id e  in tim e 
[adap ted  w ith  p e rm is s io n  from  R e ye s  and  L ea ry , 1982a].
concentration was found to be significantly de­
creased after 12 weeks o f therapy (Leary and Reyes, 
1981).
2. Mechanism o f Magnesium Deficiency
Provoked by Diuretics
Under normal circumstances, urinary Mg++ 
output ranges from 4 to 8 m m ol/day (100 to 400  
mg/day). M ost filtered Mg++ is reabsorbed in the 
nephron, 20 to 30% at the proximal convoluted  
tubule, 50 to 60% at the thick ascending portion o f  
the loop o f  Henle, and 1 to 5% at the distal con­
voluted tubule (Quamme, 1981; Q uam m e and 
Dirks, 1980). Parathyroid hormone prom otes Mg++ 
reabsorption at the loop o f  Henle, and perhaps at 
the distal convoluted tubule (Massry, 1981; 
Quamme and Dirks, 1980).
2.1 Distal Convoluted Tubular Diuretics
Hypermagnesiuria provoked by diuretics acting 
at the distal convoluted tubule cannot be explained  
solely by direct blockade o f  transparietal reabsorp­
tion o f  the cation since only 1 to 5% o f  filtered 
Mg++ is reabsorbed in the distal tubule. In normal 
volunteers the mean Cl- , N a +, fluid and M g++ 
urinary flow curves indicate that the tim e courses 
o f  all these urinary excretions are alm ost parallel 
after the administration o f  a placebo (fig. 2). Sig­
nificant dephasing was found between the tim e 
courses o f  urinary M g++ and urinary Cl- , N a+ and 
fluid after the administration o f  diuretics such as 
hydrochlorothiazide (fig. 3) and chlorthalidone 
(Leary and Reyes, 1982; Reyes and Leary, 1982a).
Long term administration o f  these diuretics 
causes hypocalciuria (Bloch et al., 1981), followed  
by hypercalcaemia, which increases magnesiuria 
directly and reduces plasma parathyroid hormone 
secretion (Quamme, 1982). The decrease in para­
thyroid hormone dim inishes the reabsorption o f  
Mg++ in the loop o f  Henle, thus further increasing 
magnesiuria. The subsequent mechanisms whereby 
distal convoluted tubular diuretics induce hyper­
magnesiuria are similar to those associated with 
loop diuretics.
Fig. 3. M ean  urinary  N a + an d  M g ++ f lo w s  a fte r the o ra l adm in ­
istra tion  o f 50m g h yd ro ch lo ro th ia z id e  to  9 h ea lth y  v o lu n tee rs  at 
the sta rt o f the e xpe r im e n t (8 a.m .). T h e  tim e  c o u rs e  o f m ag- 
n e s iu re s is  is  d e la yed  w ith  re sp e c t  to  th a t o f  n a tr iu re s is  [adap ted  
w ith p e rm iss io n  from  Lea ry  an d  R e ye s , 1982b].
2.2 Loop Diuretics
Loop diuretics block transparietal reabsorption 
o f Mg++ in the thick ascending portion o f  the loop  
o f  Henle (Quamme, 1981; Q uam m e and Dirks, 
1980). When healthy subjects are given loop di­
uretics, urinary Mg++ flow is delayed with respect 
to fluid, Cl-  and N a+ flows which are linked by 
events occurring coincidentally in the loop o f  Henle. 
This suggests that the hypermagnesiuria induced  
by loop diuretics is partly due to m echanism s other 
than the direct blockade o f  Mg++ reabsorption at 
that site (Reyes and Leary, 1983a).
Loop diuretics provoke hypercalciuria (Reyes 
and Leary, 1980) which decreases calcaemia and 
thus increases plasma parathyroid horm one (Elm- 
green et al., 1980). Parathyroid horm one m obilises 
Ca++ and Mg++ from bone, increasing the am ount 
o f  Mg++ filtered at the glomerulus and perpetuat­
ing hypermagnesiuria. Magnesium ion deficiency 
ensues eventually, unless its exogenous supply is 
increased. This deficiency is manifested by hypo- 
magnesaemia only 8 to 15 weeks after the initia­
tion o f  diuretic treatment (Leary and Reyes, 1981), 
presumably because it is initially masked by Mg++ 
mobilisation from bone to plasma.
Magnesium deficiency decreases the release o f  
parathyroid hormone to som e extent (Mahaffee et 
al., 1982) and also causes resistance to the action  
o f parathyroid hormone in bone and in the kidney 
(Fischer and Fischer, 1981). Both these factors tend 
to increase hypermagnesiuria. M oreover, frusem- 
ide has been found to directly dim inish renal sen­
sitivity to parathyroid hormone (Turlapaty and Al- 
tura, 1982). The dim inution in plasm a levels and 
bone resistance to parathyroid horm one lim it M g++ 
and Ca++ m obilisation from the main store, thus 
reinforcing hypocalcaemia, which dim inishes mag- 
nesiuria directly, i.e. independently from parathy­
roid hormone (Quamme 1982; Quam me and Dirks, 
1980); this com pensating m echanism, however, is 
o f limited clinical importance.
It is o f  interest that the loop diuretic m uzoli- 
mine 30mg and the distal tubular diuretic indap- 
amide 2.5mg do not increase 24-hour urinary M g++ 
output significantly, but both delay urinary M g++
flow with respect to N a+ in the sam e manner as 
frusemide 40mg or hydrochlorothiazide 50mg. This 
suggests that these diuretics, at their standard doses, 
stimulate mechanisms that account for diuretic-in­
duced hypermagnesiuria. The possibility that pro­
longed therapy with these formulations could  
provoke significant Mg++ depletion requires in­
vestigation. Higher doses o f  these diuretics may be 
expected to induce hypermagnesiuria acutely.
2.3 Potassium-Sparing Diuretics
The K+-sparing diuretic amiloride reduced 
urinary Mg++ excretion, although this reduction was 
not statistically significant, and did not alter the 
time course o f  its urinary flow in normal individ­
uals (Leary et al., 1983). W hen a com bination o f  
amiloride 5mg and hydrochlorothiazide 50mg was 
administered to healthy volunteers there was also 
no significant change in Mg++ output (Leary et al., 
1984). This suggests that amiloride induces Mg++- 
sparing when the amount o f  the cation passing 
through the distal convoluted tubule is increased 
by the action o f com m on diuretics at more proxi­
mal nephron sites, at least under acute experim en­
tal conditions (Leary and Reyes, 1982; Leary et al., 
1984).
3. Prophylaxis o f Magnesium Deficiency
When the comparative effects o f  hydrochloro­
thiazide 50mg, amiloride 5mg or lOmg, and a com ­
bination o f hydrochlorothiazide 50mg and amilor­
ide 5mg are considered (Leary et al., 1983; Leary 
et al., 1984), it is clear that excretions o f  N a+, Cl~ 
or fluid are costly in terms o f  M g++ and K + ex­
cretion, when hydrochlorothiazide is administered  
alone. A striking change is effected by the co­
administration o f  amiloride and offers one ap­
proach to the prophylaxis o f  diuretic-induced mag­
nesium deficiency. However, no final conclusions 
will be reached until the effects o f  long term  
administration are assessed. The responses to other 
K+-sparing diuretics remain to be evaluated. Other 
measures which merit consideration include m in­
imising the diuretic dose, avoidance o f  diuretic
formulations which cause marked Mg++ excretion 
such as chlorthalidone lOOmg, and the supplemen­
tation of dietary magnesium.
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Resume
L ’utilisation prolongee des diuretiques habituels de I’anse ou du tube distal peut entrainer une hypomagne- 
semie. Le deficit en M g+ + destabilise electriquement le myocarde et se trouve etre ainsi une cause majeure 
d ’arythmies cardiaques dues aux diuretiques. Les effets indesirables lies au deficit magnesien lors d ’un traitement 
diuretique pourraient etre evites par I’utilisation preferentielle de medicaments qui epargnent le magnesium, par
le choix d ’une dose minimum, par un complement d ’apport en magnesium ou par / ’utilisation d ’un diuretique 
qui simultanement retient le potassium et epargne le magnesium.
Zusammenfassung
Die Langzeitverabreichung von Schleifendiuretika oder solchen, die am distalen Tubulus angreifen, kann 
eine Magnesiumverarmung des Organismus verursachen. Der resultierende Mangel an M g** destabilisiert das 
M yokard elektrisch und ist eine Hauptursache fu r die den Diuretika zugeschriebenen Herzarrhythmien. Die 
durch Mg * * -Mangel verursachten Nebenwirkungen der Diuretika konnen durch Wahl von Diuretika, die keinen 
Magnesiummangel verursachen, durch Minimierung der Diuretikadosis, zusdtzliche Mg* * -Aufnahme oder 
durch die gleichzeitige Verwendung von K*-erhaltenen und Mg* * -sparenden Diuretika vermieden werden.
Sommario
La somministrazione a lungo termine di diuretici dell’ansa o del tubulo distale di uso comune pub deter- 
minare una deplezione corporea di magnesio. La risultante deficienza di M g** destabilizza elettricamente il 
miocardio ed e una delle cause principali delle aritmie cardiache imputate ai diuretici. Gli effetti negativi dei 
diuretici, dovuti ad una deplezione di M g** , possono essere evitati scegliendo diuretici che non determinano 
una carenza di magnesio, utilizzando dosi minime del diuretico, aumentando I’assunzione di M g** o usando 
contemporaneamente un diuretico risparmiatore di K* e M g** .
Resumen
La administracion prolongada de diureticos habituates del asa o del tubulo distal puede causar deplecion 
somatica de magnesio. El deficit de M g** resultante desestabiliza electricamente el miocardio y  es una de las 
principales causas de arritmias adscritas a los diureticos. Los efectos nocivos de los diureticos debidos a la deple­
cion de Mg * * pueden evitarse eligiendo diureticos que no causan deficit de magnesio, minimizando las dosis, 
suplementando la ingestion de M g** o mediante el uso simultaneo de un diuretico ahorrador de potasio y  
magnesio.
Resumo
A administragao a longo prazo dos diureticos tubulares pode causar deplegao somatica de magnesio. A defi- 
ciencia de M g** resultante desestabiliza eletricamente o miocardio, sendo uma das principals causas das arrit­
mias cardiacas atribuidas aos diureticos. Os efeitos adversos dos diureticos causados pela deplegao de M g** 
podem ser evitados em se selecionando diureticos que nao causem deficiencia de magnesio, em se minimizando 
a dose de diuretico, com suplementagao de magnesio ou com o uso concomitante de um diuretico que retenha 
K * e poupe M g * * .
Cardiovascular Toxicity of Diuretics Related to Magnesium Depletion
This review was shared by the authors. It is an expanded and 
more detailed version of the previous publications and 
repeats many of the statements made in other publications 
included in this section.
Cardiovascular Toxicity of Diuretics Related to Magnesium 
Depletion
A.J. Reyes & W .P. Leary
Departamento de Investigation Cardiovascular, Fundacion Procardias, and Universidad de la 
Republica, Montevideo, Uruguay, and Department o f Experimental and Clinical Pharmacology, 
University o f Natal, Durban, South Africa
T he chronic adm inistration o f  com m on  lo o p  or distal tubular diuretics m ay  
lead to  som atic dep letion  o f  M g2 + . T he resultant deficiency o f  this cation  
causes an increase in intram yocardial cy toso lic  C a2 + and aggravates the 
decrease in intram yocardial K + provoked  by diuretics through their 
hyperkaliuretic effect. T hus the m yocardium  is electrically destabilized  and  
cardiac arrhythm ias m ay develop . M g2+ deficiency p ositively  contributes to  
the developm ent o f  atherogenic alterations in lipid m etabolism , vasospastic  
phenom ena in the coronary and cerebrovascular territories, m yocardial 
infarction and to the retardation o f  infarct healing and the occurrence o f  
ventricular arrhythm ias during the acute phase o f  infarction.
Introduction
Modern diuretics may be divided into three categories. Loop diuretics, including 
the frusemide, bumetanide, muzolimine and piretanide, act within the kidney 
mainly at a common acceptor in the thick ascending portion of the loop of Henle 
(Reyes & Leary, 1980; Reyes, 1981). The principal sites of renal action for distal 
tubular diuretics, including thiazides, chlorthalidone, clorexolone, indapamide and 
xipamide, are at specific acceptors for each substance, in the first portion of the 
distal convoluted tubules (Reyes & Leary, 1980; Reyes, 1981). The K +-retaining 
diuretics spironolactone, amiloride and triamterene inhibit normal transparietal 
interchange between Na + , which is reabsorbed, and K+ and H + , which are 
excreted, in the final portion of the distal convoluted tubule (Reyes & Leary, 1980; 
Reyes, 1981).
Common diuretics are defined as those which act principally at the loop of 
Henle or at the distal convoluted tubule. Standard diuretic doses of diuretics are 
those provoking a natriuresis equivalent to that induced by 40 mg of frusemide 
(loop diuretics) or to 50 mg of hydrochlorothiazide (distal tubular diuretics), when 
these drugs are given orally to healthy volunteer subjects under controlled 
experimental conditions (Reyes, 1981).
The chronic administration of common diuretics at standard diuretic doses may 
give rise to diverse cardiac arrhythmias, including ventricular fibrillation, or 
sudden death, and increase the incidences of atherogenic alterations in lipid 
metabolism, atheroma, vasospastic phenomena in the coronary and
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cerebrovascular territories, myocardial infarction and arrhythmias complicating 
acute myocardial infarction (Reyes & Leary, 1980; Reyes, 1981).
Classically, K + deficiency caused by diuretics has been incriminated as the 
principal pathogenic factor in arrhythmias provoked by these drugs (Morgan e t  
a l ., 1980; Nordrehaug, 1981; Olsson, 1981). However, K + deficiency is only one 
of several contributing factors, whereas the principal determinant of diuretic- 
induced cardiac arrhythmias is Mg2 + deficiency, which is secondary to the 
hypermagnesiuria induced by common diuretics (Dyckner & Wester, 
1979,1981a,b,1982a; Rotman, 1981; Whang e t  a l . ,  1981; Sheehan & White, 1982; 
Wester & Dyckner, 1981,1982; Reyes, 1983; Reyes & Leary, 1983a,b,c). In all 
cases of cardiac arrhythmias unequivocally due to common diuretics, in which 
appropriate laboratory analyses were carried out, Mg2 + deficiency was identified as 
the causative factor and the arrhythmia was suppressed by Mg2+ supplementation, 
irrespective of overall somatic K + status (Dyckner & Wester, 1979,198la, 1982b; 
Sheehan & White, 1982).
The well-known fact that effective control of essential hypertension by 
monotherapy with distal tubular diuretics does not reduce the incidence of sudden 
death in these patients could possibly be explained by the deficiency of Mg2 + 
which these drugs cause (Reyes & Leary, 1983b).
Hypermagnesiuria and magnesium deficiency provoked by diuretics
The effects on 24-h urinary Mg2+ output of single standard doses of common 
diuretics were studied under controlled conditions in normal, biologically equiva­
lent, volunteer subjects. Clorexolone, chlorthalidone, frusemide, hydro­
chlorothiazide and xipamide induced significant hypermagnesiuria, whereas the 
loop diuretic muzolimine (30 mg), the distal convoluted tubular diuretic indapamide 
(2.5 mg) and the K +-retaining diuretic amiloride (5 or 10 mg) did not affect urinary 
Mg2+ output significantly (Figure 1). The combination of hydrochlorothiazide (50 
mg) and amiloride (5 mg) also had no effect on 24-h magnesiuria (Figure 1). All 
the formulations tested increased 24-h urinary Na+ output significantly and 
clorexolone, chlorthalidone, hydrochlorothiazide, indapamide, muzolimine and 
xipamide also increased 24-h urinary K + output significantly.
No data exist on the effects chronic administration of diuretics have on total 
body stores of Mg2 + . In a study in which plasma Mg2+ was measured before and 
during treatment with the loop diuretic piretanide (12 mg/day) in nine patients, 
the variable was found to be significantly decreased after 12 weeks of therapy 
(Leary & Reyes, 1981b) (Figure 2). Hydrochlorothiazide (50 mg) (9 patients) or 
a combination of hydrochlorothiazide (50 mg) and amiloride (5 mg) (12 patients) 
reduced plasma Mg_+ significantly in hypertensive patients given these diuretics 
as monotherapy after an average of 20 weeks (W.P. Leary, A.J. Reyes & K. van 
der Byl, unpublished work).
N o .
o f
cases
D iu r e t ic  a n d  d o s e  (m g)
13 A m i lo r id e  5
13 A m i lo r id e  1 0
7 C lo r e x o lo n e  1 0
9 C h lo r t h a l id o n e  1 0 0
9 F ru s e m id e  4 0
19 H y d r o c h lo r o t h ia z id e  5 0
9 H y d r o c h lo r o t h ia z id e  5 0
7 In d a p a m id e  2 .5
10 M u z o l im in e  3 0
13 X ip a m id e  5
13 X ip a m id e  1 0
13 X ip a m id e  2 0
19
H y d r o c h lo r o t h ia z id e  5 0  
+ a m i lo r id e  5
Figure 1 Summary o f the results from several studies in which healthy volunteer subjects were 
given single doses o f diuretic formulations. Bars depict percentage changes in 24-h urinary Mg2 + 
output after these diuretics with respect to control 24-h magnesiuria. NS =  not significant. (l)Leary 
et al., 1983a; (2)Leary & Reyes, 1982b; (3)Reyes & Leary, 1982a; (4)Reyes & Leary, 1982b; (5)Leary 
et al., 1984; (6)Leary & Reyes, 1982c; (7)Reyes et al., 1983a; (8)W.P. Leary, A.J. Reyes & K. van 
der Byl, unpublished work; (9)A.J. Reyes & W.P. Leary, unpublished work
Mechanism of magnesium deficiency provoked by diuretics
Under normal circumstances, urinary Mg2+ output ranges from 4 to 8 mmol/day 
(100-400 mg/day). Most filtered Mg2 + is reabsorbed in the nephron, 20-30% at 
the proximal convoluted tubule, 50-60% at the thick ascending portion of the 
loop of Henle and 1-5% at the distal convoluted tubule (Quamme & Dirks, 1980; 
Quamme, 1981). Parathormone (PTH) promotes Mg2+ reabsorption at the loop 
of Henle and, perhaps, at the distal convoluted tubule (Quamme & Dirks, 1980; 
Massry, 1981; Olhaberry e t  a l . ,  1983a). The kidney, which can be regarded as the 
principal regulatory organ of Mg2+ metabolism, handles this cation independently 
from CP, Na+ and K + (Quamme & Dirks, 1980; Massry, 1981; Quamme, 
1981,1982; Olhaberry e t  a l . ,  1983a).
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Figure 2 Changes in magnesaemia during the monotherapeutic treatment o f nine hypertensive 
patients with piretanide (12 mg/day). Results as mean ±  SEM. NS =  not significant. Leary & 
Reyes (1981b), by courtesy of S. Afr. Med. J.
L o o p  d i u r e t i c s
Loop diuretics block transparietal reabsorption of Mg2 + in the thick ascending 
portion of the loop of Henle (Quamme & Dirks, 1980; Quamme, 1981). This is 
independent from the blockade of Cl- reabsorption at the same anatomical level, 
which accounts for the natriuretic effect of loop diuretics (Quamme & Dirks, 1980; 
Massry, 1981). In normal volunteer subjects the mean Cl-, Na + , fluid and Mg2 + 
urinary flow curves, derived from experimental data by a mathematical model 
(Reyes & Leary, 1981a,b), indicate that the time courses of all these urinary 
excretions are almost parallel after the administration of placebo (Figure 3). When 
the same subjects are given loop diuretics, urinary Mg2+ flow is delayed with 
respect to fluid, Cl- and Na+ flows (Figure 3). This fact suggests that the 
hypermagnesiuria induced by loop diuretics is partly due to mechanisms other 
than the direct blockade of Mg2+ reabsorption (Reyes & Leary, 1983a).
Loop diuretics provoke hypercalciuria (Reyes & Leary, 1980; Reyes e t  a l . ,  1981) 
which decreases calcaemia (Figure 4) and thus increases serum parathyroid 
hormone (sPTH) (Elmgreen e t  a l . ,  1980). PTH mobilizes Ca2+ and Mg2+ from 
bone, increasing the amount of Mg2+ available for renal excretion in this manner, 
and perpetuating hypermagnesiuria (Reyes & Leary, 1983a). Mg2+ deficiency
T im e  (h)
Figure 3 Mean urinary Na+ and Mg2+ flows after the oral administration o f placebo (a; n =  10), 
frusemide (b; 40 mg, n — 9) or chlorthalidone (c; 100 mg, n =  9) to healthy volunteer subjects at hour 0 
of the experiments (08.00h). The time courses o f natriuresis and magnesiuresis after placebo are 
almost parallel; their peaks therefore practically coincide in time. After frusemide or chlorthalidone 
the time course o f magnesiuria is delayed with respect to that of natriuria. n =  number of volunteer 
subjects. Adapted from Reyes & Leary ( 1982a,b), by courtesy of Curr. Ther. Res.
ensues eventually, unless its exogenous supply is increased. Mg2+ deficiency is 
manifested by hypomagnesaemia (low plasma Mg2+ concentration) only 8-15 
weeks after the initiation of diuretic treatment (Leary & Reyes, 1981b) because it 
is initially masked by Mg2+ mobilization from bone to plasma (Reyes & Leary, 
1983a).
Mg2+ deficiency decreases the release of PTH since the cation normally activates 
parathyroid adenylate cyclase by competition with Ca2+ at the modulating site 
of the enzyme or by promotion of the synthesis of endogenous guanine nucleotides 
(Mahaffee e t  a l . ,  1982). In addition, Mg2+ deficiency causes resistance to the 
action of PTH in bone and in the kidney (Fischer & Fischer, 1981; Fischer & 
Giroux, 1981; Rude & Singer, 1981), apparently because it obtunds interaction 
between the hormone’s receptor and adenylate cyclase, an enzyme which is 
positively influenced by PTH (Thode e t  a l . ,  1981). Thus Mg2+ deficiency decreases 
plasma PTH and causes renal and bone resistance to it; these facts tend overall 
to increase hypermagnesiuria. Moreover, frusemide has been found to directly 
diminish renal sensitivity to PTH (Turlapaty & Altura, 1982). The diminution in 
plasma PTH and bone resistance to it limit Mg2+ and Ca2+ mobilization from
Figure 4 Causal diagram of the determinaton of Mg2+ deficiency provoked by loop and distal 
tubular diuretics. Changes (+  =  augmentation; -  =  diminution) resulting from increases in the 
variables at which arrows start (system dynamics notation) are depicted. PTH = parathormone. 
Reyes (1983), by courtesy of Prensa Med. Argent.
its main store, thus reinforcing hypocalcaemia, which diminishes magnesiuria 
directly, i.e. independently from PTH (Quamme & Dirks, 1980; Quamme, 1982); 
this compensating mechanism is, however, of limited quantitative importance. The 
decreases in plasma PTH and in its renal effect decrease the activity of renal 
1-hydroxylase; the synthesis of l,25-(OH2)D3 is therefore decreased and 
hypocalcaemia aggravated. Hypocalcaemia stimulates the activity of renal 1- 
hydroxylase and consequently the synthesis of l,25-(OH2)D3; hypocalcaemia and 
hypomagnesaemia are thus partially compensated for; however, this mechanism 
has no quantitative significance.
Although muzolimine (30 mg) did not increase 24-h urinary Mg2+ output 
significantly (Figure 1), it delayed urinary Mg2 + flow with respect to Na+ in the 
same manner as frusemide (40 mg) (W.P. Leary, A.J. Reyes & K. van der Byl, 
unpublished work). This indicates that muzolimine, at its standard diuretic 
dose, brings into play the mechanisms that account for loop diuretic-induced 
hypermagnesiuria. The possibility that this formulation could provoke significant 
depletion of somatic Mg2+ on prolonged administration should therefore be 
evaluated. Higher doses of this substance may be expected to induce 
hypermagnesiuria acutely.
D i s t a l  c o n v o l u t e d  t u b u l a r  d i u r e t i c s
Hypermagnesiuria provoked by diuretics acting at the distal convoluted tubule 
cannot be explained solely by direct blockade of transparietal reabsorption of the
cation since only 1-5% of filtered Mg2 + is reabsorbed in the distal tubule. In 
experiments similar to those described for frusemide, significant dephasing was 
found between the time courses of urinary Mg2 + and urinary Cl-, Na+ and fluid 
after the administration of diuretics such as hydrochlorothiazide (Leary & Reyes, 
1982c), chlorthalidone (Figure 3), xipamide (AJ. Reyes & W.P. Leary, unpublished 
work) and clorexolone (Leary & Reyes, 1982b).
The chronic administration of these diuretics causes hypocalciuria (Bloch e t  a l .,
1981), followed by hypercalcaemia, which increases magnesiuria (Quamme, 1982) 
and reduces plasma PTH (Quamme, 1982). The decrease in sPTH diminishes the 
reabsorption of Mg2+ in the loop of Henle thus further increasing magnesiuria. 
The subsequent mechanisms whereby distal convoluted tubular diuretics induce 
hypermagnesiuria are similar to those associated with loop diuretics (Figure 4).
Indapamide (2.5 mg) probably did not provoke hypermagnesiuria because the 
dose given, which exhibits the maximal antihypertensive effect (Berglund & 
Andersson, 1975; Reyes & Leary, 1981c) of this substance (Reyes e t  a l . ,  1983b), 
is well below its standard diuretic dose. However, after indapamide (2.5 mg) 
urinary Mg2+ flow was found to be delayed with respect to that of Na+ (Reyes 
e t  a l . ,  1983a), which suggests that this diuretic provokes hypermagnesiuria at 
higher doses.
P o t a s s i u m - r e t a i n i n g  d i u r e t i c s
The K +-retaining diuretic amiloride reduced urinary Mg2+ excretion, although 
this reduction was statistically not significant, and did not alter the time course 
of its urinary flow, when monodosed in normal individuals (Leary e t  a l . ,  1983a). 
When a combination of amiloride (5 mg) and hydrochlorothiazide (50 mg) was 
given acutely to healthy volunteer subjects there was also no significant change in 
Mg2+ output (Leary e t  a l . ,  1984) (Figure 1). This suggests that amiloride induces 
Mg2+ reabsorption (Devane & Ryan, 1983) and therefore acts as a Mg2+ sparer 
when the amount of the cation passing through the distal convoluted tubule is 
increased by the action of common diuretics at more proximal nephronal sites 
(Leary & Reyes, 1982a; Leary e t  a l . ,  1984). However, since amiloride provokes 
hypocalciuria, on chronic administration its putative Mg2 +-retaining direct action 
would be counterbalanced or overcome by the events that account for the Henle’s- 
loop-mediated hypermagnesiuresis induced by common distal tubular diuretics 
(W.P. Leary, AJ. Reyes & K. van der Byl, unpublished work).
Pathogenesis of cardiac arrhythmias provoked by common diuretics
The description which follows departs from the electrically ‘resting’ myocardial 
cell.
Treatment with common diuretics may significantly diminish the intramyocardial 
content of Mg2+ (Dyckner & Wester, 1979; Whang e t  a l . ,  1981; Sheehan & White,
1982). This decreases the activity of the Na + , K + -ATPase which accounts for the 
active transport of K + into and Na+ out of the cell (Na + , K + pump), since
Na + , K + -ATPase requires Mg2 + as a cofactor (Dyckner & Wester, 1979; Olhaberry 
e t  a l . ,  1983b). Consequently, the intramyocardial concentration of Na+ increases 
and that of K + decreases when Mg2 + deficiency is present. This reduction in the 
intracellular concentration of K+ is added to the somatic K + depletion resulting 
from diuretic-induced hyperkaliuresis (Morgan, 1979; Morgan e t  a l ., 1980; Reyes & 
Leary, 1980, 1982a,b; Leary & Reyes 1981b,1982b,c; Reyes e t  a l ., 1983a). Thus 
the net Mg2+ plus K + output after a diuretic, as depicted in Figure 5, would be 
indicative of its arrhythmogenic potential. Diuretics increase the amount of Na + 
reaching the final portion of the distal convoluted tubule and therefore the normal 
interchange between Na+ and K + , H + is increased. In addition, hyponatraemia 
and the relative decrease in heart output, elicited by the natriuretic action of 
diuretics, increases aldosteronaemia which further elevates the Na+-K  + ,H + 
interchange in the distal convoluted tubule (Haalboom, 1980; Reyes & Leary, 
1980; Tucker e t  a l . ,  1980). In familial hypokalaemic alkalosis with tubulopathy 
(Giillner e t  a l . ,  1981) hypermagnesiuria occurs in association with
N o .
o f
cases
D iu r e t ic  a n d  d o se  (mg)
13 A m i lo r id e  5
13 A m i lo r id e  1 0
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Figure 5 Summary o f results from several studies in which healthy volunteer subjects were given 
single doses o f diuretic formulations. Bars depict the sums o f percentage increases in 24-h urinary 
Mg2+ and K + outputs with respect to control values. For references (1) -  (9) see legend to Figure 1
hyperaldosteronaemia and hypomagnesaeraia increases aldosteronaemia 
independently from the renin-angiotensin system, but these mechanisms are of 
limited importance during the treatment of ordinary patients with common 
diuretics (Massry, 1981). Increased proton excretion in urine elevates the 
extracellular pH, thus facilitating the entrance of K + into the cell by diffusion; 
however, the factors that decrease intracellular K + predominate (Figure 6). 
Cytosolic Ca2+ concentration within the myocardium increases when Mg2 + 
deficiency is present (Wester & Dyckner, 1981). The transmitochondrial interchange 
of N a+ and Ca2+ rises because of the increase in cytosolic N a+ secondary to 
reduced Na + , K + pump activity, Na+ passing into the mitochondria and Ca + 
from them into the cytosol. Cytosolic Ca2+ also increases as a result of changes
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Figure 6 Causal diagram of the principal mechanisms whereby diuretics alter the intramyocardial 
concentrations o f Mg2 + , K + , Ca2+ and Na + . Changes (+  =  augmentation; -  = diminution) 
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in passage of the ion from the extracellular compartment which occur in Mg2 + 
deficiency (Altura, 1982; Altura & Turlapaty, 1982). The fall in intracellular Mg2 + 
concentration decreases the activity of the Mg2 +-dependent Ca2 + -ATPases that 
account for the active transport of Ca2+ from the cytosol into the endoplasmic 
reticulum, and from the cytosol to the m i l i e u  i n t e r i o r , thus augmenting cytosolic 
Ca2+ (Figure 6). Within the myocardium, the increase in cytosolic Ca2+ is the 
prime factor underlying the occurrence of cardiac arrhythmias during treatment 
with common diuretics; the decrease in intracellular K + and Mg~ + and the 
increase in cytosolic Na+ contribute to this deleterious effect of diuretics, since 
all these ionic derangements destabilize the sarcolemma electrically, increasing 
myocardial excitability (Nayler, 1981).
Other mechanisms exist which contribute to the intramyocardial electrolyte 
disturbances provoked by diuretics; these processes are less important than those 
already described (Figure 7). The haemodynamic changes induced by diuretics 
increase catecholamine secretion by the suprarenal glands. The decrease in 
intracellular Mg-+ and the increase in cytosolic Ca2 + , reinforce both this secretion 
and the release of catecholamines by the sympathetic nerve endings (Altura, 
B.M. & Altura, B.T. 1982; Altura, B.T. & Altura, B.M., 1982; Altura & 
Turlapaty, 1982). Catecholamines activate adenylate cyclase and promote the 
synthesis of adenosine 3',5'-cyclic monophosphate (cAMP) from adenosine 
5'-triphosphate (ATP). The increased adenylate cyclase activity is augmented 
because catecholamines decrease the secretion of insulin, which normally inhibits 
the activity of the enzyme. A decrease in intracellular Mg2+ would cause a fall 
in the activity of adenylate cyclase, since Mg2+ promotes the activity of the 
enzyme directly and is a cofactor for enzymes involved in the cyclation of guanosine 
nucleotide which precede the activation of adenylate cyclase (Olhaberry e t  a l . ,
1983); however, the overall effect of the various factors involved is a net increase 
in the activity of adenylate cyclase (Erdos & Maguire, 1980). An increase in cAMP 
availability is promoted by diuretics like hydrochlorothiazide (Furman, 1981) that 
inhibit phosphodiesterase, the enzyme which catalyses cAMP. The amount of 
cAMP produced depends on ATP availability. Catecholamines reduce tissue P O 2 
and thus decrease the amount of ATP synthesized; however, increased glycolysis 
and lipolysis secondary to the rise in cAMP (Figure 7) provide ATP through the 
production of free fatty acids.
An increase in ATP tends to diminish glycolysis by reducing the activity of 
phosphofructokinase, which catalyses the rate-limiting step of the glycolytic chain. 
However, glycolysis is stimulated by the cAMP-dependent activation of the 
glycogenolytic enzyme phosphatase and also because the decrease in intracellular 
Mg-+ activates phosphoenolpyruvate carboxykinase, an enzyme that catalyses 
glyconeogenesis (McNeill e t  a l . ,  1982). Free fatty acids tend to diminish glycolysis 
through inhibition of the activities of various enzymes.
Free fatty acids bind ionic Mg2+ in plasma, thus removing it from the pool 
ionic Mg2+ which is transferable to the ceil (Flink e t  a l . ,  1981). This perpetuates 
and further aggravates the intracellular Mg2+ deficiency provoked by diuretics.
Increased cAMP decreases the activity of lipoprotein lipase, thus limiting further 
free fatty acid liberation. Raised free fatty acid levels decrease the activity of
Figure 7 Causal diagram of the complementary mechanisms whereby diuretics alter the 
intramyocardial concentrations of Mg: + , K + , Ca2+ and Na + . Changes (+  =  augmentation; -  = 
diminution) resulting from increases in the variables at which arrows start (system dynamics 
notation) are depicted. Reyes (1983), by courtesy of Prensa Med. Argent.
Na + ,K + -ATPase, further altering the intramyocardial electrolyte balance (Reyes & 
Leary, 1983b). cAMP also activates cellular protein kinase, which promotes the 
phosphorylation of sarcolemmal proteins; the cell membrane permeability to 
Ca2 + , Na+ and K + and Mg2+ is thus increased in favour of their electrochemical 
gradients. Consequently, the intramyocardial concentrations of Ca2+ and Na + 
rise and those of Mg2+ and K+ fall. This is aggravated because protein synthesis 
is altered in Mg-+ deficiency, since the cation acts as a cofactor for enzymes 
involved in transcription, and because the fall in intracellular K + also affects 
protein synthesis (Gunther, 1981; Olhaberry e t  a l . ,  1983a).
Diuretics, magnesium deficiency and coronary and cerebrovascular diseases
Mg2+ deficiency has been identified as a coronary risk factor.
The incidence of coronary heart disease varies widely in different geographical 
regions and serious epidemiological studies have been carried out to identify 
variables that could explain this fact. In Finland (Karppanen, 1981; Luoma e t  a i ,  
1983) and in South Afrcia (Leary e t  a l . ,  1983b) it was found that the incidence of 
death ascribed to ischaemic heart disease is inversely correlated with the concentra­
tion of Mg2 + in drinking water. This ranges from 0.5 to 30 mg in different regions 
and can be used as an index of the Mg2+ content of foods produced in the same 
geological area. In addition, it is possible that the amount of Mg2+ present in 
drinking water is in itself an important determinant of total bodily Mg2+ (Marier, 
1982). Post-mortem studies in England have demonstrated significantly reduced 
intramyocardial and coronary arterial wall Mg2+ levels in road accident victims 
who lived in areas where water supplies have a low Mg2+ content (Chipperfield & 
Chipperfield, 1978). A comprehensive review by Marier (1982) indicates all these 
findings have been confirmed in the USA and Canada by various authors.
Plasma Mg2+ concentration is significantly lower in patients with moderately 
severe coronary heart disease, diagnosed by arteriography, than in subjects with 
mild or absent radiographic changes (Manthey e t  a l . ,  1981).
Experimentally, Mg2+ deficiency increases coronary (Turlapaty & Altura. 
1980,1982; Siegel e t  a l . ,  1981; Turlapaty e t  a i ,  1981; Altura, 1982; Altura, B.M. & 
Altura, B.T., 1982; Altura & Turlapaty, 1982) and cerebrovascular tone (Altura, 
B.T. & Altura, B.M., 1980,1982), whereas Mg2 + supplementation has a corrective 
effect. Mg_+ deficiency increases vascular reactivity to catecholamines, angiotensin. 
K + , serotonin, vasospastic peptides and neurohumoral stimuli and attenuates 
vasodilatation induced by prostaglandins or isoproterenol (Altura, 1982). Mg2 + 
and verapamil block the same Ca2 + -entrance channel to the vascular smooth 
muscle cell (Turlapaty e t  a l . ,  1981). The overall mechanisms accounting for these 
vascular changes are probably similar to those depicted in Figures 6 and 7. The 
administration of Mg2+ accelerates the rate of myocardial recovery from ischaemia 
in experimental animals (Bersohn e t  a l . ,  1982).
Experimental Mg_+ deficiency causes characteristic structural changes in the 
myocardium (Gunther e t  a l . ,  1981) and in skeletal muscle (Robeson e t  a l . , 1980). 
In myocardial fibres, there in enlargement of the interstitial space of the transverse 
tubular system and a substance, possibly calcium phosphate, precipitates in vesicles 
of the longitudinal system of the endoplasmic reticulum. Mitochondrial oedema 
with loss of mitochondrial matrix also occurs, the interstitial space is enlarged, 
filaments and fibres of isolated collagen are seen in the vicinity of the interstitial 
capillaries and the fibrocyte endoplasmic reticulum is increased (Gunther e t  a l . ,  
1981).
Stress increases catecholamine release and therefore augments Mg2+ deficiency, 
which further increases catecholamine levels (Classen, 1981). Experimentally, stress 
has been found to provoke hypermagnesiuria (Altura, 1980) and factors, such as 
noise, deplete somatic Mg2+ stores (Classen, 1981; Ising, 1981). Type-A behaviour 
(Altura, 1980), stress (Classen, 1981), catecholamines (Classen. 1981) and
alterations in plasma lipids (Rayssiguier, 1981) potentiate each other as factors 
determining Mg2+ deficiency and this interplay could explain the high incidence 
of coronary heart disease in the population with type-A behaviour.
When diuretics are given to patients who are under stress or have coronary 
heart disease, particular care should be exercised to ensure that Mg2+ deficiency 
does not develop.
Diuretics, magnesium deficiency and hypertension
The possibility that Mg2+ deficiency contributes to the development of arterial 
hypertension has been postulated on the basis of indirect experimental evidence 
(Altura, B.M. & Altura, B.T., 1982). Unfortunately, no adequate epidemiological 
studies on the relation between the incidence of hypertension and dietary Mg2 + 
content exist (McCarron, 1983).
In a recent study of hypertensive patients given prolonged diuretic therapy 
resulting in stable blood pressure values, subjects developed hypomagnesaemia. 
Oral Mg-+ supplementation in these patients resulted in an increase in 
magnesaemia and a significant reduction in blood pressure (Dyckner & Wester, 
1983), suggesting that the antihypertensive effect of diuretics may be hampered 
by the decrease in somatic Mg2+ which these substances induce. The mechanism 
whereby this occurs is unknown but may involve processes in vascular muscle 
resembling those depicted in Figures 6 and 7 (Altura, 1982). Plasma Mg2 + 
concentration should always be measured in hypertensive patients treated with 
common diuretics, and oral Mg2+ supplements should be prescribed in cases of 
hypomagnesaemia before considering the effect of a diuretic maximal and adding 
another antihypertensive to the therapeutic regimen.
Diuretics, magnesium deficiency and acute myocardial infarction
The myocardial content of Mg2+ has been found to be low in necrotic and 
perinecrotic zones (Condorelli, 1973), both in human necropsy specimens and 
after coronary artery ligation in several species. Both Mg2+ and K + concentrations 
are low in the infarcted myocardium (Sarker & Heggtreit, 1982) and the 
administration of both cations was found to accelerate healing more than 
medication with either of them given alone (Lehr, 1981). Ventricular arrhythmias 
occurring during acute myocardial infarction respond better to Mg2+ than to 
other antiarrhythmic agents (Condorelli, 1973; Morton e t a l . ,  1981; Rotman,1981). 
The mechanisms that underlie these phenomena are unknown; it might be 
speculated that hypoxia favours the exit of Mg2+ from the cell through an increase 
in permeability to the ion. Mg2+ status should be monitored in patients who are 
under treatment with common diuretics, when they suffer myocardial infarction 
or who are given diuretics during the acute phase of myocardial infarction.
Diuretic treatment, alterations in lipid and carbohydrate metabolism and 
magnesium deficiency
Common loop and distal tubular diuretics generally cause clinically significant 
alterations in plasma lipids, when they are given at standard diuretic doses to
normal volunteer subjects or hypertensive patients for more than 4 weeks. The 
changes include increases in total cholesterol (Ames & Hill, 1978; Falch & 
Schreiner, 1980; Gluck e t  a l . ,  1980; Joos e t  a l . ,  1980; Giillner e t  a l . ,  1981; Meier 
e t  a l . ,  1982) and/or triglycerides (Ames & Hill, 1978; Falch & Schreiner, 1980; 
Joos e t  al., 1980; Giillner e t  al., 1981; Leary & Reyes, 1981a; Reyes e t  al., 1981) 
and increases of the 0/a-lipoprotein (LDL/HDL) ratio (Gluck e t  al., 1979,1980; 
Grimm e t  a l . ,  1981). These alterations in plasma lipids are consistent with an 
increase in the risk of cardiovascular disease. It is possible that Mg2+ depletion 
is one of the factors leading to diuretic-induced dyslipaemias (Reyes & Leary, 
1983c), since similar derangements of lipid metabolism occur in experimental 
Mg2+ deficiency when animals are fed a high-lipid or high-carbohydrate diet 
(Rayssiguier, 1981). Most investigations of the effects which diuretics have on lipid 
metabolism (Ames & Hill, 1978; Gliick e t  a l . ,  1979,1980; Falch & Schreiner, 1980; 
Joos e t  a l . ,  1980; Boehringer e t  a l . ,  1981; Grimm e t  a l . ,  Giillner e t  a l . ,  1981; 
Robinson e t  a l . ,  1981; Weidmann e t  a l . ,  1981; Meier e t  a l . ,  1982) have been biased 
by improper control of diet or failure to take other factors, such as familial history 
of diabetes or dyslipaemia, into account. Some of the effects of diuretics on lipid 
metabolism may be explained by the increase in catecholamines elicited by these 
drugs (Figure 7); other effects could be related to the alteration in protein synthesis 
provoked by diuretics through increased K + and Mg2+ excretions (Reyes e t  a l . ,  
1983a) (Figure 7).
Both diuretics (Furman, 1981) and Mg2+ deficiency reduce glucose tolerance 
thus causing a pathophysiological picture that resembles diabetes mellitus, a 
condition that is usually accompanied by depletion of bodily Mg2+ stores and 
that may be aggravated by diuretics or by Mg2 + deficiency of any origin (Johansson 
e t  a l . ,  1981). Patients with dyslipaemias induced by diuretics have been shown to 
respond favourably to supplementation of the diet with Mg2+ chloride tablets 
(W.H. Davis, A.J. Reyes & W.P. Leary, unpublished work; A.J. Reyes, T.N. 
Acosta-Barrios & W.P. Leary, unpublished work).
Magnesium deficiency provoked by diuretics
The diagnosis of Mg2+ deficiency in its early stages is difficult (Cronin & Knochel, 
1983; Dyckner & Wester, 1982b; Erdos & Maguire, 1980; Fischer & Fischer, 1981; 
Flink, 1981; Halidmann, 1982; Roux & Courtois, 1981; Ruiz-Palomo e t  a l . ,  1983). 
Its existence should be suspected whenever diuretic treatment in standard doses 
have been prolonged, especially if any other factor exists that may precipitate or 
aggravate diuretic-induced Mg-+ deficiency cr cause Mg2+ deficiency p e r  s e  (Table 
1). Many of these factors may also provoke K+ deficiency, which frequently 
coexists with Mg' + deficiency in patients treated with diuretics. Moreover, when 
diminished serum K + and Mg2+ values are found in patients under treatment 
with diuretics, they correlate with each other (Kohvakka P t a l . ,  1982).
Clinical manifestations of Mg2+ deficiency include anorexia, nausea, apathy, 
muscular weakness, fatigue, excitation and, in some cases, delirium or coma. Other 
clinical signs are tetany, peripheral tremor involving muscles of the tongue, face 
and limbs, ataxia, vertigo, lateral and vertical nystagmus, tetany and convulsions.
Occasionally positive Chvostek and Trousseau signs, myoclonia or spontaneous 
carpopedal spasms occur. Advanced Mg2+ deficiency may be confused with 
hypocalcaemia. Atrial fibrillation is the most frequent cardiac arrhythmia, followed 
by ventricular and supraventricular extrasystoles (Sheehan & White, 1982) and 
ventricular fibrillation. The electrocardiographic signs of Mg2+ deficiency are non­
specific prolongation of the PQ, QTc and QUc intervals and flattening of the T 
waves (Davis & Ziady, 1978). Muscular derangements of the inferior portion of 
the oesophagous may lead to dysphagia.
Microcytic anaemia with decreased erythrocytic half-life, reticulocytosis and 
spherocytosis may be present in blood.
Hypocalcaemia and hypokalaemia resistant to supplementation therapy have 
been reported in association with Mg2+ deficiency and metabolic alkalosis also 
occurs. Total plasma lipids may be elevated (Erdos & Maguire, 1980; Fischer & 
Fischer, 1981; Flink, 1981; Rude & Singer, 1981; Dyckner & Wester, 1982b; 
Halidmann, 1982; Cronin & Knochel, 1983; Ruiz-Palomo e t  a l ,  1983).
No routine procedure exists for the evaluation of total Mg2+ stores. Measure­
ment of the plasma Mg-+ concentration is the procedure of choice for diagnosing 
Mg2+ deficiency, although experimental error is such that atomic absorption 
spectrometry is the only acceptable method routinely available at the moment. 
This technique measures total plasma Mg2+; diffusible Mg2+ may be evaluated, 
in plasma and tissues, by means of a selective electrode (Hess & Weingart, 1981), 
which is not yet used in the clinical laboratory.
Mg_+ deficiency is conventionally diagnosed when the total plasma Mg2 + 
concentration, referred to as magnesaemia, is < 0.75 mmol/1 (Rude & Singer, 1981; 
Dyckner & Wester, 1982a). The upper limit of normality is 1.05 mmol/1. It must 
be stressed that a normal plasma Mg2+ level does not necessarily exclude somatic 
Mg~+ deficiency, since in the early stages of the condition Mg2+ is mobilized 
from bone, retarding any fall in Mg2+ concentration.
The concentration of Mg2+ in striated muscle has been used to evaluate the 
ion content in the soft tissue (Dyckner & Wester, 1979), but it bears no linear 
relation to myocardial Mg2 + , since the cation is more readily retained in the 
myocardium than in skeletal muscle. Lymphocytes provide an adequate means 
for estimating somatic Mg2+ status, because they are metabolically active, can be 
studied repeatedly (Ryan e t  a l . ,  1981) and intralymphocytic and intramyocardial 
Mg2+ contents correlate linearly.
Table 1 Conditions that may provoke magnesium deficiency per se or may precipitate or aggravate 
magnesium deficiency during diuretic treatment. Adapted from Reyes (1983), by courtesy o f Prensa 
Med. Argent.
1 Conditions in which Mg2 + supply to the milieu interieur is decreased
1.1 Inadequate intake
1.1.1 Low Mg2+ content in all foods
1.1.2 Diet poor in Mg2 +
1.1.3 Decreased food intake
1.1.4 Parenteral nutrition with low Mg2+ content
1.2 Altered absorption
1.2.1 Malabsorption syndromes
1.2.1.1 Gluten enteropathy
1.2.1.2 Pancreatic insufficiency with steatorrhoea
1.2.1.3 Tropical sprue
1.2.1.4 Other
1.2.2 Extensive enteral resection
1.2.3 Biliary and enteric fistuli
1.2.4 Excessive intake o f oxalate and phytate
2 Conditions in which Mg2+ losses are increased
2.1 Enteric
2.1.1 Vomiting
2.1.2 Diarrhoea
2.1.3 Repetitive gastric aspiration
2.2 Excessive sweating
2.3 Renal
2.3.1 Renal insufficiency with hypermagnesiuria
2.3.2 Osmotic diuresis (glucose, mannitol, urea)
2.3.3 Alcohol
2.3.4 Drug-induced hypermagnesiuria
2.3.4.1 Antineoplastics: cisplatin
2.3.4.2 Antibiotics: amphotericin B, carbenicillin, gentamicin, ticarcillin
2.3.4.3 Cardiac glycosides
2.3.5 Chronic parenteral nutrition with liquids
2.3.6 Renal tubular acidosis
2.3.7 Diuretic phase o f acute tubular necrosis
2.3.8 Postobstructive polyuria
2.3.9 Essential familial hypermagnesiuria 
2.3.10Essential sporadic hypermagnesiuria
3 Conditions in which various factors coexist
3.1 Hungry bone syndrome
3.2 Hyperparathyroidism
3.3 Hyperthyroidism
3.4 Excessive lactation
3.5 Protein malnutrition
3.6 Diabetes mellitus
3.7 Phosphate deficiency
3.8 Metabolic acidosis
3.9 Primary hyperaldosteronism
3.10 Hypercalcaemia o f any origin
3.11 Acute pancreatitis
3.12 Third-term pregnancy
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SECTION G : REVIEWS (SPANISH)
Two publications are presented. These papers are based on 
original lectures delivered in Argentina. Adverse reactions 
to antihypertensive drugs and the pharmacology of vasoactive 
substances are reviewed. No other author is involved but the 
script was translated into Spanish by editorial staff at the 
journal.
P A P E R  G 1
Tratamiento De La Hipertension: La Farmacologia De Los 
Agentes Vasoactivos
tSSM S025-7880
M eoicina (Buenos Aires) 37 (Supl. N® 1): 102-l:;9 (1977)
Y R A T A M iE N TO  DE LA K IPE R T E N SIO N :
LA FARM ACOLOGIA BE LOS AGENTES VASOACTIVOS
WILLIAM P. P. LEARY
University of A'ntal, Durban, Republic of South A frica
La  presi6n arterial sistemica es contro- lada por mecanismos homeostaticos 
complejos, y puede ser afectada por agen- 
tes vasoactivos endogenos o medicamentos 
utilizados para regular la presion arterial. 
Las sustancias endogenas son de particular 
interes en vista de su posible papel en la 
patogenesis de la hipertension. Este trabajo 
•esta limitado a la farmacologia de los agen- 
tes vasoactivos usados en el tratamiento 
■de la presion arterial elevada.
Los compuestos vasoactivos empleados 
en esta terapeutica incluyen todas aquellas 
sustancias que actuan directamente sobre 
el musculo liso de la pared de los vasos 
sanguineos. No se discutiran los bloquean- 
tes de los receptores adrenergicos y la vaso- 
dilatacion producida por mecanismos neu- 
rogenicos distales o proximales. Las dro- 
gas: prazosin, hidralazina, minoxidil y dia- 
zoxidos, tienen particular irnportancia, y 
se analizara detalladamente su farmaco­
logia, inc.luyendo comentarios sobre sus 
mecanismos de accion y sus efectos colate- 
rales. Ademas, se hara una breve referen­
da a varios otros compuestos incluyendo 
los antagonistas de la angiotensina v las 
prostaglandinas con efectos liipotensores.
El prazosin (Fig. 1), es un derivado de 
la quinazolina que reduce la presion arte­
rial por la combinacion de un bloqueo fun- 
cional de los receptores y una relajacion 
rlirecta del musculo liso vascular, mediada
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por la inhibicion de la fosfodiesterasa.4 El 
prazosin fue desarrollado como un inhibi- 
dor de esta enzima, a partir de numerosas 
sustancias sinteticas cuyas estructuras re- 
cuerdan al 3’5’-adenosin monofosfato cicli- 
co (AMP ciclico), al guanosina monofosfa­
to ciclico (GMP ciclico), a la teofilina y a 
la papaverina.
El AMP ciclico regula numerosos cam- 
bios biologicos en celulas vivas incluyendo 
la relajacion muscular lisa. La sintesis de 
AMP ciclico a partir del ATP aumenta por 
la estimulacion de los receptores /3-adre- 
nergicos o por el bloqueo de los a-adreno- 
receptores; sus niveles tambien pueden 
ser aumentados por inhibicion de la fosfo­
diesterasa, la enzima responsable de la de- 
gradacion del AMP ciclico. Un aumento
en los niveles de AMP ciclico por cuales- 
quiera de estos mecanismos deberia, teorica- 
mente, relajar el musculo liso y producir 
una calda en la presion arterial sistemica. 
Un segundo nucleotido ciclico, el GMP ci­
clico, esta tambien presente en muchos teji- 
dos y es controlado por enzimas similares. 
La elevacion de los niveles de GMP ciclico 
en el corazon, en respuesta a la acetilcolina 
o a la inhibicion de !a fosfodiesterasa, pro­
duce una disminucion de la frecuencia 
cardiaca 3r de la fuerza de contraction.11, 17
Estudios preliminares in  v i t r o  indicaron 
que el prazosin inhibe la degradacion de 
ambos nucleotidos cidicos por la fosfodies­
terasa, y podria ademas disminuir la pre­
sion arterial sin inducir taquicardia refleja. 
I n  v iv o ,  los efectos perifericos de este com- 
puesto son mas marcados en las arteriolas, 
sugiriendo una distribucion selectiva del 
prazosin o una susceptibilidad aumentada 
a la inhibicion de la fosfodiesterasa en este 
tejido, donde la enzima esta presente en 
concentraciones relativamente bajas. El 
prazosin-2 ,4C es fijado bastante facilmen- 
te por el corazon, permitiendo la inhibicion 
de la fosfodiesterasa GMP ciclica, como se 
ha descripto anteriormente.4
El prazosin es en su mayor parte excre- 
tado despues de ser metabolizado por o- 
demetilacion, hidrolisis de la union amida, 
hidroxilacion y apertura del ciclo por oxi- 
dacion seguida por N-dealquilacion. Este 
compuesto tiene una vida media plasma- 
tica corta (1-2 horas); como en el caso del 
minoxidil y de la a-metil-dopa, sus efec­
tos anti-hipertensivos persisten despues de 
la caida de sus niveles plasmaticos, indi- 
cando una actividad mantenida a nivel de 
los receptores.11
En el hombre, el prazosin reduce la re- 
sistencia periferica total con pocos efectos 
sobre la frecuencia cardiaca, el indice sis- 
tolico y el indice cardiaco. La droga es 
generalmente administrada tres veces por 
dia y pueden necesitarse hasta cuatro se- 
manas para que comience a manifestarse 
el efecto maximo de una cierta dosis. El 
efecto antihipertensivo es mayor en la po- 
sicion erecta que en la supina, pero la hipo- 
tension ortostatica severa y los mareos son 
relativamente poco frecuentes y  no se ob- 
servan modificaciones del flujo sanguineo 
renal. La eficacia del prazosin puede ser
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aumentada por la combinacion con un diu- 
retico o con un agente bloqueante /?-adre- 
nergico/1,3S .
Se ha descripto una variedad de efectos 
colaterales incluyendo debilidad, palpitacio- 
nes, nauseas, boca seca, vision borrosa, 
edema, depresion, constipacion y. diarrea. 
Una pequena proporcion de pacientes pier- 
de la conciencia y sufre colapso despues 
de la administracion inicial de prazosin; 
este efecto esta relacionado con la dosis y 
puede ser evitado estudiando en todos los 
individuos el efecto de una pequena dosis 
de prueba.22
La hidralazina (Fig. 2) ha sido usada en 
el tratamiento de la hiper tension desde 
1950 y es probablemente el mas comun de 
los vasodilatadores.
Los mecanismos a traves de los cuales 
la hidralazina causa vasodilatacion son in- 
ciertos, aunque se sabe que suprime las 
respuestas vasculares a varios agentes vaso- 
constrictores sugiriendo una inhibicion de 
los mecanismos contractiles celulares, posi- 
blemente mediados a traves del calcio. Es­
tudios in  v i t r o  indican que la hidralazina 
inhibe la hidrolisis del AMP ciclico por la 
fosfodiesterasa, pero carece aparentemente 
de la capacidad del prazosin para inhibir 
la degradacion del GMP ciclico. En el 
hombre la hidralazina relaja la muscula- 
tura lisa arteriolar, especialmente en las 
circulaciones esplacnica, cerebral, corona- 
ria y renal, sin aumentar la capacitancia 
venosa. La respuesta simpatica refleja se­
cundaria a la vasodilatacion produce au- 
mento de la frecuencia cardiaca, de la ve-
locidad da eyeccion del ventriculo izquierdo 
y del volumen minuto cardiaco. Estos carn- 
bios pueden aumentar la presion en la ar- 
teria pulmonar en paciente* con enferme- 
dad mitral o causar dolor angumm an pa- 
tientes con insuficiencia < oronariu, a monos 
que se adminisxre un bloqueants beta con 
el vasodilatador. Posiblemente par estas 
respuestas cardiacas reflejas se dt-sarrolla 
tolerancia al efecto hipotensivo de la hidra- 
lazina.1- 11
La hidralazina se absorbs bier: despues 
de la administracion oral, tiene una gran 
afinidad por las paredes do las arterias 
musculares, alcanza sus niveles maximos 
plasmaticos a las 3 6 4 boras y pueda per- 
sistir en el plasma hasta 24 boras. Los ma- 
yores cambios metabolites despv.es de la 
absorcion son la hidrcxilacion del anillo 
ciclico, la siguiente conjugation eon. el aci- 
do glucuronico y la N-ace lilac ion Si la 
N-acetilacion se halla disminuida, puede 
producirse la acumulacion de la hidralazi- 
na con los efectos adversos consecuentes.22 
Se forman pequenas cantidades de hidra- 
zona que podrian combinarse posiblemen­
te con piridoxina produciendo una neuro- 
patia periferica. El efecto de la hidralazina 
se desarrolla despues de 15-20 minutes, 
alcanza la maxima actividad en una hora 
y dura alrededor de 6 boras. I a dilatation 
preferencial de las arteriolas minimiza los 
cambios posturales, pero pueden ocurrir 
otras respuestas adversas. Entre eilas se 
han descripto dolor de cabeza, mareos, 
nauseas, palpitaciones, sudor, congestion 
nasal, parestesias, calambres v tem'biores. 
La administracion cronica de hidralazina, 
en altas dosis, puede producir manifesta- 
ciones de artritis reumatoidea o de lupus 
eritematoso sistemico.
La hidralazina, como otros vasodilatado- 
res, puede causar retencion de agua y  sal 
con la consiguiente ganancia de peso y  ede­
ma. Estos cambios son posiblemente me- 
diados a traves del sistema renina-angio- 
tensina-aldosterona, ya que el flujo san- 
guineo renal y la filtracion glomerular no 
disminuyen por la hidralazina. La admi­
nistracion concomitante de un diuretico y 
un bloqueador /? deberia conirarrestar es­
tos efectos.15
El minoxidil (Fig. 3) es un derivado de 
la piperidino - pirimidina capaz de dismi- 
nuir la presion arterial por vasodilatation 
y, posiblemente, por atenuacion de la fun- 
cion nerviosa sirripatica.
Despuos de la administracion o»al se ab- 
sorbe rapidamente y tiene una vida media 
plasmatica corta de alrededor de cuatro bo­
ras, siendo excretado por la orina como un 
glucuronido conjugado, durante las prime- 
ras doce boras despues de la ingestion, y 
como otros dos metabolitos despues de las 
doce horas. El efecto maximo ocurre cua­
tro horas despues de la administracion del 
minoxidil y dura 24 boras o mas, depen- 
diendo de la dosis dada. La aparente falta 
de correlation entre los niveles circulantes 
en plasma y la duracion de la actividad 
sugiere su permaneiicia en los receptores 
vasculares.0 Afecta en forma semejante 
las presiones supina y erecta, de manera 
que la hipotension postural no es un pro­
blems habitual.14
El bloqueo colinergico, histaminergico y 
beta-adrenergico no interfiere con los efec­
tos del minoxidil sobre el musculo vascular, 
y fuera del sistema cardiovascular este 
compuesto tiene efectos farmacologicos mi- 
nimos.7 La libido y la eyaculacion no son 
afectadas, pero otros efectos adversos han 
sido registrados: la taquicardia refleja 
puede ser algunas veces bastante severa co­
mo para precipitar una angina de pecho, 
pero esta es controlada rapidamente por 
el bloqueo beta. La retencion de agua y 
sal puede alcanzar dimensiones considera-
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hies, pero es controlada generalmente con 
la administration de diureticos. Tambien 
se ha observado hipertricosis en la cara, 
frente y sienes y rigidez de los rasgos fa- 
ciales en pacientes tratados con minoxidil.14
La actividad reninica plasmatica esta 
aumentada por la administracion de mino­
xidil y este efecto, que es parcialmente 
controlado pOr el propranolol, ha sido atri- 
buido a un aumento de la actividad adre- 
nergica y a una disminucion en la presion 
de perfusion renal. Adernas es importante 
hacer notar que la elimination de la droga 
es principalmente una funcion de su me- 
tabolismo; la depuracion del minoxidil cor­
poral, como tal, no depende de la filtracion 
glomerular, sugiriendo que no es probable 
la excesiva acumulacion en pacientes ure- 
micos.n Comunici 'pnes preliminares con- 
firman este hecao habiendose descripto 
respuestas excelentes en pacientes refrac- 
tarios a otros tratamientos.20
El diazoxido (Fig. 4) es un potente vaso- 
dilatador estructuralmente muy semejante 
a los diureticos benzotiodiazinicos.
El diazoxido intravenoso reduce la pre­
sion arterial sistemica v pulmonar dentro 
de los 3 a 5 minutos y aumenta el volumen 
minuto cardiaco, la frecuencia cardiaca, el 
volumen sistolico y la velocidad de eyec- 
cion del ventrxculo izquierdo. La filtracion 
glomerular cae y hay una reduccion en la 
excrecion urinaria de sodio, potasio, bicar- 
bonato, acido urico y agua. Estos cambios 
duran entre 4 y 12 horas y pueden preci- 
pitar insuficiencia cardiaca en hipertensos 
uremicos, que puede generalmente supe- 
rarse con la administracion de un diuretico 
tiazidico o con furosemiaa. La relajacion 
del musculo liso uterino y la hiperglucemia 
que se observan son debidas a la disminu­
cion en la secrecion de insulina y al au­
mento en la liberacion de catecolaminas. 
La hiperglucemia responde a la adminis­
tracion de insulina o de una sulfonilurea. 
El diazoxido aurnenta la secrecion de 
renina.
El mecanismo exacto por el cual el dia­
zoxido produce vasodilatacion es descono- 
cido, aunque existen evidencias de que, de- 
alguna manera, inhibe la fosfodiesterasa 
e interfieia con los receptores vasculares- 
al cnlcio. De este modo, aunque el diazo­
xido inhibe, no competitivamente, la cons- 
triccion inducida por la noradrenalina en 
las prepnraciones arteriales “depleciona- 
das” de calcic, la resjxuesta vascular es res- 
taurada por el agregado de calcio. Esta 
accion puede ser mediada por el bloqueo- 
de los receptores al calcio, la “deplecion” 
intracelular de calcio o el bloqueo de su 
liberacion intracelular.
El diazoxido tiene la caracteristica, poco- 
cornua, de que su vida media plasmatica 
es considerablemente mayor que su efecto- 
hipotensor. Aunque el mecanismo no es 
claro, puede estar reiacionado con un alto 
grade de union reversible con las proteinas 
plasmaticas. La droga es excretada prin­
cipalmente como tal.
Los efectos colaterales pueden variar 
desde condiciones severas, tales como la in­
suficiencia cardiaca, debida a la retencion 
de agua y electrolitos, y la hipotension 
severa. marcada, que responde a la nora- 
drenalina, hasta angina, arritmias, vomi- 
tos, dolor abdominal y una sensacion de- 
quemazon a lo largo de la vena usada para 
la administracion de la droga. El edema- 
debido a la retencion de agua y sodio res­
ponde a los diureticos tiazidicos; estos, sin- 
embargo, pueden agravar los efectos hipo- 
tensores e hiperglucemiantes del diazoxido. 
La angina, la taquicardia y las arritmias 
cardiacas pueden controlarse generalmente- 
con la administracion de agentes bloquean- 
tes beta.14' 10
Las indicaciones terapeuticas del diazo­
xido en la hipertension son indefinidas has­
ta el memento, pero puede emplearse para 
tratar la encefalopatia hipertensiva y, com- 
binado con furosemida, en la hipertension 
severa asociada con nefritis aguda o insu­
ficiencia renal. El diazoxido puede com- 
binarse exitosamente con un agente blo- 
queador beta adrenergico en el tratamiento*
tie la diseccion. aguda de la aorta, pero de- 
be usarse con gran precaucion en la hyper­
tension con insuficiencia coronaria. La 
calda de la presion arterial que oeurre en 
respuesta al diazoxido no es siempre dosis 
dopendiente, y respuestas hipotensoras pe- 
ligrosus pueden ocurrir en pacientes de 
edad y en pacientes con enfermedad cere­
brovascular. El diazoxido oral es util, pero 
de eficacia incierta.--
E1 nitroprusiato de sodio (Fig. 5) es un 
antagonista funcionai de ia noradrenalina, 
la histarnina y la acetilcolina, con una ac- 
cion rnuy fugaz debido a su rapi.ua conver­
sion en tiocianato, que es excreiado por la 
orina. A diferencia de otros vasodilatado- 
res usados en el tratamiento tie la hiperten- 
sion, el nitroprusiato de sodio relaja el 
musculo liso de las venus y ?ariolas apro- 
ximadamente en igual grado. Se observa 
acumulacion de sangre en las venas y esta 
es responsabie de la caida en el volumen 
ininulo, particularmente en la posicion 
erecta, y de un aume.uto retie jo de la fre- 
cuencia cardiaca. El flujo sanguineo renal 
y la filtracion glomerular dii’icilmente cam- 
bian, pero la actividad reninica del plasma 
aumenta.14- 21
Las soluciones de nitroprusiato de sodio 
deben ser preparadas en el momenta y 
guardadas, solo por pocas boras, en la 
oscuridad.
Despues de la administracion prolonga- 
da tie nitroprusiato, especialmente en pa- 
rientes con insuficiencia renal, puede acu- 
mularse tiocianato, que algunas veces pro­
duce debilidad, nauseas, campanilleo, psi- 
cosis e hipotiroidismo. La excesiva vaso­
dilatation e hipotension puede producir 
sintomas tales coino sudoracion, vomitos,
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insomnio, dolor de eabeza, palpitaciones y 
dolor toracico, que pueden evitarse con el 
cuidadoso registro de la presion arterial.
El nitroprusiato es usado en diversas 
crisis hipertensivus y disminuye rapida- 
mente la presion arterial a los niveles de- 
seados. La respuesta es regulada facilmen- 
te alterando la velocidad de infusion, pero 
los pacientes deben ser cuidadosamente 
controlados. La falta de efecto sobre el 
volumen minuto y el volumen sistolico 
representa una desventaja cuando se nece- 
sita un aumento en la perfusion tisular o 
cuando existe coartacion de la aorta, pero 
es una ventaja importante en pacientes 
con diseccion de la aorta o severa enfer­
medad coronaria.14- -1
Otros vasodilatadores han sido sintetiza- 
dos y usados en el tratamiento de la hiper- 
tension durante los liltimos diez ailos. La 
guancidina (Fig. 6) neutraliza el efecto 
vasoconstrictor de la renina, de la angioten- 
sina, y en cierto grado, el de la adrenalina y 
la noradrenalina.23 Produce dilatacion tan- 
to de los vasos de resistencia como de capa- 
citancia, y los reflejos simpaticos no son 
afectados. En consecuencia, ]>uede aparecer 
taquicardia, pero la hipotension ortostatica 
no representa un problema. Como otros 
vasodilatadores, la guancidina produce re- 
tencion de liquido.10
La bupicomida tiene una accion similar a 
la de la hidralazina. Produce relajacion del 
musculo liso arteriolar, con la consiguiente 
caida de la resistencia periferica vascular y 
aumento reflejo de la frecuencia cardiaca, 
del volumen ininulo y de la velocidad de 
eyeccion del ventriculo izquierdo. La fil­
tracion glomerular no es afectada por la
bupicomida, indicando que determina una 
significatna dilatacion de los vasos afe- 
rentes y eferentes.5
Los vasodilataaores discutidos hasta aqui 
son familiares a ]os clinicos que se dedican 
a la hipertension; algunos han sido usados 
durante ahos. Investigaciones en curso in­
dican que una variedad de nuevos com- 
puestos reiacionados con las prostaglanai- 
nas y con la angiotensina II pueden ser 
desarrollados a corto plazo para el uso 
clinico.
Las prostaglandinas Eo, Fj y A reducen 
la pres ion arterial en los individuos hiper- 
tensos 10 aunque los efectos cardiovascula- 
res de las prostaglandinas varian segun las 
especies. La caida de la presion arterial 
es probablemente debida a vasodilatacion; 
las prostaglandinas dilatan las arteriolas 
del musculo esqueletico y de la piel, y la 
prostaglandina Ej antagoniza los efectos 
vasculares de las catecolaminas, de la vaso- 
presina y de la angiotensina.12’ 12 La inyec- 
cion intravenosa de prostaglandina Et pro­
duce taquicardia en el hombre, pero re­
duce el volumen minuto cardiaco.2 Las 
prostaglandinas naturales como agentes hi- 
potensores tienen una aplicacion mas bien 
limitada por su accion breve y sus efectos 
sistemicos desagradables; sin embargo, exis- 
te la posibilidad de obtener la sintesis de 
analogos adecuados de las prostaglandinas.
El papel de la angiotensina en la regula- 
cion de la presion arterial no esta claro, a 
pesar de los ahos invertidos en estudios 
cuidadosos tanto en el laboratorio como en 
la clinica. Sin embargo, presenta gran in- 
teres el desarrollo de antagonistas de la an­
giotensina capaces de reducir la presion 
arterial en ciertas condiciones. El 1-sarco- 
sina-8-alanina-angiotensina II es un anta- 
gonista de la angiotensina que actua en el 
receptor del musculo liso vascular y dis- 
minuye la presion arterial en el hombre 
o en los animales de laboratorio si la acti- 
vidad reninica del plasma esta elevada por 
•encima de los niveles controles por la “de- 
plecion” salina o por patologia vasculo- 
renal.0’ 8
Existen varios otros analogos, pero su uso 
■estara limitado por algun tiempo al campo 
de la investigacion.
Resumes;
S e  d is c u te  la  f a r m a c o lo g ia  d e  lo s  va so -  
d ila ta d o r e s  u sa d o s  e n  e l  t r a ta m ie n to  d e  la  
h ip e r te n s io n .  L o s  a g e n te s  u s a d o s  m a s  co- 
m u n m e n te  so n : e l  p r a z o s in ,  la  h id r a la z in a .  
e l  m in o x id i l , e l  d ia z d x id o  y  e l  n i tr o p r u -  
s ia lo , p r e s e n ta n d o  d i s t in ta s  c a r a c te r is t ic a s  
e n  lo  q u e  s e  r e j i e r e  a  la  v ia  d e  a d m in i s t r a ­
d o n ,  la  d u r a c io n  d e  s u  a c t i v id a d  y  lo s  e f e c ­
to s  c o la ts r a le s  q u e  d e te r m in a n .  L a  m a y o -  
r ia  d e  lo s  v a s o d i la ta d o r e s  p r o d u c e  ta q u i ­
c a r d ia  r e f le ja  y  e d e m a  d e b id o  a  la  r e te n -  
c io n  d e  a g u a  y  s o d io . N u e v o s  c o m p u e s to s  
d e r iv c d o s  d e  la s  p r o s ta g la n d in a s  y  d e  la 
a n g io te n s in a  p u e d e n  d e s a r r o l la r s e  e n  e l  
f u tu r o  p a r a  s u  u so  fa r m a c o lo g ic o  e n  e l  
h o m b r e .
Summary
TREATMENT OF HYPERTENSION: THE PHAR­
MACOLOGY OF VASOACTIVE AGENTS.
V a s o d i la to r s  u s e d  in  th e  t r e a tm e n t  o f  
h y p e r te n s io n  a r e  d is c u s s e d  in  t e r m s  o f  th e ir  
p h a r m a c o lo g y '. P r a z o s in ,  h y d r a la z in e ,  m i ­
n o x id i l , d ia z o x id e  a n d  n i tr o p r u s s id e  a r e  
th e  a g e n ts  m o s t  c o m m o n ly  u s e d  a n d  v a r y  
in  th e ir  r o u te  o f  a d m in is t r a t io n ,  d u r a t io n  o f  
a c tio n  a n d  s id e  e f f e c ts .  M o s t  v a s o d i la to r s  
c a u s e  r e f l e x  ta c h y c a r d ia  a n d  e d e m a  d u e  
to  s o d iu m  a n d  w a t e r  r e te n t io n .  N e w  c o m ­
p o u n d s  d e r iv e d  f r o m  p r o s ta g la n d in s  o r  a n ­
g io te n s in  m a y  b e  d e v e lo p e d  in  th e  f u tu r e .
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D i s c u s i c n
Dr. C ornua.) El mazoxidu es estruetural- 
mente similar a los diureticos iiszidicos; en 
realidad, si se lo administra intraarterial- 
mente es un diuretico. Tambien es on po- 
tente vasodiiatador, La accion diuretics se 
puede demostrar per expert ment.es do ‘ 'top- 
flow”, y es similar ai e fee to de la clorotia- 
zida. Cuando se lo adminisira por via oral 
o endovenosa predomina la accion vasodi- 
latadora y, en consecuoncia, se producen 
una serie de efectos reflejos que anulan su
capacidad diuretics y llevan a la retencion 
de sodio. Para dotorminar su accion diure­
tics se lu hifunde en la arteria renal de una 
preparacion inervada; produce vasodilata- 
ciun renal y el efecto diuretico aparece a 
nive! jy los tubulos, aparontemente en el 
mismo sitio de accion de la clorotiazida.
D r . R o b e r tso n ;  En dos pacientes tratadas 
ecu prazosin he observado la aparicion de 
un dest-o urgente y doloroso de orinar, que 
tiese parar.io al suspender ia droga. No es- 
tuda zLecicnado con infection urinaria. Se 
de Giro case similar tambien en una mujer. 
I' >r ct:a parte, en una paciente tratada con 
diazoxido observe la aparicion de hirsutis- 
rno. Dr. Leary, ^tiene usted alguna otra 
ini’ormacion al respecto?
Dr. Leary: Con respecto al primer pro- 
bieii'.a. no lo lie observado en mis pacientes 
y no se cual puede ser el mecanismo. Con 
respecto ai hirsutismo, se ha pensado que 
puede ser consecuer.cia del mayor flujo san- 
guftieo a nivel de la piel. Sin embargo, es 
dificil oxpliear la limitada distribution del 
pelo. Pienso que estas drogas pueden tener 
im efecto comiin, posiblemente a nivel en- 
docrino.
D r . D a n g e r :  Dr. Leary, ,-tiene usted algu­
na explicacion para el periodo de latencia, 
de alrededox* de cuatro semanas, entre el 
cornienzo del tratamiento con prazosin y la 
verification de efectos clinicos de natura- 
leza antihipertensiva, y si durante ese pe- 
ru.tio de latencia se- puede demostrar el de- 
sarrollo del efecto vasodiiatador y del bio- 
0, ueo alfa?
D r . L e a r y :  No, no tengo explicacion para 
el periodo de latencia, sobre todo teniendo 
en cuenta la rapida elimination de este 
compuesto. Existe un pequeno porcentaje 
de pacientes que responden agudamente y, 
an estes casos, se pueden producir acciden- 
tes graves. Uno de nuestros pacientes de 
edud avanzada fallecio aparentemente por 
este modvo.
D r . L u n g e r :  Ouisiera saber si al suspen­
der la droga se observe persistencia de los 
efectos antihinertensivos ]>or cierto tiempo. 
Eso sucede muchas veces con drogas que
tienen un periodo de latencia prolongado 
antes de establecerse sus efectos terapeu- 
ticos.
D r . L e a r y :  En mi experiencia la respues- 
ta es no. No parece haber una prolongacion 
de los efectos despues de suspender la dro- 
ga comparable con el periodo de latencia. 
Puede existir un periodo de prolongacion 
del efecto de unos pocos dias a una semana, 
pero no mas.
D r a . B a sso : En el tratamiento ambulato- 
rio de la hipertension arterial con las dro- 
gas vasoactivas disponibles, ^cual es, en su 
opinion, la mas efectiva y con menor inci- 
dencia de efectos colaterales?
D r . L e a r y :  Creo que es muy dificil con- 
testar a esa pregunta. No administraria co- 
mo rutina vasodilatadores, a menos que el 
paciente no responda a la terapeutica mas 
simple, como puede ser un diuretico con o 
sm el agregado cle un beta bloqueante. En 
este momento rni esquema es agregar, en 
case de que sea necesario, prazosin a la com- 
binacion mencionada. No utilizamos hidra- 
lazina porque en nuestra area vemos mu- 
chos casos de lupus eritematoso diseminado, 
y no empieamos el minoxidil porque no 
esta disponibie en nuestro mercado. Las des- 
ventajas de los vasodilatadores orales son 
comunes a todos. Tampoco usamos diazo- 
xido por razones regionales, ya que el 25- 
35 %  de nuestros pacientes de origen hindu 
tiene diabetes mellitus y esta droga posee 
un efecto antiinsulinico.
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La incidencia de la hipertension arterial 
en el mundo es de tal magnitud que los 
medicos suelen frecuentemente enfrentarse 
a ella haciendo necesario un acabado co- 
nocimiento de las reacciones adversas que 
pueden ocurrir durante su tratamiento. Es- 
tas reacciones pueden aparecer como cam- 
bios en los signos clinicos, en los sintomas 
o en los datos del laboratorio relacionados 
con la enfermedad hipertensiva o ser pro- 
ducidas por los medicamentos utilizados en 
el manejo de la enfermedad. Tales reac­
ciones pueden ser predecibles dadas las 
caracteristicas farmacologicas de la medi- 
cacion utilizada o impredecibles y no rela- 
cionadas con las acciones farmacologicas 
de los medicamentos.
En Ifneas generales, las reacciones ad­
versas a los agentes antihipertensivos pue­
den estar: a ) relacionadas con los agentes 
antihipertensivos p e r  se ; b )  producidas por 
interacciones entre ellos o, c )  causadas por 
interacciones entre los farmacos antihiper­
tensivos y las drogas utilizadas para el tra- 
tamiento de enfermedades independientes.
El tratamiento de eleccion para la hiper­
tension varia ligeramente de un lugar a 
otro, pero la aspiracion comun de todos 
los medicos es controlar la enfermedad v 
remediar los sintomas evitando los efec- 
tos colaterales. Esto es particularmente im- 
portante, dado que la hipertension es una 
enfermedad potencialmente letal que ge- 
neralmente solo presenta sintomatologia
despues de largo tiempo de evolucion y 
por ello, los pacientes, sin una hiperten­
sion complicada, se resisten a continuar 
la terapia si esta les causa sintomas des- 
agradables. A continuacion, se revisaran 
algunas de las reacciones a los medicamen­
tos, que deben ser reconocidas por los me­
dicos para el bienestar de sus pacientes.
Cierto numero de efectos colaterales son 
comunes a varios agentes antihipertensi­
vos, por lo tanto no seran mencionados 
repetidas veces. La hipotension, el letargo, 
la depresion, la congestion nasal o rinitis, 
sintomas gastrointestinales, el dolor de ca- 
beza, vertigos y manifestaciones alergicas 
pueden ocurrir con variada frecuencia v 
han sido asociados con los bloqueantes 
adrenergicos y con los vasodilatadores 1.
Efectos adversos asociados con las 
distintas clases de drogas
Los diuretic os son ampliamente utiliza­
dos en el inicio del tratamiento de la hi­
pertension; la mayoria de los medicos pre- 
fieren los derivados de las tiazidas o aque- 
llos que tienen menor efecto perdedor de 
potasio. Las reacciones adversas al trata­
miento con estas drogas son bien conoci- 
das y estan resumidas en la Tabla 1.
Adenitis de estos efectos indeseados de 
los diureticos han sido descriptas varias 
interacciones con otras drogas2. La oto- 
toxicidad producida por los aminoglucosi-
T a b l a  1. — Reacciones adversas a los diureticos
Derivados benzotiadizinicos y furosemida: 
Diabetes
Hipoglucemia neonatal 
Hiperuricemia 
Hipocalemia 
Hiperlipidemia 
Sindrome hiperosmolar
Diureticos de pobre efecto perdedor de potasio:
Hipercalemia
Ginecomastia
Carcinoma de mama Espironolactona
Anemia megaloblastica Triamtirene
dos puede ser aumentada por la furosemi­
da o el acido etacrinico, aunque este ulti­
mo rara vez es usado para el tratamiento 
de la hipertension. Tambien los diureticos 
refuerzan la tendencia a la hiperglucemia 
producida por el diaxozido y potencian 
marcadamente el efecto hipotensor de los 
bloqueantes adrenergicos, lo que puede 
causar problemas en pacientes no suficien- 
temente vigilados.
En la literatura medica se han descripto 
mas de 50 reacciones adversas al trata­
miento de la hipertension con los b lo ­
q u e a n te s  b e t a 1_3. Sin embargo, las com- 
plicaciones mas comunmente registradas 
en los pacientes que utilizan estos medica- 
mentos son el espasmo bronquial, el 
desencadenamiento de insuficiencia car- 
diaca y alteraciones circulatorias periferi- 
cas que especialmente aparecen si se uti- 
liza un compuesto no selectivo para recep- 
tores beta y carente de actividad simpati- 
comimetica intrinseca. Los bloqueantes 
beta se asemejan estructuralmente entre si 
y tienen efectos colaterales similares, aun­
que han sido descriptas ligeras diferencias 
farmacologicas entre ellos. Estas diferen­
cias pueden ser muy marcadas en el labo- 
ratorio, pero esto no garantiza su real 
comportamiento en el hombre. De este 
modo, drogas con actividad intrinseca de- 
mostrable, tales como el oxprenolol, pue­
den desencadenar insuficiencia circulato- 
ria en aquellos pacientes cuya funcion 
ventricular esta alterada 3. En "los pacien­
tes asmaticos, los bloqueantes beta relati- 
vamente selectivos tales como el acebuto- 
lol y el metoprolol ocasionalmente produ-
cen espasmo bronquial. La incidencia de 
frio en las extremidades y la ausencia de 
pulsos perifericos asociada con los blo­
queantes beta varia ligeramente y hay 
cierta evidencia que tanto la posesion de 
actividad intrinseca como la selectividad 
beta, disminuyen el riesgo de esta com- 
plicacion. Parece ser que la liposolubilidad 
de los bloqueantes beta o de sus meta- 
bolitos, facilitan la penetracion en el sis- 
tema nervioso central y podria explicar la 
relativa frecuencia de suehos y alucina- 
ciones que aparecen cuando se usa el pro­
pranolol y el pindolol. Las evidencias 
acumuladas sugieren que las complica- 
ciones oculares y la peritonitis esclero- 
sante rara vez se relacionan con el uso 
de otros bloqueantes beta que no sea el 
practolol.
Los bloqueantes beta rara vez se ven 
envueltos en serias complicaciones por in- 
teraccion con otras drogas, aunque se 
pueden observar severas respuestas hiper- 
tensivas, debido a la liberacion de nor- 
adrenalina, por la administracion de fenil- 
propanolamina comunmente presente en 
los medicamentos para el resfrio.
Tambien existe la posibilidad teorica de 
que los hipertensos asmaticos, tratados con 
bloqueantes beta, puedan responder ad- 
versamente a los efectos alfa adrenergicos 
de la adrenalina administrada para el 
espasmo bronquial. A dichos hipertensos. 
asmaticos solamente se les deberia admi- 
nistrar bloqueantes selectivos beta y nunca 
antes de haber probado otra terapia. Se- 
han presentado evidencias sugiriendo que 
los hipertensos diabeticos deberian ser tra­
tados con bloqueantes selectivos beta tales 
como el metoprolol y el acebutolol mas 
bien que con drogas no selectivas como 
el propranolol.
El bloqueo de los receptores betao pue­
de enmasearar signos y sintomas de hipo­
glucemia aguda y demorar los mecanis- 
mos reguladores de la homeostasis. La 
administracion de anestesicos generales a 
pacientes cuya presion arterial esta con- 
trolada por los bloqueantes beta adrener­
gicos esta en controversia, pero de cual- 
quier modo deberian monitorearse las res­
puestas cardiovasculares durante la anes- 
tesia.
Los v a s o d ila ta d o r e s  han reingresado a
la terapeutica favorecidos por la aparicion 
del prazosin y el minoxidil. Los vasodilata- 
dores puros generalmente producen reten­
tion  de sodio y agua con ganancia de 
peso y edema, taquicardia refleja y las 
respuestas no especificas a los agentes 
antihipertensivos previamente nombradas, 
incluidos los trastornos gastrointestinales 
y  la depresion 4_5. La hidralazina tambien 
ha sido asociada a un sindrome similar al 
lupus eritematoso, pero esto generalfnente 
ocurre eon pacientes que han sido trata- 
dos con mas de 200 mg por dia. Esta 
situacion se ha asociado con la baja ace- 
tilacion de la hidralazina, siendo mas co- 
mun en las mujeres blancas que en cual- 
quier otra clase de pacientes y es revertida 
por la interruption de la terapia. El mino­
xidil produce hipertricosis en mas del 50 % 
de los pacientes y en las mujeres puede 
tomar la forma de marcado lrirsutismo. 
Hipotension postural severa y colapso 
pueden ocurrir dentro de la primcra hora 
de la ingcsta de prazosin. Por csta razon, 
la mayoria de los clinicos piensan que una 
pcquena dosis de prueba, no mayor de 
0.25 mg, debe ser dada cuando el prazosin 
es lo primero que se prescribe y que los 
pacientes deben permanecer bajo vigilan- 
cia rnedica por lo menos durante ties flo­
ras despues de administrada la primera 
dosis 5.
Los diureticos disminuyen el edema v 
la retencion de liquidos y tambien poten- 
eian el efecto hipotensivo de los vasodila- 
tadores. El uso concomitante de los agen- 
tes bloqueadores beta anula la taquicardia 
refleja y tambien puede afiadir sus efectos 
aditivos bencficiosos sobre la hipertcnsion. 
La administration simultanea de fenilbu- 
tazona, corticoesteroides, carbenoxolona v 
anticonceptivos orales puede interferir con 
los efectos de estos y de otros medieamcn- 
tos antihipertensivos por la produccion de 
retencion liquida. El alcohol, los sedantes 
e hipnoticos, los tranquilizantes, la L-dopa 
y los anestesicos generales potencian el 
efecto de todos los farmacos antihiperten­
sivos, inclusive los vasodilatadores.
En la mayoria de los pacientes, la cle- 
vada presion arterial puede ser satisfacto- 
riamente controlada mediante la adminis- 
tracion criteriosa de diureticos, bloquean- 
tes beta o una combinacion de estos far­
macos con o sin el agregado de vaso­
dilatadores 6.
Sin embargo, varios de los otros agentes 
antihipertensivos son aun usados frecuen- 
temente y merecen mencionarse en una 
revision de esta naturaleza.
Los bloqueantes adrenergicos, tales 
como la guanetidina, producen frecuente- 
mente hipotension asociada con los cam- 
bios posturales y el ejercicio. Se han des- 
cripto anomalias en la funcion hepatica, 
trombocitopenias, neutropenias, reacciones 
dermatologicas tales como prurito, erite- 
mas multiformes, rush penfigoide y derma­
titis exfoliativa.
Durante el tratamiento con debrisoqui- 
na puede presentarse edema y dolor paro- 
tideo y una reaction hipertensiva a la tira- 
mina. Las perturbaciones de la funcion 
sexual en el hombre pueden ser particular - 
mente importantes.
Gran numcro de farmacos suelen inter- 
actuar con los medicamentos similares a 
la guanetidina. Una vasodilatacion adicio- 
nal, debida al alcohol o a otros vasodilata­
dores, puede ser particularmente inconve- 
niente. La combinacion con diureticos o 
agentes bloqueantes beta adrenergicos 
potencia el efecto de los bloqueadores neu- 
ronales adrenergicos sobre la presion ar­
terial, y puede agravar la hipotension 
postural. Los antidepresivos triciclicos in- 
terfieren eon la captacion de las guanidi- 
nas por la neurona adrenergica, por lo 
tanto interfieren con la accion antihiper- 
tensiva de estas drogas. Este efecto es 
tambien compartido, en cierto grado, por 
los derivados fenotiazinicos r\
Las anfetaminas, la efedrina, la fenil- 
efrina y el anorexfgeno dietilpropion des- 
plazan a la guanetidina de sus receptores 
adrenergicos, intcrfiriendo de este modo 
con sus efectos hipotensores y aumentando 
el riesgo de arritmias cardfacas. La gua- 
netidina tambien potencia el efecto de la 
cocaina, del curare y de algunos anestesi­
cos gaseosos.
La alfa m etildopa  produce efectos cola- 
tcrales en un 70-75 % de los pacientes 1 
pero estas reacciones generalmente no son 
especificas ni severas. Pueden aparecer 
dificultades en la capacidad de concentra- 
cion y en la realizacion de operaciones
simples, pero las interferencias con la re- 
gulacion simpatica generalmente son me- 
nos severas que las observadas con los 
bloqueantes de las neuronas adrenergicas. 
El test de Coombs se encuentra positivo 
en hasta un 30 % de los pacientes trata- 
dos con alfa metildopa durante mas de 
seis meses, especialmente si las dosis usa- 
das son altas. La anemia hemolitica es 
rara, y cuando ocurre no es severa y 
desaparece espontaneamente despues de 
suspender la terapia. En un tratamiento 
ininterrumpido por mas de un ano pueden 
elevarse las transaminasas del plasma y 
aparecer signos de colestasis. Generalmen­
te se retorna a la normalidad cuando se 
suspende el tratamiento, pero han sido des- 
criptas hepatitis cronicas que pueden lle- 
var a la necrosis hepatica si la droga es 
nuevamente administrada. Esta forma de 
hepatitis probablemente tenga un compo- 
nente inmune o de hipersensibilidad y en 
algunos pacientes el fenomeno L. E. es 
positivo 5.
Las interacciones con los diureticos y 
los bloqueantes beta adrenergicos general­
mente son favorables con la consecuente 
disminucion de la presion arterial y la 
posibilidad de reducir la dosis de alfa 
metildopa. Sin embargo, la accion hipo- 
tensora de la alfa metildopa puede dismi- 
nuir por la accion central de la reserpina 
y los antidepresivos triciclicos. La alfa 
metildopa anula la respuesta terapeutica 
de la L-dopa, presumiblemente por una 
inhibition competitiva, y la presion arte­
rial puede aumentar inesperadamente si 
drogas de accion simpaticomimetica indi­
recta son administradas a los pacientes 
tratados con alfa metildopa.
La r e se rp in a  es aun ampliamente usada 
en los paises en desarrollo dada su rela- 
tiva eficacia y el bajo costo en compara- 
cion con otros preparados. Es bien sabido 
que esta droga puede producir depresion 
y otros cambios de la personalidad y tam­
bien se la ha asociado con el desarrollo 
del parkinsonismo. Aparte de los trabajos 
del grupo de Boston5, hasta el momento 
no hay evidencia cierta de que produzca 
desarrollo de cancer de mama en las mu- 
jeres postmenopausicas. La reserpina po- 
tencia los efectos de las drogas sedantes
y antihipertensivas, pero ha sido descripto 
antagonismo con el curare, los anestesicos 
locales y los antidepresivos triciclicos. La 
combination de la reserpina con los di- 
gitalicos puede desencadenar arritmias 
cardiacas.
La clonidina y sus compuestos relacio- 
nados pueden controlar la presion arte­
rial sin producir hipotension ortostatica, 
pero cuando causan una marcada sedation 
suelen interferir con las actividades dia­
rias. La suspension brusca de la terapeu­
tica, en pacientes sin complicaciones o en 
aquellos con signos de toxicidad tales 
como vomitos o severas diarreas, puede 
producir un peligroso aumento de la pre­
sion arterial, alteraciones nerviosas, tem- 
blores, sudoracion y dolores de cabeza.
La clonidina potencia los efectos de los 
depresores incluyendo el alcohol y los se­
dantes, y puede antagonizar los efectos de 
los bloqueantes beta adrenergicos y de los 
antidepresivos triciclicos.
Los farmacos descriptos hasta aqui, son 
los usados generalmente hoy para el ma- 
nejo de la hipertension. E l d ia z o x id o  y  e l 
n itr o p r u s ia to  d e  so d io  son utilizados co- 
munmente en aquellas situaciones en que 
una peligrosa elevation de la presmn ar­
terial requiere su inmediata reduction. La 
rapida disminucion de la presion arterial 
mediante el diazoxido. puede producir di- 
ficultades en la perfusion tisular inclu­
yendo el cerebro y las coronarias y mar­
cada hiperglucemia que precede a la ce- 
toacidosis. Este preparado tambien pro- 
voca reacciones hematologicas y atraviesa 
la barrera placentaria con la consiguiente 
toxicidad para el feto. El uso prolongado 
de este medicamento produce hipergluce­
mia, retention de sodio y agua, hiper- 
tricosis e hiperuricemia. Tambien han 
sido descriptos accidentes de pancreatitis 
aguda.
Los efectos antihipertensivos. hiperuri- 
cemicos e hiperglucemiantes estan poten- 
ciados por el uso concomitante de las tia- 
zidas. Los bloqueantes beta adrenergicos 
aumentan los efectos hipotensivos de esta 
droga pero bloquean el aumento de la 
frecuencia cardiaca y del volumen minu- 
to. In vitro, el diazoxido desplaza a la 
warfarina de sus sitios de union con las
protefnas pl’asmaticas, por lo cual haria 
necesario modificar las dosis de anticoa- 
gulantes en el hombre. La clorpromazina 
potencia los efectos hiperglucemiantes del 
diazoxido.
La infusion de nitroprusiato tiene un 
efecto hipotensor casi inmediato producido 
por vasodilatation y acompanado por ta- 
quicardia refleja y un incremento en el 
volumen minuto 7. Si la infusion es dema- 
siado rapida, pueden aparecer sudoracio- 
nes, nauseas, vomitos, ansiedad y espas- 
mos musculares. El nitroprusiato se con- 
vierte en cianogenos, cianidos y tiociana- 
tos. Si los niveles de cianidos llegan a 
valores relativamente altos, puede ocurrir 
la muerte por envenenamiento. La veloci- 
dad de infusion no debe exceder los 
10 /j.g/min.
En esta revision se ha enfatizado sobre 
los efectos colaterales y las interacciones 
de las drogas mas corrientemente utiliza- 
das en la terapia de la hipertension. No 
se ha hecho mention de algunos nuevos 
compuestos, porque no es posible suminis- 
trar detallada informacion de todas las 
drogas accesibles y porque las reacciones 
adversas a algunos de estos agentes solo 
se haran aparentes cuando hayan sido 
usados durante un largo periodo. En este 
momento es razonable sugerir que los 
medicos que tratan la hipertension tengan 
informacion de tres o cuatro buenas drogas 
y se aseguren un acabado conocimiento de 
sus efectos colaterales mas frecuentes.
De todas maneras, deben estar atentos 
para modificar los regimenes terapeuticos 
cuando nuevas y efectivas drogas, con 
menos efectos colaterales, esten a su al- 
cance. Yo sugeriria, sin embargo, que tales 
cambios no sean hechos a la ligera sino 
cuando la experiencia general en nume- 
rosos centros haya indicado las caracteris- 
ticas de las nuevas preparaciones desa- 
rrolladas.
Resumen
L a  in c id e n c ia  d e  la  h ip e r te n s io n  e s  d e  
ta l  m a g n itu d  q u e  lo s  m e d ic o s  la  tra ta n  
f r e c u e n te m e n te  y  a  m e n u d o  a p a r e c e  e n
p a c ie n te s  q u e  p a d e c e n  o tra s  e n fe r m e d a -  
d e s . P o r  lo  ta n to , e s  n e c e sa r io  q u e  las  
r e a c c io n e s  a d v e r s a s  a  lo s  a g e n te s  a n ti- 
h ip e r te n s iv o s  s e a n  d e l  c o n o c im ie n to  d e l  
m e d ic o  p r a c tic o . E n  te r m in o s  g e n e r a le s  
ta le s  r e a c c io n e s  p u e d e n  e s ta r : a) re la c io -  
n a d a s  c o n  lo s  a g e n te s  a n tih ip e i'te n s iv o s  
per se; b) p r o d u c id a s  p o r  in te r a c c io n e s  
e n tr e  e llo s , o c) c a u sa d o s  p o r  in te r a c c io ­
n e s  e n tr e  lo s  fa rm a c o s  a n t ih ip e r te n s iv o s  y  
la s  d r o g a s  u t i l iz a d a s  p a r a  e l  tr a ta m ie n to  
d e  e n fe r m e d a d e s  in d e p e n d ie n te s .  L a s  re ­
a c c io n e s  a d v e r s a s  d e  la  c la se  a) c o n s is te n  
e n  a q u e lla s  v in c u la d a s  c o n  la  d o s is  d a d a  
y  la s  q u e  d e p e n d e n  d e  la s  p r o p ie d a d e s  
fa rm a c o lo g ic a s  d e l  m e d ic a m e n to . P o r  
e je m p lo , lo s  b lo q u e a n te s  b e ta  a d r e n e rg ic o s  
e fe c t iv a m e n te  d is m in u y e n  la  p r e s io n  a r te ­
r ia l, p e r o  su s  e f e c to s  s o b r e  lo s  r e c e p to r e s  
b e ta  p u e d e n  c a u sa r  c ie r to  g r a d o  d e  e sp a sm o  
b r o n q u ia l. E s te  e fe c to  s e  h a c e  m a s  m a n i-  
f ie s to  co n  e l  a u m e n to  d e  la  d o s is . L o s  
a g e n te s  a n t ih ip e r te n s iv o s  ta m b ie n  p u e d e n  
c a u sa r  u n a  g ra n  v a r ie d a d  d e  e fe c to s  c o la ­
te r a le s  d e b id o s  a  la  p e r d id a  d e  su  e s p e c i-  
f ic id a d ,  lo  c u a l s e  tr a d u c e  e n  a c c io n e s  
s o b r e  u n  g ra n  n u m e r o  d e  r e c e p to r e s  no  
r e la c io n a d o s  c o n  e l c o n tro l d e  la  p r e s io n  
a r te r ia l. E s ta s  r e s p u e s ta s  in c lu y e n  s in to m a s  
b ie n  c o n o c id o s , ta le s  c o m o  s e q u e d a d  d e  
la  b o c a , fa tig a , d i f ic u l ta d e s  se x u a le s  y  tra s -  
to rn o s  g a s tr o in te s t in a le s . L a s  in te r a c c io n e s  
e n tr e  lo s  a g e n te s  a n t ih ip e r te n s iv o s  o c u rren  
m e n o s  f r e c u e n te m e n te  d e  lo  q u e  p o d r ia  
p r e v e r s e  en  u n a  e n fe r m e d a d  g e n e r a lm e n te  
t r a ta d a  co n  la  p o lifa rm a c ia . C u a n d o  se  
a g r e g a n  n u e v o s  fa rm a c o s  a  un  tr a ta m ie n to  
e n  c u rso , e l  p r o b le m a  m a s  f r e c u e n te  e s  la  
s o b r e d o s is , c o n  la  c o n s ig u ie n te  s e v e r a  hi- 
p o te n s io n . L a  h ip e r te n s io n  p u e d e  a p a r e c e r  
e n  p a c ie n te s  c o n  tr a ta m ie n to  m e d ic a m e n -  
to s o  p a ra  d iv e r s a s  p a to lo g ia s , ta le s  c o m o  
la  d e p r e s io n , a r tr i t is ,  e p ile p s ia ,  p a rk in so -  
n ism o , o b e s id a d  y  a u n  e l  r e s fr io  co m u n . 
O c u rre n  Im p o r ta n te s  in te r a c c io n e s  e n tre  
lo s  fa rm a c o s  a n t ih ip e r te n s iv o s  y  lo s  a g e n ­
te s  a n t id e p r e s iv o s  ta n to  lo s  tr ic ic l ic o s  
c o m o  a q u e l lo s  q u e  a c tu a n  in d ir e c ta m e n te  
a  tr a c e s  d e  u n a  a c c io n  s im p a to m im e tic a .  
E l m e d ic o  c lin ic o  d e b e r ia  t r a ta r  d e  e v i ta r  
la  p o s ib i l id a d  d e  q u e  o cu rra n  e s to s  e fe c to s  
in d e s e a b le s  e n  su s  p a c ie n te s  h ip e r te n s o s .
1979 EFECTOS ADVERSOS DEL TRATAMIENT©
S u m m a r y
D r u g  in t e r a c t io n s  a n d  a d v e r s e  r e a c t io n s
IN  THE TREATMENT OF HYPERTENSION.
T h e  in c id e n c e  o f  h y p e r te n s io n  is  su c h  
th a t  m e d ic a l  p r a c ti t io n e r s  t r e a t  th e  c o n d i­
t io n  f r e q u e n t ly ,  o f te n  in  p a t ie n ts  su f fe r in g  
f ro m  o th e r  d is e a s e s  in  a d d i tio n . T h u s , i t  is  
im p e r a t iv e  th a t  a d v e r s e  r e sp o n se s  t o  a n ti-  
h y p e i t e n s iv e  a g e n ts  b e  c o m m o n  k n o w le d ­
g e . In  g e n e r a l t e r m s  su c h  re sp o n se s  m a y  
b e , a) r e la te d  to  a n t ih y p e r te n s iv e  a g e n ts  
per se; b) d u e  to  in te r a c tio n s  b e tw e e n  d i f ­
f e r e n t  a n t ih y p e r te n s iv e s  or, c) c a u s e d  b y  
in te r a c tio n s  b e tw e e n  a n t ih y p e r te n s iv e s  a n d  
d r u g s  g iv e n  a s  t r e a tm e n t  fo r  u n r e la te d  c o m ­
p la in ts . A d v e r s e  r e a c tio n s  in  c la ss  a) a b o ­
v e , m a y  b e  fu r th e r  s u b d iv id e d  d e p e n d in g  
u p o n  th e ir  r e la t io n s h ip  t o  d o s e  g iv e n  a n d  
to  th e  in tr in s ic  p h a r m a c o lo g ic a l  p r o p e r t ie s  
o f th e  m e d ic in e . T h u s  b e ta -a d r e n e r g ic  
b lo c k a d e  m a y  e f f e c t i v e ly  lo w e r  b lo o d  p r e s ­
su re , b u t  e f f e c ts  u p o n  b e ta -2 - r e c e p to r s  ca n  
b e  e x p e c te d  to  c a u se  s o m e  d e g r e e  o f  b ro n -  
c h o s p a s m . T h is  e f f e c t  b e c o m e s  m o re  a p ­
p a r e n t  w i th  in c re a s in g  d o s e . H y p o te n s iv e  
a g e n ts  m a y  a lso  c a u se  a  v a r ie ty  o f  s id e  
e f f e c ts  d u e  to  th e ir  la c k  o f  s p e c i f ic i ty  w h ic h  
r e s u lts  in  a c tio n s  u p o n  a  w id e  ra n g e  o f  
r e c e p to r s  u n r e la te d  to  b lo o d  p re ssu re  c o n ­
tro l . T h e s e  r e s p o n s e s  in c lu d e  w e l l-k n o w n  
s y m p to m s  su c h  a s  d r y n e s s  o f  th e  m o u th ,  
f a t ig u e , se x u a l d i f f ic u l t ie s  a n d  g a s tr o in te s ­
tin a l  u p s e ts . I n te r a c tio n s  b e tw e e n  a n t ih y ­
p e r te n s iv e  a g e n ts  o c c u r  le s s  c o m m o p ly  
th a n  m ig h t  b e  a n t ic ip a te d  in  a  c o n d it io n  
f r e q u e n t ly  t r e a te d  b y  p o ly p h a r m a c y . T h e  
c o m m o n e s t  p r o b le m  is  o v e r -d o s a g e  w i th  
c o n s e q u e n t  s e v e r e  h y p o te n s io n  o c c u rr in g  
w h e n  n e w  a g e n ts  a re  a d d e d  to  a n  e x is tin g  
t r e a tm e n t  r e g im e n . H y p e r te n s io n  m a y  o c ­
c u r  in  p a t ie n ts  u n d e r g o in g  d r u g  t r e a tm e n t  
fo r  a  v a r ie ty  o f  c o n d i tio n s  in c lu d in g  d e ­
p re ss io n , a r th r it is , e p i le p s y ,  P a rk in so n ism , 
o b e s i ty  a n d  e v e n  th e  c o m m o n  c o ld . I m ­
p o r ta n t  in te r a c tio n s  o c c u r  b e tw e e n  a n ti-  
h y p e r te n s iv e  a g e n ts  in d ir e c t ly  a c tin g  s y m -  
p a th o m im e t ic a l ly  a n d  tr ic y c l ic  a n t id e p r e s ­
sa n ts , w h ic h  d im in is h  a n t ih y p e r te n s iv e  d r u g  
e ffe c ts . T h e  p r a c tic in g  p h y s ic ia n  s h o u ld  
a t te m p t  to  a v o id  th e  p o s s ib i l i ty  o f  a ll th e s e  
u n d e s ir a b le  r e sp o n se s  o c c u rr in g  in  h is  h y ­
p e r te n s iv e  p a tie n ts .
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